

# **CANCER REPORTING IN CALIFORNIA SYSTEM STANDARDS**

## **ABSTRACTING AND CODING PROCEDURES FOR HOSPITALS**

**California Cancer Reporting System Standards**

### **Volume One**

**Eleventh Edition, September 2011**

**PREPARED BY  
California Cancer Registry  
Data Standards and Quality Control Unit**

**STATE OF CALIFORNIA  
Department of Public Health**

**CANCER SURVEILLANCE AND RESEARCH BRANCH  
Kurt Snipes, M.S., Ph.D., Chief**





# CONTENTS

<b>PREFACE TO THE ELEVENTH EDITION .....</b>	<b>XII</b>
<b>PART I. INTRODUCTION .....</b>	<b>1</b>
<b>I.1 Reporting Cancer Statistics .....</b>	<b>1</b>
<b>I.1.1 Role of the Cancer Registry.....</b>	<b>1</b>
<b>I.1.2 The California Cancer Registry .....</b>	<b>1</b>
<b>I.1.3 State Cancer Reporting Requirements .....</b>	<b>2</b>
<b>I.1.4 Confidentiality.....</b>	<b>2</b>
<b>I.1.5 Casefinding.....</b>	<b>3</b>
I.1.5.1 Sources.....	3
I.1.5.2 Follow-Up.....	4
I.1.5.1 Sources.....	4
I.1.5.2 Follow-Up.....	4
<b>I.1.6 Reporting.....</b>	<b>5</b>
I.1.6.1 Definition of Cancer .....	5
I.1.6.2 Abstracting Cancer Data .....	6
I.1.6.3 Coding.....	6
I.1.6.4 Entering Dates.....	6
I.1.6.5 Date Format and Date Flag Guide.....	7
I.1.6.6 Coding Resources .....	7
I.1.6.7 CCR Reportability Guide.....	11
<b>I.1.7 Reporting by Non-hospital Treatment Centers.....</b>	<b>11</b>
<b>I.1.8 Abstracting Requirements for Non-analytic Cases.....</b>	<b>11</b>
I.1.8.1 Autopsy Only Cases .....	12
I.1.8.2 Cases Diagnosed and Treated Elsewhere.....	12
<b>PART II. REPORTABLE NEOPLASMS.....</b>	<b>13</b>
<b>II.1 Determining Reportability .....</b>	<b>13</b>
II.1.1 Criterion for Reportability of Benign/Borderline Brain and CNS Tumors.....	13
<b>II.1.2 Identifying the Primary Neoplasm .....</b>	<b>14</b>
II.1.2.1 Metastasis .....	14
II.1.2.2 Abstracting Each Primary.....	14
<b>II.1.3 Single and Multiple Primaries .....</b>	<b>14</b>

California Cancer Reporting System Standards, Volume I

- II.1.3.1 Single Primaries.....15
- II.1.3.2 Multiple Primaries .....16
- II.1.3.3 Paired Sites .....18
- II.1.3.4 Breast Ductal and Lobular Carcinomas.....18
- II.1.3.5 Intraductal Carcinoma and Paget Disease .....18
- II.1.3.6 Lymphatic and Hematopoietic Diseases - Subsequent Diagnoses.....18
- II.1.3.7 Single and Multiple Primaries, Kaposi's Sarcoma .....18
- II.1.4 Skin Carcinomas ..... 18**
  - II.1.4.1 Skin Carcinoma Exceptions.....19
  - II.1.4.2 Reportable Skin Tumors.....19
- II.1.5 Cervix ..... 19**
- II.1.6 Ambiguous Diagnostic Terms..... 19**
  - II.1.6.1 Reportable Terms.....19
  - II.1.6.2 Non-Reportable Terms.....20
  - II.1.6.3 Negative Biopsies.....20
- II.1.7 Pathology Only, Tumor Board Only, and Consultation Only Cases ..... 20**
- II.1.8 Newly Reportable Hematopoietic Diseases (NRHD) ..... 21**
- II.1.9 Benign/Borderline Intracranial and CNS Tumors ..... 21**
  - II.1.9.1 Reportability - Benign/Borderline Brain and CNS Tumors .....22
  - II.1.9.2 Determining Multiple Primaries For Brain and CNS Tumors.....23
  - II.1.9.3 Date of Diagnosis For Benign/Borderline Brain and CNS Tumors .....26
  - II.1.9.4 Sequence Number For Benign/Borderline Brain and CNS Tumors .....26
  - II.1.9.5 Malignant Transformation - Benign/Borderline Brain and CNS Tumors.....27
  - II.1.9.6 Tumor Grade - Benign/Borderline Brain and CNS Tumors .....27
  - II.1.9.7 WHO Grade - Benign/Borderline Brain and CNS Tumors .....27
  - II.1.9.8 CS Staging - Benign/Borderline Brain and CNS Tumors.....28
- II.1.10 Borderline Ovarian Tumors..... 28**
- II.2 Abstracting: Preliminary Procedures ..... 30**
  - II.2.1 Year First Seen.....30
  - II.2.3 Accession Number .....30
  - II.2.4 Sequence Number .....31
  - II.2.5 Other Tumors .....32
- PART III. IDENTIFICATION .....33**
- III.1 Registry Information..... 33**
  - III.1.1 Abstractor ..... 33**
  - III.1.2 Suspense Flag ..... 33**
  - III.1.3 Year First Seen, Accession Number, and Sequence Number ..... 33**

<b>III.1.4 Reporting Facility .....</b>	<b>33</b>
<b>III.1.6 ACoS Approved Flag .....</b>	<b>33</b>
<b>III.2 Patient Information .....</b>	<b>34</b>
III.2.1 Name.....	34
III.2.2 Medical Record Number .....	37
III.2.3 Social Security Number .....	37
III.2.4 Phone Number (Patient) .....	39
III.2.5 Address at Diagnosis.....	39
III.2.6 Marital Status .....	42
III.2.7 Sex.....	42
III.2.8 Religion .....	43
III.2.9 Race and Ethnicity .....	45
III.2.10 Date of Birth .....	54
III.2.11 Age at Diagnosis .....	55
III.2.12 Birthplace.....	55
III.2.13 Occupation and Industry.....	55
III.2.14 Patient, No Research Contact Flag.....	57
<b>III.3 Case Identification .....</b>	<b>58</b>
III.3.1 Date of First Contact .....	58
III.3.2 Dates of Inpatient Admission and Inpatient Discharge .....	58
III.3.3 Date of Diagnosis .....	59
III.3.4 Place of Diagnosis .....	61
III.3.5 Class of Case.....	62
III.3.6 Type of Reporting Source.....	64
III.3.7 Type of Admission.....	64
III.3.8 Casefinding Source.....	65
III.3.9 Payment Source (Primary and Secondary) and Payment Source Text .....	66
III.3.10 Reporting Facility Referred From .....	68
III.3.11 Reporting Facility Referred To .....	68
III.3.12 Physicians .....	68
III.3.13 Comorbidity/Complications.....	70
III.3.14 ICD Revision, Comorbidities and Complications .....	70
III.3.15 Discovered By Screening.....	70
<b>PART IV. DIAGNOSTIC PROCEDURES.....</b>	<b>71</b>
<b>IV.1 Diagnostic Procedures Performed .....</b>	<b>71</b>
<b>IV.1.1 General Instructions.....</b>	<b>71</b>
IV.1.1.1 Location .....	71
IV.1.1.2 Tumor Size .....	71
IV.1.1.3 Extension.....	72
IV.1.1.4 Lymph Nodes.....	72
<b>IV.1.2 Physical Examination.....</b>	<b>72</b>
<b>IV.1.3 X-Ray/Scans .....</b>	<b>72</b>

<b>IV.1.4 Scopes</b> .....	<b>72</b>
<b>IV.1.5 Laboratory Tests</b> .....	<b>73</b>
<b>IV.1.6 Operative Findings</b> .....	<b>73</b>
<b>IV.1.7 Pathology</b> .....	<b>73</b>
IV.1.7.1 Pathology Report Number - Biopsy/FNA - Obsolete in 2008 .....	74
IV.1.7.2 Pathology Report Number - Surgery - Obsolete in 2008 .....	74
<b>IV.2 Diagnostic Confirmation</b> .....	<b>74</b>
IV.3 DXRX Report Identifier Data Items-Obsolete in 2010.....	76
IV.3.1 DXRX Report Facility ID (1-5) - Obsolete in 2010 .....	76
IV.4.1 Path Reporting Facility (1-5) (NEW).....	77
IV.4.2 Path Report Numbers (1-5) (New).....	77
IV.4.3 Path Date Specimen Collected (1-5) (New) .....	77
IV.4.4 Path Report Type (1-5) (New).....	77
<b>PART V. TUMOR DATA</b> .....	<b>79</b>
<b>V.1 Primary Site</b> .....	<b>79</b>
<b>V.1.1 ICD-O Coding</b> .....	<b>79</b>
<b>V.1.2 Identification of Separate Sites</b> .....	<b>81</b>
<b>V.1.3 Indefinite and Metastatic Sites</b> .....	<b>81</b>
<b>V.1.4 Special Conditions</b> .....	<b>81</b>
<b>V.1.5 Site-Specific Morphology</b> .....	<b>83</b>
<b>V.1.6 Uncertain Diagnoses</b> .....	<b>83</b>
<b>V.1.7 Multiple Primaries Related Data Items</b> .....	<b>84</b>
V.1.7.1 Ambiguous Terminology Diagnosis.....	85
V.1.7.2 Date of Conclusive Diagnosis.....	86
V.1.7.3 Multiplicity Counter .....	87
V.1.7.4 Date of Multiple Tumors.....	88
V.1.7.5 Type of Multiple Tumors Reported as a Single Primary.....	89
<b>V.2 Laterality</b> .....	<b>89</b>
V.2.1 Coding (Laterality) .....	90
V.2.2 Principal Paired Sites.....	91
V.2.3 Site Coding Restrictions.....	93
<b>V.3 Histology, Behavior, and Differentiation</b> .....	<b>93</b>
V.3.1 ICD-O .....	93
V.3.2 ICD-O Coding.....	93
V.3.3 Histologic Type .....	94
V.3.4 Behavior .....	96

# California Cancer Reporting System Standards, Volume I

V.3.5 Grade and Differentiation .....	98
V.3.6 Edits of Primary Site/Histology Codes .....	107
<b>V.4 Coding Systems .....</b>	<b>109</b>
V.4.1 Extent of Disease.....	109
V.4.2 Collaborative Stage Data Collection System.....	109
<b>V.5 Stage at Diagnosis .....</b>	<b>114</b>
V.5.1 Codes .....	114
V.5.2 Staging Definitions.....	115
V.5.3 Ambiguous Terms.....	115
V.5.4 Staging - Time Period .....	116
V.5.5 Autopsy Reports.....	116
V.5.6 Staging by Physician .....	116
V.5.7 Contradictory Reports.....	116
V.5.8 Summary Stage - In Situ (Code 0) .....	117
V.5.9 Summary Stage - Localized (Code 1).....	118
V.5.10 Summary Stage - Regional (Codes 2, 3, 4, 5).....	118
V.5.11 Summary Stage - Distant (Code 7) .....	120
V.5.12 Summary Stage - Unstageable (Code 9).....	120
V.5.13 Special Rules for Lymph Nodes .....	120
V.5.14 Lymph-Vascular Invasion .....	121
<b>V.6 Tumor Markers.....</b>	<b>122</b>
V.6.1 Tumor Marker 1 .....	122
V.6.2 Tumor Marker 2 .....	122
V.6.3 Tumor Marker 3 .....	122
V.6.4 Tumor Marker California-1.....	122
<b>V.7 AJCC Staging and Other ACoS Items .....</b>	<b>122</b>
V.7.1 The TNM System.....	122
V.7.2 TNM Data Entry.....	123
V.7.3 TNM Stage Basis .....	123
V.7.4 TNM Staging Elements (Clinical and Pathological) .....	123
V.7.5 AJCC Stage Group (Clinical and Pathological) .....	124
V.7.6 TNM Coder (Clinical, Pathological, and Other) .....	124
V.7.7 TNM Edition.....	125
V.7.8 Pediatric Stage.....	125
V.7.9 Pediatric Stage System .....	126
V.7.10 Pediatric Stage Coder .....	128
<b>PART VI . TREATMENT .....</b>	<b>129</b>
<b>VI.1 First Course of Treatment: General Instructions.....</b>	<b>129</b>
VI.1.1 Special Situations .....	130
<b>VI.1.2 Treatment Definitions .....</b>	<b>132</b>
Definitive Cancer Treatment .....	132
Cancer Tissue.....	132
Palliative.....	132

California Cancer Reporting System Standards, Volume I

Antineoplastic Drugs .....132

Active Surveillance.....132

Disease Recurrence .....132

Treatment Failure.....133

Watchful Waiting.....133

**VI.1.3 First Course of Treatment - Data Entry ..... 133**

VI.1.3.1 First Course of Treatment - Codes.....133

VI.1.3.2 First Course of Treatment - Dates.....134

VI.1.3.3 First Course of Treatment - Text .....134

VI.1.3.4 First Course of Treatment - Refused.....135

VI.1.3.5 No First Course of Treatment.....135

VI.1.3.6 First Course of Treatment - Unknown.....135

**VI.2 First Course of Treatment: Surgery Introduction..... 136**

VI.2.1 Surgery of the Primary Site.....136

VI.2.2 Scope of Regional Lymph Node Surgery.....138

VI.2.3 Number of Regional Lymph Nodes Examined.....140

VI.2.4 Surgery of Other Regional Sites, Distant Sites, or Distant Lymph Nodes .....140

VI.2.5 Date of Surgery .....141

VI.2.6 Treatment Facility Number.....142

VI.2.7 Surgical Margins of the Primary Site.....142

VI.2.8 Reconstructive Surgery - Immediate .....142

VI.2.9 Reason for No Surgery of the Primary Site .....143

VI.2.10 Diagnostic or Staging Procedures.....143

VI.2.11 Date of Diagnostic or Staging Surgical Procedures.....145

VI.2.12 Sources for Information (Surgery).....146

VI.2.13 Special Rules for Coding Ambiguous Cases (Surgery).....146

VI.2.14 Systemic Therapy With Surgery Sequence .....147

**VI.3 First Course of Treatment: Radiation Therapy..... 147**

VI.3.1 Types of Radiation.....148

VI.3.1.3 Other Internal Radiation .....149

VI.3.2 Radiation Therapy Summary Codes .....149

VI.3.3 Radiation - Regional RX Modality.....150

VI.3.4 Radiation - Boost RX Modality .....151

VI.3.5 Date of Radiation Therapy.....152

VI.3.6 Reason for No Radiation.....153

VI.3.7 Radiation Sequence With Surgery.....153

VI.3.8 Location of Radiation Treatment.....154

**VI.4 First Course of Treatment - Chemotherapy ..... 154**

VI.4.1 Names of Chemotherapeutic Agents .....154

VI.4.2 Chemotherapy Codes .....155

VI.4.3 Date of Chemotherapy.....155

**VI.5 First Course of Treatment - Hormone (Endocrine) Therapy ..... 156**

VI.5.1 Hormones.....156

VI.5.2 Hormone (Endocrine) Surgery.....157

VI.5.3 Hormone (Endocrine) Radiation.....157

VI.5.4 Hormone Therapy Codes.....157



California Cancer Reporting System Standards, Volume I

VI.5.5 Date of Hormone Therapy .....158

**VI.6 First Course of Treatment - Immunotherapy (Biological Response Modifier Therapy) ..... 159**

VI.6.1 Immunotherapy Agents.....159

VI.6.2 Immunotherapy Codes .....159

VI.6.3 Date of Immunotherapy.....160

**VI.7 First Course of Treatment - Transplant/Endocrine Procedures ..... 161**

VI.7.1 Transplant/Endocrine Codes.....161

VI.7.2 Date of Transplant/Endocrine Procedure .....162

**VI.8 First Course of Treatment - Other Therapy ..... 163**

VI.8.1 Other Therapy Codes .....163

VI.8.2 Date of Other Therapy.....164

VI.9 RX Summary – Treatment Status .....164

VI.9.1 Protocol Participation.....165

**PART VII. FOLLOW-UP ..... 166**

**VII.1 Follow-Up Information ..... 166**

VII.1.1 Required Data.....166

VII.1.2 Sources of Follow-Up Information.....167

VII.1.3 Current Status of Follow-Up Information.....167

VII.1.4 Shared Follow-Up.....167

**VII.2 Follow-Up Data Items ..... 167**

VII.2.1 Date of Last Contact .....167

VII.2.2 Vital Status .....168

VII.2.3 Date Last Tumor Status.....168

VII.2.4 Tumor Status .....168

VII.2.5 Quality of Survival .....169

VII.2.6 Last Type of Follow-Up.....169

VII.2.7 Last Follow-Up Facility.....172

VII.2.8 Next Type Follow-Up.....172

VII.2.9 Next Follow-Up Facility.....172

VII.2.10 Follow-Up Physician .....173

VII.2.11 Alternate Medical Record Number .....173

VII.2.12 Recurrence Information .....173

VII.2.13 Death Information.....175

VII.2.14 Follow-Up Remarks .....175

**VII.3 Contact Name/Address File ..... 175**

VII.3.1 Follow-Up Resources.....175

VII.3.2 Contact # .....175

VII.3.3 Contacts #2 through #6 .....176

**PART VIII. REMARKS AND EXTRA HOSPITAL INFORMATION..... 177**

**VIII.1 Remarks and Final Diagnosis ..... 177**

California Cancer Reporting System Standards, Volume I

VIII.1.1 Required Data Items .....177  
VIII.1.2 Confidential Remarks .....177  
VIII.1.3 More Remarks .....177

**VIII.2 Regional Data ..... 177**

**VIII.3 Extra Facility Information ..... 177**

**VIII.4 Clinical Indicators ..... 178**

**VIII.5 Tumor History ..... 178**

**PART IX. TRANSMITTAL OF CASE INFORMATION AND QUALITY CONTROL ..... 179**

**IX.1 Transmittal of Case Information..... 179**  
IX.1.1 Timeliness .....179  
IX.1.2 Corrections .....179  
IX.1.3 Deletions .....186

**IX.2 Quality Control..... 186**  
IX.2.1 Completeness .....187  
IX.2.2 Accuracy .....187  
IX.2.3 Timeliness .....188

**APPENDICES ..... 189**

**APPENDIX A: Histology Codes for Lymphomas and Leukemias ..... 189**

**APPENDIX B: Postal Abbreviations ..... 193**

**APPENDIX C: Codes for States and Territories of the United States and Provinces and Territories Of Canada..... 195**

**APPENDIX D.1: Codes for Countries in Alphabetic Order ..... 197**

**APPENDIX D.2: Codes for Countries in Numerical Order ..... 210**

**APPENDIX E: Rules for Determining Residency of Military Personnel Assigned to Ships and Crews of Merchant Vessels ..... 223**

**APPENDIX F: California Hospital Code Numbers..... 225**

**APPENDIX G.1: Codes for Religions in Code Order ..... 225**

**APPENDIX G.2 Codes for Religions in Alphabetical Order ..... 229**

**APPENDIX J: Patient Information Sheet ..... 234**

**APPENDIX K-1 Codes for Casefinding (For Cases Diagnosed January 1, 2011 and Later) ..... 236**

**APPENDIX K-2 Codes for Casefinding (For Cases Diagnosed Jan 1, 2010 to Dec 31, 2010) ..... 246**

**APPENDIX K-3 Codes for Casefinding (For Cases Diagnosed Jan 1 to Dec 31, 2009) ..... 254**

**APPENDIX K-4 Codes for Casefinding (Between Jan 1, and Dec 31, 2008) ..... 260**

**APPENDIX K-5 Codes for Casefinding (Prior to 2007) ..... 263**

**APPENDIX L.1: Codes for California Counties In Alphabetic Order ..... 265**

**APPENDIX L.2: Codes for California Counties in Numeric Order ..... 266**

**APPENDIX M.1: Common Acceptable Symbols AND Abbreviations (In Order of Terms) ..... 267**

**APPENDIX M.2: Common Acceptable Symbols and Abbreviations (In Order of Abbreviations) ..... 281**

**APPENDIX N: ICD-O-3 Codes to be Considered One Primary Site When Determining Multiple Primaries ..... 295**

**Appendix O: Spanish Surnames..... 297**

**APPENDIX Q1 ROADS SURGERY CODES ..... 298**

    Q1 Surgery Codes – ANUS: (For Cases Diagnosed prior to January 1, 2003) .....298

    Q1 Surgery Codes – BLADDER (For Cases Diagnosed prior to January 1, 2003) .....300

    Q1 Surgery Codes - BONES,PERIPHERAL NERVES, & SOFT TISSUES (For Cases Diagnosed prior to January 1 2003).....306

    Q1 Surgery Codes - BRAIN & OTHER PARTS OF THE CENTRAL NERVOUS SYSTEM (For Cases Diagnosed prior to January 1, 2003) .....309

    Q1 Surgery Codes – BREAST (For Cases Diagnosed prior to January 1, 2003) .....312

    Q1 Surgery Codes - CERVIX UTERI (For Cases Diagnosed prior to January 1, 2003) .....317

    Q1 Surgery Codes – COLON (For Cases Diagnosed prior to January 1, 2003) .....322

    Q1 Surgery Codes - CORPUS UTERI (For Cases Diagnosed prior to January 1, 2003).....330

    Q1 Surgery Codes – ESOPHAGUS (For Cases Diagnosed prior to January 1, 2003) .....335

    Q1 Surgery Codes - KIDNEY, RENAL PELVIS & URETER (For Cases Diagnosed prior to January 1, 2003) .....340

    Q1 Surgery Codes – LARYNX (For Cases Diagnosed prior to January 1, 2003) .....344

    Q1 Surgery Codes - LIVER INTRATRAHEPATIC BILE DUCTS (For Cases Diagnosed prior to January 1, 2003) .....350

    Q1 Surgery Codes – LUNG (For Cases Diagnosed prior to January 1, 2003) .....353

    Q1 Surgery Codes – ORAL (For Cases Diagnosed prior to January 1, 2003) .....358

    Q1 Surgery Codes – OVARY (For Cases Diagnosed prior to January 1, 2003) .....364

    Q1 Surgery Codes – PANCREAS (For Cases Diagnosed prior to January 1, 2003).....369

    Q1 Surgery Codes – PAROTID (For Cases Diagnosed prior to January 1, 2003) .....374

    Q1 Surgery Codes – PHARYNX (For Cases Diagnosed prior to January 1, 2003) .....378

    Q1 Surgery Codes – PROSTATE (For Cases Diagnosed prior to January 1, 2003) .....383

California Cancer Reporting System Standards, Volume I

Appendix Q1 Surgery Codes – RECTOSIGMOID (For Cases Diagnosed prior to January 1, 2003).....388

Q1 Surgery Codes – RECTUM (For Cases Diagnosed prior to January 1, 2003).....393

Q1 Surgery Codes – SKIN (For Cases Diagnosed prior to January 1, 2003) .....397

Q1 Surgery Codes - SPLEEN & LYMPH NODES (For Cases Diagnosed prior to January 1, 2003).....403

Q1 Surgery Codes – SKIN (For Cases Diagnosed prior to January 1, 2003) .....408

Q1 Surgery Codes – STOMACH (For Cases Diagnosed prior to January 1, 2003) .....412

Q1 Surgery Codes – THYROID (For Cases Diagnosed prior to January 1, 2003).....418

Appendix Q1 Surgery Codes – TESTIS (For Cases Diagnosed prior to January 1, 2003) ..421

Q1 Surgery Codes - ALL OTHER SITES (For Cases Diagnosed prior to January 1, 2003) .425

**Q2 FORDS SURGERY CODES ..... 428**

Q2: ANUS (For Cases Diagnosed on or after January 1, 2003) .....428

Q2 BLADDER: (For Cases Diagnosed on or after January 1, 2003).....430

Q2 BONES, PERIPHERAL NERVES and SOFT TISSUES (For Cases Diagnosed On or After January 1, 2003) .....432

Q2 BRAIN (For Cases Diagnosed on or after January 1, 2003).....433

Appendix Q-2 BREAST (For Cases Diagnosed on or after January 1, 2003).....434

Q2 CERVIX UTERI (For Cases Diagnosed on or after January 1, 2003).....437

Q2 COLON (For Cases Diagnosed on or after January 1, 2003) .....440

Q2 CORPUS UTERI (For Cases Diagnosed on or after January 1, 2003) .....442

Q2 ESOPHAGUS (For Cases Diagnosed on or after January 1, 2003) .....444

Q2 HEMATOPOIETIC/ RETICULOENDOTHELIAL/ IMMUNOPROLIFERATIVE/ MYELOPROLIFERATIVE DISEASE (For Cases Diagnosed on or after January 1, 2003) .....446

Q2 KIDNEY, RENAL, PELVIS, and URETER (For Cases Diagnosed on or after January 1, 2003).....446

Q2 Larynx (For Cases Diagnosed on or after January 1, 2003).....448

Q2 LIVER AND INTRAHEPATIC BILE DUCTS (For Cases Diagnosed on or after January 1, 2003).....449

Q2 LUNG (For Cases Diagnosed on or after January 1, 2003) .....451

Q2 LYMPH NODES (For Cases Diagnosed on or after January 1, 2003) .....453

Q2 ORAL CAVITY (For Cases Diagnosed on or after January 1, 2003) .....454

Q2 OVARY (For Cases Diagnosed on or after January 1, 2003).....456

Q2 PANCREAS (For Cases Diagnosed on or after January 1, 2003) .....458

Q2 PAROTID and OTHER UNSPECIFIED Glands (For Cases Diagnosed on or after January 1, 2003) .....458

Q2 PHARYNX (For Cases Diagnosed on or after January 1, 2003) .....460

Q2 PROSTATE (For Cases Diagnosed on or after January 1, 2003) .....462

Q2 RECTOSIGMOID (For Cases Diagnosed on or after January 1, 2003) .....463

Q2 RECTUM (For Cases Diagnosed on or after January 1, 2003).....465

Q2 SKIN (For Cases Diagnosed on or after January 1, 2003) .....467

Q2 SPLEEN (For Cases Diagnosed on or after January 1, 2003) .....468

Q2 STOMACH (For Cases Diagnosed on or after January 1, 2003) .....470

Q2 TEST (For Cases Diagnosed on or after January 1, 2003) .....472

Q2 THYROID GLAND (For Cases Diagnosed on or after January 1, 2003) .....473

Q2 OTHER SITES (For Cases Diagnosed on or after January 1, 2003) .....473

Q2 UNKNOWN and ILL DEFINED PRIMARY Sites (For Cases Diagnosed on or after January 1, 2003) .....476

**APPENDIX R: ICD-O-3 Lymphatic and Hematopoietic Diseases - Subsequent Diagnoses ..... 477**

**APPENDIX S: DSQC Memos ..... 477**

**APPENDIX U: Table of Data Items and Their Required Status..... 478**

**APPENDIX V: Brain and CNS Site/Histology Listing..... 486**

**APPENDIX W: Race and Nationality Descriptions..... 529**  
 Appendix W.1: Race and Nationality Descriptions (Numeric) .....530  
 Appendix W.2: Race and Nationality Descriptions Alphabetic.....545

**APPENDIX X: National Provider Identifier (NPI) Codes..... 561**

**APPENDIX Y 1 Index to CSv02.03 Site Specific Factors..... 563**

**APPENDIX Y 2 Index to CSv02.02 Site Specific Factors..... 563**

**APPENDIX Z.1: CER Data Dictionary ..... 563**

**APPENDIX Z.2: CER Required CSv02.03 Site Specific Factors..... 563**  
 Breast C50.0-C50.6, C50.8-C50.9 .....564  
 Colon C18.0, C18.2-C18.9 .....566  
 NET Colon C18.0, C18.2-C18.9.....568  
 GIST Colon C18.0, C18.2-C18.9 .....570  
 Rectum C19.9, C20.9.....572  
 NET Rectum C19.9, C20.9.....574  
 GIST Rectum C19.9, C20.9.....576  
 Appendix C18.1 .....578  
 Carcinoid / NET Appendix C18.1 .....580  
 GIST Appendix C18.1 .....582  
 Chronic Myelogenous Leukemia (CML) C42.1 .....584

**APPENDIX Z.3: CER Required Biomarker - BCR-ABL - for CML ..... 586**

**APPENDIX Z.4: CER Required Growth Factors for Breast, Colon, Rectum, Appendix, and CML ..... 586**

## PREFACE TO THE ELEVENTH EDITION

The staff of the Data Standards and Quality Control (DSQC) Unit of the California Cancer Registry presents the eleventh edition, of Cancer Reporting in California: Abstracting and Coding Procedures for Hospitals, Volume I, dated May 2011. The CCR provides Volume I in two formats. One version is in HTML and is interactive and fully searchable. The other version is a printable, PDF version for downloading. Changes to this document are identified through the use of *italicized, bolded, maroon-colored font*.

Thankfully, the changes for 2011 are relatively minor compared to the 2010 data changes. Many of the changes in Collaborative Stage relate to conversions to correct problems identified in 2010. A new CS schema has been added for 2011 and there are modifications to the CS Site Specific Factors.

Other data items with data entry code changes include Marital Status and the Multiplicity Counter.

Clarifications have also been added to the surgery codes, along with a new surgery code for the breast schema.

Appendix Y – CS Site Specific Factor Requirements Table, has been revised to reflect the 2011 changes in reporting requirements for CCR/SEER and CoC . As an added feature, the 2011 version includes histologies for each schema.

New for 2011: Appendix Z1 and Z2 – Data Dictionary and CSv02.03 Site Specific Factors required for the Comparative Effectiveness Research Project, added as optional data collection for reporting facilities, except in Region 3 where the CCR Data Collection Unit will be collecting these data items in cooperation with reporting facilities.

A document titled Cancer Reporting in California: Abstracting and Coding Procedures for Hospitals, California Cancer Reporting System Standards, Volume I, Changes and Clarifications –11th Edition, April 2011, provides a detailed summary of the changes in Volume I. This document is posted to the CCR web site.

I want to acknowledge Lois Inferrera, RHIA, CTR as the lead for the revision of Volume I for 2011, Dennis O'Neal, Alan Houser, MA, MPH, and Cathy Schindler for their technical expertise and editorial assistance. Thanks also to the following DSQC Quality Control Staff, for their review, suggestions and assistance in revising this document: Kathy Vance, BA, CTR, Taina Valone, RHIA, CTR, Kyle Ziegler, CTR, Cheryl Moody, BS, CTR and Marianne Schlecht, CTR.

For reporting facilities in California, please send corrections, comments, and suggestions regarding this document to your regional registry. They will send/forward this information to our unit. If individuals or facilities that are not part

## California Cancer Reporting System Standards, Volume I

of the California reporting system need copies, they may download Volume I from the California Cancer Registry web site.

As always, I want to thank you for your dedicated commitment to ensure data of the highest quality. The data you provide is the cornerstone of the California Cancer Registry and its mission - searching for the causes and cures of cancer.

Winnie Roshala, B.A., CTR  
Data Standards and Quality Control Unit Chief





## **PART I. INTRODUCTION**

### **I.1 Reporting Cancer Statistics**

The systematic gathering of information about the incidence of cancer in designated populations is an indispensable tool in the struggle to contain the disease. With access to reliable statistics on the occurrence of different types of cancer, the people affected, the treatment provided, and other epidemiological factors, researchers and public health officials are better able to identify problems and evaluate remedies. Findings from such studies include possible environmental influences on the development of neoplasms, the susceptibility of certain ethnic and social groups to particular neoplasms, the need for oncology services in various locales, and the appropriateness of diagnostic and therapeutic procedures.

#### **I.1.1 Role of the Cancer Registry**

Many California hospitals have had their own cancer registries since the 1950's in accordance with guidelines established by the American College of Surgeons (ACoS) and its requirements for accreditation of oncology services. The main purpose of a hospital registry is to provide physicians with the data needed to maintain quality of care through peer review and to compare performance with recognized standards. However, a more comprehensive level of reporting is required by state law and that level is supported by the California Cancer Registry and its statewide database system, Eureka DMS.

#### **I.1.2 The California Cancer Registry**

Information from hospital registries and other sources is gathered by the California Cancer Registry (CCR) primarily for use in epidemiological research and for monitoring the occurrence of cancer in the state. A unit in the Chronic Disease Surveillance and Research Branch of the California Department of Public Health, the CCR was established in 1947 as a pilot study to determine the feasibility of basing a central registry on data reported by hospitals. The study was successful and the registry gradually expanded its coverage from nine hospitals to thirty six, most of which were located in the San Francisco Bay area and Los Angeles County. As a result, valuable statistics were developed about the survival of cancer patients. But since the data did not apply to a defined segment of the population, it was not possible to calculate the incidence of cancer. A section covering the population of Alameda County was therefore added to the registry in 1960. When the National Cancer Institute (NCI) undertook its Third National Cancer Survey in 1969, the population-based registration was extended to the entire San Francisco Oakland Standard Metropolitan Statistical Area (SF-O SMSA) consisting of Alameda, Contra Costa, Marin, San Francisco, and San Mateo counties. Support for the SF-O SMSA registration was subsequently provided by the NCI's Surveillance, Epidemiology and End Results (SEER) Program. Established in 1973, SEER is among the largest population-based registries in

the Western world, covering approximately 36 million people in eleven designated regions of the United States.

Expansion of the registration to the SF-O SMSA produced a number of important benefits. It strengthened the DHS's ability to estimate the incidence of cancer in California, ascertain risk factors in the occurrence of the disease, study variations in risks among different ethnic groups and social classes, identify changes in the incidence of various forms of cancer in subgroups of the population, and study long-term changes in the interrelationship of incidence, early diagnosis, treatment, length of survival, and mortality for a greater understanding of cancer. In addition, it greatly increased the number of cases available to researchers for epidemiological studies of human cancer and its relationship to the environment, genetics, cancer in different species, and other fields. Because of these benefits, the CCR's coverage was extended to the State's entire population, which now totals over 37 million people.

### **I.1.3 State Cancer Reporting Requirements**

Provisions of the [California Health and Safety Code](#) enacted in 1985 (Sections 103875 and 103885) mandate the establishment of a statewide system of cancer reporting. The purpose of the system is to *conduct a Program of epidemiological assessments of the incidence of cancer*, with a view to identifying cancer hazards to the public health and their remedies. Under the code, *any hospital or other facility providing therapy to cancer patients within an area designated as a cancer reporting area shall report each case of cancer to the department or the authorized representative of the department.*

#### **January 1, 2001 Forward**

*Beginning January 1, 2001, diagnoses of borderline and benign primary intracranial and central nervous system (CNS) tumors are also reportable, as well as borderline ovarian cancer and Newly Reportable Hematopoietic Diseases (NRHD) (see Section II.1.8).*

It is the reporting facility's responsibility to inform patients that their cancer diagnosis has been reported to the California Cancer Registry as required by regulations that govern the cancer reporting law. A Patient Information Sheet has been developed by the California Department of Public Health, which may be used to inform patients. Please refer to [Appendix J](#). A reporting facility may modify this information sheet, if they so choose.

### **I.1.4 Confidentiality**

The [California Health and Safety Code](#) stipulates that the identity of patients whose cases are reported to the CCR must be held in the strictest confidence. Information that could be used to identify a patient may not be released to or discussed with anyone other than authorized personnel at the reporting hospital or other reporting sources, unless prior informed consent is received from the patient. Section 100330 of the code states:

All records of interviews, written reports and statements procured by the state Department of Public Health or by any other person, agency or organization acting jointly with the state department, in connection with special morbidity and mortality studies shall be confidential insofar as the identity of the individual patient is concerned and shall be used solely for the purposes of the study. The furnishing of such information to the state or its authorized representative, or to any other cooperating individual, agency or organization in any such special study, shall not subject any person, hospital, sanitarium, rest home, nursing home, or other organization furnishing such information to any action for damages.

The CCR also has a policy of maintaining the confidentiality of any information that could be used to identify the caseload of a specific facility or physician.

Under certain circumstances confidential information may be released for research purposes without the patient's consent. Legal provisions for these exceptions to the rules of confidentiality are contained in the Information Practices Act, Civil Code 1798.24. (See [Appendix J](#) for a sample Patient Information Sheet for use in notifying patients that cancer is reportable.)

For more information regarding the CCR's confidentiality policy, please see the CCR web site.

## **I.1.5 Casefinding**

The foundation of the State's cancer reporting system is the hospital, and a key to successful registration is a casefinding system within the hospital for identifying patients with reportable cancers. Although exact procedures might vary from hospital to hospital, they ordinarily involve careful monitoring of the records kept by the services and departments that usually deal with cancer cases.

### **I.1.5.1 Sources**

The principal sources for a hospital's identification of cancer patients are:

- Pathology reports, including histology, cytology, hematology, bone marrow, and autopsy findings. Since pathologic studies are made for most patients suspected of having cancer, the majority of reportable cases can be found by reviewing or obtaining copies of reports with positive or indicative diagnoses.
- Daily discharges

- Disease indexes (See Appendix K for applicable ICD-9-CM codes used in medical records departments.)
- Outpatient records
- Surgery reports
- Radiation therapy logs
- Nuclear medicine logs
- Radiology logs, including logs of scans

### **I.1.5.2 Follow-Up**

To meet the requirements of the State's cancer reporting system, it is necessary to periodically determine the vital status and condition of registered patients. One method of obtaining this information is through the casefinding process. Reporting facilities must have a systematic method of identifying patients who are re-admitted to the hospital or who are treated on an outpatient basis, whether for the reported cancer or for another condition. This information can be used to update the reported patient's vital status and condition.

See [Part VII](#) for additional information.

### **I.1.5.1 Sources**

The principal sources for a facility's identification of cancer patients are:

- Pathology reports, including histology, cytology, hematology, bone marrow, and autopsy findings. Since pathologic studies are made for most patients suspected of having cancer, the majority of reportable cases can be found by reviewing or obtaining copies of reports with positive or indicative diagnoses.
- Daily facility and clinic discharges
- Disease indexes (See [Appendix K](#) for applicable ICD-9-CM codes used in health information/medical record departments.)
- Outpatient records
- Surgery reports
- Radiation therapy logs
- Nuclear medicine logs
- Radiology logs, including logs of scans

### **I.1.5.2 Follow-Up**

To meet the requirements of the State's cancer reporting system, it is necessary to periodically determine the vital status and condition of registered patients. One method of obtaining this information is through the casefinding process. Reporting facilities must have a systematic method of identifying patients who are re-admitted to the hospital or who are treated

on an outpatient basis, whether for the reported cancer or for another condition. This information can be used to update ported patient's vital status and condition.

See [Section VII.1](#) for additional information.

## **I.1.6 Reporting**

The reporting facility must report every case of cancer first seen as an inpatient or outpatient, either with evidence of cancer or for cancer-directed treatment, on or after the date that mandatory reporting was declared for the region (the region's reference date). Refer to the [Regional Registry Reference Date Guide](#) for the specific date when mandatory reporting began in each region.

There are two methods of reporting cancer cases to the CCR.

- A full abstract is required for any case diagnosed and/or treated at the reporting facility (analytic cases) and for most nonanalytic cases. For the list of required data items included in a full abstract, see [Appendix U](#).
- A CMR or other approved notification mechanism is used to identify cancer cases with limited information. These cases are diagnosed and treated elsewhere, however they must be submitted to the regional registry/CCR for incidence reporting. The CCR/Region may request the reporting facility to submit an abstract for incidence reporting if the case submitted via CMR is not found in the CCR database.

Refer to the [Required Method of Reporting Guide](#) for the CCR's reporting requirements.

### **I.1.6.1 Definition of Cancer**

Cancer is defined by the [Health and Safety Code](#) for registry purposes, as "all malignant neoplasms, regardless of the tissue of origin, including malignant lymphoma, Hodgkin Disease, and leukemia, but excluding basal cell and squamous cell carcinoma of the skin."

#### **January 1, 2001 and Forward**

Effective with cases diagnosed January 1, 2001, benign and uncertain behavior intracranial and central nervous system (CNS) tumors became reportable along with newly reportable histologies published in ICD-O-3. Although borderline ovarian tumors changed behavior in ICD-O-3 from /3 (malignant) to /1 (borderline), the CCR will continue to require reporting them. They are to be coded with a behavior code of /1. The CCR establishes an official list of reportable neoplasms annually. A tumor must be reported if it is diagnosed as cancer by any physician (including a pathologist or radiologist), surgeon, or dentist.

**January 1, 1996 and Forward**

Effective with cases diagnosed January 1, 1996, carcinoma in situ (including squamous cell and adenocarcinoma) of the cervix and CIN III (cervical intraepithelial neoplasia, grade III) are no longer reportable to the CCR.

**I.1.6.2 Abstracting Cancer Data**

Information about cancer cases is reported to the CCR in the form of abstracts, which summarize pertinent information about individual cases. (Refer to [Appendix U](#) -- Data Items and Their Required Status). If in doubt about how certain fields should be completed, the regional registry should be contacted.

Whatever reporting software is used, rules for entering data must be followed precisely. The text summaries required for the sections on diagnostic procedures and treatment must be as concise as possible. Every required data item must be completed, and the entries must be accurate, concise, and clear. All codes **must** be supported by text documentation on the abstract.

**I.1.6.3 Coding**

Much of the information is entered in codes consisting of numbers or characters. All codes **must** be supported by text documentation on the abstract.

**I.1.6.4 Entering Dates**

For cases diagnosed January 1, 2010 and forward, or following installation of CSV2 software, dates transmitted between facility registries and central registries changed to improve the interoperability or communication of cancer registry data with other electronic record systems. Registry software may display dates in the traditional manner or in the interoperable format.

Traditional dates are displayed in MMDDCCYY form, with 99 representing unknown day or month portions, and 99999999 representing a completely unknown date. In traditional form, some dates also permit 88888888 or 00000000 for special meaning.

Interoperable dates are displayed in CCYYMMDD form, with the unknown portions of the date filled with blank spaces. If a date is entirely blank, an associated date flag is used to explain the missing date. An allowable date must contain the year.

Consult your software vendor for specific data entry instructions.

Description	Traditional Date	Interoperable Date	Date Flag
Full date known	MMDDCCYY	CCYYMMDD	Blank
Month and year known	MM99CCYY	CCYYMMbb	Blank
Year only known	9999CCYY	CCYYbbbb	Blank
Unknown date	99999999	bbbbbbbb	10, 11, 12, or 15*

b= blank

\* Allowable date flag values

### I.1.6.5 Date Format and Date Flag Guide

For cases diagnosed January 1, 2010 and forward, or following installation of CSV2 software, dates transmitted between facility registries and central registries changed to improve the interoperability or communication of cancer registry data with other electronic record systems. Registry software may display dates in the traditional manner or in the interoperable format.

Traditional dates are displayed in MMDDCCYY form, with 99 representing unknown day or month portions, and 99999999 representing a completely unknown date. In traditional form, some dates also permit 88888888 or 00000000 for special meaning.

Interoperable dates are displayed in CCYYMMDD form, with the unknown portions of the date filled with blank spaces. If a date is entirely blank, an associated date flag is used to explain the missing date. An allowable date must contain the year.

Consult your software vendor for specific data entry instructions.

Description	Traditional Date	Interoperable Date	Date Flag
Full date known	MMDDCCYY	CCYYMMDD	Blank
Month and year known	MM99CCYY	CCYYMMbb	Blank
Year only known	9999CCYY	CCYYbbbb	Blank
Unknown date	99999999	bbbbbbbb	10, 11, 12, or 15*

b= blank                      \* Allowable date flag values

Refer to the [Date Flag Guide](#) for the allowable values for each date flag field.

### I.1.6.6 Coding Resources

<b>A registry must have certain reference works for coding, in addition to this manual.</b>	
<i>Data Collection of Primary Central Nervous System Tumors</i>	<a href="http://www.cdc.gov/cancer/npcr/pdf/btr/braintumorguide.pdf">http://www.cdc.gov/cancer/npcr/pdf/btr/braintumorguide.pdf</a>
<i>Collaborative Staging Data Collection System Coding Instructions</i>	Collaborative Stage Work Group of the American Joint Committee on Cancer. <i>Collaborative Stage Data Collection System Coding Instructions, version 02.00.00</i> . Incorporates updates through April 2010. <a href="http://www.cancerstaging.org/cstage/manuals/index.html">http://www.cancerstaging.org/cstage/manuals/index.html</a>
<b><i>Collaborative Staging Data Collection System Coding Instructions</i></b>	<b><i>Collaborative Stage Work Group of the American Joint Committee on Cancer. Collaborative Stage Data Collection System Coding Instructions, version 02.03.02</i></b> <a href="http://www.cancerstaging.org/cstage/manuals/index.html">http://www.cancerstaging.org/cstage/manuals/index.html</a>

California Cancer Reporting System Standards, Volume I

<p><i>Collaborative Staging Manual and Coding Instructions</i></p>	<p>Collaborative Staging Task Force of the American Joint Committee on Cancer. Version 01.04 Jointly published by American Joint Committee on Cancer (Chicago, IL) and U.S. Department of Health and Human Services (Bethesda, MD), 2004, NIH Publication Number 04-5496. <a href="http://cancerstaging.org/cstage/manuals/archives.html">http://cancerstaging.org/cstage/manuals/archives.html</a></p>
<p><i>Hematopoietic Database (Hematopoietic DB)</i></p>	<p>SEER (Surveillance, Epidemiology, and End Results Program). [www.seer.cancer.gov] Hematopoietic and Lymphoid Database, Version 1.6 released 04/12/2010 National Cancer Institute, DCCPS, Surveillance Research Program. <b>Version 1.6.2, updated 10/20/10.</b> <a href="http://seer.cancer.gov/tools/heme/index.html">http://seer.cancer.gov/tools/heme/index.html</a></p>
<p><i>2010 Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual</i></p>	<p>Johnson CH, Adamo M, Peace S (eds.), 2010 Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual National Cancer Institute, Bethesda, MD 20892-8316 <a href="http://seer.cancer.gov/tools/heme/index.html">http://seer.cancer.gov/tools/heme/index.html</a></p>
<p><i>International Classification of Diseases for Oncology (ICD-O)</i></p>	<p>Fritz, A., Percy, C. et al, eds. 3rd ed. Geneva; World Health Organization, 2000.</p>
<p><i>International Classification of Diseases for Oncology (ICD-O)</i></p>	<p>Percy, C., VanHolten, V., and Muir, C., eds. 2d ed. Geneva: World Health Organization, 1990.</p>
<p><i>2007 Multiple Primary and Histology Coding Rules Manual</i></p>	<p>SEER (Surveillance, Epidemiology, and End Results Program). [Bethesda]: National Institutes of Health, National Cancer Institute, January 01, 2007. <a href="http://seer.cancer.gov/tools/mphrules/download.html">http://seer.cancer.gov/tools/mphrules/download.html</a></p>
<p><i>SEER Extent of Disease—1988 Codes and Coding Instructions</i></p>	<p>SEER (Surveillance, Epidemiology, and End Results Program). 3rd ed. [Bethesda]: National Institutes of Health, National Cancer Institute, 1998. NIH Pub. No. 98-1999.</p>
<p><i>Summary Staging Guide for the Cancer Surveillance, Epidemiology and End Results Reporting (SEER) Program</i></p>	<p>SEER (Surveillance, Epidemiology, and End Results Program). [Bethesda]: U.S. Department of Health and Human Services, Public Health Services, NIH, April 1977, reprinted July 1986.</p>
<p><i>SEER*Rx <b>Version 1.5.0.</b> The Cancer Registrar's Interactive Antineoplastic Drug</i></p>	<p>SEER (Surveillance, Epidemiology, and End Results Program). [Bethesda]: U.S. Department of Health and Human Services, Public Health Services, National Institutes of Health, 2007 (applicable for cases diagnosed</p>



California Cancer Reporting System Standards, Volume I

<i>Database</i>	January 1, 2005 forward). <b>Updated 09/24/10.</b> <a href="http://seer.cancer.gov/tools/seerrx/index.html">http://seer.cancer.gov/tools/seerrx/index.html</a>
<i>Self-Instructional Manual for Tumor Registrars: Book 8—Antineoplastic Drugs</i>	SEER (Surveillance, Epidemiology, and End Results Program). 3d ed. [Bethesda]: U.S. Department of Health and Human Services, Public Health Services, National Institutes of Health, 1994 (applicable for cases diagnosed prior to January 1, 2005).
AJCC Cancer Staging Manual	AJCC (American Joint Committee on Cancer). 7th ed. New York: Springer-Verlag, 2010.
<i>Manual for Staging of Cancer</i>	AJCC (American Joint Committee on Cancer). 6th ed. New York: Springer-Verlag, 2002.
<i>Standards of the Commission on Cancer Volume II: Facility Oncology Registry Data Standards (FORDS)</i>	ACoS (American College of Surgeons Commission on Cancer). Chicago: American College of Surgeons Commission on Cancer, January 2003, revised 2007, 2010 <b>and 2011.</b> <a href="http://www.facs.org/cancer/coc/fords/FORDS_for_2011_01012011.pdf">http://www.facs.org/cancer/coc/fords/FORDS_for_2011_01012011.pdf</a>
<b>Helpful references, although not necessary for abstracting and coding, include the following:</b>	
<i>California Cancer Registry Inquiry System</i>	California Cancer Registry, California Public Health Institute <a href="https://dsqc.ccr.ca.gov/logon.aspx">https://dsqc.ccr.ca.gov/logon.aspx</a>
<i>SEER Inquiry System (SINQ): Resolved Questions</i>	SEER (Surveillance, Epidemiology, and End Results Program) <a href="http://seer.cancer.gov/seer inquiry/index.php">http://seer.cancer.gov/seer inquiry/index.php</a>
<i>CAnswer Forum</i>	Commission on Cancer, American College of Surgeons <a href="http://cancerbulletin.facs.org/forums/content.php">http://cancerbulletin.facs.org/forums/content.php</a>
<b><i>A Cancer Registrar's Guide to Collecting Industry and Occupation</i></b>	<b><i>Department of Health and Human Services Centers of Disease Control and Prevention National Institute of Occupational Safety and Health</i></b> <b><a href="http://www.cdc.gov/niosh/docs/2011-173/">http://www.cdc.gov/niosh/docs/2011-173/</a></b>
<i>SEER Program: Comparative Staging Guide for Cancer</i>	SEER (Surveillance, Epidemiology, and End Results Program). [Bethesda]: National Institutes of Health, National Cancer Institute, 1993. NIH Pub. No. 93-3640.

<p><i>SEER Program Coding and Staging Manual 2010</i></p>	<p>Adamo MB, Johnson CH, Ruhl JL, Dickie LA, (eds). 2010 SEER Program Coding and Staging Manual. National Cancer Institute, NIH Publication number 10-5581, Bethesda, MD.  <a href="http://seer.cancer.gov/tools/codingmanuals">http://seer.cancer.gov/tools/codingmanuals</a></p>
<p><i>WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues</i></p>	<p>Edited by H. Swerdlow, E. Campo, et al. 4<sup>th</sup> ed. IARC, Lyon 2008</p>

**Cancer Registrar Training**

The following training resources are available for cancer registrars.

Hematopoietic & Lymphoid Neoplasms Online Training - <http://seer.cancer.gov/tools/heme/training>/Educational recordings of presentations for the hematopoietic and lymphoid neoplasms project

Multiple Primary and Histology Coding Rules Training - Recordings of the online MP/H Rules Training sessions.

SEER's Training Web Site - Web-based training modules for cancer registration and surveillance.

SEER Self Instructional Manuals for Tumor Registrars - A collection of instructional manuals in PDF format.

SEER Advanced Topics for Registry Professionals - An event that provides advanced training in data collection and coding.

Shambaugh, E., ed-in-chief. [Bethesda]: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, various years.  
<http://seer.cancer.gov/training/manuals>

*Book One-Objectives and Functions of a Tumor Registry*  
2d ed, 1980. [New edition is in preparation.]

*Book Two-Cancer Characteristics and Selection of Cases*  
3d ed, 1992. NIH Pub. No. 92-993

*Book Three-Tumor Registrar Vocabulary: The Composition of Medical Terms*  
2d ed, 1993. NIH Pub. No. 93-1078.

*Book Four-Human Anatomy as Related to Tumor Formation*  
2d ed, 1993. NIH Pub. No. 93-2161.

*Book Five-Abstracting a Medical Record: Patient Identification, History, and Examinations*  
2d ed, 1993. NIH Pub. No. 93-1263

*Book Seven-Statistics and Epidemiology for Tumor Registrars*  
1994

<i>International Classification of Diseases for Oncology (ICD-O)</i>	World Health Organization. Geneva: World Health Organization, 1976.
<i>International Classification of Diseases for Oncology (ICD-O)</i>	Percy, C., and VanHolten, V. Field Trial Edition. Geneva: World Health Organization, 1988.
<i>U.S. Postal Service National Zip Code &amp; Post Office Directory.</i>	<a href="http://www.usps.com/">http://www.usps.com/</a>

### **I.1.6.7 CCR Reportability Guide**

Please refer to the [Reportability Guide](#) for information on specific histologies and sites for tumors that are reportable or not reportable to the CCR.

### **I.1.7 Reporting by Non-hospital Treatment Centers**

Not all abstracting requirements apply to free-standing radiation therapy centers and other cancer treatment centers that are not part of hospitals and do not have inpatient facilities. Usually, patients seen at these facilities have been hospitalized elsewhere previously, and the treatment center is not the primary source for detailed information about their diagnostic work-ups. However, case reports from such facilities afford a quality check on the hospitals' reports and, even more important, provide data that complete the information about the patient's first course of treatment. Without these reports, statewide data on patterns of care would not be accurate or clinically useful.

When submitting abstracts, treatment centers must provide complete patient identification and treatment information, but they are not required to fill in text fields for diagnostic procedures that were performed elsewhere (see Section IV.1). Recording stage is also important. When planning treatment, the radiation therapist often performs the most thorough assessment of stage available for the case.

The treatment center's abstract must be prepared in the same electronic format used by other facilities, although many of the data fields may be left blank or coded as unknown. Required data are listed in [Appendix U](#).

### **I.1.8 Abstracting Requirements for Non-analytic Cases**

A population-based registry like California's must record all cases, regardless of place of diagnosis or class of case, even though the American College of Surgeons (ACoS) does not require hospitals to abstract non-analytic cases.

Therefore, the CCR requires that non-analytic cases be abstracted and submitted. For definitions of non-analytic and analytic cases and class of case, see [Section III.3.5](#).

### **I.1.8.1 Autopsy Only Cases**

Abstracting requirements for Autopsy Only (Class 38) cases are the same as those for analytic cases.

### **I.1.8.2 Cases Diagnosed and Treated Elsewhere**

Reporting requirements for cases diagnosed and treated elsewhere are less stringent than those for other cases. The reporting hospital's medical record often does not contain the required data, or contains only secondhand data. Report any information included in the medical record, but it is not necessary to obtain missing information, although a hospital may choose to do so. Text information about diagnostic procedures limited to a brief statement of the patient's history and the reason for the present admission must be included. Enter the statement in the Physical Exam text area.

Even though information for many required data fields might not be available, all of the fields must be completed. If necessary, enter the codes for UNKNOWN or NONE.

## PART II. REPORTABLE NEOPLASMS

The essential criteria for a reportable tumor is a diagnosis of cancer by a physician, surgeon, or dentist, even if it is not pathologically confirmed.

### II.1 Determining Reportability

Every reporting facility must report all cases, inpatient or outpatient, admitted on or after the regional registry's reference date with a neoplasm classified in the morphology section of ICD-O-3 (International Classification of Diseases for Oncology, Third Edition, 2000) as malignant or in situ, including those discovered at an autopsy. The only exceptions are certain carcinomas of the skin. See [Section II.1.4](#). Neoplasms described by terms synonymous with in situ are reportable. See [Section V.5.8.1](#) for a list of these terms. Effective with cases diagnosed January 1, 2001, benign and uncertain behavior intracranial and central nervous system (CNS) tumors become reportable along with newly reportable histologies published in ICD-O-3. Although borderline ovarian tumors changed behavior in ICD-O-3 from /3 (malignant) to /1 (borderline), the CCR will continue to require reporting them. Other benign neoplasms are not reportable. For a list of reportable and non-reportable neoplasms, refer to the morphology section of ICD-O-3.

#### II.1.1 Criterion for Reportability of Benign/Borderline Brain and CNS Tumors

In determining whether a tumor is reportable, the basic criterion is a diagnosis of cancer by a physician, surgeon, or dentist, even if it is not pathologically confirmed. For vague and ambiguous diagnostic terms, see [Section II.1.6](#). A positive pathology report takes precedence over any other report or statement in a patient's chart. In case of doubt about the reportability of a tumor, contact the hospital's regional registry for advice.

For benign and borderline brain and CNS tumors, there must be a corresponding ICD-O-3 histology code for any CNS tumor-related diagnosis.

- The terms "tumor" and "neoplasm" are diagnostic and reportable for non-malignant brain and CNS primaries.
- The terms "mass" and "lesion" are not reportable for non-malignant brain and CNS primaries, but may be used for initial casefinding purposes.
- The terms "hypodense mass" or "cystic neoplasm" are not reportable even for CNS tumors.

See [Section II.1.9.1 Reportability - Benign/Borderline Brain and CNS Tumors](#).

## **II.1.2 Identifying the Primary Neoplasm**

Accurate identification of a patient's primary neoplasm is essential for determination of the extent to which the disease has progressed. It is also imperative for successful use of the data by research scientists and public health officials.

A primary neoplasm is the original lesion, as compared to a tumor that has developed as a result of metastasis or extension. A patient might have many lesions that developed from one tumor or different tumors that developed independently.

### **II.1.2.1 Metastasis**

Metastasis is the dissemination of tumor cells from the primary site to a remote part of the body. It is important to distinguish metastatic lesions from new primaries. A metastatic lesion is not a primary tumor. Pathologic reports are usually the best source. The term "secondary" is sometimes used for a metastatic lesion. Since the lymphatic system is one of the main routes of metastasis, frequent reference will be found in examinations of the lymph nodes. Occurrence of a lesion in a lymph node ordinarily indicates metastasis.

### **II.1.2.2 Abstracting Each Primary**

A separate abstract must be prepared for each primary reportable neoplasm present at the time of admission unless it was previously reported. This would ordinarily exclude a tumor identified only by its history.

For definitions and rules, see [Section II.1.3](#) and [Section V.1](#).

## **II.1.3 Single and Multiple Primaries**

The CCR has adopted the SEER policy for reporting whether lesions are single or multiple primaries. The policy states:

The determination of how many primary cancers a patient has is, of course, a medical decision, but operational rules are needed in order to ensure consistency of reporting by all participants. Basic factors include the site of origin, the date of diagnosis, the histologic type, the behavior of the neoplasm (i.e., in situ vs. malignant), and laterality. In some neoplasms, one must be careful since different histologic terms are used to describe progressive stages or phases of the same disease process.

Therefore, for purposes of statewide reporting, the following operational rules take precedence over the physician's determination of the number of primaries. Refer to [Section V.1.2](#) for the rules for determining site.

**January 1, 2007 and Forward**

Beginning with cases and tumors diagnosed January 1, 2007 forward, the CCR requires the use of the [2007 Multiple Primary and Histology Coding Rules Manual](#). The 2007 Multiple Primary and Histology rules replace all previous multiple primary rules except those for hematopoietic neoplasms.

The rules are effective for cases diagnosed on or after January 1, 2007. Do not use these rules to abstract cases diagnosed prior to January 1, 2007.

If there is a previously diagnosed cancer primary before January 1, 2007, do not change the previous primary based on the new rules. Use the new rules for any new tumor diagnosed after January 1, 2007, to determine if it is an additional primary. Refer to the SEER Multiple Primary and Histology Coding Rules Manual for specific instructions.

**Note:** Use the 2007 Multiple Primary and Histology rules to determine the number of primaries to be abstracted. Do not use the Multiple Primary and Histology Rules to determine reportability, stage or to assign grade.

### **January 1, 2005 through December 31, 2006**

For cases diagnosed January 1, 2005 through December 31, 2006, apply the SEER Multiple Primary and Histology Rules as written in the SEER Program Coding and Staging Manual, 2004.

### **Prior to January 1, 2005**

For cases diagnosed prior to January 1, 2005, refer to [Section II.1.3.1](#).

## **II.1.3.1 Single Primaries**

### **January 1, 2007 and Forward**

For cases and tumors diagnosed January 1, 2007 forward, apply the SEER Multiple Primary and Histology Coding Rules.

### **January 1, 2005 through December 31, 2006**

For cases diagnosed January 1, 2005 through December 31, 2006, apply the SEER Multiple Primary and Histology Rules as written in the SEER Program Coding and Staging Manual, 2004.

### **Prior to January 1, 2005**

For cases diagnosed prior to January 1, 2005, the following are to be considered single primaries:

- A single lesion of one histologic type, even if the lesion crosses site boundaries (for definitions of site boundaries and histologic types. See Sections V.1 and V.3 respectively.
- A single lesion with multiple histologic types. See [Section V.3.3.3](#) for coding instructions.
- A new cancer with the same histology as an earlier one, if diagnosed in the same site within two months.
- Multiple lesions of the same histologic type, if diagnosed in the same site within two months. Furthermore, if one lesion has a behavior code of in situ and another a malignant behavior code, they are to be

reported as a single primary whose behavior is malignant. (For definition of behavior codes, see [Section V.3.4](#).)

- Two lesions occurring within two months of each other in a single site are considered a single primary if one is reported as (adeno)carcinoma, NOS, and the other is a more specific type of (adeno)carcinoma. For coding instructions, see [Section V.3.3.3.2](#).

### **II.1.3.2 Multiple Primaries**

#### **January 1, 2007 Forward**

For cases and tumors diagnosed January 1, 2007 forward, apply the [2007 Multiple Primary and Histology Coding Rules Manual](#).

#### **January 1, 2005 through December 31, 2006**

For cases diagnosed January 1, 2005 through December 31, 2006, apply the SEER Multiple Primary and Histology Rules as written in the SEER Program Coding and Staging Manual, 2004.

#### **Prior to January 1, 2005**

For cases diagnosed prior to January 1, 2005, the following are to be considered separate primaries:

- A new cancer with the same histology and behavior as an earlier one, if diagnosed in the same site after two months, unless stated to be recurrent or metastatic.

*Exception #1:* For bladder cancers with site codes C67.0-C67.9 and morphology codes 8120 8130 and adenocarcinomas of the prostate (C61.9), a single report of the first invasive lesion only is required.

*Exception #2:* If there is an in situ followed by an invasive cancer in the same site more than two months apart, report as two primaries even if noted to be a recurrence. The invasive case must be diagnosed 1/1/95 or later. Effective with cases diagnosed January 1, 1998, and later, this also applies to bladder and prostate sites. For these two sites, the first invasive case must be diagnosed 1/1/98 and later. The purpose of this guideline is to ensure that a case is counted as an incidence case, *i.e.*, invasive, when data are analyzed by the regional and central registry.

- Multiple lesions of different histologic types in the same site, whether occurring simultaneously or at different times. (Note: Different histologic terms are sometimes used to describe progressive stages or phases of the same disease process.)
- Multiple lesions of different histologic types in different sites.

See also:

- [Section II.1.3.3 Paired Sites](#)
- [Section II.1.3.4 Breast Ductal and Lobular Carcinomas](#)



- [Section II.1.3.6 Lymphatic and Hematopoietic Diseases - Subsequent Diagnoses](#)
- [Section II.1.3.7 Other Single and Multiple Primaries](#)

### **II.1.3.3 Paired Sites**

#### **January 1, 2007 Forward**

For cases diagnosed January 1, 2007 forward, apply the [2007 Multiple Primary and Histology Coding Rules Manual](#) for determining how many primaries are involved in paired sites.

See [Section V.2](#) Laterality

### **II.1.3.4 Breast Ductal and Lobular Carcinomas**

#### **January 1, 2007 Forward**

For cases diagnosed January 1, 2007 forward, apply the Multiple Primary and Histology Coding Rules for determining how many primaries are involved in breast tumors with ductal and lobular carcinoma. See [2007 Multiple Primary and Histology Coding Rules Manual](#).

### **II.1.3.5 Intraductal Carcinoma and Paget Disease**

#### **January 1, 2007 Forward**

For cases and tumors diagnosed January 1, 2007 forward, refer to the [2007 Multiple Primary and Histology Coding Rules Manual](#) to determine how to code breast tumors with intraductal carcinoma and Paget Disease.

#### **Prior to January 1, 2007**

For cases diagnosed prior to January 1, 2007, enter code 8543/3 for a combination of intraductal carcinoma (8500/2) and Paget Disease (8540/3).

### **II.1.3.6 Lymphatic and Hematopoietic Diseases - Subsequent Diagnoses**

For cases diagnosed January 1, 2010 and forward, or following installation of CSV2 software, please refer to the 2010 Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual and Hematopoietic Database.

### **II.1.3.7 Single and Multiple Primaries, Kaposi's Sarcoma**

Kaposi's Sarcoma (9140/3) is to be reported only once.

## **II.1.4 Skin Carcinomas**

Basal and squamous cell carcinomas of the skin are not reportable. Specifically, do not report the following histologies occurring in the skin (site codes C44.0-C44.9):

- 8000-8005 Neoplasms, malignant, NOS, of the skin
- 8010-8046 Epithelial carcinomas of the skin
- 8050-8084 Papillary and squamous cell carcinomas of the skin
- 8090-8110 Basal cell carcinomas of the skin

### II.1.4.1 Skin Carcinoma Exceptions

**Genitalia** Report all carcinomas of the external genital organs, including the vulva, scrotum, and penis (ICD-O-3 site codes C51.9, C63.2, and C60.9).

**ACOS Requirements** Hospitals may include other sites to comply with the requirements of the American College of Surgeons or the facility's cancer committee. However, these should not be reported to the registry.

### II.1.4.2 Reportable Skin Tumors

All other malignant tumors of the skin, such as adnexal carcinomas (e.g., carcinomas of the sweat gland, sebaceous gland, ceruminous gland, and hair follicle), adenocarcinomas, lymphomas, melanomas, sarcomas, and Merkel cell tumor must be reported regardless of site. Any carcinoma arising in a hemorrhoid is reportable since hemorrhoids arise in mucosa, not in the skin.

### II.1.5 Cervix

Carcinoma in situ (including squamous cell and adenocarcinoma) of the cervix and cervical intraepithelial neoplasia, grade III (CIN III) are not reportable effective with cases diagnosed January 1, 1996 and later. See [Section I.1.6.1](#).

### II.1.6 Ambiguous Diagnostic Terms

Vague or ambiguous terms are sometimes used by physicians to describe a tumor when its behavior is uncertain. This occurs primarily when there is no histologic diagnosis. Reporting requirements depend on the term used.

#### II.1.6.1 Reportable Terms

- Apparently (malignant)
- Appears to\*
- Comparable with\*
- Compatible with (a malignancy)\*
- Consistent with (a malignancy)
- Favor (a malignancy)
- Malignant appearing\*
- Most likely (malignant)
- Presumed (malignant)
- Probable (malignancy)
- Suspect or suspected (malignancy)
- Suspicious (of malignancy)
- Typical (of/for malignancy)

\*Effective with cases diagnosed January 1, 1998 and later.

### **II.1.6.2 Non-Reportable Terms**

Do not report the tumor if the only term used is:

- Approaching (malignancy)
- Cannot be ruled out
- Equivocal (for malignancy)
- Possible (malignancy)
- Potentially malignant
- Questionable (malignancy)
- Rule out (malignancy)
- Suggests (malignancy)
- Very close to (malignancy)
- Worrisome (for malignancy)

\* Without additional information

Note: If cytology is reported as "suspicious," do not interpret this as a diagnosis of cancer. Abstract the case only if a positive biopsy or a physician's clinical impression of cancer supports the cytology findings.

If a phrase such as "strongly suggestive" or "highly worrisome" is used, disregard the modifier ("-ly") and refer to the guidelines above regarding the primary term.

### **II.1.6.3 Negative Biopsies**

A cytologically confirmed case with a negative biopsy must be evaluated carefully. If the biopsy rules out the presence of cancer, do not report the case. But if a negative biopsy does not rule out the presence of cancer, the case is considered to be cytologically confirmed and is reportable.

See [Section IV.2](#) Diagnostic Confirmation.

### **II.1.7 Pathology Only, Tumor Board Only, and Consultation Only Cases**

Abstract reporting by facilities is not mandatory for malignancies diagnosed by the pathology department on the basis of slides or specimens submitted from outside the hospital, cases seen only by the hospital's tumor board, and cases seen for consultation only. However, the facility must notify the regional registry about these types of cases in order to verify that all cancers in the population have been recorded. Regional registries establish alternative reporting mechanisms for use when an abstract is not prepared -- for example, submission of a copy of the pathology report or the DHS's "Confidential Morbidity Report" (CMR form). In the interest of ensuring complete information about the incidence of cancer, the CCR requests hospitals to report a first diagnosis even if the patient is not seen at the hospital (for example, a biopsy performed in a doctor's office). But a

confirmation diagnosis -- that is, review of a diagnosis already made at another hospital -- need not be reported.

It is sometimes difficult to identify a consultation only case, especially at a large teaching hospital. As a guideline, the CCR recommends determination of who is ultimately responsible for treatment decisions and follow-up of the patient.

If the reporting hospital is responsible, an abstract should be submitted.

If the reporting hospital is confirming a diagnosis made elsewhere, rendering a second opinion, or recommending treatment to be delivered and managed elsewhere, an abstract is not required, although the regional registry **must** be notified of the case using one or both of the following methods:

- Submit the patient's pathology report
- Submit a completed Confidential Morbidity Report (CMR) form

When in doubt about whether or not to submit a report, either consult the regional registry or report the case using a CMR form.

## **II.1.8 Newly Reportable Hematopoietic Diseases (NRHD)**

For cases diagnosed January 1, 2010 and forward, or following installation of CSV2 software, please refer to the [2010 Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual and Hematopoietic Database](#).

## **II.1.9 Benign/Borderline Intracranial and CNS Tumors**

The CCR requires reporting of all intracranial and CNS benign and borderline tumors and has since 1/1/2001. However, the National Benign Brain Tumor Cancer Registries Amendment Act, signed into law in October 2002, which created Public law 107-260, required the collection of benign and borderline intracranial and CNS tumors beginning with cases diagnosed 1/1/2004 forward.

The CCR requires that follow-up be performed on these cases. Due to this national implementation, several elements of reporting these entities have changed.

Refer to topics Section II.1.9.1 through Section II.1.9.8 for specifics.

### II.1.9.1 Reportability - Benign/Borderline Brain and CNS Tumors

With the national implementation, any tumor diagnosed on January 1, 2004 or later with a behavior code of 0 or 1 will be collected for the following site codes based on ICD-O-3:

- Meninges (C70.0 - C70.9)
- Brain (C71.0 - C71.9)
- Spinal Cord, Cranial Nerves, and Other Parts of Central Nervous System (C72.0 - C72.9)
- Pituitary gland (C75.1)
- Craniopharyngeal duct (C75.2)
- Pineal gland (C75.3)

Note: Benign Schwannomas (9560/0) of the cranial nerves only are reportable to the CCR. Benign Schwannomas occurring in the spinal cord, peripheral nerves or peripheral nerve root are not reportable to the CCR.

The histology codes (also based on ICD-O-3) have been expanded and are listed in [Appendix V](#) for ICD-O-3 Primary Brain and CNS Site/Histology Listing.

Juvenile astrocytomas/pilocytic astrocytomas should continue to be reported as 9421/3. Only benign brain tumor cases with a diagnosis year of 2001 forward are required to be reported to the CCR. Do not report benign brain tumor cases with an unknown year of diagnosis, unless you know that the year of diagnosis is 2001 forward. Apply the rules under [Section III.3.3.2](#) - Vague Dates to determine a date of diagnosis if it is known that the benign brain case was diagnosed after 2001.

#### Reportable Terminology

In order to be reportable, there must be a corresponding ICD-O-3 histology code for any CNS tumor related diagnosis.

- The terms "tumor" and "neoplasm" are diagnostic and reportable for non-malignant brain and CNS primaries.
- The terms "mass" and "lesion" are not reportable for non-malignant brain and CNS primaries, but may be used for initial casefinding purposes.
- The terms "hypodense mass" or "cystic neoplasm" are not reportable even for CNS tumors.

## II.1.9.2 Determining Multiple Primaries For Brain and CNS Tumors

This page contains a discussion of determining the number of primaries. You can review this page in sequence or you can click one of the following links and jump directly to Site, Histology, Timing, or Laterality.

- [Site\(s\)](#)
- [Histologies](#)
- [Timing](#)
- [Laterality](#)

### Site

Non-malignant CNS tumors are different primaries at the subsite level.

### Examples

Meningioma of cervical spine dura (C70.1) and separate meningioma overlying the occipital lobe (C70.0, cerebral meninges). Count and abstract as 2 separate primary tumors.

The exception is when one of the primaries has an NOS site code (C\_\_.9), and the other primary is a specific subsite within the same rubric. Meninges, NOS (C70.9) with spinal meninges (C70.1) or cerebral meninges (C70.0). Count as a single primary and code to the specific subsite.

### Histology

Refer to the Histology Groups Table below, using the rules in priority order:

Histologic Group	ICD-O-3 Histology Code
Choroid plexus neoplasms	9390/0, 9390/1
Ependymomas	9383, 9394, 9444
Neuronal and neuronal-glial neoplasms	9384, 9412, 9413, 9442, 9505/1, 9506
Neurofibromas	9540/0, 9540/1, 9541, 9550, 9560/0
Neurinomatosis	9560/1
Neurothekeoma	9562
Neuroma	9570
Perineuroma, NOS	9571/0

1. If all histologies are in the same histologic grouping or row in the table, then the histology is the same. Histologies that are in the same groupings are a progression, differentiation or subtype of a single histologic category.

### Example

A subependymal giant cell astrocytoma (9384/1) of the cerebrum (C71.0) and a gliofibroma (9442/1) of the Island of Reil (C71.0), count as a single primary.\*

2. If the first 3 digits are the same as the first 3 digits of any histology in a grouping or row in the table above, then the histology is the same.

### Example

A ganglioglioma (9505/1) of the cerebellum (C71.6) and a neurocytoma (9506/1) of the cerebellopontine angle (C71.6), count as a single primary.\*

\*NOTE: If one histology is an NOS and the other is more specific, code the specific histology. If both histologies are NOS or both are specific, code the histology that was diagnosed first.

3. If the first 3 digits are the same but one or both histology codes are not found on the table above, then the histology is considered the same.

### Example

Clear cell meningioma (9538/1) of the cerebral meninges and a separate transitional meningioma (9537/0) in another part of the same hemisphere, count as a single primary.

4. If the histologies are listed in different groupings in the table, they are different histologies.
5. If the first three digits of the histology code are different, and one or both histologies is not listed in the table above, the histology types are different. Report as 2 primaries.

## Timing

If a non-malignant tumor of the same histology and same site as an earlier one is subsequently diagnosed at any time, it is considered to be the same primary.

## Laterality

Beginning with malignant and benign/borderline CNS tumors diagnosed January 1, 2004 forward, the following sites require a laterality code of 1-5, or 9:

- C70.0 Cerebral meninges, NOS
- C71.0 Cerebrum
- C71.1 Frontal lobe
- C71.2 Temporal lobe



California Cancer Reporting System Standards, Volume I

- C71.3 Parietal lobe
- C71.4 Occipital lobe
- C72.2 Olfactory nerve
- C72.3 Optic nerve
- C72.4 Acoustic nerve
- C72.5 Cranial nerve

Laterality is used to determine if multiple non-malignant CNS tumors are counted as multiple primary tumors.

- If same site and same histology and laterality is same side, one side unknown or not applicable, then code single primary
- If same site and same histology and laterality is both sides, then code separate primaries

Counting Non-Malignant Primaries

B = Benign/borderline tumor

M = Malignant tumor

Counting Malignant Primaries

Same Histology *unless stated to be metastatic or recurrent															
Tumor									Timing months	Same Site			Different Site		
1st		Same Histology		Timing (months)	Same Site			Different Site			side	side	side		
1st	2nd	Same side	Other side		Unkn side	Same side	Other side	Unkn side	side	side				side	side
B	B	NA	1	2	1	2	2	2							
B	M	< 2	2	2	2	2	2	2							
B	M	2 +	2	2	2	2	2	2							
Different Histology															
Tumor		Timing (months)	Same Site			Different Site			side	side	side	side			
1st	2nd		Same side	Other side	Unkn side	Same side	Other side	Unkn side							
B	B	NA	2	2	2	2	2	2							
B	M	< 2	2	2	2	2	2	2							
B	M	2 +	2	2	2	2	2	2							
M	M								< 2	1	1	1	2*	2*	2*
M	M								2 +	2*	2*	2*	2*	2*	2*
M	B								NA	2	2	2	2	2	2
Different Histology **unless one histology is a specific subtype of the other															
Tumor		Timing (months)	Same Site			Different Site			side	side	side	side			
1st	2nd		Same side	Other side	Unkn side	Same side	Other side	Unkn side							
M	M	< 2	2**	2**	2**	2	2	2							
M	M	2 +	2	2	2	2	2	2							

M	B	NA	2	2	2	2	2	2
---	---	----	---	---	---	---	---	---

B = Benign/borderline tumor

M = Malignant tumor

### II.1.9.3 Date of Diagnosis For Benign/Borderline Brain and CNS Tumors

As the CCR began reporting benign brain and CNS tumors prior to national reporting implementation, there are two sets of rules for establishing the Date of Diagnosis for benign and malignant brain tumors.

#### January 1, 2004 and Forward

For cases diagnosed January 1, 2004 forward, record the date a recognized medical practitioner states the patient has a reportable tumor, whether that diagnosis was made clinically or pathologically. If a clinical diagnosis, do not change the date of diagnosis/when there is a subsequent tissue diagnosis.

#### Example

A CT scan done 4/1/04 states brain tumor. The patient has surgery on 4/5/04 and a biopsy reveals an astrocytoma. The date of diagnosis is 4/1/04.

#### January 1, 2001 to December 31, 2003

For cases diagnosed January 1, 2001 to December 31, 2003, use the most definitive source of diagnostic confirmation as the date of diagnosis.

#### Example

A CT scan done 2/1/03 states brain tumor. The patient has surgery on 2/5/03 and a biopsy reveals an astrocytoma. The date of diagnosis is 2/5/03.

### II.1.9.4 Sequence Number For Benign/Borderline Brain and CNS Tumors

#### January 1, 2001 and Forward

A primary non-malignant tumor of any of the sites specified on or after January 1, 2001 is reportable.

The sequence number for the tumor is in the range 60-87.

The sequencing of non-malignant tumors does not **effect** the sequencing of malignant tumors and vice versa.

A malignancy (sequence 00) will remain 00 if followed by a non-malignant tumor (sequence 60-87).

#### Example

First tumor, benign meningioma, sequence 60.

Second tumor, astrocytoma, sequence 00.

### II.1.9.5 Malignant Transformation - Benign/Borderline Brain and CNS Tumors

If a benign or borderline tumor transforms into a malignancy, abstract the malignancy as a new primary. If there is a change in WHO grade from a WHO I to a higher WHO grade, abstract as a new primary malignancy. If a malignant CNS tumor transforms into a higher grade tumor, do not change histology or grade and do not abstract as a new primary. This determination is made by the pathologist based on review of slides.

#### Example

Non-malignant WHO grade I to malignant WHO grade III. Complete two abstracts, one for the non-malignant tumor and one for the malignant tumor.

Situation	Create new abstract?
Benign /0 to borderline /1	No*
Benign /0 to malignant /3	Yes
Borderline /1 to malignant /3	Yes
Malignant /3 to malignant /3	No*
WHO Grade I to Grade II, III, or IV	Yes
WHO Grade II to III or IV	No*
WHO Grade III to IV	No*

\* Abstract as one primary using original histology and note progression in remarks.

### II.1.9.6 Tumor Grade - Benign/Borderline Brain and CNS Tumors

Always assign "tumor" grade 9 for non-malignant brain and CNS tumors. Do not code WHO grade in the 6th digit histology data field.

### II.1.9.7 WHO Grade - Benign/Borderline Brain and CNS Tumors

Code the WHO grade classification as documented in the medical record in Collaborative Staging Site Specific Factor 1, for Brain and other Central Nervous System sites.

- WHO grade I generally describes non-malignant or benign tumors; however, non-malignant tumors should not be coded as Grade I unless WHO grade is specifically stated in the source document.
- WHO grade II generally describes a malignant tumor but it can describe a non-malignant tumor depending on histologic type.

- WHO grade III and IV describe malignant tumors.

For certain types of CNS tumors, no WHO grade is assigned.

References:

[Collaborative Stage Data Collection System Coding Instructions](#)

[Data Collection of Primary Central Nervous System Tumors](#)

### **II.1.9.8 CS Staging - Benign/Borderline Brain and CNS Tumors**

For cases diagnosed January 1, 2010 and forward, or following installation of CSV2 software, refer to [Collaborative Stage Data Collection System Coding Instructions](#).

#### **January 1, 2004 and Forward**

For intracranial and CNS benign and borderline tumor cases diagnosed January 1, 2004 and prior to January 1, 2010, apply [Collaborative Staging and Coding Manual](#).

#### **January 1, 2001 to December 31, 2003**

For intracranial and CNS benign and borderline tumor cases diagnosed from January 1, 2001 to December 31, 2003, the CCR does not require that these cases be staged. The CCR recommends that these cases be coded as EOD 99 (Unknown). If your registry uses SEER Summary Stage, it is recommended that these cases be coded to 9.

### **II.1.10 Borderline Ovarian Tumors**

Due to ongoing studies, the CCR is continuing to require that borderline ovarian tumors be reported for cases diagnosed January 1, 2010 and forward.

Recording Collaborative Staging data items will be simplified using the coding guidelines provided below that were developed with the assistance of the CCR's Cancer Epidemiology and Research Unit and regional registries.

In addition, active follow-up will no longer be required for cases diagnosed January 1, 2001 and forward. Follow-up will be obtained through passive follow-up linkages performed at the CCR. Reporting facilities may elect to continue conducting active follow-up on these cases. These cases will only be visually edited for failed electronic edits.

#### **2010 Coding Guidelines**

##### **CSV2 Suggested Codes\***

CS Extension	999
CS Tumor Size /Extension Eval	9
CS Lymph Nodes	999
CS Lymph Nodes Eval	9
Regional Lymph Nodes Positive	99

California Cancer Reporting System Standards, Volume I

Regional Lymph Nodes Examined	99
CS Mets	99
CS Mets at DX - Bone	9
CS Mets at DX - Brain	9
CS Mets at DX - Liver	9
CS Mets at DX - Lung	9
CS Mets Eval	9

**CS Tumor Size:** Continue to code tumor size as directed in the Collaborative Stage (CS) Data Collection System

**SSF 1-SSF 5:** 999

**SSF 6 - SSF 25:** 988

Class of Case: 34, 36 (using the 2010 revised codes)

\* Registrars may choose to include a value other than the suggested codes in any of the fields.

Although borderline ovarian tumors changed behavior in ICD-O-3 from /3 (malignant) to /1 (borderline), the CCR will continue to require reporting them. They are to be coded with a behavior code of /1.

As listed in Appendix 6 of the ICD-O-3 Code Manual, reportable borderline ovarian tumors include the following terms and morphology codes:

Serous cystadenoma, borderline malignancy	8442/1
Serous tumor, NOS, of low malignant potential	8442/1
Papillary cystadenoma, borderline malignancy	8451/1
Serous papillary cystic tumor of borderline malignancy	8462/1
Papillary serous cystadenoma, borderline malignancy	8462/1
Papillary serous tumor of low malignant potential	8462/1
Atypical proliferative papillary serous tumor	8462/1
Serous surface papillary tumor of borderline malignancy	8463/1
Mucinous cystic tumor of borderline malignancy	8472/1
Mucinous cystadenoma, borderline malignancy	8472/1
Pseudomucinous cystadenoma, borderline malignancy	8472/1
Mucinous tumor, NOS, of low malignant potential	8472/1
Papillary mucinous cystadenoma, borderline malignancy	8473/1
Papillary pseudomucinous cystadenoma, borderline malignancy	8473/1
Papillary mucinous tumor of low malignant potential	8473/1

**January 1, 2008 and Forward**

Beginning with the implementation of Collaborative Staging, Version 01.04.00, and for borderline ovarian cases diagnosed on or after January 1, 2008, code CS Extension to 99.

### **January 1, 2004 and Forward**

Apply the Collaborative Staging ovary scheme for cases diagnosed on or after January 1, 2004. Do not use Collaborative Staging Extension code 00 (in situ) for borderline ovarian tumors. Follow-up is required for these cases.

### **Prior to January 1, 2004**

For cases diagnosed prior to January 1, 2004, these cases are to be staged according to the ovary scheme in the EOD Manual.

## **II.2 Abstracting: Preliminary Procedures**

Each patient in a hospital's cancer registry is identified by a permanent nine-digit accession number and each of the patient's primary tumors is identified by a different two-digit sequence number. The accession number remains the same in every abstract prepared by the hospital for the patient, but the sequence number is different.

The first four digits of the accession number usually represents the year first seen for the patient. See [Section II.2.1](#). The last five digits usually represent the approximate chronological order of the abstracts prepared for that year.

Each abstract must contain an accession number and each patient can only have one accession number. Check to see if the patient already has an accession number, then use that number when it is available. Assign an accession number only when the patient did not have one assigned previously.

### **II.2.1 Year First Seen**

Certain abstracting software applications, request Year First Seen.

Enter the four digit year during which the patient was first seen at the reporting hospital for diagnosis or treatment of the neoplasm reported in this abstract. For patients seen at the end of the year, use the year of diagnosis as the year first seen for this primary.

#### **Example**

A patient is admitted to the reporting hospital in December 1992 and is diagnosed in January 1993. Assign 1993 as the year first seen for this primary.

### **II.2.3 Accession Number**

This data item identifies the patient and the tumor. Each patient entered in a hospital registry is assigned a unique accession number, and each primary diagnosed for that patient is assigned a sequence number. The first four digits of the accession number usually represents the year first seen for the

patient. See [Section II.2.1](#). The last five digits usually represents the approximate chronological order of the abstracts prepared for that year.

The accession number never changes. Accession numbers are never reassigned, even if a patient is removed from the registry.

## Examples

If the patient was admitted or the tumor was diagnosed on February 11, 2005, the first four digits are 2005. If the abstract for the reported tumor was the 285th prepared for 2005, the accession number is 200500285.

Two abstracts are being prepared for a patient with one primary tumor diagnosed in 2004 and another in 2006. The first four digits of the accession number are 2004 and the next five represent the abstract's place in the chronological order of cases reported for 2004. The same accession number must be used for the second and subsequent abstracts. (However, the year first seen for the first tumor is 2004 and for the second it is 2006.)

## II.2.4 Sequence Number

Sequence refers to the chronological position of a patient's primary tumor among all the reportable tumors occurring during the patient's lifetime, whether they exist at the same or at different times and whether or not they are entered in the reporting hospital's registry. If two or more reportable neoplasms are diagnosed at the same time, the lowest sequence number is assigned to the diagnosis with the worst prognosis. If no difference in prognosis is evident, the decision is arbitrary.

Sequence Codes for Tumors with Invasive and In Situ Behavior:

00	ONE PRIMARY MALIGNANCY
01	FIRST OF TWO OR MORE PRIMARIES
02	SECOND OF TWO OR MORE PRIMARIES
59	FIFTY-NINTH OR HIGHER OF FIFTY-NINE OR MORE PRIMARIES
99	UNSPECIFIED IN SITU/ INVASIVE SEQUENCE NUMBER OR UNKNOWN

Sequence Codes for Benign and Uncertain Behavior CNS Tumors, Borderline Ovarian Tumors and Cases Reportable by Agreement:

60	ONE BENIGN OR BORDERLINE TUMOR REPORTABLE BY AGREEMENT
61	FIRST OF TWO OR MORE BENIGN OR BORDERLINE TUMORS
62	SECOND OF TWO OR MORE BENIGN OR BORDERLINE TUMORS
87	TWENTY-SEVENTH OF TWENTY-SEVEN OR MORE TUMORS
88	UNSPECIFIED BENIGN, BORDERLINE, TUMOR OF UNCERTAIN BEHAVIOR AND REPORTABLE BY AGREEMENT SEQUENCE NUMBER

Effective with cases diagnosed 1/1/2003 forward, use numeric sequence codes in the range of 00-35 to indicate reportable neoplasms of malignant or in situ behavior. Cases of juvenile astrocytomas, diagnosed prior to 1/1/2001, but entered after 1/1/2003 also use a sequence code in the 00-35 range

Effective with cases diagnosed 1/1/2003 forward, reportable borderline ovarian tumors, benign and uncertain behavior CNS tumors and cases that are reportable by agreement must be sequenced using numeric codes (60-87).

NOTE: Alphabetic sequence codes are no longer allowed.

#### **II.2.4.1 Simultaneous Diagnosis**

When two or more of the patient's tumors were diagnosed simultaneously, assign the lowest sequence number to the one with the worst prognosis. To determine worst prognosis you can review the following topics (or entire topic area).

See [Section V.5](#), Stage at Diagnosis

See [Section V.3.5](#), Grade and Differentiation.

If these sections do not reveal the worst prognosis, assign sequence numbers in the order in which the abstracts are prepared.

#### **Example**

A patient's medical record shows a history of three primary malignant (reportable) tumors in the past and two simultaneously diagnosed recent malignant tumors, one of which is the subject of this report, for a total of five malignancies. The stage of the tumor being reported is regional, whereas the stage of the second of the multiple tumors is localized, a better prognosis. Assign sequence number 04 to the tumor being reported. The number for the second multiple primary is 05.

#### **II.2.4.2 Updating**

If more tumors are diagnosed before the report is submitted, the sequence number must be updated if it was originally coded as 00 or 60, designating a single tumor.

#### **II.2.5 Other Tumors**

In the Remarks area, record the primary sites, histologies, and diagnosis dates of other reportable tumors that the patient had before the diagnosis of the tumor being reported.



## PART III. IDENTIFICATION

### III.1 Registry Information

Registry information fields may be used by reporting facilities or regional registries for local purposes.

#### III.1.1 Abstractor

Enter the abstractor's initials, beginning the left most space. If there are fewer than three initials, leave the trailing spaces blank. Abstractor initials should clearly reflect the identity of the person abstracting the case.

##### January 1, 2007 and Forward

Beginning in January 2007, each reporting facility must submit a list of names and initials of all abstractors in their facility, including temporary staff. Changes to this list must be submitted to the region as abstractors no longer create abstracts at the facility or when new abstractors are added.

#### III.1.2 Suspense Flag

This section was software specific and deleted in 2008.

#### III.1.3 Year First Seen, Accession Number, and Sequence Number

This section was software specific and deleted in 2008.

#### III.1.4 Reporting Facility

Enter the reporting facility's CCR assigned reporting facility code or the facility's name.

[Reporting facilities in alphabetic order.](#)

[Reporting facilities in code order.](#)

#### III.1.6 ACoS Approved Flag

Enter the status of the hospital's ACoS cancer program approval. The following codes are to be used:

1	CANCER PROGRAM APPROVED
2	CANCER PROGRAM NOT APPROVED

NOTE: Code 1 is also to be used for hospitals who have three-year approval with a contingency or one-year approval.

## III.2 Patient Information

### III.2.1 Name

The CCR relies on patient identification information for matching data in the abstract with data about the patient from other sources. It is imperative, therefore, that reporting facilities use the same rules for entering names, dates, and other information. ***Although reporting facility systems may have different name-related data entry requirements, the CCR requires the following information and formatting for patient name.***

#### Guidelines for Entering Patient Name:

- Enter the patient's last name, first name, middle name, maiden name, and any known alias.
- Begin at the far left of each field.
- Do not enter punctuation marks or spaces (except hyphens ***or apostrophes*** when part of the last name, ***first name, middle name, maiden name, alias last name, alias first name, and mother's first name***).
- Use uppercase letters only.
- Do not enter the gender or marital status-Mr., Mrs., Miss, Ms.-or similar forms of address in other languages before the name. For religious order names, see [Section III.2.1.7](#).
- Spell out abbreviated names (e.g., Robt. = Robert). However, if a name includes the word Saint (e.g., Saint James), abbreviate Saint and connect it to the rest of the name as one word ("STJAMES"), then enter "SAINTJAMES," without a space, under Alias Last Name. See [Section III.2.1.5](#).
- If the patient is a child under age 18 living with its parent(s) or guardian(s), record the name(s) of the parent(s) or guardian(s) in the Remarks area.

#### III.2.1.1 Last Name

Note the following guidelines for entering the patient's last name:

- Enter the patient's entire last name.
- Include the hyphen ***or apostrophe*** in a name, but do not enter any other non-alphabetic characters.
- If the last name contains more than 40 characters, enter only the first 40.
- If the patient has no last name or the name cannot be determined, enter NLN.

- If a patient's last name has changed, enter the current last name in the Last Name field and move the original name to the Alias field.

### III.2.1.2 First Name

For the first name enter no more than the first 40 characters. ***Include the hyphen or apostrophe in a name, but do not enter any other non-alphabetic characters.***

If a woman uses her husband's full name (e.g., Mrs. John Smith), try to learn her first name.

If the patient has no first name or the name cannot be determined, enter NFN.

If the patient's first name is not a common male or female name or it is ambiguous with regard to gender, include a statement in the Remarks field confirming the patient's gender.

### III.2.1.3 Middle Name

Enter the middle name, up to 40 characters, or middle initial. ***Include the hyphen or apostrophe in a name, but do not enter any other non-alphabetic characters.***

Leave the space blank if there is no middle name or initial or if it is not known.

### III.2.1.4 Maiden Name

Enter a woman's maiden name, if known, even if it has been entered in the Last Name field.

- Include the hyphen ***or apostrophe*** in a name, but do not enter any other non-alphabetic characters.
- If the name is longer than 40 characters, enter only the first 40.
- Leave the field blank if maiden name is not applicable or it is not known.

### III.2.1.5 Alias Last Name

Enter up to 40 characters in the Alias Last Name field.

- An alias (also known as, or AKA) surname used by the patient.
- The spelled out version of a name containing the word Saint. Do not leave a blank space between the words.
- Certain religious order names. See [Section III.2.1.7](#).
- The first part of a Chinese name that might appear as a last name on another report. (For example, Sun Yat sen might appear elsewhere as Sun, Yat sen or Yat sen Sun).
- Include the hyphen ***or apostrophe*** in a name, but do not enter any other non-alphabetic characters.

- Leave the field blank if there is no alias last name.
- Do not enter a maiden name in the Alias Last Name field, but use the Maiden Name field. See [Section III.2.1.4](#).

### III.2.1.6 Alias First Name

In the Alias First Name Field enter up to **40** characters. Including:

- An alias (also known as, or AKA) first name used by the patient.
- Include the hyphen *or apostrophe* in a name, but do not enter any other non-alphabetic characters.
- Leave the field blank if there is no alias first name.

### III.2.1.7 Religious Names

Do not enter religious designations like Sister, Brother, or Father unless the patient's secular name is unknown. However, when the secular name is known, enter the last name of the religious name under Alias Last Name. When the religious name only is known, enter the last name under Last Name, the designation under First Name, and the religious first name under Middle Name.

#### Examples

1. Religious name: Sister Mary Anthony

Secular name: Jane Smith

Report as: (last name) Smith

(first name) Jane

(alias) Anthony

Religious name: Sister Mary Anthony

Secular name: Smith (first name unknown)

Report as: (last name) Smith

(first name) Sister

(alias) Anthony

Religious name: Sister Mary Anthony

Secular name: unknown

Report as: (last name) Anthony

(first name) Sister

(middle name) Mary

### III.2.1.8 Name Suffix

A name suffix is a title that would follow the name in a letter. It is frequently a generation identifier. It helps to distinguish between patients with the same name.

- Do not use punctuation.
- Leave blank if the patient does not have a name suffix.

Use this field to name suffixes such as Jr, Sr, III, IV.

Do not use this field to record suffices such as MD, PhD, as these suffices will be stripped off at the central registry.

### III.2.1.9 Mother's First Name

Enter the patient's mother's first name in this field.

- This is to be entered for all patients, not just children.
- It is 40 characters in length.
- ***Include the hyphen or apostrophe in a name, but do not enter any other non-alphabetic characters.***
- If this name is not available, this field may be left blank.

### III.2.2 Medical Record Number

Enter the medical record number assigned to the patient at the reporting hospital. For hospitals using a serial numbering system, enter the latest number assigned at the time of abstracting. (This will not be updated.)

If a patient has not been assigned a medical record number at the time the abstract is prepared, certain other identifying numbers may be entered. For example:

- Some hospitals enter the log number assigned by the radiation therapy department, preceded by the letters RT, for patients who do not have a medical record number but are receiving radiation therapy.
- For outpatients who are not admitted and not seen in the radiation therapy department, the assigned number can be preceded with the letters OP.
- If a number is not assigned, enter a code meaningful to the hospital. This field should not be left blank.
- Medical Records numbers can be alphanumeric and should be left justified.
- Do not use punctuation or leave a blank space. Enter leading zeroes that are part of the number.

### III.2.3 Social Security Number

A patient's **full** social security number is **critical** for identification of multiple reports of the same cancer so that they are not counted as separate cases.

***It is the responsibility of the cancer registrar to ensure full access to the patient's social security number.***

Two fields are provided: a nine-character field for the number and a two-character field for a suffix. If the suffix is only one character, leave a trailing blank space in the Suffix field. The medical record might contain the patient's actual social security number, or a Medicare claim number with a suffix indicating the patient's relationship to the wage earner or primary beneficiary/claimant, or both. (The suffix A, for example, indicates that the patient is the wage earner or primary beneficiary/claimant and the social security number is the patient's.) Make every effort to ascertain the patient's own number. Enter it and its suffix in the fields provided.

***All efforts should be made to obtain a patient's full social security number. However, if only a partial social security number is obtained, it should be entered as 99999999. Document the actual partial social security number in the Remarks text field.***

If the patient's own number cannot be determined, enter whatever number (including its suffix) is available from the medical record. Do not combine the suffix from one number with a different number. When not entering a suffix, leave the two character field blank. If the social security number is not known, enter 9's. Military hospitals use the sponsor's social security number plus a numeric prefix as the clinic number or medical record number. Disregard such a number when entering the social security number and suffix, but enter it in the Medical Record Number field when appropriate. See [Section III.2.2](#) for instructions.

The following values are not allowed:

- First three digits cannot be 000 or 666
- Fourth and fifth digits cannot be 00
- Last four digits cannot be 0000
- First digit cannot be 9 (except for 999999999)

Examples

1. Social security number from face sheet: 111-22-3333

Medicare claim number: 123-45-6789B

Enter 111-22-3333.

2. Social security number from face sheet: 222-33-4444D5

No other numbers recorded in chart.

Enter 222-33-4444D5.

3. Social security number from face sheet: not recorded

Clinic record number at Air Force hospital: 30-333-44-5555

Enter 999-99-9999.

### III.2.4 Phone Number (Patient)

This field is to be used for entering the patient's current telephone number including the area code.

Enter all 0's, if there is no phone.

Leave blank, if the phone number is unknown.

Update this field with the most current telephone number, when follow-up indicates that the telephone number has been changed.

### III.2.5 Address at Diagnosis

For all population-based registries, it is essential to have accurate statistics on the occurrence of types of cancer in defined geographical areas. The main purpose of the address field, therefore, is to identify the patient's residence at the time the cancer was first diagnosed, not the patient's current address.

Every effort should be made to determine the correct address.

Rules for determining residency are based on those used by the U.S. Department of Commerce for the 1990 Census of Population.

It is important to follow the rules exactly, because the central registry uses automated data processing methods that reject non-standard entries. The data are used for grouping cases by geographic area.

#### III.2.5.1 Rules for Recording Address

Following are the rules for recording the address:

Enter the address of the patient's *Usual Residence* on the date of the initial diagnosis. See [Section III.3.3](#) for definition of date of diagnosis.

- *Usual Residence* is where the patient lives and sleeps most of the time and is not necessarily the same as the legal or voting residence.
- Do not record a temporary address, such as a friend's or relative's.
- If both a street address and a P.O. Box are given, use the street address.
- For military personnel and their families living on base, the address is that of the base. For personnel living off base, use the residence address. For details about military personnel assigned to ships and about crews of merchant vessels, see [Appendix E](#).
- For institutionalized patients, including those who are incarcerated or in nursing, convalescent, or rest homes, the address is that of the institution.
- Use the current address of a college student. But for children in boarding schools below the college level enter the parents' address.

- If the case is nonanalytic (see [Section III.3.5](#) for criteria), use the address at admission unless there is a documented reason to suspect that the patient resided elsewhere at the time of diagnosis. If there is such an indication, record what is known of the address at diagnosis.
- If the patient is homeless or transient with no usual residence, enter the street, city and zip code as unknown but code county of residence to the county where the hospital is located and code the state to California.
- Persons with more than one residence (snowbirds) are considered residents of the place they designate as their residence at the time of diagnosis if their usual residence cannot be determined.

### **III.2.5.2 Number and Street at DX**

When entering number and street at diagnosis, note the following requirements:

- Use up to **60** characters for the street address.
- Only letters, numbers, spaces, and the number symbol (#), slash (/), hyphen (-), comma (,), and period (.) may be entered.
- House numbers must precede the street name.
- Insert a single space between each component in the street address (e.g., "NEW MONTGOMERY STREET").
- Direction (e.g., North, West) and street types (e.g., Avenue, Road) may be abbreviated (e.g., N MAIN ST). However, do not abbreviate a direction that is the name of a street (e.g., 123 NORTH ST).
- Use intersection addresses (e.g., "FOURTH AND MAIN"), post office box numbers, and building names (e.g., "HOTEL NEW HAMPSHIRE") only if an exact address is not available in the medical record, business office, or elsewhere.
- Place a unit designation directly after the house number (e.g., "139A MAIN ST") or after the street name (e.g., "106 CHURCH STREET 1ST FLOOR," "36 EASTERN CIRCLE APT A").
- If the address contains more than **60** characters, omit the least important elements, such as the apartment or space number. Do not omit elements needed to locate the address in a census tract, such as house number, street, direction or quadrant, and street type.
- Abbreviate as needed, using the standard address abbreviations listed in the *U.S. Postal Service National Zip Code and Post Office Directory* published by the U.S. Postal Service. If the address cannot be determined, enter the word "UNKNOWN."



- The field, Patient Address at Diagnosis Supplemental, provides the ability to record additional address information such as the name of a place or facility (i.e., a nursing home or name of an apartment complex) at the time of diagnosis. Use up to 60 characters for this field. If the patient has multiple tumors, the address may be different for subsequent primaries. Do not update this data item if the patient's address changes.

### **III.2.5.3 City at Dx**

Enter a maximum of 50 characters and spaces. Keep spaces in names consisting of more than one word, but do not use punctuation (e.g., "LOS ANGELES," "SAN FRANCISCO," "ST PAUL").

If a patient's usual place of residence at the time of diagnosis was in a foreign country, enter the name of the city in the foreign country.

Enter the word "UNKNOWN" if the city where the patient lived can not be determined.

### **III.2.5.4 Data Entry, State**

For states in the U.S. and provinces in Canada, enter the standard two letter Postal Service abbreviation.

California is CA.

For other states, U.S. Territories and Canadian provinces, see [Appendix B](#).

### **III.2.5.5 Data Entry, ZIP**

Enter the five-digit or nine-digit U.S. postal zip code or the proper postal code for any other country. When entering only five digits, leave the last spaces blank.

Enter 8's in the entire field, if the patient resided outside the U.S. or Canada at time of diagnosis and the zip code is unknown.

To obtain an unknown zip code, consult the U.S. Postal Service National Zip Code and Post Office Directory, published by the U.S. Postal Service, or phone the local post office.

If the code cannot be determined and it is a U.S. or Canadian resident, enter 9's in the entire field.

### **III .2.5.6 County at DX**

For California residents, enter the code for the county of residence at the time of diagnosis. Some abstracting software will automatically enter the code if the county name is entered. Consult maps or reference works as needed to determine the correct county. If your software vendor provides FIPS codes for this data field, see Appendix L.1 and L.2 for code conversions.

Required California county codes, in alphabetical order, are listed in [Appendix L.1](#).

Required California county codes, in numerical order, are listed in [Appendix L.2](#).

***For states other than California, enter 000 for County at DX.***

Enter code 220 for Canada, NOS, or the specific code for the known Canadian province.

Canadian province codes are listed in [Appendix C](#).

***For non-United States or Canadian residents, use the country of residence.***

Country codes, in alphabetical order, are listed in [Appendix D.1](#).

Country codes, in numerical order, are listed in [Appendix D.2](#).

### **III.2.5.7 City at DX, USPS - Obsolete in 2010**

This data item became obsolete in 2010 because City at DX has been expanded to 50 characters.

### **III.2.6 Marital Status**

Incidence of cancer and sites of cancer have shown correlations to marital status. These patterns are also different among races. Thus this data item is very important to researchers.

Use the following codes to report the patient's marital status at the time of first diagnosis.

- 1 SINGLE (never married, including only marriage annulled)
- 2 MARRIED (including common law)
- 3 SEPARATED
- 4 DIVORCED
- 5 WIDOWED
- 6 Unmarried or Domestic Partner (same sex or opposite sex, registered or unregistered)***
- 9 UNKNOWN

### **III.2.7 Sex**

Enter one of the following codes for the patient's sex:

- 1 MALE
- 2 FEMALE
- 3 HERMAPHRODITE/INTERSEXED (persons with sex chromosome abnormalities)
- 4 TRANSSEXUAL/TRANSGENDERED (persons who desire or plan to undergo or have undergone sex change surgery)
- 9 UNKNOWN

If the patient's first name is not a common male or female name or it is ambiguous with regard to gender, include a statement in the Remarks field confirming the patient's gender.

### III.2.8 Religion

Enter the code for the patient's religion or creed.

Use code 99 if the religion is not stated.

01	NONE
02	AGNOSTIC
03	ATHEIST
04	NONE, AGNOSTIC, ATHEIST (OLD)
05	CATHOLIC; ROMAN CATHOLIC
06	CHRISTIAN, NOS; PROTESTANT, NOS
PROTESTANT DENOMINATIONS:	
07	AFRICAN METHODIST EPISCOPAL (AME)
08	ANGLICAN; CHURCH OF ENGLAND
09	BAPTIST
10	COMMUNITY
11	CONGREGATIONAL
12	EPISCOPALIAN
13	LUTHERAN
14	METHODIST
15	PRESBYTERIAN
16	UNITARIAN
17	PROTESTANT DENOMINATION, OTHER
18	CHRISTIAN REFORMED
19	DISCIPLES OF CHRIST
20	DUTCH REFORMED
21	FIRST CHRISTIAN
22	INTERDENOMINATIONAL
23	MORAVIAN
24	NON-DENOMINATIONAL
25	SEAMAN'S CHURCH
26	TRINITY
27	UNIVERSAL
28	PROTESTANT, OTHER
ORTHODOX:	
29	ARMENIAN ORTHODOX
30	COPTIC
31	GREEK ORTHODOX
32	RUSSIAN ORTHODOX
33	SERBIAN ORTHODOX
34	LEBANESE MARONITE; MARONITE; ORTHODOX, CHRISTIAN, OTHER; ORTHODOX, CHRISTIAN, NOS

California Cancer Reporting System Standards, Volume I

CHRISTIAN SECTS:	
35	JEHOVAH'S WITNESSES
36	CHRISTIAN SCIENCE
37	MORMON; LATTER DAY SAINTS
38	SEVENTH-DAY ADVENTIST
39	FRIENDS; QUAKER
CHRISTIAN SECTS-OTHER:	
40	AMISH
41	MENNONITES
42	APOSTOLIC
43	ARMENIAN APOSTOLIC
44	ASSEMBLIES OF GOD
45	BRETHREN; BROTHERS
46	CHRISTIAN APOSTOLIC
47	CHURCH OF ARMEDIAN
48	CHURCH OF CHRIST
49	CHURCH OF GOD
50	CHURCH OF MESSIANITY
51	CHURCH OF THE DIVINE
52	CHURCH OF THE OPEN DOOR
53	CONGREGATIONAL HOLY; HOLY CONGREGATIONAL
54	COVENANT
55	DIVINE SCIENCE
56	EVANGELICAL
57	FUNDAMENTAL
58	FOURSQUARE
59	FULL GOSPEL
60	HOLINESS
61	HOLY INNOCENTS
62	NAZARENE
63	NEW APOSTOLIC
64	PENTECOSTAL
65	RELIGIOUS SCIENCE
66	SALVATION ARMY
67	SCIENCE OF MIND
68	UNITY
69	CHRISTIAN SECTS, OTHER
70	JEWISH
71	JEWISH ORTHODOX; ORTHODOX JEWISH
WESTERN OTHER:	
72	BAHA'I
73	CRICKORIAN; ETHICAL CULTURE; GREGORIAN; LAWSONIAN; MASON; METAPHYSICS; OCCULT; PEACE OF MIND; PEOPLE'S; SELF-REALIZATION; SOCIETY OF LIFE; SPIRITUALIST; THEOSOPHY; TRUTH SEAKER
74	MOLIKAN; MOLOKAN

75	WESTERN RELIGION OR CREED, OTHER; WESTERN RELIGION OR CREED, NOS
76	KO
EASTERN RELIGIONS:	
77	BUDDHIST; ZEN; ZEN BUDDHISM
78	DROUZE
79	CONFUCIANISM; TOAISM
80	JAIN
81	NATION OF ISLAM
82	MOSLEM; MUSLIM; MOHAMMEDAN
83	HINDU
84	ISLAM
85	PARSEE; ZOROASTRIAN
86	SHINTO
87	SIKH
88	VEDANTA
89	ORIENTAL PHILOSOPHY; EASTERN RELIGION, OTHER; EASTERN RELIGION, NOS
90	AMERICAN INDIAN RELIGIONS; NATIVE AMERICAN TRADITIONAL RELIGIONS
91	HAITIAN/AFRICAN/BRAZILIAN RELIGIONS, OTHER; SANTORIA; VODOO
92	SHAMANISM
93	OTHER TRADITIONAL OR NATIVE RELIGION
94	SCIENTOLOGY
98	OTHER
99	UNSPECIFIED; UNKNOWN

Note: Effective with cases diagnosed January 1, 1998, new codes and definitions were added for religion. Religion codes prior to 1998 were converted. The new codes and definitions are to be used for all cases.

### III.2.9 Race and Ethnicity

Race and ethnicity are two of the most important data items to epidemiologists who investigate cancer. Differences in incidence rates among ethnic groups generate hypotheses for research. The National Cancer institute has recognized the need to better explain the cancer burden in racial/ethnic minorities and is concerned with research on the full diversity of the U.S. population. The CCR recognizes the importance of these data items and relies on quality data to assist researchers in identifying and reducing disparities due to race and ethnicity.

The CCR requires that race code documentation must be supported by text documentation for those cases where there is conflicting information. Outlined below are examples of when text documentation would be required. A text statement indicating patient's race, i.e., "Pt is Japanese", is required for conflicting types of cases. Such remarks must be entered in either the physical exam or remarks text fields.

NOTE: These examples are not intended to demonstrate all possible scenarios.

**Scenarios Demonstrating Conflicting Race Information**

- |   |   |
|---|---|
| <p><b>A</b> Name: June Hashimoto<br/>                 Race: White<br/>                 Birthplace: Unknown<br/>                 Marital Status: Single</p>          | <p><b>B</b> Name: Bob Nguyen<br/>                 Race: White<br/>                 Birthplace: Mexico</p>   |
| <p><b>C</b> Name: Robert Jackson<br/>                 Race: Mexican<br/>                 Birthplace: California</p>   | <p><b>D</b> Name: Moon Smith<br/>                 Race: Japanese<br/>                 Birthplace: California<br/>                 Marital Status: Married</p>       |
| <p><b>E</b> Name: Maria Tran<br/><br/>                 Race: White<br/>                 Birthplace: Spain<br/>                 Marital Status: Separated</p>        | <p><b>F</b> Name: Carlos Johnson<br/><br/>                 Race: Black<br/>                 Ethnicity: Hispanic<br/>                 Marital Status: California</p> |
| <p><b>G</b> Name: Arlene Thompson<br/>                 Race: Filipino<br/>                 Birthplace: California<br/>                 Marital Status: Divorced</p> |   |

Cases with conflicting information that lack supporting text documentation will be returned as queries and counted as discrepancies.

While race code documentation is only required when there is conflicting information, CCR recognizes the importance of race code documentation and strongly recommends that registrars document race in the physical exam or remarks fields. Remember to search beyond the face-sheet for the most definitive race and/or ethnicity information.

Race and ethnicity are defined by specific physical, heredity and cultural traditions, not by birthplace or place of residence. Beginning with cases diagnosed January 1, 2000, four race fields were added to the data set in addition to the existing race field. These fields were added so that patients who belong to more than one racial category can be coded with multiple races, consistent with the 2000 Census. The codes for all five fields are identical with the exception of Code 88 - No further race documented. Code 88 is not to be used for coding the first race field.

Code 99 is to be used for coding the second through fifth race field if the first race field is unknown. If information about the patient's race or races is not given on the face-sheet of the medical record, the physical examination, history, or other sections may provide race information.

### January 1, 2004 and Forward

Effective with cases diagnosed January 1, 2004 forward, apply the following SEER race coding guideline:

Race (and ethnicity) are defined by specific physical, heredity and cultural traditions or origins, not necessarily by birthplace, place of residence, or citizenship. 'Origin' is defined by the Census Bureau as the heritage, nationality group, lineage, or in some cases, the country of birth of the person or the person's parents or ancestors before their arrival in the United States.

1. All resources in the facility, including the medical record, face-sheet, physician and nursing notes, photographs, and any other sources, must be used to determine race. If a facility does not print race in the medical record but does maintain it in electronic form, the electronic data must also be reviewed.
2. Record the primary race(s) of the patient in fields Race 1, Race 2, Race 3, Race 4, and Race 5. The five race fields allow for the coding of multiple races consistent with the Census 2000. Rules 2 - 8 further specify how to code Race 1, Race 2, Race 3, Race 4 and Race 5. See the editing guidelines that follow for further instructions. If a person's race is a combination of white and any other race(s), code to the appropriate other race(s) first and code white in the next race field.
  - a. If a person's race is a combination of Hawaiian and any other race(s), code Race 1 as 07 Hawaiian and code the other races in Race 2, Race 3, Race 4, and Race 5 as appropriate.

#### Example:

Patient is described as Japanese and Hawaiian. Code Race 1 as 07 Hawaiian, Race 2 as 05 Japanese, and Race 3 through Race 5 as 88.

- b. If the person is not Hawaiian, code Race 1 to the first stated non-white race (using race codes 02 - 98).

#### Example:

Patient is stated to be Vietnamese and Black. Code Race 1 as 10 Vietnamese, Race 2 as 02 Black, and Race 3 through Race 5 as 88.

**Note:** In the following scenarios, only the race code referred to in the example is coded. For cases diagnosed after January 1, 2000, all race fields must be coded.

3. The fields Place of Birth, Race, Marital Status, Name, Maiden Name, and Hispanic Origin are inter-related. Use the following guidelines in order:
  - a. Code the patient's stated race, if possible. Refer to [Appendix W](#), "Race and Nationality Descriptions from the 2000 Census and Bureau of Vital Statistics" for guidance.

### **Examples:**

Patient is stated to be Japanese. Code as 05 Japanese.

Patient is stated to be German-Irish. Code as 01 White.

Patient is stated to be German-Irish. Code as 01 White.

**Exception:** When the race is recorded as Oriental, Mongolian, or Asian (codable to 96 Other Asian) and the place of birth is recorded as China, Japan, the Philippines, or another Asian nation, code the race based on birthplace information.

### **Examples:**

The person's race is recorded as Asian and the place of birth is recorded as Japan. Code race as 05 Japanese because it is more specific than 96 Asian, NOS.

The person describes himself as an Asian-American born in Laos. Code race as 11 Laotian because it is more specific than 96 Asian, NOS.

- b. If the patient's race is determined on the basis of the races of relatives, there is no priority to coding race, other than to list the non-white race(s) first.

### **Example:**

The patient is described as Asian-American with Korean parents. Code race as 08 Korean because it is more specific than 96 Asian-American.

- c. If no race is stated in the medical record, or if the stated race cannot be coded, review the documentation for a statement of a race category.

### **Examples:**

Patient described as a black female. Code as 02 Black.

Patient describes herself as multi-racial (nothing more specific) and nursing notes say "African-American." Code as 02 Black.

Patient states she has a Polynesian mother and Tahitian father. Code Race 1 as 25 Polynesian, Race 2 as 26 Tahitian and Race 3 through Race 5 as 88.

- d. If race is unknown or not stated in the medical record and birth place is recorded, in some cases race may be inferred from the nationality. Refer to Appendix W "Race and Nationality Descriptions from the 2000 Census and Bureau of Vital Statistics" to identify nationalities from which race codes may be inferred.



### **Examples:**

Record states: "This native of Portugal." Code race as 01 White per the Appendix W.

Record states: "This patient was Nigerian." Code race as 02 Black per the Appendix W.

Exception: If the patient's name is incongruous with the inferred race, code Race 1 through Race 5 as 99, Unknown.

### **Examples:**

Patient's name is Siddhartha Rao and birthplace is listed as England. Code Race 1 through Race 5 as 99 Unknown.

Patient's name is Ping Chen and birthplace is Ethiopia. Code Race 1 through Race 5 as 99 Unknown.

- e. Use of patient name in determining race
  - i. Do not code race from name alone, especially for females with no maiden name given
  - ii. In general, a name may be an indicator of a racial group, but should not be taken as the only indicator of race.
  - iii. A patient name may be used to identify a more specific race code.

### **Examples:**

Race reported as Asian, name is Hatsu Mashimoto. Code race as 05 Japanese.

Birthplace is reported as Guatemala and name is Jose Chuicol [name is Mayan]. Code race as 03 Native American.

### **Example:**

Alice Gomez is a native of Indiana (implied birthplace: United States).

Code Race 1 through Race 5 as 99 Unknown, because we know nothing about her race.

- 4. Persons of Spanish or Hispanic origin may be of any race, although persons of Mexican, Central American, South American, Puerto Rican, or Cuban origin are usually white. Do NOT code a patient stated to be Hispanic or Latino as 98 Other Race in Race 1 and 88 in Race 2 through Race 5.

## Example:

Miss Sabrina Fitzsimmons is a native of Brazil.

Code race as 01 White per Appendix W.

Note: Race and ethnicity are coded independently.

5. When the race is recorded as African-American, code race as 02.
6. Code 03 should be used for any person stated to be Native American or [western hemisphere] Indian, whether from North, Central, South, or Latin America.
7. Death certificate information may be used to supplement antemortem race information only when race is coded unknown in the patient record or when the death certificate information is more specific.

## Examples:

In the cancer record Race 1 through Race 5 are coded as 99 Unknown.

The death certificate states race as black.

Change cancer record for Race 1 to 02 Black and Race 2 through Race 5 to 88.

Race 1 is coded in the cancer record as 96 Asian.

Death certificate gives birthplace as China.

Change Race 1 in the cancer record to 04 Chinese and code Race 2 through Race 5 as 88.

8. Code as white (01) when the race is described as white (01) but the place of birth is Hawaii.

For cases diagnosed prior to January 1, 2000, only the first race field is to be completed and patients of mixed parentage are to be classified according to the race or ethnicity of the mother. For cases diagnosed January 1, 2000 and later, this no longer applies. Enter each race given. For cases diagnosed prior to January 1, 2004, no "primary" race is designated, and multiple races may be listed in any order, consistent with the 2000 Census. When any of the race fields are coded as Other Asian - Code 96, Pacific Islander, NOS - Code 97, or Other - Code 98" and a more specific race is given which is not included in the list of race codes, this more specific race must be entered in the Remarks field. (When a patient is described as Asian or Oriental and the birthplace is recorded as a specific Asian country, use the birthplace if possible to assign a more specific code.) If there is no information on race in the medical record, a statement documenting that there is no information must be entered in the Remarks Field.

### III.2.9.1 Codes For Race Field

Enter the most appropriate code for a patient's race(s) or ethnicity:

California Cancer Reporting System Standards, Volume I

01	WHITE
02	BLACK
03	AMERICAN INDIAN, ALEUTIAN, OR ESKIMO
04	CHINESE
05	JAPANESE
06	FILIPINO
07	HAWAIIAN
08	KOREAN
09	FORMERLY ASIAN INDIAN OR PAKISTANI, RETIRED EFFECTIVE 1/1/10. See replacement codes 15-17.
10	VIETNAMESE
11	LAOTIAN
12	HMONG
13	KAMPUCHEAN (CAMBODIAN)
14	THAI
15	ASIAN INDIAN OR PAKISTANI, NOS
16	ASIAN INDIAN
17	PAKISTANI
20	MICRONESIAN, NOS
21	CHAMORRO
22	GUAMANIAN, NOS
25	POLYNESIAN, NOS
26	TAHITIAN
27	SAMOAN
28	TONGAN
30	MELANESIAN, NOS
31	FIJI ISLANDER
32	NEW GUINEAN
88	NO FURTHER RACE DOCUMENTED (Do not use for coding the first race field)
90	OTHER SOUTH ASIAN*, INCLUDING BANGLADESHI, BHUTANESE, NEPALESE, SIKKIMESE, SRI LANKAN (CEYLONESE)
96	OTHER ASIAN, INCLUDING BURMESE, INDONESIAN, ASIAN, NOS AND ORIENTAL, NOS
97	PACIFIC ISLANDER, NOS
98	OTHER
99	UNKNOWN

Following are some of the ethnic groups included in the White category:

Example A person of Chinese ancestry born in Thailand and living in Hawaii at the time of diagnosis is to be reported as Chinese (code 04) instead of Thai (code 14) or Hawaiian (code 07).

For cases diagnosed January 1, 2010 and forward use codes 15 Asian Indian or Pakistani, NOS, code 16 Asian Indian, and code 17 Pakistani. Code 09 Asian Indian, Pakistani was retired.

## California Cancer Reporting System Standards, Volume I

Note: Per 2004 SEER guidelines, races previously coded to 09 – Asian Indian were to be coded to 96 - Other Asian. For consistency in these codes over time, the CCR created a new code, code 90 for Other South Asian that includes Bangladeshi, Bhutanese, Nepalese, Sikkimese, Sri Lankan (Ceylonese). Cases are converted from 90 to 96 for Calls for Data.

- Afghan
- Albanian
- Algerian
- Arabian
- Armenian
- Australian
- Austrian
- Bulgarian
- Caucasian
- Central American\*
- Cuban\*\*
- Cypriot
- Czechoslovakian
- Dominican\*\*
- Egyptian
- Greek
- Gypsy
- Hungarian
- Iranian
- Iraqi
- Israeli
- Italian
- Jordanian
- Latino
- Lebanese
- Mexican\*
- Moroccan
- Palestinian
- Polish
- Portuguese
- Puerto Rican\*\*
- Rumanian
- Russian
- Saudi Arabian
- Slavic
- Slovene
- South American\*
- Spanish
- Syrian
- Tunisian
- Turkish
- Yugoslavian

\* Unless specified as Indian (code 03).

\*\* Unless specified as Black (code 02).

### III.2.9.2 Spanish/Hispanic Origin

The Spanish/Hispanic Origin field is for identifying patients of Spanish or Hispanic origin or descent. The field corresponds to a question asked in the U.S. census. Included are people whose native tongue is Spanish, who are nationals of a Spanish speaking Latin American country or Spain, and/or who identify with Spanish or Hispanic culture (such as Chicanos living in the American Southwest). Coding is independent of the Race field, since persons of Hispanic origin might be described as white, black, or some other race in the medical record. Spanish origin is not the same as birth in a Spanish language country. Birthplace might provide guidance in determining the correct code, but do not rely on it exclusively. Information about birthplace is entered separately. See [Section III.2.12](#). In the Spanish/Hispanic Origin field, enter one of the following codes:

0	NON-SPANISH, NON-HISPANIC
1	MEXICAN (including Chicano, NOS)
2	PUERTO RICAN
3	CUBAN
4	SOUTH OR CENTRAL AMERICAN (except Brazilian)
5	OTHER SPECIFIED SPANISH ORIGIN (includes European; excludes DOMINICAN REPUBLIC for cases diagnosed January 1, 2005 forward)
6	SPANISH, NOS; HISPANIC, NOS; LATINO, NOS (There is evidence other than surname or maiden name that the person is Hispanic, but he/she cannot be assigned to any category of 1-5.)
7	SPANISH SURNAME ONLY (only evidence of person's Hispanic origin is surname or maiden name, and there is no contrary evidence that the person is not Hispanic.)**
8	DOMINICAN REPUBLIC (for cases diagnosed on or after January 1, 2005)
9	UNKNOWN WHETHER SPANISH OR NOT

For cases diagnosed 2010 and forward, per SEER guidelines, do not presume that Portuguese, Brazilians and Filipinos are to be Spanish or non-Spanish.

Assign code 7 if the name is on the Spanish Surname list. Use code 0 if not found on the Spanish Surname list. See [Appendix O](#) for the Spanish Surname list.

The primary source for coding is an ethnic identifier stated in the medical record.

If the record describes the patient as Mexican, Puerto Rican, or another specific ethnicity or origin included in codes 1 to 5 or 8, enter the appropriate code whether or not the patient's surname or maiden name is Spanish.

If the patient has a Spanish surname, but the record contains information that he or she is not of Hispanic origin, use code 0, Non-Spanish. (American

Indians frequently have Spanish surnames but are not considered to be of Spanish origin in the sense meant here.)

If the record does not state an origin that can be assigned to codes 1-5 or 8 and there is evidence other than surname that the person is Hispanic, use code 6, Spanish, NOS.

If the record does not state an origin that can be assigned to codes 0-6, base the code on the patient's name, and use code 7, Spanish Surname Only.

Use code 7, Spanish Surname Only, for a woman with a Spanish maiden name or a male patient with a Spanish Surname.

If a woman's maiden name is not Spanish, use code 0, Non-Spanish, Non-Hispanic.

But if her maiden name is not known or not applicable and she has a Spanish Surname, use code 7.

If race is not known (Race code 99), use code 9, Unknown Whether Spanish or Not, unless the patient's last name appears on the Spanish surname list, then use code 7, Spanish surname only .

Code 7, Spanish Surname Only (or code 6, Spanish, NOS, if diagnosed prior to January 1, 1994) may be used for patients whose name appears on the official list of Spanish Surnames, but code 9 is the preferred code.

## Examples:

A woman whose married surname is Gonzales but who is stated to be of Japanese origin should be coded 0.

A patient who is stated to be South American but does not have a Spanish surname should be coded 4, South or Central American.

A woman is identified as white in the medical record. Her married name is Anderson, and her maiden name is Chavez. Enter code 7, Spanish, Surname Only.

Note: The CCR has adopted the official list of Spanish Surnames from the 1980 U.S. Census, and this list should be used to assign code 7. See Appendix O.

### III.2.10 Date of Birth

For cases diagnosed January 1, 2010 and forward, or following installation of CSV2 software, see [Section I.1.6.4](#) and [Section I.1.6.5](#) for Coding and Entering Dates.

Consult with your software vendor for specific data entry instructions.

#### III.2.10.1 Date of Birth Flag

For cases diagnosed January 1, 2010 and forward, or following installation of CSV2 software, this data item is used to explain why there is no appropriate

value in the corresponding date field. Since only actual known dates are entered in interoperable date items, flags are used to explain the reason the date field is blank. Depending on the registry software being used, these changes may be transparent to the registrar.

**Codes:**

12	Date of Birth cannot be determined
Blank	Full or partial date recorded

### III.2.11 Age at Diagnosis

Age at First Diagnosis is a required field. Usually, the Age at First Diagnosis is calculated and generated by the abstracting software. If the Age at First Diagnosis is not calculated and generated by the abstracting software, calculate the age and enter it into this field.

### III.2.12 Birthplace

Enter the name of the state, territory, or country where the patient was born.

### III.2.13 Occupation and Industry

Because the identification of occupational cancer is an important aspect of cancer research, every effort should be made to record the occupation and the industry in which the patient works or worked, regardless of whether the patient was employed at the time of admission. Ideally, the information should pertain to the longest held job (other than housework performed in the patient's home).

Review all admissions in the patient's medical record, including those before the diagnosis of cancer, and record the best information available. It is not necessary to request parts of the medical record predating diagnosis solely to determine occupation and industry, but review all admissions in the parts pulled for abstracting.

Good sources of information include admission and discharge summaries, face sheets, history and physical examination reports, oncology consultation reports, and health and social history questionnaires the patient has completed. The CCR will code the occupation and industry using the United States Bureau of the Census occupation and industry classifications.

*Please refer to <http://www.cdc.gov/niosh/docs/2011-173/>*

#### III.2.13.1 Occupation

Enter any available information about the kind of work performed (e.g., television repairman, chemistry teacher, bookkeeper, construction worker), up to 100 characters associated with the longest held occupation.

- Avoid the use of abbreviations where possible.

- If an occupation is recorded in the chart without mention of its being the longest held, indicate this with an asterisk next to the entry (e.g., insurance salesman\*).
- If the patient is not employed, try to determine the longest held occupation.
- Do not enter a term such as "homemaker," "student," "retired," "unemployed," or "disabled" unless no other information can be obtained.
- If no information is available, enter "NR" (not recorded). Do not leave this field blank.

*Please refer to <http://www.cdc.gov/niosh/docs/2011-173/>*

### **III.2.13.2 Industry**

Enter any available information about the industry associated with the longest held occupation (e.g., automotive repair, junior high school, trucking, house construction), up to 100 characters.

If the chart identifies the employer's name but does not describe the industry, enter the employer's name (and city if available). If only an abbreviation is given for the industry or employer (e.g., PERS, USD, or FDIC), record it even if its meaning is not known. However, avoid the use of abbreviations where possible.

If no information is available, enter "NR" (not recorded). Do not leave this field blank.

*Please refer to <http://www.cdc.gov/niosh/docs/2011-173/>*

### **III.2.13.3 Children**

If the patient is a child, enter "Child" in the Occupation field, beginning in the leftmost space.

Also record any information available about the occupations of the parents and the industries in which they are employed.

Record the occupation and industry of both parents if the information is in the medical record. If there is not enough room, however, give priority to the father's occupation and industry. Precede information about a parent with "FA" (father) or "MO" (mother).

## **Examples:**

1. Patient is 10 years old. Father is a field engineer with an oil company. Mother is an artist (NOS). Complete the Occupational and Industry fields as follows:

Occupation: Child—FA: field engineer MO: artist



Industry: FA: oil industry

2. Patient is 14 years old. Father's occupation is not recorded. Mother is a biology professor at a university. Complete the Occupational and Industry fields as follows:

Occupation: Child—MO: biology professor

Industry: MO: University

***Please refer to <http://www.cdc.gov/niosh/docs/2011-173/>***

### **III.2.14 Patient, No Research Contact Flag**

This flag is to be set to code 1, 2, or 3 if there is documentation on the medical record or if the cancer registry has been contacted by the patient or the patient's physician saying that they do not want to be included in research studies. ***Cases coded to 4 or 5 should not be contacted for research studies. Codes 4 and 5 are generated by the CCR.***

If there is no information with regard to the patient's not wanting inclusion in one or more research studies, this flag should remain set to 0.

Code 0 - There is no information with regard to the patient's not wanting inclusion in one or more research studies.

Code 1 - Hospital First Notified - would be entered.

Codes 2 and 3 are for regional and central registry use.

Code 4 - Out of State Case, Not for Research - is generated by the CCR.

***Code 5 - VA cases, Not for Research - is generated by the CCR.***

The purpose of this code is to notify CCR and its regional registries that a case has been shared from another state and that this case cannot be given to researchers without approval of that state registry. It is not to be set for patients not wanting to be contacted during routine annual follow-up. Please use the Follow-up Switch for this purpose. This is a required data item and cannot be blank. The codes are:

0	NO FLAG
1	HOSPITAL FIRST NOTIFIED
2	REGION FIRST NOTIFIED
3	CCR FIRST NOTIFIED
4	OUT OF STATE CASE, NOT FOR RESEARCH
<b>5</b>	<b><i>VA CASES, NOT FOR RESEARCH</i></b>

### III.3 Case Identification

While some of the data reported on the Case Identification screens are only for identification and document control, the Date of Diagnosis serves as the basis for computing incidence, survival, and other statistics. Accurate recording of the date of the first diagnosis of a reportable neoplasm is especially important.

#### III.3.1 Date of First Contact

For cases diagnosed January 1, 2010 and forward, or following installation of CSv2 software, see [Section I.1.6.4](#) and [Section I.1.6.5](#) for Coding and Entering Dates.

For Inpatients, enter the first date of admission as an inpatient for the reportable neoplasm, or the actual date when the diagnosis of a reportable neoplasm was made during a hospitalization.

For Outpatients, enter the date first diagnosed, treated, or seen as an outpatient for the reportable neoplasm.

Consult with your software vendor for specific data entry instructions.

##### III.3.1.1 Date of First Contact Flag

For cases diagnosed January 1, 2010 and forward, or following installation of CSv2 software, this data item is used to explain why there is no appropriate value in the corresponding date field. Since only actual known dates are entered in interoperable date items, flags are used to explain the reason the date field is blank. Depending on the registry software being used, these changes may be transparent to the registrar.

**Codes:**

12	Date of first contact cannot be determined
Blank	Full or partial date recorded

#### III.3.2 Dates of Inpatient Admission and Inpatient Discharge

For cases diagnosed January 1, 2010 and forward, or following installation of CSv2 software, see [Section I.1.6.4](#) and [Section I.1.6.5](#) for Coding and Entering Dates.

Enter the dates of the dates of "Inpatient Admission and Inpatient Discharge" to the reporting facility for the most definitive surgery.

If the patient does not have surgery, use the inpatient admission and discharge dates for any other cancer-directed therapy.

If the patient has not had cancer-directed therapy, use the dates of inpatient admission and discharge for diagnostic evaluation.

Consult with your software vendor for specific data entry instructions.

### III.3.2.1 Date of Inpatient Admission Flag

For cases diagnosed January 1, 2010 and forward, or following installation of CSv2 software, this data item is used to explain why there is no appropriate value in the corresponding date field. Since only actual known dates are entered in interoperable date items, flags are used to explain the reason the date field is blank. Depending on the registry software being used, these changes may be transparent to the registrar.

**Codes:**

10	No information, unknown if an inpatient
11	Patient was never an inpatient
12	Patient was inpatient but the date is unknown
Blank	Full or partial date recorded

### III.3.2.2 Date of Inpatient Discharge Flag

For cases diagnosed January 1, 2010 and forward, or following installation of CSv2 software, this data item is used to explain why there is no appropriate value in the corresponding date field. Since only actual known dates are entered in interoperable date items, flags are used to explain the reason the date field is blank. Depending on the registry software being used, these changes may be transparent to the registrar.

**Codes**

10	No information, unknown if an inpatient
11	Patient was never an inpatient
12	Patient was inpatient but the date is unknown
Blank	Full or partial date recorded

### III.3.3 Date of Diagnosis

For cases diagnosed January 1, 2010 and forward, or following installation of CSv2 software, see [Section I.1.6.4](#) and [Section I.1.6.5](#) for Coding and Entering Dates.

***Effective for all cases identified/first seen 1/1/2010 and forward, a completely unknown date of diagnosis is no longer allowed for all analytic cases (Class of Case 00-22). At a minimum, the year of diagnosis is required for all cases. The year of diagnosis must be known or estimated and cannot be blank or unknown. For instructions on determining a date of diagnosis, refer to [Section III.3.3.2](#), [Section III.3.3.3](#), and [DSQC Memo #2011-04](#). Documentation must be provided for the basis of the estimated date.***

Enter the date a physician, surgeon, or dentist first stated that the patient has cancer, whether or not the diagnosis was ever confirmed microscopically.

The rule applies even if the cancer was confirmed at a later date and whether or not the diagnosis was made at the reporting hospital or before admission.

However, if upon clinical and/or pathological review of a previous condition it is determined that the patient had the tumor at an earlier date, enter that date (that is, backdate the diagnosis). For cases diagnosed at autopsy, enter the date of death. If diagnosis date is not known, see [Section III.3.3.3](#).

Beginning in 2009, diagnosis and treatment dates for a fetus prior to birth are to be assigned the actual date of the event. In the past, those dates were set by rule to the date the baby was born.

Consult with your software vendor for specific data entry instructions.

### III.3.3.1 Coding Dates

For cases diagnosed January 1, 2010 and forward, or following installation of CSv2 software, see [Section I.1.6.4](#) and [Section I.1.6.5](#) for Coding and Entering Dates.

Consult with your software vendor for specific data entry instructions.

### III.3.3.2 Vague Dates

***Enter an approximate date when the exact date cannot be determined. At a minimum, a year of diagnosis is required for all analytic cases (Class of Case 00-22). The year of diagnosis must be known or estimated and cannot be blank or unknown. The date of first cancer directed therapy may be used as the date of diagnosis, if the therapy was initiated before definitive confirmation of the diagnosis. Documentation must be provided for the basis of the estimated date.***

### III.3.3.3 Approximation

***At a minimum, a year of diagnosis is required for all analytic cases (Class of Case 00-22). Use the date treatment was started if the patient receives a first course of treatment before a definitive diagnosis. Documentation must be provided for the basis of the estimated date.***

***Use the following coding procedures for estimating dates relating to diagnosis.***

#### ***ESTIMATING YEAR***

- ***Use whatever information is available to calculate the year.***
- ***Code the year of admission when there is no basis for estimation.***

<b><i>TERMS</i></b>	<b><i>CODE TO</i></b>
<b><i>Couple of years ago</i></b>	<b><i>Two years ago</i></b>

<i>Few years ago</i>	<i>Three years ago</i>
----------------------	------------------------

**ESTIMATING MONTH**

- o *Use whatever information is available to calculate the month.*
- o *Leave the month blank if there is no basis for approximation.*

<b>TERMS</b>	<b>CODE TO</b>
<i>Recently</i>	<i>Enter the month and year of admission, and unknown ("99") for the day. If patient was admitted during the first week of a month, enter the previous month.</i>
<i>Several months ago</i>	<i>Assume the case was first diagnosed <u>three months</u> before admission with the day unknown when the patient was not previously treated or if a course of treatment started elsewhere was continued at the reporting hospital.</i>
<i>Spring</i>	<i>Enter as April.</i>
<i>Summer</i>	<i>Enter as July.</i>
<i>Fall or Autumn</i>	<i>Enter as October.</i>
<i>Winter</i>	<i>Enter as December or January based on available information i.e. end/beginning of year.</i>
<i>Early in the year</i>	<i>Enter as January.</i>
<i>Middle of the year</i>	<i>Enter as July.</i>
<i>End of the year</i>	<i>Enter as December.</i>
<i>Late in the year</i>	<i>Enter as December.</i>

**III.3.3.4 Date of Diagnosis Flag**

*The date of diagnosis flag should only be used for non-analytic cases with an unknown month and year of diagnosis.*

**Codes**

12	Date of Diagnosis cannot be determined
Blank	Full or partial date recorded

**III.3.4 Place of Diagnosis**

If the case was not first diagnosed at the reporting hospital, enter whatever is known about the place of diagnosis:

Another Hospital	Enter the hospital's name, the city, and the state.
Physician Only	Enter physician's name and address. If the physician is on the reporting hospital's medical staff, also enter "Staff

	Physician."
Hospital and Physician Unknown	Enter name of city, state, or country where diagnosis was first made.
No Information Available	Enter "unknown."

### III.3.5 Class of Case

Class of Case is divided into two basic categories. Analytic cases (codes 00-22) are grouped according to the location of diagnosis and first course of treatment. Analytic cases are required to be abstracted by the CCR, as well as by accredited CoC facilities. These cases are included in treatment and survival analyses.

Nonanalytic cases include codes 30-49 and 99. The CCR requires that specific nonanalytic cases be abstracted by the reporting facility. See [Section 1.1.6](#) for specific CCR reportability requirements. The facility's Cancer Committee may also direct reporting of nonanalytic cases. Nonanalytic cases are not required to be abstracted by the CoC and are not included in treatment and survival analyses.

CODES	DEFINITION
<b>ANALYTIC CLASSES OF CASE</b>	
<b>INITIAL DIAGNOSIS AT REPORTING FACILITY</b>	
00	Initial diagnosis at the reporting facility AND all treatment or a decision not to treat was done elsewhere <i>Note: Beginning in 2010, Class of Case 00 includes cases diagnosed by the facility that are treated in physician offices, as well as, cases when it is known that the patient went elsewhere for treatment. Facility Referred To must be documented.</i>
10	Initial diagnosis at the reporting facility or in a staff physician's* office AND all or part of first course treatment or a decision not to treat was at the reporting facility, NOS
11	Initial diagnosis in a staff physician's* office AND part of first course treatment was done at the reporting facility
12	Initial diagnosis in a staff physician's* office AND all first course treatment or a decision not to treat was done at the reporting facility
13	Initial diagnosis at the reporting facility AND part of first course treatment was done <b>elsewhere</b>
14	Initial diagnosis at the reporting facility AND all first course treatment or a decision not to treat was done at the reporting facility
<b>INITIAL DIAGNOSIS ELSEWHERE, FACILITY INVOLVED IN FIRST COURSE THERAPY</b>	
20	Initial diagnosis elsewhere AND all or part of first course treatment was done at the reporting facility, NOS

21	Initial diagnosis elsewhere AND part of first course treatment was done <b><i>elsewhere</i></b>
22	Initial diagnosis elsewhere AND all first course of treatment or a decision not to treat was done at the reporting facility
<b>NON-ANALYTIC CLASSES OF CASE</b>	
<b>PATIENT APPEARS IN PERSON AT REPORTING FACILITY; BOTH INITIAL DIAGNOSIS AND TREATMENT ELSEWHERE</b>	
30	Initial diagnosis and all first course treatment elsewhere AND reporting facility participated in diagnostic workup
31	Initial diagnosis and all first course treatment provided elsewhere AND reporting facility provided in-transit care
32	Diagnosis AND all first course treatment provided elsewhere AND patient presents at reporting facility with disease recurrence or persistence <i>Example: A patient with active disease admitted for other medical condition</i>
33	Diagnosis AND all first course treatment provided elsewhere AND patient presents at reporting facility with disease history only <i>Note: Not required to be reported to the CCR.</i>
34	Type of cases not required by CoC to be accessioned AND initial diagnosis AND all or part of first course treatment by reporting facility <i>Cases required to be reported and followed by the CCR in this category include:</i> <ul style="list-style-type: none"> <li>• <i>Benign and borderline intracranial/CNS tumors diagnosed 1/1/2001 - 12/31/2003 only Note: For cases diagnosed on or after 1/1/04 when these diagnoses became nationally reportable, use Class of Case codes 00-22.</i></li> <li>• <i>Intraepithelial neoplasia grade III tumors as follows:</i> <ul style="list-style-type: none"> <li>○ <i>Anus (AIN III) cases, diagnosed 1/1/2001 forward</i></li> <li>○ <i>Vagina (VAIN III) cases, diagnosed 1/1/1992 forward</i></li> <li>○ <i>Vulva (VIN III) cases, diagnosed 1/1/1992 forward</i></li> </ul> </li> <li>• <i>Borderline ovarian tumors (see Section II.I.10 for specific histology codes), diagnosed 1/1/2001 forward Note: Effective 1/1/2010, active follow-up is no longer required for borderline ovarian cases diagnosed 1/1/2001 forward.</i></li> </ul>
35	Cases diagnosed before program's Reference Date AND initial diagnosis AND all or part of first course treatment by reporting facility
36	Type of cases not required by CoC to be accessioned AND initial diagnosis elsewhere AND all or part of first course treatment by reporting facility <i>Cases required to be reported and followed by the CCR in this category include:</i> <ul style="list-style-type: none"> <li>• <i>Benign and borderline intracranial/CNS tumors diagnosed 1/1/2001 - 12/31/2003 only Note: For cases diagnosed on or after 1/1/04 when these diagnoses became nationally reportable, use Class of Case codes 00-22.</i></li> <li>• <i>Intraepithelial neoplasia grade III tumors as follows:</i> <ul style="list-style-type: none"> <li>○ <i>Anus (AIN III) cases, diagnosed 1/1/2001 forward</i></li> <li>○ <i>Vagina (VAIN III) cases, diagnosed 1/1/1992 forward</i></li> <li>○ <i>Vulva (VIN III) cases, diagnosed 1/1/1992 forward</i></li> </ul> </li> <li>• <i>Borderline ovarian tumors (see Section II.I.10 for specific histology</i></li> </ul>

	<i>codes), diagnosed 1/1/2001 forward Note: Effective 1/1/2010, active follow-up is no longer required for borderline ovarian cases diagnosed 1/1/2001 forward.</i>
37	Cases diagnosed before program's Reference Date AND initial diagnosis elsewhere AND all or part of first course treatment by reporting facility
38	Initial diagnosis established by autopsy at the reporting facility, cancer not suspected prior to death
<b>PATIENT DOES NOT APPEAR IN PERSON AT REPORTING FACILITY</b>	
40	Diagnosis AND all first course treatment given at the same staff physician's* office
41	Diagnosis AND all first course treatment given in two or more different staff physician* offices
42	Nonstaff physician, clinic or other facility, not part of reporting facility, accessioned by reporting facility for diagnosis and/or treatment by that entity (for example, hospital abstracts cases from an independent radiation facility)
43	Pathology or other lab specimens only
49	Death certificate only
<b>UNKNOWN RELATIONSHIP TO REPORTING FACILITY</b>	
99	Nonanalytic case of unknown relationship to facility

*\* A staff physician is a physician who is employed by the reporting facility, under contract with it, or a physician who has routine practice privileges there.*

### III.3.6 Type of Reporting Source

A one-digit code represents the source of information about the patient's neoplasm. Codes are arranged in the order of the precedence of the sources, with a hospital record first. Code this field in the following priority order: 1, 2, 8, 4, 3, 5, 6, 7. The codes are:

1	HOSPITAL INPATIENT/MANAGED HEALTH PLANS WITH COMPREHENSIVE, UNIFIED MEDICAL RECORDS
2	RADIATION TREATMENT CENTERS OR MEDICAL ONCOLOGY CENTERS (HOSPITAL-AFFILIATED OR INDEPENDENT)
3	LABORATORY, hospital or private (e.g., pathology specimen only)
4	PRIVATE MEDICAL PRACTITIONER
5	NURSING HOME, CONVALESCENT HOSPITAL, OR HOSPICE
6	AUTOPSY ONLY (neoplasm discovered and diagnosed for the first time as a result of an autopsy—see Section III.3.5)
7	DEATH CERTIFICATE ONLY
8	OTHER HOSPITAL OUTPATIENT UNITS/SURGERY CENTERS

Note: For Class 40 and 41 cases, enter code 1 for reporting source and code 2 for type of admission.

### III.3.7 Type of Admission



Enter one of the following codes representing the type(s) of admission at the reporting hospital during the four months after the patient was seen there for the first time.

1	INPATIENT ONLY
2	OUTPATIENT ONLY
3*	TUMOR BOARD ONLY
4*	PATHOLOGY SPECIMEN ONLY
5	INPATIENT AND OUTPATIENT
6	INPATIENT AND TUMOR BOARD
7	OUTPATIENT AND TUMOR BOARD
8	INPATIENT, OUTPATIENT, AND TUMOR BOARD
9	UNKNOWN (may appear in archival files but is not entered by hospitals)

\*See [Section I.1.6](#) Reporting, Required Method of Reporting Guide

### III.3.8 Casefinding Source

Determine where the case was first identified, and enter the appropriate code. However, if a hospital and a non-hospital source identified the case independently of each other, enter the code for the non-hospital source (i.e., codes 30-95 have priority over codes 10-29).

If the case was first identified at a cancer reporting facility (codes 10-29), code the earliest source of identifying information.

Case first identified at cancer reporting facility:

10	REPORTING HOSPITAL, NOS
20	PATHOLOGY DEPARTMENT REVIEW (surgical pathology reports, autopsies, or cytology reports)
21	DAILY DISCHARGE REVIEW (daily screening of charts of discharged patients in the medical records department)
22	DISEASE INDEX REVIEW (review of disease index in the medical records department)
23	RADIATION THERAPY DEPARTMENT/CENTER
24	LABORATORY REPORTS (other than pathology reports, code 20)
25	OUTPATIENT CHEMOTHERAPY
26	DIAGNOSTIC IMAGING/RADIOLOGY (other than radiation therapy, code 23; includes nuclear medicine)
27	TUMOR BOARD
28	HOSPITAL REHABILITATION SERVICE OR CLINIC
29	OTHER HOSPITAL SOURCE (including clinic, NOS or outpatient department, NOS)

Case first identified by source other than a cancer reporting facility:

30	PHYSICIAN INITIATED CASE (e.g., CMR)
----	--------------------------------------

40	CONSULTATION ONLY OR PATHOLOGY ONLY REPORT (not abstracted by reporting hospital)
50	PRIVATE PATHOLOGY LABORATORY REPORT
60	NURSING HOME INITIATED CASE
70	CORONER'S OFFICE RECORDS REVIEW
75	MANAGED CARE ORGANIZATION (MCO) OR INSURANCE RECORDS
80	DEATH CERTIFICATE FOLLOW BACK (case identified through death clearance)
85	OUT-OF-STATE CASE SHARING
90	OTHER NON REPORTING HOSPITAL SOURCE
95	QUALITY CONTROL REVIEW (case initially identified through quality control activities of a regional registry or the CCR)
99	UNKNOWN

If a death certificate, private pathology laboratory report, consultation only report from a hospital, or other report was used to identify a case that was then abstracted from a different source, enter the code for the source that first identified the case, not the source from which it was abstracted. If the regional registry or CCR identifies a case and asks a reporting facility to abstract it, enter the code specified by the regional registry or CCR.

### III.3.9 Payment Source (Primary and Secondary) and Payment Source Text

These data items have been added for hospital-based registrars to collect payment information on their cancer patients at the time of diagnosis. It consists of three fields, one for recording the primary source of payment, one for recording the secondary source of payment, and a 40-character alphanumeric field for collecting the specific name of the payment source, i.e., Foundation Health Plan, Blue Shield, etc.

The primary payment source and text fields are required and may not be left blank. Record the primary payer from the information available at diagnosis.

When the primary payer at diagnosis is unknown, record the information available during the initial treatment period.

Enter the secondary payment source if it is available in the medical record.

The CCR has adopted the codes and definitions used by the American College of Surgeons. The codes are the same for both fields and are as follows:

Code	Label	Definition
01	NOT INSURED	Patient has no insurance and is declared a charity write-off.
02	NOT INSURED, SELF PAY	Patient has no insurance and is declared responsible for charges.
10	INSURANCE, NOS	Type of insurance unknown or other than the types listed in codes 20, 21, 31, 35, 60–68.
20	PRIVATE INSURANCE: MANAGED CARE, HMO,	An organized system of prepaid care for a group of enrollees usually within a defined geographic area.

California Cancer Reporting System Standards, Volume I

	OR PPO	Generally formed as one of four types: a group model, an independent physician association (IPA), a network, or a staff model. "Gate-keeper model" is another term for describing this type of insurance.
21	PRIVATE INSURANCE: FEE-FOR SERVICE	An insurance plan that does not have a negotiated fee structure with the participating hospital. Type of insurance plan not coded as 20.
28	HMO	California specific code
29	PPO	California specific code
31	MEDICAID	State government administered insurance for persons who are uninsured, below the poverty level, or covered under entitlement programs. Medicaid other than described in code 35.
35	MEDICAID ADMINISTERED THROUGH A MANAGED CARE PLAN	Patient is enrolled in Medicaid through a Managed Care program (for example, HMO or PPO). The Managed Care plan pays for all incurred costs.
60	MEDICARE WITHOUT SUPPLEMENT, MEDICARE, NOS	Federal government funded insurance for persons who are 62 years of age or older, or are chronically disabled (Social Security insurance eligible). Not described in codes 61, 62, or 63.
61	MEDICARE WITH SUPPLEMENT, NOS	Patient has Medicare and another type of unspecified insurance to pay costs not covered by Medicare.
62	MEDICARE - ADMINISTERED THROUGH A MANAGED CARE PLAN	Patient is enrolled in Medicare through a Managed Care plan (for example, HMO or PPO). The Managed Care plan pays for all incurred costs
63	MEDICARE WITH PRIVATE SUPPLEMENT	Patient has Medicare and private insurance to pay costs not covered by Medicare.
64	MEDICARE WITH MEDICAID ELIGIBILITY	Federal government Medicare insurance with State Medicaid administered supplement.
65	TRICARE	Department of Defense program providing supplementary civilian-sector hospital and medical services beyond a military treatment facility to military dependents, retirees, and their dependents. Formally CHAMPUS (Civilian Health and Medical Program of the Uniformed Services).
66	MILITARY	Military personnel or their dependents who are treated at a military facility.
67	VETERANS AFFAIRS	Veterans who are treated in Veterans Affairs facilities.
68	INDIAN/PUBLIC HEALTH SERVICES	Patient who receives care at an Indian Health Service facility or at another facility, and the medical costs are reimbursed by the Indian Health Service. Patient receives care at a Public Health Service facility or at another facility, and medical costs are reimbursed by the Public Health Service.

89	COUNTY FUNDED, NOS	California specific code
99	INSURANCE STATUS UNKNOWN	It is unknown from the patient's medical record whether or not the patient is insured.

NOTE: Codes 28-HMO, 29-PPO and 89-County Funded, NOS are California specific codes. Effective with 2004 cases, codes 28-HMO and 29-PPO are converted to code 20-Managed Care, for submission to standard setting agencies. Effective with 2006 cases, code 89-County Funded, NOS, is converted to code 31-Medicaid for submission to standard setting agencies.

### III.3.10 Reporting Facility Referred From

If the diagnosis was made before admission (diagnosed PTA), enter the CCR assigned reporting facility code for the other facility at which the patient was previously seen for the disease.

[Reporting facilities in alphabetic order.](#)

[Reporting facilities in code order.](#)

### III.3.11 Reporting Facility Referred To

If the patient is seen at another hospital or other facility for specialized cancer treatment or any other cancer-related reason after admission to the reporting hospital, enter the facility's name or CCR assigned reporting facility code.

[Reporting facilities in alphabetic order.](#)

[Reporting facilities in code order.](#)

### III.3.12 Physicians

Each hospital must maintain its own roster of physicians and their code or NPI numbers. The non-NPI numbers codes are based on the physicians' California license numbers.

As physicians who treat cancer patients join the hospital staff, they must be added to the roster with their license or NPI numbers. If the license number is unavailable, assign a temporary number, beginning it with the letter X to differentiate it from regular codes. When the license number becomes available, update the files as soon as possible.

#### III.3.12.1 Physician License Numbers

State physician's license numbers are nine characters.

For license numbers less than eight characters, insert zero(s) after the first alpha character. For handling a nine-character number, enter the alpha character and drop the first zero.

For dentists, the same instructions apply.

For osteopaths, add a leading O (alpha character) and then enter the entire eight-character code . For handling a nine-character number, drop the zero after O2.

**Examples:**

Physician - A23456 would be entered A0023456

Dentist - D00056789 would be entered D0056789

Osteopath - O20A4422 would be entered O20A4422 or for nine digit O20A44222 would be entered O2A44222

**NOTE:** It is important to note that the first character of the osteopath license is an alpha character and the third character is a zero.

Facilities may enter out-of-state license numbers. The first character must be an X. If this number is less than seven characters, insert zeroes between the X and the license number.

**III.3.12.2 Entering Physician NPI Codes**

**January 1, 2007 Forward**

Beginning with cases diagnosed January 1, 2007, if available, enter the physician NPI code, in the respective field. See [Appendix X](#) for further details.

The managing physician field may not be blank.

- If there is no managing physician, or the managing physician cannot be determined, the code for "unknown physician" or "license number not assigned" (99999999) must be entered.
- If the managing physician is the same as another physician, (i.e., the medical oncologist) the license number must be entered in both places.

Use the following codes for Surgeon, Radiation Oncologist, and Medical Oncologist:

**Surgeon**

00000000	No surgery and no surgical consultation performed
88888888	Non - surgeon performed procedure
99999999	Physician is unknown or an identification number is not assigned.

**Radiation Oncologist**

00000000	No radiation therapy or radiation therapy consult performed
99999999	Physician is unknown or an identification number is not assigned.

**Medical Oncologist**

00000000	No chemotherapy or chemotherapy consult was performed
----------	---

99999999	Physician is unknown or an identification number is not assigned.
----------	---

Additional Physicians are designated by their role in the case, i.e. referring, consulting, and other.

For instructions regarding Follow-Up Physician, see [Section VII.2.10](#).

### III.3.13 Comorbidity/Complications

Enter the patient's preexisting medical conditions, factors influencing health status, and/or complications during the patient's hospital stay for the treatment of the cancer. These factors may affect treatment decisions and influence outcomes.

Although data collection for these fields is not required by the CCR, Comorbidity/Complications 1-10 will be collected from CoC facilities. Comorbidity/Complications fields 7-10 were added in 2006. Refer to the [FORDS Manual Revised for 2010](#) for instructions.

### III.3.14 ICD Revision, Comorbidities and Complications

This item indicates the coding system from which the *Comorbidities and Complications* (secondary diagnoses) codes are provided. *ICD Revision Comorbidities and Complications* is to be recorded for patients diagnosed on or after January 1, 2006. This data item is not required by the CCR, but it is required for ACoS approved facilities. The CCR will collect this data item from ACoS approved facilities only.

ICD Revision Comorbidity and Complications codes are as follows:

0	No secondary diagnosis reported
1	ICD - 10
9	ICD - 9
Blank	Comorbidities and Complications not collected

### III.3.15 Discovered By Screening

This field has been added for the purpose of tracking which cancer cases were first diagnosed via screening programs. If this information is not available, the field may be left blank.

This item is an existing optional data item as part of the Department of Defense Data Set and will be collected and transmitted from facilities completing the Department of Defense Data Set.

This item is not required by the CCR.

#### Codes

0	No (discovered by some other method such as symptomatic patient)
1	Routine screening exam (e.g. routine screening mammogram in asymptomatic

	patient)
2	Hospital screening program (targeted to a particular cancer)
3	State-sponsored screening program
4	Nationally-sponsored screening program
5	Other type of screening (e.g., American Cancer Society screening project)
9	Unknown if via screening (default)

## PART IV. DIAGNOSTIC PROCEDURES

### IV.1 Diagnostic Procedures Performed

The purpose of the information is to provide as complete a description as possible of a patient's tumor and the extent to which it has spread.

Report the results of physical examinations and diagnostic procedures for all analytic cases and for autopsy only (class 38) cases.

Reporting diagnostic procedures is optional for non-analytic cases, however record a brief statement of the patient's history and the reason for the present admission in the Physical Exam text area.

#### IV.1.1 General Instructions

Following installation of CSv2 software, text fields have been expanded to 1000 characters, however, only pertinent text should be entered. Text must support **all** coded data items and must be entered in a clear and concise manner.

In the text fields for recording the results of diagnostic examinations, enter all pertinent findings, negative as well as positive, in chronological order. Enter the date first, then the name of each procedure, then the results and other pertinent information. Do not record details unrelated to cancer. Use standard medical abbreviations when possible to save space.

See [Appendix M.1](#) for common acceptable abbreviations in alphabetical order.

See [Appendix M.2](#) for common acceptable abbreviations in numerical order.

Enter text for both site and histology in the fields designated.

##### IV.1.1.1 Location

When recording location as the results of diagnostic examinations, record where the tumor is located in the primary site, such as the lobe, quadrant, etc.

##### IV.1.1.2 Tumor Size

For cases diagnosed January 1, 2010 and forward, or following installation of CSv2 software, refer to [Collaborative Stage Data Collection System Coding Instructions](#).

### **January 1, 2004 and Forward**

For cases diagnosed January 1, 2004 and forward, apply the Collaborative Staging rules for documenting tumor size.

#### **IV.1.1.3 Extension**

For cases diagnosed January 1, 2010 and forward, or following installation of CSv2 software, refer to [Collaborative Stage Data Collection System Coding Instructions](#).

### **January 1, 2008 and Forward**

For cases diagnosed January 1, 2008 forward, apply the Collaborative Staging rules and guidelines for documenting tumor extension.

#### **IV.1.1.4 Lymph Nodes**

For cases diagnosed January 1, 2010 and forward, or following installation of CSv2 software, refer to the [Collaborative Stage Data Collection System Coding Instructions](#) for rules and guidelines for documenting lymph node involvement.

### **January 1, 2008 and Forward**

For cases diagnosed January 1, 2008 forward, apply the Collaborative Staging rules and guidelines for documenting lymph node involvement.

## **IV.1.2 Physical Examination**

Record the dates of the patient's physical examinations and all findings about the presence or absence of neoplasm, particularly the location of the primary tumor, its size, the extent to which it has spread, and involvement of lymph nodes.

### **IV.1.3 X-Ray/Scans**

When recording X-Rays or Scans, enter dates and pertinent positive and negative results of X-rays, computerized axial tomography (CT- or CAT-scans), magnetic resonance imaging (MRI), echosonography, and other imaging.

If a metastatic series is reported, record the results of each study in the series. Enter a description of the primary tumor, including size, location, and whether or not multi-focal.

Enter "none" if no X-rays or scans were performed.

### **IV.1.4 Scopes**

Record dates and positive and negative findings of laryngoscopies, sigmoidoscopies, mediastinoscopies, and other endoscopic procedures.

Include mention of biopsies, washings, and other procedures performed during the examinations, but enter their results in the Pathology section.

Record size of an observed lesion, if given.



Enter "none" if no endoscopic examination was performed.

### **IV.1.5 Laboratory Tests**

Laboratory tests and tumor markers recorded in CSv2 site specific factor fields must be documented in the laboratory text field by using the actual name of the test. Do not use "SSF 1-25" to identify the test. Documentation includes date, test type, value, and interpretation (elevated, borderline or normal).

Enter dates, names, and results of laboratory tests or procedures used in establishing the diagnoses of neoplasms or metastases, such as serum protein electrophoresis for multiple myeloma or Waldenstrom's macroglobulinemia, serum alpha fetoprotein (AFP) for liver cancer, and other tumor marker studies.

Record T-and B-cell marker studies on leukemias and lymphomas, but enter hematology reports for leukemia and myeloma under Pathology.

In leukemia cases where both bone marrow and chromosomes are analyzed, the bone marrow results take precedence in coding histologic type, unless more specific information is given in the cytogenetic report. See [Section IV.2](#).

Subcategories of acute myeloid leukemia are described according to cytogenetic abnormalities. If these abnormalities are included in a laboratory report, they take precedence in coding histologic type.

The chromosome study or cytogenetic and molecular biological data results can be recorded here. Enter "none" if no pertinent laboratory tests were performed.

Document the date, test type, value and interpretation (elevated, borderline or normal) of any pertinent tumor markers or lab tests in the lab text field.

### **IV.1.6 Operative Findings**

Record dates, names, and relevant findings of diagnostic surgical procedures, such as biopsies, dilation and curettage (D & C), and laparotomy.

For definitive surgery entered under treatment, record pertinent findings. See Sections VI.2.1 through VI.2.9.

Record tumor size, if given, and any statements about observed nodes, even if they are not involved.

### **IV.1.7 Pathology**

In the pathology text area, enter the source of the specimen(s), size of the largest tumor, and other details needed per the following list:

- Describe the location of the primary site or sub-site and laterality of the primary tumor. See [Section V.1](#) and [Section V.2](#).

- Record the histologic diagnosis and identify the appropriate ICD-O-3 code. See [Section V.3.2](#) and [Section V.3.3](#).
- Describe multiple tumors and multiple sites of origin.
- Document the extent of disease and stage at diagnosis. See [Section V.4.1](#) and [Section V.4.2](#).
- Describe the number of lymph nodes examined and the number positive for cancer.
- Determine the method of diagnosis or confirmation.
- Identify all specimens examined microscopically.

Record all tumor related gross (non-microscopic) and microscopic cytologic and histologic finding whether positive or negative, and include differentiation. If additional space is needed, continue the pathology text in the Staging Text field.

For details about microscopic diagnoses, see [Section IV.2](#).

For grade and differentiation, see [Section V.3.5](#).

If there is a pathology report, all the Path Report fields must be completed. If the medical record only includes "hearsay" information or the physician only refers to a report finding, but there is no report in the medical record, do not complete the Path Report fields, but include the information in the text field.

Enter the facility ID number, dates, report types, and pathology numbers.

See Path Report Facility (1-5) [Section IV.4.1](#), Path Report Numbers (1-5) [Section IV.4.2](#), Path Date Specimen Collected (1-5) [Section IV.4.3](#), and Path Report Type (1-5) [Section IV.4.4](#).

### **IV.1.7.1 Pathology Report Number - Biopsy/FNA - Obsolete in 2008**

This data item became obsolete with the implementation of DXRX Report Number, January 1, 2008.

### **IV.1.7.2 Pathology Report Number - Surgery - Obsolete in 2008**

This data item became obsolete with the implementation of DXRX Report Number, January 1, 2008.

## **IV.2 Diagnostic Confirmation**

A gauge of the reliability of histologic and other data is the method of confirming that the patient has cancer.

Coding for the confirmation field is in the order of the conclusiveness of the method with the lowest number taking precedence over other codes. The most conclusive method, microscopic analysis of tissue, is therefore coded as

1, while microscopic analysis of cells, the next most conclusive method, is coded as 2.

Medical records must be studied to determine what methods were used to confirm the diagnosis of cancer. The most conclusive method should be coded in the confirmation field. As the confirmation field covers the patient's entire medical history in regard to the primary tumor, follow-up data might change the coding. The codes, in the order of their conclusiveness, are:

### **Microscopic Confirmation**

#### **1 POSITIVE HISTOLOGY**

Use for microscopic confirmation based on biopsy, including punch biopsy, needle biopsy, bone marrow aspiration, curettage, and conization. Code 1 also includes microscopic examination of frozen section specimens and surgically removed tumor tissue, whether taken from the primary or a metastatic site. In addition, positive hematologic findings regarding leukemia and NRHD are coded 1. Cancers first diagnosed as a result of an autopsy or previously suspected and confirmed in an autopsy are coded 1 if microscopic examination is performed on the autopsy specimens.

#### **2 POSITIVE CYTOLOGY, NO POSITIVE HISTOLOGY**

Cytologic diagnoses based on microscopic examination of cells, rather than tissue. Do not use code 2 if cancer is ruled out by a histologic examination.

Included are sputum, cervical, and vaginal smears; fine needle aspiration from breast or other organs; bronchial brushings and washings; tracheal washings; prostatic secretions; gastric, spinal, or peritoneal fluid; and urinary sediment. Also include diagnoses based on paraffin block specimens from concentrated spinal, pleural, or peritoneal fluid.

#### **3 POSITIVE HISTOLOGY PLUS**

Positive immunophenotyping AND/OR positive genetic studies

Note: Code 3 was adopted for use effective with 2010 diagnoses. Use only for hematopoietic and lymphoid neoplasms 9590/3-9992/3.

#### **4 POSITIVE MICROSCOPIC CONFIRMATION, METHOD NOT SPECIFIED**

Cases with a history of microscopic confirmation, but no information about whether based on examination of tissue or cells.

### **No Microscopic Confirmation**

#### **5 POSITIVE LABORATORY TEST OR MARKER STUDY**

Clinical diagnosis of cancer based on certain laboratory tests or marker studies that are clinically diagnostic for cancer. Examples are the presence of alpha fetoprotein (AFP) for liver cancer and an abnormal electrophoretic spike for multiple myeloma or Waldenstrom's macroglobulinemia. Although an elevated PSA is nondiagnostic of cancer, if the physician uses the PSA as a basis for diagnosing prostate cancer with no other workup, record as code 5.

- 6 **DIRECT VISUALIZATION WITHOUT MICROSCOPIC CONFIRMATION**  
Includes diagnoses by visualization and/or palpation during surgical or endoscopic exploration, or by gross autopsy. Do not use code 6 if visualization or palpation during surgery or endoscopy is confirmed by a positive histology or cytology report.
- 7 **RADIOGRAPHY WITHOUT MICROSCOPIC CONFIRMATION**  
Includes all diagnostic radiology, scans, ultrasound, and other imaging technologies not confirmed by a positive histologic or cytologic report or by direct visualization.
- 8 **CLINICAL DIAGNOSIS ONLY (Other than 5, 6, or 7)**  
Cases diagnosed by clinical methods other than direct visualization and/or palpation during surgery, endoscopy, or gross autopsy, if not confirmed microscopically.

### **IV.3 DXRX Report Identifier Data Items-Obsolete in 2010**

Refer to IV.4.1 Path Report Facility (1-5), IV.4.2 Path Report Numbers (1-5), IV.4.3 Path Date Specimen Collected (1-5), and IV.4.4 Path Report Type (1-5).

See [Section IV.4.1](#)

See [Section IV.4.2](#)

See [Section IV.4.3](#)

See [Section IV.4.4](#)

#### **IV.3.1 DXRX Report Facility ID (1-5) - Obsolete in 2010**

This data item became obsolete with the implementation of Path Reporting Facility ID 1-5 [Section IV.4.1](#), January 1, 2010.

#### **IV.3.2 DXRX Report Number (1-5) - Obsolete in 2010**

This data item became obsolete with the implementation of Path Report Numbers 1-5 [Section IV.4.2](#), January 1, 2010.

#### **IV.3.3 DXRX Report Date (1-5) - Obsolete in 2010**

This data item became obsolete with the implementation of Path Date Spec Collect 1-5 [Section IV.4.3](#), January 1, 2010.

#### **IV.3.4 DXRX Report Type (1-5) - Obsolete in 2010**

This data item became obsolete with the implementation of Path Report Type 1-5 [Section IV.4.4](#), January 1, 2010.

#### **IV.3.5 Text - Staging**

This text field can be used to document additional staging and diagnostic workup information. Text information that supports the Path Report data items (1-5) should be listed here, identifying each report by using the R1- R5

designation. Each path report must be identified in the text field as R1 - R5 with R1 referencing Path Report 1, R2 referencing Report 2, etc.

As a reminder, record the text for each pathology report type (see the Path Report Type listing, [IV.4.4 Path Report Type \(1-5\)](#) in the Path Text field. If additional space is necessary, continue the text documentation in the Text - Staging field. Path Reports other than each Path report must be identified in the text field as R1 - R5 with R1 referencing Path Report 1, R2 referencing Report 2, etc.

#### **IV.4.1 Path Reporting Facility (1-5) (NEW)**

For cases diagnosed January 1, 2010 and forward, or following installation of CSV2 software, this data item identifies the pathology facility that produced the report. Enter the reporting facility's CCR assigned reporting facility code. This data item replaces CCR data item, DXRX Report Facility ID, and is a required.

[Reporting facilities in alphabetic order.](#)

[Reporting facilities in code order.](#)

#### **IV.4.2 Path Report Numbers (1-5) (New)**

For cases diagnosed January 1, 2010 and forward, or following installation of CSV2 software, this data item is a unique sequential number assigned by a laboratory to the corresponding pathology report for the case. This data item replaces CCR data item, DXRX Report Number, and is required.

#### **IV.4.3 Path Date Specimen Collected (1-5) (New)**

For cases diagnosed January 1, 2010 and forward, or following installation of CSV2 software, this data item collects the date and time of the specimen collection for the cancer being reported, not the date read or date the report was typed. This data item replaces CCR data item, DXRX Report Date, and is required.

Enter the date and, if available, the time the specimen was collected.

#### **IV.4.4 Path Report Type (1-5) (New)**

For cases diagnosed January 1, 2010 and forward, or following installation of CSV2 software, this data item describes the type of report transmitted to the cancer registry and may need to be classified at the central cancer registry. This data item accommodates information for only one path report. If additional path reports were prepared, enter the path report type(s) in Path Report Type 2 through Path Report Type 5. This data item is required by the CCR.

Consult your software vendor for specific data entry instructions.

01	Pathology
----	-----------

California Cancer Reporting System Standards, Volume I

02	Cytology
03	Gyn Cytology
04	Bone Marrow (biopsy/aspirate)
05	Autopsy
06	Clinical Laboratory Blood Work, NOS
07	Tumor Marker (p53, CD's Ki, CEA, HER2/neu, etc.)
08	Cytogenetics
09	Immunohistochemical Stains
10	Molecular Studies
11	Flow Cytometry, Immunophenotype
98	Other
99	Unknown

## PART V. TUMOR DATA

### V.1 Primary Site

It is essential to identify the original (primary) site of a tumor rather than a metastatic (secondary) site.

- Identify the primary site by careful scrutiny of all reports in the patient's medical record.
- Where information in the record is conflicting, statements in the pathology report generally take precedence over other statements.
- If the record does not provide a clear answer, ask the patient's physician.
- If the only information available is the secondary site, then it should be reported in accordance with the instructions in [Section V.1.3](#).

#### V.1.1 ICD-O Coding

The Primary Site field codes are found in the topography section of ICD-O\*.

In the ICD-O index, the site is indicated by a three-digit number preceded by a "C".

In the topography section, the first two digits stand for the part of the body and the third digit for a specific area in the part. Listings are arranged in the numerical order of the three digits. When entering the code, omit the period following the second digit.

#### Examples

(1) All entries under lung have the first three characters C34, followed by a final digit indicating the subsite:

C34 BRONCHUS AND LUNG

C34.0 Main bronchus

Carina

Hilus of lung

C34.1 Upper lobe, lung

Lingula of lung

Upper lobe, bronchus

C34.2 Middle lobe, lung

Middle lobe, bronchus

C34.3 Lower lobe, lung

Lower lobe, bronchus

C34.8 Overlapping lesion of lung or bronchus

C34.9 Lung, NOS (not otherwise specified)

Bronchus, NOS  
Bronchiole  
Bronchogenic  
Pulmonary, NOS

A computerized axial tomographic (CT or CAT) scan of a patient's chest revealed a large malignancy in the upper lobe of the left lung. The correct ICD-O-2 code is therefore C34.1, which should be entered C341.

(2) The site cardia of the stomach (the part of the stomach at the opening of the esophagus) is listed in the ICD-O-2 index under "cardia" or "stomach, cardia" as T-C16.0, which should be entered C160.

Code the last digit of the primary site code to '8' when a single tumor overlaps an adjacent subsite(s) of an organ and the point of origin cannot be determined.

#### Examples

The patient has a 5 cm tumor that involves the dorsal surface and anterior 2/3 of the tongue.

Code the primary site to C028 (overlapping lesion of tongue).

Code the last digit of the primary site code to '9' for single primaries, when multiple tumors arise in different subsites of the same anatomic site, unless the subsite is defined in one of the site groups listed in the SEER Site Grouping Table. Refer to the SEER Site Grouping Table in the section entitled "How to Determine Same vs Different Primary Site" to determine the primary site code for specified site groups.

During a TURB, the physician describes multiple papillary tumors in the bladder neck (C675) and the lateral wall of the bladder (C672). Code the primary site as bladder, NOS (C679).

Patient has an infiltrating duct tumor in the upper outer quadrant (C504) of the right breast and another infiltrating duct carcinoma in the lower inner (C503) quadrant of the right breast. Code the primary site as breast, NOS (C509).

For Primary Site coding rules:

See [Section V.1.2](#) Identification of Separate Sites

See [Section V.1.3](#) Indefinite and Metastatic Sites

See [Section V.1.4](#) Special Conditions



See [Section V.1.5](#) Site-Specific Morphology

See [Section V.1.6](#) Uncertain Diagnoses

## V.1.2 Identification of Separate Sites

### For Cases Diagnosed January 1, 2007 and Forward

Beginning with cases diagnosed January 1, 2007 forward, the 2007 Multiple Primary and Histology Rules must be used to determine the number of primaries. Do not apply these rules to cases diagnosed prior to January 1, 2007. Refer to the [2007 Multiple Primary and Histology Coding Rules Manual](#) for details and instructions.

When determining multiple primaries for solid malignant tumors, do not use a physician's statement to decide whether the patient has a recurrence of a previous cancer or a new primary. Use the multiple primary rules as written unless a pathologist compares (slide review) the present tumor to the "original" tumor and states that this tumor is a recurrence of a cancer from the previous primary.

**This does not apply to metastatic tumors.**

In applying MP/H rules, tumor recurrences only relate to the organ of origin. Metastatic tumors in regional and distant site are not considered tumor recurrences when applying the MP/H rules.

See [Section VII.2.12](#)

## V.1.3 Indefinite and Metastatic Sites

Assign codes from the following categories only when the primary site cannot be identified exactly:

### NOS

Use NOS (not otherwise specified) subcategory when a subsite or tissue of an organ is not specifically listed in ICD-O-3. Do not use NOS if a more descriptive term is available.

### Codes C76.0 - C76.8

Use these codes for diagnoses referring to regions and ill defined sites of the body, such as "head", "thorax", "abdomen", "pelvis", "upper limb," and "lower limb". These sites typically contain several types of tissue (e.g., bone, skin, soft tissue), which might not be specified on the diagnostic statement. If the tissue in which the tumor originated can be identified, use a more specific site code.

### Code C80.9

Use this code when the primary site is not known and the only information available is the metastatic, or secondary site.

## V.1.4 Special Conditions

For leukemia and lymphoma cases diagnosed January 1, 2010 and forward, or following installation of CSv2 software, please refer to the [2010 Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual and the Hematopoietic Database](#).

Special rules apply to the following tumors:

### **Subareolar/Retroareolar Tumor**

Code as the central portion of the breast (C50.1), which indicates that the tumor arose in the breast tissue beneath the nipple, but not in the nipple itself.

### **Ductal And Lobular Breast Lesions**

See [Section II.1.3.4](#) for a discussion of certain mixed ductal and lobular lesions of the female breast. If these lesions occur in different quadrants of the same breast, the site code is C50.9.

### **Melanoma**

If the primary site is unknown, assume the primary site is the skin and enter C44.9.

Unless it is stated to be a recurrent or metastatic melanoma, record each melanoma as a separate primary when any of the following apply:

- The occurrences are more than two months apart
- The fourth character of the ICD-O topography code for skin (C44. \_) is different
- The first three digits of the ICD-O-3 morphology code are different
- An in situ melanoma is followed by an invasive melanoma
- The occurrences are within the same sub-site code, but different lateralities or different trunk sides, such as chest and back

### **Neuroblastoma**

Code neuroblastomas of ill defined sites for the most likely site in each case. (Adrenal medulla is a common site.) If the location of the primary tumor is unknown, code as connective, subcutaneous, and other soft tissue, NOS (C49.9).

### **Kaposi's Sarcoma**

Code the primary site as the site in which the tumor arises. If Kaposi's sarcoma arises in the skin and another site simultaneously, or if no primary site is stated, code the primary site as skin (C44. \_).

### **Familial Polyposis**

When multiple carcinomas arising in familial polyposis involve multiple segments of the colon or the colon and rectum, code the primary site as colon, NOS (C18.9).

## Colon

If there is no other information given regarding subsite except for the measurement given in the colonoscope, the measurement may be used to assign subsite. If the colonoscope measurement is used to assign a specific subsite, the CCR's standard reference is the colon diagram in the *AJCC Cancer Staging Manual, 5<sup>th</sup> Edition*, page 85. A copy of this diagram is also available in DSQC Memo 2000-04, page 2. (Note, select DSQC Memo 2000-04 from the 2004 folder that will be visible in the Historical DSQC Memo interactive book.)

If there is conflicting information in the medical record with regard to subsite and there is no surgical resection, code the subsite as stated by the physician. If there is a surgical resection, code the subsite as stated in the operative report, or a combination of the operative report and the pathology report.

### V.1.5 Site-Specific Morphology

Certain types of neoplasms arise only or usually in certain organs, such as hepatoma (the liver), nephroblastoma (the kidney), retinoblastoma (the retina).

If the diagnosis in the medical record refers only to the histologic type, look it up in the ICD-O-3 index. In instances of site-specific morphology, the index refers to a topographic code. Enter that code if no site is specified in the diagnosis, or if only the metastatic site is given.

#### Example:

The code C22.0 (liver) is given after listings in the ICD-O-3 index for hepatoma, NOS; hepatoma, benign; hepatoma, embryonal; and hepatoma, malignant.

If the site designated by a physician is different from the site referred to in the ICD-O-3 index, report the site specified by the physician.

### V.1.6 Uncertain Diagnoses

Vague or ambiguous terms are sometimes used by physicians when indicating the primary site of a tumor. Interpretation of terms in this context is like their interpretation in a diagnosis of cancer itself. See [Section II.1.6.1](#).

Interpret the following terms as indication of the primary site:

- Apparently (malignant)
- Appears to
- Comparable with
- Compatible with (a malignancy)

Consistent with (a malignancy)  
Favor (a malignancy)  
Malignant appearing  
Most likely (malignant)  
Presumed (malignant)  
Probable (malignancy)  
Suspect or suspected (malignancy)  
Suspicious (of malignancy)  
Typical (of/for malignancy)

Do not interpret the following terms as indication of the primary site:

Approaching (malignancy)  
Cannot be ruled out  
Equivocal (for malignancy)  
Possible (malignancy)  
Potentially malignant  
Questionable (malignancy)  
Rule out (malignancy)  
Suggests (malignancy)  
Very close to (malignancy)  
Worrisome (for malignancy)

### **V.1.7 Multiple Primaries Related Data Items**

For cases diagnosed January 1, 2007 and forward, apply the [2007 Multiple Primary and Histology Coding Rules](#) to code the following fields:

- Ambiguous Terminology
- Date of Conclusive Diagnosis
- Multiplicity Counter
- Date of Multiple Tumors
- Multiple Tumor Reported as a Single Primary

Leave these fields blank for cases diagnosed prior to January 1, 2007.

See [Section V.1.7.1](#) Ambiguous Terminology Diagnosis

See [Section V.1.7.2](#) Date of Conclusive Diagnosis

See [Section V.1.7.3](#) Multiplicity Counter

See [Section V.1.7.4](#) Date of Multiple Tumors

### V.1.7.1 Ambiguous Terminology Diagnosis

#### January 1, 2007 Forward

Beginning with cases diagnosed January 1, 2007 and forward, this data item identifies all cases, including DCO and autopsy only cases which are reportable based only on ambiguous terminology. Ambiguous terms that are considered reportable include the following:

- Apparent(ly)
- Appears (effective with cases diagnosed 1/1/1998 and later)
- Comparable with (effective with cases diagnosed 1/1/1998 and later)
- Compatible with (effective with cases diagnosed 1/1/1998 and later)
- Consistent with
- Favor(s)
- Malignant appearing (effective with cases diagnosed 1/1/1998 and later)
- Most likely
- Presumed
- Probable
- Suspect(ed)
- Suspicious (for)
- Typical (of)
- Definitions

**Ambiguous terminology** - Terms that have been mandated as reportable when used in a diagnosis. For more details, see [Section II.1.6](#).

#### Examples:

Clinical: a physician’s statement that the patient most likely has lung cancer.

Laboratory tests: A CBC suspicious for leukemia.

Pathology: A prostate biopsy compatible with adenocarcinoma.

**Conclusive terminology** - A clear and definite statement of cancer. The statement may be from a physician (clinical diagnosis); or may be from a laboratory test, autopsy, cytologic findings, and/or pathology.

Ambiguous Terminology Diagnosis Codes:

Code	Description	Timeframe
0	<b>Conclusive term.</b> There was a conclusive diagnosis within 60 days of the original diagnosis. Case was accessioned based on conclusive terminology. Includes all diagnostic methods such as clinical diagnosis, cytology, pathology, etc.	Within 60 days of the date of initial diagnosis.
1	<b>Ambiguous term only.</b> The case was accessioned based	Not

	only on ambiguous terminology. There was no conclusive terminology during the first 60 days following the initial diagnosis. Includes all diagnostic methods except cytology. Note: Cytology is excluded because registrars are not required to collect cases with ambiguous terms describing a cytology diagnosis.	Applicable
2	<b>Ambiguous term followed by conclusive term.</b> The case was originally assigned a code 1 (was accessioned based only on ambiguous terminology). More than 60 days after the initial diagnosis the information is being updated to show that a conclusive diagnosis was made by any diagnostic method including clinical diagnosis, cytology, pathology, autopsy, etc.	60 days or more after the date of diagnosis
9	<b>Unknown term.</b> There is no information about ambiguous terminology.	Not Applicable

1. Use Code 0 when a case is accessioned based on conclusive terminology. The diagnosis includes clear and definite terminology describing the malignancy within 60 days of the original diagnosis.

Note: Usually the patient undergoes a diagnostic work-up because there is a suspicion of cancer (ambiguous terminology). For example, a mammogram may show calcifications suspicious for intraductal carcinoma; the date of the mammogram is the date of initial diagnosis. When there is a clear and definite diagnosis within 60 days of that mammogram (date of initial diagnosis) such as the pathology from an excisional biopsy showing intraductal carcinoma, assign a code 0.

2. Use Code 1 when a case is accessioned based on ambiguous terminology and there is no clear and definite terminology used to describe the malignancy within 60 days of the date of initial diagnosis. The diagnosis may be from a pathology report, a radiology report, an imaging report, or on the medical record.

3. Use Code 2 when a case is accessioned based on ambiguous terminology followed by clear and definite terminology more than 60 days after the initial diagnosis.

4. Follow-back to a physician or subsequent readmission (following the initial 60 days period) may eventually confirm cancer (conclusive cancer term more than 60 days after ambiguous term). Assign Code 2.

5. Leave this data item blank for cases diagnosed prior to 01/01/2007.

Cases accessioned based on ambiguous terminology (Code 1) should be excluded from case selection in research studies. Direct patient contact is not recommended. See [2007 Multiple Primary and Histology Coding Rules](#).

### V.1.7.2 Date of Conclusive Diagnosis

For cases diagnosed January 1, 2010 and forward, or following installation of CSv2 software, see [Section I.1.6.4](#) and [Section I.1.6.5](#) for Coding and Entering Dates.

Enter the date a definite statement of malignancy is made following an initial diagnosis based on ambiguous terminology only. The date of conclusive diagnosis must be greater than 60 days following the initial (ambiguous terminology only) diagnosis.

Note: If the date of conclusive diagnosis is made after 60 days, change the code for the data item "Ambiguous Terminology" from 1 to 2 and enter the date that the malignancy was described clearly and definitely in Date of Conclusive Terminology.

Consult with your software vendor for specific data entry instructions.

See [2007 Multiple Primary and Histology Coding Rules Manual](#).

### V.1.7.2.1 Date of Conclusive Diagnosis Flag

For cases diagnosed January 1, 2010 and forward, or following installation of CSV2 software, this data item is used to explain why there is no appropriate value in the corresponding date field. Since only actual known dates are entered in interoperable date items, flags are used to explain the reason the date field is blank. Depending on the registry software being used, these changes may be transparent to the registrar.

#### Codes

10	Unknown if based on ambiguous terminology
11	Date cannot be determined, diagnosed originally or within 60 days using unambiguous terminology
12	Date cannot be determined, diagnosed using ambiguous terminology, conclusively diagnosed > 60 days later
15	Diagnosed using ambiguous terminology, no conclusive diagnosis followed
Blank	Full or partial date recorded

### V.1.7.3 Multiplicity Counter

Code the number of tumors being abstracted as a single primary at the time of diagnosis or the number of reportable tumors that occur within one year of the original diagnosis reported as a single primary using the 2007 SEER Multiple Primary and Histology Coding Rules. Do not count metastasis.

When there is a tumor or tumors with separate single or multiple foci, ignore/do not count the foci.

Change code from 01 to 02 when a second tumor is determined to be the same primary as the first tumor within one year of the initial date of diagnosis. Leave this field blank for cases diagnosed prior to January 1, 2007.

Use code 01 when:

- There is a single tumor in the primary site being abstracted.
- There is a single tumor with separate foci of tumor.

- It is unknown if there is a single tumor or multiple tumors and the multiple primary rules instructs you to default to a single tumor.

Use code 88 for:

- Leukemia
- Lymphoma
- Immunoproliferative disease
- Unknown primary

Use code 99 when:

- The original pathology report is not available and the documentation does not specify whether there was a single or multiple tumors in the primary site.
- The tumor is described as multifocal or multicentric and the number of tumors is not mentioned.
- The tumor is described as diffuse or disseminated.
- The operative or pathology report describes multiple tumors but does not give an exact number.

Multiplicity Counter Codes:

<b>00</b>	<b><i>NO PRIMARY IDENTIFIED</i></b>
01	ONE TUMOR ONLY
02	TWO TUMORS PRESENT
03	THREE TUMORS PRESENT
"	
"	
88	INFORMATION ON MULTIPLE TUMOR NOT COLLECTED/NOT APPLICABLE FOR THIS SITE
<b>89</b>	<b><i>MULTICENTRIC, MULTIFOCAL, NUMBER UNKNOWN</i></b>
99	MULTIPLE TUMORS PRESENT, UNKNOWN HOW MANY, <b><i>DIFFUSE, DISSEMINATED</i></b>

See [2007 Multiple Primary and Histology Coding Rules Manual](#).

### V.1.7.4 Date of Multiple Tumors

For cases diagnosed January 1, 2010 and forward, or following installation of CSv2 software, see [Section I.1.6.4](#) and [Section I.1.6.5](#) for Coding and Entering Dates.

Enter the date the patient is diagnosed with multiple tumors reported as a single primary using the 2007 SEER Multiple Primary and Histology Coding Rules.

Enter the Date of Diagnosis as the Date of Multiple Tumors when multiple reportable tumors are abstracted and reported as a single primary at the time of the initial diagnosis.



Change the code from zeros (00000000) to the date that the second tumor was diagnosed when the second tumor is determined to be the same primary as the first tumor and both are abstracted as a single primary.

Multiple tumors must have the same histology as the original tumor and must be located in the same organ or primary site as the original tumor, using the primary site and histology coding rules.

The Date of Multiple Tumors must occur within one year following the initial/first diagnosis of the reported tumor.

Consult with your software vendor for specific data entry instructions.

See [2007 Multiple Primary and Histology Coding Rules Manual](#).

#### **V.1.7.4.1 Date of Multiple Tumors Flag**

For cases diagnosed January 1, 2010 and forward, or following installation of CSV2 software, this data item is used to explain why there is no appropriate value in the corresponding date field. Since only actual known dates are entered in interoperable date items, flags are used to explain the reason the date field is blank.

Depending on the registry software being used, these changes may be transparent to the registrar.

#### **Codes**

11	Multiple tumors not collected for this site/histology
12	Date cannot be determined, but known to be multiple tumors
15	Single tumor
Blank	Full or partial date recorded

#### **V.1.7.5 Type of Multiple Tumors Reported as a Single Primary**

Code the type of multiple tumors that are abstracted as a single primary using the [2007 Multiple Primary and Histology Coding Rules Manual](#).

Multiple tumors found in the same organ or in a single primary site may occur at the time of initial diagnosis or within one year of the initial diagnosis. Ignore metastatic tumors for this data item.

#### **January 1, 2007 and Forward**

For cases diagnosed on or after January 1, 2007, change this code from 00 to another code when subsequent tumor(s) are determined to be the same primary as the first tumor and are abstracted as a single primary, within one year of the initial diagnosis.

## **V.2 Laterality**

Because topographic codes do not distinguish between the right and left side of a paired site - such as the lung - the location (laterality) of a primary

tumor must be recorded. The main purpose is to identify the origin of the tumor.

See [Section V.2.1](#) Coding (Laterality)

See [Section V.2.2](#) Principal Paired Sites

See [Section V.2.3](#) Site Coding Restriction

## V.2.1 Coding (Laterality)

Code numbers for recording laterality are:

0 NOT A PAIRED SITE

1 RIGHT SIDE ORIGIN OF PRIMARY

2 LEFT SIDE ORIGIN OF PRIMARY

3 ONE SIDE ONLY INVOLVED, BUT RIGHT OR LEFT SIDE ORIGIN NOT SPECIFIED

4 BOTH SIDES INVOLVED, BUT ORIGIN UNKNOWN (including bilateral ovarian primaries of the same histologic type, diagnosed within two months of each other; bilateral retinoblastomas; and bilateral Wilms' tumors)

5 PAIRED SITE, MIDLINE TUMOR

9 PAIRED SITE, BUT NO INFORMATION AVAILABLE CONCERNING LATERALITY

Never use code 4 for bilateral primaries for which separate abstracts are prepared or when the side of origin is known and the tumor has spread to the other side.

### Example:

A left ovarian primary with metastases to the right ovary is code 2, rather than code 4.

For malignant and benign/borderline brain and CNS tumors, effective with cases diagnosed January 1, 2004 forward, the following sites require a laterality code using codes 1- 5 or 9:

C70.0 Cerebral meninges, NOS

C71.0 Cerebrum

C71.1 Frontal lobe

C71.2 Temporal lobe

C71.3 Parietal lobe

C71.4 Occipital lobe

C72.2 Olfactory nerve

C72.3 Optic nerve

C72.4 Acoustic nerve

C72.5 Cranial nerve, NOS

All other CNS/brain subsites of C70, C71, and C72 are coded Laterality = 0 (not a paired organ) regardless of the date of diagnosis. All pituitary and pineal gland and craniopharyngeal duct tumors (C75.1-3) are coded Laterality = 0 (not a paired site).

All primary brain and CNS tumors diagnosed prior to January 1, 2004, are coded Laterality = 0 (not a paired site).

## V.2.2 Principal Paired Sites

Laterality codes of 1, 2, 3, 4, 5 or 9 must be entered for certain parts of the body. The requirement includes any subsite, except those specifically noted. Enter those exclusions as 0 (not a paired site).

ICD-O-3 codes and sites for which laterality codes must be entered are:

C07.9 Parotid gland

C08.0 Submandibular gland

C08.1 Sublingual gland

C09.0 Tonsillar fossa

C09.1 Tonsillar pillar

C09.8 Overlapping lesion of tonsil

C09.9 Tonsil, NOS

C30.0 Nasal cavity—*excluding nasal cartilage, nasal septum*

C30.1 Middle ear

C31.0 Maxillary sinus

C31.2 Frontal sinus

C34.0 Main bronchus—*excluding carina*

C34.1-C34.9 Lung

C38.4 Pleura, NOS

C40.0 Upper limb long bones, scapula

C40.1 Upper limb short bones

C40.2 Lower limb long bones

C40.3 Lower limb short bones

C41.3 Rib, clavicle—*excluding sternum*

C41.4 Pelvic bones—*excluding sacrum, coccyx, symphysis pubis*

## California Cancer Reporting System Standards, Volume I

- C44.1 Eyelid skin
- C44.2 External ear skin
- C44.3 Skin of other and unspecified parts of face
- C44.5 Trunk skin
- C44.6 Upper limb and shoulder skin
- C44.7 Lower limb and hip skin
- C47.1 Peripheral nerves and autonomic nervous system of upper limb and shoulder
- C47.2 Peripheral nerves and autonomic nervous system of lower limb and hip
- C49.1 Connective, subcutaneous, and other soft tissues of upper limb and shoulder
- C49.2 Connective, subcutaneous, and other soft tissues of lower limb and hip
- C50.0-C50.9 Breast
- C56.9 Ovary
- C57.0 Fallopian tube
- C62.0 C62.9 Testis
- C63.0 Epididymis
- C63.1 Spermatic cord
- C64.9 Kidney, NOS
- C65.9 Renal pelvis
- C66.9 Ureter
- C69.0-C69.9 Eye and adnexa
- C70.0 Cerebral meninges, NOS (excluding diagnoses prior to 2004)
- C71.0 Cerebrum (excluding diagnoses prior to 2004)
- C71.1 Frontal lobe (excluding diagnoses prior to 2004)
- C71.2 Temporal lobe (excluding diagnoses prior to 2004)
- C71.3 Parietal lobe (excluding diagnoses prior to 2004)
- C71.4 Occipital lobe (excluding diagnoses prior to 2004)
- C72.2 Olfactory nerve (excluding diagnoses prior to 2004)
- C72.3 Optic nerve (excluding diagnoses prior to 2004)
- C72.4 Acoustic nerve (excluding diagnoses prior to 2004)
- C72.5 Cranial nerve, NOS (excluding diagnoses prior to 2004)
- C74.0-C74.9 Adrenal gland

C75.4 Carotid body

### V.2.3 Site Coding Restrictions

#### From January 1/1/2004 and Forward

From January 1, 2004 and forward, the Laterality field must only be coded for sites listed in Volume I, [Section V.2.2](#) including benign and malignant CNS tumors. All other non-paired sites, including unknown primaries, must be coded to 0.

#### Prior to January 1, 2004

Prior to 1/1/2004, completion of this field was optional for sites not listed in Section V.2.2.

## V.3 Histology, Behavior, and Differentiation

The five digit histology field consists of two parts:

1. The morphology, or cell type, of the primary tumor (first four digits).
2. The tumor's behavior - that is, the degree of malignancy or how the tumor can be expected to eventually behave.

A separate one digit differentiation code represents the grade, or degree of differentiation, of neoplastic tissue-that is, the extent to which cells have the specialized characteristics of a particular tissue or organ.

In general, the less differentiated the cells, the more aggressive the tumor.

### V.3.1 ICD-O

#### January 1, 2001 and Forward (ICD-O-3)

The CCR has adopted the ICD-O-3 (*International Classification of Diseases for Oncology*, Third Edition, 2000) Morphology section as its official morphology code system for all cases diagnosed January 1, 2001 forward.

#### Prior to January 1, 2001 (ICD-O-2)

Cases diagnosed prior to January 1, 2001, must be coded using the *International Classification of Diseases for Oncology*, Second Edition, 1990 (ICD-O-2).

Note: Although ICD-O-3 is referenced in coding site and histology throughout this document, unless otherwise noted, these statements apply to ICD-O-2 coding also.

### V.3.2 ICD-O Coding

Coding for the histologic type and behavior consists of the five digits in the morphology section of ICD-O. In the ICD-O index the codes are preceded by the letter "M". The first three digits of the ICD-O code represent the histologic type. The fourth digit represents a subtype.

#### Example

Synovial-Like Neoplasms has the general code 904\_. Listed under synovial-like neoplasms are:

9040/3 Synovial sarcoma, NOS  
9041/3 Synovial sarcoma, spindle cell  
9042/3 Synovial sarcoma, epithelioid cell  
9043/3 Synovial sarcoma, biphasic  
9044/3 Clear cell sarcoma, except of kidney

Morphology listings in ICD-O also include as the fifth digit the usual behavior code. For circumstances in which other behavior codes are to be entered, see [Section V.3.4](#). For differentiation codes, see [Section V.3.5](#). When entering the ICD-O code, drop the slash following the fourth digit.

ICD-O-3 contains new morphology terms and synonyms, terms that changed morphology code from ICD-O-2, terms that changed from tumor-like lesions to neoplasms, and terms that changed behavior code. ICD-O-3 also deleted and/or replaced terms.

### V.3.3 Histologic Type

Histology is the study of the minute structure of cells, tissues, and organs in relation to their functions. It is primarily through histological analysis that neoplasms are identified. Determination of the correct histology code can be one of the most difficult aspects of abstracting. Training and experience are essential for development of the ability to assign the correct code. The rules are taken from the SEER Program. They provide guidance, but no set of rules can cover all situations.

#### January 1, 2007 and Forward

Beginning with cases diagnosed January 1, 2007, the [2007 Multiple Primary and Histology Rules Manual](#) must be used to determine histologic type. Refer to the 2007 Multiple Primary and Histology Coding Rules Manual for details and instructions.

#### Prior to January 1, 2007

For cases diagnosed January 1, 2005 through December 31, 2006, apply the Multiple Primary and Histology Rules Manual as written in the SEER Program Coding and Staging Manual, 2004.

Ask the regional registry for advice when the rules do not seem to apply to a case or when their application results in a code that seems incorrect. In addition, it is always appropriate to ask for advice about coding from a pathologist or clinician familiar with the case. Document in a text field, every source of information used.

#### V.3.3.1 Sources for Determining Histology

For hematopoietic and lymphoid cases diagnosed January 1, 2010 and forward, or following installation of CSv2 software, please refer to the [2010 Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual and the Hematopoietic Database](#).

### **January 1, 2007 and Forward**

For cases or tumors diagnosed after January 1, 2007, refer to the [2007 Multiple Primary and Histology Coding Rules Manual](#) to determine histology.

#### **V.3.3.2 Basic Rule**

For hematopoietic and lymphoid cases diagnosed January 1, 2010 and forward, or following installation of CSv2 software, please refer to the [2010 Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual and the Hematopoietic Database](#).

### **January 1, 2007 and Forward**

Before attempting to code histology, determine whether the case involves a single primary or multiple primaries.

For cases diagnosed January 1, 2007 and forward, refer to the [2007 Multiple Primary and Histology Coding Rules Manual](#).

See [Section II.1.3](#).

#### **V.3.3.3 Variations in Terminology**

For hematopoietic and lymphoid cases diagnosed January 1, 2010 and forward, or following installation of CSv2 software, please refer to the [2010 Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual and the Hematopoietic Database](#).

### **January 1, 2007 and Forward**

For cases diagnosed January 1, 2007 and forward, refer to the [2007 Multiple Primary and Histology Coding Rules Manual](#).

#### **V.3.3.4 Unspecified Malignancies**

Enter the code for neoplasm (8000) for unspecified terms such as "malignant tumor," "malignant neoplasm", and "cancer". Do not use the code for a clinically malignant tumor that has not been microscopically confirmed (9990).

Use code 8001 (malignant cells, NOS), if a diagnosis is based only on a cytology report stating "malignant cells".

See also [Section IV.2](#).

#### **V.3.3.5 Metastatic Site**

### **January 1, 2007 and Forward**

Beginning with cases diagnosed January 1, 2007 and forward, the [2007 Multiple Primary and Histology Coding Rules Manual](#) must be used to determine histologic type. Do not apply these rules to cases diagnosed prior to January 1, 2007. Refer to the historic coding instructions.

#### **V.3.3.6 Leukemia and Lymphoma Codes**

For hematopoietic and lymphoid cases diagnosed January 1, 2010 and forward, or following installation of CSv2 software, please refer to the [2010](#)

[Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual and the Hematopoietic Database.](#)

### V.3.3.7 Special Cases

#### January 1, 2007 and Forward

Beginning with cases diagnosed January 1, 2007 and forward, the 2007 Multiple Primary and Histology Coding Rules Manual must be used to determine histologic type. Refer to the [2007 Multiple Primary and Histology Rules Manual](#) for details and instructions.

### V.3.4 Behavior

To code behavior, use the best information in the pathology report, regardless of whether it appears in the microscopic description, final diagnosis, or comments. If an AJCC staging form provides the best information, use it if the form is signed by a physician. ICD-O-3 assigns a behavior code as the fifth digit of the histology number following the slash. For example, in the number 8012/3 for large cell carcinoma, the 3 is the behavior code.

#### Codes

/0*	BENIGN
/1*	UNCERTAIN WHETHER BENIGN OR MALIGNANT
	BORDERLINE MALIGNANCY (except cystadenomas in the range 844-849)
	LOW MALIGNANT POTENTIAL
/2	CARCINOMA IN SITU
	Intraepithelial
	Non-infiltrating
	Non-invasive
/3	MALIGNANT, PRIMARY SITE
/6**	MALIGNANT, METASTATIC SITE
	MALIGNANT, SECONDARY SITE
/9**	MALIGNANT, UNCERTAIN WHETHER PRIMARY OR METASTATIC SITE

\* Not reportable to the California Cancer Registry, except for brain and CNS tumors, beginning with cases diagnosed January 1, 2001.

\*\* Reportable behavior, but enter code 3.

#### V.3.4.1 ICD-O/Pathology Conflicts

If there is a conflict between the behavior code specified by ICD-O for a histologic subtype and the behavior described by a pathologist in the final diagnosis, the pathologic diagnosis generally prevails. ICD-O codes only indicate the usual behavior.

#### V.3.4.2 In Situ Coding

The term "in situ" means a tumor that meets all microscopic criteria for malignancy, except invasion of basement membrane. For further discussion of "in situ", see [Section V.5.8](#).



"In situ" behavior can be determined only by pathologic examination and not by clinical evidence alone. If a tumor is classifiable as "in situ" according to the time period rules for stage at diagnosis see [Section V.5](#), code the tumor as "in situ". In other words, a behavior code of 2, "in situ", corresponds to a stage code of 0, "in situ" and vice versa. Computer and visual edits will verify that the codes in these two fields correspond. Do not interpret terms like "approaching in situ" or "very close to in situ" as "in situ".

Reportable terms indicating "in situ" behavior include:

AIN III (anal intraepithelial neoplasia, Grade II-III or III)\*\*

Bowen's Disease

DCIS (ductal carcinoma in situ)

DIN 3 (ductal intraepithelial neoplasia 3)\*\*

Clark's level 1 for melanoma (limited to epithelium)

Confined to epithelium

Hutchinson's melanotic freckle

Intracystic, non-infiltrating

Intraductal

Intraepidermal

Intraepithelial

Intrasquamous

Involvement up to but not including the basement membrane

LCIS (lobular carcinoma in situ)

Lentigo maligna

LIN (laryngeal intraepithelial neoplasia)\*\*

Lobular neoplasia, Grade III

No stromal invasion

Non-infiltrating

Non-invasive

PanIN-III (pancreatic intraepithelial neoplasia III)\*\*\*

Precancerous melanosis

Preinvasive

Queyrat's erythroplasia

Stage 0

VAIN III (vaginal intraepithelial neoplasia, Grade II-III or III)\*

VIN III (vulvar intraepithelial neoplasia, Grade II-III or III)\*

- \* Effective with cases diagnosed 1/1/1992 and later
- \*\* Effective with cases diagnosed 1/1/2001 and later
- \*\*\* Cases diagnosed January 2004 and later.

All other terms have been reportable since the region's reference date.

### **Not Reportable (Reminder)**

As a reminder, carcinoma "in situ" (including squamous cell and adenocarcinoma) of the cervix and Cervical Intraepithelial Neoplasia, CIN III, are not reportable effective with cases diagnosed January 1, 1996 and later. Prostatic Intraepithelial Neoplasia (PIN III), morphology code 8148/2 is also not reportable to the CCR.

### **V.3.4.3 Microinvasion**

Code a pathologic diagnosis of "microinvasive"--meaning the earliest stage of invasion--as malignant, not "in situ".

For the diagnosis of microinvasive squamous cell carcinoma, a common form of cervical cancer, use the morphology code provided by ICD-O-3, 8076/3.

### **V.3.5 Grade and Differentiation**

Code the grade, or degree of differentiation, as stated in the final pathologic diagnosis.

Do not code as "not stated" if there is a relevant statement in the microscopic description. If there is a difference in grade between two pathologic specimens, code a known grade over an unknown grade.

Exception: For noninvasive bladder tumor, assign code 9 (unknown) to the Grade field. This applies to only histology codes 8120/2 (Transitional cell (urothelial) carcinoma in situ and 8130/2 (Papillary transitional cell (papillary urothelial) noninvasive carcinoma). See DSQC Memo #2010-01.

A grade stated in a histopathology report takes precedence over one stated in a cytology report.

Information on an AJCC staging form may be used if the form is signed by a physician.

If a needle biopsy or excisional biopsy of a primary site has a differentiation given and the excision or resection does not, code the information from the needle/incisional biopsy. If there is no grade provided for the primary site, code as 9, even if a grade is given for a metastatic site.

Do not use FIGO grade to code differentiation. FIGO grade is something completely different from FIGO stage. If the only grade provided is a FIGO grade, code grade to 9, unknown.

When a patient receives neoadjuvant therapy, code the grade from the pathology report prior to neoadjuvant therapy. Code 9 (grade unknown) when the pathology is after neoadjuvant therapy or it is unknown whether the pathology is before or after neoadjuvant therapy.

The codes are:

1	Grade I grade i grade 1 Well differentiated Differentiated, NOS
2	Grade II grade ii grade 2 Moderately differentiated Moderately well differentiated Partially well differentiated Partially differentiated Intermediate differentiation Low grade, NOS
3	Grade III grade iii grade 3 Poorly differentiated Moderately undifferentiated Relatively undifferentiated Slightly differentiated Dedifferentiated Medium grade, NOS
4	Grade IV grade iv grade 4 Undifferentiated Anaplastic High grade, NOS
5**	T-Cell T-Precursor
6**	B-Cell Pre B B-Precursor
7**	Null Cell Non-T-Non-B
8**	NK (Natural Killer Cell)
9	Grade or Differentiation Not Determined or Not Stated

\*\*Apply to leukemias and lymphomas only. See Section [V.3.5.7](#).

See [Section II.1.9.7](#) WHO Grade

See [Section V.3.5.6](#) Gleason's Score

See [Section V.3.5.7](#) Lymphomas and Leukemias

See [Section V3.5.8](#) Bloom-Richardson Grade for Breast Cancer

See [Section V.3.5.9](#) Grading Astrocytomas

### V.3.5.1 Mixed Differentiation

If a diagnosis indicates different degrees of differentiation in the same neoplasm, enter the code with the highest number, even if it does not represent the majority of the neoplasm. This could include different degrees of differentiation between the biopsy and resection specimens.

#### Example:

The final diagnosis states predominantly grade II, focally grade III.

Code as grade III.

### V.3.5.2 Microscopic Description

If the final pathologic diagnosis states one degree of differentiation, while the microscopic description states another, enter the code for the final diagnosis.

#### Examples:

The microscopic description states moderately differentiated squamous cell carcinoma with poorly differentiated areas. The final diagnosis states moderately differentiated squamous cell carcinoma. Enter code 2 (8070/32).

But if the final pathologic diagnosis does not state the degree of differentiation, code the grade stated in the microscopic description.

The microscopic description states moderately differentiated squamous cell carcinoma with poorly differentiated areas.

The final diagnosis states squamous cell carcinoma. Enter code 3 (8070/33).

### V.3.5.3 Variation in Terms for Degree of Differentiation

Use the higher grade when different terms are used for the degree of differentiation as follows:

Term	Grade	Code
Low grade	I-II	2
Medium grade; intermediate grade	II-III	3
High grade	III-IV	4
Partially well differentiated	I-II	2
Moderately undifferentiated	III	3
Relatively undifferentiated	III	3

Occasionally a grade is written as "2/3" or "2/4" meaning this is grade 2 of a 3-grade system or grade 2 of a 4-grade system, respectively.

**To code in a three grade system,** refer to the following codes:

Histologic Grade	Nuclear Grade	Description	Code
------------------	---------------	-------------	------

<b>Histologic Grade</b>	<b>Nuclear Grade</b>	<b>Description</b>	<b>Code</b>
1/3, or I/III	1/2, 1/3	Low Grade	2
2/3, or II/III	2/3	Medium Grade	3
3/3, or III/III	2/2, 3/3	High Grade	4

To code in a two-grade system, refer to the following codes:

<b>Histologic Grade</b>	<b>Description</b>	<b>Code</b>
1/2, or I/II	Low Grade	2
2/2, or II/II	High Grade	4

See [Section V.3.5.11](#) Grade Path Value

See [Section V.3.5.12](#) Grade Path System

### **V.3.5.4 In Situ**

Medical reports ordinarily do not contain statements about differentiation of in situ lesions. But if a statement is made, enter the code indicated.

### **V.3.5.5 Brain Tumors**

Magnetic Resonance Imaging (MRI) or Positron Emission Tomography (PET) can sometimes establish the grade of a brain tumor.

If there is no tissue diagnosis, but grade or differentiation is stated in a MRI or PET report, base the grade code on the report.

However, if there is a tissue diagnosis, do not base the grade code on any other source.

### **V.3.5.6 Gleason's Score**

A special descriptive method, Gleason's Score, is used for prostate cancer. It is obtained by adding two separate numbers to produce a score in the range of 2 to 10. First, a number is assigned to the predominant (primary) pattern (i.e., the pattern that comprises more than half the tumor). Then a number is assigned to the lesser (secondary) pattern, and the two numbers are added to obtain Gleason's Score.

If only one number is stated, and it is 5 or less, assume that it represents the primary pattern. If the number is higher than 5, assume that it is the score. If there are two numbers, add them to obtain the score.

Sometimes, the number 10 is written after Gleason's Score to show the relationship between the actual score and the highest possible score (e.g., Gleason's 3/10 indicates a score of 3).

If a number is not identified as Gleason's, assume that a different grading system was used and code appropriately.

When both grade and Gleason's Score are provided in the same specimen, code the grade. When they are in different specimens, code to the highest grade.

If only Gleason's Score (2-10) is available, convert it to grade according to the following table:

Gleason's Score	Grade	Code
2, 3, 4	I	1
5, 6	II	2
7*, 8, 9, 10	III	3

\* The grade and code for Gleason's Score 7 were revised in 2003. See historic coding instructions for specific information.

Note: This grading system is coded in a site-specific factor for the applicable CS schema.

### V.3.5.7 Lymphomas and Leukemias

For hematopoietic and lymphoid cases diagnosed January 1, 2010 and forward, or following installation of CSv2 software, please refer to the [2010 Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual and Hematopoietic Database](#).

Note: This grading system is coded in a site-specific factor for the applicable CS schema.

### V.3.5.8 Bloom-Richardson Grade for Breast Cancer

Beginning with breast cancer cases diagnosed January 1, 1996, the Bloom-Richardson grading system should be used, if available.

Synonyms include: Modified Bloom-Richardson, Scarff-Bloom-Richardson, Nottingham, SBR Grading, BR Grading, Elston-Ellis modification of Bloom-Richardson grading system. This grading scheme is based on three morphologic features as follows:

- Degree of tumor tubule formation
- Tumor mitotic activity
- Nuclear pleomorphism of tumor cells (nuclear grade)

Seven possible scores are condensed into three Bloom-Richardson grades. The three grades then translate into well-differentiated (BR low grade), moderately differentiated (BR intermediate grade) and poorly differentiated (BR high grade).

Tumor tubule formation	Score
>75% of tumor cells arranged in tubules	1
>10% and <75%	2
<10%	3
Number of mitoses (low power scanning (X100), find most mitotically tumor area, proceed to high power (x400)	
<10 mitoses in 10 high-power fields	1
>10 and <20 mitoses	2

>20 mitoses per 10 high power fields	3
Nuclear pleomorphism (nuclear grade)	
Cell nuclei are uniform in size and shape, relatively small, have dispersed chromatin patterns, and are without prominent nucleoli	1
Cell nuclei are somewhat pleomorphic, have nucleoli, and are intermediate size	2
Cell nuclei are relatively large, have prominent nucleoli or multiple nucleoli, coarse chromatin patterns, and vary in size and shape	3

To obtain the final Bloom-Richardson (Nottingham) score, add score from tubule formation plus number of mitoses score, plus score from nuclear pleomorphism.

The combined score converts to the following BR grade:

Bloom-Richardson (Nottingham) combined scores	Differentiation/BR Grade	ICD-O-3 6th digit
3, 4, 5	Well-differentiated (BR low grade)	1
6, 7	Moderately differentiated (BR intermediate grade)	2
8, 9	Poorly differentiated (BR high grade)	3

There are coding rules and conventions to be used to code breast cancer cases. Use grade or differentiation information from the breast histology in the following priority order:

- Bloom-Richardson (Nottingham) scores 3-9 converted to grade (see conversion table below)
- Bloom-Richardson grade (low, intermediate, high)
- Nuclear grade only
- Terminology (well diff, mod diff...)
- Histologic grade (grade I, grade ii...)

Caution : In this grading system, the terms low, intermediate, and high are codes 1, 2, and 3 respectively. This is an exception to the usual rule for all other grading systems which code "low", "intermediate", and "high" as 2, 3, and 4 respectively. In the Bloom-Richardson system, if grades 1, 2, and 3 are specified, these should be coded 1, 2, and 3 respectively.

Bloom-Richardson (Nottingham) Scores	Bloom-Richardson Grade	Nuclear Grade	Terminology	Histologic Grade	Code
3- 5 points	Low Grade	1/3, 1/2	Well Differentiated	(BR low grade)	1
6, 7 points	Intermediate	2/3	Moderately	(BR intermediate	2

Bloom-Richardson (Nottingham) Scores	Bloom-Richardson Grade	Nuclear Grade	Terminology	Histologic Grade	Code
	Grade		differentiated	grade)	
8, 9 points	High Grade	2/2, 3/3	Poorly Differentiated	(BR high grade)	3

Note: This grading system is coded in a site-specific factor for the applicable CS schema.

### V.3.5.9 Grading Astrocytomas

ICD-O-3 rules are to be used for grading astrocytomas. The World Health Organization coding of aggressiveness is reserved for assignment of grade for staging. If there is no information on grade, code as follows:

Term	ICD-O-3 6th digit
Anaplastic astrocytoma	4
Astrocytoma (low grade)	2
Glioblastoma multiforme	9
Pilocytic astrocytoma	9
Astrocytoma Grade 1	1
Astrocytoma Grade 2	2
Astrocytoma Grade 3	3
Astrocytoma Grade 4	4

Note: This grading system is coded in a site-specific factor for the applicable CS schema.

### V.3.5.10 Fuhrman's Grade for Renal Cell Carcinoma January 1, 2004 and Forward

Effective with cases diagnosed January 1, 2004, the priority order for coding grade for renal cell carcinoma (site code C64.9) is as follows:

1. Fuhrman's grade
2. Nuclear grade
3. Terminology (well diff, moderately diff...)
4. Histologic grade (grade I, grade II...)

Fuhrman's grade is based on 3 parameters:

- Nuclear diameter: in microns
- Nuclear outline: regular or irregular
- Nucleoli (visibility): present or not and at what power (low or high power)



Fuhrman's grade (I-IV) is the sum of the points for all 3 parameters.

These prioritization rules do not apply to Wilm's tumor (morphology code 8960).

Note: This grading system is coded in a site-specific factor for the applicable CS schema.

### V.3.5.11 Grade Path System (New)

For cases January 1, 2010 and forward or following installation of CSv2 software, this data item records whether a two, three or four grade system was used in the pathology report to describe the grade. This item is used in conjunction with Grade Path Value. This data item is required by the CCR.

- Code this item from the same tissue as that used to code Grade/Differentiation. This item records how the original grade of the tumor was described.
- Code the value corresponding to the number of grades used in the grading system reported in the pathology report.

Leave the item blank if:

- Case is diagnosed prior to 2010.
- No pathological grade is available.
- Only a verbal description of grade is reported (for example, moderately differentiated).
- Another grading system is used in the pathology report. For example, do not report grading systems such as Bloom-Richardson for breast primaries, Fuhrman for kidney, Gleason for prostate, or WHO grade. Those grading systems are coded in a site-specific factor for the applicable CS schema.
- Case is a lymphoma or hematopoietic malignancy (9590-9992).

Note: This item and Grade Path Value should both be coded or both should be blank. If both are coded, Grade/Differentiation must not be 9.

Code	Definition
Blank	No 2, 3, or 4 grade system available. Unknown.
2	A 2-grade grading system was used (2, II or

	ii)
3	A 3-grade grading system was used (3, III or iii)
4	A 4-grade grading system was used (4, IV or iv)

See [Section V.3.5.8](#) Bloom-Richardson Grade for Breast Cancer.

See [Section V.3.5.10](#) Fuhrman's Grade for Renal Cell Carcinoma.

See [Section V.3.5.6](#) Gleason's Score.

See [Section V.3.5.7](#) Lymphoma and Leukemia grades.

See [Section V.3.5.9](#) Grading Astrocytomas.

**V.3.5.12 Grade Path Value (New)**

For cases January 1, 2010 and forward or following installation of CSv2 software, this data item records the numeric grade reported in the pathology report. This item supplements but does not replace Grade/Differentiation.

This data item is required by the CCR.

- Code this item from the same tissue as that used to code Grade/Differentiation. This item records how the original grade of the tumor was described.
- Code the value of the numeric grade from the pathology report if the Grade Path system was 2-4. Code the histologic grade in priority over a nuclear or architectural grade.
- Do not convert the terms well, moderately, or poorly differentiated, low/high, or anaplastic into codes in this field. Leave blank if that is all that is available.

Leave the item blank if:

- Case is diagnosed prior to 2010.
- Numeric grade is given, but the grading system is not stated (for example, Grade 1, with no information about the grade system).
- Another grading system is used in the pathology report. For example, do not report grading systems such as Bloom-Richardson for breast primaries, Fuhrman for kidney, Gleason for prostate, or WHO grade. Those grading systems are coded in a site-specific factor for the applicable CS schema.
- Case is a lymphoma or hematopoietic malignancy (9590-9992).

Note: This item and Grade Path System should both be coded or both should be blank. If both are coded, Grade/Differentiation must not be 9. Grade Path Value can never be larger than Grade Path System.

Code	Definition
Blank	No 2, 3, or 4 grade system available. Unknown.
1	Recorded as Grade I, i or 1 of a 2-4 grade system
2	Recorded as Grade II, ii or 2 of a 2-4 grade system

3	Recorded as Grade III, iii or 3 of a 3-4 grade system
4	Recorded as Grade IV, iv of a 4 grade system

See [Section V.3.5.8](#) Bloom-Richardson Grade for Breast Cancer.

See [Section V.3.5.10](#) Fuhrman's Grade for Renal Cell Carcinoma.

See [Section V.3.5.6](#) Gleason's Score.

See [Section V.3.5.7](#) Lymphoma and Leukemia grades.

See [Section V.3.5.9](#) Grading Astrocytomas.

## V.3.6 Edits of Primary Site/Histology Codes

Certain combinations of histology and primary site codes indicate errors in coding. The CCR data management system (Eureka) edit data and reject false combinations. False combinations (edit errors) must be corrected before the data management system can store the data and make it available for research.

Disallowed combinations are of two types:

- Those involving the first four digits of the histology field (morphology code).
- Those involving the behavior code (fifth digit of the histology field).

### V.3.6.1 Morphology/Site Codes

Some combinations of morphology and site codes are rejected because another site code more accurately reflects the tissue of origin. For example, a liposarcoma (8850/3) arising in the abdominal wall should be coded as site C49.4, soft tissues of abdomen, instead of C76.2, abdomen, NOS. Contact the regional or central registry for coding assistance, if required. Following are combinations of morphology and site codes that are rejected:

#### Morphology/Site Code

1. 8090-8096, Basal cell carcinomas, with
  - C00.\_ Lip
  - C19.9 Rectosigmoid
  - C20.9-C21.8 Rectum and anus
2. 8720-8790, Melanoma, with
  - C48.0 C48.8 Retroperitoneum/ peritoneum
  - C38.1 C38.8 Pleura and Mediastinum
  - C40.0-C41.9 Bone
  - C76.\_ Other and ill-defined sites
3. 8010-8671 Epithelial & with
  - C38.1-C38.8 Pleura and Mediastinum

- specialized gonadal
  - C40.0-C41.9\* Bone tumors
  - C47.0-C47.9 Peripheral Nerves
  - C49.0-C49.9 Soft Tissues
  - C70.0-C72.9 Brain and Other Nervous System
4. 8940–8941, Mixed tumors, with
- C38.1 C38.8 Pleura and Mediastinum
  - C40.0-C41.9\* Bone
  - C47.0-C47.9 Peripheral Nerves
  - C49.0-C49.9 Soft tissues
  - C70.0-C71.9 Brain
  - C72.\_ Other nervous system
  - C76.\_ Other and ill defined sites
- \*Site C40.0-C41.9 (bone) with histology 8070 (squamous cell carcinoma) is possible.
5. 9250 9340, Bone tumors, with
- C30.0-C31.9 Nasal cavity, sinuses
6. 8800-8811, 8813-8831, 8840-8920, 8990-8991, 9040-9044, 9120-9170, 9240-9251, 9540-9560, 9580-9581, Sarcomas and other soft-tissue tumors, with
- 76.\_ Other and ill defined sites
7. 9500 Neuroblastoma, NOS with C64.9 Kidney, NOS

### **V.3.6.2 Behavior/Site Codes**

Do not code in situ behavior with a primary site that is unknown or ill defined. Therefore, if the behavior code is 2 (in situ), the following primary site codes are rejected as errors:

- C26.9 Gastrointestinal tract, NOS
  - Alimentary tract, NOS
  - Digestive organs, NOS
- C39.9 Ill defined sites within respiratory system
  - Respiratory tract, NOS
- C55.9 Uterus, NOS
  - Uterine, NOS
- C57.9 Female genital tract, NOS
  - Female genital organs, NOS

- Female genitourinary tract, NOS
  - Urethrovaginal septum
  - Vesicocervical tissue
  - Vesicovaginal septum
- C63.9 Male genital organs, NOS
  - Male genital tract, NOS
  - Male genitourinary tract, NOS
- C68.9 Urinary system, NOS
- C72.9 Nervous system, NOS
  - Central nervous system
    - Epidural
    - Extradural
    - Parasellar
- C75.9 Endocrine gland, NOS
- C76.\_ Other and ill-defined sites
- C80.9 Unknown primary site

## **V.4 Coding Systems**

### **V.4.1 Extent of Disease**

Extent of Disease (EOD) coding applies to cases diagnosed prior to January 1, 2004. EOD staging was replaced by Collaborative Staging for cases diagnosed January 1, 2004 and forward.

### **V.4.2 Collaborative Stage Data Collection System**

For cases diagnosed January 1, 2010 and forward, or following installation of CSV2 software, CS Site-Specific Factor items (7-25) have been added to code additional site-specific information needed to derive TNM or AJCC stage, or to code prognostic factors that have an effect on stage or survival. This data item belongs to the Collaborative Stage (CS) Data Collection System. The Collaborative Stage Data Collection System is based on the AJCC Cancer Staging Manual, 6th and 7th editions.

The Collaborative Stage Data Collection System provides a single uniform set of codes and rules for coding extent of disease (EOD) and stage information to meet the needs of all of the participating standard setters. When CS data items are coded, a computer algorithm provides the derivation for T, N, M, and stage.

To code, see the most current version of the [Collaborative Stage Data Collection System Manual and Coding Instructions](#) for rules, site-specific codes, and coding structures.

Additional educational information is available in [Part 1- Section 2: Lab Tests, Tumor Markers and Site-Specific Factor Notes](#).

For CS SSF data items not required by the CCR, enter code 988. For CS SSF data items required by the CCR with an unknown value, enter code 999.

Refer to Volume 1, Appendix Y, for the list of CS Site-Specific Factors required by the CCR by schema.

The following CSv2 data items are required effective with cases diagnosed January 1, 2010 and forward:

- CS Extension
- CS Lymph Nodes
- Regional Nodes Positive
- Regional Nodes Examined
- CS Mets at Diagnosis
- CS Mets at DX Bone
- CS Mets at DX Brain
- CS Mets at DX Liver
- CS Mets at DX Lung
- CS Site Specific Factor 1
- CS Site Specific Factor 2
- CS Site Specific Factor 3
- CS Site Specific Factor 4
- CS Site Specific Factor 5
- CS Site Specific Factor 6
- CS Site Specific Factor 7
- CS Site Specific Factor 8
- CS Site Specific Factor 9
- CS Site Specific Factor 10
- CS Site Specific Factor 11
- CS Site Specific Factor 12
- CS Site Specific Factor 13
- CS Site Specific Factor 14
- CS Site Specific Factor 15
- CS Site Specific Factor 16
- CS Site Specific Factor 17
- CS Site Specific Factor 18
- CS Site Specific Factor 19
- CS Site Specific Factor 20
- CS Site Specific Factor 21
- CS Site Specific Factor 22

- CS Site Specific Factor 23
- CS Site Specific Factor 24
- CS Site Specific Factor 25
- CS Tumor Size/Extension Evaluation
- CS Lymph Node Evaluation
- CS Metastasis Evaluation
- CS Version Input Current
- Derived AJCC-7 T Descriptor
- Derived AJCC-7 T
- Derived AJCC-7 N Descriptor
- Derived AJCC-7 N
- Derived AJCC-7 M Descriptor
- Derived AJCC-7 M
- Derived AJCC-7 Stage Group

### **January 1, 2008 and Forward**

Although Collaborative Staging has been required by the CCR since 2004, effective with cases diagnosed January 1, 2008 and forward, SEER (and thus the CCR) expanded the requirement to also include the CS Evaluation fields. Thus the following CS fields are required effective with cases diagnosed January 1, 2008 and forward:

- CS Extension
- CS Lymph Nodes
- Regional Nodes Positive\*
- Regional Nodes Examined
- CS Mets at Diagnosis
- CS Site Specific Factor 1
- CS Site Specific Factor 2
- CS Site Specific Factor 3
- CS Site Specific Factor 4
- CS Site Specific Factor 5
- CS Site Specific Factor 6
- CS Tumor Size/Extension Evaluation
- CS Lymph Node Evaluation
- CS Metastasis Evaluation
- Derived AJCC T Descriptor
- Derived AJCC N Descriptor
- Derived AJCC M Descriptor

#### V.4.2.1 CS Mets at DX – Bone

For cases diagnosed January 1, 2010 and forward, or following installation of CSv2 software, CS Mets at DX - Bone identifies the presence of discontinuous or distant metastatic involvement of bone at time of diagnosis. This includes only bone, not bone marrow. This data item is required by the CCR.

The presence of metastatic bone disease at diagnosis is an independent prognostic indicator, and it is used by Collaborative Stage Data Collection System to derive TNM-M codes and SEER Summary Stage codes for some sites.

**Codes:**

0	No distant (discontinuous) metastases identified either clinically or pathologically, negative findings on imaging reports, or metastases other than bone identified
1	Distant (discontinuous) metastases identified clinically or pathologically, or if primary site is bone and there are metastases in different bone or bones.
8	CS Mets at DX is coded as 98 (not applicable for site). Not applicable sites include hematopoietic, reticuloendothelial, immunoproliferative and myeloproliferative neoplasms, Hodgkin and non-Hodgkin lymphoma, Kaposi sarcoma, other and ill-defined primary sites, unknown primary site.
9	CS Mets at Dx is coded to 99. There are known distant metastases but it is not known whether the distant metastases include bone.

For additional coding instructions refer to [Collaborative Stage Data Collection System Manual and Coding Instructions](#).

#### V.4.2.2 CS Mets at DX – Brain

For cases diagnosed January 1, 2010 and forward, or following installation of CSv2 software, CS Mets at DX - Brain identifies the presence of discontinuous or distant involvement of brain at time of diagnosis. This includes only the brain, not spinal cord or other parts of the central nervous system. This data item is required by the CCR.

The presence of metastatic brain disease at diagnosis is an independent prognostic indicator, and it is used by Collaborative Staging to derive TNM-M codes and SEER Summary Stage codes for some site.

**Codes:**

0	No distant (discontinuous) metastases identified either clinically or pathologically, negative findings on imaging reports, or metastases other than brain identified
1	Distant (discontinuous) metastases identified clinically or pathologically, <b>or if</b> primary site is brain and there are metastases within the brain.
8	CS Mets at DX is coded as 98 (not applicable for site). Not applicable sites include hematopoietic, reticuloendothelial, immunoproliferative and myeloproliferative neoplasms, Hodgkin and non-Hodgkin lymphoma, Kaposi sarcoma, other and ill-defined primary sites, unknown primary site.
9	CS Mets at Dx is coded to 99. There are known distant metastases but it is



	not known whether the distant metastases include brain.
--	---

For additional coding instructions refer to [Collaborative Stage Data Collection System Manual and Coding Instructions](#).

#### V.4.2.3 CS Mets at DX – Liver

For cases diagnosed January 1, 2010 and forward, or following installation of CSv2 software, CS Mets at DX identifies the presence of discontinuous or distant metastatic involvement of the liver at time of diagnosis and involvement may be single or multiple. This data item is required by the CCR.

The presence of metastatic liver disease at diagnosis is an independent prognostic indicator, and it is used by Collaborative Staging to derive TNM-M codes and SEER Summary Stage codes for some site.

##### Codes:

0	No distant (discontinuous) metastases identified either clinically or pathologically, negative findings on imaging reports, or metastases other than liver identified
1	Distant (discontinuous) metastases identified clinically or pathologically, <b>or if</b> primary site is liver and there are metastases within the liver.
8	CS Mets at DX is coded as 98 (not applicable for site). Not applicable sites include hematopoietic, reticuloendothelial, immunoproliferative and myeloproliferative neoplasms, Hodgkin and non-Hodgkin lymphoma, Kaposi sarcoma, other and ill-defined primary sites, unknown primary site.
9	CS Mets at Dx is coded to 99. There are known distant metastases but it is not known whether the distant metastases include liver.

For additional coding instructions refer to [Collaborative Stage Data Collection System Manual and Coding Instructions](#).

#### V.4.2.4 CS Mets at DX – Lung

For cases diagnosed January 1, 2010 and forward, or following installation of CSv2 software, CS Mets at DX identifies the presence of discontinuous or distant metastatic involvement of the lung at time of diagnosis. This includes only the lung, not pleura or pleural fluid. This data item is required by the CCR.

The presence of metastatic lung disease at diagnosis is an independent prognostic indicator, and it is used by Collaborative Staging to derive TNM-M codes and SEER Summary Stage codes for some site.

##### Codes

0	No distant (discontinuous) metastases identified either clinically or pathologically, negative findings on imaging reports, or metastases other than lung identified
1	Distant (discontinuous) metastases identified clinically or pathologically, <b>or if</b> primary site is lung and there are metastases within the lung.
8	CS Mets at DX is coded as 98 (not applicable for site). Not applicable sites

	include hematopoietic, reticuloendothelial, immunoproliferative and myeloproliferative neoplasms, Hodgkin and non-Hodgkin lymphoma, Kaposi sarcoma, other and ill-defined primary sites, unknown primary site.
9	CS Mets at Dx is coded to 99. There are known distant metastases but it is not known whether the distant metastases include lung.

For additional coding instructions refer to [Collaborative Stage Data Collection System Manual and Coding Instructions](#).

## V.5 Stage at Diagnosis

Stage at Diagnosis is a grouping of cases into broad categories, for example, localized, regional, and distant. This is different than Extent of Disease which is a detailed description of the spread of the disease from the site of origin.

### January 1, 2004 and Forward

Beginning with cases diagnosed January 1, 2004 and forward, the CCR requires the collection of Collaborative Staging (CS) data items necessary to derive AJCC T, N, M, Stage Group, Summary Stage 1977, and Summary Stage 2000.

### Prior to January 1, 2004

For cases seen prior to January 1, 2004, apply the following guidelines:

In the Stage at Diagnosis field, enter the code that represents the farthest tumor involvement as indicated by all the evidence obtained from diagnostic and therapeutic procedures performed during the first course of treatment or within four months after the date of diagnosis, whichever is earlier. (See Section VI.1 for definitions of first course of treatment and definitive treatment.) Coding must be supported by textual information entered under Diagnostic Procedures (see Section IV.1).

Stage at Diagnosis is not required beginning with cases diagnosed January 1, 1994. Hospitals wishing to do so may continue its use.

### Prior to January 1, 1994

Cases diagnosed prior to January 1, 1994 must continue to be staged using SEER Summary Staging Guide 1977. this document is available from SEER.

### Rules for Summary State 1978 and SEER Summary Stage 2000

Although Summary Stage is not required by the CCR, it is required by NAACCR and NPCR. The rules for using SEER Summary Stage 1977 and SEER Summary Stage 2000 are as follows:

Cancer cases diagnosed before January 1, 2001 should be assigned a summary stage according to SEER Summary Stage Guide 1977.

Cases diagnosed on or after January 1, 2001 should be assigned a stage according to SEER Summary Stage 2000.

### V.5.1 Codes

Always base coding on the site-specific schemes presented in the *Summary Staging Guide for the Cancer Surveillance, Epidemiology and End Results*

*Reporting (SEER) Program*, which is available as a separate publication or as Book 6 of the *Self Instructional Manual for Tumor Registrars*. See [Section I.1.6.5](#).

Instructions in [Section V.5.8](#), [Section V.5.9](#), [Section V.5.10](#), and [Section V.5.11](#) are provided for guidance only. The codes are:

0	IN SITU
1	LOCALIZED
2	REGIONAL, DIRECT EXTENSION ONLY
3	REGIONAL, LYMPH NODES ONLY
4	REGIONAL, DIRECT EXTENSION AND LYMPH NODES
5	REGIONAL, NOS
7	DISTANT METASTASES OR SYSTEMIC DISEASE (REMOTE)
9	UNSTAGEABLE (stage cannot be determined from available information)
Blank	NOT DONE

## V.5.2 Staging Definitions

Terms commonly used to describe stage include:

### **Invasion**

Local spread of a neoplasm by infiltration into or destruction of adjacent tissue.

### **Microinvasive**

The earliest invasive stage. Applied to cervical cancer, describes a small cancer that has invaded the stroma to a limited extent. The FIGO stage is IA. See [Section V.3.4.3](#) and [Section V.5.9.4](#).

### **Direct Extension**

A continuous infiltration or growth from the primary site into other tissue or organs (compare to metastasis).

### **Metastasis**

Dissemination of tumor cells in a discontinuous fashion from the primary site to other parts of the body—for example, by way of the circulatory system or a lymphatic system.

### **Regional**

Organs or tissues related to a site by physical proximity. Also applies to the first chain of lymph nodes draining the area of the site.

## V.5.3 Ambiguous Terms

Physicians sometimes use ambiguous terms to indicate the involvement of tissue or an organ by a tumor. Refer to the [Collaborative Stage Data Collection System Coding Instructions](#), for a list of ambiguous terms.

See [Section V.1.7.1](#) Ambiguous Terminology Diagnosis

### V.5.4 Staging - Time Period

Report the stage of each case at the time of diagnosis. Consider all diagnostic and therapeutic information obtained during the first course of treatment or within four months after the date of diagnosis, whichever is earlier. This time limitation ensures that the stage recorded is based on the same information that was used to plan the patient's treatment. Exclude progression of the disease since the time of the original diagnosis. See [Section VI.1.1](#) for the analogous rule concerning first course of treatment.

#### Example

A patient with lung cancer is staged "regional lymph nodes" by the physician on the basis of positive mediastinal lymph nodes and radiation therapy is instituted. Four weeks into the treatment course the patient develops neurological symptoms, and further work-up reveals previously unsuspected brain metastases. The treatment plan is changed to take this new manifestation into account. Since the disease has progressed since the time of original diagnosis, the stage would not be changed to distant

### V.5.5 Autopsy Reports

Include pertinent findings from autopsy reports if the patient dies within four months of the diagnosis of the cancer. However, as with other types of information, exclude data about progression of the disease since the time of the original diagnosis.

### V.5.6 Staging by Physician

When a physician has assigned a stage using the TNM, FIGO, Dukes', or any other system, use the information as a guide for coding stage, especially when information in the medical record is ambiguous or incomplete regarding the extent to which the tumor has spread. For a discussion of TNM, see [Section V.7](#). However, take certain precautions:

- Physicians might use different versions of a staging system at the same time, and a specific designation of stage might have different meanings. To determine the corresponding summary stage code, it is essential to know exactly which version a physician is using.
- Some staging systems (FIGO for example) use clinical information only, whereas CCR's Stage at Diagnosis includes all information, clinical, surgical, and pathological, that falls into the time period. Use the physician's clinical stage if no pathological information is available.

### V.5.7 Contradictory Reports

Sometimes the stage is stated incorrectly in the medical record due to a typographical, transcription, or similar error. If the stage recorded in one report is clearly contradicted in another, query the physician or the registry's medical consultant. Do not code stage based on information that appears to be inaccurate.

## V.5.8 Summary Stage - In Situ (Code 0)

A diagnosis of in situ, which must be based on microscopic examination of tissue or cells, means that a tumor has all the characteristics of malignancy except invasion, that is, the basement membrane has not been penetrated. A tumor that displays any degree of invasion is not classified as in situ.

For example, even if a report states *carcinoma in situ of the cervix showing microinvasion of one area*, the tumor is not in situ and code 0 is incorrect. However, a primary tumor might involve more than one site (for example, cervix and vagina, labial mucosa and gingiva) and still be in situ, as long as it does not show any invasion.

### V.5.8.1 Terms Indicating In Situ

Certain terms indicate an in situ stage. Also see [Section V.3.4.2](#).

AIN (anal intraepithelial neoplasia Grade II-III)\*\*

Bowen's Disease

DCIS (ductal carcinoma in situ)

DIN 3 (ductal intraepithelial neoplasia 3)\*\*

CIN III (cervical intraepithelial neoplasia, grade III)\*

Clark's level 1 for melanoma (limited to epithelium)

Confined to epithelium

Hutchinson's melanotic freckle, nos

Intracystic, non infiltrating

Intraductal

Intraepidermal

Intraepithelial

Intrasquamous

Involvement up to but not including the basement membrane

LCIS (lobular carcinoma in situ)

Lentigo maligna

LIN (laryngeal intraepithelial neoplasia)\*\*

Lobular neoplasia, Grade III

No stromal invasion

Non infiltrating

Non invasive

PanIN-III (pancreatic intraepithelial neoplasia III)\*\*\*

Precancerous melanosis

Preinvasive

Queyrat's erythroplasia

Stage 0

Vaginal intraepithelial neoplasia, Grade III (VAIN III)\*

Vulvar intraepithelial neoplasia, Grade III (VIN III)\*

\* Cases diagnosed January 1992 and later.

\*\* Cases diagnosed January 2001 and later.

\*\*\*Cases diagnosed January 2004 and later.

### **V.5.8.2 In Situ Stage - Behavior Code**

If a tumor is staged in situ, the behavior code is 2. See [Section V.3.4](#).

## **V.5.9 Summary Stage - Localized (Code 1)**

Localized denotes a tumor that is invasive, but is still confined entirely to the organ of origin. For most sites, the tumor might be widely invasive or have spread within the organ, as long as it does not extend beyond the outer limits of the organ of origin and there is no evidence of metastasis to other parts of the body.

### **V.5.9.1 Staging Rules for Inaccessible Sites**

For cases diagnosed January 1, 2010 and forward, or following installation of CSv2 software, refer to [Collaborative Stage Data Collection System Coding Instructions](#) manual for coding instructions.

### **V.5.9.2 Staging - Vessel and Lymphatic Involvement**

Invasion of blood vessels, lymphatics, and nerves within the primary site is a localized stage, unless there is evidence of invasion outside the site.

### **V.5.9.3 Staging - Multicentric Tumors**

Tumors with more than one focus, or starting point, are considered to be localized unless extension beyond the primary site has occurred. But a tumor that has developed a "satellite" nodule, that is, a lesion secondary to the primary one, might not be localized. Refer to the [Collaborative Stage Data Collection System Coding Instructions](#) for rules about satellite lesions.

### **V.5.9.4 Staging - Microinvasive**

Microinvasive, a term used by pathologists to describe the earliest invasive stage, has a precise meaning for cancer of certain sites. Microinvasive cancers are staged as localized, code 1. (Microinvasive squamous cell carcinoma is a common form of cervical cancer, for which ICD-O provides a specific morphology code—8076/3.)

## **V.5.10 Summary Stage - Regional (Codes 2, 3, 4, 5)**

A tumor at the Regional stage has grown beyond the limits of the organ of origin into adjacent organs or tissues by direct extension and/or to regional

lymph nodes by metastasis. Neoplasms appearing to be in the regional stage must be evaluated very carefully to make sure they have not spread any farther.

## Example

A malignant tumor of the stomach or of the gallbladder often passes through the wall of the primary organ into surrounding tissue.

Before coding as regional, make certain that radiological or scan examinations do not reveal metastasis to a lung or bone and that findings during surgery do not include metastasis to the liver or serosal surfaces that are not regional.

Also check progress notes and the discharge summary for any mention of metastasis.

### V.5.10.1 Summary Stage - Regional, Direct Extension Only (Code 2)

At times a cancer spreads to surrounding organs or tissue with no involvement of regional lymph nodes. Before assigning code 2 to such a case, make sure that tissue adjacent to the original organ is actually involved. The terms "penetrating" and "extension" are sometimes used to describe spreading within an organ, such as the large intestine or bladder, in which case the stage might still be localized (code 1). The Summary Staging Guide lists organs and structures considered to be regional for each site. Also see [Section V.5.3](#) for interpretation of ambiguous terms.

### V.5.10.2 Summary Stage - Regional, Lymph Nodes Only (Code 3)

If a cancer continues to grow after the onset of local invasion, the regional lymph nodes draining the area usually become involved at some point. Enter code 3 if nodal involvement is indicated but there is no other evidence of extension beyond the organ of origin. Words like "local" and "metastasis" appearing in medical records sometimes cause confusion in coding this stage. Failure to recognize the names of regional lymph nodes might lead to incorrect staging. The Summary Staging Guide and the American Joint Committee on Cancer's Manual for Staging of Cancer (see Section I.1.6.5) contain helpful information about the names of nodes.

## Examples

Diagnoses such as "carcinoma of the stomach with involvement of the local lymph nodes" should, lacking further evidence, be considered regional and staged as code 3.

Statements like "carcinoma of the breast with auxiliary lymph node metastasis" and "carcinoma of the stomach with metastasis to perigastric nodes" indicate metastasis to regional nodes and should be staged as code 3.

### **V.5.10.3 Bilateral Lymph Node Involvement**

Bilateral lymph node metastases are considered regional for primaries on the midline of the body (for example, on the tongue, esophagus, or uterus), and should be coded as 3. But bilateral regional node involvement of primaries that are not on the midline (like the breast) indicates that the cancer has spread to remote tissue (code 7).

### **V.5.10.4 Summary Stage - Regional, Direct Extension and Lymph Nodes (Code 4)**

Enter code 4 when a tumor has metastasized to regional lymph nodes and also has spread to regional tissue via direct extension, but there is no evidence of metastasis to a distant site or distant lymph nodes.

### **V.5.10.5 Summary Stage - Regional, NOS (Code 5)**

If available information only states that a cancer has spread regionally, stage as code 5. Also use code 5 for a nodal lymphoma described as regional which is sometimes stated in the record as Stage II. See [Section V.5.6](#) and [Section V.7.5](#).

### **V.5.11 Summary Stage - Distant (Code 7)**

Enter code 7 for any tumor that extends beyond the primary site by:

- Direct extension beyond adjacent organs or tissues specified as regional in the Summary Staging Guide.
- Metastasis to distant lymph nodes.
- Development of discontinuous secondary or metastatic tumors. (These often develop in the liver or lungs, because all venous blood flows through these organs and the veins are invaded more easily than the thicker walled arteries.)

Code 7 also includes contralateral or bilateral lymph node metastases, if the primary site is not located along the midline of the body (for example, in the breast, lung, bronchus, ovary, testis, or kidney). Also included in code 7 are systemic diseases such as leukemia and multiple myeloma.

### **V.5.12 Summary Stage - Unstageable (Code 9)**

If information in medical records is insufficient to assign a stage, enter code 9. Code 9 is required when the primary tumor site is not known. For non-analytic cases, code 9 is appropriate unless the stage at the time of the initial diagnosis is known.

### **V.5.13 Special Rules for Lymph Nodes**

For cases diagnosed January 1, 2010 and forward, or following installation of CSv2 Software, refer to [Collaborative Stage Data Collection System Coding Instructions](#) manual for coding instructions.



Refer to the instructions below for counting regional lymph nodes for a core needle biopsy or aspiration followed by a dissection.

- Add 1 to the number of regional lymph nodes positive and examined when the core biopsy or aspiration is positive for metastases, the lymph node dissection does not include the area where the core biopsy or aspiration was done and that lymph node was a regional lymph node for the primary site.
- Add 1 only to the number of regional lymph nodes examined when the core biopsy or aspiration is negative for metastases and that lymph node was a regional lymph node for the primary site. Note: You would not add 1 to regional lymph nodes positive because the biopsy or aspiration was negative for metastases.
- Do not add to the regional lymph nodes examined or positive when the area biopsied or aspirated is included in the dissection.

### V.5.14 Lymph-Vascular Invasion

For cases diagnosed January 1, 2010 and forward, or following installation of CSv2 software, lymph-vascular invasion identifies the presence or absence of tumor cells in lymphatic channels (not lymph nodes) or blood vessels with the primary tumor as noted microscopically by the pathologist. Lymph-vascular invasion is an indicator of prognosis. The CCR requires that this data item be collected for primary sites penis and testis only.

This item may be left blank for cases diagnosed before 2010.

The primary source of this information is the College of American Pathologists (CAP) synoptic report or checklist. If that is not available, code from the pathology report or a physician's statement, in that order of priority.

Codes

0	Pathology report indicates no lymph-vascular invasion
1	Lymph-vascular invasion is identified anywhere in a primary specimen
8	No pathologic examination of primary site tissue performed
9	Primary tissue was sent to pathology, but the report cannot be found or surgery was at a different facility and the information was not provided to the reporting facility
9	Pathology report indicates that the presence of lymph-vascular invasion could not be determined

## V.6 Tumor Markers

For cases diagnosed January 1, 2010 and forward, or following installation of CSv2 software, Tumor Markers 1-3 and Tumor Marker California 1 (HER2/neu) are collected as site-specific factors. Refer to [Collaborative Stage Data Collection System Coding Instructions Site Specific Factor Fields](#) (Part 1, Section 2).

### V.6.1 Tumor Marker 1

For cases diagnosed January 1, 2010 and forward, or following installation of CSv2 software, this data item is collected as a site-specific factor. Refer to [Collaborative Stage Data Collection System Coding Instructions - Site Specific Factor Fields](#) (Part 1, Section 2).

### V.6.2 Tumor Marker 2

For cases diagnosed January 1, 2010 and forward, or following installation of CSv2 software, this data item is collected as a site-specific factor. Refer to [Collaborative Stage Data Collection System Coding Instructions - Site Specific Factor Fields](#) (Part 1, Section 2).

### V.6.3 Tumor Marker 3

For cases diagnosed January 1, 2010 and forward, or following installation of CSv2 software, this data item is collected as a site-specific factor. Refer to [Collaborative Stage Data Collection System Coding Instructions - Site Specific Factor Fields](#) (Part 1, Section 2).

### V.6.4 Tumor Marker California-1

This data item has been replaced by CS breast schema site-specific factors 8-14.

For cases diagnosed January 1, 2010 and forward, or following installation of CSv2 software, Tumor Marker California 1 (HER2/neu) is collected as a site-specific factor. Refer to [Collaborative Stage Data Collection System Coding Instructions - Site Specific Factor Fields](#) (Part 1, Section 2).

## V.7 AJCC Staging and Other ACoS Items

### January 1, 2008 and Forward

Effective with cases diagnosed January 1, 2008 forward, physician-assigned pathologic AJCC staging will no longer be required to be collected by ACoS approved facilities.

### V.7.1 The TNM System

#### January 1, 2004 and Forward

Beginning with cases diagnosed January 1, 2004 and forward, the CCR requires the collection of Collaborative Staging (CS) data items necessary to derive AJCC T, N, M, and Stage Group.

As the *AJCC Manual for Staging of Cancer* explains, the TNM system "is based on the premise that cancers of similar histology or site of origin share similar patterns of growth and extension. The size of the untreated cancer or tumor (T) increases progressively and at some point in time regional lymph node involvement (N) and finally, distant metastases (M) occur."

Because classifications are different for each primary site, and coding for extension depends on precise anatomical identification, the AJCC manual must be referred to for data entry unless the coding is provided by physicians in the medical records. But fundamentally the system consists of assigning appropriate numbers or letters to the three fields:

- T (primary tumor)
- N (nodal involvement)
- M (distant metastasis)

For those sites not included in the AJCC Manual for Staging of Cancer, the Summary Staging Guide for Surveillance Epidemiology and End Results Group (SEER) is to be used. For a list of these sites, please refer to *AJCC Manual for Staging of Cancer, Sixth Edition*.

### V.7.2 TNM Data Entry

In entering data, do not include the letters T, N, or M, even though they are part of the code.

### V.7.3 TNM Stage Basis

This data item identifies the nature of the information on which AJCC staging is based. The *AJCC Cancer Staging Manual* provides specific recommendations about which information should be used for each type of staging at each primary site.

The codes are as follows:

S*	Surgical evaluative
R	Retreatment
A	Autopsy

\* Not used in the 3rd or 4th edition of the AJCC manual.

### V.7.4 TNM Staging Elements (Clinical and Pathological)

#### January 1, 2004 and Forward

Beginning with cases diagnosed January 1, 2004 and forward, the CCR requires the collection of Collaborative Staging (CS) data items necessary to derive AJCC T, N, M, and Stage Group. See AJCC Cancer Staging Manual, Seventh Edition (Not available electronically).

## V.7.5 AJCC Stage Group (Clinical and Pathological)

### January 1, 2004 and Forward

Beginning with cases diagnosed January 1, 2004 and forward, the CCR requires the collection of Collaborative Staging (CS) data items necessary to derive AJCC T, N, M, Stage Group. See AJCC Cancer Staging Manual, Seventh Edition (not available electronically).

When entering a stage summary code, be sure to include any letter used for the tumor, for example; 3A, 2C. If there is no letter, leave the second digit in the field blank. The codes are:

STAGE 0	0	STAGE IIC	2C
STAGE 0A	0A	STAGE III	3
STAGE 0IS	0S	STAGE IIIA	3A
STAGE I	1	STAGE IIIB	3B
STAGE IA	1A	STAGE IIIC	3C
STAGE IA1	A1	STAGE IV	4
STAGE IA2	A2	STAGE IVA	4A
STAGE IB	1B	STAGE IVB	4B
STAGE IB1	B1	STAGE IVC	4C
STAGE IB2	B2	OCCULT	OC
STAGE IC	1C	NOT APPLICABLE	88
STAGE IS	1S		
STAGE II	2	RECURRENT, UNKNOWN, STAGE X	99
STAGE IIA	2A		
STAGE IIB	2B		

### January 1, 2004 and Forward

Beginning with cases diagnosed January 1, 2004 and forward, the CCR requires the collection of Collaborative Staging (CS) data items necessary to derive AJCC T, N, M, Stage Group.

### Prior to January 1, 2004

For cases diagnosed prior to January 1, 2004, the AJCC manual contains instructions for coding summaries of TNM staging.

## V.7.6 TNM Coder (Clinical, Pathological, and Other)

Record the responsible person for performing the TNM staging on the case.

The TNM Coder (Clinical) and TNM Coder (Pathological) are to be used in conjunction with clinical and pathological TNM staging.

These fields will be transmitted to the state registry.

The codes are as follows:

0 NOT STAGED

- 1 MANAGING PHYSICIAN
- 2 PATHOLOGIST
- 3 PATHOLOGIST AND MANAGING PHYSICIAN
- 4 CANCER COMMITTEE CHAIR, CANCER LIAISON PHYSICIAN, REGISTRY PHYSICIAN ADVISOR
- 5 CANCER REGISTRAR
- 6 CANCER REGISTRAR AND PHYSICIAN
- 7 STAGING ASSIGNED AT ANOTHER FACILITY
- 8 CASE IS NOT ELIGIBLE FOR STAGING
- 9 UNKNOWN, NOT FOUND IN PATIENT RECORD

### **V.7.7 TNM Edition**

Record which edition of TNM staging was used to stage a case. The codes are as follows:

- 00 NOT STAGED
- 01 FIRST EDITION
- 02 SECOND EDITION
- 03 THIRD EDITION
- 04 FOURTH EDITION
- 05 FIFTH EDITION
- 06 SIXTH EDITION
- 07 SEVENTH EDITION
- 88 NOT APPLICABLE (cases that do not have an AJCC staging scheme and staging was not done)
- 99 UNKNOWN

The TNM Edition field may be left blank.

### **V.7.8 Pediatric Stage**

This scheme is to be used for the purpose of entering the stage for pediatric patients only.

#### **January 1, 1996 and Forward**

Pediatric Stage includes patients who are younger than twenty (20) years of age and diagnosed January 1, 1996 or later.

Use Code 88 - not applicable, for patients twenty years of age and older.

Use code 99 for pediatric leukemia cases.

For cases diagnosed prior to 1996, both pediatric and non-pediatric, this field may be left blank.

Record the stage assigned by the Managing Physician.

The codes are as follows:

1	STAGE I
1A	STAGE IA (rhabdomyosarcomas & related sarcomas)
1B	STAGE IB (rhabdomyosarcomas & related sarcomas)
2	STAGE II
2A	STAGE IIA (rhabdomyosarcomas & related sarcomas)
2B	STAGE IIB (rhabdomyosarcomas & related sarcomas)
2C	STAGE IIC (rhabdomyosarcomas & related sarcomas)
3	STAGE III
3A	STAGE IIIA (liver, rhabdo. & related sarcomas, Wilms')
3B	STAGE IIIB (liver, rhabdo. & related sarcomas, Wilms')
3C	STAGE IIIC (Wilms' tumor)
3D	STAGE IIID (Wilms' tumor)
3E	STAGE IIIE (Wilms' tumor)
4	STAGE IV
4A	STAGE IVA (bone)
4B	STAGE IVB (bone)
4S	STAGE IVS (neuroblastoma)
5	STAGE V (Wilms' tumor/retinoblastoma)
A	STAGE A (neuroblastoma)
B	STAGE B (neuroblastoma)
C	STAGE C (neuroblastoma)
D	STAGE D (neuroblastoma)
DS	STAGE DS (neuroblastoma)
88	NOT APPLICABLE (not a pediatric case)
99	UNSTAGED, UNKNOWN

### V.7.9 Pediatric Stage System

This scheme is to be used for pediatric patients only.

#### January 1, 2004 and Forward

Beginning with cases diagnosed January 1, 2004 and forward, the CCR requires the collection of Collaborative Staging (CS) data items necessary to derive AJCC T, N, M, Stage Group.

#### Prior to January 1, 2004

## California Cancer Reporting System Standards, Volume I

For cases diagnosed prior to January 1, 2004, the AJCC manual contains instructions for coding summaries of TNM staging.

Pediatric Stage includes patients who are younger than twenty (20) years of age and diagnosed January 1, 1996 or later.

Use Code 88 - not applicable, for patients twenty years of age and older.

For cases diagnosed prior to 1996, both pediatric and non-pediatric, this field may be left blank.

Record in this field the staging system used by the Managing Physician.

The codes are as follows:

00	NONE
01	AMERICAN JOINT COMMITTEE ON CANCER (AJCC)
02	ANN ARBOR
03	CHILDREN'S CANCER GROUP (CCG)
04	EVANS
05	GENERAL SUMMARY
06	INTERGROUP EWINGS
07	INTERGROUP HEPATOBLASTOMA
08	INTERGROUP RHABDOMYOSARCOMA
09	INTERNATIONAL SYSTEM
10	MURPHY
11	NATIONAL CANCER INSTITUTE (Pediatric Oncology)
12	NATIONAL WILMS' TUMOR STUDY
13	PEDIATRIC ONCOLOGY GROUP (POG)
14	REESE-ELLSWORTH
15	SEER EXTENT OF DISEASE
16	CHILDREN'S ONCOLOGY GROUP (COG)
88	NOT APPLICABLE
97	OTHER
99	UNKNOWN

### V.7.10 Pediatric Stage Coder

This data item is to be used for pediatric cases only diagnosed January 1, 1996 and later. It identifies the person who staged the case.

The ACoS states that the managing physician is responsible for staging analytical cases. The CCR concurs and feels that this applies to non-analytic cases, also.

If the staging has not been done by the physician, the registrar does not have to stage the case. Enter 0 for not staged.

For patients older than twenty (20), enter 0.

For cases diagnosed prior to 1996, this field may be left blank. The codes are as follows:

0	NOT STAGED
1	MANAGING PHYSICIAN
2	PATHOLOGIST
3	OTHER PHYSICIAN
4	ANY COMBINATION OF 1, 2 OR 3
5	REGISTRAR
6	ANY COMBINATION OF 5 WITH 1, 2 OR 3
7	OTHER
8	STAGED, INDIVIDUAL NOT SPECIFIED
9	UNKNOWN IF STAGED



## **PART VI. TREATMENT**

### **VI.1 First Course of Treatment: General Instructions**

In the treatment section, record all cancer directed therapy administered as part of the first course of treatment. It includes any therapeutic procedure directed at cancer tissue, whether in a primary or metastatic site, whatever the mode of treatment, and regardless of the sequence and degree of completion of any component part.

Effective with cases diagnosed January 1, 1998, a new definition for first course therapy was to be followed. In addition, note the definition for leukemias in see [Section VI.1.1](#). Use the older definition for cases diagnosed prior to January 1, 1998.

The following rules are to be followed for first course therapy, and they are in the order of precedence:

1. If there is a documented, planned first course of therapy, first course ends at the completion of this treatment plan, regardless of the duration of the treatment plan.
2. If the patient is treated according to a facility's standards of practice, first course ends at the completion of the treatment.
3. First course therapy includes all treatment received before disease progression or treatment failure.
4. When there is no documentation of a treatment plan or progression, recurrence or a treatment failure, first course therapy ends one year after the date of diagnosis. Any treatment given after one year is second course therapy in the absence of a documented treatment plan or a standard of treatment.
5. If a patient refuses all treatment modalities and does not change his/her mind within a reasonable time frame, or if the physician opts not to treat the patient, record that there was no treatment in the first course.

If treatment is given for symptoms/disease progression after a period of "watchful waiting," this treatment is not considered part of first course. For example, if a physician and patient choose a "wait and watch" approach to prostate cancer or chronic lymphocytic leukemia and the patient becomes symptomatic, consider the symptoms to be an indication that the disease has progressed and that any further treatment is not part of first course. The data item RX-Treatment Status was added to summarize the status of all treatment modalities. This data item is a summary of whether treatment was given, including an option that identifies active surveillance or watchful waiting.

The CCR expects every reporting facility that has a tumor registry to obtain information about the entire first course therapy from the medical record and, if necessary, the physicians themselves, regardless of where the treatment was administered. If it cannot be determined whether an intended therapy was actually performed, record that it was recommended but it is not known whether the procedure was administered. (For example, Enter "Radiation therapy, recommended; unknown if given.") Reporting facilities preparing initial case reports for the sole purpose of meeting state mandatory reporting requirements may elect to record only the treatment documented in their medical records.

Abstractors are provided with two fields to record first course of treatment information. The first treatment field for each modality (except surgery) is known as "Treatment Summary." This field should include any first course treatment administered for that modality, regardless of where it was administered, including treatment administered at the reporting facility. The second treatment field for each modality (except surgery) is known as "Treatment At This Hospital." This field should only include first course treatment administered at the reporting facility, respective to each modality.

Note: For cases diagnosed January 1, 2010 and forward, referral to an oncologist is considered a recommendation. Registry personnel should follow-up on these cases to determine whether chemotherapy was administered or not, and code accordingly.

Prior to January 1, 2010, referral does not equal a recommendation.

## **VI.1.1 Special Situations**

### **In Utero Diagnoses and Treatment**

Beginning in 2009, the dates of diagnosis and treatment for tumors developed while in utero should reflect the dates on which they occur. In the past, these dates were assigned to the date the baby was born.

### **Treatment Performed Elsewhere**

Record any part of the first course of treatment administered at another facility before the patient was admitted to the reporting facility or after discharge. Also record the name of the facility where the treatment was administered.

### **Leukemia**

Leukemia is grouped or typed by how quickly the disease develops and worsens. Chronic leukemia gets worse slowly; acute leukemia, quickly.

Leukemias are also grouped by the type of white blood cell that is affected: lymphoid leukemia and myeloid leukemia.

First course for Leukemia and Hematopoietic Diseases

### **Definitions**

*Consolidation:* Repetitive cycles of chemotherapy given immediately after the remission.

*Induction:* Initial intensive course of chemotherapy.

*Maintenance:* Chemotherapy given for a period of month or years to maintain remission.

*Remission:* The bone marrow shows normal cellular characteristics (is normocellular), with less than 5% blasts, no signs or symptoms of the disease, no signs or symptoms of central nervous system leukemia or other extramedullary infiltration, and all of the following laboratory values within normal limits: white blood cell count and differential, hematocrit/hemoglobin level, and platelet count.

### **Treatment for leukemia is divided into three phases**

- 1) Remission induction (chemotherapy and/or biologic response modifiers)
- 2) CNS prophylaxis or consolidation (irradiation to brain, chemotherapy)
- 3) Remission continuation or maintenance (chemotherapy or bone marrow transplants)

### **Coding First Course of Therapy for Leukemia and Hematopoietic Diseases**

- 1) If a patient has a partial or complete remission during the first course of therapy
  - a) Code all therapy that is "remission-inducing" as first course
  - b) Code all therapy that is "consolidation " as first course
  - c) Code all therapy that is "remission-maintaining" as first courseNote: Do not record treatment given after the patient relapses (is no longer in remission)
- 2) Some patient do not have a remission. A change in the treatment plan indicates a failure to induce remission. If the patient does not have a remission:
  - a) Record the treatment given in an attempt to induce a remission
  - b) Do not record treatment administered after the change in treatment plan

For leukemia and lymphoma cases diagnosed January 1, 2010 and forward, refer to [2010 Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual and the Hematopoietic Database](#).

## **VI.1.2 Treatment Definitions**

Certain treatment terms include:

### **Definitive Cancer Treatment**

Therapy that normally modifies, controls, removes, or destroys proliferating tumor tissue, whether primary or metastatic, even if it cannot be considered curative for a particular patient in view of the extent of disease, incompleteness of treatment, apparent lack of response, size of the dose administered, mortality during surgery, or other reason. The term excludes therapy that has no effect on malignant tissue. Procedures administered for the sole purpose of relieving symptoms are therefore not considered to be cancer treatment.

### **Cancer Tissue**

Proliferating malignant cells or an area of active production of malignant cells. Sometimes malignant cells are found in tissue in which they did not originate and are not reproducing. A procedure that removes cancer cells but does not attack a site of proliferation of the cells (thoracentesis, for example) is not considered cancer treatment.

### **Palliative**

Ordinarily means (1) non-curative, or (2) alleviation of symptoms. If used for a procedure that is directed toward symptoms only, the therapy is not considered to be treatment (e.g., colostomy, removal of fluid—even if cancer cells are present—to ease pressure, neurosurgery to relieve pain).

### **Antineoplastic Drugs**

Applies to medications that prevent the development, maturation, or spread of cancer cells. Included are drugs for chemotherapy (see Section VI.4), hormonal treatment (see Section VI.5), and immunotherapy (see Section VI.6). For cases diagnosed 1/1/2005 forward, registrars must use SEER\*Rx, for coding systemic treatment (i.e. chemotherapy, hormone therapy, and immunotherapy). SEER\*Rx is the downloadable, interactive antineoplastic drug database that replaces SEER Self-Instructional Manual Book 8, Antineoplastic Drugs. The software can be downloaded from the [SEER\\*Rx Web Site](#).

### **Active Surveillance**

See Watchful Waiting.

### **Disease Recurrence**

For solid tumors, see the Multiple Primary and Histology Coding Rules manual and for hematopoietic and lymphoid neoplasms see the Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding manual and the Hematopoietic Database to determine disease recurrence.

## Treatment Failure

The treatment modalities did not destroy or modify the cancer cells. The tumor either became larger (disease progression) or stayed the same size after treatment.

## Watchful Waiting

A treatment option for patients with slow, indolent diseases, such as prostate cancer. The physician closely monitors the patient and delays treatment until the patient becomes symptomatic or exhibits other signs of disease progression, such as rising PSA. Also referred to as Active Surveillance.

## VI.1.3 First Course of Treatment - Data Entry

Enter codes, dates, and written summaries to reflect the first course of treatment.

### VI.1.3.1 First Course of Treatment - Codes

Numeric codes summarize each modality of treatment (surgery, radiation, chemotherapy, etc.). For each modality except surgery, code a summary of the entire first course of treatment. See [Section VI.2](#) for coding each surgery field.

In the field provided, assign a separate code to that portion of the treatment administered at the reporting facility.

Beginning with cases diagnosed January 1, 1998, treatment given by a physician on the medical staff of a facility should not be recorded as treatment given at that reporting facility.

For cases diagnosed prior to January 1, 1998, treatment given in a staff physician's office should be recorded as if given at the reporting facility.

The codes for surgical procedures have one or two digits.

The codes for the reason no surgery, reason no radiation, reason no chemotherapy and reason no hormone therapy have been incorporated into each respective treatment modality field.

Other codes have two digits, with a 00 always meaning no procedure performed for that type of treatment.

### Definitions

*Chemoembolization:* a procedure in which the blood supply to the tumor is blocked surgically or mechanically and anticancer drugs are administered directly into the tumor. This permits a higher concentration of drug to be in contact with the tumor for a longer period of time. Code as Chemotherapy.

*Radioembolization:* embolization combined with injecting small radioactive beads or coils into an organ or tumor. Code as Radiation therapy.

*Tumor embolization with alcohol or tumor embolization NOS*: the intentional blockage of an artery or vein to stop the flow of blood through the desired vessel. Code as Other therapy, see [Section VI.8.1](#).

### **VI.1.3.2 First Course of Treatment - Dates**

For cases diagnosed January 1, 2010 and forward, or following installation of CSV2 software, dates transmitted between facility registries and central registries changed to improve the interoperability or communication of cancer registry data with other electronic record systems. Registry software may display dates in the traditional manner, or in the interoperable format.

Traditional dates are displayed in MMDDCCYY form, with 99 representing unknown day or month portions, and 99999999 representing a completely unknown date. In traditional form, some dates also permit 88888888 or 00000000 for special meaning.

Interoperable dates are display in CCYYMMDD form, with the unknown portions of the date filled with blank spaces. If a date is entirely blank, an associated date flag is used to explain the missing date.

Consult your software vendor for specific data entry instructions.

Enter the date treatment was started for each modality. For instructions about entering dates, see [Section I.1.6.4](#). If the treatment was administered in courses (as in a radiation therapy series) or included different procedures (for example, excisional biopsy and a resection), enter the date the first procedure was performed.

#### **From 1/1/2009 and Forward**

In Utero Diagnoses and Treatment

Beginning in 2009, the dates of diagnosis and treatment for tumors developed while in utero should reflect the dates on which they occur. In the past, these dates were assigned to the date the baby was born.

#### **From 1/1/03 Forward**

The Date of Systemic Therapy will be generated from Date of Chemotherapy, Date of Hormone, Date of Immunotherapy, and Date of Transplant/Endocrine Procedures effective with cases diagnosed 1/1/03.

### **VI.1.3.3 First Course of Treatment - Text**

In the text field following the Start Date field, describe the treatment as succinctly as possible. If more than one procedure was performed, describe each one in chronological order. Indicate where the procedure was performed, unless it was at the reporting facility. The text field may be left blank when the type of treatment was not provided. But if no cancer-directed surgery is performed, record the reason in the text field for surgery.

NOTE: There is no text field for bone marrow transplant and endocrine procedures. Record text information regarding bone marrow transplants and endocrine procedures in the immunotherapy text field.

#### **VI.1.3.4 First Course of Treatment - Refused**

If the patient or patient's guardian refuses surgery to the primary site, enter code 7 in the Reason for No Surgery field. Use code 87 in the respective treatment field if the patient or patient's guardian refuses that modality and record the fact in the text field. However, if a treatment that was originally refused was subsequently performed as part of the first course of treatment, enter the appropriate code for the procedure.

#### **VI.1.3.5 No First Course of Treatment**

If a patient did not receive any of the treatments described in Sections VI.2—VI.7, the surgery summary code would be 00 and all the other treatment summary fields would contain a 00. For example, the case might be Autopsy Only, or the patient might have received only symptomatic or supportive therapy. Explain briefly why no definitive treatment was given (for example, "terminal," "deferred"). If definitive treatment was refused, see [Section VI.1.3.4](#) for coding instructions. A facility that is preparing initial case reports to only meet state mandatory reporting requirements may also use 00 if no treatment is documented in its medical records (code 99 should not be used in this situation).

The data item RX-Treatment Status was added to summarize the status of all treatment modalities. This data item is a summary of whether treatment was given, including an option that identifies active surveillance or watchful waiting.

Note: For cases diagnosed January 1, 2010 and forward, referral to an oncology specialist is considered a recommendation. Registry personnel should follow up on these cases to determine whether treatment was administered or not, and code accordingly.

Prior to January 1, 2010, referral does not equal a recommendation.

#### **VI.1.3.6 First Course of Treatment - Unknown**

In coding treatment, code 99 or 9 (unknown) should generally be used only for cases in which the first course of treatment is unknown. Enter 99 or 9 for each modality of treatment, leave the treatment date fields blank, and state briefly why the information is not available. Do not use code 99 or 9 for a component part of the treatment summary. For example, if surgical resection was performed and it is not known whether chemotherapy was administered, do not enter a 99 in the Chemotherapy field -- use code 00. If specific treatment is recommended, but it is not known whether it was administered, enter a statement to this effect and code the appropriate summary fields for Immunotherapy and Other Therapy with code 88 (code 8 for Surgery) and At This Hospital fields with code 00.

Note: For cases diagnosed January 1, 2010 and forward, referral to a specialist is considered a recommendation. Registry personnel should follow up on these cases to determine whether treatment was administered or not, and code accordingly.

Prior to January 1, 2010, referral does not equal a recommendation.

## **VI.2 First Course of Treatment: Surgery**

### **Introduction**

In abstracting surgical treatment, the total or partial removal (except an incisional biopsy) of tumor tissue must be recorded in the text field, whether from a primary or metastatic site. Also record procedures that remove normal tissue--for example, dissection of non-cancerous lymph nodes--if they are part of the first course of treatment. (Brushings, washings, aspiration of cells and peripheral blood smears are not considered surgical procedures, but they might have to be recorded as diagnostic procedures.) See [Section IV.1](#).

#### **VI.2.1 Surgery of the Primary Site**

See Appendix Q for Site-Specific Surgery Codes

Generally, cancer-directed surgery includes most procedures that involve removal of a structure (those with the suffix "ectomy") and such procedures as:

- Biopsy, excisional (which has microscopic residual disease or no residual disease)
- Biopsy, NOS, that removes all tumor tissue
- Chemosurgery (Moh's technique)
- Conization
- Cryosurgery
- Dessication and Curettage for bladder and skin tumors
- Electrocautery
- Fulguration for bladder, skin, and rectal neoplasms
- Laser therapy
- Local excision with removal of cancer tissue (including excisional biopsy but excluding incisional biopsy)
- Photocoagulation
- Splenectomy for lymphoma or leukemia
- Surgery removing metastatic malignant tissue
- Transurethral resection (TUR) with removal of tumor tissue of bladder or prostatic tumors

Do not code pre-surgical embolization of hypervascular tumors with particles, coils or alcohol. These pre-surgical embolizations are typically performed to



make the resection of the primary tumor easier. Examples where pre-surgical embolization is used include meningiomas, hemangiomas, paragangliomas, and renal cell metastases in the brain.

For codes 00 through 79, the response positions are hierarchical. Last-listed responses take precedence over responses written above. Code 98 takes precedence over code 00. Use codes 80 and 90 only if more precise information about the surgery is unavailable. Surgery to remove regional tissue or organs is coded in this item only if the tissue/organs are removed in continuity with the primary site, except where noted in Appendix Q.

Refer to Appendix Q-1 for cases diagnosed prior to January 1, 2003. Refer to Appendix Q-2 for cases diagnosed on or after January 1, 2003.

Enter the procedures in chronological order. If more than three surgical procedures are performed on a patient, the earliest surgery and the most definitive surgery must be included.

Surgery of the Primary Site consists of three two-character fields which are to be used to record surgeries of the primary site only. If an en bloc resection is performed which removes regional tissue or organs with the primary site(s) part of a specific code definition, it should be coded. An en bloc resection is the removal of organs in one piece at one time.

### **Examples:**

Patient undergoes a modified radical mastectomy. The breast and auxiliary contents are removed in one piece (en bloc).

Surgery would be coded 50 for modified radical mastectomy regardless of whether nodes were found by pathology in the specimen.

For non-en bloc resections, record the resection of a secondary or metastatic site in the Surgery of Other Regional Site(s), Distant Site(s) or Distant Lymph Node(s).

Refer to Appendix Q for the site-specific surgery codes. They are hierarchical with less specific (NOS) terms followed by more specific terms. See the example.

## Examples:

50 Gastrectomy, NOS WITH removal of a portion of esophagus

51 Partial or subtotal gastrectomy

52 Near total or total gastrectomy

### NOTES:

Codes 10-90 have priority over code 99.

Codes 10-84 have priority over codes 90 and 99.

Codes 10-79 have priority over codes 80, 90 and 99, where 80 is site-specific surgery, not otherwise specified.

If surgery removes the remaining portion of an organ, code the total removal of the organ.

Biopsies that remove all gross tumor or leave only microscopic margins should be coded to surgery of the primary site.

The patient had a resection of a stomach remnant and portion of the esophagus at the time of their second procedure.

The first procedure was a partial gastrectomy, NOS - code 30.

The second procedure would be code 52 for a total gastrectomy.

A patient had a lobectomy--code 31--for cancer in August 1998. The remainder of the lung was surgically removed in November 1998.

The second procedure would be code 40--resection of whole lung.

If the only information available is that the patient was referred to a surgeon, medical oncologist or radiation oncologist, with no confirmation that treatment was administered, code no treatment given.

Reminder: For cases diagnosed January 1, 2010 and forward, referral to a specialist is considered a recommendation. Registry personnel should follow-up on these cases to determine whether treatment was administered or not and code accordingly.

Note: Prior to January 1, 2010, referral does not equal a recommendation.

## VI.2.2 Scope of Regional Lymph Node Surgery

These three one-character fields are to be used to record surgeries performed on regional lymph nodes. Record the farthest regional lymph node removed regardless of involvement with disease. There is no minimum number of nodes that must be removed. If a regional lymph node was aspirated or biopsied, code regional lymph node(s) removed, NOS (1).

For counting regional lymph nodes for a core needle biopsy or aspiration followed by a dissection, see [Section V.5.13](#) Special Rules for Lymph Nodes.

### January 1, 2003 and Forward

California Cancer Reporting System Standards, Volume I

Starting with cases diagnosed January 1, 2003 forward, RX Summ, Scope of Reg LN Surg is not be coded according to site. It is coded using a single scheme for all sites. The three procedure fields must continue to be coded for 2003 forward cases. The codes for Scope of Regional LN's are as follows:

0	NONE No regional lymph node surgery. No lymph nodes found in the pathologic specimen. Diagnosed at autopsy.
1	BIOPSY OR ASPIRATION OF REGIONAL LYMPH NODE, NOS Biopsy or aspiration of regional lymph node(s) regardless of the extent of involvement of disease.
2	SENTINEL LYMPH NODE BIOPSY Biopsy of the first lymph node or nodes that drain a defined area of tissue within the body. Sentinel node(s) are identified by the injection of a dye or radio label at the site of the primary tumor.
3	NUMBER OF REGIONAL NODES REMOVED UNKNOWN OR NOT STATED; REGIONAL LYMPH NODE REMOVED, NOS Sampling or dissection of regional lymph node(s) and the number of nodes is unknown or not stated. The procedure is not specified as sentinel node biopsy.
4	1-3 REGIONAL LYMPH NODES REMOVED Sampling or dissection of regional lymph node(s) with fewer than four lymph nodes found in the specimen. The procedure is not specified as sentinel node biopsy.
5	4 OR MORE REGIONAL LYMPH NODES REMOVED Sampling or dissection of regional lymph nodes with at least four lymph nodes found in the specimen. The procedure is not specified as sentinel node biopsy.
6	SENTINEL NODE BIOPSY AND CODE 3,4, OR 5 AT SAME TIME, OR TIMING OUT NOT STATED Code 2 was performed in a single surgical event with code 3, 4, or 5. Or, code 2 and 3, 4, or 5 was performed, but timing was not stated in patient record.
7	SENTINEL NODE BIOPSY AND CODE 3,4, OR 5 AT DIFFERENT TIMES Code 2 was followed in a subsequent surgical event by procedures coded as 3, 4, or 5.
9	UNKNOWN OR NOT APPLICABLE It is unknown whether regional lymph node surgery was performed; death certificate-only; for lymphomas with a lymph node primary site; an unknown or ill-defined primary; primaries of the brain, meninges, spinal cord, cranial nerves and other part of the CNS (including the pituitary gland, <b>craniopharyngeal duct, and pineal gland</b> ), or for hematopoietic, reticuloendothelial, immunoproliferative, or myeloproliferative disease.

Cases diagnosed prior to January 1, 2003 must be coded in a new field, Scope of Regional LN 98-02. Refer to Appendix Q-1 for these codes.

Each site contains a list of nodes which are regional. Any nodes not contained on these lists are distant and should be coded in Surgery of Other Regional Site(s), Distant Site(s), or Distant Lymph Node(s).

In Appendix Q-1 for head and neck primaries diagnosed prior to January 1, 2003, the fields are to be used for neck dissections. Codes 2-5 indicate only that a neck dissection procedure was performed. They do not imply that nodes were found during the pathologic examination of the surgical specimen. Code the neck dissection even if no nodes were found in the specimen.

### **VI.2.3 Number of Regional Lymph Nodes Examined**

Record the number of lymph nodes identified in the pathology report during each surgical procedure of the regional lymph nodes. The codes are the same for all sites. Refer to Appendix Q-1 for these codes, which are to be entered in chronological order. If no regional lymph nodes were identified in the pathology report, leave the field blank even if the surgical procedure includes a lymph node dissection (i.e., modified radical mastectomy) or if the operative report documents removal of the nodes.

Note: This field is not cumulative. It does not replace or duplicate the "Regional Lymph Nodes Examined" field used in Extent of Disease coding.

Effective with cases diagnosed on or after January 1, 2003, the fields for Rx Summ-Reg LN Examined and Rx Hosp-Reg LN Examined are no longer required by the CCR and the CoC. Information regarding the number of lymph nodes has been incorporated into the scope fields. However, the summary field for cases diagnosed prior to January 1, 2003 must continue to be coded.

Use code 99 for an Unknown Primary Hematopoietic/Reticuloendothelial/Immunoproliferative/Myeloproliferative Disease Primaries, Lymphoma, Brain (including the pituitary gland) and Primaries of III-Defined Sites.

### **VI.2.4 Surgery of Other Regional Sites, Distant Sites, or Distant Lymph Nodes**

There are three one-character fields to be used to record removal of tissue other than the primary tumor or organ of origin. This would not be an en bloc resection. See example #1. Code the removal of non-primary site tissue which the surgeon may have suspected to be involved with malignancy even if the pathology was negative. Do not code the incidental removal of tissue for reasons other than malignancy. See example #2. These procedures are to be entered in chronological order. If no surgery was performed of other regional or distant sites or distant lymph nodes, leave the fields blank.

Starting with cases diagnosed January 1, 2003 forward, RX Summ - Surg Oth Reg/Dis and its corresponding procedure fields are not coded according to site. Rather, they are coded using a single scheme for all sites. The new codes are as follows:

0	NONE No surgical procedure of nonprimary site
1	NONPRIMARY SURGICAL PROCEDURE PERFORMED Nonprimary surgical resection to other site(s), unknown if whether the site(s) is regional or distant.
2	NONPRIMARY SURGICAL PROCEDURE TO OTHER REGIONAL SITES Resection of regional site.
3	NONPRIMARY SURGICAL PROCEDURE TO DISTANT LYMPH NODE(S) Resection of distant lymph node(s).
4	NONPRIMARY SURGICAL PROCEDURE TO DISTANT SITE Resection of distant site.
5	COMBINATION OF CODES Any combination of surgical procedures 2, 3, or 4.
9	UNKNOWN It is unknown whether any surgical procedure of a nonprimary site was performed. Death certificate only.

NOTE: Use code 1 if any surgery is performed to treat tumors of Unknown or III-defined Primary sites (C76.0-76.8, C80.9) or for Hematopoietic/Reticuloendothelial/Immunoproliferative disease (C42.0, C42.1, C42.3, C42.4, or M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992.)

Cases diagnosed prior to January 1, 2003 are to be coded in a new field, Surgery Other 98-02. Refer to Appendix Q-1 for these codes.

This field is for all procedures that do not meet the definitions of Surgery of Primary Site or Scope of Regional Lymph Nodes.

#### Example #1

The patient has an excisional biopsy of a hard palate lesion removed from the roof of the mouth and a resection of a metastatic lung nodule during the same procedure.

Code the resection of the lung nodule as 4 (distant site).

#### Example #2

During a colon resection, the surgeon noted that the patient had cholelithiasis and removed the gallbladder.

Do not code removal of the gallbladder.

## VI.2.5 Date of Surgery

For cases diagnosed January 1, 2010 and forward, or following installation of CSv2 software, see [Section I.1.6.4](#) and [Section I.1.6.5](#) for Coding and Entering Dates.

Enter the date of surgery performed for each surgical procedure. There are three date fields available to be used in conjunction with each definitive

procedure performed. Procedures for this date field include Surgery of the Primary Site, Scope of Regional Lymph Node Surgery or Surgery of Other Regional/Distant Sites. These must be entered in chronological order.

Consult with your software vendor for specific data entry instructions.

### **VI.2.5.1 Date of Surgery Flag**

For cases diagnosed January 1, 2010 and forward, or following installation of CSv2 software, this data item is used to explain why there is no appropriate value in the corresponding date field. Since only actual known dates are entered in interoperable date items, flags are used to explain the reason the date field is blank. Depending on the registry software being used, these changes may be transparent to the registrar.

#### **Codes**

10	Unknown whether any procedure performed
11	No procedure planned or performed
12	Date cannot be determined for procedure performed
Blank	Full or partial date recorded

### **VI.2.6 Treatment Facility Number**

These fields are used in conjunction with each surgical procedure performed. If the procedure was performed at the reporting facility, the CCR assigned reporting facility code should be entered.

The fields are to be left blank if no cancer-directed surgery was performed.

[Reporting facilities in alphabetic order.](#)

[Reporting facilities in code order.](#)

### **VI.2.7 Surgical Margins of the Primary Site**

This field is not required by the CCR effective with cases diagnosed January 1, 2000, but it is required by the ACoS. It describes the status of the surgical margins after each resection of the primary tumor.

For cases diagnosed after January 1, 2003, please refer to the Facility Oncology Registry Data Standards.

For cases diagnosed prior to January 1, 2003, please refer to [Appendix Q-1](#) for the site-specific codes.

### **VI.2.8 Reconstructive Surgery - Immediate**

#### **January 1, 2003 and Forward**

Beginning with cases diagnosed, January 1, 2003, this field is no longer required by the CCR or the CoC. Information with regards to reconstruction is incorporated into the Surgery of the Primary Site field.

#### **Prior to January 1, 2003**

The old field was retained and cases diagnosed prior to January 1, 2003 must continue to be coded.

For these cases, refer to Appendix Q-1.

Record the procedure in both the *Reconstructive Summary* and *At This Hospital* fields and in the surgery text field if it was performed subsequent to surgery as part of the planned first course of therapy. This procedure improves the shape and appearance or function of body structures that are missing, defective, damaged, or misshapen by cancer or cancer-directed therapies.

### VI.2.9 Reason for No Surgery of the Primary Site

If surgery of the primary site was performed, enter 0.

Reason for No Surgery only applies to the Surgery of the Primary Site field, not Scope of Regional Lymph Node Surgery or Surgery Other Regional/Distant Sites.

For sites where "Surgery of the Primary Site" is coded to 00 or 98 (hematopoietic included) use code 1.

Effective with cases diagnosed 1/1/2003, Code 5, *surgery not performed because patient died* was added. Definitions for codes 1, 2, and 6 were modified.

0	SURGERY OF THE PRIMARY SITE PERFORMED
1	SURGERY OF THE PRIMARY SITE NOT PERFORMED BECAUSE IT WAS NOT PART OF THE PLANNED FIRST COURSE TREATMENT
2	SURGERY OF THE PRIMARY SITE NOT PERFORMED BECAUSE OF CONTRAINDICATIONS DUE TO PATIENT RISK FACTORS (COMORBID CONDITIONS, ADVANCED AGE, ETC.)
5	SURGERY OF THE PRIMARY SITE WAS NOT PERFORMED BECAUSE THE PATIENT DIED PRIOR TO PLANNED OR RECOMMENDED SURGERY (code added in 2003)
6	SURGERY OF THE PRIMARY SITE WAS RECOMMENDED BUT NOT PERFORMED. NO REASON WAS NOTED IN THE PATIENT'S RECORD
7	SURGERY OF THE PRIMARY SITE WAS RECOMMENDED BUT REFUSED BY THE PATIENT, FAMILY MEMBER OR GUARDIAN. THE REFUSAL IS NOTED IN THE PATIENT'S RECORD.
8	SURGERY OF THE PRIMARY SITE WAS RECOMMENDED BUT UNKNOWN IF PERFORMED. FURTHER FOLLOW-UP IS RECOMMENDED.
9	NOT KNOWN IF SURGERY OF THE PRIMARY SITE WAS RECOMMENDED OR PERFORMED; DEATH CERTIFICATE ONLY AND AUTOPSY ONLY CASES

### VI.2.10 Diagnostic or Staging Procedures

Record surgical procedures performed solely for establishing a diagnosis and or determining stage of disease. If there is more than one surgical diagnostic

or staging procedure, record the first one performed. Some of the procedures should be recorded in the Operative Findings field.

Beginning with cases diagnosed January 1, 2003 forward, this field does not include palliative treatment/procedures. Palliative treatment/procedures are recorded in a separate field. The CCR does not require that palliative treatment/procedures be recorded but the CoC does require this field. Please consult the FORDS Manual for instructions regarding the palliative procedure field.

Surgical diagnostic or staging procedures include:

- Biopsy, incisional or NOS (if a specimen is less than or equal to 1 cm, assume the biopsy to have been incisional unless otherwise specified)

**Note:** If a lymph node is biopsied or removed to diagnose or stage lymphoma, and that node is NOT the only node involved with lymphoma, used code O2. If there is only a single lymph node involved with lymphoma, use the data item Surgical Procedure of Primary Site to code these procedures.

- Dilation and curettage for invasive cervical cancer
- Dilation and curettage for invasive or in situ cancers of the corpus uteri, including choriocarcinoma
- Surgery in which tumor tissue is not removed, for example
- Bypass surgery—colostomy, esophagostomy, gastrostomy, nephrostomy, tracheostomy, urethrostomy, stent placement

**NOTE:** Removal of fluid (paracentesis or thoracentesis) even if cancer cells are present is not a surgical procedure. Do not code brushings, washings, or hematologic findings (peripheral blood smears). These are not considered surgical procedures.

- Exploratory surgery—celiotomy, cystotomy, gastrotomy, laparotomy, nephrotomy, thoracotomy

**NOTE:** If both an incisional biopsy of the primary site and an incisional biopsy of a metastatic site are done, use code O2 (Incisional biopsy of primary site).

**Do Not Code:**

- Brushings, washings, cell aspirations and hematologic findings (peripheral smears), as they are NOT considered surgical procedures and should not be coded in the Diagnostic or Staging Procedures field. Code positive brushings, washings and cell aspirations, and hematologic findings (peripheral smears) as cytologic diagnostic confirmation in the Diagnostic Confirmation field.
- Surgical procedures which aspirate, biopsy, or remove regional lymph nodes in effort to diagnose and/or stage disease in this data item. Use the data item Scope of Regional Lymph Node Surgery to code these



procedures. Do not record the date of surgical procedures which aspirate, biopsy, or remove regional lymph nodes in the data item Date of Surgical Diagnostic and Staging Procedure.

- Excisional biopsies with clear or microscopic margins in this data item. Use the data item Surgical Procedure of Primary Site to code these procedures.
- Palliative surgical procedures in this data item.

### **VI.2.10.1 Diagnostic or Staging Procedure Codes**

00	NO SURGICAL DIAGNOSTIC OR STAGING PROCEDURE
01	INCISIONAL, NEEDLE, OR ASPIRATION BIOPSY OF OTHER THAN PRIMARY SITE (Code microscopic residual disease or no residual disease as Surgery of Other Regional Site[s], Distant Site[s], or Distant Lymph Nodes[s])
02	INCISIONAL, NEEDLE, OR ASPIRATION BIOPSY OF PRIMARY SITE (Code Microscopic residual disease or no residual disease as Surgery of Primary Site)
03	EXPLORATORY SURGERY ONLY (no biopsy)
04	BYPASS SURGERY OR OSTOMY ONLY (no biopsy)
05	COMBINATION OF 03 PLUS 01 OR 02
06	COMBINATION OF 04 PLUS 01 OR 02
07	DIAGNOSTIC OR STAGING PROCEDURE, NOS
09	UNKNOWN IF DIAGNOSTIC OR STAGING PROCEDURE DONE

NOTE: Give priority to:

Codes 01-07 over code 09.

Codes 01-06 over code 07.

Codes in the range 01-06 are hierarchial.

### **VI.2.11 Date of Diagnostic or Staging Surgical Procedures**

For cases diagnosed January 1, 2010 and forward, or following installation of CSv2 software, see Section [1.1.6.4](#) and Section [1.1.6.5](#) for Coding and Entering Dates.

Enter the date of the earliest surgical diagnostic and/or staging procedure in this field.

Consult with your software vendor for specific data entry instructions.

### **VI.2.11 Date of Diagnostic or Staging Surgical Procedures Flag**

For cases diagnosed January 1, 2010 and forward, or following installation of CSv2 software, this data item is used to explain why there is no appropriate value in the corresponding date field. Since only actual known dates are entered in interoperable date items, flags are used to explain the reason the date field is blank. Depending on the registry software being used, these changes may be transparent to the registrar.

**Codes**

10	Unknown whether a surgical diagnostic or staging procedure was performed
11	No surgical diagnostic or staging procedure was performed
12	Date cannot be determined for surgical diagnostic or staging performed
Blank	Full or partial date recorded

**VI.2.12 Sources for Information (Surgery)**

To ascertain exactly what procedures were performed, read the operative and pathology reports thoroughly. Do not depend on the title of an operative report, because it might be incomplete. If the operative report is unclear about what tissue was excised, or the operative and pathology reports contain different information, use the pathology report unless there is reason to doubt its accuracy.

**VI.2.13 Special Rules for Coding Ambiguous Cases (Surgery)**

There are specific rules for coding certain ambiguous situations:

**Excision of Multiple Primaries**

If multiple primaries are excised at the same time, enter the appropriate code for each site.

**Examples:**

A total abdominal hysterectomy was performed for a patient with two primaries, one of the cervix and one of the endometrium.

Code each site as having had a total abdominal hysterectomy.

A total colectomy was performed on a patient with multiple primaries in several segments of the colon.

Code total colectomy for each of the primary segments.

**Excisional Biopsy**

Record an excisional biopsy as first surgical treatment, whether followed by further definitive surgery or not and whether or not residual tumor was found in a later resection. If there is no statement that the initial biopsy was excisional, yet no residual tumor was found at a later resection, assume that the biopsy was excisional.

**Extranodal Lymphomas**

When coding surgery for extranodal lymphomas, use the appropriate code for the extranodal site. For example, use a code for the stomach to code a lymphoma of the stomach.

## VI.2.14 Systemic Therapy With Surgery Sequence

### January 1, 2006 and Forward

For cases diagnosed 1/1/2006 forward, code the sequence in which systemic therapy and surgical procedures were performed as part of the first course of treatment.

Use the following codes:

0	No systemic therapy and /or surgical procedures; unknown if surgery and/or systemic therapy given.
2	Systemic therapy before surgery
3	Systemic therapy after surgery
4	Systemic therapy both before and after surgery <b>Note: At least two courses of systemic therapy must be given to assign code 4.</b>
5	Intraoperative systemic therapy
6	Intraoperative systemic therapy with other therapy administered before or after surgery
9	Sequence unknown

If first course of treatment includes (codes 10-90 in Surgery of the Primary Site fields, codes 1-7 in the Scope of Regional Lymph Node Surgery fields, and codes 1-8 in the Surgery of Other Regional(s), Distant Site(s), or Distant Lymph Node(s) fields) and systemic therapy, use codes 2-9. For all other cases, use code 0.

## VI.3 First Course of Treatment: Radiation Therapy

The name or chemical symbol and method of administration of any radiation therapy that is directed toward tumor tissue or given prophylactically must be documented in the text field.

Do not include radiation for hormonal effect, such as irradiation of non-cancerous endocrine glands.

Do not include irradiation of the male breast to prevent gynecomastia.

### January 1, 2008 and Forward

For cases diagnosed 1/1/2008 forward, the data item, Radiation Location Treatment is required by the CCR. This data item identifies the location of the facility in which radiation treatment was administered during first course of treatment.

### January 1, 2003 and Forward

For cases diagnosed 1/1/2003 forward, *Radiation - Regional RX Modality* and *Radiation - Boost RX Modality*, are required to code first course radiation therapy. Software conversions of these two fields generate the Radiation Therapy Summary field.

**Additional Note**

The field "Radiation Therapy at this Hospital" will no longer be required by the CCR beginning with cases diagnosed 1/1/2003.

**VI.3.1 Types of Radiation**

The principal types of radiation therapy are the external administration of radioactive beams, implantation of radioactive material, and the internal administration of radioisotopes by other than implantation. Radioactive materials include the following:

- Au<sup>198</sup> gold
- Co<sup>60</sup> cobalt
- Cr<sup>32</sup>PO<sub>4</sub> phosphocol
- CrPO<sub>4</sub> chromic phosphate
- Cs cesium
- I<sup>125</sup> iodine
- I<sup>131</sup> iodine
- Ir<sup>192</sup> iridium
- P<sup>32</sup> phosphorus
- Pb<sup>210</sup> lead
- Ra<sup>226</sup> radium
- Rn<sup>222</sup> radon
- Ru<sup>106</sup> ruthenium
- Sr<sup>90</sup> strontium
- Y<sup>90</sup> yttrium

**VI.3.1.1 Beam Radiation**

Radiation is classified as beam when the source of radioactivity is outside the patient, as in a cobalt machine or linear accelerator. Examples of beam radiation are:

- Betatron
- Brachytron
- Cobalt
- Cyclotron
- Grenz ray
- Helium ion or other heavy particle beam
- Linear accelerator (LINAC)
- MeV
- Neutron beam
- Spray radiation
- Stereotactic radiosurgery, such as gamma knife and proton beam
- X-ray

### VI.3.1.2 Radioactive Implants

Record the name or chemical symbol and method of administration of any radioactive material administered by implants, molds, seeds, needles, or intracavity applicators. (Heyman capsules, Fletcher suit, and Fletcher after loader are methods of isotope application. Interpret these terms as radioactive implants.)

Record High Dose Rate (HDR) and Low Dose Rate (LDR) Brachytherapy as radioactive implants - Code 2.

Code I-125 treatment for prostate cancer to brachytherapy (code 2) and treatment modality to low dose radiotherapy (LDR), code 53.

### VI.3.1.3 Other Internal Radiation

Record the name or chemical symbol and method of administration of any radioactive material given orally, intracavitary, or by intravenous injection.

### VI.3.2 Radiation Therapy Summary Codes

The following codes will be generated for recording radiation therapy in the summary field.

#### January 1, 2003 and Forward

Beginning with cases diagnosed 1/1/2003, *Radiation - Regional RX Modality* and *Radiation - Boost RX Modality*, are required to code first course radiation therapy. Also, radiation to the brain and CNS for lung and leukemia cases are to be coded in the *Radiation - Regional RX Modality* and *Radiation - Boost RX Modality* fields.

0	NONE
1	BEAM RADIATION
2	RADIOACTIVE IMPLANTS
3	RADIOISOTOPES
4	COMBINATION OF 1 WITH 2 OR 3
5	RADIATION, NOS (method or source not specified)
9	UNKNOWN IF RADIATION THERAPY RECOMMENDED OR GIVEN

#### Additional Note

The field "Radiation Therapy at this Hospital" will no longer be required by the CCR beginning with cases diagnosed 1/1/2003.

#### January 1, 1998 and Forward

Beginning with cases diagnosed January 1, 1998, radiation to the brain and central nervous system for lung cancers and leukemias only is to be recorded in the Radiation Summary and Radiation At This Hospital fields. Include prophylactic treatment and treatment of known spread to the CNS.

### VI.3.3 Radiation - Regional RX Modality

Record the dominant modality of radiation therapy used to deliver the most clinically significant regional dose to the primary volume of interest during the first course of treatment. The CCR requires the collection of this field. This data item and Radiation-Boost RX Modality are converted to generate the RX Summ-Radiation.

Radioembolization is embolization combined with injection of small radioactive beads or coils into an organ or tumor. Code Radiation Modality as brachytherapy, code 50, when tumor embolization is performed using a radioactive agent or radioactive seeds.

Code I-125 treatment for prostate cancer to brachytherapy, low dose radiotherapy (LDR), code 53.

The codes for Radiation-Regional RX Modality are as follows:

00	NO RADIATION TREATMENT; DIAGNOSED AT AUTOPSY
20	EXTERNAL BEAM, NOS
21	ORTHOVOLTAGE
22	COBALT-60, CESIUM-137
23	PHOTONS (2-5 MV)
24	PHOTONS (6-10 MV)
25	PHOTONS (11-19 MV)
26	PHOTONS (>19 MV)
27	PHOTONS (MIXED ENERGIES)
28	ELECTRONS
29	PHOTONS AND ELECTRONS MIXED
30	NEUTRONS, WITH OR WITHOUT PHOTONS/ELECTRONS
31	IMRT
32	CONFORMAL OR 3-D THERAPY
40	PROTONS
41	STEREOTACTIC RADIOSURGERY, NOS
42	LINAC RADIOSURGERY
43	GAMMA KNIFE
50	BRACHYTHERAPY, NOS
51	BRACHYTHERAPY, INTRACAVITARY, LDR
52	BRACHYTHERAPY, INTRACAVITARY, HDR
53	BRACHYTHERAPY, INTERSTITIAL, LDR
54	BRACHYTHERAPY, INTERSTITIAL, HDR
55	RADIUM
60	RADIOISOTOPES, NOS
61	STRONTIUM-89
62	STRONTIUM-90
98	OTHER, NOS
99	UNKNOWN; DEATH CERTIFICATE ONLY

Clarification: Intracavitary use of Cobalt-60 or Cesium-137 should be coded as 50 or 51. (See *FORDS Manual* for code definitions).

There is no hierarchy for this data item. If multiple radiation therapy modalities are used to treat the patient, code the dominant modality. In the rare occasion where 2 modalities are combined in a single volume (IMRT photons with an electron "patch" for example), code the appropriate radiation modality item to the highest level of complexity, i.e. the IMRT.

Note: For cases diagnosed January 1, 2010 and forward, referral to a radiation oncologist is considered a recommendation. Follow-up on these cases is required to determine whether radiation was administered or not, and code accordingly.

Prior to January 1, 2010, referral does not equal a recommendation.

**Prior to January 1, 2003**

\*NOTE: For cases diagnosed prior to January 1, 2003, the codes reported in this data item describe any radiation administered to the patient as part or all of the first course of therapy. Codes 80 and 85 describe specific converted descriptions of radiation therapy coded according to Vol. II, ROADS, and DAM rules and should not be used to record regional radiation for cases diagnosed on or later than January 1, 2003.

**VI.3.4 Radiation - Boost RX Modality**

Record the dominant modality of radiation therapy used to deliver the most clinically significant boost dose to the primary volume of interest during the first course of treatment. This is accomplished with external beam fields of reduced size (relative to the regional treatment fields), implants, stereotactic radiosurgery, conformal therapy, or IMRT. External beam boosts may consist of two or more successive phases with progressively smaller fields generally coded as a single entity.

The CCR requires the collection of this data item. This data item and Radiation-Regional RX Modality are converted to generate the RX Summ-Radiation.

Radioembolization is embolization combined with injection of small radioactive beads or coils into an organ or tumor. Code Radiation Modality as brachytherapy, code 50, when tumor embolization is performed using a radioactive agent or radioactive seeds.

The codes are as follows:

00	NO BOOST TREATMENT; DIAGNOSED AT AUTOPSY
20	EXTERNAL BEAM, NOS
21	ORTHOVOLTAGE
22	COBALT-60, CESIUM-137
23	PHOTONS (2-5 MV)
24	PHOTONS (6-10 MV)
25	PHOTONS (11-19 MV)
26	PHOTONS (>19 MV)
27	PHOTONS (MIXED ENERGIES)

28	ELECTRONS
29	PHOTONS AND ELECTRONS MIXED
30	NEUTRONS, WITH OR WITHOUT PHOTONS/ELECTRONS
31	IMRT
32	CONFORMAL OR3-D THERAPY
40	PROTONS
41	STEREOTACTIC RADIOSURGERY, NOS
42	LINAC RADIOSURGERY
43	GAMMA KNIFE
50	BRACHYTHERAPY, NOS
51	BRACHYTHERAPY, INTRACAVITARY, LDR
52	BRACHYTHERAPY, INTRACAVITARY, HDR
53	BRACHYTHERAPY, INTERSTITIAL, LDR
54	BRACHYTHERAPY, INTERSTITIAL, HDR
55	RADIUM
60	RADIOISOTOPES, NOS
61	STRONTIUM-89
62	STRONTIUM-90
98	OTHER, NOS
99	UNKNOWN; DEATH CERTIFICATE ONLY

Clarification: Intracavitary use of Cobalt-60 or Cesium-137 should be coded as 50 or 51. (See the FORDS Manual for code definitions).

There is no hierarchy for this data item. If multiple radiation therapy boost modalities are used to treat the patient, code the dominant modality.

Note: For cases diagnosed January 1, 2010 and forward, referral to a radiation oncologist is considered a recommendation. Follow-up on these cases is required to determine whether radiation was administered or not, and code accordingly.

Prior to January 1, 2010, referral does not equal a recommendation.

### **VI.3.5 Date of Radiation Therapy**

For cases diagnosed January 1, 2010 and forward, or following installation of CSv2 software, see **Section I.1.6.4** and **Section I.1.6.5** for Coding and Entering Dates.

Record the date on which radiation therapy began at any facility as part of the first course treatment.

Consult with your software vendor for specific data entry instructions.

#### **VI.3.5.1 Date Radiation Therapy Flag**

For cases diagnosed January 1, 2010 and forward, or following installation of CSv2 software, this data item is used to explain why there is no appropriate value in the corresponding date field. Since only actual known dates are entered in interoperable date items, flags are used to explain the reason the date field is blank. Depending on the registry software being used, these changes may be transparent to the registrar.



**Codes:**

10	Unknown whether radiation therapy was given
11	No radiation therapy planned or given
12	Date cannot be determined for radiation therapy received during first course
15	Radiation therapy is planned; start date is not yet available
Blank	Full or partial date recorded

**VI.3.6 Reason for No Radiation**

The following codes are to be used to record the reason the patient did not undergo radiation treatment:

0	RADIATION TREATMENT PERFORMED
1	RADIATION TREATMENT NOT PERFORMED BECAUSE IT WAS NOT A PART OF THE PLANNED FIRST COURSE TREATMENT
2	RADIATION CONTRAINDICATED BECAUSE OF OTHER CONDITIONS OR OTHER PATIENT RISK FACTORS (CO-MORBID CONDITIONS, ADVANCED AGE, ETC)
5	RADIATION TREATMENT NOT PERFORMED BECAUSE THE PATIENT DIED PRIOR TO PLANNED OR RECOMMENDED TREATMENT
6	RADIATION TREATMENT WAS RECOMMENDED BUT NOT PERFORMED. NO REASON WAS NOTED IN THE PATIENT'S RECORD.
7	RADIATION TREATMENT WAS RECOMMENDED BUT REFUSED BY THE PATIENT, FAMILY MEMBER OR GUARDIAN. THE REFUSAL IS NOTED IN THE PATIENT'S RECORD.
8	RADIATION RECOMMENDED, UNKNOWN IF DONE
9	UNKNOWN IF RADIATION RECOMMENDED OR PERFORMED; DEATH CERTIFICATE AND AUTOPSY ONLY CASES

NOTE: Include radiation to the brain and central nervous system when coding this field.

**January 1, 2003 and Forward**

NOTE: Beginning with cases diagnosed 1/1/2003, Code 5 - radiation not performed because patient died was added. Definitions for codes 1, 2, and 6 were also modified.

**VI.3.7 Radiation Sequence With Surgery**

Code the sequence in which radiation and surgical procedures were performed as part of the first course of treatment. Use the following codes:

0	NOT APPLICABLE treatment did not include both surgery and radiation, or unknown whether both were administered; diagnosed at autopsy
2	RADIATION BEFORE SURGERY
3	RADIATION AFTER SURGERY
4	RADIATION BOTH BEFORE AND AFTER SURGERY <i>Note: At least two courses of radiation therapy must be given to assign code 4.</i>
5	INTRAOPERATIVE RADIATION
6	INTRAOPERATIVE RADIATION WITH OTHER RADIATION GIVEN BEFORE OR

	AFTER SURGERY
9	SEQUENCE UNKNOWN, BUT BOTH SURGERY AND RADIATION WERE GIVEN

Use codes 2-9 if the first course of treatment includes (codes 10–90 in Surgery of the Primary Site fields, codes 1-7 in the Scope of Regional Lymph Node Surgery fields, and codes 1-8 in the Surgery of Other Regional Site(s), Distant Site(s), or Distant Lymph Node(s) fields) and radiation.

For all other cases, use code 0.

### VI.3.8 Location of Radiation Treatment

#### January 1, 2008 and Forward

Beginning January 1, 2008, code the location of the facility in which radiation treatment was administered during first course of treatment. Use the following codes:

0	NO RADIATION TREATMENT
1	ALL RADIATION TREATMENT AT THIS FACILITY
2	REGIONAL TREATMENT AT THIS FACILITY, BOOST ELSEWHERE
3	BOOST RADIATION AT THIS FACILITY, REGIONAL ELSEWHERE
4	ALL RADIATION TREATMENT ELSEWHERE
8	OTHER, NOS
9	UNKNOWN

### VI.4 First Course of Treatment - Chemotherapy

Chemotherapy includes the use of any chemical to attack or treat cancer tissue, unless the chemical achieves its effect through change of the hormone balance or by affecting the patient's immune system. In coding consider only the agent, not the method of administering it, although the method of administration may be recorded. Chemotherapy typically is administered orally, intravenously, or intracavitary, and sometimes topically or by isolated limb perfusion. The drugs are frequently given in combinations that are referred to by acronyms or protocols. Do not record the protocol numbers alone. Two or more single agents given at separate times during the first course of cancer directed therapy are considered to be a combination regimen.

SEER\*Rx is the downloadable, interactive antineoplastic drug database that replaces SEER Self-Instructional Manual Book 8, Antineoplastic Drugs. The software can be downloaded from the [SEER\\*Rx Web Site](#).

#### VI.4.1 Names of Chemotherapeutic Agents

In the text field, the generic or trade names of the drugs used for chemotherapy must be recorded. Include agents that are in the investigative or clinical trial phase.

#### January 1, 2005 and Forward

For cases diagnosed 1/1/2005 forward, registrars must use SEER\*Rx, for coding systemic treatment (i.e. chemotherapy, hormone therapy, and immunotherapy). SEER\*Rx is the downloadable, interactive antineoplastic drug database that replaces SEER Self-Instructional Manual Book 8, Antineoplastic Drugs. The software can be downloaded from the [SEER\\*Rx Web Site](#).

### VI.4.2 Chemotherapy Codes

Use the following codes for recording chemotherapy in the Summary field.

Code chemoembolization as 01, 02, or 03 depending on the number of chemotherapeutic agents involved.

Use codes 00-87 for recording chemotherapy in the At This Hospital field.

00	NONE, CHEMOTHERAPY WAS NOT PART OF THE PLANNED FIRST COURSE OF THERAPY. DIAGNOSED AT AUTOPSY
01	CHEMOTHERAPY, NOS.
02	SINGLE-AGENT CHEMOTHERAPY.
03	MULTI-AGENT CHEMOTHERAPY ADMINISTERED AS FIRST COURSE THERAPY.
82	CHEMOTHERAPY WAS NOT RECOMMENDED/ADMINISTERED BECAUSE IT WAS CONTRAINDICATED DUE TO PATIENT RISK FACTORS (i.e., COMORBID CONDITIONS, ADVANCED AGE).
85	CHEMOTHERAPY NOT ADMINISTERED BECAUSE THE PATIENT DIED PRIOR TO PLANNED OR RECOMMENDED THERAPY.
86	CHEMOTHERAPY WAS NOT ADMINISTERED. IT WAS RECOMMENDED BY THE PATIENT'S PHYSICIAN, BUT WAS NOT ADMINISTERED AS PART OF THE FIRST COURSE OF THERAPY. NO REASON WAS STATED IN PATIENT RECORD.
87	CHEMOTHERAPY WAS NOT ADMINISTERED. IT WAS RECOMMENDED BY THE PATIENT'S PHYSICIAN, BUT THIS TREATMENT WAS REFUSED BY THE PATIENT, A PATIENT'S FAMILY MEMBER, OR THE PATIENT'S GUARDIAN. THE REFUSAL WAS NOTED IN PATIENT RECORD.
88	CHEMOTHERAPY WAS RECOMMENDED, BUT IT IS UNKNOWN IF IT WAS ADMINISTERED.
99	IT IS UNKNOWN WHETHER A CHEMOTHERAPEUTIC AGENT(S) WAS RECOMMENDED OR ADMINISTERED BECAUSE IT IS NOT STATED IN PATIENT RECORD. DEATH CERTIFICATE ONLY.

Note: For recording Therapy at this Hospital, do not use code 99 if Class of Case is coded to 00, 30 or 31.

Note: For cases diagnosed January 1, 2010 and forward, referral to a medical oncologist is considered a recommendation. Follow-up on these cases is required to determine whether chemotherapy was administered or not, and code accordingly.

Prior to January 1, 2010, referral does not equal a recommendation.

### VI.4.3 Date of Chemotherapy

For cases diagnosed January 1, 2010 and forward, or following installation of CSV2 software, see [Section I.1.6.4](#) and [Section I.1.6.5](#) for Coding and Entering Dates.

Record the date on which chemotherapy began at any facility as part of first course of treatment.

Consult with your software vendor for specific data entry instructions.

### **VI.4.3.1 Date Chemotherapy Flag**

For cases diagnosed January 1, 2010 and forward, or following installation of CSV2 software, this data item is used to explain why there is no appropriate value in the corresponding date field. Since only actual known dates are entered in interoperable date items, flags are used to explain the reason the date field is blank. Depending on the registry software being used, these changes may be transparent to the registrar.

#### **Codes**

10	Unknown whether any chemotherapy was given
11	No chemotherapy planned or given
12	Date cannot be determined for chemotherapy received during first course
15	Chemotherapy is planned; start date is not yet available
Blank	Full or partial date recorded

## **VI.5 First Course of Treatment - Hormone (Endocrine) Therapy**

Report the administration of hormones, anti-hormones, or steroids to attack cancer tissue by changing the patient's hormone balance. Record surgery performed for hormonal effect (such as castration) and radiation for hormonal effect for breast and prostate cancers only. When steroids are combined with chemotherapy, record their use, in addition to reporting the chemotherapy in the chemotherapy section.

SEER\*Rx is the downloadable, interactive antineoplastic drug database that replaces SEER Self-Instructional Manual Book 8, Antineoplastic Drugs. The software can be downloaded from the [SEER\\*Rx Web Site](#).

### **VI.5.1 Hormones**

Cancer-directed treatment with hormones and anti-hormones must be documented in the text field for all sites.

Report cancer directed use of adenocorticotrophic hormones for treatment of leukemias, lymphomas, multiple myelomas, and breast and prostate cancers. But report as hormone therapy any hormonal agent that is given in combination with chemotherapy (e.g., MOPP or COPP) for cancer of any site whether it affects the cancer cells or not.

For cases diagnosed 1/1/2005 forward, registrars must use SEER\*Rx, for coding systemic treatment (i.e. chemotherapy, hormone therapy, and immunotherapy). SEER\*Rx is the downloadable, interactive antineoplastic drug database that replaces SEER Self-Instructional Manual Book 8, Antineoplastic Drugs. The software can be downloaded from the [SEER\\*Rx Web Site](#).

### **VI.5.1.1 Agents for Endometrial and Kidney Tumors**

Refer to the [SEER\\*Rx Web Site](#) for more information.

### **VI.5.1.2 Agents For Thyroid Cancer**

Refer to the [SEER\\*Rx Web Site](#) for further information.

## **VI.5.2 Hormone (Endocrine) Surgery**

This data item is coded in the "Transplant/Endocrine Procedure" field see [Section VI.7](#). For reporting purposes, endocrine surgery is defined as the total surgical removal of an endocrine gland (both glands or all of a remaining gland in the case of paired glands). Record endocrine surgery for treatment of cancer of the breast or prostate only. The procedures are:

- Adrenalectomy
- Hypophysectomy
- Oophorectomy (breast)
- Orchiectomy (prostate)

If tumor tissue is present in a gland removed in the course of endocrine therapy, record the procedure as surgical treatment also.

## **VI.5.3 Hormone (Endocrine) Radiation**

This data item is coded in the "Transplant/Endocrine Procedure" field see [Section VI.7](#). Report any type of radiation directed toward an endocrine gland to affect hormonal balance if:

- The treatment is for cancers of the breast and prostate.
- Both paired glands (ovaries, testes, adrenals) or all of a remaining gland have been irradiated.

## **VI.5.4 Hormone Therapy Codes**

Use the following codes for recording hormone therapy in the Summary field. Use codes 00-87 for recording hormone therapy at this hospital. The codes for Reason No Hormone have been incorporated into this field.

00	NONE, HORMONE THERAPY WAS NOT PART OF THE PLANNED FIRST COURSE THERAPY.
01	HORMONE THERAPY ADMINISTERED AS FIRST COURSE THERAPY.
82	HORMONE THERAPY WAS NOT RECOMMENDED/ADMINISTERED BECAUSE IT WAS CONTRAINDICATED DUE TO PATIENT RISK FACTORS (IE, COMORBID

	CONDITIONS, ADVANCED AGE).
85	HORMONE THERAPY WAS NOT ADMINISTERED BECAUSE THE PATIENT DIED PRIOR TO PLANNED OR RECOMMENDED THERAPY.
86	HORMONE THERAPY WAS NOT ADMINISTERED. IT WAS RECOMMENDED BY THE PATIENT'S PHYSICIAN, BUT WAS NOT ADMINISTERED AS PART OF THE FIRST COURSE THERAPY. NO REASON WAS STATED IN PATIENT RECORD.
87	HORMONE THERAPY WAS NOT ADMINISTERED. IT WAS RECOMMENDED BY THE PATIENT'S PHYSICIAN, BUT THIS TREATMENT WAS REFUSED BY THE PATIENT, A PATIENT'S FAMILY MEMBER, OR THE PATIENT'S GUARDIAN. THE REFUSAL WAS NOTED IN THE PATIENT RECORD.
88	HORMONE THERAPY WAS RECOMMENDED, BUT IT IS UNKNOWN IF IT WAS ADMINISTERED.
99	IT IS UNKNOWN WHETHER A HORMONAL AGENT(S) WAS RECOMMENDED OR ADMINISTERED BECAUSE IT IS NOT STATED IN PATIENT RECORD. DEATH CERTIFICATE ONLY.

Note: For recording Therapy at this Hospital, do not use code 99 if Class of Case is coded to 00, 30, or 31.

Note: For cases diagnosed January 1, 2010 and forward, referral to a medical oncologist is considered a recommendation. Follow-up on these cases is required to determine whether hormone therapy was administered or not, and code accordingly.

Prior to January 1, 2010, referral does not equal a recommendation.

### VI.5.5 Date of Hormone Therapy

For cases diagnosed January 1, 2010 and forward, or following installation of CSv2 software, see [Section I.1.6.4](#) and [Section I.1.6.5](#) for Coding and Entering Dates.

Record the date on which hormone therapy began at any facility as part of first course of treatment.

Consult with your software vendor for specific data entry instructions.

#### VI.5.5.1 Date of Hormone Therapy Flag

For cases diagnosed January 1, 2010 and forward, or following installation of CSv2 software, this data item is used to explain why there is no appropriate value in the corresponding date field. Since only actual known dates are entered in interoperable date items, flags are used to explain the reason the date field is blank. Depending on the registry software being used, these changes may be transparent to the registrar.

**Codes:**

10	Unknown whether any hormone therapy was given
11	No hormone therapy planned or given
12	Date cannot be determined for hormone therapy received during first course
15	Hormone therapy is planned; start date is not yet available

Blank	Full or partial date recorded
-------	-------------------------------

## VI.6 First Course of Treatment - Immunotherapy (Biological Response Modifier Therapy)

Immunotherapy/Biological response modifier therapy (BRM) is a generic term covering everything done to the immune system to alter it or change the host response to a cancer (defense mechanism).

SEER\*Rx is the downloadable, interactive antineoplastic drug database that replaces SEER Self-Instructional Manual Book 8, Antineoplastic Drugs. The software can be downloaded from the [SEER\\*Rx Web Site](#).

### VI.6.1 Immunotherapy Agents

Immunotherapy agents must be recorded in the text field.

#### January 1, 2005 and Forward

For cases diagnosed 1/1/2005 forward, registrars must use SEER\*Rx, for coding systemic treatment (i.e. chemotherapy, hormone therapy, and immunotherapy). SEER\*Rx is the downloadable, interactive antineoplastic drug database that replaces SEER Self-Instructional Manual Book 8, Antineoplastic Drugs. The software can be downloaded from the [SEER\\*Rx Web Site](#).

Report the following as immunotherapy:

- ASILI (active specific intralymphatic immunotherapy)
- Blocking factors
- Interferon
- Monoclonal antibodies\*
- Transfer factor (specific or non specific)
- Virus therapy

\*Some monoclonal antibodies are used to deliver chemotherapy or radiation agents to the tumor, not to kill the tumor immunologically. Consult SEER\*RX to determine how to appropriately code monoclonal antibodies. See the SEER Manual, p. 128.

### VI.6.2 Immunotherapy Codes

#### January 1, 2003 and Forward

Effective with cases diagnosed 1/1/2003, this data item was modified. Codes for transplants and endocrine procedures were removed and were coded in a separate field called RX Summ - Transplnt/Endocr. The length of this field was changed from 1 to 2 characters. The codes for reason for no immunotherapy (BRM) given were incorporated into this scheme.

Use codes 00-87 for recording immunotherapy in the At This Hospital field.

Use the following codes for recording immunotherapy in the Summary field.

00	NONE, IMMUNOTHERAPY WAS NOT PART OF THE PLANNED FIRST COURSE OF THERAPY
01	IMMUNOTHERAPY ADMINISTERED AS FIRST COURSE THERAPY
82	IMMUNOTHERAPY WAS NOT RECOMMENDED/ADMINISTERED BECAUSE IT WAS CONTRAINDICATED DUE TO PATIENT RISK FACTORS (i.e. COMORBID CONDITIONS, ADVANCED AGE).
85	IMMUNOTHERAPY WAS NOT ADMINISTERED BECAUSE THE PATIENT DIED PRIOR TO PLANNED OR RECOMMENDED THERAPY.
86	IMMUNOTHERAPY WAS NOT ADMINISTERED. IT WAS RECOMMENDED BY THE PATIENT'S PHYSICIAN, BUT WAS NOT ADMINISTERED AS PART OF THE FIRST COURSE OF THERAPY. NO REASON WAS STATED IN PATIENT RECORD.
87	IMMUNOTHERAPY WAS NOT ADMINISTERED. IT WAS RECOMMENDED BY THE PATIENT'S PHYSICIAN, BUT THIS TREATMENT WAS REFUSED BY THE PATIENT, A PATIENT'S FAMILY MEMBER, OR THE PATIENT'S GUARDIAN. THE REFUSAL WAS NOTED IN THE PATIENT RECORD.
88	IMMUNOTHERAPY WAS RECOMMENDED, BUT IT IS UNKNOWN IF IT WAS ADMINISTERED.
99	IT IS UNKNOWN WHETHER AN IMMUNOTHERAPEUTIC AGENT(S) WAS RECOMMENDED OR ADMINISTERED BECAUSE IT IS NOT STATED IN PATIENT RECORD. DEATH CERTIFICATE ONLY.

Note: For recording Therapy at this Hospital, do not use code 99 if Class of Case is coded to 00, 30, or 31.

Note: For cases diagnosed January 1, 2010 and forward, referral to a medical oncologist is considered a recommendation. Follow-up on these cases is required to determine whether immunotherapy was administered or not, and code accordingly.

Prior to January 1, 2010, referral does not equal a recommendation.

### VI.6.3 Date of Immunotherapy

For cases diagnosed January 1, 2010 and forward, or following installation of CSv2 software, see [Section I.1.6.4](#) and [Section I.1.6.5](#) for Coding and Entering Dates.

Record the date on which immunotherapy began at any facility as part of first course of treatment.

Consult with your software vendor for specific data entry instructions.

#### VI.6.3.1 Date of Immunotherapy Flag

For cases diagnosed January 1, 2010 and forward, or following installation of CSv2 software, this data item is used to explain why there is no appropriate value in the corresponding date field. Since only actual known dates are entered in interoperable date items, flags are used to explain the reason the date field is blank. Depending on the registry software being used, these changes may be transparent to the registrar.



**Codes**

10	Unknown whether immunotherapy was given
11	No immunotherapy planned or given
12	Date cannot be determined for immunotherapy received during first course
15	Immunotherapy is planned; start date is not yet available
Blank	Full or partial date recorded

**VI.7 First Course of Treatment - Transplant/Endocrine Procedures**

Record systemic therapeutic procedures administered as part of first course of treatment. These include bone marrow transplants, stem cell harvests, surgical and/or radiation endocrine therapy. Information on transplants and endocrine procedures was removed from the Rx Summ-BRM (Immunotherapy) field and moved to this field. Bone marrow and stem cell procedures are now coded in this field along with endocrine surgery or radiation.

For cases prior to January 1, 2003, a conversion was required using both the Rx Summ - BRM (Immunotherapy) and Rx Summ - Hormone fields. Although the CoC did not add a corresponding "At this Hospital" field, the CCR required this field in order to provide consistency, since all of the other treatment fields except radiation have a hospital-level field during this time period.

Code systemic irradiation or total body irradiation (TBI) prior to bone marrow transplant as treatment. Any chemotherapy given in preparation for the TBI is also coded as treatment. Both irradiation and chemotherapy destroy cancer cells in the bone marrow.

**VI.7.1 Transplant/Endocrine Codes**

Use the following codes for recording transplant/endocrine procedures in the Summary field. Use codes 00-87 for recording transplant/endocrine procedures in the At This Hospital field.

00	NO TRANSPLANT PROCEDURE OR ENDOCRINE THERAPY WAS ADMINISTERED AS PART OF THE FIRST COURSE THERAPY
10	A BONE MARROW TRANSPLANT PROCEDURE WAS ADMINISTERED, BUT THE TYPE WAS NOT SPECIFIED
11	BONE MARROW TRANSPLANT - AUTOLOGOUS
12	BONE MARROW TRANSPLANT - ALLOGENEIC
20	STEM CELL HARVEST
30	ENDOCRINE SURGERY AND/OR ENDOCRINE RADIATION THERAPY
40	COMBINATION OF ENDOCRINE SURGERY AND/OR RADIATION WITH A TRANSPLANT PROCEDURE. (COMBINATION OF CODES 30 AND 10, 11, 12, OR

	20.)
82	HEMATOLOGIC TRANSPLANT AND/OR ENDOCRINE SURGERY/RADIATION WERE NOT RECOMMENDED/ADMINISTERED BECAUSE IT WAS CONTRAINDICATED DUE TO PATIENT RISK FACTORS (I.E., COMORBID CONDITIONS, ADVANCED AGE).
85	HEMATOLOGIC TRANSPLANT AND/OR ENDOCRINE SURGERY/RADIATION WERE NOT ADMINISTERED BECAUSE THE PATIENT DIED PRIOR TO PLANNED OR RECOMMENDED THERAPY.
86	HEMATOLOGIC TRANSPLANT AND/OR ENDOCRINE SURGERY/RADIATION WERE NOT ADMINISTERED. IT WAS RECOMMENDED BY THE PATIENT'S PHYSICIAN, BUT WAS NOT ADMINISTERED AS PART OF THE FIRST COURSE THERAPY. NO REASON WAS STATED IN PATIENT RECORD.
87	HEMATOLOGIC TRANSPLANT AND/OR ENDOCRINE SURGERY/RADIATION WERE NOT ADMINISTERED. IT WAS RECOMMENDED BY THE PATIENT'S PHYSICIAN, BUT THIS TREATMENT WAS REFUSED BY THE PATIENT, A PATIENT'S FAMILY MEMBER, OR THE PATIENT'S GUARDIAN. THE REFUSAL WAS NOTED IN PATIENT RECORD.
88	HEMATOLOGIC TRANSPLANT AND/OR ENDOCRINE SURGERY/RADIATION WAS RECOMMENDED, BUT IT IS UNKNOWN IF IT WAS ADMINISTERED.
99	IT IS UNKNOWN WHETHER HEMATOLOGIC TRANSPLANT AND/OR ENDOCRINE SURGERY/RADIATION WAS RECOMMENDED OR ADMINISTERED BECAUSE IT IS NOT STATED IN PATIENT RECORD. DEATH CERTIFICATE ONLY.

Note: For recording Therapy at this Hospital, do not use code 99 if Class of Case is coded to 00, 30 or 31.

Note: For cases diagnosed January 1, 2010 and forward, referral to a specialist for hematologic transplant or endocrine procedures is considered a recommendation. Follow-up on these cases is required to determine whether a procedure was performed or not, and code accordingly.

Prior to January 1, 2010, referral does not equal a recommendation.

### **VI.7.2 Date of Transplant/Endocrine Procedure**

For cases diagnosed January 1, 2010 and forward, or following installation of CSv2 software, see [Section I.1.6.4](#) and [Section I.1.6.5](#) for Coding and Entering Dates.

Record the date on which the transplant/endocrine procedure took place at any facility as part of the first course treatment.

Consult with your software vendor for specific data entry instructions.

## VI.8 First Course of Treatment - Other Therapy

Record definitive, cancer-directed treatment that cannot be assigned to any other category, for example:

- Hyperbaric oxygen (as adjunct to definitive treatment).
- Hyperthermia (given alone or in combination with chemotherapy, as in isolated heated limb perfusion for melanoma).
- Cancer vaccines are still in the experimental phase. Currently, clinical trials use cancer vaccines for brain, breast, colon, kidney, lung, melanoma, and ovary.
- Any experimental drug that cannot be classified elsewhere.
- Double blind clinical trial information where the type of agent administered is unknown and/or there is any use of a placebo. However, after the code is broken, report the treatment under the appropriate category (a correction record should be submitted when the data are available).
- Unorthodox and unproven treatment, such as laetrile or krebiozen.

For Newly Reportable Hematopoietic Diseases (NRHD) only, specify in the Remarks field and use code 1 "Other Therapy" for the following:

- Transfusions/Plasmapheresis
- Phlebotomy/Blood Removal
- Supportive Care
- Aspirin
- Observation

### VI.8.1 Other Therapy Codes

Use codes 0-7 for recording other therapy in the At This Hospital field.

0	NO OTHER CANCER DIRECTED THERAPY EXCEPT AS CODED ELSEWHERE. DIAGNOSED AT AUTOPSY.
1	OTHER CANCER DIRECTED THERAPY Examples: <ul style="list-style-type: none"> <li>• Embolization using alcohol as an embolizing agent</li> <li>• Embolization to a site other than the liver where the embolizing agent is unknown</li> <li>• PUVA (psoralen and long-wave ultraviolet radiation) treatments for melanoma</li> </ul>
2	OTHER EXPERIMENTAL CANCER DIRECTED THERAPY (not included elsewhere)
3	DOUBLE BLIND CLINICAL TRIAL, CODE NOT YET BROKEN
6	UNPROVEN THERAPY
7	PATIENT OR PATIENT'S GUARDIAN REFUSED THERAPY WHICH WOULD HAVE BEEN CODED 1-3 ABOVE

8	OTHER CANCER DIRECTED THERAPY RECOMMENDED, UNKNOWN IF ADMINISTERED
9	UNKNOWN IF OTHER THERAPY RECOMMENDED OR ADMINISTERED. DEATH CERTIFICATE ONLY.

Note: For recording Therapy at this Hospital, do not use code 9 if Class of Case is coded to 00, 30, or 31.

Note: For cases diagnosed January 1, 2010 and forward, referral to a specialist is considered a recommendation. Follow-up on these cases is required to determine whether treatment was administered or not, and code accordingly.

Prior to January 1, 2010, referral does not equal a recommendation.

### VI.8.2 Date of Other Therapy

For cases diagnosed January 1, 2010 and forward, or following installation of CSv2 software, see [Section I.1.6.4](#) and [Section I.1.6.5](#) for Coding and Entering Dates.

Record the date on which Other Therapy began at any facility as part of first course treatment.

Consult with your software vendor for specific data entry instructions.

#### VI.8.2.1 Date of Other Therapy Flag

For cases diagnosed January 1, 2010 and forward, or following installation of CSv2 software, this data item is used to explain why there is no appropriate value in the corresponding date field. Since only actual known dates are entered in interoperable date items, flags are used to explain the reason the date field is blank. Depending on the registry software being used, these changes may be transparent to the registrar.

**Codes:**

10	Unknown whether other therapy was given
11	No other therapy planned or given
12	Date cannot be determined for other therapy received during first course
15	Other therapy is planned; start date is not yet available
Blank	Full or partial date recorded

### VI.9 RX Summary – Treatment Status

For cases diagnosed January 1, 2010 and forward, or following installation of CSv2 software, this data item is used to summarize the status for all treatment modalities. It is used in conjunction with Date of Initial RX and/or Date of 1st Course RX-CoC and each modality of treatment with their respective date field to document whether treatment was given or not given, whether it is unknown if treatment was given, or whether treatment was given on an unknown date. Active surveillance (watchful waiting) is also documented. This data item is required by the CCR.

**Codes**

0	No treatment given, <i>treatment refused, or physician decides not to treat for any reason such as the presence of comorbidities</i>
1	Treatment given
2	Active surveillance (watchful waiting)
9	Unknown if treatment was given

**VI.9.1 Protocol Participation**

**January 1, 2001 and Forward**

Beginning with cases diagnosed January 1, 2001, the CCR requires that this field be collected and transmitted to the CCR. The codes are as follows:

<b>National Protocols</b>	
00	Not Applicable
01	NSABP
02	GOG
03	RTOG
04	SWOG
05	ECOG
06	POG
07	CCG
08	CALGB
09	NCI
10	ACS
11	National Protocol, NOS
12	ACOS-OG
13	VA [Veterans Administration]
14	COG [Children's Oncology Group]
15	CTSU [Clinical Trials Support Unit]
16-50	National Trials
<b>Locally Defined</b>	
51-79	Locally Defined
80	Pharmaceutical
81-84	Locally Defined
85	In-House Trial
86-88	Locally Defined
89	Other
90-98	Locally Defined
99	Unknown

## **PART VII. FOLLOW-UP**

### **VII.1 Follow-Up Information**

A function of the California cancer reporting system is annual monitoring of patients to ascertain survival rates.

Therefore, if follow-up information is available before an abstract is submitted, include the follow-up information in the abstract.

Facilities with cancer programs approved by ACoS must update follow-up data annually (consult ACoS Guidelines for requirements). Obtain the information from medical records (if the patient has been readmitted), or from the patient's physician, contact letters, and telephone calls.

Annual follow-up is not required for a hospital that does not have a tumor registry and is submitting an abstract only to meet state reporting requirements. The CCR does not impose follow-up requirements beyond what a hospital chooses to do for its own purposes. For example, if a hospital elects not to follow non analytic cases, the CCR will not expect to receive follow-up information for such cases.

Effective January 1, 2010 and forward, follow-up is still required for the following tumors, although they are categorized in Class of Case 34 or 36:

- Benign and borderline CNS tumors diagnosed between January 1, 2001 and December 31, 2003 (before the national benign and borderline CNS tumor reporting requirement was implemented)
- VIN III
- VAIN III
- AIN III

Effective January 1, 2010 and forward, follow-up is no longer required for borderline ovarian cases diagnosed January 1, 2001 and forward.

#### **VII.1.1 Required Data**

Some follow-up data items are optional for reporting to the CCR but might be required by the ACoS, for shared follow-up involving other institutions, or by the reporting facility for in-house data.

The CCR's required items are:

- Date of Last Patient Contact
- Vital Status
- Date Last Tumor Status
- Tumor Status
- Last Follow-up Facility
- Death information

### **VII.1.2 Sources of Follow-Up Information**

Follow-up information must be based on documentation of contact with the patient in one of the following forms:

- Direct response to a letter or phone call to the patient or other contact person
- A report by the patient's physician
- Re-admission to the facility as an inpatient or outpatient
- Death certificate

It might be necessary to trace the patient through such agencies and organizations as the registrar of voters, welfare agencies, labor unions, religious groups, or the Office of the State Registrar for a death certificate.

### **VII.1.3 Current Status of Follow-Up Information**

Current status is defined as contact with the patient within 15 months of the date the follow-up is reported.

Although current information is preferred, updated information that is not current should still be reported.

### **VII.1.4 Shared Follow-Up**

In those cases where a patient is being followed by more than one reporting facility, the regional or the central registry may designate a facility responsible for follow-up in an effort to prevent physicians and patients from receiving requests for information from many sources.

Shared follow-up which discloses the source or name of the facility requires a signed agreement from each participating registry.

Follow-up may be shared without a signed agreement as long as the source is not disclosed.

This does not preclude a facility's registry from submission of more current information about its patients. Shared follow-up is instituted only by agreement among participating facilities in a region.

## **VII.2 Follow-Up Data Items**

Follow-up data items provide information about the outcome of cancers and the results of treatment. A patient's survival time is calculated on the basis of Date of Diagnosis and Date of Last Contact.

See sections VII.2.1 through VII.2.13 for specific information.

### **VII.2.1 Date of Last Contact**

For cases diagnosed January 1, 2010 and forward, or following installation of CSV2 software, see [Section I.1.6.4](#) and [Section I.1.6.5](#) for Coding and Entering Dates.

Enter the date the patient was last seen or heard from or the date of death. Do not enter the date the information was forwarded or received.

If no follow-up information has been received, enter the date of discharge from the hospital. All abstracts submitted for a patient must contain the same Date of Last Contact.

Consult with your software vendor for specific data entry instructions.

### **VII.2.1.1 Date of Last Contact Flag**

For cases diagnosed January 1, 2010 and forward, or following installation of CSV2 software, this data item is used to explain why there is no appropriate value in the corresponding date field. Since only actual known dates are entered in interoperable date items, flags are used to explain the reason the date field is blank. Depending on the registry software being used, these changes may be transparent to the registrar.

#### **Codes**

12	Date cannot be determined
Blank	Full or partial date recorded

### **VII.2.2 Vital Status**

Enter the code representing whether the patient was still alive on the date of last contact. If a patient with more than one primary has died, be sure to record the fact in all the abstracts.

The codes are:

0 DEAD

1 ALIVE

### **VII.2.3 Date Last Tumor Status**

Enter the date of the last information obtained on the primary (tumor) being followed. This field has been added for patients with multiple primaries.

### **VII.2.4 Tumor Status**

Summarize the best available information about the status of the tumor on the date of last contact. The field applies only to the tumor for which the abstract is submitted, regardless of any other tumors the patient might have.

#### **Codes**

1	FREE—NO EVIDENCE OF THIS CANCER
2	NOT FREE—EVIDENCE STILL EXISTS OF THIS CANCER
9	UNKNOWN—STATUS OF THIS CANCER UNKNOWN



## VII.2.5 Quality of Survival

Enter the code that best characterizes the patient's quality of survival. This item is not required by the CCR.

### Codes

0	NORMAL ACTIVITY
1	SYMPTOMATIC AND AMBULATORY
2	AMBULATORY MORE THAN 50%, OCCASIONALLY NEEDS ASSISTANCE
3	AMBULATORY LESS THAN 50%, NURSING CARE NEEDED
4	BEDRIDDEN, MAY REQUIRE HOSPITALIZATION
8	NOT APPLICABLE, DEAD
9	UNKNOWN/UNSPECIFIED

Reporting facilities may use another coding system or scale adopted by the facility's cancer committee.

## VII.2.6 Last Type of Follow-Up

There are two fields which are to be used to enter the source of the most recent follow-up information about the patient:

See [Section VII.2.6.1](#) - Last Type of Tumor Follow-Up

See [Section VII.2.6.2](#) - Last Type of Patient Follow-Up

### VII.2.6.1 Last Type of Tumor Follow-Up

This field is to be used to enter information representing the source of the most recent information on the tumor being followed. Reporting facilities ordinarily use codes from the first of the three following groups, i.e., 00-15, unless instructed otherwise by their regional or central registry.

Follow-up obtained by hospital from:	
00	ADMISSION BEING REPORTED
01	READMISSION TO REPORTING FACILITY
02	FOLLOW-UP REPORT FROM PHYSICIAN
03	FOLLOW-UP REPORT FROM PATIENT
04	FOLLOW-UP REPORT FROM RELATIVE
05	OBITUARY
07	FOLLOW-UP REPORT FROM HOSPICE
08	FOLLOW-UP REPORT FROM OTHER FACILITY
09	OTHER SOURCE
11	TELEPHONE CALL TO ANY SOURCE
12	SPECIAL STUDIES
14	ARS (AIDS REGISTRY SYSTEM)
15	COMPUTER MATCH WITH DISCHARGE DATA
Follow-up obtained by regional registry from:	
20	LETTER TO A PHYSICIAN
22	COMPUTER MATCH WITH MEDICARE OR MEDICAID FILE
23	COMPUTER MATCH WITH HMO FILE

	25	NATIONAL DEATH INDEX
	26	COMPUTER MATCH WITH STATE DEATH TAPE
	29	COMPUTER MATCH, OTHER OR NOS
	30	OTHER SOURCE
	31	TELEPHONE CALL TO ANY SOURCE
	32	SPECIAL STUDIES
	34	ARS (AIDS REGISTRY SYSTEM)
	35	COMPUTER MATCH WITH DISCHARGE DATA
	36	OBITUARY
Follow-up obtained by central (state) registry from:		
	40	LETTER TO A PHYSICIAN
	41	TELEPHONE CALL TO ANY SOURCE
	52	COMPUTER MATCH WITH MEDICARE OR MEDICAID FILE
	53	COMPUTER MATCH WITH HMO FILE
	55	NATIONAL DEATH INDEX
	56	COMPUTER MATCH WITH STATE DEATH TAPE
	59	COMPUTER MATCH, OTHER OR NOS
	60	OTHER SOURCE
Follow-up obtained by hospitals or facilities usually done by the regional/central registry:		
	73	COMPUTER MATCH WITH HMO FILE
	76	COMPUTER MATCH WITH STATE DEATH TAPE
Additional Codes:		
	99	SOURCE UNKNOWN

### VII.2.6.2 Last Type of Patient Follow-Up

This field is to be used to enter the code representing the source of the most recent information about the patient being followed. Reporting hospitals ordinarily use codes from the first of the three following groups, i.e., 00-15.

Follow-up obtained by hospital from:		
	00	ADMISSION BEING REPORTED
	01	READMISSION TO REPORTING FACILITY
	02	FOLLOW-UP REPORT FROM PHYSICIAN
	03	FOLLOW-UP REPORT FROM PATIENT
	04	FOLLOW-UP REPORT FROM RELATIVE
	05	OBITUARY
	06	FOLLOW-UP REPORT FROM SOCIAL SECURITY ADMINISTRATION OR MEDICARE
	07	FOLLOW-UP REPORT FROM HOSPICE
	08	FOLLOW-UP REPORT FROM OTHER FACILITY
	09	OTHER SOURCE
	11	TELEPHONE CALL TO ANY SOURCE
	12	SPECIAL STUDIES
	13	EQUIFAX
	14	ARS (AIDS REGISTRY SYSTEM)
	15	COMPUTER MATCH WITH DISCHARGE DATA

California Cancer Reporting System Standards, Volume I

	16	SSDI MATCH
Follow-up obtained by regional registry from:		
	20	LETTER TO A PHYSICIAN
	21	COMPUTER MATCH WITH DEPARTMENT OF MOTOR VEHICLES FILE
	22	COMPUTER MATCH WITH MEDICARE OR MEDICAID FILE
	23	COMPUTER MATCH WITH HMO FILE
	24	COMPUTER MATCH WITH VOTER REGISTRATION FILE
	25	NATIONAL DEATH INDEX
	26	COMPUTER MATCH WITH STATE DEATH TAPE
	27	DEATH MASTER FILE (SOCIAL SECURITY)
	29	COMPUTER MATCH, OTHER OR NOS
	30	OTHER SOURCE
	31	TELEPHONE CALL TO ANY SOURCE
	32	SPECIAL STUDIES
	33	EQUIFAX
	34	ARS (AIDS REGISTRY SYSTEM)
	35	COMPUTER MATCH WITH DISCHARGE DATA
	36	OBITUARY
	37	COMPUTER MATCH WITH CHANGE OF ADDRESS SERVICE
	38	TRW
	39	REGIONAL REGISTRY FOLLOW-UP LIST
Follow-up obtained by central (state) registry from:		
	40	LETTER TO A PHYSICIAN
	41	TELEPHONE CALL TO ANY SOURCE
	48	Research Study Follow Up
	50	CMS (CENTER FOR MEDICARE & MEDICAID SERVICES)
	51	COMPUTER MATCH WITH DEPARTMENT OF MOTOR VEHICLES FILE
	52	CALIFORNIA MEDICAL REVIEW INC
	53	COMPUTER MATCH WITH HMO FILE
	54	COMPUTER MATCH WITH VOTER REGISTRATION FILE
	55	NATIONAL DEATH INDEX
	56	COMPUTER MATCH WITH STATE DEATH TAPE
	57	COMPUTER MATCH WITH MEDI-CAL
	58	COMPUTER MATCH WITH SOCIAL SECURITY DEATH FILE
	59	COMPUTER MATCH, OTHER OR NOS
	60	OTHER SOURCE
	61	SOCIAL SECURITY - SSN
	62	SPECIAL STUDIES
	65	COMPUTER MATCH WITH OSHPD HOSPITAL DISCHARGE DATA BASE
	66	COMPUTER MATCH WITH NATIONAL CHANGE OF ADDRESS FILE
	67	SSA - EPIDEMIOLOGICAL VITAL STATUS
	68	PROPERTY TAX LINKAGE
	69	STATE DEATH TAPE (INCREMENTAL)
Follow-up obtained by hospitals or facilities usually done by the regional/central registry:		
	73	COMPUTER MATCH WITH HMO FILE

	76	COMPUTER MATCH WITH STATE DEATH TAPE
Regional Registry (Additional Codes)		
	80	SOCIAL SECURITY ADMINISTRATION
	81	PROPERTY TAX LINKAGE
	82	PROBE360
	83	SSDI - INTERNET
	84	E-PATH
	85	PATH LABS
	86	PATIENT
	87	RELATIVE
Unknown Source		
	99	SOURCE UNKNOWN

### VII.2.7 Last Follow-Up Facility

Enter the CCR assigned reporting facility code for the reporting facility or agency that provided the most recent follow-up information.

[Reporting facilities in alphabetic order.](#)

[Reporting facilities in code order.](#)

### VII.2.8 Next Type Follow-Up

Record the method of obtaining follow-up information about the patient for the next report. If the patient has died, leave the field blank.

The codes are:

0	SUBMIT A REQUEST FOR THE PATIENT'S CHART TO THE REPORTING FACILITY'S MEDICAL RECORDS DEPARTMENT
1	SEND A FOLLOW-UP LETTER TO THE PATIENT'S PHYSICIAN
2	SEND A FOLLOW-UP LETTER TO THE PERSON DESIGNATED AS THE CONTACT FOR THE PATIENT
3	CONTACT THE PATIENT OR DESIGNATED CONTACT BY TELEPHONE
4	REQUEST FOLLOW-UP INFORMATION FROM ANOTHER FACILITY
5	FOLLOW-UP BY A METHOD NOT DESCRIBED ABOVE
6	SEND A FOLLOW-UP LETTER TO THE PATIENT
7	PATIENT PRESUMED LOST, STOP PRINTING FOLLOW-UP LETTERS
8	* FOREIGN RESIDENT, FOLLOW-UP DISCONTINUED OR NOT INITIATED
9	DO NOT FOLLOW-UP (except code 8)

\* Foreign residents may be followed at the hospital's option, in which case do not use code 8.

### VII.2.9 Next Follow-Up Facility

Enter the CCR assigned reporting facility code of the hospital, facility, or agency responsible for the next follow-up of the patient.

[Reporting facilities in alphabetic order.](#)

[Reporting facilities in code order.](#)

## VII.2.10 Follow-Up Physician

Enter the name or code number of the attending physician—not a resident or intern—responsible for the patient. If a different physician is to receive the next follow-up letter, enter that physician's name or code number. (For instructions about entering codes, see [Section III.3.12.1.](#))

Enter code 99999999 if there is no Follow-Up Physician.

Enter code 99999999 if the Follow-Up Physician is "unknown" or "license number not assigned."

### January 1, 2007 and Forward

Beginning with cases diagnosed January 1, 2007, enter the physician NPI code in the respective field, if it is available. See [Appendix X](#) for further details.

## VII.2.11 Alternate Medical Record Number

An alternate medical record number, such as the patient's record number at the next follow-up facility, may be entered for the convenience of the facility performing the follow-up. The Alternate Medical Record Number field should usually be changed if the Next Follow-Up Hospital field is changed. The item is not required, and is not transmitted to the CCR.

## VII.2.12 Recurrence Information

If a patient's primary tumor recurred after a period of complete remission, the Date of First Recurrence and Type of First Recurrence must be coded by American College of Surgeons-approved registries. The data are optional for reporting to the California Cancer Registry. Code only the first recurrence and do not update the fields except to correct data entry errors.

### VII.2.12.1 Date of First Recurrence

Enter the date of first recurrence of a primary tumor that recurred after a period of complete remission. See [Section I.1.6.4](#) for entering dates. If the exact date is not known, enter an estimate based on the best available information. If the patient was never free of the primary tumor or did not experience a recurrence, leave the field as zeros.

### VII.2.12.2 Type of First Recurrence

Enter one of the following codes to indicate the type of first recurrence:

00	NONE, DISEASE FREE
01	IN SITU
06	RECURRENCE FOLLOWING DIAGNOSIS OF AN IN SITU LESION OF THE SAME SITE
10	LOCAL
11	TROCAR SITE
15	COMBINATION OF 10 AND 11
16	LOCAL RECURRENCE FOLLOWING AN IN SITU LESION OF THE SAME SITE
17	COMBINATION OF 16 WITH 10, 11 AND/OR 15

California Cancer Reporting System Standards, Volume I

20	REGIONAL, NOS
21	REGIONAL TISSUE
22	REGIONAL LYMPH NODES
25	COMBINATION OF 21 AND 22
26	REGIONAL RECURRENCE FOLLOWING AN IN SITU LESION OF THE SAME SITE
27	COMBINATION OF 26 WITH 21, 22, AND/OR 25
30	ANY COMBINATION OF 10, 11, AND 20, 21 OR 22
36	ANY COMBINATION OF RECURRENCE FOLLOWING AN IN SITU LESION OF THE SAME SITE WITH 10, 11, 20, 21 OR 22
40	DISTANT RECURRENCE, AND THERE IS INSUFFICIENT INFORMATION AVAILABLE TO CODE TO 46-62
46	DISTANT RECURRENCE OF AN IN SITU TUMOR
51	DISTANT RECURRENCE OF INVASIVE TUMOR IN THE PERITONEUM ONLY. PERITONEUM INCLUDES PERITONEAL SURFACES OF ALL STRUCTURES WITHIN THE ABDOMINAL CAVITY AND/OR POSITIVE ASCITIC FLUID.
52	DISTANT RECURRENCE OF AN INVASIVE TUMOR IN THE LUNG ONLY. LUNG INCLUDES THE VISCERAL PLEURA.
53	DISTANT RECURRENCE OF AN INVASIVE TUMOR IN THE PLEURA ONLY. PLEURA INCLUDES THE PLEURAL SURFACE OF ALL STRUCTURES WITHIN THE THORACIC CAVITY AND/OR POSITIVE PLEURAL FLUID.
54	DISTANT RECURRENCE OF AN INVASIVE TUMOR IN THE LIVER ONLY.
55	DISTANT RECURRENCE OF AN INVASIVE TUMOR IN BONE ONLY. THIS INCLUDES BONES OTHER THAN THE PRIMARY SITE.
56	DISTANT RECURRENCE OF AN INVASIVE TUMOR IN THE CNS ONLY. THIS INCLUDES THE BRAIN AND SPINAL CORD, BUT NOT THE EXTERNAL EYE.
57	DISTANT RECURRENCE OF AN INVASIVE TUMOR IN THE SKIN ONLY. THIS INCLUDES SKIN OTHER THAN THE PRIMARY SITE.
58	DISTANT RECURRENCE OF AN INVASIVE TUMOR IN LYMPH NODE ONLY. REFER TO THE STAGING SCHEME FOR A DESCRIPTION OF LYMPH NODES THAT ARE DISTANT FOR A PARTICULAR SITE.
59	DISTANT SYSTEMIC RECURRENCE OF AN INVASIVE TUMOR ONLY. THIS INCLUDES LEUKEMIA, BONE MARROW METASTASIS, CARCINOMATOSIS, GENERALIZED DISEASE.
60	DISTANT RECURRENCE OF AN INVASIVE TUMOR IN A SINGLE DISTANT SITE (51-58) AND LOCAL, TROCAR AND/OR REGIONAL RECURRENCE (10-15, 20-25, OR 30).
62	DISTANT RECURRENCE OF AN INVASIVE TUMOR IN MULTIPLE SITES (RECURRENCES THAT CAN BE CODED TO MORE THAN ONE CATEGORY 51-59).
70	SINCE DIAGNOSIS, PATIENT HAS NEVER BEEN DISEASE-FREE. THIS INCLUDES CASES WITH DISTANT METASTASIS AT DIAGNOSIS, SYSTEMIC DISEASE, UNKNOWN PRIMARY, OR MINIMAL DISEASE THAT IS NOT TREATED.
88	DISEASE HAS RECURRED, BUT THE TYPE OF RECURRENCE IS UNKNOWN
99	IT IS UNKNOWN WHETHER THE DISEASE HAS RECURRED OR IF THE PATIENT WAS EVER DISEASE-FREE

NOTE: The Distant Recurrence Sites field has been removed and incorporated into the Type of First Recurrence field.

### **VII.2.13 Death Information**

If the patient has died, enter the code for the state or country where the death occurred in the Place of Death field. (The code for California is 097. See [Appendix C](#), [Appendix D1](#), and [Appendix D2](#) for other codes.) If the patient is still alive, enter 997. Hospitals are not required to complete the *Cause of Death* field or *DC (Death Certificate) File No.* field.

To report that a patient has died, make every attempt to find the month and year of death. Approximations are acceptable when all attempts to find the date of death have failed.

### **VII.2.14 Follow-Up Remarks**

This section was software specific and deleted in 2008. The information entered here was not transmitted to the CCR.

## **VII.3 Contact Name/Address File**

The Contact Name/Address File is for generating follow-up letters to the patient or designated contact(s). Space is provided for the name and address of the patient and up to five contacts for information about the patient. Enter names and addresses exactly as they are to appear in the heading of the letter, using capital and lower case letters, punctuation, and special characters like # for number. But in the Phone field, enter the area code and number without spaces, dashes, or other marks.

A supplemental field has been added which provides the ability to record additional address information such as the name of a place or facility (i.e., a nursing home or name of an apartment complex). This supplemental field is limited to 60 characters.

### **VII.3.1 Follow-Up Resources**

This section was software specific and deleted in 2008.

### **VII.3.2 Contact #**

In the Contact #1 fields enter the following:

- The patient's name preceded by Mr., Mrs., Ms., or followed by Jr. or Sr. (up to 60 characters and spaces)
- The current street address or post office box (up to 60 characters and spaces)
- The current city (up to 50 characters and spaces)
- The two character Postal Service abbreviation for the state (see [Appendix B](#) for abbreviations)
- The zip code (up to ten characters and spaces)

If the patient is under 18, enter a parent's name and address.

Addresses in foreign countries may be entered, including foreign postal codes.

Entry of a telephone number is required for all patients alive at the time the case is abstracted. Include the area code.

If the telephone number changes at the time of follow-up, it needs to be changed in this field. If there is no phone, enter all 0's.

In the Patient Address Current--Supplemental field, record the place or facility (i.e., nursing home or name of an apartment complex) of the patient's current usual residence. If the patient has multiple tumors, the address may be different for subsequent primaries. Update this data item if a patient's address changes. This supplemental field is limited to 60 characters.

### **VII.3.3 Contacts #2 through #6**

If available in the abstracting software, enter the names, addresses, and phone numbers of up to six people designated as contacts for the case.

A supplemental follow-up contact field has been added. This data item provides the ability to store additional address information such as the name of a place or facility, a nursing home, or the name of an apartment complex. It can be used to generate a follow-up inquiry, and must correspond to the other fields in the follow-up contact address. If the patient has multiple tumors, Follow-Up Contact--Suppl should be the same. This supplemental field is limited to 60 characters.



## **PART VIII. REMARKS AND EXTRA HOSPITAL INFORMATION**

### **VIII.1 Remarks and Final Diagnosis**

Textual information that does not fit into its designated field can be recorded in the Remarks area. Indicate the name of the field being extended and enter the overflow information. Also record other pertinent information for which there is no designated field.

The last two lines of this section are available for recording the final cancer diagnosis (FDX) as determined by a recognized medical practitioner. This information is ideally found in the discharge summary or progress notes.

Record the date of the notation and the final diagnosis, including stage if given. If there is no final diagnosis in the medical record, please state FDX: NR; do not leave this field blank.

#### **VIII.1.1 Required Data Items**

Certain required data must be recorded in the Remarks section:

Other tumors See [Section II.2.5](#).

Race of patient, when coded as "Other" or if there is conflicting race information. See [Section III.2.9](#).

Parent or guardian of a child whose case is being reported. (Information about the parent is also entered in the Contact #1 area. Section [VII.3.2](#).)

#### **VIII.1.2 Confidential Remarks**

**January 1, 2009**

This section was software specific and was removed at the conclusion of 2008.

#### **VIII.1.3 More Remarks**

**January 1, 2009**

This section was software specific and was removed at the conclusion of 2008.

### **VIII.2 Regional Data**

Use of the Regional Data fields is determined by the regional registry, which designates the codes to be entered.

### **VIII.3 Extra Facility Information**

The Extra Facility Information fields (also called User Data) are provided for the convenience of the reporting hospital, which determines how they are to be used. All the fields may be left blank. The information is not sent to the CCR.

## **VIII.4 Clinical Indicators**

These fields have been added for use by hospitals. There is space to record up to 30 clinical indicators.

## **VIII.5 Tumor History**

These fields are available for recording the tumor history of the patient for each tumor.

## **PART IX. TRANSMITTAL of CASE INFORMATION and QUALITY CONTROL**

### **IX.1 Transmittal of Case Information**

All cases must be transmitted electronically and must be encrypted and password protected.

The frequency of transmittals must be arranged between the reporting facility and the regional or central registry, but must be quarterly at least. For very large facilities, monthly or even weekly transmittals might be appropriate to allow a more even work flow for quality control at the regional or central registry.

#### **IX.1.1 Timeliness**

Submit all reports to the regional or central registry assigned to the reporting facility. Unless the regional or central registry requests an immediate report on a patient or patients, do not submit an abstract until all the required information has been entered, but no later than six months after admission of the patient.

#### **IX.1.2 Corrections**

If errors or omissions are discovered after an abstract has been transmitted, the corrections and the reason they were entered must be sent to the regional registry or central registry if any of the following fields is changed.

- Accession Number
- Address at Diagnosis - City
- Address at Diagnosis - No. & Street
- Address at Diagnosis - Supplemental
- Address At Diagnosis - State
- Address At Diagnosis - Zip Code
- Address At Diagnosis City USPS
- Alias First Name
- Alias Last Name
- Ambiguous Terminology Diagnosis
- Behavior Code ICD-O-3
- Birth Date
- Birthplace
- Casefinding Source
- Chemotherapy at This Hospital
- Chemotherapy Summary
- Class of Case
- Comorbidity/Complication 1

Comorbidity/Complication 2  
Comorbidity/Complication 3  
Comorbidity/Complication 4  
Comorbidity/Complication 5  
Comorbidity/Complication 6  
Comorbidity/Complication 7  
Comorbidity/Complication 8  
Comorbidity/Complication 9  
Comorbidity/Complication 10  
County of Residence at Diagnosis  
CS Tumor Size  
CS Tumor Size/Extension Evaluation  
CS Extension  
CS Lymph Nodes  
CS Lymph Node Evaluation  
CS Metastasis at Diagnosis  
CS Mets at Diagnosis Evaluation  
CS Site Specific Factor 1  
CS Site Specific Factor 2  
CS Site Specific Factor 3  
CS Site Specific Factor 4  
CS Site Specific Factor 5  
CS Site Specific Factor 6  
CS Site Specific Factor 7  
CS Site Specific Factor 8  
CS Site Specific Factor 9  
CS Site Specific Factor 10  
CS Site Specific Factor 11  
CS Site Specific Factor 12  
CS Site Specific Factor 13  
CS Site Specific Factor 14  
CS Site Specific Factor 15  
CS Site Specific Factor 16  
CS Site Specific Factor 17  
CS Site Specific Factor 18  
CS Site Specific Factor 19  
CS Site Specific Factor 20  
CS Site Specific Factor 21  
CS Site Specific Factor 22

CS Site Specific Factor 23  
CS Site Specific Factor 24  
CS Site Specific Factor 25  
CS Tumor Size/Ext Evaluation  
CS Reg Nodes Evaluation  
Mets Evaluation  
Date of Birth  
Date of Birth Flag  
Date of Chemotherapy  
Date of Chemotherapy Flag  
Date of Conclusive Diagnosis  
Date of Conclusive Diagnosis Flag  
Date of Diagnosis  
Date of Diagnosis Flag  
Date of Diagnostic or Staging Procedures  
Date of Diagnostic or Staging Procedures Flag  
Date of First Admission  
Date of First Contact  
Date of First Contact Flag  
Date of Hormone Therapy  
Date of Hormone Therapy Flag  
Date of Initial Therapy  
Date of Initial Therapy Flag  
Date of Immunotherapy  
Date of Immunotherapy (BRM) Flag  
Date of Inpatient Admission  
Date of Inpatient Admission Flag  
Date of Inpatient Discharge  
Date of Inpatient Discharge Flag  
Date of Most Definitive Surgery  
Date of Most Definitive Surgery Flag  
Date of Multiple Tumors  
Date of Multiple Tumors Flag  
Date of Other Therapy  
Date of Other Therapy Flag  
Date of Radiation Therapy  
Date of Radiation Therapy Flag  
Date of Surgery  
Date of Surgery Flag

Date of Surgery - Procedure 1  
Date of Surgery - Procedure 1 Flag  
Date of Surgery - Procedure 2  
Date of Surgery - Procedure 2 Flag  
Date of Surgery - Procedure 3  
Date of Surgery - Procedure 3 Flag  
Date of Systemic Therapy  
Date of Systemic Therapy Flag  
Date of Transplant/Endocrine Procedures  
Date of Transplant/Endocrine Procedures Flag  
Derived AJCC T  
Derived AJCC N  
Derived AJCC M  
Derived AJCC Stage Group  
Derived SS2000  
Derived SS1977  
Diagnostic Confirmation  
Diagnostic or Staging Procedures at This Hospital  
Diagnostic or Staging Procedure Summary  
Discovered by Screening  
DxRx Report Facility (1-5)  
DxRx Report Number (1-5)  
DxRx Report Date (1-5)  
DxRx Report Type (1-5)  
Extent of Disease - Extension  
Extent of Disease - Extension (Path)  
Extent of Disease - Lymph Node Involvement  
First Name  
Grade Path System  
Grade Path Value  
Histology - Behavior - (ICD-O-2)  
Histology - Type - (ICD-O-3)  
Histology - Grade/Differentiation  
Histology - Type - (ICD-O-2)  
Hormone Therapy at This Hospital  
Hormone Therapy Summary  
Hospital Number (Reporting)  
Hospital Referred From  
Hospital Referred To

ICD Revision Comorbidities  
Immunotherapy at This Hospital  
Immunotherapy Summary  
Industry - Text  
Last Name  
Laterality  
Lymph-Vascular Invasion  
Maiden Name  
Marital Status  
Mets at DX - Bone  
Mets at DX - Brain  
Mets at DX - Liver  
Mets at DX - Lung  
Medical Record Number  
Middle Name  
Mother's First Name  
Multiple Tumors Reported as One Primary  
Multiplicity Counter  
Name Suffix  
Number of Regional Lymph Nodes  
NPI Hospital Referred From  
NPI Hospital Referred To  
NPI Following Registry  
NPI Physician Managing  
NPI Physician Follow-up  
NPI Physician Primary Surgeon  
NPI Physician Radiation Oncologist  
NPI Physician Medical Oncologist  
NPI Reporting Facility  
Examined - Summary  
Occupation - Text  
Other Therapy at This Hospital  
Other Therapy Summary  
Path Reporting Facility ID (1-5)  
Path Report Number (1-5)  
Path Date Specimen Collected (1-5)  
Path Report Type (1-5)  
Pathology Report Number - Biopsy/FNA  
Pathology Report Number - Surgery

## California Cancer Reporting System Standards, Volume I

Patient No Research Contact Flag  
Payment Source (Primary & Secondary)  
Payment Source Text (Primary)  
Pediatric Stage  
Pediatric Stage Coder  
Pediatric Stage System  
Physicians  
Protocol Participation  
Race 1  
Race 2  
Race 3  
Race 4  
Race 5  
Radiation Summary  
Radiation - Regional Rx Modality  
Radiation - Boost Treatment Modality  
Radiation - Location of RX  
Radiation/Surgery Sequence  
Reason No Radiation  
Reason for No Surgery  
Regional Data  
Regional Nodes Examined (Number)  
Regional Nodes Positive (Number)  
Religion  
Scope of Regional Lymph Node Surgery at This Hospital  
Scope of Regional Lymph Node Surgery - Procedure 1  
Scope of Regional Lymph Node Surgery - Procedure 2  
Scope of Regional Lymph Node Surgery - Procedure 3  
Scope of Regional Lymph Node Surgery - Summary  
Scope of Regional Lymph Node Surgery 98-02  
Sequence Number - Hospital  
Sex  
Site - Primary (ICD-O-2)  
Social Security Number  
Social Security Number Suffix  
Spanish/Hispanic Origin  
Summary Stage 1977  
Summary Stage 2000  
Surgical Procedure/Other Site at This Hospital



Surgical Procedure/Other Site - Procedure 1  
Surgical Procedure/Other Site - Procedure 2  
Surgical Procedure/Other Site - Procedure 3  
Surgical Procedure/Other Site - Summary  
Surgical Procedure/Other Site 98-02  
Surgery of Primary Site at This Hospital  
Surgery of the Primary Site - Procedure 1  
Surgery of the Primary Site - Procedure 2  
Surgery of the Primary Site - Procedure 3  
Surgery of Primary Site - Summary  
Surgery of Primary Site 98-02  
Surgery Summary - Reconstructive  
Systemic/Surgery Sequence  
Text-Diagnostic Procedures - Physical Examination  
Text-Diagnostic Procedures - X-ray  
Text-Diagnostic Procedures - Scopes  
Text-Diagnostic Procedures - Tests  
Text-Diagnostic Procedures - Operative  
Text-Diagnostic Procedures - Pathological  
Text-Site  
Text-Histology  
Text-Staging  
Text Rx-Surgery  
Text Rx-Radiation (Beam)  
Text Rx-Radiation (Other)  
Text Rx-Chemotherapy  
Text Rx-Hormone Therapy  
Text Rx-Immunotherapy  
Text Rx-Other Therapy  
Text-Remarks  
Text-Final Diagnosis  
TNM Coder (Clinical)  
TNM Coder (Path)  
TNM Edition  
TNM M Code (Clinical)  
TNM M Code (Path)  
TNM N Code (Clinical)  
TNM N Code (Path)  
TNM Stage (Clinical)

TNM Stage (Path)  
TNM T Code (Clinical)  
TNM T Code (Path)  
Transplant/Endocrine Procedures at This Hospital  
Transplant/Endocrine Procedures- Summary  
Treatment Hospital Number - Procedure 1  
Treatment Hospital Number - Procedure 2  
Treatment Hospital Number - Procedure 3  
Treatment Summary (RX Sum)  
Tumor Marker 1  
Tumor Marker 2  
Tumor Marker 3  
Tumor Marker-CA-1  
Tumor Size  
Type of Admission  
Type of Reporting Source  
Year First Seen

In the text field displayed on the screen, enter an explanation of why the changes are being made. If the only reason is that the regional registry notified the hospital of the change or correction, simply enter the word "REGION" (use capital letters), beginning in the first space of the first line in the field.

**Example**

A case has been transmitted as an Primary Unknown (site code C80.9), Carcinoma, NOS (histology 8010/3), and Stage Unknown (code 9), based on a biopsy of the brain. Four months later, the patient dies and an autopsy reveals that, in fact, the cancer was an oat cell carcinoma of the right upper lobe of the lung that had metastasized widely at diagnosis. Change the site code to C34.1, laterality to code 1, histology to 8042/3, and stage to Distant Metastases, code 7. When the request for the reason for the changes appears, enter a statement such as "Autopsy final DX: oat cell CA, RUL lung, mets to left lung, hilar and mediastinal lymph nodes, brain, and liver."

**IX.1.3 Deletions**

Delete any duplicate records if a case is found to have been abstracted and sent to the regional or central registry more than once.

Delete a previously reported case if subsequent evidence disproves the presence of cancer, or if what was thought to be a new primary cancer is later found to be a manifestation of an earlier primary cancer.

All deletions must be reported to the regional or central registry.

**IX.2 Quality Control**

The CCR and regional registries have procedures for assuring the quality of the data produced by the reporting system. Staff from both the regional registry and the CCR visit cancer reporting facilities to perform quality control audits. The CCR has established uniform standards of quality for facility data in three areas: completeness, accuracy, and timeliness.

### **IX.2.1 Completeness**

Completeness, the extent to which all required cases have been reported, is assessed by a casefinding audit performed at the reporting facility and by the monitoring of death certificates. The minimum acceptable level of completeness for a reporting facility is 97 percent. See Part II, Reportable Neoplasms, for a discussion of which cases must be abstracted. Descriptions of the protocols and procedures for evaluating completeness are available from the CCR.

### **IX.2.2 Accuracy**

Accuracy is the extent to which the data submitted match the information in the medical record and have been correctly coded. It encompasses accurate abstracting, correct application of coding rules, and correct entry into and retrieval from the computer.

Accuracy is evaluated using various methods:

- Visual editing
- Computer edits
- Reabstracting audits

The CCR's regional registries perform visual editing on a percentage of the abstracts submitted by hospital registries. Feedback is provided to hospitals on the results of visual editing.

A visual editing accuracy rate was established at 97% in January 2000. This rate applies to cancer reporting facilities and not to individual cancer registry abstractors. The reporting facility is responsible for cancer reporting requirements, not specific individuals; therefore, an accuracy rate reflects the facility's compliance with regulations. Please refer to the CCR web site at [www.ccrca.org](http://www.ccrca.org) for the current list of visually edited data items.

Non-analytic cases are included in the accuracy rate. The regions visually edit them, although not as extensively as the analytic cases. Review is limited to verifying that there is supporting documentation to validate the coded data fields.

Computer edits are also used to assess the quality of data submitted. The CCR provides a standard set of edits for abstracting software. These edits are performed on data at the time of abstracting. The measure used to evaluate accuracy is the percent of a facility's cases that fail an edit. CCR's cases must pass the interfield edits specified in Cancer Reporting in California: Data Standards for Regional Registries and California Cancer Registry (California Cancer Reporting System Standards, Volume III).

The CCR's edit set contains a number of edits that require review . After review and confirmation that the abstracted information is correct, a flag must be set so that repeated review is not necessary and a case can be set to complete. See Appendix T for a list of these over-rides. Please follow the instructions provided by your facility abstracting software vendor for using these flags.

Another method of assessing accuracy is to reabstract cases in the facilities. A sample of cases from each facility is reabstracted by specially trained personnel. The measure used is the number of discrepancies found in related categories of items.

### **IX.2.3 Timeliness**

Timeliness involves how quickly the reporting facility submits a case to a regional registry or central registry after admission of the patient. Regional registries and the central registry monitor the timeliness of data submitted by facilities. The standard established by the CCR is that 97 percent of cases must be received by the regional registry or central registry within six months of admission and 100 percent must be received within 12 months of admission.

Although every effort should be made to complete cases before they are transmitted to the regional registry or central registry, it is recognized that some cancer cases undergo treatment later than six-months from the date of admission. If these or other cases are going to exceed the six-month due date, they must be transmitted without treatment data and this must be documented on the abstract. This treatment information must be submitted later in a correction record. These correction records should not be sent in any later than two months after the six-month deadline, or eight months after the date of admission. If these corrections will be sent in later than eight months because treatment has not been completed, the region or central registry must be notified.

## APPENDICES

### APPENDIX A: Histology Codes for Lymphomas and Leukemias

For cases diagnosed January 1, 2010 and forward, or following installation of CSV2 software, please refer to the [2010 Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual and Hematopoietic Database](#).

#### January 1, 1998 and Forward

**LEUKEMIA TERMS.** *Effective for cases diagnosed January 1, 1998, and after.*

The following rules are to be used. They are in priority order:

1. Code the FAB (French-American-British) classification. FAB is implied if the description includes "L" or "M" with a number such as "L2" or "M5". If more than one FAB classification is listed, use the NOS code. Example:

Path: "Acute myelogenous leukemia, probably M1 or M2...."

Code to 9861/3, Acute myeloid leukemia, NOS

2. If the diagnostic statement lists a specific acute leukemia cell type, code that term. If more than one term is listed, use rules in ICD-O-2.

In addition to these rules, the following information will assist in assigning codes:

- "Maturation" and "differentiation" are synonymous.
- Code "acute non-lymphocytic leukemia" as 9861/3, acute myelogenous leukemia, NOS.
- Code "acute biphenotypic leukemia" or "mixed lineage leukemias" to 9801/3, acute leukemia, NOS.
- Terms equivalent to granulocytic are: myeloblastic, myelocytic, myelogenous, myeloid, non-lymphocytic.
- Terms equivalent to lymphocytic are: lymphoblastic, lymphoid, lymphatic.

ICD-O Code	Term
9821/3	Acute lymphoblastic leukemia, L1 type (*) Acute lymphocytic leukemia, L1 type (*) Acute lymphoid leukemia, L1 type (*) Acute lymphatic leukemia, L1 type (*) Lymphoblastic leukemia, L1 type (*)

California Cancer Reporting System Standards, Volume I

	FAB L1 (*)
9826/3	FAB L3 (*)
9828/3	Acute lymphoblastic leukemia, L2 type Acute lymphocytic leukemia, L2 type Acute lymphoid leukemia, L2 type Acute lymphatic leukemia, L2 type Lymphoblastic leukemia, L2 type FAB L2
9840/3	FAB M6 (*)
9861/3	Acute myeloid leukemia, NOS (*) Acute myeloblastic leukemia, NOS (*) Acute granulocytic leukemia, NOS (*) Acute myelogenous leukemia, NOS (*) Acute myelocytic leukemia, NOS (*)
9866/3	FAB M3 (*)
9867/3	Acute myelomonocytic leukemia, NOS (*) FAB M4 (*)
9871/3	Acute myelomonocytic leukemia with eosinophils FAB M4E
9872/3	Acute myeloid leukemia, minimal differentiation Acute myeloblastic leukemia, minimal differentiation Acute granulocytic leukemia, minimal differentiation Acute myelogenous leukemia, minimal differentiation Acute myelocytic leukemia, minimal differentiation FAB M0
9873/3	Acute myeloid leukemia without maturation Acute myeloblastic leukemia without maturation Acute granulocytic leukemia, without maturation Acute myelogenous leukemia, without maturation Acute myelocytic leukemia, without maturation FAB M1
9874/3	Acute myeloid leukemia with maturation Acute myeloblastic leukemia with maturation Acute granulocytic leukemia, with maturation Acute myelogenous leukemia, with maturation Acute myelocytic leukemia, with maturation FAB M2
9891/3	FAB M5 (*) FAB M5A (*) FAB M5B (*)
9910/3	Megakaryoblastic leukemia, NOS (C42.1) FAB M7

(\*) New terms for existing numbers



**January 1, 1998 and Forward**

**LYMPHOMA TERMS.** *Effective for cases diagnosed January 1, 1995, and after.*

<b>ICD-O Code</b>	<b>Term</b>
9673/3	Mantle cell lymphoma (*)
9688/3	T-cell rich B-cell lymphoma
9708/3	Subcutaneous panniculitic T-cell lymphoma
9710/3	Marginal zone lymphoma, NOS
9714/3	Anaplastic large cell lymphoma (ALCL), CD30+ (*)
9715/3	Mucosal-Associated Lymphoid Tissue (MALT) lymphoma
9716/3	Hepatosplenic $\gamma\delta$ (gamma - delta) cell lymphoma
9717/3	Intestinal T-cell lymphoma Enteropathy associated T-cell lymphoma

(\*) New terms for existing numbers



## APPENDIX B: Postal Abbreviations

The CCR has adopted official USPS abbreviations for coding of States and Possessions, Street Suffixes, and Secondary Unit Designations. Please refer to the [USPS website](#).

### Postal Abbreviations for States and Territories of the United States

AL	ALABAMA	NH	NEW HAMPSHIRE
AK	ALASKA	NJ	NEW JERSEY
AS	AMERICAN SAMOA	NM	NEW MEXICO
AZ	ARIZONA	NY	NEW YORK
AR	ARKANSAS	NC	NORTH CAROLINA
CA	CALIFORNIA	ND	NORTH DAKOTA
CO	COLORADO	MP	NORTHERN MARIANA ISLANDS
CT	CONNECTICUT	OH	OHIO
DE	DELAWARE	OK	OKLAHOMA
DC	DISTRICT OF COLUMBIA	OR	OREGON
FL	FLORIDA	PW	PALAU
GA	GEORGIA	PA	PENNSYLVANIA
GU	GUAM	PR	PUERTO RICO
HI	HAWAII	RI	RHODE ISLAND
ID	IDAHO	SC	SOUTH CAROLINA
IL	ILLINOIS	SD	SOUTH DAKOTA
IN	INDIANA	TN	TENNESSEE
IA	IOWA	TX	TEXAS
KS	KANSAS	TT	TRUST TERRITORIES
KY	KENTUCKY	UM	US MINOR OUTLYING ISLANDS
LA	LOUISIANA	US	RESIDENT OF UNITED STATES, NOS
ME	MAINE	UT	UTAH
MD	MARYLAND	VT	VERMONT
MH	MARSHALL ISLANDS	VA	VIRGINIA
MA	MASSACHUSETTS	VI	VIRGIN ISLANDS
MI	MICHIGAN	DC	WASHINGTON, DISTRICT OF
FM	MICRONESIA, FEDERATED STATE OF	WA	WASHINGTON, STATE OF
MN	MINNESOTA	WV	WEST VIRGINIA
MS	MISSISSIPPI	WI	WISCONSIN
MO	MISSOURI	WY	WYOMING
MT	MONTANA	XX	NOT U.S., U.S. TERRITORY, NOT CANADA, AND COUNTRY IS KNOWN
NE	NEBRASKA	YY	NOT U.S., U.S. TERRITORY, NOT CANADA, AND COUNTRY IS UNKNOWN
NV	NEVADA	ZZ	RESIDENCE IS UNKNOWN

**United States Military Personnel Serving Abroad**

AA	American Territories-US Military abroad
AE	Europe-US Military abroad
AP	Pacific-US Military abroad

**Canadian Province/ Territory**

AB	ALBERTA	NS	NOVA SCOTIA
BC	BRITISH COLUMBIA	NU	NUNAVUT
CD	CANADA, NOS	ON	ONTARIO
MB	MANITOBA	PE	PRINCE EDWARD ISLAND
NB	NEW BRUNSWICK	QB	QUEBEC
NL	NEWFOUNDLAND AND LABRADOR	SK	SASKATCHEWAN
NT	NORTHWEST TERRITORIES	YT	YUKON TERRITORIES

## APPENDIX C: Codes for States and Territories of the United States and Provinces and Territories Of Canada

### US States/Territories

ALABAMA	037
ALASKA	091
AMERICAN SAMOA	121
ARIZONA	087
ARKANSAS	071
CALIFORNIA	097
COLORADO	083
CONNECTICUT	007
DELAWARE	017
DISTRICT OF COLUMBIA	022
FLORIDA	035
GEORGIA	033
GUAM	126
HAWAII	099
IDAHO	081
ILLINOIS	061
INDIANA	045
IOWA	053
KANSAS	065
KENTUCKY	047
LOUISIANA	073
MAINE	002
MARSHALL ISLANDS	131
MARYLAND	021
MASSACHUSETTS	005
MICRONESIA, FEDERATED STATES OF	123
MICHIGAN	041
MINNESOTA	052
MISSISSIPPI	039
MISSOURI	063
MONTANA	056
NEBRASKA	067
NEVADA	085
NEW HAMPSHIRE	003
NEW JERSEY	008
NEW MEXICO	086
NEW YORK	011
NORTH CAROLINA	025
NORTH DAKOTA	054
NORTHERN MARIANA ISLANDS	129

California Cancer Reporting System Standards, Volume I

OHIO	043
OKLAHOMA	075
OREGON	095
PALAU	139
PENNSYLVANIA	014
PUERTO RICO	101
RHODE ISLAND	006
SOUTH CAROLINA	026
SOUTH DAKOTA	055
TENNESSEE	031
TEXAS	077
UTAH	084
VERMONT	004
VIRGINIA	023
VIRGIN ISLANDS	102
WASHINGTON, DISTRICT OF	022
WASHINGTON, STATE OF	093
WEST VIRGINIA	024
WISCONSIN	051
WYOMING	082
U.S.A., STATE UNKNOWN	000

**CANADIAN PROVINCE/ TERRITORY**

ALBERTA	224
BRITISH COLUMBIA	226
CANADA, NOS	220
MANITOBA	224
NEW BRUNSWICK	221
NEWFOUNDLAND AND LABRADOR	221
NORTHWEST TERRITORIES	225
NOVA SCOTIA	221
NUNAVUT	227
ONTARIO	223
PRINCE EDWARD ISLAND	221
QUEBEC	222
SASKATCHEWAN	224
YUKON TERRITORIES	225

## APPENDIX D.1: Codes for Countries in Alphabetic Order

Codes in Alphabetic Order	
ABYSSINIA	585
ADEN	629
AFARS/ISSAS	583
AFGHANISTAN	638
AFRICA, NOS	500
AFRICA-CENTRAL (OTHER WEST)	539
AFRICA-SUDANESE COUNTRIES	520
AFRICAN COASTAL ISLANDS	580
ALABAMA	037
ALASKA	091
ALBANIA	481
ALBERTA	224
ALGERIA	513
AMERICA, NORTH	260
AMERICAN SAMOA	121
ANATOLIA	611
ANDAMAN ISLANDS	641
ANDORRA	443
ANGOLA	543
ANGUILLA	245
ANNAM	665
ANTARCTICA	750
ANTIGUA	245
ANTILLES	245
ARABIA	629
ARABIAN PENINSULA	629
ARGENTINA	365
ARIZONA	087
ARKANSAS	071
ARMENIA	633
ARMENIA TURKISH	611
ARUBA	245
ASIA MINOR, NOS	610
ASIA, NOS	600
ASIA-ARAB COUNTRIES, NOS	620
ASIA-EAST, NOS	680
ASIA-MID-EAST, NOS	640
ASIA-NEAR EAST, NOS	610
ASIA-SOUTHEAST, NOS	650
ASIAN REPUBLICS OF FORMER USSR	634
ATLAN/CARIB US OTHER	109

California Cancer Reporting System Standards, Volume I

Codes in Alphabetic Order	
ATLANTIC/CARIBBEAN AREA, U.S. POSSESSIONS	100
AUSTRALIA/AUST NEW GUINEA	711
AUSTRIA	436
AZERBAIDZHAN SSR	633
AZERBAIJAN	633
AZORES	445
BAHAMAS	247
BAHRAIN	629
BALEARIC ISL	443
BALTIC REPUBLIC, NOS	463
BALTIC STATES, NOS	463
BANGLADESH	645
BARBADOS	245
BARBUDA	245
BASUTOLAND	545
BAVARIA	431
BECHUANALAND	545
BELARUS	457
BELGIUM	433
BELIZE	252
BENIN	539
BERMUDA	246
BESSARABIA	456
BHUTAN	643
BIOKO	539
BOHEMIA	452
BOLIVIA	355
BOPHUTHATSWANA	545
BORNEO	673
BOSNIA-HERZOGOVINA	453
BOTSWANA	545
BRAZIL	341
BRITISH COLUMBIA	226
BRITISH GUIANA	331
BRITISH HONDURAS	252
BRUNEI	671
BULGARIA	454
BURKINA FASO	520
BURMA	649
BURUNDI	579
BYELORUSSIA	457
CABINDA	543
CAICOS ISLANDS	245
CALIFORNIA	097

California Cancer Reporting System Standards, Volume I

Codes in Alphabetic Order	
CAMBODIA	663
CAMEROON	539
CANADA, NOS	220
CANADA-MARITIME PROVINCE	221
CANADA-NUNAVUT	227
CANADA-NW TERR/YUKON	225
CANADA-PRAIRIE PROVINCE	224
CANAL ZONE	110
CANARY ISL	443
CANTON/ENDERBURY ISL	122
CAPE COLONY	545
CAPE VERDE ISL	445
CARIBBEAN ISL NEC	245
CARIBBEAN, NOS	245
CAROLINE ISL (MICRONESA, FEDERATED STATES OF)	123
CARTIER ISLANDS	711
CAUCASIAN REPUBLICS OF FORMER USSR	633
CAYMAN ISLANDS	245
CENTRAL AFRICA, NOS	500
CENTRAL AFRICAN REPUBLIC	539
CENTRAL AMERICA, NOS	250
CEYLON	647
CHAD	520
CHANNEL ISL	401
CHILE	361
CHINA, NOS	681
CHINA, PEOPLE'S REPUBLIC	682
CHINA, REPUBLIC OF	684
CHRISTMAS ISLAND	723
CISSEL	545
COCHIN CHINA	665
COCOS ISLANDS	711
COLOMBIA	311
COLORADO	083
COMOROS	580
CONGO BELGIAN	541
CONGO BRAZZAVILLE	539
CONGO FRENCH	539
CONGO LEOPOLDVILLE	541
CONNECTICUT	007
COOK ISL (NEW ZEALAND)	124
CORSICA	441
COSTA RICA	256

California Cancer Reporting System Standards, Volume I

Codes in Alphabetic Order	
COTE D'IVOIRE	539
CRETE	471
CROATIA	453
CUBA	241
CURACAO	245
CYPRUS	495
CYRENAICA	517
CZECH REPUBLIC	452
CZECHOSLOVAKIA	452
DAHOMY	539
DALMATIA	453
DELAWARE	017
DENMARK	425
DJIBOUTI	583
DOBROVA	449
DOMINICA	245
DOMINICAN REPUBLIC	243
DUTCH EAST INDIES	673
DUTCH GUIANA	332
EAST AFRICA, NOS	570
EAST GERMANY	431
ECUADOR	345
EGYPT	519
EIRE	410
EL SALVADOR	254
ELLICE ISL	125
ENDERBURY ISL	122
ENGLAND	401
EQUATORIAL AFRICA	500
EQUATORIAL GUINEA	539
ERITREA	585
ESTONIA	458
ESTONIAN S.S.R.	458
ETHIOPIA	585
EUROPE, NOS	499
EUROPE-CENTRAL, NOS	499
EUROPE-EASTERN, NOS	499
EUROPE-GERMANIC, NOS	430
EUROPE-MEDITER ILS NEC	490
EUROPE-OTHER MAINLAND, NOS	470
EUROPE-ROMANCE LANG, NOS	440
EUROPE-SLAVIC, NOS	450
FALKLAND ISLANDS	381
FAROE ISLANDS	425



California Cancer Reporting System Standards, Volume I

Codes in Alphabetic Order	
FERNANDO PO	539
FIJI	721
FINLAND	429
FLORIDA	035
FORMOSA	684
FOTUNA	721
FRANCE/MONACO	441
FREE STATE	545
FRENCH GUIANA	333
FUTUNA ISLANDS	721
GABON	539
GALAPAGOS ISLANDS	345
GAMBIA	539
GAZA STRIP	631
GEORGIA	033
GEORGIA (USSR)	633
GERMAN DEMOCRATIC REPUBLIC	431
GERMANIC COUNTRIES	430
GERMANY	431
GERMANY, EAST	431
GERMANY, FEDERAL REPUBLIC OF	431
GERMANY, WEST	431
GHANA	539
GIBRALTAR	485
GILBERT ISLANDS	122
GREAT BRITAIN, NOS	400
GREECE	471
GREENLAND	210
GRENADA	245
GRENADINES	245
GUADALOUPE	245
GUAM	126
GUATAMALA	251
GUERNSEY	401
GUIANA BRITISH	331
GUIANA DUTCH	332
GUIANA FRENCH	333
GUINEA	539
GUINEA PORTUGUESE	539
GUINEA-BISSAU	539
GUYANA	331
HAITI	242
HAWAII	099
HOLLAND	432

California Cancer Reporting System Standards, Volume I

Codes in Alphabetic Order	
HONDURAS	253
HONG KONG	683
HUNGARY	475
ICELAND	421
IDAHO	081
ILLINOIS	061
INDIA	641
INDIANA	045
INDO-CHINA, NOS	660
INDONESIA	673
IOWA	053
IRAN	637
IRAQ	627
IRAQ-SAUDI ARABIAN NEUTRAL ZONE	620
IRELAND	410
ISLE OF MAN	401
ISRAEL	631
ISSAS	583
ITALY/SAN MARINO	447
IVORY COAST (COTE D'IVOIRE)	539
JAMAICA	244
JAN MAYEN	423
JAPAN	693
JAVA	673
JERSEY	401
JOHNSTON ATOLL	127
JORDAN	625
KAMEROON	539
KAMPUCHEA	663
KANSAS	065
KAZAKH SSR	634
KAZAKHSTAN	634
KENTUCKY	047
KENYA	575
KIRGHIZ SSR	634
KIRIBATI	122
KOREA	695
KOREA, NORTH	695
KOREA, SOUTH	695
KUWAIT	629
KYRGYSTAN	634
KYRGYZ	634
LABRADOR	221
LAOS	661

California Cancer Reporting System Standards, Volume I

Codes in Alphabetic Order	
LAPLAND, NOS	420
LATIN AMERICA, NOS	265
LATVIA	459
LATVIAN S.S.R.	459
LEBANON	623
LEEWARD ISL	245
LESOTHO	545
LIBERIA	539
LIBYA	517
LIECHTENSTEIN	437
LINE ISL SOUTHERN	122
LITHUANIA	461
LITHUANIAN S.S.R.	461
LOUISIANA	073
LUXEMBOURG	434
MACAO	686
MACAU	686
MACEDONIA	453
MADAGASCAR	555
MADEIRA ISL	445
MAINE	002
MALAGASY REPUBLIC	555
MALAWI	551
MALAY PENINSULA	671
MALAYSIA/SINGAPORE/BRUNEI	671
MALDIVES	640
MALI	520
MALTA	491
MANITOBA	224
MARSHALL ISL	131
MARTINIQUE	245
MARYLAND	021
MASSACHUSETTS	005
MAURITANIA	520
MAURITIUS	580
MAYOTTE	580
MEDITERRANEAN ISLANDS, OTHER	490
MELANESIA (MELANESIAN ISL)	721
MESOPOTAMIA	610
MEXICO	230
MICHIGAN	041
MICRONESIA	723
MICRONESIAN ISL	723
MIDWAY ISL	132

California Cancer Reporting System Standards, Volume I

Codes in Alphabetic Order	
MINNESOTA	052
MIQUELON	249
MISSISSIPPI	039
MISSOURI	063
MOLDAVIA	456
MOLDAVIAN S.S.R.	456
MOLDOVA	456
MONACO	441
MONGOLIA	691
MONTANA	056
MONTENEGRO	453
MONTserrat	245
MORAVIA	452
MOROCCO	511
MOZAMBIQUE	553
MYANMAR	649
NAMIBIA	545
NAMPO SHOTO SOUTHERN	133
NATAL	545
NAURU	723
NEBRASKA	067
NEPAL/BHUTAN/SIKKIM	643
NETHERLANDS	432
NETHERLANDS ANTILLES	245
NEVADA	085
NEVIS	245
NEW BRUNSWICK	221
NEW CALEDONIA	725
NEW ENGLAND	001
NEW GUINEA AUSTRALIAN	711
NEW GUINEA NORTHEAST	711
NEW GUINEA PAPUA	711
NEW GUINEA, NOS	673
NEW HAMPSHIRE	003
NEW HEBRIDES	721
NEW JERSEY	008
NEW MEXICO	086
NEW YORK	011
NEW ZEALAND	715
NEWFOUNDLAND	221
NICARAGUA	255
NIGER	520
NIGERIA	531
NIUE	715

California Cancer Reporting System Standards, Volume I

Codes in Alphabetic Order	
NORFOLK ISLANDS	711
NORTH AFRICA, NOS	510
NORTH AMERICA	260
NORTH AMERICAN ISL, NOS	240
NORTH CAROLINA	025
NORTH DAKOTA	054
NORTHERN IRELAND	404
NORTHWEST TERRITORY	225
NORWAY	423
NOT US, NOS	998
NOVA SCOTIA	221
NYASALAND	551
OCEANA, NOS	720
OHIO	043
OKINAWA	693
OKLAHOMA	075
OMAN AND MUSCAT	629
ONTARIO	223
ORANGE FREE STATE	545
OREGON	095
ORKNEY ISLANDS	403
PACIFIC ISL, NOS	720
PACIFIC ISLANDS, TRUST TERRITORY	123
PAKISTAN EAST	645
PAKISTAN WEST	639
PAKISTAN, NOS	639
PALAU	139
PALESTINE ARAB	625
PALESTINE JEWISH	631
PALESTINIAN NATIONAL AUTHORITY-PNA	631
PANAMA	257
PAPUA	711
PARAGUAY	371
PENNSYLVANIA	014
PERSIA	637
PERSIAN GULF STATES, NOS	629
PERU	351
PHILIPPINES	675
PHOENIX ISLANDS	122
PITCAIRN	725
POLAND	451
POLYNESIA	725
POLYNESIA, NOS	720
POLYNESIAN ISL	725

California Cancer Reporting System Standards, Volume I

Codes in Alphabetic Order	
PORTUGAL	445
PORTUGUESE GUINEA	539
PRINCE EDWARD ISL	221
PRINCIPE	543
PUERTO RICO	101
QATAR	629
QUATAR	629
QUEBEC	222
REPUBLIC OF CHINA	684
REPUBLIC OF IRELAND	410
REPUBLIC OF SOUTH AFRICA	545
REUNION	580
RHODE ISLAND	006
RHODESIA	547
RHODESIA NORTHERN	549
RHODESIA SOUTHERN	547
RIO MUNI	539
ROMANIA	449
RUANDA	577
RUMANIA	449
RUSSIA, NOS	455
RUSSIAN FEDERATION (FORMER U.S.S.R.)	455
RUSSIAN S.F.S.R.	455
RWANDA	577
RYUKYU ISL (JAPAN)	134
SAHARA	520
SAMOA AMERICAN	121
SAMOA, WESTERN	725
SAN MARINO	447
SAO TOME	543
SARDINIA	447
SASKATCHEWAN	224
SAUDI ARABIA	629
SCANDANAVIA NOS	420
SCOTLAND	403
SENEGAL	539
SERBIA	453
SEYCHELLES	580
SHETLAND ISLANDS	403
SIAM	651
SICILY	447
SIERRA LEONE	539
SIKKIM	643
SINGAPORE	671

California Cancer Reporting System Standards, Volume I

Codes in Alphabetic Order	
SLAVIC COUNTRIES	450
SLAVONIA	453
SLOVAK REPUBLIC	452
SLOVAKIA	452
SLOVENIA	453
SOLOMON ISLANDS	721
SOMALI REPUBLIC	581
SOMALIA	581
SOMALILAND FRENCH	583
SOMALILAND, NOS	581
SOUTH AFRICA, NOS	540
SOUTH AMERICA, NOS	300
SOUTH AMERICAN ISLANDS	380
SOUTH CAROLINA	026
SOUTH DAKOTA	055
SOUTH WEST AFRICA	545
SOUTHERN EUROPE, NOS	499
SOUTHERN LINE ISLANDS	122
SPAIN/ANDORRA	443
SPANISH SAHARA	520
SRI LANKA	647
ST. CHRISTOPHER-NEVIS	245
ST. HELENA	580
ST. KITTS	245
ST. LUCIA	249
ST. PIERRE	249
ST. VINCENT	245
SUDAN	520
SUMATRA	673
SURINAM	332
SVALBARD	423
SWAN ISL	135
SWAZILAND	545
SWEDEN	427
SWITZERLAND	435
SYRIA	621
TADZHIK SSR	634
TAIWAN	684
TAJIKISTAN	634
TANGANYIKA	571
TANZANIA	571
TANZANYIKA	571
TENNESSEE	031
TEXAS	077

California Cancer Reporting System Standards, Volume I

Codes in Alphabetic Order	
THAILAND	651
TIBET	685
TOBAGO	245
TOGO	539
TOKELAU ISL (NEW ZEALAND)	136
TONGA	725
TONKIN	665
TRANS-JORDAN	625
TRANSKEI	545
TRANSVAAL	545
TRANSYLVANIA	449
TRINIDAD	245
TRIPOLI	517
TRIPOLITANIA	517
TRUCIAL STATES	629
TUNISIA	515
TURKEY	611
TURKMEN SSR	634
TURKMENISTAN	634
TURKS ISLANDS	245
TUVALU ISLANDS	125
UGANDA	573
UKRAINE/MOLDAVIA	456
UKRANIAN S.S.R.	456
ULSTER	404
UNION OF SOUTH AFRICA	545
UNITED ARAB EMIRATES	629
UNITED ARAB REPUBLIC	519
UNITED KINGDOM, NOS	400
UNITED STATES, NOS	000
UNKNOWN	999
UPPER VOLTA	520
URUGUAY	375
URUNDI	579
US POSS-ATL/CARIB, NOS	100
US POSS-PACIFIC	120
US, NOS	000
US-CENTRAL MIDWEST, NOS	060
US-MOUNTAIN STATES, NOS	080
US-NEW ENGLAND, NOS	001
US-NORTH ATLANTIC, NOS	010
US-NORTH CENTRAL, NOS	040
US-NORTH MIDWEST, NOS	050
US-PACIFIC STATES, NOS	090



California Cancer Reporting System Standards, Volume I

Codes in Alphabetic Order	
US-SOUTH MID ATLANTIC, NOS	020
US-SOUTH MIDWEST, NOS	070
US-SOUTHEASTERN, NOS	030
USSR, NOS	455
UTAH	084
UZBECK SSR	634
UZBEKISTAN	634
VANUATU	721
VATICAN CITY	447
VENDA	545
VENEZUELA	321
VERMONT	004
VIET NAM	665
VIETNAM	665
VIRGIN ISL - US	102
VIRGIN ISLANDS, BRITISH	245
VIRGINIA	023
WAKE ISLAND	137
WALES	402
WALLACHIA	449
WALLIS ISLANDS	721
WASHINGTON	093
WASHINGTON DC	022
WEST AFRICA, FRENCH	530
WEST AFRICAN COUNTRIES, OTHER	539
WEST BANK	631
WEST GERMANY	431
WEST INDIES	245
WEST INDIES, NOS	245
WEST VIRGINIA	024
WESTERN SAHARA	520
WESTERN SAMOA	725
WHITE RUSSIA	457
WINDWARD ISLANDS	245
WISCONSIN	051
WYOMING	082
YEMEN	629
YEMEN, PEOPLE'S DEMOCRATIC REPUBLIC	629
YEMEN, SOUTHERN	629
YUGOSLAVIA	453
YUKON	225
ZAIRE	541
ZAMBIA	549
ZANZIBAR	571

Codes in Alphabetic Order	
ZIMBABWE	547

## APPENDIX D.2: Codes for Countries in Numerical Order

Codes in Numeric Order	
000	UNITED STATES, NOS
000	US NOS
001	NEW ENGLAND
001	US-NEW ENGLAND, NOS
002	MAINE
003	NEW HAMPSHIRE
004	VERMONT
005	MASSACHUSETTS
006	RHODE ISLAND
007	CONNECTICUT
008	NEW JERSEY
010	US-NORTH ATLANTIC, NOS
011	NEW YORK
014	PENNSYLVANIA
017	DELAWARE
020	US-SOUTH MID ATLANTIC, NOS
021	MARYLAND
022	WASHINGTON DC
023	VIRGINIA
024	WEST VIRGINIA
025	NORTH CAROLINA
026	SOUTH CAROLINA
030	US-SOUTHEASTERN, NOS
031	TENNESSEE
033	GEORGIA
035	FLORIDA
037	ALABAMA
039	MISSISSIPPI
040	US-NORTH CENTRAL, NOS
041	MICHIGAN
043	OHIO
045	INDIANA
047	KENTUCKY
050	US-NORTH MIDWEST, NOS
051	WISCONSIN
052	MINNESOTA
053	IOWA

California Cancer Reporting System Standards, Volume I

054	NORTH DAKOTA
055	SOUTH DAKOTA
056	MONTANA
060	US-CENTRAL MIDWEST, NOS
061	ILLINOIS
063	MISSOURI
065	KANSAS
067	NEBRASKA
070	US-SOUTH MIDWEST, NOS
071	ARKANSAS
073	LOUISIANA
075	OKLAHOMA
077	TEXAS
080	US-MOUNTAIN STATES, NOS
081	IDAHO
082	WYOMING
083	COLORADO
084	UTAH
085	NEVADA
086	NEW MEXICO
087	ARIZONA
090	US-PACIFIC STATES, NOS
091	ALASKA
093	WASHINGTON
095	OREGON
097	CALIFORNIA
099	HAWAII
100	US POSS-ATL/CARIB, NOS
101	PUERTO RICO
102	VIRGIN ISL - US
109	ATLAN/CARIB US OTHER
110	CANAL ZONE
120	US POSS-PACIFIC
121	AMERICAN SAMOA
121	SAMOA AMERICAN
122	CANTON/ENDERBURY ISL
122	ENDERBURY ISL
122	GILBERT ISLANDS
122	LINE ISLANDS, SOUTHERN
122	PHOENIX ISLANDS
122	SOUTHERN LINE ISLANDS
123	CAROLINE ISL, MICRONESIA (FEDERAL STATES OF)
124	COOK ISLAND (NEW ZEALAND)
125	TUVALU (ELLICE ISLANDS)
126	GUAM
127	JOHNSTON ATOLL

California Cancer Reporting System Standards, Volume I

129	MARIANA ISL
131	MARSHALL ISL
132	MIDWAY ISL
133	NAMPO SHOTO SOUTHERN
134	RYUKYU ISLAND (JAPAN)
135	SWAN ISL
136	TOKELAU ISLAND (NEW ZEALAND)
137	WAKE ISLAND
139	PALAU
200	WESTERN HEMISPHERE, NOS
210	GREENLAND
220	CANADA, NOS
221	CANADA-MARITIME PROVINCE
221	LABRADOR
221	NEW BRUNSWICK
221	NEWFOUNDLAND
221	NOVA SCOTIA
221	PRINCE EDWARD ISL
222	QUEBEC
223	ONTARIO
224	ALBERTA
224	CANADA-PRAIRIE PROVINCE
224	MANITOBA
224	SASKATCHEWAN
225	CANADA-NW TERR/YUKON
225	NORTHWEST TERRITORY
225	YUKON
226	BRITISH COLUMBIA
227	CANADA- NUNAVUT
230	MEXICO
240	NORTH AMERICAN ISL, NOS
241	CUBA
242	HAITI
243	DOMINICAN REPUBLIC
244	JAMAICA
245	ANGUILLA
245	ANTIGUA
245	ANTILLES
245	ARUBA
245	BARBADOS
245	BARBUDA
245	CAICOS ISLANDS
245	CARIBBEAN ISL NEC
245	CAYMAN ISLANDS
245	CURACAO
245	DOMINICA

California Cancer Reporting System Standards, Volume I

245	GRENADINES
245	GRENADA
245	GUADALOUPE
245	LEEWARD ISLANDS
245	MARTINIQUE
245	MONTSERRAT
245	NETHERLANDS ANTILLES
245	ST. CHRISTOPHER-NEVIS
245	ST. KITTS
245	ST. LUCIA
245	ST. VINCENT
245	TOBAGO
245	TRINIDAD
245	TURKS ISLANDS
245	VIRGIN ISLANDS, BRITISH
245	WEST INDIES, BRITISH
245	WEST INDIES, NOS
245	WINDWARD ISLANDS
246	BERMUDA
247	BAHAMAS
249	ST. PIERRE AND MIQUELON
250	CENTRAL AMERICA, NOS
251	GUATAMALA
252	BELIZE
252	BRITISH HONDURAS
253	HONDURAS
254	EL SALVADOR
255	NICARAGUA
256	COSTA RICA
257	PANAMA
260	AMERICA, NORTH
260	NORTH AMERICA, NOS
265	LATIN AMERICA, NOS
300	SOUTH AMERICA, NOS
311	COLOMBIA
321	VENEZUELA
331	BRITISH GUIANA
331	GUIANA BRITISH
331	GUYANA
332	DUTCH GUIANA
332	GUIANA DUTCH
332	SURINAM
333	FRENCH GUIANA
333	GUIANA FRENCH
341	BRAZIL
345	ECUADOR

California Cancer Reporting System Standards, Volume I

345	GALAPAGOS ISLANDS
351	PERU
355	BOLIVIA
361	CHILE
365	ARGENTINA
371	PARAGUAY
375	URUGUAY
380	SOUTH AMERICAN ISLANDS
381	FALKLAND ISLANDS
400	GREAT BRITAIN, NOS
400	UNITED KINGDOM, NOS
401	CHANNEL ISL
401	ENGLAND
401	GUERNSEY
401	ISLE OF MAN
401	JERSEY
402	WALES
403	ORKNEY ISLANDS
403	SCOTLAND
403	SHETLAND ISLANDS
404	NORTHERN IRELAND
404	ULSTER
410	EIRE
410	IRELAND
410	REPUBLIC OF IRELAND
420	LAPLAND, NOS
420	SCANDANAVIA, NOS
421	ICELAND
423	JAN MAYEN
423	NORWAY
423	SVALBARD
425	DENMARK
425	FAROE ISLANDS
427	SWEDEN
429	FINLAND
430	EUROPE-GERMANIC, NOS
431	BAVARIA
431	GERMANY
432	HOLLAND
432	NETHERLANDS
433	BELGIUM
434	LUXEMBOURG
435	SWITZERLAND
436	AUSTRIA
437	LIECHTENSTEIN
440	EUROPE-ROMANCE LANG, NOS

California Cancer Reporting System Standards, Volume I

441	CORSICA
441	FRANCE/MONACO
441	MONACO
443	ANDORRA
443	BALEARIC ISL
443	CANARY ISL
443	SPAIN/ANDORRA
445	AZORES
445	CAPE VERDE ISL
445	MADEIRA ISL
445	PORTUGAL
447	ITALY/SAN MARINO
447	SAN MARINO
447	SARDINIA
447	SICILY
447	VATICAN CITY
449	DOBRUJA
449	MOLDAVIA RUMANIA
449	ROMANIA
449	RUMANIA
449	TRANSYLVANIA
449	WALLACHIA
450	EUROPE-SLAVIC, NOS
451	POLAND
452	BOHEMIA
452	CZECH REPUBLIC
452	CZECHOSLOVAKIA
452	MORAVIA
452	SLOVAKIA
452	SLOVAK REPUBLIC
453	BOSNIA-HERZOGOVINA
453	CROATIA
453	DALMATIA
453	MACEDONIA
453	MONTENEGRO
453	SERBIA
453	SLAVONIA
453	SLOVENIA
453	YUGOSLAVIA (FORMER)
454	BULGARIA
455	RUSSIA, NOS (RUSSIAN S.F.S.R.)
455	RUSSIAN FEDERATION (FORMER) U.S.S.R
455	RUSSIA
455	USSR, NOS
456	BESSARABIA
456	MOLDAVIA

California Cancer Reporting System Standards, Volume I

456	MOLDAVIAN SSR
456	UKRAINE/MOLDOVA
456	UKRANIAN SSR
457	BELARUS
457	BYELORUSSIA
457	WHITE RUSSIA
458	ESTONIA (ESTONIAN SSR)
459	LATVIA (LATVIAN SSR)
461	LITHUANIA (LITHUANIAN SSR)
463	BALTIC REPUBLIC(S), NOS
470	EUROPE-OTHER MAINLAND, NOS
471	CRETE
471	GREECE
475	HUNGARY
481	ALBANIA
485	GIBRALTAR
490	EUROPE-MEDITER ILS NEC
491	MALTA
495	CYPRUS
499	CENTRAL EUROPE, NOS
499	EASTERN EUROPE, NOS
499	EUROPE, NOS
499	NORTHERN EUROPE, NOS
499	SOUTHERN EUROPE, NOS
499	WESTERN EUROPE, NOS
500	EQUATORIAL AFRICA, NOS
500	AFRICA, NOS
500	CENTRAL AFRICA, NOS
510	NORTH AFRICA NOS
511	MOROCCO
513	ALGERIA
515	TUNISIA
517	CYRENAICA
517	LIBYA
517	TRIPOLITANIA
517	TRIPOLI
519	EGYPT
519	UNITED ARAB REPUBLIC
520	AFRICA-SUDANESE COUNTRIES
520	BURKINA FASO (UPPER VOLTA)
520	CHAD
520	MALI
520	MAURITANIA
520	NIGER
520	SAHARA
520	SUDAN



California Cancer Reporting System Standards, Volume I

520	WESTERN (SPANISH) SAHARA
530	FRENCH WEST AFRICA, NOS
530	WEST AFRICA
531	NIGERIA
539	AFRICA-CENTRAL (OTHER WEST)
539	BENIN
539	CAMEROON
539	CENTRAL AFRICAN REPUBLIC
539	CONGO
539	CONGO FRENCH
539	CONGO BRAZZAVILLE
539	COTE D'IVOIRE (IVORY COAST)
539	DAHOMY
539	EQUATORIAL GUINEA
539	FERNANDO PO
539	GABON
539	GAMBIA
539	GHANA
539	GUIANA BISSAU
539	GUIANA PORTUGUESE
539	GUINEA
539	KAMEROON
539	LIBERIA
539	PORTUGUESE GUINEA
539	RIO MUNI
539	SENEGAL
539	SIERRA LEONE
539	TOGO
540	SOUTH AFRICA, NOS
541	CONGO BELGIAN
541	CONGO LEOPOLDVILLE
541	CONGO/KINSHASA
541	ZAIRE
543	ANGOLA
543	CABINDA
543	PRINCIPE
543	SAO TOME
545	BASUTOLAND
545	BECHUANALAND
545	BOPHUTHATSWANA
545	BOTSWANA
545	CAPE COLONY
545	CISKEL
545	FREE STATE (ORANGE FREE STATE)
545	LESOTHO
545	NAMIBIA

California Cancer Reporting System Standards, Volume I

545	NATAL
545	REPUBLIC OF SOUTH AFRICA
545	SOUTH WEST AFRICA
545	SWAZILAND
545	TRANSKEI
545	TRANSVAAL
545	UNION OF SOUTH AFRICA
545	VENDA
547	RHODESIA SOUTHERN
547	RHODESIA
547	ZIMBABWE
549	RHODESIA NORTHERN
549	ZAMBIA
551	MALAWI
551	NYASALAND
553	MOZAMBIQUE
555	MADAGASCAR
555	MALAGASY REPUBLIC
570	EAST AFRICA, NOS
571	TANGANYIKA
571	TANZANIA
571	TANZANYIKA
571	ZANZIBAR
573	UGANDA
575	KENYA
577	RUANDA
577	RWANDA
579	BURUNDI
579	URUNDI
580	AFRICAN COASTAL ISLANDS
580	COMOROS
580	MAURITIUS
580	MAYOTTE
580	REUNION
580	SEYCHELLES
580	ST. HELENA
581	SOMALIA
581	SOMALILAND, NOS
581	SOMALI REPUBLIC
583	AFARS/ISSAS
583	DJIBOUTI
583	ISSAS
583	SOMALILAND FRENCH
585	ABYSSINIA
585	ERITREA
585	ETHIOPIA

California Cancer Reporting System Standards, Volume I

600	ASIA, NOS
610	ASIA-NEAR EAST, NOS
610	MESOPOTAMIA
611	ANATOLIA
611	ASIA MINOR, NOS
611	TURKEY
620	ASIA-ARAB COUNTRIES, NOS
620	IRAQ-SAUDI ARABIA NEUTRAL ZONE
621	SYRIA
623	LEBANON
625	JORDAN
625	PALESTINE ARAB
625	TRANS-JORDAN
627	IRAQ
629	ADEN
629	ARABIAN PENINSULA
629	ARABIA
629	BAHRAIN
629	KUWAIT
629	OMAN AND MUSCAT
629	PERSIAN GULF STATES, NOS
629	QATAR
629	QUATAR
629	SAUDI ARABIA
629	TRUCIAL STATES
629	UNITED ARAB EMIRATES
629	YEMEN
631	GAZA
631	ISRAEL
631	PALESTINE (PALESTINIAN NATIONAL AUTHORITY-PNA)
631	WEST BANK
633	ARMENIA
633	AZERBAIDZHAN SSR
633	AZERBAIJAN
633	CAUCASIAN REPUBLICS OF FORMER USSR
633	GEORGIA (USSR)
634	KAZAKHSTAN
634	KAZAKH SSR
634	KIRGHIZ SSR
634	KYRGYSTAN
634	OTHER ASIAN REPUBLICS OF FORMER USSR
634	TADZHIK SSR
634	TAJIKISTAN
634	TURKMEN SSR
634	TURMENISTAN
634	UZBECK SSR

California Cancer Reporting System Standards, Volume I

634	UZBEKISTAN
637	IRAN
637	PERSIA
638	AFGHANISTAN
639	PAKISTAN NOS
639	PAKISTAN WEST
640	ASIA-MID-EAST, NOS
640	MALDIVES
641	ANDAMAN ISLANDS
641	INDIA
643	BHUTAN
643	NEPAL/BHUTAN/SIKKIM
643	SIKKIM
645	BANGLADESH
645	PAKISTAN EAST
647	CEYLON
647	SRI LANKA
649	BURMA
649	MYANMAR
650	ASIA-SOUTHEAST, NOS
651	SIAM
651	THAILAND
660	INDO-CHINA, NOS
661	LAOS
663	CAMBODIA
663	KAMPUCHEA
665	ANNAM
665	COCHIN CHINA
665	TONKIN
665	VIET NAM
665	VIETNAM
671	BRUNEI
671	MALAY PENINSULA
671	MALAYSIA/SINGAPORE/BRUNEI
671	SINGAPORE
673	BORNEO
673	DUTCH EAST INDIES
673	INDONESIA
673	JAVA
673	NEW GUINEA, NOS
673	SUMATRA
675	PHILIPPINES
680	ASIA-EAST, NOS
681	CHINA, NOS
682	CHINA, PEOPLE'S REPUBLIC
683	HONG KONG

California Cancer Reporting System Standards, Volume I

684	CHINA, REPUBLIC OF
684	FORMOSA
684	REPUBLIC OF CHINA
684	TAIWAN
685	TIBET
686	MACAO
686	MACAU
691	MONGOLIA
693	JAPAN
693	OKINAWA
695	KOREA
695	NORTH KOREA
695	SOUTH KOREA
711	AUSTRALIA/AUST NEW GUINEA
711	CARTIER ISLANDS
711	COCOS ISLANDS
711	NEW GUINEA AUSTRALIAN
711	NEW GUINEA NORTHEAST
711	NEW GUINEA PAPUA
711	NORFOLK ISLANDS
711	PAPUA
715	NEW ZEALAND
715	NIUE
720	OCEANA, NOS
720	PACIFIC ISL, NOS
720	POLYNESIA, NOS
721	FIJI
721	FOTUNA
721	FUTUNA ISLANDS
721	MELANESIA (MELANESIA ISLANDS)
721	NEW HEBRIDES
721	SOLOMON ISLANDS
721	VANUATA
721	WALLIS ISLANDS
723	CHRISTMAS ISLAND
723	MICRONESIA (MICRONESIAN ISLANDS)
723	NAURU
725	NEW CALEDONIA
725	PITCAIRN
725	POLYNESIA (POLYNESIAN ISLANDS)
725	SAMOA, WESTERN
725	TONGA
725	WESTERN SAMOA
750	ANTARCTICA
998	NOT US NOS
999	UNKNOWN



## **APPENDIX E: Rules for Determining Residency of Military Personnel Assigned to Ships and Crews of Merchant Vessels**

Cancer reporting facilities that serve patients in the U.S. Navy or Merchant Marine need detailed rules for determining whether their patients are residents of their region for purposes of cancer reporting. The rules for determining residency are the same as those used by the Census Bureau. The guidelines that follow were adapted from U.S. Department of Commerce publications.

Note: Also see Appendix B - Postal Code Abbreviations, for military personnel serving abroad.

### **NAVY PERSONNEL**


Patients diagnosed with cancer while their ships are deployed overseas are considered overseas residents for cancer-reporting purposes. For ships not deployed overseas, specific rules (shown in the chart below) apply. The Navy assigns a home port to each of its ships. If a ship that is not deployed overseas is not berthed in its home port, any crew member diagnosed with cancer is considered a resident of the home port. If the ship is berthed in its home port, and the home port has fewer than 1000 naval personnel assigned to ships, a crew member diagnosed with cancer is considered a resident of the ship. If, however, the home port has more than 1000 naval personnel assigned to ships and the cancer patient has a usual residence within 50 miles of the home port, the person's residence is the home, not the ship itself. If the patient's usual residence is more than 50 miles from the home port, he or she is considered to be a resident of the ship. For patients who are considered residents of a ship, code residence as the ship's home port unless the home port is contained in more than one municipality. In that case, code the patient's residence as the municipality immediately adjacent to the dock or pier where the ship is berthed.

### **CREWS OF MERCHANT VESSELS**

Crews of U.S. vessels outside the U.S., or crews of vessels flying a foreign flag, are considered non-residents. If a U.S. vessel is not berthed in a U.S. port but is in territorial waters, and the port of destination is inside the U.S., a crew member diagnosed with cancer is considered a resident of the port of destination. If the destination is outside the U.S., the home port of the ship is considered the patient's residence. If a U.S. vessel is berthed in a U.S. port at the time of diagnosis, the patient is a resident of that port.

**CHART**

Summary of Rules for Determining Residency of Navy Personnel Assigned to Ships



\* If home port is maintained in more than municipality, code patient as resident of the municipality immediately adjacent to the dock or pier where the ship is berthed.



## APPENDIX F: California Hospital Code Numbers

California Hospital lists by facility code or facility name are now posted on the CCR web site.

### California Hospital Code Numbers in Code Order

[http://www.ccrca.org/DSOC\\_Pubs/CCR\\_Hospital\\_Codes/Code\\_Order\\_Cal\\_Hosp\\_Code\\_Numbers\\_1\\_11\\_0\\_0.pdf](http://www.ccrca.org/DSOC_Pubs/CCR_Hospital_Codes/Code_Order_Cal_Hosp_Code_Numbers_1_11_0_0.pdf)

### California Hospital Code Numbers in Alphabetic Order

[http://www.ccrca.org/DSOC\\_Pubs/CCR\\_Hospital\\_Codes/Alpha\\_Order\\_Cal\\_Hosp\\_Code\\_Numbers\\_1\\_11\\_0\\_0.pdf](http://www.ccrca.org/DSOC_Pubs/CCR_Hospital_Codes/Alpha_Order_Cal_Hosp_Code_Numbers_1_11_0_0.pdf)

## APPENDIX G.1: Codes for Religions in Code Order

Codes for Religions in Code Order	
01	NONE
02	AGNOSTIC
03	ATHEIST
04	*NONE, AGNOSTIC, ATHEIST (OLD)
05	*ROMAN CATHOLIC
05	CATHOLIC
06	CHRISTIAN, NOS
06	PROTESTANT, NOS
<b>PROTESTANT DENOMINATIONS:</b>	
07	*AFRICAN METHODIST EPISCOPAL (AME)
08	ANGLICAN
08	CHURCH OF ENGLAND
09	BAPTIST
10	COMMUNITY
11	CONGREGATIONAL
12	EPISCOPALIAN
13	LUTHERAN
14	METHODIST
15	PRESBYTERIAN
16	UNITARIAN
17	*PROTESTANT DENOMINATION, OTHER
18	CHRISTIAN REFORMED
19	DISCIPLES OF CHRIST
20	*DUTCH REFORMED
21	FIRST CHRISTIAN

Codes for Religions in Code Order	
22	INTERDENOMINATIONAL
23	MORAVIAN
24	NON-DENOMINATIONAL
25	SEAMAN'S CHURCH
26	TRINITY
27	UNIVERSAL
28	PROTESTANT, OTHER
<b>ORTHODOX:</b>	
29	ARMENIAN ORTHODOX
29	ORTHODOX, ARMENIAN
30	*COPTIC
31	GREEK ORTHODOX
31	ORTHODOX, GREEK
32	ORTHODOX, RUSSIAN
32	RUSSIAN ORTHODOX
33	SERBIAN ORTHODOX
33	ORTHODOX, SERBIAN
34	*LEBANESE MARONITE
34	*MARONITE
34	*ORTHODOX, CHRISTIAN, OTHER
34	*ORTHODOX, CHRISTIAN, NOS
<b>CHRISTIAN SECTS:</b>	
35	JEHOVAH'S WITNESSES
36	CHRISTIAN SCIENCE
37	MORMON
37	LATTER DAY SAINTS
38	SEVENTH-DAY ADVENTIST
39	FRIENDS
39	QUAKER
<b>CHRISTIAN SECTS-OTHER:</b>	
40	AMISH
41	MENNONITES
42	APOSTOLIC
43	ARMENIAN APOSTOLIC
44	ASSEMBLIES OF GOD
45	BRETHREN
45	BROTHERS
46	CHRISTIAN APOSTOLIC
47	CHURCH OF ARMEDIAN
48	CHURCH OF CHRIST
49	CHURCH OF GOD
50	CHURCH OF MESSIANITY
51	CHURCH OF THE DIVINE
52	CHURCH OF THE OPEN DOOR
53	CONGREGATIONAL HOLY

California Cancer Reporting System Standards, Volume I

Codes for Religions in Code Order	
53	HOLY CONGREGATIONAL
54	COVENANT
55	DIVINE SCIENCE
56	EVANGELICAL
57	FUNDAMENTAL
58	FOURSQUARE
59	FULL GOSPEL
60	HOLINESS
61	HOLY INNOCENTS
62	NAZARENE
63	NEW APOSTOLIC
64	PENTECOSTAL
65	RELIGIOUS SCIENCE
66	SALVATION ARMY
67	SCIENCE OF MIND
68	UNITY
69	*CHRISTIAN SECTS, OTHER
70	JEWISH
71	*ORTHODOX JEWISH
71	*JEWISH ORTHODOX
<b>WESTERN OTHER:</b>	
72	BAHA'I
73	CRICKORIAN
73	ETHICAL CULTURE
73	GREGORIAN
73	LAWSONIAN
73	MASON
73	METAPHYSICS
73	OCCULT
73	PEACE OF MIND
73	PEOPLE'S
73	SELF-REALIZATION
73	SOCIETY OF LIFE
73	SPIRITUALIST
73	THEOSOPHY
73	TRUTH SEEKER
74	MOLIKAN
74	MOLOKAN
75	*WESTERN RELIGION OR CREED, OTHER
75	*WESTERN RELIGION OR CREED, NOS
76	KO
<b>EASTERN RELIGIONS:</b>	
77	BUDDHIST
77	*ZEN
77	*ZEN BUDDHISM

California Cancer Reporting System Standards, Volume I

Codes for Religions in Code Order	
78	DROUZE
79	*CONFUCIANISM
79	*TAOISM
80	*JAIN
81	*NATION OF ISLAM
82	MOSLEM
82	MUSLIM
82	MOHAMMEDAN
83	HINDU
84	ISLAM
85	*PARSEE
85	ZOROASTRIAN
86	SHINTO
87	*SIKH
88	VEDANTA
89	ORIENTAL PHILOSOPHY
89	*EASTERN REGLIGION, OTHER
89	*EASTERN RELIGION, NOS
90	*AMERICAN INDIAN RELIGIONS
90	*NATIVE AMERICAN TRADITIONAL RELIGIONS
91	*HAITIAN/AFRICAN/BRAZILIAN RELIGIONS, OTHER
91	*SANTORIA
91	*VOODOO
92	*SHAMANISM
93	*OTHER TRADITIONAL OR NATIVE RELIGION
<b>94</b>	<b><i>Scientology</i></b>
98	*OTHER
99	UNSPECIFIED, UNKNOWN

\*NEW OR REVISED LABEL

## APPENDIX G.2 Codes for Religions in Alphabetical Order

Codes for Religions in Alphabetical Order	
AFRICAN METHODIST EPISCOPAL (AME)	07
AGNOSTIC	02
AMERICAN INDIAN RELIGIONS	90
AMISH	40
ANGLICAN	08
APOSTOLIC	42
ARMENIAN APOSTOLIC	43
ARMENIAN ORTHODOX	29
ASSEMBLIES OF GOD	44
ATHEIST	03
BAHA'I	72
BAPTIST	09
BRETHREN	45
BROTHERS	45
BUDDHIST	77
CATHOLIC	05
CHRISTIAN APOSTOLIC	46
CHRISTIAN REFORMED	18
CHRISTIAN SCIENCE	36
CHRISTIAN SECTS, OTHER	69
CHRISTIAN, NOS	06
CHURCH OF ARMEDIAN	47
CHURCH OF CHRIST	48
CHURCH OF ENGLAND	08
CHURCH OF GOD	49
CHURCH OF MESSIANITY	50
CHURCH OF THE DIVINE	51
CHURCH OF THE OPEN DOOR	52
COMMUNITY	10
CONFUCIANISM	79
CONGREGATIONAL HOLY	53

California Cancer Reporting System Standards, Volume I

Codes for Religions in Alphabetical Order	
CONGREGATIONAL	11
COPTIC	30
COVENANT	54
CRICKORIAN	73
DISCIPLES OF CHRIST	19
DIVINE SCIENCE	55
DROUZE	78
DUTCH REFORMED	20
EASTERN RELIGION, NOS	89
EASTERN RELIGION, OTHER	89
EPISCOPALIAN	12
ETHICAL CULTURE	73
EVANGELICAL	56
FIRST CHRISTIAN	21
FOURSQUARE	58
FRIENDS	39
FULL GOSPEL	59
FUNDAMENTAL	57
GREEK ORTHODOX	31
GREGORIAN	73
HAITIAN/AFRICAN/BRAZILIAN RELIGIONS, OTHER	91
HINDU	83
HOLINESS	60
HOLY CONGREGATIONAL	53
HOLY INNOCENTS	61
INTERDENOMINATIONAL	22
ISLAM	84
JAIN	80
JEHOVAH'S WITNESS	35
JEWISH ORTHODOX	71
JEWISH	70
KO	76
LATTER DAY SAINTS	37
LAWSONIAN	73
LEBANESE MARONITE	34

California Cancer Reporting System Standards, Volume I

Codes for Religions in Alphabetical Order	
LUTHERAN	13
MARONITE	34
MASON	73
MENNONITES	41
METAPHYSICS	73
METHODIST	14
MOHAMMEDAN	82
MOLIKAN	74
MOLOKAN	74
MORAVIAN	23
MORMON	37
MOSLEM	82
MUSLIM	82
NATION OF ISLAM	81
NATIVE AMERICAN TRADITIONAL RELIGIONS	90
NAZARENE	62
NEW APOSTOLIC	63
NON-DENOMINATIONAL	24
NONE, AGNOSTIC, ATHEIST (OLD)	04
NONE	01
OCCULT	73
ORIENTAL PHILOSOPHY	89
ORTHODOX, ARMENIAN	29
ORTHODOX, CHRISTIAN, NOS	34
ORTHODOX, CHRISTIAN, OTHER	34
ORTHODOX, GREEK	31
ORTHODOX, JEWISH	71
ORTHODOX, RUSSIAN	32
ORTHODOX, SERBIAN	33
OTHER TRADITIONAL OR NATIVE RELIGION	93
OTHER	98
PARSEE	85
PEACE OF MIND	73
PENTACOSTAL	64
PEOPLE'S	73

California Cancer Reporting System Standards, Volume I

Codes for Religions in Alphabetical Order	
PRESBYTERIAN	15
PROTESTANT DENOMINATION, OTHER	17
PROTESTANT, NOS	06
PROTESTANT, OTHER	28
QUAKER	39
RELIGIOUS SCIENCE	65
ROMAN CATHOLIC	05
RUSSIAN ORTHODOX	32
SALVATION ARMY	66
SANTORIA	91
SCIENCE OF MIND	67
<b><i>Scientology</i></b>	<b>94</b>
SEAMAN'S CHURCH	25
SELF-REALIZATION	73
SERBIAN ORTHODOX	33
SEVENTH-DAY ADVENTIST	38
SHAMANISM	92
SHINTO	86
SIKH	87
SOCIETY OF LIFE	73
SPIRITUALIST	73
TAOISM	79
THEOSOPHY	73
TRINITY	26
TRUTH SEEKER	73
UNITARIAN	16
UNITY	68
UNIVERSAL	27
UNSPECIFIED, UNKNOWN	99
VEDANTA	88
VOODOO	91
WESTERN RELIGION OR CREED, NOS	75
WESTERN RELIGION OR CREED, OTHER	75
ZEN BUDDHISM	77
ZEN	77



California Cancer Reporting System Standards, Volume I

Codes for Religions in Alphabetical Order	
ZOROASTRIAN	85

## **APPENDIX J: Patient Information Sheet**

CCR suggests the following statement be used by hospitals and physicians in notifying their patients that cancer and other specific benign and borderline tumors are reportable entities:

### **CALIFORNIA CANCER REPORTING SYSTEM**

#### **PATIENT INFORMATION SHEET**

California Department of Health Services (CDHS) is mandated under state law (Health and Safety Code, Section 103885) to gather information on the amount and type of cancer occurring throughout the state. Beginning January 1, 2001 and forward, diagnoses of borderline and benign primary intracranial and central nervous system (CNS) tumors are also reportable, as well as borderline ovarian cancer and Newly Reportable Hematopoietic Diseases (NRHD) listed below. The purpose of the law is to help identify preventable causes of cancer and specific borderline and benign tumors.

For the system to be useful, it must obtain complete and accurate counts of all new cancers and reportable tumors that occur. Therefore the new law requires hospitals and physicians to notify the appropriate regional registry of each new case of cancer and reportable tumor.

The information collected is confidential under California Health and Safety Code Sections 100330 and 103885, Civil Code, Sections 56.05 and 1798, Government Code, Sections 6250-62-65, and Federal Law PL 104-191. CDHS has more than 50 years' experience in handling confidential records. Laws, regulations and programmatic safeguards are in place throughout the system to assure that the identities of patients are not revealed. Some cancer patients may, however, be contacted later by CDHS or the regional cancer registries as part of their ongoing investigations into the causes of cancer.

NRHD include the following :

#### Chronic Myeloproliferative Diseases

- Polycythemia vera
- Chronic myeloproliferative disease
- Myelosclerosis with myeloid metaplasia
- Essential thrombocythemia
- Chronic neutrophilic leukemia
- Hypereosinophilic syndrome

Myelodysplastic Syndromes

- Refractory anemia
- Refractory anemia with sideroblasts
- Refractory anemia with excess blasts
- Refractory anemia with excess blasts  
in Transformation
- Refractory cytopenia with multilineage

Dysplasia

- Myelodysplastic syndrome with 5q-syndrome
- Therapy-related myelodysplastic syndrome
- Other New Diagnoses
- Langerhans cell histiocytosis, disseminated
- Acute biphenotypic leukemia
- Precursor lymphoblastic leukemia
- Aggressive NK cell leukemia
- Chronic neutrophilic leukemia
- Hypereosinophilic syndrome
- Leukemias with cytogenetic abnormalities
- Dendritic cell sarcoma.

## APPENDIX K-1 Codes for Casefinding (For Cases Diagnosed January 1, 2011 and Later)

### Screening List of OF ICD-9-CM Codes for Casefinding

Certain ICD-9-CM\* codes used by medical records departments for discharge diagnoses identify cases of malignant neoplasms that are reportable to the California Cancer Registry. Case finding procedures must include the review of medical records coded with the following numbers. Newly reportable diseases are followed by the ICD-O-3 morphology and behavior code in parentheses.

**NOTE: Casefinding codes for borderline ovarian tumors (235.0-236.6) are included in the Supplementary List #2.**

The following information is taken directly from the SEER web site:

<http://seer.cancer.gov/tools/casefinding/case2011long.html>.

### Fiscal Year 2011 Casefinding List: Expanded Version

Some ranges are expressed with only 1 decimal place (e.g. 237.0-237.9) while some codes within that range may have two decimal places (e.g. 237.71 and 237.72). All codes in the range are included.

Comprehensive ICD-9-CM Casefinding Code List for Reportable Tumors (Effective Date: 1/1/2011)	
ICD-9-CM Code^	Explanation of Code
140.0 – 208.92	Malignant Neoplasms
209.00 – 209.29	Neuroendocrine tumors
209.30	Malignant poorly differentiated neuroendocrine carcinoma, any site <i>Reportable inclusion terms:</i> <i>High grade neuroendocrine carcinoma, any site</i> <i>Malignant poorly differentiated neuroendocrine tumor NOS</i>
209.31 – 209.36	Merkel cell carcinoma
209.70 – 209.79	Secondary neuroendocrine tumors <i>Reportable inclusion terms:</i> <i>Secondary carcinoid + tumors</i> <b>Note: All neuroendocrine or carcinoid tumors specified as secondary are malignant</b>
225.0 – 225.9	Benign neoplasm of brain and spinal cord neoplasm
227.3	Benign neoplasm of pituitary gland and craniopharyngeal duct (pouch)

California Cancer Reporting System Standards, Volume I

	<p><i>Reportable inclusion terms:</i>  <i>Benign neoplasm of craniobuccal pouch, hypophysis, Rathke's pouch or sella turcica</i></p>
227.4	Benign neoplasm of pineal gland
228.02	<p>Hemangioma; of intracranial structures  <i>Reportable inclusion terms:</i>  <i>Angioma NOS, Cavernous nevus, Glomus tumor, Hemangioma (benign)</i></p>
228.1	<p>Lymphangioma, any site  <b>This code includes Lymphangiomas of Brain, Other parts of nervous system and endocrine glands, which are reportable.</b></p>
230.0 – 234.9	Carcinoma in situ
236.0	<p>Endometrial stroma, low grade (8931/1)  <i>Reportable inclusion terms:</i>  <i>Stromal endometriosis (8931/3 per ICD-O-3)</i>  <i>Stromal myosis (endolymphatic) (8931/3 per ICD-O-3)</i>  <i>Stromatosis, endometrial (8931/3 per ICD-O-3)</i></p>
237.0 – 237.1	Neoplasm of uncertain behavior [borderline] of pituitary gland, craniopharyngeal duct and pineal gland
237.5 – 237.6	Neoplasm of uncertain behavior [borderline] of brain, spinal cord and meninges
237.72	<p>Neurofibromatosis, type 2 [acoustic neurofibromatosis]  <b>Note: Acoustic neuromas growing along the acoustic nerve.</b>          See "supplementary" list for Neurofibromatosis, unspecified (237.70) and Neurofibromatosis, type 1 (237.71)</p>
237.9	Neoplasm of other and unspecified parts of nervous system (cranial nerves)
238.4	Polycythemia vera (9950/3)
238.6	<p>Neoplasm of uncertain behavior of other and unspecified sites and tissues, Plasma cells (Plasmacytoma, extramedullary, 9734/3)  <i>Reportable inclusion terms:</i>  <i>Plasmacytoma NOS (9731/3)</i>  <i>Solitary myeloma (9731/3)</i></p>
238.7	<p>Other lymphatic and hematopoietic tissues  <b>Note: This code was expanded 10/2006. It is now a subcategory and is no longer valid for use for coding purposes. It should be included in extract programs for quality control purposes.)</b></p>
238.71	<p>Essential thrombocythemia (9962/3)  <i>Reportable inclusion terms:</i>  <i>Essential hemorrhagic thrombocythemia</i></p>

California Cancer Reporting System Standards, Volume I

	<i>Idiopathic (hemorrhagic) thrombocythemia</i>
<b>238.72</b>	Low grade myelodysplastic syndrome lesions (includes 9980/3, 9982/3, 9983/3, 9985/3) <i>Reportable inclusion terms:</i> <i>Refractory anemia (RA) (9980/3)</i> <i>Refractory anemia with excess blasts-1 (RAEB-1) (9983/3)</i> <i>Refractory anemia with ringed sideroblasts (RARS) (9982/3)</i> <i>Refractory cytopenia with multilineage dysplasia (RCMD) (9985/3)</i> <i>Refractory cytopenia with multilineage dysplasia and ringed sideroblasts (RCMD-RS) (9985/3)</i>
<b>238.73</b>	High grade myelodysplastic syndrome lesions (includes 9983/3) <i>Reportable inclusion terms:</i> <i>Refractory anemia with excess blasts-2 (RAEB-2)</i>
<b>238.74</b>	Myelodysplastic syndrome with 5q deletion (9986/3) <i>Reportable inclusion terms:</i> <i>5q minus syndrome NOS</i>
<b>238.75</b>	Myelodysplastic syndrome, unspecified (9985/3, 9987/3)
<b>238.76</b>	Myelofibrosis with myeloid metaplasia (9961/3) <i>Reportable inclusion terms:</i> <i>Agnogenic myeloid metaplasia</i> <i>Idiopathic myelofibrosis (chronic)</i> <i>Myelosclerosis with myeloid metaplasia</i>
<b>238.77</b>	Post transplant lymphoproliferative disorder (9987/3)
<b>238.79</b>	Other lymphatic and hematopoietic tissues (includes 9960/3, 9961/3, 9970/1, 9931/3) <i>Reportable inclusion terms:</i> <i>Lymphoproliferative disease (chronic) NOS (9970/1)</i> <i>Megakaryocytic myelosclerosis (9961/3)</i> <i>Myeloproliferative disease (chronic) NOS (9960/3)</i> <i>Panmyelosis (acute) (9931/3)</i>
<b>239.6</b>	Neoplasms of unspecified nature, brain
<b>239.7</b>	Neoplasms of unspecified nature; endocrine glands and other parts of nervous system
<b>273.2</b>	Other paraproteinemias <i>Reportable inclusion terms:</i> <i>Franklin's disease (heavy chain) (9762/3)</i> <i>Heavy chain disease (9762/3)</i> <i>Mu-chain disease (9762/3)</i>
<b>273.3</b>	Macroglobulinemia <i>Reportable inclusion terms:</i>

California Cancer Reporting System Standards, Volume I

	<i>Waldenström's macroglobulinemia (9761/3)</i> <i>Waldenström's (macroglobulinemia) syndrome</i>
<b>277.89</b>	Other specified disorders of metabolism Hand-Schuller-Christian disease Histiocytosis (acute) (chronic) Histiocytosis (chronic)
<b>288.4</b>	Hemophagocytic syndrome (9751/3, 9754/3) <i>Reportable inclusion terms:</i> <i>Histiocytic syndromes</i>
<b>795.06</b>	Papanicolaou smear of cervix with cytologic evidence of malignancy
<b>795.16</b>	Papanicolaou smear of vagina with cytologic evidence of malignancy
<b>796.76</b>	Papanicolaou smear of anus with cytologic evidence of malignancy
<b>V10.0 – V10.89</b>	Personal history of malignancy <b>Note: Screen for recurrences, subsequent primaries, and/or subsequent treatment</b>
<b>V10.90</b>	Personal history of unspecified malignant neoplasm <b>Note: Effective Date: 10/1/09. Screen for recurrences, subsequent primaries, and/or subsequent treatment</b>
<b>V10.91</b>	Personal history of malignant neuroendocrine tumor, carcinoid tumor, Merkel cell carcinoma <b>Note: Effective Date: 10/1/09. Screen for recurrences, subsequent primaries, and/or subsequent treatment</b>
<b>V12.41</b>	Personal history of benign neoplasm of the brain

The following codes are not reportable per se, but they should alert registrars to look for the first malignant neoplasm associated with these codes.

**Supplementary List #1-ICD-9-CM Codes that Should Be Followed by or Associated with a Neoplasm Code<sup>^</sup>**

ICD-9-CM Code <sup>^</sup>	Explanation of Code
<b>258.02 – 258.03</b>	Multiple endocrine neoplasia (MEN) type IIA and IIB (rare familial cancer syndrome) <b>Note: Use additional codes to identify any malignancies and other conditions associated with the syndrome</b>
<b>285.22</b>	Anemia in neoplastic disease <b>Note: Assign also a code for the neoplasm causing the anemia</b> <b>Excludes: anemia due to antineoplastic chemotherapy, new code 285.3</b>
<b>289.83</b>	Myelofibrosis (NOS) (9961/3) <b>Note: Not every case of myelofibrosis is associated with a</b>

	<b>malignancy. Review terms included in ICD-O-3 to determine if case is reportable. See ICD-9-CM</b>
<b>338.3</b>	Neoplasm related pain (acute, chronic); Cancer associated pain; Pain due to malignancy (primary/secondary); Tumor associated pain
<b>511.81</b>	Malignant pleural effusion <b>Note : Code first malignant neoplasm if known. If the primary site is not known, code 199.0, disseminated carcinomatosis, or code 199.1, malignancy NOS, should be assigned</b>
<b>789.51</b>	Malignant ascites <b>Note : Code first malignant neoplasm if known. If the primary site is not known, code 199.0, disseminated carcinomatosis, or code 199.1, malignancy NOS, should be assigned</b>

NOTE: Cases with these codes should be screened as registry time allows. These are neoplasm-related secondary conditions for which there should also be a primary diagnosis of a reportable neoplasm. Experience in the SEER registries has shown that using the supplementary list increases casefinding for benign brain and CNS, hematopoietic, and other reportable neoplasms.

**Supplementary List #2-ICD-9-CM Code List to Screen for Cancer Cases Not Identified by Other Codes (Effective Date: 1/1/2011)^**

<b>ICD-9-CM Code^</b>	<b>Explanation of Code</b>
<b>042</b>	Acquired Immunodeficiency Syndrome (AIDS) <b>Note: This is not a malignancy. Medical coders are instructed to add codes for AIDS-associated malignancies. Screen 042 for history of cancers that might not be coded.</b>
<b>079.4</b>	Human papillomavirus
<b>079.50 – 079.59</b>	Retrovirus (HTLV, types I, II and 2)
<b>209.40-209.69</b>	Benign carcinoid tumors
<b>210.0 – 229.9</b>	Benign neoplasms (except for 225.0-225.9, 227.3, 227.4, 228.02, and 228.1, which are listed in the Reportable list) <b>Note: Screen for incorrectly coded malignancies or reportable by agreement tumors.</b>
<b>235.0 – 236.7, 236.90 – 236.99</b>	Neoplasms of uncertain behavior (except for 236.0, which is listed in the Reportable list) <b>Note: Screen for incorrectly coded malignancies or reportable by agreement tumors</b>
<b>237.2 – 237.4</b>	Neoplasm of uncertain behavior of adrenal gland, paraganglia and other and unspecified endocrine glands <b>Note: Screen for incorrectly coded malignancies or reportable by agreement tumors</b>



<b>237.70 – 237.71</b>	Neurofibromatosis, unspecified and Type 1 <b>Note: An inherited condition with developmental changes in the nervous system, muscles, bones and skin; multiple soft tumors (neurofibromas) distributed over the whole body. (See "must report" for Neurofibromatosis, type 2, 237.72)</b>
<b>237.73</b>	Schwannomatosis <b>Note: Effective date 10/1/2010. Screen for incorrectly coded malignancies or reportable by agreement tumors</b>
<b>237.79</b>	Other neurofibromatosis <b>Note: Effective date 10/1/2010 Screen for incorrectly coded malignancies or reportable by agreement tumors</b>
<b>238.0 – 239.9</b>	Neoplasms of uncertain behavior (except for 238.4, 238.6, 238.71-238.79, 239.6, 239.7, which are listed in the Reportable list) <b>Note: Screen for incorrectly coded malignancies or reportable by agreement tumors</b>
<b>253.6</b>	Syndrome of inappropriate secretion of antidiuretic hormone <b>Note: Part of the paraneoplastic syndrome. See note of explanation in the "notes" section.</b>
<b>259.2</b>	Carcinoid Syndrome
<b>259.8</b>	Other specified endocrine disorders
<b>273.0</b>	Polyclonal hypergammaglobulinemia (Waldenstrom) <b>Note: Review for miscodes</b>
<b>273.1</b>	Monoclonal gammopathy of undetermined significance (9765/1) <b>Note: Screen for incorrectly coded Waldenstrom macroglobulinemia or progression</b>
<b>273.8</b>	Other disorders of plasma protein metabolism
<b>273.9</b>	Unspecified disorder of plasma protein metabolism <b>Note: Screen for incorrectly coded Waldenstrom's macroglobulinemia</b>
<b>275.42</b>	Hypercalcemia <b>Note: Part of the paraneoplastic syndrome. See note of explanation in the "notes" section.</b>
<b>277.88</b>	Tumor lysis syndrome/Tumor lysis syndrome following antineoplastic drug therapy
<b>279.00</b>	Hypogammaglobulinemia <b>Note: Predisposed to lymphoma or stomach cancer</b>
<b>279.02 – 279.06</b>	Selective IgM immunodeficiency <b>Note: Associated with lymphoproliferative disorders</b>
<b>279.10</b>	Immunodeficiency with predominant T-cell defect, NOS
<b>279.12</b>	Wiskott-Aldrich Syndrome
<b>279.13</b>	Nezelof's Syndrome

California Cancer Reporting System Standards, Volume I

279.2 – 279.9	Combined immunity deficiency – Unspecified disorder of immune mechanism
284.81	Red cell aplasia (acquired, adult, with thymoma)
284.89	Other specified aplastic anemias due to drugs (chemotherapy or immunotherapy), infection, radiation
284.9	Aplastic anemia, unspecified <b>Note: Review for miscodes</b>
285.0	Sideroblastic anemia
285.3	Antineoplastic chemotherapy induced anemia (Anemia due to antineoplastic chemotherapy)
288.03	Drug induced neutropenia
288.3	Eosinophilia <b>Note: This is the code for eosinophilia (9964/3). Not every case of eosinophilia is associated with a malignancy. Diagnosis must be "Hypereosonophilic syndrome" to be reportable.</b>
289.6	Familial polycythemia <b>Note: This is a symptom of polycythemia vera.</b>
289.89	Other specified diseases of blood and blood-forming organs <b>Note: Review for miscodes</b>
289.9	Other specified diseases of blood and blood-forming organs
323.81	Encephalomyelitis; specified cause NEC <b>Note: Part of the paraneoplastic syndrome. See note of explanation in the "notes" section.</b>
379.59	Opsoclonia <b>Note: Part of the paraneoplastic syndrome. See note of explanation in the "notes" section.</b>
528.01	Mucositis due to antineoplastic therapy
630	Hydatidiform Mole (9100/0) <b>Note: This is a benign tumor that can become malignant. If malignant, it should be reported as Choriocarcinoma (9100/3) and will have a malignancy code in the 140-209 range.</b>
686.01	Pyoderma gangrenosum <b>Note: Part of the paraneoplastic syndrome. See note of explanation in the "notes" section.</b>
695.89	Sweet's syndrome <b>Note: Part of the paraneoplastic syndrome. See note of explanation in the "notes" section.</b>
701.2	Acanthosis nigricans <b>Note: Part of the paraneoplastic syndrome. See note of explanation in the "notes" section.</b>

<b>710.3</b>	Dermatomyositis <b>Note: Part of the paraneoplastic syndrome. See note of explanation in the "notes" section.</b>
<b>710.4</b>	Polymyositis <b>Note: Part of the paraneoplastic syndrome. See note of explanation in the "notes" section.</b>
<b>733.10 – 733.16</b>	Pathologic fracture <b>Note: pathologic fractures can be due to bone structure weakening by pathological processes (e.g. osteoporosis, neoplasms and osteomalacia)</b>
<b>758.0</b>	Down's Syndrome <b>Note: Screen for myeloid leukemia associated with Down's Syndrome (9898/3)</b>
<b>785.6</b>	Enlargement of lymph nodes <b>Note: Screen for large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease (9738/3)</b>
<b>790.93</b>	Elevated prostate specific antigen [PSA]
<b>795.8_</b>	Abnormal tumor markers; Elevated tumor associated antigens [TAA]; Elevated tumor specific antigens [TSA]; <b>Excludes: Elevated prostate specific antigen [PSA] (790.93)</b>
<b>795.81</b>	Elevated carcinoembryonic antigen [CEA]
<b>795.82</b>	Elevated cancer antigen 125 [CA 125]
<b>795.89</b>	Other abnormal tumor markers
<b>999.31</b>	Infection due to central venous catheter (porta-cath)
<b>999.81</b>	Extravasation of vesicant chemotherapy
<b>E879.2</b>	Adverse effect of radiation therapy
<b>E930.7</b>	Adverse effect of antineoplastic therapy
<b>E933.1</b>	Adverse effect of immunosuppressive drugs
<b>V07.31, V07.39</b>	Other prophylactic chemotherapy
<b>V07.8</b>	Other specified prophylactic measure
<b>V12.72</b>	Colonic polyps (history of)
<b>V15.3</b>	Irradiation: previous exposure to therapeutic or ionizing radiation
<b>V42.81</b>	Organ or tissue replaced by transplant, Bone marrow transplant
<b>V42.82</b>	Transplant; Peripheral stem cells
<b>V51.0</b>	Encounter for breast reconstruction following mastectomy
<b>V52.4</b>	Breast prosthesis and implant

California Cancer Reporting System Standards, Volume I

V54.2_	Aftercare for healing pathologic fracture
V58.0	Encounter for radiation therapy
V58.1	Encounter for antineoplastic chemotherapy and immunotherapy <b>Note: This code was discontinued as of 10/2006 but should be included in extract programs for quality control purposes</b>
V58.11	Encounter for antineoplastic chemotherapy
V58.12	Encounter for antineoplastic immunotherapy
V58.42	Aftercare following surgery for neoplasm
V58.9	Unspecified aftercare
V66.1	Convalescence following radiotherapy
V66.2	Convalescence following chemotherapy
V66.7	Encounter for palliative care
V67.01	Follow-up vaginal pap smear Vaginal pap smear, status-post hysterectomy for malignant condition
V67.1	Radiation therapy follow up
V67.2	Chemotherapy follow up
V71.1	Observation for suspected malignant neoplasm
V76.0 – V76.9	Special screening for malignant neoplasm
V78.0 – V78.9	Special screening for disorders of blood and blood-forming organs
V82.71	Screening for genetic disease carrier status
V82.79	Other genetic screening
V82.89	Genetic screening for other specified conditions
V82.9	Genetic screening for unspecified condition
V84.01 – V84.09	Genetic susceptibility to malignant neoplasm
V84.81	Genetic susceptibility to multiple endocrine neoplasia [MEN]
V86.0	Estrogen receptor positive status [ER+]
V86.1	Estrogen receptor negative status [ER-]
V87.41	Personal history of antineoplastic chemotherapy

**NOTES:**

Prostatic Intraepithelial Neoplasia (PIN III) M-8148/2 is not required by SEER.

Pilocytic/juvenile astrocytoma M-9421 moved from behavior /3 (malignant) to /1 (borderline malignancy) in ICD-O-3. However, SEER registries will CONTINUE to report these cases and code behavior a /3 (malignant).

Borderline cystadenomas M-8442, 8451, 8462, 8472, 8473, of the ovaries moved from behavior /3 (malignant) to /1 (borderline malignancy) in ICD-O-3. SEER registries are not required to collect these cases for diagnoses made 1/1/2001 and after. However, cases diagnosed prior to 1/1/2001 should still be abstracted and reported to SEER.

Codes 253.6, 686.01, 695.89, 701.2, 710.3 and 710.4 are part of the paraneoplastic syndrome. "Paraneoplastic syndrome isn't cancer. It's a disease or symptom that is the consequence of cancer but is not due to the local presence of cancer cells. A paraneoplastic syndrome may be the first sign of cancer."

<sup>^</sup> *International Classification of Diseases, Ninth Revision, Clinical Modification, 2011.*

## APPENDIX K-2 Codes for Casefinding (For Cases Diagnosed Jan 1, 2010 to Dec 31, 2010)

### Screening List of OF ICD-9-CM Codes for Casefinding

Certain ICD-9-CM\* codes used by medical records departments for discharge diagnoses identify cases of malignant neoplasms that are reportable to the California Cancer Registry. Case finding procedures must include the review of medical records coded with the following numbers. Newly reportable diseases are followed by the ICD-O-3 morphology and behavior code in parentheses.

[The following information is taken directly from the SEER web site: http://seer.cancer.gov/tools/casefinding/fy2010long.html](http://seer.cancer.gov/tools/casefinding/fy2010long.html)

### Fiscal Year 2010 Casefinding List: Expanded Version

Some ranges are expressed with only 1 decimal place (e.g. 237.0-237.9) while some codes within that range may have two decimal places (e.g. 237.71 and 237.72). All codes in the range are included.

These tables are also available in a printable version (PDF).

Comprehensive ICD-9-CM Casefinding Code List for Reportable Tumors (Effective Date: 1/1/2010)	
ICD-9-CM Code <sup>^</sup>	Explanation of Code
140.0 – 208.92	Malignant Neoplasms
209.00 – 209.29	Neuroendocrine tumors
209.30	Malignant poorly differentiated neuroendocrine carcinoma, any site <i>Reportable inclusion terms:</i> <i>High grade neuroendocrine carcinoma, any site</i> <i>Malignant poorly differentiated neuroendocrine tumor NOS</i>
209.31 – 209.36	Merkel cell carcinoma <b>Note: Effective date 10/1/09</b>
209.70 – 209.79	Secondary neuroendocrine tumors <b>Note: Effective Date 10/1/09</b> <i>Reportable inclusion terms:</i> <i>Secondary carcinoid + tumors</i> <b>Note: All neuroendocrine or carcinoid tumors specified as secondary are malignant</b>
225.0 – 225.9	Benign neoplasm of brain and spinal cord neoplasm
227.3	Benign neoplasm of pituitary gland and craniopharyngeal duct (pouch) <i>Reportable inclusion terms:</i> <i>Benign neoplasm of craniobuccal pouch, hypophysis, Rathke's</i>

California Cancer Reporting System Standards, Volume I

	<i>pouch or sella turcica</i>
<b>227.4</b>	Benign neoplasm of pineal gland
<b>227.9</b>	Benign neoplasm; endocrine gland, site unspecified
<b>228.02</b>	Hemangioma; of intracranial structures <i>Reportable inclusion terms:</i> <i>Angioma NOS, Cavernous nevus, Glomus tumor, Hemangioma (benign)</i>
<b>228.1</b>	Lymphangioma, any site
<b>230.0 – 234.9</b>	Carcinoma in situ <i>Reportable inclusion terms:</i> <i>Intraepithelial neoplasia III</i>
<b>236.0</b>	Endometrial stroma, low grade (8931/1) <i>Reportable inclusion terms:</i> <i>Stromal endometriosis (8931/3 per ICD-O-3)</i> <i>Stromal myosis (endolymphatic) (8931/3 per ICD-O-3)</i> <i>Stromatosis, endometrial (8931/3 per ICD-O-3)</i>
<b>237.0 – 237.9</b>	Neoplasm of uncertain behavior [borderline] of endocrine glands and nervous system
<b>238.4</b>	Polycythemia vera (9950/3)
<b>238.6</b>	Neoplasm of uncertain behavior of other and unspecified sites and tissues, Plasma cells (Plasmacytoma, extramedullary, 9734/3) <i>Reportable inclusion terms:</i> <i>Plasmacytoma NOS (9731/3)</i> <i>Solitary myeloma (9731/3)</i>
<b>238.7</b>	Other lymphatic and hematopoietic tissues <b>Note: This code was expanded 10/2006. It is now a subcategory and is no longer valid for use for coding purposes. It should be included in extract programs for quality control purposes.)</b>
<b>238.71</b>	Essential thrombocythemia (9962/3) <i>Reportable inclusion terms:</i> <i>Essential hemorrhagic thrombocythemia</i> <i>Idiopathic (hemorrhagic) thrombocythemia</i>
<b>238.72</b>	Low grade myelodysplastic syndrome lesions (includes 9980/3, 9982/3, 9983/3, 9985/3) <i>Reportable inclusion terms:</i> <i>Refractory anemia (RA) (9980/3)</i> <i>Refractory anemia with excess blasts-1 (RAEB-1) (9983/3)</i> <i>Refractory anemia with ringed sideroblasts (RARS) (9982/3)</i> <i>Refractory cytopenia with multilineage dysplasia (RCMD) (9985/3)</i> <i>Refractory cytopenia with multilineage dysplasia and ringed sideroblasts (RCMD-RS) (9985/3)</i>
<b>238.73</b>	High grade myelodysplastic syndrome lesions (includes 9983/3)

California Cancer Reporting System Standards, Volume I

	<p><i>Reportable inclusion terms:</i>  <i>Refractory anemia with excess blasts-2 (RAEB-2)</i></p>
<b>238.74</b>	<p>Myelodysplastic syndrome with 5q deletion (9986/3)  <i>Reportable inclusion terms:</i>  <i>5q minus syndrome NOS</i></p>
<b>238.75</b>	<p>Myelodysplastic syndrome, unspecified (9985/3, 9987/3)</p>
<b>238.76</b>	<p>Myelofibrosis with myeloid metaplasia (9961/3)  <i>Reportable inclusion terms:</i>  <i>Agnogenic myeloid metaplasia</i>  <i>Idiopathic myelofibrosis (chronic)</i>  <i>Myelosclerosis with myeloid metaplasia</i></p>
<b>238.77</b>	<p>Post transplant lymphoproliferative disorder (9987/3)</p>
<b>238.79</b>	<p>Other lymphatic and hematopoietic tissues (includes 9960/3, 9961/3, 9970/1, 9931/3)  <i>Reportable inclusion terms:</i>  <i>Lymphoproliferative disease (chronic) NOS (9970/1)</i>  <i>Megakaryocytic myelosclerosis (9961/3)</i>  <i>Myeloproliferative disease (chronic) NOS (9960/3)</i>  <i>Panmyelosis (acute) (9931/3)</i></p>
<b>239.6</b>	<p>Neoplasms of unspecified nature, brain</p>
<b>239.7</b>	<p>Neoplasms of unspecified nature; endocrine glands and other parts of nervous system</p>
<b>239.81 – 239.89</b>	<p>Neoplasms of unspecified nature; other specified sites  <b>Note: Effective Date 10/1/09</b></p>
<b>273.2</b>	<p>Other paraproteinemias  <i>Reportable inclusion terms:</i>  <i>Franklin's disease (heavy chain) (9762/3)</i>  <i>Heavy chain disease (9762/3)</i>  <i>Mu-chain disease (9762/3)</i></p>
<b>273.3</b>	<p>Macroglobulinemia  <i>Reportable inclusion terms:</i>  <i>Waldenström's macroglobulinemia (9761/3)</i>  <i>Waldenström's (macroglobulinemia) syndrome</i></p>
<b>288.3</b>	<p>Eosinophilia  Note: This code is for eosinophilia, which is not reportable. Do not abstract unless diagnosis is "Hypereosinophilic syndrome (9964/3)."</p>
<b>795.06</b>	<p>Papanicolaou smear of cervix with cytologic evidence of malignancy</p>
<b>795.16</b>	<p>Papanicolaou smear of vagina with cytologic evidence of malignancy</p>
<b>796.76</b>	<p>Papanicolaou smear of anus with cytologic evidence of malignancy</p>
<b>V10.0 – V10.89</b>	<p>Personal history of malignancy  <b>Note: Screen for recurrences, subsequent primaries, and/or</b></p>



	<b>subsequent treatment</b>
<b>V10.90</b>	Personal history of unspecified malignant neoplasm <b>Note: Effective Date: 10/1/09. Screen for recurrences, subsequent primaries, and/or subsequent treatment</b>
<b>V10.91</b>	Personal history of malignant neuroendocrine tumor, carcinoid tumor, Merkel cell carcinoma <b>Note: Effective Date: 10/1/09. Screen for recurrences, subsequent primaries, and/or subsequent treatment</b>
<b>V12.41</b>	Personal history of benign neoplasm of the brain

The following codes are not reportable per se, but they should alert registrars to look for the first malignant neoplasm associated with these codes.

Supplementary List #1-ICD-9-CM Codes that Should Be Followed by or Associated with a Neoplasm Code	
ICD-9-CM Code <sup>^</sup>	Explanation of Code
<b>258.02 – 258.03</b>	Multiple endocrine neoplasia (MEN) type IIA and IIB (rare familial cancer syndrome) <b>Note: Use additional codes to identify any malignancies and other conditions associated with the syndrome</b>
<b>285.22</b>	Anemia in neoplastic disease <b>Note: Assign also a code for the neoplasm causing the anemia</b> <b>Excludes: anemia due to antineoplastic chemotherapy, new code 285.3</b>
<b>289.83</b>	Myelofibrosis (NOS) (9961/3) <b>Note: Not every case of myelofibrosis is associated with a malignancy. Review terms included in ICD-O-3 to determine if case is reportable. See ICD-9-CM</b>
<b>338.3</b>	Neoplasm related pain (acute, chronic); Cancer associated pain; Pain due to malignancy (primary/secondary); Tumor associated pain
<b>511.81</b>	Malignant pleural effusion <b>Note : Code first malignant neoplasm if known. If the primary site is not known, code 199.0, disseminated carcinomatosis, or code 199.1, malignancy NOS, should be assigned</b>
<b>789.51</b>	Malignant ascites <b>Note : Code first malignant neoplasm if known. If the primary site is not known, code 199.0, disseminated carcinomatosis, or code 199.1, malignancy NOS, should be assigned</b>

California Cancer Reporting System Standards, Volume I

NOTE: Cases with these codes should be screened as registry time allows. These are neoplasm-related secondary conditions for which there should also be a primary diagnosis of a reportable neoplasm. Experience in the SEER registries has shown that using the supplementary list increases casefinding for benign brain and CNS, hematopoietic neoplasms, and other reportable diseases.

Supplementary List #2-ICD-9-CM Code List to Screen for Cancer Cases Not Identified by Other Codes (Effective Date: 1/1/2010)
ICD-9-CM Code ^
<b>042</b>
<b>079.4</b>
<b>079.50 – 079.59</b>
<b>209.40-209.69</b>
<b>210.0 – 229.9</b>
<b>235.0 – 236.6</b>
<b>238.0 – 239.9</b>
<b>253.6</b>
<b>259.2</b>
<b>259.8</b>
<b>273.0</b>
<b>273.1</b>
<b>273.9</b>
<b>275.42</b>
<b>277.88</b>
<b>279.00</b>
<b>279.02 – 279.06</b>
<b>279.10</b>
<b>279.12</b>
<b>279.13</b>
<b>279.2 – 279.9</b>
<b>284.81</b>
<b>284.89</b>
<b>284.9</b>
<b>285.0</b>
<b>285.3</b>

California Cancer Reporting System Standards, Volume I

<b>288.03</b>
<b>289.89</b>
<b>323.81</b>
<b>379.59</b>
<b>528.01</b>
<b>630</b>
<b>686.01</b>
<b>695.89</b>
<b>701.2</b>
<b>710.3</b>
<b>710.4</b>
<b>785.6</b>
<b>790.93</b>
<b>795.8</b>
<b>795.81</b>
<b>795.82</b>
<b>795.89</b>
<b>999.31</b>
<b>999.81</b>
<b>E879.2</b>
<b>E930.7</b>
<b>E933.1</b>
<b>V07.31, V07.39</b>
<b>V07.8</b>
<b>V12.72</b>
<b>V15.3</b>
<b>V42.81</b>
<b>V42.82</b>
<b>V51.0</b>
<b>V52.4</b>
<b>V54.2</b>
<b>V58.0</b>
<b>V58.1</b>

<b>V58.11</b>
<b>V58.12</b>
<b>V58.42</b>
<b>V66.1</b>
<b>V66.2</b>
<b>V67.1</b>
<b>V67.2</b>
<b>V71.1</b>
<b>V76.0 – V76.9</b>
<b>V78.0 – V78.9</b>
<b>V82.71</b>
<b>V82.79</b>
<b>V82.89</b>
<b>V82.9</b>
<b>V84.01 – V84.09</b>
<b>V84.81</b>
<b>V86.0</b>
<b>V86.1</b>
<b>V87.41</b>

**NOTES:**

- Prostatic Intraepithelial Neoplasia (PIN III) M-8148/2 is not required by SEER.
- Pilocytic/juvenile astrocytoma M-9421 moved from behavior /3 (malignant) to /1 (borderline malignancy) in ICD-O-3. However, SEER registries will CONTINUE to report these cases and code behavior a /3 (malignant) .
- Borderline cystadenomas M-8442, 8451, 8462, 8472, 8473, of the ovaries moved from behavior /3 (malignant) to /1 (borderline malignancy) in ICD-O-3. SEER registries are not required to collect these cases for diagnoses made 1/1/2001 and after. However, cases diagnosed prior to 1/1/2001 should still be abstracted and reported to SEER.
- These diseases are part of the paraneoplastic syndrome.  
 “Paraneoplastic syndrome isn’t cancer. It’s a disease or symptom that is the consequence of cancer but is not due to the local presence of cancer cells. A paraneoplastic syndrome may be the first sign of cancer.”

<sup>^</sup> *International Classification of Diseases, Ninth Revision, Clinical Modification, 2009.*

## APPENDIX K-3 Codes for Casefinding (For Cases Diagnosed Jan 1 to Dec 31, 2009)

### Screening List of OF ICD-9-CM Codes for Casefinding

Certain ICD-9-CM\* codes used by medical records departments for discharge diagnoses identify cases of malignant neoplasms that are reportable to the California Cancer Registry. Case finding procedures must include the review of medical records coded with the following numbers. Newly reportable diseases are followed by the ICD-O-3 morphology and behavior code in parentheses.

The following information was taken directly from the SEER web site.

### Fiscal Year 2009 Casefinding List

The Fiscal Year 2009 Comprehensive ICD-9-CM Casefinding and Supplementary ICD-9-CM Code Lists are to be used to identify cases diagnosed January 1, 2009 and later. The revised tables include new and expanded ICD-9-CM codes. The revised tables also now include paraneoplastic syndromes indicated by \* in Explanation of Code.

The 2009 Comprehensive ICD-9-CM Casefinding Code List is designed to assist in casefinding activities that are performed to identify reportable neoplasms, including benign brain and CNS tumors which became reportable in 2004, among a variety of casefinding sources that use ICD-9-CM\* codes (modified October 2008) to characterize a diagnosis.

### Comprehensive ICD-9-CM Casefinding Code List for Reportable Tumors (Effective Date: 1/1/2009 forward)

ICD-9-CM Code <sup>^</sup>	Explanation of Code
140.0 – 208.9	Malignant Neoplasms
209.0 – 209.3	Neuroendocrine tumors (Effective date: 1/1/09)
225.0 – 225.9	Benign neoplasm of brain and spinal cord neoplasm
227.3 – 227.4	Benign neoplasm of pituitary gland, pineal body, and other intracranial endocrine-related structures
227.9	Benign neoplasm; endocrine gland, site unspecified
228.02	Hemangioma; of intracranial structures
228.1	Lymphangioma, any site
230.0 – 234.9	Carcinoma in situ

California Cancer Reporting System Standards, Volume I

<b>236.0</b>	Endometrial stroma, low grade (8931/1)
<b>237.0 – 237.9</b>	Neoplasm of uncertain behavior [borderline] of endocrine glands and nervous system
<b>238.4</b>	Polycythemia vera (9950/3)
<b>238.6</b>	Solitary plasmacytoma (9731/3) Extramedullary plasmacytoma (9734/3)
<b>238.7</b>	Other lymphatic and hematopoietic tissues (This code was discontinued as of 10/2006 but should be included in extract programs for quality control purposes)
<b>238.71</b>	Essential thrombocythemia (9962/3)
<b>238.72</b>	Low grade myelodysplastic syndrome lesions (includes 9980/3, 9982/3, 9985/3)
<b>238.73</b>	High grade myelodysplastic syndrome lesions (includes 9983/3)
<b>238.74</b>	Myelodysplastic syndrome with 5q deletion (9986/3)
<b>238.75</b>	Myelodysplastic syndrome, unspecified (9985/3)
<b>238.76</b>	Myelofibrosis with myeloid metaplasia (9961/3)
<b>238.77</b>	Post transplant lymphoproliferative disorder (9987/3)
<b>238.79</b>	Other lymphatic and hematopoietic tissues (includes 9960/3, 9961/3, 9970/1, 9931/3)
<b>239.6</b>	Neoplasms of unspecified nature, brain
<b>239.7</b>	Neoplasms of unspecified nature; endocrine glands and other parts of nervous system
<b>259.2</b>	Carcinoid Syndrome
<b>259.8</b>	Other specified endocrine disorders
<b>273.2</b>	Gamma heavy chain disease (9762/3); Franklin's disease (9762/3)
<b>273.3</b>	Waldenstrom macroglobulinemia (9761/3)
<b>285.22</b>	Anemia in neoplastic disease
<b>288.3</b>	Hypereosinophilic syndrome (9964/3)
<b>289.83</b>	Myelofibrosis (NOS) (9961/3)
<b>289.89</b>	Other specified diseases of blood and blood-forming
<b>511.81</b>	Malignant pleural effusion (code first malignant neoplasm if known)
<b>789.51</b>	Malignant ascites (code first malignant neoplasm if known)
<b>795.06</b>	Papanicolaou smear of cervix with cytologic evidence of malignancy
<b>795.16</b>	Papanicolaou smear of vagina with cytologic evidence of malignancy

<b>795.76</b>	Papanicolaou smear of anus with cytologic evidence of malignancy
<b>V10.0 – V10.9</b>	Personal history of malignancy (screen for recurrences, subsequent primaries, and/or subsequent treatment)

Many new codes and conditions have been added to the Supplementary ICD-9-CM Code List. It is recommended that each registry screen cases using the supplementary list as time permits. Experience among the SEER registries has proven that using the supplementary list significantly improves casefinding outcomes for benign brain and CNS tumors, hematopoietic and lymphoid neoplasms, and other reportable diseases.

NOTE: Cases with these codes should be screened only as registry time allows. Some codes represent neoplasm-related secondary conditions for which there should also be a primary diagnosis of a reportable neoplasm. Complete casefinding would include investigation of patient records with diagnoses represented on either list.

**Supplementary ICD-9-CM Code List to Screen for Cancer Cases Not Identified by Other Codes (Effective Date: 1/1/09)**

ICD-9-CM Code^	Explanation of Code
<b>042</b>	Acquired Immunodeficiency Syndrome (AIDS) (This is not a malignancy. Medical coders are instructed to add codes for AIDS-associated malignancies. Screen 042 for history of cancers that might not be coded.)
<b>079.4</b>	Human papillomavirus
<b>079.50 – 079.59</b>	Retrovirus (HTLV, types I, II and 2)
<b>210.0 – 229.9</b>	Benign neoplasms (screen for incorrectly coded malignancies or reportable by agreement tumors)
<b>235.0 – 236.6</b>	Neoplasms of uncertain behavior (screen for incorrectly coded malignancies or reportable by agreement tumors)
<b>238.0 – 239.9</b>	Neoplasms of uncertain behavior (screen for incorrectly coded malignancies or reportable by agreement tumors)
<b>253.6</b>	Syndrome of inappropriate secretion of antidiuretic hormone*
<b>258.02 – 258.03</b>	Multiple endocrine neoplasia (MEN) type IIA and IIB (rare familial cancer syndrome)
<b>273.0</b>	Polyclonal hypergammaglobulinemia (Waldenstrom) review for miscodes
<b>273.1</b>	Monoclonal gammopathy of undetermined significance (9765/1) (screen for incorrectly coded Waldenstrom macroglobulinemia or progression)
<b>273.9</b>	Unspecified disorder of plasma protein metabolism (screen for



California Cancer Reporting System Standards, Volume I

	incorrectly coded Waldenstrom's macroglobulinemia)
<b>275.42</b>	Hypercalcemia*
<b>279.00</b>	Hypogammaglobulinemia (predisposed to lymphoma or stomach cancer)
<b>279.02 – 279.06</b>	Selective IgM immunodeficiency (associated with lymphoproliferative disorders)
<b>279.10</b>	Immunodeficiency with predominant T-cell defect, NOS
<b>279.12</b>	Wiskott-Aldrich Syndrome
<b>279.13</b>	Nezelof's Syndrome
<b>279.2 – 279.9</b>	Combined immunity deficiency – Unspecified disorder of immune mechanism
<b>284.81</b>	Red cell aplasia (acquired, adult, with thymoma)
<b>284.89</b>	Other specified aplastic anemias due to drugs (chemotherapy or immunotherapy), infection, radiation
<b>288.03</b>	Drug induced neutropenia
<b>323.81</b>	Encephalomyelitis; specified cause NEC*
<b>338.3</b>	Neoplasm related pain (acute, chronic); Cancer associated pain; Pain due to malignancy (primary/secondary); Tumor associated pain
<b>379.59</b>	Opsoclonia*
<b>528.01</b>	Mucositis due to antineoplastic therapy
<b>686.01</b>	Pyoderma gangrenosum*
<b>695.89</b>	Sweet's syndrome*
<b>701.2</b>	Acanthosis nigricans*
<b>710.3</b>	Dermatomyositis*
<b>710.4</b>	Polymyositis*
<b>790.93</b>	Elevated prostate specific antigen [PSA]
<b>795.8</b>	Abnormal tumor markers; Elevated tumor associated antigens [TAA]; Elevated tumor specific antigens [TSA]; Excludes: elevated prostate specific antigen [PSA] (790.93)
<b>795.81</b>	Elevated carcinoembryonic antigen [CEA]
<b>795.82</b>	Elevated cancer antigen 125 [CA 125]
<b>795.89</b>	Other abnormal tumor markers
<b>999.31</b>	Infection due to central venous catheter (porta-cath) (Effective Date: 1/1/2009)
<b>999.81</b>	Extravasation of vesicant chemotherapy (Effective Date: 1/1/2009)

California Cancer Reporting System Standards, Volume I

<b>E879.2</b>	Adverse effect of radiation therapy
<b>E930.7</b>	Adverse effect of antineoplastic therapy
<b>E933.1</b>	Adverse effect of immunosuppressive drugs
<b>V07.3</b>	Other prophylactic chemotherapy (screen for incorrectly coded malignancies)
<b>V07.8</b>	Other specified prophylactic measure
<b>V15.3</b>	Irradiation: previous exposure to therapeutic or ionizing radiation
<b>V42.81</b>	Organ or tissue replaced by transplant, Bone marrow transplant
<b>V42.82</b>	Transplant; Peripheral stem cells
<b>V51.0</b>	Encounter for breast reconstruction following mastectomy (Effective Date: 1/1/2009)
<b>V52.4</b>	Breast prosthesis and implant (Effective Date: 1/1/2009)
<b>V58.0</b>	Encounter for radiation therapy
<b>V58.1</b>	Encounter for antineoplastic chemotherapy and immunotherapy (This code was discontinued as of 10/2006 but should be included in extract programs for quality control purposes)
<b>V58.11</b>	Encounter for antineoplastic chemotherapy
<b>V58.12</b>	Encounter for antineoplastic immunotherapy
<b>V58.42</b>	Aftercare following surgery for neoplasm
<b>V66.1</b>	Convalescence following radiotherapy
<b>V66.2</b>	Convalescence following chemotherapy
<b>V67.1</b>	Radiation therapy follow up
<b>V67.2</b>	Chemotherapy follow up
<b>V76.0 – V76.9</b>	Special screening for malignant neoplasm
<b>V78.0 – V78.9</b>	Special screening for disorders of blood and blood-forming organs
<b>V82.71</b>	Screening for genetic disease carrier status
<b>V82.79</b>	Other genetic screening
<b>V82.89</b>	Genetic screening for other specified conditions
<b>V82.9</b>	Genetic screening for unspecified condition
<b>V84.01 – V84.09</b>	Genetic susceptibility to malignant neoplasm
<b>V86.0</b>	Estrogen receptor positive status [ER+]
<b>V86.1</b>	Estrogen receptor negative status [ER-]

**V87.41**

Personal history of antineoplastic chemotherapy

**NOTES:**

Prostatic Intraepithelial Neoplasia (PIN III) M-8148/2 will NOT be collected by SEER registries.

Pilocytic/juvenile astrocytoma M-9421 moved from behavior /3 (malignant) to /1 (borderline malignancy) in ICD-O-3. However, SEER registries will CONTINUE to report these cases and code behavior a /3 (malignant). Borderline cystadenomas M-8442, 8451, 8462, 8472, 8473, of the ovaries moved from behavior /3 (malignant) to /1 (borderline malignancy) in ICD-O-3. SEER registries are not required to collect these cases for diagnoses made 1/1/2001 and after. However, cases diagnosed prior to 1/1/2001 should still be abstracted and reported to SEER registries.

The World Health Organization (WHO) diagnosis "B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma" is coded as 9823/3, and cross-referenced to 9670/3, malignant lymphoma, small B lymphocytic, NOS. If this WHO term is used to describe malignancy in blood or bone marrow, code 9823/3; if the term is used to describe malignance in tissue, lymph nodes or any organ in combination with blood or bone marrow, code 9670/3.

<sup>^</sup> *International Classification of Diseases, Ninth Revision, Clinical Modification, 2009.*

## APPENDIX K-4 Codes for Casefinding (Between Jan 1, and Dec 31, 2008)

### Screening List of OF ICD-9-CM Codes for Casefinding

Certain ICD-9-CM\* codes used by medical records departments for discharge diagnoses identify cases of malignant neoplasms that are reportable to the California Cancer Registry. Case finding procedures must include the review of medical records coded with the following numbers. Newly reportable diseases are followed by the ICD-O-3 morphology and behavior code in parentheses.

The following information was taken directly from the SEER web site.

ICD-9-CM* CODE	
042	AIDS (review cases for AIDS-related malignancies)
140.0-208.9	Malignant neoplasms (primary and secondary)
203.1	Plasma cell leukemia (9733/3)
205.1	Chronic neutrophilic leukemia (9963/3)
225.0-227.4	Benign central nervous system neoplasms
230.0–234.9	Carcinoma in situ (exclude skin codes 232.0-232.9, and cervix code 233.1)
235.0–238.9	Neoplasms of uncertain behavior
236.2	Ovarian neoplasms of uncertain behavior (8442/1, 8451/1, 8462/1, 8472/1, 8473/1)
237.0–237.9	Central nervous system neoplasms of uncertain behavior
238.4	Polycythemia vera (9950/3)
238.6	Solitary plasmacytoma (9731/3)
238.6	Extramedullary plasmacytoma (9734/3)
238.71	Essential thrombocythemia (was 238.7; 9962/3) Essential (hemorrhagic) thrombocythemia Essential thrombocytosis Idiopathic (hemorrhagic) thrombocythemia Primary thrombocytosis
238.72	Low grade myelodysplastic syndrome lesions Refractory anemia (was 284.9; 9980/3) Refractory anemia with ringed sideroblasts (RARS) (was 285.0; 9982/3) Refractory cytopenia with multilineage dysplasia (RCMD) (was 238.7; 9985/3) Refractory cytopenia with multilineage dysplasia and ringed sideroblasts (RCMD-RS) was 238.7; 9985/3)
238.73	High grade myelodysplastic syndrome lesions Refractory anemia with excess blasts-1 (RAEB-1) (was 285.0; 9983/3)

California Cancer Reporting System Standards, Volume I

	Refractory anemia with excess blasts-2 (RAEB-2) (was 285.0; 9983/3)
238.74	Myelodysplastic syndrome with 5q deletion (was 238.7; 9986/3) 5q minus syndrome NOS Excludes: constitutional 5q deletion (758.39) (not reportable) high grade myelodysplastic syndrome with 5q deletion (238.73)
238.75	Myelodysplastic syndrome, unspecified (was 238.7; 9985/3, 9989/3)
238.76	Myelosclerosis with myeloid metaplasia (9961/3) Agnogenic myeloid metaplasia Idiopathic myelofibrosis (chronic) Myelosclerosis with myeloid metaplasia Primary myelofibrosis Excludes: myelofibrosis NOS (289.83) myelophthitic anemia (284.2) (not reportable) myelophthisis (284.2) (not reportable) secondary myelofibrosis (289.83)
238.79	Other lymphatic and hematopoietic tissues Lymphoproliferative disease (chronic) NOS (was 238.7; 9970/1) Megakaryocytic myelosclerosis (was 238.7; 9961/3) Myeloproliferative disease (chronic) NOS (was 238.7; 9960/3) Panmyelosis (acute) (was 238.7; 9931/3)
239.0–239.9	Neoplasms of unspecified nature
273.2	Gamma heavy chain disease Franklin's disease
273.3	Waldenstrom's macroglobulinemia
273.9	Unspecified disorder of plasma protein metabolism (screen for potential 273.3 miscodes)
288.3	Hypereosinophilic syndrome (9964/3)
289.83	Myelofibrosis (9932/3) Myelofibrosis, NOS Secondary myelofibrosis Code first underlying disorder, such as: malignant neoplasm of breast (174.0-174.9, 175.0-175.9) Excludes: Idiopathic myelofibrosis (238.76) leukoerythroblastic anemia (238.2) (not reportable) (238.76) myelofibrosis with myeloid metaplasia myelophthitic anemia (284.2) (not reportable) myelophthisis (284.2) (not reportable)

California Cancer Reporting System Standards, Volume I

	primary myelofibrosis (238.76)
289.89	Other specified diseases of blood and blood-forming organs
V07.3	Other prophylactic chemotherapy
V07.8	Other specified prophylactic measures
V10.0-V10.9	Personal history of malignant neoplasms
V58.0	Radiotherapy session
V58.1	Maintenance chemotherapy
V66.1	Convalescence following radiotherapy
V66.2	Convalescence following chemotherapy
V67.1	Follow-up exam following radiotherapy
V67.2	Follow-up exam following chemotherapy
V71.1	Observation for suspected malignant neoplasm
V76.0-V76.9	Special screening for malignant neoplasms
V86	Estrogen receptor status

**Please Note:**

- Code 042 is not a combination code of AIDS with specified malignancies.
- Prostatic Intraepithelial Neoplasia (PIN III), morphology code 8148/2 is not reportable to the CCR.
- Pilocytic/juvenile astrocytoma, morphology code 9421, is reportable as a /3 behavior code and is assigned a regular tumor sequence number per SEER requirements, effective with cases diagnosed 1/1/2001 and forward.
- Ovarian borderline cystadenomas, morphology codes 8442/1, 8451/1, 8462/1, 8472/1 and 8473/1, which changed behavior codes from /3 to /1 will continue to be reportable to the CCR. These tumors are to be sequenced following the American College of Surgeons guideline for benign tumors.

## APPENDIX K-5 Codes for Casefinding (Prior to 2007)

### Screening List of OF ICD-9-CM Codes for Casefinding

Certain ICD-9-CM\* codes used by medical records departments for discharge diagnoses identify cases of malignant neoplasms that are reportable to the California Cancer Registry. Case finding procedures must include the review of medical records coded with the following numbers. Newly reportable diseases are followed by the ICD-O-3 morphology and behavior code in parentheses.

The following information was taken directly from the SEER website.

ICD-9-CM* CODE	
042	AIDS (review cases for AIDS-related malignancies)
140.0-208.9	Malignant neoplasms (primary and secondary)
203.1	Plasma cell leukemia (9733/3)
205.1	Chronic neutrophilic leukemia (9963/3)
225.0-227.4	Benign central nervous system neoplasms
230.0–234.9	Carcinoma in situ (exclude skin codes 232.0-232.9, and cervix code 233.1)
235.0–238.9	Neoplasms of uncertain behavior
236.2	Ovarian neoplasms of uncertain behavior (8442/1, 8451/1, 8462/1, 8472/1, 8473/1)
237.0–237.9	Central nervous system neoplasms of uncertain behavior
238.4	Polycythemia vera (9950/3)
238.6	Solitary plasmacytoma (9731/3)
238.6	Extramedullary plasmacytoma (9734/3)
238.7	Chronic myeloproliferative disease (9960/3)
238.7	Myelosclerosis with myeloid metaplasia (9961/3)
238.7	Essential thrombocythemia (9962/3)
238.7	Refractory cytopenia with multilineage dysplasia (9985/3)
238.7	Myelodysplastic syndrome with 5q-syndrome (9986/3)
238.7	Therapy-related myelodysplastic syndrome (9987/3)
239.0–239.9	Neoplasms of unspecified nature
273.2	Gamma heavy chain disease Franklin's disease
273.3	Waldenstrom's macroglobulinemia
273.9	Unspecified disorder of plasma protein metabolism (screen for potential 273.3 miscodes)
284.9	Refractory anemia (9980/3)
285.0	Refractory anemia with ringed sideroblasts (9982/3)

California Cancer Reporting System Standards, Volume I

285.0	Refractory anemia with excess blasts (9983/3)
285.0	Refractory anemia with excess blasts in transformation (9984/3)
288.3	Hypereosinophilic syndrome (9964/3)
289.8	Acute myelofibrosis (9932/3)
V07.3	Other prophylactic chemotherapy
V07.8	Other specified prophylactic measures
V10.0-V10.9	Personal history of malignant neoplasms
V58.0	Radiotherapy session
V58.1	Maintenance chemotherapy
V66.1	Convalescence following radiotherapy
V66.2	Convalescence following chemotherapy
V67.1	Follow-up exam following radiotherapy
V67.2	Follow-up exam following chemotherapy
V71.1	Observation for suspected malignant neoplasm
V76.0–V76.9	Special screening for malignant neoplasms

\* *International Classification of Diseases, 9th Revision, Clinical Modification, 4th ed.*



## APPENDIX L.1: Codes for California Counties In Alphabetic Order

(in alphabetical order)						
Name	California County Code	US FIPS Code		Name	California County Code	US FIPS Code
ALAMEDA	001	001		ORANGE	030	059
ALPINE	002	003		PLACER	031	061
AMADOR	003	005		PLUMAS	032	063
BUTTE	004	007		RIVERSIDE	033	065
CALAVERAS	005	009		SACRAMENTO	034	067
CALIFORNIA NOS	000	998		SAN BENITO	035	069
COLUSA	006	011		SAN BERNARDINO	036	071
CONTRA COSTA	007	013		SAN DIEGO	037	073
DEL NORTE	008	015		SAN FRANCISCO	038	075
EL DORADO	009	017		SAN JOAQUIN	039	077
FRESNO	010	019		SAN LUIS OBISPO	040	079
GLENN	011	021		SAN MATEO	041	081
HUMBOLDT	012	023		SANTA BARBARA	042	083
IMPERIAL	013	025		SANTA CLARA	043	085
INYO	014	027		SANTA CRUZ	044	087
KERN	015	029		SHASTA	045	089
KINGS	016	031		SIERRA	046	091
LAKE	017	033		SISKIYOU	047	093
LASSEN	018	035		SOLANO	048	095
LOS ANGELES	019	037		SONOMA	049	097
MADERA	020	039		STANISLAUS	050	099
MARIN	021	041		SUTTER	051	101
MARIPOSA	022	043		TEHAMA	052	103
MENDOCINO	023	045		TRINITY	053	105
MERCED	024	047		TULARE	054	107
MODOC	025	049		TUOLUMNE	055	109
MONO	026	051		US NOT CALIF	000	998
MONTEREY	027	053		VENTURA	056	111
NAPA	028	055		YOLO	057	113
NEVADA	029	057		YUBA	058	115

## APPENDIX L.2: Codes for California Counties in Numeric Order

(in numerical order)						
California County Code	US FIPS Code	Name	California County Code	US FIPS Code	Name	
000	998	CALIFORNIA NOS	029	057	NEVADA	
000	998	US NOT CALIF	030	059	ORANGE	
001	001	ALAMEDA	031	061	PLACER	
002	003	ALPINE	032	063	PLUMAS	
003	005	AMADOR	033	065	RIVERSIDE	
004	007	BUTTE	034	067	SACRAMENTO	
005	009	CALAVERAS	035	069	SAN BENITO	
006	011	COLUSA	036	071	SAN BERNARDINO	
007	013	CONTRA COSTA	037	073	SAN DIEGO	
008	015	DEL NORTE	038	075	SAN FRANCISCO	
009	017	EL DORADO	039	077	SAN JOAQUIN	
010	019	FRESNO	040	079	SAN LUIS OBISPO	
011	021	GLENN	041	081	SAN MATEO	
012	023	HUMBOLDT	042	083	SANTA BARBARA	
013	025	IMPERIAL	043	085	SANTA CLARA	
014	027	INYO	044	087	SANTA CRUZ	
015	029	KERN	045	089	SHASTA	
016	031	KINGS	046	091	SIERRA	
017	033	LAKE	047	093	SISKIYOU	
018	035	LASSEN	048	095	SOLANO	
019	037	LOS ANGELES	049	097	SONOMA	
020	039	MADERA	050	099	STANISLAUS	
021	041	MARIN	051	101	SUTTER	
022	043	MARIPOSA	052	103	TEHAMA	
023	045	MENDOCINO	053	105	TRINITY	
024	047	MERCED	054	107	TULARE	
025	049	MODOC	055	109	TUOLUMNE	
026	051	MONO	056	111	VENTURA	
027	053	MONTEREY	057	113	YOLO	
028	055	NAPA	058	115	YUBA	

## APPENDIX M.1: Common Acceptable Symbols AND Abbreviations (In Order of Terms)

Do not use non-standard abbreviations in abstracts. When abbreviating words in an address, refer to the [USPS website](#). For short names of antineoplastic drugs, consult the [SEER Rx](#). Other accepted abbreviations are:

<b>SYMBOLS &amp; ABBREVIATIONS</b>	<b>SYMBOLS</b>
-	Minus, Negative
#	Number
#	Pound(s)
&	And
(sn)	(sentinel node)
/	Comparison
@	At
^	Above
+	Plus, Positive
<	Decrease, Less/Less than
=	Equal(s)
>	Greater/Greater than
>	Increase, More/More than
	<b>ABBREVIATIONS</b>
Abdomen (abdominal)	ABD
Abdominal perineal	AP
Abnormal	ABN
Above knee (amputation)	AK(A)
Absent/Absence	ABS
Abstract/Abstracted	ABST
Achilles tendon reflex	ATR
Acid phosphatase	ACID PHOS
Acquired Immune Deficiency Syndrome	AIDS
Activities of daily living	ADL
Acute granulocytic leukemia	AGL
Acute lymphocytic leukemia	ALL
Acute myelogenous leukemia	AML
Acute myocardial infarction	AMI
Acute renal failure	ARF
Acute Respiratory Distress (Disease) Syndrome	ARDS
Acute tubular necrosis	ATN
Adenocarcinoma	ADENOCA
Adenosine triphosphate	ATP
Adjacent	ADJ
Admission/Admit	ADM

California Cancer Reporting System Standards, Volume I

<b>SYMBOLS &amp; ABBREVIATIONS</b>	<b>SYMBOLS</b>
Adrenal cortex	AC
Adrenal cortical hormone	ACH
Adrenocorticotrophic hormone	ACTH
Adult-onset Diabetes Mellitus	AODM
Affirmative	AFF
Against medicalAdvice	AMA
AIDS-related condition (complex)	ARC
AIDS-related disease	ARD
Air contrast barium enema	ACBE
Albumin	ALB
Alcohol	ETOH
Alkaline phosphatase	ALK PHOS
Alpha-fetoprotein	AFP
Also known As	AKA
Ambulatory	AMB
Amount	AMT
Amputation	AMP
Amyotrophic lateral sclerosis	ALS
Anal intraepithelial neoplasia, Grade I-III	AIN I-III
Anaplastic	ANAP
Angiography/Angiogram	ANGIO
Anterior	ANT
Anteroposterior	AP
Antidiuretic hormone	ADH
Antigen	AG
Aortic stenosis	A-STEN
Apparently	APPL'Y
Appendix	APP
Approximately	APPROX
Arrhythmia	ARRHY
Arterial blood gases	ABG
Arteriosclerosis/Arteriosclerotic	AS
Arteriosclerotic cardiovascular disease	ASCVD
Arteriosclerotic heart disease	ASHD
Arteriosclerotic Peripheral Vascular Disease	ASPVD
Arteriovenous	AV
Arteriovenous malformation	AVM
Artery (ial)	ART
As soon As possible	ASAP
Ascending colon	A-COLON
Aspiration	ASP
Aspirin, Acetylsalicylic Acid	ASA
Atrial fibrillation	A FIB
Atrial flutter	A FLUTTER

California Cancer Reporting System Standards, Volume I

<b>SYMBOLS &amp; ABBREVIATIONS</b>	<b>SYMBOLS</b>
Atrial premature complexes	APC
Atrial stenosis/insufficiency/incompetence	AI
Atypical ductal hyperplasia	ADH
Auscultation & percussion	A&P
Autoimmune hemolytic Anemia	AIHA
Autonomic nervous system	ANS
Autopsy	AUT
Average	AVG
Axilla(ry)	AX
Bacillus Calmette-Guerin	BCG
Barium	BA
Barium enema	BE
Bartholin's, Urethral & Skene's	BUS
Basal cell carcinoma	BCC
Before noon	AM
Below knee (amputation)	BK(A)
Benign prostatic hypertrophy/hyperplasia	BPH
Bilateral	BIL
Bilateral salpingo-oophorectomy	BSO
Bile duct	BD
Biological response modifier	BRM
Biopsy	BX
Bipolar affective disorder	BAD
Black female	B/F
Black male	B/M
Bladder tumor	BT
Blood pressure	BP
Blood urea nitrogen	BUN
Blood volume	BV
Bone marrow biopsy	BMBx
Bone marrow transplant	BMT
Bone marrow	BM
Bowel movement	BM
Bowel Sounds	BS
Breast cancer type 1 or 2 susceptibility protein	BRCA 1 or 2
Breast self-examination	BSE
Breath Sounds	BRS
Bright Red Blood (per Rectum)	BRB (PR)
Brother	BRO
Calcium	CA
Capsule (s)	CAP(S)
Carbohydrate antigen 125	CA-125
Carcinoembryonic antigen	CEA
Carcinoma <i>in situ</i>	CIS

California Cancer Reporting System Standards, Volume I

<b>SYMBOLS &amp; ABBREVIATIONS</b>	<b>SYMBOLS</b>
Carcinoma*	CA
Cardiovascular disease	CVD
CAT/CT scan/Computerized axial tomography	CT
CD117	c-KIT
Centigray	cGy
Centimeter	CM
Central nervous system	CNS
Cerebrospinal fluid	CSF
Cerebrovascular accident	CVA
Cervical intraepithelial neoplasia, Grade I-III	CIN I-III
Cervical spine	C-SPINE
Cervical vertebrae	C1-C7
Change	CHG
Chemotherapy	CHEMO/CTX
Chest X-ray	CXR
Chromogenic in situ hybridization	CISH
Chronic	CHR
Chronic granulocytic leukemia	CGL
Chronic lymphocytic leukemia	CLL
Chronic myeloid (myelocytic) leukemia	CML
Chronic obstructive lung disease	COLD
Chronic obstructive pulmonary disease	COPD
Chronic renal failure	CRF
Chronic ulcerative Colitis	CUC
Cigarettes	CIG
Circumferential resection margin	CRM
Clear	CLR
Cobalt 60	CO60
Collaborative stage	CS
College of American Pathology	CAP
Colon, Ascending	A-COLON
Colon, Sigmoid	SIG COLON
Colon, Transverse	TRANS-COLON
Colony-stimulating factor	C-SF
Complaint (-ning) of	C/O
Complete blood Count	CBC
Complete remission	CR
Congenital heart disease	CHD
Congestive heart failure	CHF
Consistent with	C/W
Continue/continuous	CONT
Contralateral	CONTRA
Coronary artery bypass graft	CABG
Coronary artery disease	CAD

California Cancer Reporting System Standards, Volume I

<b>SYMBOLS &amp; ABBREVIATIONS</b>	<b>SYMBOLS</b>
Coronary Care unit	CCU
Cubic Centimeter	CC
Cystic fibrosis	CF
Cystoscopy	CYSTO
Cytology	CYTO
Date of birth	DOB
Date of Death	DOD
Dead on arrival	DOA
Decrease(d)	DECR
Deep inferior epigastric perforator reconstruction surgery	DIEP
Deep tendon reflex	DTR
Deep vein thrombosis	DVT
Deoxyribonucleic acid	DNA
Dermatology	DERM
Descending colon	D-COLON
Diabetes mellitus	DM
Diagnosis	DX
Diameter	DIAM
Diethylstilbestrol	DES
Differentiated/differential	DIFF
Digital rectal examination	DRE
Dilatation and curettage	D&C
Discharge	DISCH
Discontinue(d)	DC
Disease	DIS, DZ
Disseminated intravascular coagulopathy	DIC
Doctor	PMD, DR, MD
Ductal carcinoma <i>in situ</i>	DCIS
Ductal Intraepithelial Neoplasia 3	DIN 3
Dyspnea on exertion	DOE
Ears, nose, and throat	ENT
Electrocardiogram	ECG/EKG
Electroencephalogram	EEG
Electromyogram	EMG
Emergency room	ER
End stage renal disease	ESRD
Endoscopic retrograde cholangiopancreatography	ERCP
Enlarged	ENLGD
Esophagogastric junction	EGJ
Esophagogastro-duodenoscopy	EGD
Essential thrombocytopenia	ET
Estrogen receptor (assay)	ER, ERA
Evaluation	EVAL

California Cancer Reporting System Standards, Volume I

<b>SYMBOLS &amp; ABBREVIATIONS</b>	<b>SYMBOLS</b>
Every	Q
Every day	QD
Examination	EXAM
Examination under Anesthesia	EUA
Excision/excised	EXC(D)
Expired	EXP
Exploratory	EXPL
Exploratory laparotomy	EXPL LAP
Extend/extension	EXT
Extended Care Facility	ECF
External*	EXT
Extracapsular spread/extension	ECS/ECE
Extremity*	EXT
Eyes, Ears, Nose and Throat	EENT
Family (Medical) History	F(M)H
Father	FA
Fever of unknown origin	FUO
Fine needle aspiration	FNA
Fine needle aspiration biopsy	FNAB
Fingerbreadth	FB
Floor of mouth	FOM
Fluid	FL
Fluorescence in situ hybridization	FISH
Fluoroscopy	FLURO
Follicular lymphoma international prognostic index	FLIPI
Follow-up	FU
For example	E.G.
Fracture	FX
Frequent/Frequency	FREQ
Frozen section	FS
Full thickness skin graft	FTSG
Gallbladder	GB
Gastroenterostomy	GE
Gastroesophageal	GE
Gastroesophageal reflux disease	GERD
Gastrointestinal	GI
Gastrointestinal stromal tumor	GIST
General/Generalized	GEN
Genitourinary	GU
Gleason grade	GG
Gleason score	GS
Grade	GR
Gram	GM
Grandfather, Great grandfather	GF, GGF



California Cancer Reporting System Standards, Volume I

<b>SYMBOLS &amp; ABBREVIATIONS</b>	<b>SYMBOLS</b>
Grandmother, Great grandmother	GM, GGM
Gray, unit of absorbed radiation	Gy
Gynecology	GYN
Head, Eyes, Ears, Nose, Throat	HEENT
Hematocrit	HCT
Hematoxylin & eosin stain	H&E
Hemoglobin	HGB
Hepatitis A (virus)	HAV
Hepatitis B (virus)	HBV
Hepatitis C (virus)	HCV
Hepatitis D (virus)	HDV
Hepatosplenomegaly	HSM
High dose rate	HDR
High grade	HG
High power field	HPF
History	HX
History and physical	H&P
History of	HO, H/O
History of Present Illness	HPI
Hormone	HORM
Hospital	HOSP
Hour/Hours	HR(S)
Human chorionic gonadotropin	HCG
Human epidermal growth factor receptor 2	HER2/neu
Human Immunodeficiency Virus	HIV
Human Papilloma Virus	HPV
Human T-Lymphotropic Virus Type III	HTLV-III
Hypertension	HTN
Hypertensive cardiovascular disease	HCVD
Hypertensive vascular disease	HVD
Hysterectomy	HYST
Idiopathic hypertrophic subaortic stenosis	IHSS
Idiopathic myelofibrosis	IMF
Idiopathic thrombocytopenia	ITP
Immunoglobulin	IG
Immunohistochemical	IHC
Impression	IMP
Incision & drainage	I&D
Includes/Including	INCL
Increase(d)	INCR
Inferior	INF
Inferior vena cava	IVC
Infiltrating	INFILT
Inflammatory bowel disease	IBD

<b>SYMBOLS &amp; ABBREVIATIONS</b>	<b>SYMBOLS</b>
Inpatient	IP
Insulin-dependent diabetes mellitus	IDDM
Intensity modulated radiation therapy	IMRT
Intensive care unit	ICU
Intercostal margin	ICM
Intercostal space	ICS
Intermittent positive pressure breathing	IPPB
Internal	INT
Internal Mammary Artery	IMA
Internal Prognostic Index	IPI
International Federation of Gynecology & Obstetrics	FIGO
International normalized ratio	INR
International Society of Urological Pathology	ISUP
Interstitial lung disease	ILD
Intramuscular	IM
Intrathecal	IT
Intravenous	IV
Intravenous cholangiogram	IVCA
Intravenous pyelogram	IVP
Invade(s)/invading/invasion	INV
Involve(s)/involvement/involving	INVL
Iodine	I
Iodine-131	I-131
Ipsilateral	IPSI
Irregular	IRREG
Isolated tumor cells	ITCs
Janus activated kinase 1 or 2	JAK 1 or 2
Jugular venous distention	JVD
Juvenile rheumatic arthritis	JRA
Kaposi sarcoma	KS
Kidneys, ureters, bladder	KUB
Kilogram	KG
Kilovolt	KV
Laboratory	LAB
Lactic dehydrogenase	LDH
Laparotomy	LAP
Large	LRG
Laryngeal Intraepithelial Neoplasia	LIN
Last menstrual period	LMP
Lateral	LAT
Left	L, LT
Left bundle branch block	LBBB
Left costal margin	LCM
Left lower extremity	LLE

California Cancer Reporting System Standards, Volume I

<b>SYMBOLS &amp; ABBREVIATIONS</b>	<b>SYMBOLS</b>
Left lower lobe	LLL
Left lower quadrant	LLQ
Left salpingo-oophorectomy	LSO
Left upper extremity	LUE
Left upper lobe	LUL
Left upper outer quadrant	LUOQ
Left upper quadrant	LUQ
Licensed practical nurse	LPN
Light chain deposition disease	LCDD
Linear accelerator	LINAC
Liter	L
Liver, Kidney, Spleen (Bladder)	LKS(B)
Liver/spleen scan	LS SCAN
Lobular Carcinoma In Situ	LCIS
<b><i>Loss of Heterozygosity (18q)</i></b>	<b><i>LOH</i></b>
Low dose rate	LDR
Low grade	LG
Lower extremity	LE
Lower inner quadrant	LIQ
Lower outer quadrant	LOQ
Lumbar Puncture	LP
Lumbar spine	L-SPINE
Lumbar vertebra	L1-L5
Lumbosacral	LS
Lupus erythematosus	LUP ERYTH
Lymph node dissection	LND
Lymph node(s)	LN(S)
Lymphadenopathy	LAD/LAN
Lymphadenopathy-associated virus	LAV
<b><i>Lymphovascular invasion</i></b>	<b><i>LVI</i></b>
Macrophage colony-stimulating factor	M-CSF
Magnetic resonance cholangiopancreatography	MRCP
Magnetic resonance imaging	MRI
Main stem bronchus	MSB
Malignant	MALIG
Mandible/mandibular	MAND
Maxilla(ry)	MAX
Maximum	MAX
Mean diameter nucleoli	MLN
Medical center	MC
Medical Doctor	DR, MD
Medication	MED
Merkel cell carcinoma	MCC
Metastatic, Metastases/Metastasis	MET, METS

California Cancer Reporting System Standards, Volume I

<b>SYMBOLS &amp; ABBREVIATIONS</b>	<b>SYMBOLS</b>
Methicillin Resistant Staphylococcus Aureus	MRSA
Methylguanine methyltransferase enzyme	MGMT
Microgram	MCG
<b><i>Microsatellite Instability</i></b>	<b><i>MSI</i></b>
Microscopic	MICRO
Microvascular density	MVD
Midclavicular Line	MCL
Middle lobe	ML
Millicurie (hours)	MC(H)
Milligram (hours)	MG(H)
Milliliter	ML
Millimeter	MM
Million (electron) volts	MV, MEV
Minimum	MIN
Minute	MIN
Mitral valve prolapse	MVP
Mixed combined immunodeficiency	MCID
Mixed connective tissue disease	MCTD
Moderate (ly)	MOD
Moderately differentiated	MD, MOD DIFF
Modified radical Mastectomy	Mab
Monoclonal antibodies	MRM
Monclonal gammopathy of unknown significance	MGUS
Mother	MO
Multifocal arterial tachycardia	MAT
Multifocal premature ventricular contraction	MPVC
Multiple	MULT
Multiple gated acquisition scan	MUGA
Multiple Myeloma	MM
Multiple sclerosis	MS
Myasthenia gravis	MG
Myocardial infarction	MI
Nausea and Vomiting	N&V
Neck vein distention	NVD
Negative	NEG
Neoplasm	NEOPL
Neurology	NEURO
No evidence of disease	NED
No significant findings	NSF
Non small cell carcinoma	NSCCA
Non-Hodgkins lymphoma	NHL
Normal	NL
Not applicable	NA
Not otherwise specified	NOS

California Cancer Reporting System Standards, Volume I

<b>SYMBOLS &amp; ABBREVIATIONS</b>	<b>SYMBOLS</b>
Not recorded	NR
Nursing home	NH
Obstetrics	OB
Obstructed (-ing, -ion)	OBST
Operating room	OR
Operation	OP
Operative Report	OP RPT
Organic brain syndrome	OBS
Orthopedics	ORTHO
Otology	OTO
Ounce	OZ
Outpatient	OP
Packs Per day	PPD
Palpated (-able)	PALP
Pancreatic intraepithelial neoplasia, Grade III	PanIN III
Papanicolaou smear	PAP
Papillary	PAP
Past/personal (medical) history	PMH
Pathologic complete remission	pCR
Pathology	PATH
Patient	PT
Pediatrics	PEDS
Pelvic inflammatory disease	PID
Peptic ulcer disease	PUD
Percussion and Auscultation	P&A
Percutaneous	PERC
Percutaneous transhepatic cholecystogram	PTC
Peripheral vascular disease	PVD
Phosphorus 32	P32
Physical examination	PE
Physiotherapy/Physical therapy	PT
Platelets	PLT
Polycythemia vera	PV
Poorly differentiated	PD, POOR DIFF
Positive	POS
Positron emission tomography	PET
Possible	POSS
Posterior	POST
Posteroanterior	PA
Postoperative (-ly)	POST OP
Postoperative Day	POD
Pound(s)	LB(S)
Premature atrial contraction	PAC
Preoperative (-ly)	PRE OP

California Cancer Reporting System Standards, Volume I

<b>SYMBOLS &amp; ABBREVIATIONS</b>	<b>SYMBOLS</b>
Prescription	RX
Present Illness	PI
Previous	PREV
Primary acquired melanosis	PAM
Primary care physician	PCP
Prior to admission	PTA
Probable (-ly)	PROB
Proctoscopy	PROCTO
Progesterone receptor (assay)	PR, PRA
Prostatic intraepithelial neoplasia, Grade III	PIN III
Prostatic specific antigen	PSA
Pulmonary	PULM
Pulmonary Artery	PA
Quadrant	QUAD
Radiation	RAD
Radiation absorbed dose	RAD
Radiation therapy	RT
Radical	RAD
Radioimmunoassay	RIA
Radium	RA
Received	REC'D
Red blood cells (count)	RBC
Regarding	RE
Regional medical center	RMC
Regular	REG
Regular sinus Rhythm	RSR
Resection (ed)	RESEC
Respiratory	RESPIR
Review of outside films	ROF
Review of outside slides	ROS
Review of Systems	ROS
Rheumatic heart disease	RHD
Rheumatoid arthritis	RA
Right	R, RT
Right bundle branch block	RBBB
Right costal margin	RCM
Right inner quadrant	RIQ
Right lower extremity	RLE
Right lower lobe	RLL
Right lower quadrant	RLQ
Right middle lobe	RML
Right outer quadrant	ROQ
Right salpingo-oophorectomy	RSO
Right upper extremity	RUE

California Cancer Reporting System Standards, Volume I

<b>SYMBOLS &amp; ABBREVIATIONS</b>	<b>SYMBOLS</b>
Right upper lobe	RUL
Right upper quadrant	RUQ
Rule Out	RO, R/O
Sacral Spine	S-SPINE
Sacral vertebra	S1-S5
Salpingo-oophorectomy	SO
Satisfactory	SATIS
Sequential Multiple Analysis (Biochem Profile)	SMA
Serum glutamic oxaloacetic transaminase	SGOT
Serum Glutamic Pyruvic Transaminase	SGPT
Severe combined immunodeficiency Syndrome	SCID
Short(ness) of breath	SOB
Sick Sinus Syndrome	SSS
Sister	SIS
Skilled Nursing Facility	SNF
Small	SM, SML
Small Bowel	SB, SML BWL
Small bowel obstruction	SBO
Specimen	SPEC
Spine, Lumbar	L-SPINE
Spine, Sacral	S-SPINE
Spine, Thoracic	T-SPINE
Split thickness Skin graft	STSG
Squamous	SQ
Squamous	SQUAM
Squamous cell carcinoma	SCC
Status post	S/P
Stereotactic radiosurgery	SRS
Subcutaneous	SUBCU, SUBQ
Summary Stage	SS
Superior vena cava	SVC
Surgery/Surgical	SURG
Suspicious/suspected	SUSP
Symptoms	SX
Syndrome of inappropriate ADH	SIADH
Systemic lupus erythematosus	SLE
Thoracic	T
Thoracic spine	T-SPINE
Thoracic Vertebra	T1-T12
Thromboticthrombocytopenia purpura	TTP
Times	X
Total abdominal hysterectomy	TAH
Total abdominal hysterectomy-bilateral salpingo-oophorectomy	TAH-BSO

California Cancer Reporting System Standards, Volume I

<b>SYMBOLS &amp; ABBREVIATIONS</b>	<b>SYMBOLS</b>
Total body irradiation	TBI
Total parenteral nutrition	TPN
Total vaginal hysterectomy	TVH
Transient ischemic attack	TIA
Transitional cell carcinoma	TCC
Transurethral resection	TUR
Transurethral resection bladder	TURB
Transurethral Resection Bladder (Tumor)	TURB(T)
Transurethral resection prostate	TURP
Transverse colon	TRANS-COLON
Transverse rectus abdominis myocutaneous	TRAM
Treatment	RX, TX
True vocal cord	TVC
Tuberculosis	TB
Tumor Size	TS
Twice a day (daily)	BID
Ultrasound	US
Undifferentiated	UNDIFF
Unknown	UNK
Upper extremity	UE
Upper gastrointestinal (series)	UGI
Upper inner quadrant	UIQ
Upper outer quadrant	UOQ
Upper respiratory infection	URI
Urinary tract infection	UTI
Vagina/Vaginal	VAG
Vaginal hysterectomy	VAG HYST
Vaginal intraepithelial neoplasia, Grade I-III	VAIN I-III
Vascular	VASC
Visceral pleural invasion	VPI
V-ki-RAS 2	KRAS
Vulvar intraepithelial neoplasia, Grade I-III	VIN I-III
Well differentiated WD,	WELL DIFF
White blood cells (count)	WBC
White female	W/F
White male	W/M
With	W/ or C
Within normal limits	WNL
Without	W/O
Wolff-Parkinson-White syndrome	WPW
Work-up	W/U
World Health Organization	WHO
Xray	XR
Year	YR



## APPENDIX M.2: Common Acceptable Symbols and Abbreviations (In Order of Abbreviations)

Do not use non-standard abbreviations in abstracts. When abbreviating words in an address, refer to the [USPS website](#). For short names of antineoplastic drugs, consult the [SEER Rx](#). Other accepted abbreviations are:

	<b>SYMBOLS</b>
-	Minus, Negative
#	Number (usually placed before a number)
#	Pound(s) (usually placed after a number)
&	And
(sn)	(sentinel node)
/	Comparison
@	At
^	Above
+	Plus, Positive
<	Decrease, Less/Less than
=	Equal(s)
>	Greater/Greater than
>	Increase, More/More than
<b>ABBREVIATIONS</b>	
*	<i>Context-sensitive abbreviation: Meaning of the abbreviation should be readily apparent from the context in which it is used.</i>
A FIB	Atrial fibrillation
A FLUTTER	Atrial flutter
A&P	Auscultation & percussion
ABD	Abdomen (abdominal)
ABG	Arterial blood gases
ABN	Abnormal
ABS	Absent/Absence
ABST	Abstract/Abstracted
AC	Adrenal cortex
ACBE	Air contrast barium enema
ACH	Adrenal cortical hormone
ACID PHOS	Acid phosphatase
A-COLON	Ascending colon
ACTH	Adrenocorticotrophic hormone
ADENOCA	Adenocarcinoma
ADH *	Antidiuretic hormone
ADH *	Atypical ductal hyperplasia
ADJ	Adjacent
ADL	Activities of daily living
ADM	Admission/Admit
AFF	Affirmative

California Cancer Reporting System Standards, Volume I

AFP	Alpha-fetoprotein
AG	Antigen
AGL	Acute granulocytic leukemia
AI	Atrial stenosis/insufficiency/incompetence
AIDS	Acquired Immune Deficiency Syndrome
AIHA	Autoimmune hemolytic Anemia
AIN I-III	Anal intraepithelial neoplasia, Grade I-III
AK(A) *	Above knee (amputation)
AKA *	Also known As
ALB	Albumin
ALK PHOS	Alkaline phosphatase
ALL	Acute lymphocytic leukemia
ALS	Amyotrophic lateral sclerosis
AM	Before noon
AMA	Against medicalAdvice
AMB	Ambulatory
AMI	Acute myocardial infarction
AML	Acute myelogenous leukemia
AMP	Amputation
AMT	Amount
ANAP	Anaplastic
ANGIO	Angiography/Angiogram
ANS	Autonomic nervous system
ANT	Anterior
AODM	Adult-onset Diabetes Mellitus
AP *	Abdominal perineal
AP *	Anteroposterior
APC	Atrial premature complexes
APP	Appendix
APPL'Y	Apparently
APPROX	Approximately
ARC	AIDS-related condition (complex)
ARD	AIDS-related disease
ARDS	Acute Respiratory Distress (Disease) Syndrome
ARF	Acute renal failure
ARRHY	Arrhythmia
ART	Artery (ial)
AS	Arteriosclerosis/Arteriosclerotic
ASA	Aspirin, Acetylsalicylic Acid
ASAP	As soon As possible
ASCVD	Arteriosclerotic cardiovascular disease
ASHD	Arteriosclerotic heart disease
ASP	Aspiration
ASPVD	Arteriosclerotic Peripheral Vascular Disease
A-STEN	Aortic stenosis

California Cancer Reporting System Standards, Volume I

ATN	Acute tubular necrosis
ATP	Adenosine triphosphate
ATR	Achilles tendon reflex
AUT	Autopsy
AV	Arteriovenous
AVG	Average
AVM	Arteriovenous malformation
AX	Axilla(ry)
B/F	Black female
B/M	Black male
BA	Barium
BAD	Bipolar affective disorder
BCC	Basal cell carcinoma
BCG	Bacillus Calmette-Guerin
BD	Bile duct
BE	Barium enema
BID	Twice a day (daily)
BIL	Bilateral
BK(A)	Below knee (amputation)
BM *	Bone marrow
BM *	Bowel movement
BMBx	Bone marrow biopsy
BMT	Bone marrow transplant
BP	Blood pressure
BPH	Benign prostatic hypertrophy/hyperplasia
BRB (PR)	Bright Red Blood (per Rectum)
BRCA 1 or 2	Breast cancer type 1 or 2 susceptibility protein
BRM	Biological response modifier
BRO	Brother
BS	Bowel Sounds
BRS	Breath Sounds
BSE	Breast self-examination
BSO	Bilateral salpingo-oophorectomy
BT	Bladder tumor
BUN	Blood urea nitrogen
BUS	Bartholin's, Urethral & Skene's
BV	Blood volume
BX	Biopsy
C/O	Complaint (-ning) of
C/W	Consistent with
C1-C7	Cervical vertebrae
CA *	Calcium
CA *	Carcinoma
CA-125	Carbohydrate antigen 125
CABG	Coronary artery bypass graft

California Cancer Reporting System Standards, Volume I

CAD	Coronary artery disease
CAP *	College of American Pathology
CAP(S) *	Capsule (s)
CBC	Complete blood Count
CC	Cubic Centimeter
CCU	Coronary Care unit
CEA	Carcinoembryonic antigen
CF	Cystic fibrosis
CGL	Chronic granulocytic leukemia
cGy	Centigray
CHD	Congenital heart disease
CHEMO/CTX	Chemotherapy
CHF	Congestive heart failure
CHG	Change
CHR	Chronic
CIG	Cigarettes
CIN I-III	Cervical intraepithelial neoplasia, Grade I-III
CIS	Carcinoma <i>in situ</i>
CISH	Chromogenic in situ hybridization
c-KIT	CD117
CLL	Chronic lymphocytic leukemia
CLR	Clear
CM	Centimeter
CML	Chronic myeloid (myelocytic) leukemia
CNS	Central nervous system
CO 60	Cobalt 60
COLD	Chronic obstructive lung disease
CONT	Continue/continuous
CONTRA	Contralateral
COPD	Chronic obstructive pulmonary disease
CR	Complete remission
CRF	Chronic renal failure
CRM	Circumferential resection margin
CS	Collaborative stage
CSF	Cerebrospinal fluid
C-SF	Colony-stimulating factor
C-SPINE	Cervical spine
CT	CAT/CT scan/Computerized axial tomography
CUC	Chronic ulcerative Colitis
CVA	Cerebrovascular accident
CVD	Cardiovascular disease
CXR	Chest X-ray
CYSTO	Cystoscopy
CYTO	Cytology
D&C	Dilatation and curettage

California Cancer Reporting System Standards, Volume I

DC	Discontinue(d)
DCIS	Ductal carcinoma <i>in situ</i>
D-COLON	Descending colon
DECR	Decrease(d)
DERM	Dermatology
DES	Diethylstilbestrol
DIAM	Diameter
DIC	Disseminated intravascular coagulopathy
DIEP	Deep inferior epigastric perforator
DIFF	Differentiated/differential
DIN 3	Ductal Intraepithelial Neoplasia 3
DIS, DZ	Disease
DISCH	Discharge
DM	Diabetes mellitus
DNA	Deoxyribonucleic acid
DOA	Dead on arrival
DOB	Date of birth
DOD	Date of Death
DOE	Dyspnea on exertion
DR, MD	Medical Doctor
DRE	Digital rectal examination
DTR	Deep tendon reflex
DVT	Deep vein thrombosis
DX	Diagnosis
E.G.	For example
ECF	Extended Care Facility
ECG/EKG	Electrocardiogram
ECS/ECE	Extracapsular spread/extension
EEG	Electroencephalogram
EENT	Eyes, Ears, Nose and Throat
EGD	Esophagogastro-duodenoscopy
EGJ	Esophagogastric junction
EMG	Electromyogram
ENLGD	Enlarged
ENT	Ears, nose, and throat
ER *	Emergency room
ER *, ERA	Estrogen receptor (assay)
ERCP	Endoscopic retrograde cholangiopancreatography
ESRD	End stage renal disease
ET	Essential thrombocytopenia
ETOH	Alcohol
EUA	Examination under Anesthesia
EVAL	Evaluation
EXAM	Examination
EXC(D)	Excision/excised

California Cancer Reporting System Standards, Volume I

EXP	Expired
EXPL	Exploratory
EXPL LAP	Exploratory laparotomy
EXT *	Extend/extension
EXT *	External
EXT *	Extremity
FA	Father
F(M)H	Family (Medical) History
FB	Fingerbreadth
FIGO	International Federation of Gynecology & Obstetrics
FISH	Fluorescence in situ hybridization
FL	Fluid
FLIPI	Follicular lymphoma international prognostic index
FLURO	Fluoroscopy
FNA	Fine needle aspiration
FNAB	Fine needle aspiration biopsy
FOM	Floor of mouth
FREQ	Frequent/Frequency
FS	Frozen section
FTSG	Full thickness skin graft
FU	Follow-up
FUO	Fever of unknown origin
FX	Fracture
GB	Gallbladder
GE *	Gastroenterostomy
GE *	Gastroesophageal
GEN	General/Generalized
GERD	Gastroesophageal reflux disease
GF, GGF	Grandfather, Great grandfather
GG	Gleason grade
GI	Gastrointestinal
GIST	Gastrointestinal stromal tumor
GM *	Gram
GM *, GGM	Grandmother, Great grandmother
GR	Grade
GS	Gleason score
GU	Genitourinary
Gy	Gray, unit of absorbed radiation
GYN	Gynecology
H&E	Hematoxylin & eosin stain
H&P	History and physical
HAV	Hepatitis A (virus)
HBV	Hepatitis B (virus)
HCG	Human chorionic gonadotropin
HCT	Hematocrit

California Cancer Reporting System Standards, Volume I

HCV	Hepatitis C (virus)
HCVD	Hypertensive cardiovascular disease
HDR	High dose rate
HDV	Hepatitis D (virus)
HEENT	Head, Eyes, Ears, Nose, Throat
HER2/neu	Human epidermal growth factor receptor 2
HG	High grade
HGB	Hemoglobin
HIV	Human Immunodeficiency Virus
HO, H/O	History of
HORM	Hormone
HOSP	Hospital
HPF	High power field
HPI	History of Present Illness
HPV	Human Papilloma Virus
HR(S)	Hour/Hours
HSM	Hepatosplenomegaly
HTLV-III	Human T-Lymphotropic Virus Type III
HTN	Hypertension
HVD	Hypertensive vascular disease
HX	History
HYST	Hysterectomy
I	Iodine
I&D	Incision & drainage
I-131	Iodine-131
IBD	Inflammatory bowel disease
ICM	Intercostal margin
ICS	Intercostal space
ICU	Intensive care unit
IDDM	Insulin-dependent diabetes mellitus
IMF	Idiopathic myelofibrosis
IG	Immunoglobulin
IHC	Immunohistochemical
IHSS	Idiopathic hypertrophic subaortic stenosis
ILD	Interstitial lung disease
IM	Intramuscular
IMA	Internal Mammary Artery
IMP	Impression
IMRT	Intensity modulated radiation therapy
INCL	Includes/Including
INCR	Increase(d)
INF	Inferior
INFILT	Infiltrating
INR	International normalized ratio
INT	Internal

California Cancer Reporting System Standards, Volume I

INV	Invade(s)/invading/invasion
INVL	Involve(s)/involvement/involving
IP	Inpatient
IPI	Internal Prognostic Index
IPPB	Intermittent positive pressure breathing
IPSI	Ipsilateral
IRREG	Irregular
ISUP	International Society of Urological Pathology
IT	Intrathecal
ITCs	Isolated tumor cells
ITP	Idiopathic thrombocytopenia
IV	Intravenous
IVC	Inferior vena cava
IVCA	Intravenous cholangiogram
IVP	Intravenous pyelogram
JAK 1 or 2	Janus activated kinase 1 or 2
JRA	Juvenile rheumatic arthritis
JVD	Jugular venous distention
KG	Kilogram
KRAS	V-ki-RAS 2
KS	Kaposi sarcoma
KUB	Kidneys, ureters, bladder
KV	Kilovolt
L *	Liter
L *, LT	Left
L1-L5	Lumbar vertebra
LAB	Laboratory
LAD/LAN	Lymphadenopathy
LAP	Laparotomy
LAT	Lateral
LAV	Lymphadenopathy-associated virus
LB(S)	Pound(s)
LBBS	Left bundle branch block
LCDD	Light chain deposition disease
LCIS	Lobular Carcinoma In Situ
LCM	Left costal margin
LDH	Lactic dehydrogenase
LDR	Low dose rate
LE	Lower extremity
LG	Low grade
LIN	Laryngeal Intraepithelial Neoplasia
LINAC	Linear accelerator
LIQ	Lower inner quadrant
LKS(B)	Liver, Kidney, Spleen (Bladder)
LLE	Left lower extremity



California Cancer Reporting System Standards, Volume I

LLL	Left lower lobe
LLQ	Left lower quadrant
LMP	Last menstrual period
LN(S)	Lymph node(s)
LND	Lymph node dissection
<b>LOH</b>	<b>Loss of heterozygosity (18q)</b>
LOQ	Lower outer quadrant
LP	Lumbar Puncture
LPN	Licensed practical nurse
LRG	Large
LS	Lumbosacral
LS SCAN	Liver/spleen scan
LSO	Left salpingo-oophorectomy
L-SPINE	Lumbar spine
LUE	Left upper extremity
LUL	Left upper lobe
LUOQ	Left upper outer quadrant
LUP ERYTH	Lupus erythematosus
LUQ	Left upper quadrant
<b>LVI</b>	<b>Lymphovascular invasion</b>
Mab	Monoclonal antibodies
MALIG	Malignant
MAND	Mandible/mandibular
MAT	Multifocal arterial tachycardia
MAX *	Maxilla(ry)
MAX *	Maximum
MC *	Medical center
MC *(H)	Millicurie (hours)
MCC	Merkel cell carcinoma
MCG	Microgram
MCID	Mixed combined immunodeficiency
MCL	Midclavicular Line
M-CSF	Macrophage colony-stimulating factor
MCTD	Mixed connective tissue disease
MD, MOD DIFF	Moderately differentiated
MED	Medication
MET, METS	Metastatic, Metastases/Metastasis
MG	Myasthenia gravis
MG(H)	Milligram (hours)
MGMT	Methylguanine methyltransferase enzyme
MGUS	Monoclonal gammopathy of unknown significance
MI	Myocardial infarction
MICRO	Microscopic
MIN *	Minimum
MIN *	Minute

California Cancer Reporting System Standards, Volume I

<b>MIS</b>	<b>Microsatellite instability</b>
ML *	Middle lobe
ML *	Milliliter
MLN	Mean diameter nucleoli
MM *	Millimeter
MM *	Multiple Myeloma
MO	Mother
MOD	Moderate (ly)
MPVC	Multifocal premature ventricular contraction
MRCP	Magnetic resonance cholangiopancreatography
MRI	Magnetic resonance imaging
MRM	Modified radical Mastectomy
MRSA	Methicillin Resistant Staphylococcus Aureus
MS	Multiple sclerosis
MSB	Main stem bronchus
MUGA	Multiple gated acquisition scan
MULT	Multiple
MV, MEV	Million (electron) volts
MVD	Microvascular density
MVP	Mitral valve prolapse
N&V	Nausea and Vomiting
NA	Not applicable
NED	No evidence of disease
NEG	Negative
NEOPL	Neoplasm
NEURO	Neurology
NH	Nursing home
NHL	Non-Hodgkins lymphoma
NL	Normal
NOS	Not otherwise specified
NR	Not recorded
NSCCA	Non small cell carcinoma
NSF	No significant findings
NVD	Neck vein distention
OB	Obstetrics
OBS	Organic brain syndrome
OBST	Obstructed (-ing, -ion)
OP *	Operation
OP *	Outpatient
OR	Operating room
ORTHO	Orthopedics
OTO	Otology
OZ	Ounce
P&A	Percussion and Auscultation
P32	Phosphorus 32

California Cancer Reporting System Standards, Volume I

PA *	Posteroanterior
PA *	Pulmonary Artery
PAC	Premature atrial contraction
PALP	Palpated (-able)
PAM	Primary acquired melanosis
PanIN III	Pancreatic intraepithelial neoplasia, Grade III
PAP *	Papanicolaou smear
PAP *	Papillary
PATH	Pathology
PCP	Primary care physician
pCR	Pathologic complete remission
PD, POOR DIFF	Poorly differentiated
PE	Physical examination
PEDS	Pediatrics
PERC	Percutaneous
PET	Positron emission tomography
PI	Present Illness
PID	Pelvic inflammatory disease
PIN III	Prostatic intraepithelial neoplasia, Grade III
PLT	Platelets
PMD, DR, MD	Doctor
PMH	Past/personal (medical) history
POD	Postoperative Day
POS	Positive
POSS	Possible
POST	Posterior
POST OP	Postoperative (-ly)
PPD	Packs Per day
PR, PRA	Progesterone receptor (assay)
PRE OP	Preoperative (-ly)
PREV	Previous
PROB	Probable (-ly)
PROCTO	Proctoscopy
PSA	Prostatic specific antigen
PT *	Patient
PT *	Physiotherapy/Physical therapy
PTA	Prior to admission
PTC	Percutaneous transhepatic cholecystogram
PUD	Peptic ulcer disease
PULM	Pulmonary
PV	Polycythemia vera
PVD	Peripheral vascular disease
Q	Every
QD	Every day
QUAD	Quadrant

California Cancer Reporting System Standards, Volume I

R, RT	Right
RA	Radium
RA	Rheumatoid arthritis
RAD *	Radiation
RAD *	Radiation absorbed dose
RAD *	Radical
RBBB	Right bundle branch block
RBC	Red blood cells (count)
RCM	Right costal margin
RE	Regarding
REC'D	Received
REG	Regular
RESEC	Resection (ed)
RESPIR	Respiratory
RHD	Rheumatic heart disease
RIA	Radioimmunoassay
RIQ	Right inner quadrant
RLE	Right lower extremity
RLL	Right lower lobe
RLQ	Right lower quadrant
RMC	Regional medical center
RML	Right middle lobe
RO, R/O	Rule Out
ROF	Review of outside films
ROQ	Right outer quadrant
ROS *	Review of outside slides
ROS *	Review of Systems
OP RPT	Operative Report
RSO	Right salpingo-oophorectomy
RSR	Regular sinus Rhythm
RT	Radiation therapy
RUE	Right upper extremity
RUL	Right upper lobe
RUQ	Right upper quadrant
RX *	Prescription
RX *, TX	Treatment
S/P	Status post
S1-S5	Sacral vertebra
SATIS	Satisfactory
SB, SML BWL	Small Bowel
SBO	Small bowel obstruction
SCC	Squamous cell carcinoma
SCID	Severe combined immunodeficiency Syndrome
SGOT	Serum glutamic oxaloacetic transaminase
SGPT	Serum Glutamic Pyruvic Transaminase

California Cancer Reporting System Standards, Volume I

SIADH	Syndrome of inappropriate ADH
SIG COLON	Sigmoid colon
SIS	Sister
SLE	Systemic lupus erythematosus
SM, SML	Small
SMA	Sequential Multiple Analysis (Biochem Profile)
SNF	Skilled Nursing Facility
SO	Salpingo-oophorectomy
SOB	Short(ness) of breath
SPEC	Specimen
SQ	Squamous
SQUAM	Squamous
SRS	Stereotactic radiosurgery
SS	Summary Stage
S-SPINE	Sacral Spine
SSS	Sick Sinus Syndrome
STSG	Split thickness Skin graft
SUBCU, SUBQ	Subcutaneous
SURG	Surgery/Surgical
SUSP	Suspicious/suspected
SVC	Superior vena cava
SX	Symptoms
T	Thoracic
T1-T12	Thoracic Vertebra
TAH	Total abdominal hysterectomy
TAH-BSO	Total abdominal hysterectomy-bilateral salpingo-oophorectomy
TB	Tuberculosis
TBI	Total body irradiation
TCC	Transitional cell carcinoma
TIA	Transient ischemic attack
TPN	Total parenteral nutrition
TRAM	Transverse rectus abdominis myocutaneous
TRANS-COLON	Transverse colon
TS	Tumor Size
T-SPINE	Thoracic spine
TTP	Thromboticthrombocytopenia purpura
TUR	Transurethral resection
TURB	Transurethral resection bladder
TURB(T)	Transurethral Resection Bladder (Tumor)
TURP	Transurethral resection prostate
TVC	True vocal cord
TVH	Total vaginal hysterectomy
UE	Upper extremity
UGI	Upper gastrointestinal (series)
UIQ	Upper inner quadrant

California Cancer Reporting System Standards, Volume I

UNDIFF	Undifferentiated
UNK	Unknown
UOQ	Upper outer quadrant
URI	Upper respiratory infection
US	Ultrasound
UTI	Urinary tract infection
VAG	Vagina/Vaginal
VAG HYST	Vaginal hysterectomy
VAIN I-III	Vaginal intraepithelial neoplasia, Grade I-III
VASC	Vascular
VIN I-III	Vulvar intraepithelial neoplasia, Grade I-III
VPI	Visceral pleural invasion
W/ or C	With
W/F	White female
W/M	White male
W/O	Without
W/U	Work-up
WBC	White blood cells (count)
WELL DIFF	Well differentiated WD,
WHO	World Health Organization
WNL	Within normal limits
WPW	Wolff-Parkinson-White syndrome
X	Times
XR	Xray
YR	Year

## APPENDIX N: ICD-O-3 Codes to be Considered One Primary Site When Determining Multiple Primaries

For cases diagnosed January 1, 2010 and forward, or following installation of CSv2 software, refer to [Collaborative Stage Data Collection System Coding Instructions](#).

ICD-O-3 Codes	Site Groupings
C01 C02	Base of tongue Other and unspecified parts of tongue
C05 C06	Palate Other and unspecified parts of mouth
C07 C08	Parotid gland Other and unspecified major salivary glands
C09 C10	Tonsil Oropharynx
C12 C13	Pyriform sinus Hypopharynx
C19 C20	Rectosigmoid junction Rectum
C23 C24	Gallbladder Other and unspecified parts of biliary tract
C30 C31	Nasal cavity and middle ear Accessory sinuses
C33 C34	Trachea Bronchus and lung

California Cancer Reporting System Standards, Volume I

<b>ICD-O-3 Codes</b>	<b>Site Groupings</b>
C37 C38.0-.3 C38.8	Thymus Heart and mediastinum Overlapping lesion of heart, mediastinum, and pleura
C40 C41	Bones, joints and articular cartilage of limbs Bones, joints and articular cartilage of other and unspec. sites
C51 C52 C57.7 C57.8-.9	Vulva Vagina Other specified female genital organs Overlapping lesion and female genital tract, NOS
C60 C63	Penis Other and unspecified male genital organs
C64 C65 C66 C68	Kidney Renal pelvis Ureter Other and unspecified urinary organs
C74 C75	Adrenal gland Other endocrine glands and related structures



## **Appendix O: Spanish Surnames**

[Click here to view a searchable Appendix O, Spanish Surnames](#)

## APPENDIX Q1 ROADS SURGERY CODES

### Q1 Surgery Codes – ANUS: (For Cases Diagnosed prior to January 1, 2003)

#### C21.9

#### Surgical Approach

##### Codes

0	None; no cancer-directed surgery of primary site
1	Endoscopy, NOS
2	Not image guided
3	Image guided
4	Open, NOS
5	Not assisted by endoscopy
6	Assisted by endoscopy
9	Unknown; not stated; death certificate <b>only</b>

#### Surgery of Primary Site

##### Codes

00	None; no cancer-directed surgery of primary site
<b>Procedures for codes 10-14 include, but are not limited to:</b> Cryosurgery; Electrocautery; Excisional biopsy; Laser; Thermal ablation.	
10	Local tumor destruction, NOS ( <b>without pathology specimen</b> )
11	Photodynamic therapy (PDT)
12	Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
13	Cryosurgery
14	Laser
	No specimen sent to pathology from this surgical event.
20	Local tumor excision, NOS ( <b>with pathology specimen</b> )
21	Photodynamic therapy (PDT)
22	Electrocautery
23	Cryosurgery
24	Laser ablation
25	Laser excision
26	Polypectomy
27	Excisional biopsy
	Specimen sent to pathology from this surgical event. Margins of resection may have microscopic involvement.
60	Abdominal perineal resection, NOS
90	Surgery, NOS
99	Unknown if cancer-directed surgery performed; death certificate <b>only</b>

## Surgical Margins

### Codes

0	All margins grossly and microscopically negative
1	Margins involved, NOS
2	Microscopic involvement
5	Macroscopic involvement
7	Margins not documented
8	No cancer-directed surgery of primary site
9	Unknown whether margins were involved or negative; death certificate <b>only</b>

## Scope of Regional Lymph Node Surgery

### Codes

0	No regional lymph nodes removed
1	Regional lymph nodes removed, NOS
2	Perirectal, anorectal lymph nodes
3	Internal iliac lymph nodes (hypogastric), unilateral
4	Inguinal lymph nodes, unilateral
5	Combination of 2 and 4
6	Bilateral internal iliac and/or bilateral inguinal lymph nodes
9	Unknown; not stated; death certificate <b>only</b>

## Number of Regional Lymph Nodes Examined

### Codes

00	No regional lymph nodes removed
01	One regional lymph node removed
02	Two regional lymph nodes removed
90	Ninety or more regional lymph nodes removed
95	No regional lymph nodes removed but aspiration of regional lymph nodes was performed
96	Regional lymph node removal documented as a sampling and number of lymph nodes unknown/not stated
97	Regional lymph node removal documented as dissection and number of lymph nodes unknown/not stated
98	Regional lymph nodes surgically removed but number of lymph nodes unknown/not stated and not documented as sampling or dissection
99	Unknown; not stated; death certificate <b>only</b>

## Surgery of Other Regional Site(S), Distant Site(S) or Distant Lymph Node(S)

### Codes

0	None; no surgery to other regional or distant sites
1	Surgery to other sites or nodes, NOS; unknown if regional or distant
2	Other regional sites
3	Distant lymph nodes
4	Distant sites

5	Combination of 4 <b>with</b> 2 or 3
9	Unknown; not stated; death certificate <b>only</b>

**Reconstruction/Restoration - First Course**

**Codes**

0	No reconstruction/restoration
1	Colostomy (permanent)
2	Ileostomy, NOS
3	<b>without</b> a reservoir or pouch
4	<b>with</b> an abdominal reservoir or pouch
5	<b>with</b> an anal reservoir or pouch; artificial sphincter
9	Unknown; not stated; death certificate <b>only</b>

**Q1 Surgery Codes – BLADDER (For Cases Diagnosed prior to January 1, 2003)**

**C67.0-C67.9**

**Surgical Approach**

**Codes**

- 0 None; no cancer-directed surgery of primary site
- 1 Endoscopy, NOS
  - 2 Cystoscopy (TURB)
  - 3 Laparoscopy
- 4 Open, NOS
  - 5 Not assisted by endoscopy (laparoscopy)
  - 6 Assisted by endoscopy (laparoscopy)
- 9 Unknown; not stated; death certificate **only**

**Surgery of Primary Site**

**Codes**

- 00 None; no cancer-directed surgery of primary site
- 10 Local tumor destruction, NOS (**without pathology specimen**)
  - 11 Photodynamic therapy (PDT)

- 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
- 13 Cryosurgery
- 14 Laser

No specimen sent to pathology from this surgical event.

20 Local tumor excision, NOS **with pathology specimen)**

- 21 Photodynamic therapy (PDT)
- 22 Electrocautery
- 23 Cryosurgery
- 24 Laser ablation
- 25 Laser excision
- 26 Polypectomy
- 27 Excisional biopsy (TURB)

Specimen sent to pathology from this surgical event.

- 30 Partial cystectomy
- 50 Simple/total/complete cystectomy
- 60 Radical cystectomy (male only)

This code is used only for men. It involves the removal of bladder and prostate, with or without urethrectomy. If a radical cystectomy is the procedure name for a woman, use code 71.

70 Pelvic exenteration, NOS

- 71 Radical cystectomy (female only); anterior exenteration

A radical cystectomy in a female includes removal of bladder, uterus, ovaries, entire vaginal wall and entire urethra.

- 72 Posterior exenteration

73 Total exenteration

Includes removal of all pelvic contents and pelvic lymph nodes.

74 Extended exenteration

Includes pelvic blood vessels or bony pelvis.

80 Cystectomy, NOS

90 Surgery, NOS

99 Unknown if cancer-directed surgery performed; death certificate **only**

## Surgical Margins

### Codes

0 All margins grossly and microscopically negative

1 Margins involved, NOS

2 Microscopic involvement

5 Macroscopic involvement

7 Margins not documented

8 No cancer-directed surgery of primary site

9 Unknown whether margins were involved or negative; death certificate **only**

## Scope of Regional Lymph Node Surgery

The regional lymph nodes are:
Hypogastric
Iliac (internal, external, NOS)
Obturator
Pelvic, NOS
Perivesical
Presacral
Sacral (lateral, sacral promontory [Gerota's])



**Codes**

- 0 No regional lymph nodes removed
- 1 Regional lymph nodes removed, NOS; not stated if bilateral or unilateral
  - 2 Unilateral regional lymph nodes
  - 3 Bilateral regional lymph nodes
- 9 Unknown; not stated; death certificate **only**

**Number of Regional Lymph Nodes Examined**

**Codes**

- 00 No regional lymph nodes removed
- 01 One regional lymph node removed
- 02 Two regional lymph nodes removed
- 90 Ninety or more regional lymph nodes removed
- 95 No regional lymph nodes removed but aspiration of regional lymph nodes was performed
- 96 Regional lymph node removal documented as a sampling and number of lymph nodes unknown/not stated
- 97 Regional lymph node removal documented as dissection and number of lymph nodes unknown/not stated
- 98 Regional lymph nodes surgically removed but number of lymph nodes unknown/not stated and not documented as sampling or dissection
- 99 Unknown; not stated; death certificate **only**



## Surgery of Other Regional Site(S), Distant Site(S) or Distant Lymph Node(S)

**DO NOT CODE** the partial or total removal of a ureter during a cystectomy.

### Codes

- 0 None; no surgery to other regional or distant sites
- 1 Surgery to other sites or nodes, NOS; unknown if regional or distant
  - 2 Other regional sites
  - 3 Distant lymph nodes
  - 4 Distant sites
  - 5 Combination of 4 **with** 2 or 3
- 9 Unknown; not stated; death certificate **only**

## Reconstruction/Restoration - First Course

### Codes

- 0 No reconstruction/restoration
- 1 Conduit diversion
- 2 Continent reservoir (a bladder substitute)

**Types of continent reservoirs include, but are not limited to:** Hemi Kock; Ileal reservoir; Ileocecal reservoir; Indiana or Mainz pouch; Koch; Studer pouch; W shaped ileoneobladder by Hautmann.

- 8 Reconstruction/restoration recommended, unknown if performed
- 9 Unknown; not stated; death certificate **only**

## **Q1 Surgery Codes - BONES, PERIPHERAL NERVES, & SOFT TISSUES (For Cases Diagnosed prior to January 1 2003)**

**Bones, Joints, and Articular Cartilage C40.0-C41.9, Peripheral Nerves and Autonomic Nervous System C47.0-C47.9, Connective, Subcutaneous and Other Soft Tissues C49.0-C49.9**

### **Surgical Approach**

#### **Codes**

- 0 None; no cancer-directed surgery of primary site
- 1 Endoscopy, NOS
  - 2 Not image guided
  - 3 Image guided
- 4 Open, NOS
  - 5 Not assisted by endoscopy
  - 6 Assisted by endoscopy
- 9 Unknown; not stated; death certificate **only**

### **Surgery of Primary Site**

#### **Codes**

- 00 None; no cancer-directed surgery of primary site
- 10 Local tumor destruction or excision
- 20 Partial resection/internal hemipelvectomy (pelvis)
- 30 Radical excision or resection of lesion with limb salvage
- 40 Amputation of limb
  - 41 Partial amputation of limb
  - 42 Total amputation of limb
- 50 Major amputation, NOS
  - 51 Forequarter, including scapula

- 52 Hindquarter, including ilium/hip bone
- 53 Hemipelvectomy
- 90 Surgery, NOS
- 99 Unknown if cancer-directed surgery performed; death certificate **only**

### **Surgical Margins**

#### **Codes**

- 0 All margins grossly and microscopically negative
- 1 Margins involved, NOS
  - 2 Microscopic involvement
  - 5 Macroscopic involvement
- 7 Margins not documented
- 8 No cancer-directed surgery of primary site
- 9 Unknown whether margins were involved or negative; death certificate **only**

### **Scope of Regional Lymph Node Surgery**

#### **Codes**

- 0 No regional lymph nodes removed
- 1 Regional lymph nodes removed, NOS
- 9 Unknown; not stated; death certificate **only**

### **Number of Regional Lymph Nodes Examined**

#### **Codes**

- 00 No regional lymph nodes removed
- 01 One regional lymph node removed
- 02 Two regional lymph nodes removed
- ..

- 90 Ninety or more regional lymph nodes removed
- 95 No regional lymph nodes removed but aspiration of regional lymph nodes was performed
- 96 Regional lymph node removal documented as a sampling and number of lymph nodes unknown/not stated
- 97 Regional lymph node removal documented as dissection and number of lymph nodes unknown/not stated
- 98 Regional lymph nodes surgically removed but number of lymph nodes unknown/not stated and not documented as sampling or dissection
- 99 Unknown; not stated; death certificate **only**

### **Surgery of Other Regional Site(S), Distant Site(S) or Distant Lymph Node(S)**

#### **Codes**

- None; no surgery to other regional or distant sites
- 0
- 1 Surgery to other sites or nodes, NOS; unknown if regional or distant
  - 2 Other regional sites
  - 5 Distant lymph nodes
  - 6 Distant sites
  - 7 Combination of 6 **with** 2 or 5
- 9 Unknown; not stated; death certificate **only**

### **Reconstruction/Restoration - First Course**

#### **Codes**

- 0 No reconstruction/restoration
- 1 Flap, graft, or any "plasty," NOS
  - 2 without implant/prosthesis

- 3 with implant/prosthesis
- 8 Reconstruction/restoration recommended, unknown if performed
- 9 Unknown; not stated; death certificate **only**

## **Q1 Surgery Codes - BRAIN & OTHER PARTS OF THE CENTRAL NERVOUS SYSTEM (For Cases Diagnosed prior to January 1, 2003)**

### **Meninges C70.0-C70.9, Brain C71.0-C71.9, Other Parts of Central Nervous System C72.0-C72.9**

#### **Surgical Approach**

##### **Codes**

- 0 None; no cancer-directed surgery of primary site
- 4 Open
- 9 Unknown; not stated; death certificate **only**

#### **Surgery of Primary Site**

##### **Codes**

- 00 None; no cancer-directed surgery of primary site
- 10 Local tumor destruction
- 20 Excision of tumor, lesion, or mass
  - 21 Subtotal resection, NOS
  - 22 Partial resection
  - 23 Debulking
- 30 Excision of tumor, lesion, or mass, NOS
  - 31 Total resection
  - 32 Gross resection
- 40 Partial resection, NOS
  - 41 Partial lobe
  - 42 Partial meninges

- 43 Partial nerve(s)
  - 50 Total resection (lobectomy of brain)
  - 60 Radical resection
- Resection of primary site plus partial or total removal of surrounding organs/tissue
- 90 Surgery, NOS
  - 99 Unknown if cancer-directed surgery performed; death certificate **only**

### Surgical Margins

#### Codes

- 0 All margins grossly and microscopically negative
- 1 Margins involved, NOS
  - 2 Microscopic involvement
  - 5 Macroscopic involvement
- 7 Margins not documented
- 8 No cancer-directed surgery of primary site
- 9 Unknown whether margins were involved or negative; death certificate **only**

### Scope of Regional Lymph Node Surgery

**There are no regional lymph nodes for brain.** Code no regional lymph nodes removed (0). Central nervous system sites, however have regional lymph nodes.

#### Codes

- 0 No regional lymph nodes removed
- 1 Regional lymph nodes removed, NOS
- 9 Unknown; not stated; death certificate **only**

### Number of Regional Lymph Nodes Examined

**There are no regional lymph nodes for brain.** Code no regional lymph nodes removed (00). Central nervous system tumors, however, have regional lymph nodes.

**Codes**

- 00 No regional lymph nodes removed
- 01 One regional lymph node removed
- 02 Two regional lymph nodes removed
- ..
- 90 Ninety or more regional lymph nodes removed
- 95 No regional lymph nodes removed but aspiration of regional lymph nodes was performed
- 96 Regional lymph node removal documented as a sampling and number of lymph nodes unknown/not stated
- 97 Regional lymph node removal documented as dissection and number of lymph nodes unknown/not stated
- 98 Regional lymph nodes surgically removed but number of lymph nodes unknown/not stated and not documented as sampling or dissection
- 99 Unknown; not stated; death certificate **only**

**Surgery of Other Regional Site(S), Distant Site(S) or Distant Lymph Node(S)**

**Codes**

- 0 None; no surgery to other regional or distant sites
- 1 Surgery to other sites or nodes, NOS; unknown if regional or distant
  - 2 Other regional sites
  - 5 Distant lymph nodes
  - 6 Distant sites
  - 7 Combination of 6 **with** 2 or 5
- 9 Unknown; not stated; death certificate **only**

## Reconstruction/Restoration - First Course

### Codes

- 9 Not applicable (There are no known reconstructive procedures for this site.)

## Q1 Surgery Codes – BREAST (For Cases Diagnosed prior to January 1, 2003)

### C50.0-C50.9

## Surgical Approach

### Codes

- 0 None; no cancer-directed surgery of primary site
- 4 Open approach, NOS
  - 5 without dye or needle localization
  - 6 with dye or needle localization
- 9 Death certificate **only**

## Surgery of Primary Site

### Codes

- 00 None; no cancer-directed surgery of primary site

Procedures coded as 10-17 remove the gross primary tumor and some of the breast tissue (breast conserving or preserving). There may be microscopic residual tumor.

- 10 Partial mastectomy, NOS; less than total mastectomy, NOS
  - 11 Nipple resection
  - 12 Lumpectomy or excisional biopsy
  - 13 Reexcision of the biopsy site (usually for gross or microscopic residual disease)
  - 14 Wedge resection



- 15 Quadrantectomy
- 16 Segmental mastectomy
- 17 Tylectomy
- 30 Subcutaneous mastectomy

A subcutaneous mastectomy is the removal of breast tissue without the nipple and areolar complex or overlying skin. **This procedure is rarely performed to treat malignancies.**

- 40 Total (simple) mastectomy, NOS
  - 41 **without** removal of uninvolved contralateral breast
  - 42 **with** removal of uninvolved contralateral breast

A simple mastectomy removes all breast tissue, the nipple, and areolar complex. An axillary dissection is not done. For single primaries only, code removal of involved contralateral breast under the data item Surgery of Other Regional Site(s), Distant Site(s), or Distant Lymph Node(s).

- 50 Modified radical mastectomy
  - 51 **without** removal of uninvolved contralateral breast
  - 52 **with** removal of uninvolved contralateral breast

Removes all breast tissue, the nipple, the areolar complex, and variable amounts of breast skin. The procedure involves an en bloc resection of the axilla. The specimen may or may not include a portion of the pectoralis major muscle. Includes an en bloc axillary dissection. For single primaries only, code removal of involved contralateral breast under the data item Surgery of Other Regional Site(s), Distant Site(s), or Distant Lymph Node(s).

- 60 Radical mastectomy, NOS
  - 61 **without** removal of uninvolved contralateral breast

62 **with** removal of uninvolved contralateral breast

Removal of breast tissue, nipple, areolar complex, a variable amount of skin, pectoralis minor, and pectoralis major. Includes an en bloc axillary dissection. For single primaries only, code removal of involved contralateral breast under the data item Surgery of Other Regional Site(s), Distant Site(s), or Distant Lymph Node(s).

70 Extended radical mastectomy

71 **without** removal of uninvolved contralateral breast

72 **with** removal of uninvolved contralateral breast

Removal of breast tissue, nipple, areolar complex, variable amounts of skin, pectoralis minor, and pectoralis major. Includes removal of internal mammary nodes and an en bloc axillary dissection. For single primaries only, code removal of involved contralateral breast under the data item Surgery of Other Regional Site(s), Distant Site(s), or Distant Lymph Node(s).

80 Mastectomy, NOS

90 Surgery, NOS

99

Unknown if cancer-directed surgery performed; death certificate **only**

## Surgical Margins

Since the codes are hierarchical, if more than one code is applicable, use the numerically higher code. For example, if multiple margins are microscopically and macroscopically involved, code the macroscopic involvement(s).

Multiple margins are two separate margins, both of which are microscopically involved with tumor. **Do not code** multiple margins (4) if **one margin** has multiple foci of tumor.

## Codes

0 All margins grossly and microscopically negative

- 1 Margins involved, NOS
  - 2 Microscopic involvement
    - 3 Single margin
    - 4 Multiple margins
  - 5 Macroscopic involvement
- 7 Margins not documented
- 8 No cancer-directed surgery of primary site
- 9 Unknown whether margins were involved or negative; death certificate **only**

### Scope of Regional Lymph Node Surgery

#### Codes

- 0 No regional lymph nodes removed
- 1 Sentinel lymph nodes removed

A sentinel node is the first node to receive drainage from a primary tumor. It is identified by an injection of a dye or radio label at the site of the primary tumor

- 2 Regional lymph nodes removed, NOS; axillary, NOS (Levels I, II, or III lymph nodes) Intramammary, NOS
  - 3 Combination of 1 and 2
  - 4 Internal mammary
  - 5 Combination of 4 **with** any of 1-3
- 9 Unknown; not stated; death certificate **only**

### Number of Regional Lymph Nodes Examined

#### Codes

- 00 No regional lymph nodes removed
- 01 One regional lymph node removed
- 02 Two regional lymph nodes removed

- 90 Ninety or more regional lymph nodes removed
- 95 No regional lymph nodes removed but aspiration of regional lymph nodes was performed
- 96 Regional lymph node removal documented as a sampling and number of lymph nodes unknown/not stated
- 97 Regional lymph node removal documented as dissection and number of lymph nodes unknown/not stated
- 98 Regional lymph nodes surgically removed but number of lymph nodes unknown/not stated and not documented as sampling or dissection
- 99 Unknown; not stated; death certificate **only**

### **Surgery of Other Regional Site(S), Distant Site(S) Or Distant Lymph Node(S)**

**Do not code** removal of fragments or tags of muscles; removal of the pectoralis minor; the resection of pectoralis muscles, NOS; or the resection of fascia with no mention of muscle.

#### **Codes**

- 0 None; no surgery to other regional or distant sites
- 1 Surgery to other sites or nodes, NOS; unknown if regional or distant
  - 2 Other regional sites
  - 3 Distant lymph nodes
  - 4 Distant sites
    - 5 Removal of involved contralateral breast (single primary only)
  - 6 Combination of 4 or 5 **with** 2 or 3
- 9 Unknown; not stated; death certificate **only**

### **Reconstruction/Restoration - First Course**

The insertion of a tissue expander is often the beginning of the reconstructive procedure.

**Codes**

- 0 No reconstruction/restoration
- 1 Reconstruction, NOS (unknown if flap)
  - 2 Implant; reconstruction **without** flap
  - 3 Reconstruction **with** flap, NOS
    - 4 Latissimus dorsi flap
    - 5 Abdominus recti flap
    - 6 Flap, NOS + implant
    - 7 Latissimus dorsi flap + implant
    - 8 Abdominus recti + implant
- 9 Unknown; not stated; death certificate **only**

**Q1 Surgery Codes - CERVIX UTERI (For Cases Diagnosed prior to January 1, 2003)**

**C53.0-C53.9**

**Surgical Approach**

**Codes**

- 0 None; no cancer-directed surgery of primary site
- 1 Vaginal, NOS
  - 2 Not assisted by endoscopy
  - 3 Assisted by colposcopy
  - 4 Assisted by laparoscopy
- 5 Open, NOS
  - 6 Not assisted by endoscopy
  - 7 Assisted by endoscopy

0 Unknown; not stated; death certificate **only**

### Surgery of Primary Site

**For invasive cancers**, dilation and curettage is coded as an incisional biopsy (02) under the data item Non-Cancer-Directed Surgery.

#### Code

00 None; no cancer-directed surgery of primary site

10 Local tumor destruction, NOS (**without pathology specimen**)

11 Photodynamic therapy (PDT)

12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)

13 Cryosurgery

14 Laser

15 LEEP

No specimen sent to pathology from this surgical event.

20 Local tumor destruction or excision, NOS (**with pathology specimen**)

21 Electrocautery

22 Cryosurgery

23 Laser

24 Cone biopsy **with** gross excision of lesion

25 Dilatation and curettage; endocervical curettage (cancer-directed for in situ only)

26 Excisional biopsy, NOS

27 Cone biopsy

28 LEEP

29 Trachelectomy; removal of cervical stump;

cervicectomy

Specimen sent to pathology from this surgical event.

- 30 Total hysterectomy (simple, pan ) **without** removal of tubes and ovaries

Total hysterectomy removes both the corpus and cervix uteri and may also include a portion of vaginal cuff.

- 40 Total hysterectomy (simple, pan ) **with** removal of tubes or ovary

Total hysterectomy removes both the corpus and cervix uteri and may also include a portion of vaginal cuff.

- 50 Modified radical or extended hysterectomy; radical hysterectomy; extended radical hysterectomy

51 Modified radical hysterectomy

52 Extended hysterectomy

53 Radical hysterectomy; Wertheim's procedure

54 Extended radical hysterectomy

- 60 Hysterectomy, NOS, **with** or **without** removal of tubes and ovaries

61 **without** removal of tubes and ovaries

62 **with** removal of tubes and ovaries

- 70 Pelvic exenteration

71 Anterior exenteration

Includes bladder, distal ureters, and genital organs **with** their ligamentous attachments and pelvic lymph nodes. The removal of pelvic lymph nodes is also coded under the data item Surgery of Other Regional Site(s), Distant Site(s), or Distant Lymph Node(s).

72 Posterior exenteration

Includes rectum and rectosigmoid **with** ligamentous attachments and pelvic lymph nodes. The removal of pelvic lymph nodes is also coded under the data item Surgery of Other Regional Site(s), Distant Site(s), or Distant Lymph Node(s).

73 Total exenteration

Includes removal of all pelvic contents and pelvic lymph nodes. The removal of pelvic lymph nodes is also coded under the data item Surgery of Other Regional Site(s), Distant Site(s), or Distant Lymph Node(s).

74 Extended exenteration

Includes pelvic blood vessels or bony pelvis

90 Surgery, NOS

99 Unknown if cancer-directed surgery performed; death certificate **only**

### Surgical Margins

#### Codes

0 All margins grossly and microscopically negative

1 Margins involved, NOS

2 Microscopic involvement

5 Macroscopic involvement

7 Margins not documented

8 No cancer-directed surgery of primary site

9 Unknown whether margins were involved or negative; death certificate **only**

### Scope of Regional Lymph Node Surgery

<b>The regional lymph nodes are:</b>



Common iliac
External iliac
Hypogastric (obturator)
Internal iliac
Paracervical
Parametrial
Presacral
Sacral

**Codes**

- 0 No regional lymph nodes removed
- 1 Regional lymph nodes removed, NOS
- 9 Unknown; not stated; death certificate **only**

**Number of Regional Lymph Nodes Examined**

**Codes**

- 00 No regional lymph nodes removed
- 01 One regional lymph node removed
- 02 Two regional lymph nodes removed
- ..
- 90 Ninety or more regional lymph nodes removed
- 95 No regional lymph nodes removed but aspiration of regional lymph nodes was performed
- 96 Regional lymph node removal documented as a sampling and number of lymph nodes unknown/not stated
- 97 Regional lymph node removal documented as dissection and number of lymph nodes unknown/not stated
- 98 Regional lymph nodes surgically removed but number of lymph nodes unknown/not stated and not documented as sampling or dissection
- 99 Unknown; not stated; death certificate **only**

## **Surgery of Other Regional Sites(s), distant Site(s) or Distant Lymph Node(s)**

**Do not code** the incidental removal of an appendix. **Do not code** an omentectomy **if** it was the only surgery performed in addition to hysterectomy. Incidental removal is when an organ is removed for a reason unrelated to the malignancy.

### **Codes**

- 0 None; no surgery to other regional or distant sites
- 1 Surgery to other sites or nodes, NOS; unknown if regional or distant
  - 2 Other regional sites
  - 3 Distant lymph nodes, NOS
    - 4 Periaortic lymph nodes
  - 5 Distant sites
  - 6 Combinations of 5 with 4
  - 7 Combination of 5 **with** 2 or 3
- 9 Unknown; not stated; death certificate **only**

## **Reconstruction/Restoration - First Course**

### **Codes**

- 0 No reconstruction/restoration
- 1 Vaginal reconstruction
- 2 Urinary reconstruction
- 3 Bowel reconstruction/restoration
- 4 Combination of 3 with 1 or 2
- 8 Reconstruction/restoration recommended, unknown if performed
- 9 Unknown; not stated; death certificate **only**

## **Q1 Surgery Codes – COLON (For Cases Diagnosed prior to January 1, 2003)**

**C18.0-C18.9**

**Surgical Approach**

**Codes**

0 None; no cancer-directed surgery of primary site

1 Endoscopy, NOS

**Endoscopy procedures include:** Colonoscopy;  
Laparoscopy; Sigmoidoscopy

2 Not image guided

3 Image guided

4 Open, NOS

5 Not assisted by endoscopy

6 Assisted by endoscopy

9 Unknown; not stated; death certificate **only**

## Surgery of Primary Site

**Code** removal/surgical ablation of single or multiple liver metastases under the data item Surgery of Other Regional Site(s), Distant Site(s) or Distant Lymph Node(s).

### Codes

00 None; no cancer-directed surgery of primary site

10 Local tumor destruction, NOS (**without pathology specimen**)

11 Photodynamic therapy (PDT)

12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)

13 Cryosurgery

14 Laser

No specimen sent to pathology from this surgical event.

20 Local tumor excision, NOS (**with pathology specimen**)

21 Photodynamic therapy (PDT)

22 Electrocautery

23 Cryosurgery

24 Laser ablation

25 Laser excision

26 Polypectomy

27 Excisional biopsy

Specimen sent to pathology from this surgical event.

**Procedures coded 30-31 include, but are not limited to:** Appendectomy (for an appendix primary only); Enterocolectomy; Ileocolectomy; Partial colectomy, NOS; Partial resection of transverse colon and flexures; Segmental resection, e.g., cecectomy; Sigmoidectomy

30 Partial colectomy, but less than hemicolectomy

31 Partial colectomy **with** permanent colostomy

(Hartmann's operation)

**Also code** colostomy in the data item Reconstruction/Restoration.

- 40 Hemicolectomy or greater (but less than total); right or left colectomy

A hemicolectomy is the removal of total right or left colon and a portion of transverse colon.

- 50 Total colectomy

Removal of colon from cecum to the rectosigmoid or a portion of the rectum.

- 60 Total proctocolectomy

Commonly used for familial polyposis or polyposis coli.

- 70 Colectomy or coloproctectomy **with** an en bloc resection of other organs; pelvic exenteration

**Code 70** includes any colectomy (partial, hemicolectomy, or total) **with** an en bloc resection of any other organs. The other organs may be partially or totally removed. Procedures that may be a **part of an en bloc resection** include, but are not limited to: oophorectomy, partial proctectomy, rectal mucosectomy **En bloc** resection is the removal of organs in one piece at one time.

**The creation of ileal reservoir** which is a part of a pelvic exenteration **must also be coded** in the data item Reconstruction/Restoration.

- 80 Colectomy, NOS

- 90 Surgery, NOS

- 99 Unknown if cancer-directed surgery performed; death certificate **only**

## Surgical Margins

### Codes

- 0 All margins grossly and microscopically negative
- 1 Margins involved, NOS
  - 2 Microscopic involvement
  - 5 Macroscopic involvement
- 7 Margins not documented
- 8 No cancer-directed surgery of primary site
- 9 Unknown whether margins were involved or negative; death certificate **only**

### Scope of Regional Lymph Node Surgery

The pathology report often describes regional lymph nodes by their anatomic location: colic nodes; mesenteric nodes; peri-\epi-\para-\colic. Regional lymph nodes differ for each anatomical subsite. The following list identifies the regional lymph nodes for each subsite of the colon:

Cecum and appendix	Anterior cecal Ileocolic Posterior cecal Right colic
Ascending colon	Ileocolic Middle colic Right colic
Hepatic flexure	Middle colic Right colic
Transverse colon	Middle colic
Splenic flexure	Inferior mesenteric Middle colic, left colic
Descending colon	Inferior mesenteric Left colic Sigmoid
Sigmoid colon	Inferior mesenteric Sigmoid mesenteric

Sigmoidal  
Superior rectal(hemorrhoidal)

Superior mesenteric, external iliac and common iliac nodes are distant lymph nodes. **Code** the removal of any of these nodes in the data item Surgery of Other Regional Site(s), Distant Site(s), or Distant Lymph Node(s).

**Codes**

- 0 No regional lymph nodes removed
- 1 Regional lymph nodes removed, NOS
- 9 Unknown; not stated; death certificate **only**

**Number of Regional Lymph Nodes Examined**

**Codes**

- 00 No regional lymph nodes removed
- 01 One regional lymph node removed
- 02 Two regional lymph nodes removed
  
- 90 Ninety or more regional lymph nodes removed
- 95 No regional lymph nodes removed but aspiration of regional lymph nodes was performed
- 96 Regional lymph node removal documented as a sampling and number of lymph nodes unknown/not stated
- 97 Regional lymph node removal documented as dissection and number of lymph nodes unknown/not stated
- 98 Regional lymph nodes surgically removed but number of lymph nodes unknown/not stated and not documented as sampling or dissection
- 99 Unknown; not stated; death certificate **only**

**Surgery of Other Regional Site(S), Distant Site(S), or Distant Lymph Node(S)**

**DO NOT CODE** the incidental removal of appendix, gallbladder, bile ducts, or spleen. Incidental removal is when an organ is removed for a reason unrelated to the malignancy (gallbladder removed for obvious cholelithiasis).



### Codes

- 0 None; no surgery to other regional or distant sites
- 1 Surgery to other sites or nodes, NOS; unknown if regional or distant
  - 2 Removal of other regional sites, **only**
  - 3 Removal/surgical ablation of single liver metastasis
  - 4 Removal/surgical ablation of multiple liver metastases
  - 5 Combination of codes 2 and 3 or 2 and 4
  - 6 Removal of other distant sites or distant lymph nodes, **only**
  - 7 Combination of code 6 **with** 3 or 5
  - 8 Combination of code 6 **with** 4
- 9 Unknown; not stated; death certificate **only**

### Reconstruction/Restoration - First Course

**Do not code anastomosis as reconstruction.**

### Codes

- 0 No reconstruction/restoration
- 1 Colostomy (permanent)
- 2 Ileostomy, NOS
  - 3 **without** a reservoir or pouch
  - 4 **with** an abdominal reservoir or pouch
  - 5 **with** an anal reservoir or pouch; artificial sphincter
- 9 Unknown; not stated; death certificate **only**

## Q1 Surgery Codes - CORPUS UTERI (For Cases Diagnosed prior to January 1, 2003)

Corpus uteri C54.0-C54.9, Uterus NOS C55.9

### Surgical Approach

#### Codes

- 0 None; no cancer-directed surgery of primary site
- 1 Vaginal, NOS
  - 2 Not assisted by endoscopy
  - 3 Assisted by colposcopy
  - 4 Assisted by laparoscopy
- 5 Open, NOS
  - 6 Not assisted by endoscopy
  - 7 Assisted by endoscopy
- 9 Unknown; not stated; death certificate **only**

### Surgery of Primary Site

**For invasive cancers**, dilation and curettage is coded as an incisional biopsy (02) under the data item Non-Cancer-Directed Surgery.

#### Codes

- 00 None; no cancer-directed surgery of primary site
- 10 Local tumor destruction, NOS (**without pathology specimen**)
  - 11 Photodynamic therapy (PDT)
  - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
  - 13 Cryosurgery
  - 14 Laser
  - 15 LEEP

No specimen sent to pathology from this surgical event.

Procedures in code 20 include but are not limited to:  
Cryosurgery; Electrocautery ; Excisional biopsy ; Laser ablation;  
Thermal ablation.

20 Local tumor destruction or excision, NOS; simple excision, NOS **with pathology specimen**

21 Electrocautery

22 Cryosurgery

23 Laser

24 Excisional biopsy

25 Polypectomy

26 Myomectomy

Specimen sent to pathology from this surgical event.  
Margins of resection may have microscopic involvement.

30 Subtotal hysterectomy/supracervical hysterectomy/fundectomy **with** or **without** removal of tube(s) and ovary(ies).

31 **without** tube(s) and ovary(-ies)

32 **with** tube(s) and ovary(-ies)

Cervix left in place.

40 Total hysterectomy (simple, pan ) **without** removal of tube(s) and ovary(-ies)

Removes both the corpus and cervix uteri. It may also include a portion of the vaginal cuff.

50 Total hysterectomy (simple, pan ) **with** removal of tube(s) or ovary(-ies)

Removes both the corpus and cervix uteri. It may also include a portion of the vaginal cuff.

60 Modified radical or extended hysterectomy; radical hysterectomy; extended radical hysterectomy

- 61 Modified radical hysterectomy
- 62 Extended hysterectomy
- 63 Radical hysterectomy; Wertheim's procedure
- 64 Extended radical hysterectomy
- 70 Hysterectomy, NOS, **with** or **without** removal of tube(s) and ovary(-ies)
  - 71 **without** removal of tube(s) and ovary(-ies)=
  - 72 **with** removal of tube(s) and ovary(-ies)
- 80 Pelvic exenteration
  - 81 Anterior exenteration

Includes bladder, distal ureters, and genital organs **with** their ligamentous attachments and pelvic lymph nodes. The removal of pelvic lymph nodes is also coded under the data item Surgery of Other Regional Site(s), Distant Site(s), or Distant Lymph Node(s).
  - 82 Posterior exenteration

Includes rectum and rectosigmoid **with** ligamentous attachments and pelvic lymph nodes. The removal of pelvic lymph nodes is also coded under the data item Surgery of Other Regional Site(s), Distant Site(s), or Distant Lymph Node(s).
  - 83 Total exenteration

Includes removal of all pelvic contents and pelvic lymph nodes. The removal of pelvic lymph nodes is also coded under the data item Surgery of Other Regional Site(s), Distant Site(s), or Distant Lymph Node(s).
  - 84 Extended exenteration

Includes pelvic blood vessels or bony pelvis
- 90 Surgery, NOS
- 99 Unknown if cancer-directed surgery performed; death certificate **only**

## Surgical Margins

### Codes

- 0 All margins grossly and microscopically negative
- 1 Margins involved, NOS
  - 2 Microscopic involvement
  - 5 Macroscopic involvement
- 7 Margins not documented
- 8 No cancer-directed surgery of primary site
- 9 Unknown whether margins were involved or negative; death certificate **only**

## Scope of Regional Lymph Node Surgery

### The regional lymph nodes are:

Common iliac and external iliac  
Hypogastric (obturator)  
Para aortic  
Parametrial  
Sacral

### Codes

- 0 No regional lymph nodes removed
- 1 Regional lymph nodes removed, NOS
  - 2 Pariaortic with or without other regional lymph nodes
- 9 Unknown; not stated; death certificate **only**

## Number of Regional Lymph Nodes Examined

### Codes

- 00 No regional lymph nodes removed
- 01 One regional lymph node removed
- 02 Two regional lymph nodes removed
- ..
- 90 Ninety or more regional lymph nodes removed

- 95 No regional lymph nodes removed but aspiration of regional lymph nodes was performed
- 96 Regional lymph node removal documented as a sampling and number of lymph nodes unknown/not stated
- 97 Regional lymph node removal documented as dissection and number of lymph nodes unknown/not stated
- 98 Regional lymph nodes surgically removed but number of lymph nodes unknown/not stated and not documented as sampling or dissection
- 99 Unknown; not stated; death certificate **only**

### **Surgery of Other Regional Site(s), Distant Sites(s), or Distant Lymph Nodes (s)**

**Do not code** the incidental removal of an appendix. **Do not code** an omentectomy **if** it was the only surgery performed in addition to hysterectomy. Incidental removal is when an organ is removed for a reason unrelated to the malignancy.

#### **Codes**

- 0 None; no surgery to other regional or distant sites
- 1 Surgery to other sites or nodes, NOS; unknown if regional or distant
  - 2 Other regional sites
  - 3 Distant lymph nodes, NOS
    - 4 Periaortic lymph nodes
  - 5 Distant sites
  - 6 Combinations of 5 with 4
  - 7 Combination of 5 **with** 2 or 3
- 9 Unknown; not stated; death certificate **only**

### **Reconstruction/Restoration - First Course**

#### **Codes**

- 0 No reconstruction/restoration

- 1 Vaginal reconstruction
- 2 Urinary reconstruction
- 3 Bowel reconstruction/restoration
- 4 Combination of 3 with 1 or 2
- 8 Reconstruction/restoration recommended, unknown if performed
- 9 Unknown; not stated; death certificate **only**

## **Q1 Surgery Codes – ESOPHAGUS (For Cases Diagnosed prior to January 1, 2003)**

**C15.0-C15.9**

### **Surgical Approach**

#### **Codes**

- 0 None; no cancer-directed surgery of primary site

Endoscopy procedures include: Esophagoscopy; Mediastinoscopy; Thoracoscopy

- 1 Endoscopy, NOS
  - 2 Not image guided
  - 3 Image guided
- 4 Open, NOS
  - 5 Trans-hiatal
  - 6 Thoracotomy (includes split sternum)
  - 7 Laparotomy
- 9 Unknown; not stated; death certificate **only**

### **Surgery of Primary Site**

#### **Codes**

- 00 None; no cancer-directed surgery of primary site

10 Local tumor destruction, NOS (**without pathology specimen**)

11 Photodynamic therapy (PDT)

PDT: Exposing photo-sensitive drugs to specific wave lengths of light in the presence of oxygen causing drug to become cytotoxic.

12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)

13 Cryosurgery

Laser

No specimen sent to pathology from this surgical event.

20 Local tumor excision, NOS (**with pathology specimen**)

21 Photodynamic therapy (PDT)

22 Electrocautery

23 Cryosurgery

24 Laser ablation

25 Laser excision

26 Polypectomy

27 Excisional biopsy

Specimen sent to pathology from this surgical event.

30 Partial esophagectomy

40 Total esophagectomy

50 Partial esophagectomy **with** laryngectomy and/or gastrectomy, NOS

51 **with** laryngectomy

52 **with** gastrectomy, NOS



- 53 Partial gastrectomy
- 54 Total gastrectomy
- 55 Combination of 51 **with** any of 52-54
- 60 Total esophagectomy, NOS **with** laryngectomy and/or gastrectomy, NOS
  - 61 **with** laryngectomy
  - 62 **with** gastrectomy, NOS
  - 63 Partial gastrectomy
  - 64 Total gastrectomy
  - 65 Combination of 61 **with** any of 62-64
- 70 Esophagectomy, NOS **with** pharyngectomy and laryngectomy
- 80 Esophagectomy, NOS
- 90 Surgery, NOS
- 99 Unknown if cancer-directed surgery performed; death certificate only

## **Surgical Margins**

### **Codes**

- 0 All margins grossly and microscopically negative
- 1 Margins involved, NOS
  - 2 Microscopic involvement
  - 5 Macroscopic involvement
- 7 Margins not documented
- 8 No cancer-directed surgery of primary site
- 9 Unknown whether margins were involved or negative; death certificate **only**

### Scope of Regional Lymph Node Surgery

<b>Regional lymph nodes are different for each anatomical subsite. The following list identifies nodes classified as regional for each subsite:</b>	
Cervical esophagus:	Cervical, NOS Internal jugular Periesophageal Scalene Supraclavicular Upper cervical
Intrathoracic esophagus (upper, middle, lower):	Carinal Hilar (pulmonary roots) Internal jugular Mediastinal, NOS Paracardial Periesophageal Perigastric Peritracheal Superior mediastinal Tracheobronchial

#### Codes

- 0 No regional lymph nodes removed
- 1 Regional lymph nodes removed, NOS
- 9 Unknown; not stated; death certificate **only**

Celiac nodes are distant for intrathoracic esophagus. Code removal of celiac nodes in the data item Surgery of Other Regional Site(s), Distant Site(s), or Distant Lymph Node(s).

### Number of Regional Lymph Nodes Examined

#### Codes

- 00 No regional lymph nodes removed
- 01 One regional lymph node removed
- 02 Two regional lymph nodes removed
- ..
- 90 Ninety or more regional lymph nodes removed

- 95 No regional lymph nodes removed but aspiration of regional lymph nodes was performed
- 96 Regional lymph node removal documented as a sampling and number of lymph nodes unknown/not stated
- 97 Regional lymph node removal documented as dissection and number of lymph nodes unknown/not stated
- 98 Regional lymph nodes surgically removed but number of lymph nodes unknown/not stated and not documented as sampling or dissection
- 99 Unknown; not stated; death certificate **only**

**Surgery of Other Regional Site(S), Distant Site(S) or Distant Lymph Node(S)**

**Codes**

- 0 None; no surgery to other regional or distant sites
- 1 Surgery to other sites or nodes, NOS; unknown if regional or distant
  - 2 Other regional sites
  - 3 Distant lymph nodes
  - 4 Distant sites
  - 5 Combination of 4 with 2 or 3
- 9 Unknown; not stated; death certificate only

**Reconstruction/Restoration - First Course**

<b>Code only the following reconstructive procedures:</b>
Myocutaneous flaps (pectoralis major, trapezius) Reconstruction of mandible Regional flaps

**Codes**

- 0 No reconstruction/restoration

- 1 Reconstruction/restoration, NOS
  - 2 **without** implant/prosthesis
  - 3 **with** implant/prosthesis
- 8 Reconstruction/restoration recommended, unknown if performed
- 9 Unknown; not stated; death certificate **only**

## **Q1 Surgery Codes - KIDNEY, RENAL PELVIS & URETER (For Cases Diagnosed prior to January 1, 2003)**

**Kidney C64.9, Renal Pelvis C65.9, Ureter C66.9**

### **Surgical Approach**

#### **Codes**

- 0 None; no cancer directed surgery of primary site
- 1 Endoscopy, NOS
  - 2 Not image guided
  - 3 Image guided
- 4 Open, NOS
  - 5 Not assisted by endoscopy
  - 6 Assisted by endoscopy
- 9 Unknown; not stated; death certificate **only**

### **Surgery of Primary Site**

#### **Codes**

- 00 None; no cancer-directed surgery of primary site
- 10 Local tumor destruction, NOS (**without pathology specimen**)
  - 11 Photodynamic therapy (PDT)
  - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)

13 Cryosurgery

14 Laser

No specimen sent to pathology from this surgical event.

20 Local tumor excision, NOS (**with pathology specimen**)

21 Photodynamic therapy (PDT)

22 Electrocautery

23 Cryosurgery

24 Laser ablation

25 Laser excision

26 Polypectomy

27 Excisional biopsy

Specimen sent to pathology from this surgical event.

**Procedures coded 30 include, but are not limited to:** Cryosurgery; Electrocautery; Excisional biopsy; Laser; Segmental resection; Thermal ablation; Wedge resection.

30 Partial or subtotal nephrectomy (kidney or renal pelvis) or partial ureterectomy (ureter)

Margins of resection are grossly negative. There may be microscopic involvement

40 Complete/total/simple nephrectomy for kidney  
parenchyma  
Nephroureterectomy

Includes bladder cuff for renal pelvis or ureter

50 Radical nephrectomy

May include removal of a portion of vena cava, adrenal gland(s), Gerota's fascia, perinephric fat, or partial/total ureter

70 Any nephrectomy (simple, subtotal, complete, partial, simple, total, radical) **plus** an en bloc resection of

other organ(s) (colon, bladder)

The other organs, such as colon or bladder, may be partially or totally removed.

- 80 Nephrectomy, NOS  
Ureterectomy, NOS
- 90 Surgery, NOS
- 99 Unknown if cancer-directed surgery performed; death certificate **only**

### Surgical Margins

#### Codes

- 0 All margins grossly and microscopically negative
- 1 Margins involved, NOS
  - 2 Microscopic involvement
  - 5 Macroscopic involvement
- 7 Margins not documented
- 8 No cancer-directed surgery of primary site
- 9 Unknown whether margins were involved or negative; death certificate **only**

### Scope of Regional Lymph Node Surgery

The regional lymph nodes are	
Kidney	Aortic (para-aortic, periaortic, lateral aortic) Paracaval Renal hilar Retroperitoneal, NOS
Renal pelvis	Aortic Paracaval Renal hilar Retroperitoneal, NOS
Ureter	Iliac (common, internal [hypogastric],

external)
Paracaval
Pelvic, NOS
Periureteral
Renal hilar

**Codes**

- 0 No regional lymph nodes removed
- 1 Regional lymph nodes removed, NOS; not stated if bilateral or unilateral
  - 2 Unilateral regional lymph nodes
  - 3 Bilateral regional lymph nodes
- 9 Unknown; not stated; death certificate **only**

**Number of Regional Lymph Nodes Examined**

**Codes**

- 00 No regional lymph nodes removed
- 01 One regional lymph node removed
- 02 Two regional lymph nodes removed
- ..
- 90 Ninety or more regional lymph nodes removed
- 95 No regional lymph nodes removed but aspiration of regional lymph nodes was performed
- 96 Regional lymph node removal documented as a sampling and number of lymph nodes unknown/not stated
- 97 Regional lymph node removal documented as dissection and number of lymph nodes unknown/not stated
- 98 Regional lymph nodes surgically removed but number of lymph nodes unknown/not stated and not documented as sampling or dissection
- 99 Unknown; not stated; death certificate **only**

## **Surgery of Other Regional Site(S), Distant Site(S) or Distant Lymph Node(S)**

**DO NOT CODE** the incidental removal of ribs during the operative approach.

### **Codes**

- 0 None; no surgery to other regional or distant sites
- 1 Surgery to other sites or nodes, NOS; unknown if regional or distant
  - 2 Other regional sites
  - 3 Distant lymph nodes
  - 4 Distant sites
  - 5 Combination of 4 **with** 2 or 3
- 9 Unknown; not stated; death certificate **only**

## **Reconstruction/Restoration - First Course**

### **Codes**

- 0 No reconstruction/restoration
- 1 Kidney transplant (primary site)
- 8 Reconstruction/restoration recommended, unknown if performed
- 9 Unknown; not stated; death certificate **only**

## **Q1 Surgery Codes – LARYNX (For Cases Diagnosed prior to January 1, 2003)**

**Tonsil C09.0-C09.9, Oropharynx C10.0-C10.9, Nasopharynx C11.0-C11.9, Pyriform Sinus C12.9, Hypopharynx C13.0-C13.9, Pharynx C14.0**

## **Surgical Approach**

### **Codes**

- 0 None; no cancer-directed surgery of primary site
- 4 Open



9 Death certificate **only**

**Surgery of Primary Site**

**Codes**

00 None; no cancer-directed surgery of primary site

10 Local tumor destruction, NOS (**without pathology specimen**)

11 Photodynamic therapy (PDT)

PDT: Exposing photo-sensitive drugs to specific wave lengths of light in the presence of oxygen causing drug to become cytotoxic.

12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)

13 Cryosurgery

14 Laser

No specimen sent to pathology from this surgical event.

20 Local tumor excision, NOS (**with pathology specimen**)

21 Photodynamic therapy (PDT)

22 Electrocautery

23 Cryosurgery

24 Laser ablation

25 Laser excision

26 Polypectomy

27 Excisional biopsy

Specimen sent to pathology from this surgical event.

30 Less than total parotidectomy, NOS

31 Facial nerve spared

- 32 Facial nerve sacrificed
- 33 Superficial lobe **only**
  - 34 Facial nerve spared
  - 35 Facial nerve sacrificed
- 36 Deep lobe (**with** or **without** superficial lobe)
  - 37 Facial nerve spared
  - 38 Facial nerve sacrificed
- 40 Total parotidectomy, NOS
  - 41 Facial nerve spared
  - 42 Facial nerve sacrificed
- 50 Radical parotidectomy, NOS
  - 51 **without** removal of temporal bone
  - 52 **with** removal of temporal bone
- 80 Parotidectomy, NOS
- 90 Surgery, NOS
- 99 Unknown if cancer-directed surgery performed; death certificate **only**

## **Surgical Margins**

### **Codes**

- 0 All margins grossly and microscopically negative
- 1 Margins involved, NOS
  - 2 Microscopic involvement
  - 5 Macroscopic involvement
- 7 Margins not documented
- 8 No cancer-directed surgery of primary site
- 9 Unknown whether margins were involved or negative;

death certificate **only**

### Scope of Regional Lymph Node Surgery

Regional cervical lymph nodes are:
Buccal (facial)
Caudal jugular (deep cervical)
Cranial jugular (deep cervical)
Dorsal cervical (superficial cervical)
Medial jugular (deep cervical)
Occipital
Paratracheal (anterior cervical)
Parotid
Prelaryngeal (anterior cervical)
Retroauricular (mastoid, posterior auricular)
Retropharyngeal
Submandibular (submaxillary)
Submental
Supraclavicular

#### Codes

- 0 No regional lymph nodes removed
- 1 Regional lymph nodes removed, NOS
  - 2 Neck dissection, NOS
    - 3 Selective, limited; nodal sampling; "berry picking"
    - 4 Modified/modified radical
    - 5 Radical
- 9 Unknown; not stated; death certificate **only**

Terminology of neck dissection (Robbins et al. 1991): A radical neck dissection includes the removal of all ipsilateral cervical lymph node groups, i.e., lymph nodes from levels I through V (submental, submandibular, cranial jugular, medial jugular, caudal jugular, dorsal cervical nodes along the accessory nerve, and supraclavicular), and removal of the spinal accessory nerve, internal jugular vein and sternocleidomastoid muscle. In a modified radical neck dissection, the same lymph nodes are removed as in a radical neck dissection; however, one or more nonlymphatic structures are preserved. A selective neck dissection preserves one or more lymph node groups routinely removed in radical neck dissection.

## Number of Regional Lymph Nodes Examined

### Codes

- 00 No regional lymph nodes removed
- 01 One regional lymph node removed
- 02 Two regional lymph nodes removed
  
- 90 Ninety or more regional lymph nodes removed
- 95 No regional lymph nodes removed but aspiration of regional lymph nodes was performed
- 96 Regional lymph node removal documented as a sampling and number of lymph nodes unknown/not stated
- 97 Regional lymph node removal documented as dissection and number of lymph nodes unknown/not stated
- 98 Regional lymph nodes surgically removed but number of lymph nodes unknown/not stated and not documented as sampling or dissection
- 99 Unknown; not stated; death certificate **only**

## Surgery of Other Regional Site(S), Distant Site(S) or Distant Lymph Node(S)

### Codes

- 0 None; no surgery to other regional or distant sites
- 1 Surgery to other sites or nodes, NOS; unknown if regional or distant
  - 2 Other regional sites
  - 3 Distant lymph nodes
  - 4 Distant sites
  - 5 Combination of 4 **with** 2 or 3
- 9 Unknown; not stated; death certificate **only**

**Reconstruction/Restoration - First Course  
Codes**

- 0 No reconstruction/restoration
- 1 Flaps, grafts, or any type of "plasty," NOS
  - 2 **without** implant/prosthesis
  - 3 **with** implant/prosthesis
- 8 Reconstruction/restoration recommended, unknown if performed
- 9 Unknown; not stated; death certificate **only**

## **Q1 Surgery Codes - LIVER INTRATRAHEPATIC BILE DUCTS (For Cases Diagnosed prior to January 1, 2003)**

### **C22.0-C22.1**

#### **Surgical Approach**

##### **Codes**

- 0 None; no cancer-directed surgery of primary site
- 1 Endoscopy **only**, NOS (laparoscopy)
  - 2 Not image guided
  - 3 Image guided
- 4 Open, NOS
  - Not assisted by endoscopy
  - Assisted by endoscopy
- 9 Unknown; not stated; death certificate **only**

#### **Surgery of Primary Site**

##### **Codes**

- 00 None; no cancer-directed surgery of primary site
- 10 Local tumor destruction, NOS
  - 11 Photodynamic therapy (PDT)
  - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
  - 13 Cryosurgery
  - 14 Laser
  - 15 Alcohol (PEI)
  - 16 Heat
  - 17 Other (ultrasound, acetic acid)
- 20 Wedge resection, NOS; segmental resection
- 30 Lobectomy, NOS
  - 31 Simple

32 Extended

Extended lobectomy: resection of a single lobe plus a segment of another lobe.

40 Excision of a bile duct (for an intrahepatic bile duct primary only)

70 Total hepatectomy with transplant

Liver transplant must also be coded under the data item Reconstruction/Restoration.

80 Hepatectomy, NOS

90 Surgery, NOS

99 Unknown if cancer-directed surgery performed; death certificate **only**

## Surgical Margins

### Codes

0 All margins grossly and microscopically negative

1 Margins involved, NOS

2 Microscopic involvement

5 Macroscopic involvement

7 Margins not documented

8 No cancer directed surgery of primary site

9 Unknown whether margins were involved or negative; death certificate **only**

## Scope of Regional Lymph Node Surgery

### Regional lymph nodes are the hilar nodes:

Along the portal vein  
Along the inferior vena cava  
Along the proper hepatic artery  
At the hepatic pedicle

**Codes**

- 0 No regional lymph nodes removed
- 1 Regional lymph nodes removed, NOS
- 9 Unknown; not stated; death certificate **only**

**Number of Regional Lymph Nodes Examined**

**Codes**

- 00 No regional lymph nodes removed
- 01 One regional lymph node removed
- 02 Two regional lymph nodes removed
- ..
- 90 Ninety or more regional lymph nodes removed
- 95 No regional lymph nodes removed but aspiration of regional lymph nodes was performed
- 96 Regional lymph node removal documented as a sampling and number of lymph nodes unknown/not stated
- 97 Regional lymph node removal documented as dissection and number of lymph nodes unknown/not stated
- 98 Regional lymph nodes surgically removed but number of lymph nodes unknown/not stated and not documented as sampling or dissection
- 99 Unknown; not stated; death certificate **only**

**Surgery of Other Regional Site(S), Distant Site(S) or Distant Lymph Node(S)**

**Codes**

- 0 None; no surgery to other regional or distant sites
- 1 Surgery to other sites or nodes, NOS; unknown if regional or distant
- 2 Other regional sites



- 3 Distant lymph nodes (includes inferior phrenic lymph nodes)
- 4 Distant sites
- 5 Combination of 4 **with** 2 or 3
- 9 Unknown; not stated; death certificate **only**

### **Reconstruction/Restoration - First Course Codes**

- 0 No reconstruction/restoration
- 1 Rioux en Y; hepatojejunostomy including stent
- 2 Liver transplant
- 9 Unknown; not stated; death certificate **only**

### **Q1 Surgery Codes – LUNG (For Cases Diagnosed prior to January 1, 2003)**

**C34.0-C34.9**

#### **Surgical Approach Codes**

- 0 None; no cancer-directed surgery of primary site
- 1 Endoscopy, NOS
  - 2 Bronchoscopy
  - 3 Mediastinoscopy
  - 4 Thoracoscopy
- 5 Open, NOS (thoracotomy, sternotomy)
  - 6 Not assisted by endoscopy
  - 7 Assisted by endoscopy
- 9 Unknown; not stated; death certificate **only**

## Surgery of Primary Site

### Codes

- 00 None; no cancer-directed surgery of primary site
- 10 Local tumor destruction or excision, NOS
  - 11 Excision
  - 12 Laser ablation or excision
  - 13 Cautery; fulguration
  - 14 Bronchial sleeve resection **only**
- 20 Resection of less than one lobe
  - 21 Wedge resection
  - 22 Segmental resection, including lingulectomy
- 30 Resection of at least one lobe, but less than the whole lung (partial pneumonectomy, NOS)
  - 31 Lobectomy
  - 32 Bilobectomy

Procedures coded 40 include, but are not limited to: Complete pneumonectomy; Pneumonectomy, NOS; Sleeve pneumonectomy; Standard pneumonectomy; Total pneumonectomy.

- 40 Resection of whole lung
- 50 Resection of lung **with** an en bloc resection of other organs
  - 51 Wedge resection
  - 52 Lobectomy
  - 53 Bilobectomy
  - 54 Pneumonectomy (less than a radical or extended pneumonectomy)

**En bloc resection is the removal of organs in one piece at one time.**

60 Radical pneumonectomy

Radical pneumonectomy is a complete pneumonectomy **with** removal of mediastinal lymph nodes. Removal of mediastinal nodes is also coded in the data fields Scope of Regional Lymph Node Surgery and Number of Regional Lymph Nodes Removed.

70 Extended radical pneumonectomy

An extended radical pneumonectomy is a radical pneumonectomy (including removal of mediastinal nodes) and the removal of other tissues or nodes. Removal of mediastinal nodes is also coded in the data fields Scope of Regional Lymph Node Surgery and Number of Regional Lymph Nodes Removed.

80 Resection of lung, NOS

90 Surgery, NOS

99 Unknown if cancer-directed surgery performed; death certificate **only**

## Surgical Margins

### Codes

0 All margins grossly and microscopically negative

1 Margins involved, NOS

2 Microscopic involvement

5 Macroscopic involvement

7 Margins not documented

8 No cancer-directed surgery of primary site

9 Unknown whether margins were involved or negative; death certificate **only**

## Scope of Regional Lymph Node Surgery

<p><b>Mediastinal nodes are:</b></p> <p>Aortic (includes subaortic, aortcopulmonary window, periaortic, including ascending aorta or including azygos)</p> <p>Periesophageal</p> <p>Peritracheal (including those that may be designated tracheobronchial, i.e., lower peritracheal, phrenic)</p> <p>Pre- and retrotracheal (includes precarinal)</p> <p>Pulmonary ligament</p> <p>Subcarinal</p>
---

### Codes

- 0 No regional lymph nodes removed
- 1 Regional lymph node(s) removed, NOS
- 2 Intrapulmonary (includes interlobar, lobar, segmental), ipsilateral hilar and/or ipsilateral peribronchial nodes
- 3 Ipsilateral mediastinal and/or subcarinal nodes
- 4 Combination of 2 & 3
- 5 Contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene and/or supraclavicular nodes
- 6 Combination of 5 with 2 or 3
- 9 Unknown; not stated; death certificate only

## Number OF Regional Lymph Nodes Examined

### Codes

- 00 No regional lymph nodes removed
- 01 One regional lymph node removed
- 02 Two regional lymph nodes removed
- ..
- 90 Ninety or more regional lymph nodes removed
- 95 No regional lymph nodes removed but aspiration of regional lymph nodes was performed
- 96 Regional lymph node removal documented as a

sampling and number of lymph nodes unknown/not stated

- 97 Regional lymph node removal documented as dissection and number of lymph nodes unknown/not stated
- 98 Regional lymph nodes surgically removed but number of lymph nodes unknown/not stated and not documented as sampling or dissection
- 99 Unknown; not stated; death certificate **only**

### **Surgery of Other Regional Site(S), Distant Site(S) or Distant Lymph Node(S)**

#### **Codes**

- 0 None; no surgery to other regional sites, distant sites or distant lymph nodes
- 1 Surgery to other sites or nodes, NOS; unknown if regional or distant
- 2 Surgery to a regional site **only**
- 3 Removal of a solitary lesion in the same lung (primary site), different (non primary) lobe

There is one primary. Patient has two tumors with the same histology in different lobes of the same lung.

- 4 Resection of metastasis in a distant sites or resection of distant lymph nodes(s), NOS
- 5 Removal of a solitary lesion in the contralateral lung

Patient has one primary. There is a primary tumor or tumor(s) in one lung and a solitary metastatic lesion in the contralateral lung.

- 6 Removal of a solitary lesion in a distant site or a distant lymph node, NOS

This includes, but is not limited to the removal of a solitary metastatic brain lesion.

- 7 Removal of multiple lesions in distant sites
- 9 Unknown; not stated; death certificate **only**

### **Reconstruction/Restoration - First Course**

#### **Codes**

- 0 No reconstruction/restoration
- 1 Chest wall reconstruction/restoration, NOS
- 9 Unknown; not stated; death certificate **only**

### **Q1 Surgery Codes – ORAL (For Cases Diagnosed prior to January 1, 2003)**

**Lip C00.0-C00.9, Base of Tongue C01.9, Other Parts of Tongue C02.0-C09.9,**

**Gum C03.0-C03.9, Floor of Mouth C04.0-C04.9, Palate C05.0-C05.9,**

#### **Surgical Approach**

##### **Codes**

- 0 None; no cancer-directed surgery of primary site
- 1 Endoscopy, NOS
- 2 Not image guided
- 3 Image guided
- 4 Open, NOS
- 5 Not assisted by endoscopy
- 6 Assisted by endoscopy
- 9 Unknown; not stated; death certificate **only**

#### **Surgery of Primary Site**

##### **Codes**

- 00 None; no cancer-directed surgery of primary site
- 10 Local tumor destruction, NOS (**without pathology specimen**)

11 Photodynamic therapy (PDT)

PDT: Exposing photo-sensitive drugs to specific wave lengths of light in the presence of oxygen causing drug to become cytotoxic.

12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)

13 Cryosurgery

14 Laser

No specimen sent to pathology from this surgical event.

**Procedures in codes 20-27 include, but are not limited to:** Shave; Wedge resection

20 Local tumor excision, NOS (**with pathology specimen**)

21 Photodynamic therapy (PDT)

22 Electrocautery

23 Cryosurgery

24 Laser ablation

25 Laser excision

26 Polypectomy

27 Excisional biopsy

Specimen sent to pathology from this surgical event.

**Procedures in code 30 include, but are not limited to:** Hemiglossectomy; Partial glossectomy

30 Wide excision, NOS

**Procedures in codes 40-43 include, but are not limited to:** Radical glossectomy

40 Radical excision of tumor, NOS

- 41 Radical excision of tumor **only**
- 42 Combination of 41 **with** en bloc mandibulectomy (marginal, segmental, hemi , or total)
- 43 Combination of 41 **with** en bloc maxillectomy (partial, subtotal, total)
- 90 Surgery, NOS
- 99 Unknown if cancer-directed surgery performed; death certificate **only**

### Surgical Margins

#### Codes

- 0 All margins grossly and microscopically negative
- 1 Margins involved, NOS
  - 2 Microscopic involvement
  - 5 Macroscopic involvement
- 7 Margins not documented
- 8 No cancer-directed surgery of primary site
- 9 Unknown whether margins were involved or negative; death certificate **only**

### Scope of Regional Lymph Node Surgery

<b>Regional cervical lymph nodes are:</b>
Caudal jugular (deep cervical)
Cranial jugular (deep cervical)
Dorsal cervical (superficial cervical)
Medial jugular (deep cervical)
Occipital
Paratracheal (anterior cervical)
Prelaryngeal (anterior cervical)
Retroauricular (mastoid, posterior auricular)
Submandibular (submaxillary)
Submental
Supraclavicular

#### Codes



- 0 No regional lymph nodes removed
- 1 Regional lymph nodes removed, NOS
  - 2 Neck dissection, NOS
    - 3 Selective, limited; nodal sampling; "berry picking"
    - 4 Modified/modified radical
    - 5 Radical
- 9 Unknown; not stated; death certificate **only**

Terminology of neck dissection (Robbins et al. 1991): A radical neck dissection includes the removal of all ipsilateral cervical lymph node groups, i.e., lymph nodes from levels I through V (submental, submandibular, cranial jugular, medial jugular, caudal jugular, dorsal cervical nodes along the accessory nerve, and supraclavicular), and removal of the spinal accessory nerve, internal jugular vein and sternocleidomastoid muscle. In a modified radical neck dissection the same lymph nodes are removed as in a radical neck dissection; however, one or more non lymphatic structures are preserved. A selective neck dissection preserves one or more lymph node groups routinely removed in radical neck dissection.

### **Number of Regional Lymph Nodes Examined Codes**

- 00 No regional lymph nodes removed
- 01 One regional lymph node removed
- 02 Two regional lymph nodes removed
- ..
- 90 Ninety or more regional lymph nodes removed
- 95 No regional lymph nodes removed but aspiration of regional lymph nodes was performed
- 96 Regional lymph node removal documented as a sampling and number of lymph nodes unknown/not stated
- 97 Regional lymph node removal documented as dissection and number of lymph nodes unknown/not stated

- 98 Regional lymph nodes surgically removed but number of lymph nodes unknown/not stated and not documented as sampling or dissection
- 99 Unknown; not stated; death certificate **only**

## **Surgery of Other Regional Site(S), Distant Site(S) or Distant Lymph Node(S)**

### **Codes**

- 0 None; no surgery to other regional or distant sites
- 1 Surgery to other sites or nodes, NOS; unknown if regional or distant
  - 2 Other regional sites
    - 3 Mandibulectomy (marginal, segmental, hemi , or total)
    - 4 Maxillectomy (partial, subtotal, or total)

Code a mandibulectomy or a maxillectomy in this field only if the procedure is **not** a part of an en bloc resection of the primary tumor. If the mandibulectomy or maxillectomy **is** a part of an en bloc resection of the primary tumor, code under Surgery of Primary Site.

- 5 Distant lymph nodes
- 6 Distant sites
- 7 Combination of 6 **with** 2, 3, 4, or 5
- 9 Unknown; not stated; death certificate **only**

## **Reconstruction/Restoration - First Course**

### **Codes**

- 0 No reconstruction/restoration
- 1 Flaps, grafts, or any type of "plasty," NOS
  - 2 **without** implant/prosthesis
  - 3 **with** implant/prosthesis
- 8 Reconstruction/restoration recommended, unknown if performed
- 9 Unknown; not stated; death certificate **only**

## Q1 Surgery Codes – OVARY (For Cases Diagnosed prior to January 1, 2003)

C56.9

### Table of Contents

<b>TYPE CHAPTER TITLE (LEVEL 1)</b> .....	<b>1</b>
<b>Type chapter title (level 2)</b> .....	<b>2</b>
Type chapter title (level 3).....	3
<b>TYPE CHAPTER TITLE (LEVEL 1)</b> .....	<b>4</b>
<b>Type chapter title (level 2)</b> .....	<b>5</b>
Type chapter title (level 3).....	6

### Codes

- 0 None; no cancer-directed surgery of primary site
- 1 Endoscopy, NOS (laparoscopy)
  - 2 Not image guided
  - 3 Image guided

**Open approaches include, but are not limited to:** Low transverse abdominal incision; Vertical abdominal incision.

- 4 Open, NOS
  - 5 Not assisted by endoscopy
  - 6 Assisted by endoscopy
- 9 Unknown; not stated; death certificate **only**

### Surgery of Primary Site

#### Codes

- 00 None; no cancer-directed surgery of primary site
- 10 Total removal of tumor or (single) ovary, NOS
  - 11 Resection of ovary (wedge, subtotal, or partial) **only**, NOS; unknown if hysterectomy done

- 12 **without** hysterectomy
- 13 **with** hysterectomy
- 14 Unilateral (salpingo ) oophorectomy; unknown if hysterectomy done
  - 15 **with** hysterectomy
  - 16 **without** hysterectomy
- 20 Bilateral (salpingo ) oophorectomy; unknown if hysterectomy done
  - 21 **without** hysterectomy
  - 22 **with** hysterectomy
- 30 Unilateral or bilateral (salpingo ) oophorectomy **with omentectomy**, NOS; partial or total; unknown if hysterectomy done
  - 31 **without** hysterectomy
  - 32 **with** hysterectomy
- 60 Debulking; cytoreductive surgery, NOS
  - 61 **with** colon (including appendix) and/or small intestine resection (not incidental)
  - 62 **with** partial resection of urinary tract (not incidental)
  - 63 Combination of 61 and 62

Debulking is a partial removal of the tumor mass and can involve the removal of multiple organ sites. It may include removal of ovaries and/or the uterus (a hysterectomy). The pathology report may or may not identify ovarian tissue. A debulking is usually followed by another treatment modality such as chemotherapy.

- 70 Pelvic exenteration, NOS

- 71 Anterior

Includes bladder, distal ureters, and genital organs **with** their ligamentous attachments and pelvic lymph nodes. The removal of pelvic lymph nodes is also coded under the data item Surgery of Other Regional Site(s), Distant Site(s), or Distant Lymph Node(s).

72 Posterior

Includes rectum and rectosigmoid **with** ligamentous attachments and pelvic lymph nodes. The removal of pelvic lymph nodes is also coded under the data item Surgery of Other Regional Site(s), Distant Site(s), or Distant Lymph Node(s).

73 Total

Includes removal of all pelvic contents and pelvic lymph nodes. The removal of pelvic lymph nodes is also coded under the data item Surgery of Other Regional Site(s), Distant Site(s), or Distant Lymph Node(s).

74 Extended

Includes pelvic blood vessels or bony pelvis.

80 (Salpingo ) oophorectomy, NOS

90 Surgery, NOS

99 Unknown if cancer-directed surgery performed; death certificate **only**

### Surgical Margins

For this site only, this field will describe the residual tumor burden after cancer-directed surgery.

#### Codes

0 No visible residual tumor

1 Visible residual tumor, NOS

2 Visible residual tumor, cumulative maximum of less than 1 cm

3 Visible residual tumor, cumulative maximum of at least 1 cm, not more than 2 cm

4 Visible residual tumor, cumulative maximum of more than 2 cm

8 No cancer directed surgery of primary site

- 9 Unknown whether visible residual tumor was present;  
death certificate **only**

## Scope of Regional Lymph Node Surgery

<b>The regional lymph nodes are:</b>
--------------------------------------

Common iliac External iliac Hypogastric (obturator) Inguinal Lateral sacral Paraaortic Pelvic, NOS Retroperitoneal, NOS
--

### Codes

- 0 No regional lymph nodes removed
- 1 Regional lymph nodes removed, NOS
- 9 Unknown; not stated; death certificate **only**

## Number of Regional Lymph Nodes Examined

### Codes

- 00 No regional lymph nodes removed
- 01 One regional lymph node removed
- 02 Two regional lymph nodes removed
- ..
- 90 Ninety or more regional lymph nodes removed
- 95 No regional lymph nodes removed but aspiration of regional lymph nodes was performed
- 96 Regional lymph node removal documented as a sampling and number of lymph nodes unknown/not stated
- 97 Regional lymph node removal documented as dissection and number of lymph nodes unknown/not stated
- 98 Regional lymph nodes surgically removed but number of lymph nodes unknown/not stated and not documented as sampling or dissection



99 Unknown; not stated; death certificate **only**

### **Surgery of Other Regional Site(S), Distant Site(S) or Distant Lymph Node(S)**

**Do not code** an incidental removal of the appendix. Incidental removal is when an organ is removed for a reason unrelated to the malignancy.

#### **Codes**

- 0 None; no surgery to other regional or distant sites
- 1 Surgery to other sites or nodes, NOS; unknown if regional or distant
  - 2 Other regional sites
  - 3 Distant lymph nodes
  - 4 Distant sites
  - 5 Combination of 4 **with** 2 or 3
- 9 Unknown; not stated; death certificate **only**

### **Reconstruction/Restoration - First Course**

#### **Codes**

- 0 No reconstruction/restoration
- 1 Urinary reconstruction
- 2 Bowel reconstruction/restoration
- 3 Combination of 1 and 2
- 8 Reconstruction/restoration recommended, unknown if performed
- 9 Unknown; not stated; death certificate **only**

### **Q1 Surgery Codes – PANCREAS (For Cases Diagnosed prior to January 1, 2003)**

**C25.0-25.9**

#### **Surgical Approach**

##### **Codes**

- 0 None; no cancer-directed surgery of primary site
- 1 Endoscopy, NOS (laparoscopy)
  - 2 Not image guided
  - 3 Image guided
- 4 Open, NOS
  - 5 Not assisted by endoscopy
  - 6 Assisted by endoscopy
- 9 Unknown; not stated; death certificate **only**

### **Surgery of Primary Site**

#### **Codes**

- 00 None; no cancer-directed surgery of primary site
- 10 Local excision of tumor, NOS
- 20 Partial pancreatectomy, NOS
- 40 Total pancreatectomy
- 50 Local or partial pancreatectomy and duodenectomy
  - 51 Without subtotal gastrectomy
  - 52 With subtotal gastrectomy (Whipple)
- 60 Total pancreatectomy and subtotal gastrectomy or duodenectomy
- 70 Extended pancreatoduodenectomy
- 80 Pancreatectomy, NOS
- 90 Surgery, NOS
- 99 Unknown if cancer-directed surgery performed; death certificate **only**

### **Surgical Margins**

#### **Codes**

- 0 All margins grossly and microscopically negative
- 1 Margins involved, NOS
  - 2 Microscopic involvement
  - 5 Macroscopic involvement
- 7 Margins not documented
- 8 No cancer-directed surgery of primary site
- 9 Unknown whether margins were involved or negative; death certificate **only**

### Scope of Regional Lymph Node Surgery

<b>The regional lymph nodes are:</b>
Celiac (head only)
Hepatic artery
Infrapyloric (head only)
Lateral aortic
Pancreaticolienal (body and tail only)
Peripancreatic (superior, inferior, anterior, posterior splenic)
Retroperitoneal
Splenic (body and tail only)
Subpyloric (head only)
Superior mesenteric

### Codes

- 0 No regional lymph nodes removed
  - 1 Regional lymph nodes removed, NOS
  - 2 Extended lymphadenectomy

An extended pancreaticoduodenectomy incorporates selected aspects of the Whipple procedure and regional pancreatectomy. A wide Kocher maneuver removes all lymphatic tissue over the medical aspect of the right kidney, inferior vena cava, and left renal vein.

- 9 Unknown; not stated; death certificate **only**



## Number of Regional Lymph Nodes Examined

### Codes

- 00 No regional lymph nodes removed
- 01 One regional lymph node removed
- 02 Two regional lymph nodes removed
- ..
- 90 Ninety or more regional lymph nodes removed
- 95 No regional lymph nodes removed but aspiration of regional lymph nodes was performed
- 96 Regional lymph node removal documented as a sampling and number of lymph nodes unknown/not stated
- 97 Regional lymph node removal documented as dissection and number of lymph nodes unknown/not stated
- 98 Regional lymph nodes surgically removed but number of lymph nodes unknown/not stated and not documented as sampling or dissection
- 99 Unknown; not stated; death certificate **only**

## Surgery of Other Regional Site(S), Distant Site(S) or Distant Lymph Node(S)

### Codes

- 0 None; no surgery to other regional or distant sites
- 1 Surgery to other sites or nodes, NOS; unknown if regional or distant
  - 2 Removal of other regional sites, **only**
  - 3 Removal of distant nodes
  - 4 Removal of distant site
  - 5 Combination of 2 **with** 3 and/or 4
- 9 Unknown; not stated; death certificate **only**

## Reconstruction/Restoration - First Course

### Codes

- 9 Not applicable (There are no known reconstructive procedures for this site.)

## Q1 Surgery Codes – PAROTID (For Cases Diagnosed prior to January 1, 2003)

Parotid Gland C07.9, Major Salivary Glands C08.0-C08.9

### Surgical Approach

#### Codes

- 0 None; no cancer-directed surgery of primary site
- 4 Open
- 9 Death certificate **only**

### Surgery of Primary Site

#### Codes

- 00 None; no cancer-directed surgery of primary site
- 10 Local tumor destruction, NOS (**without pathology specimen**)

- 11 Photodynamic therapy (PDT)

PDT: Exposing photo-sensitive drugs to specific wave lengths of light in the presence of oxygen causing drug to become cytotoxic.

- 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
  - 13 Cryosurgery
  - 14 Laser

No specimen sent to pathology from this surgical event.

- 20 Local tumor excision, NOS (**with pathology specimen**)

- 21 Photodynamic therapy (PDT)
- 22 Electrocautery
- 23 Cryosurgery
- 24 Laser ablation
- 25 Laser excision
- 26 Polypectomy
- 27 Excisional biopsy

Specimen sent to pathology from this surgical event.

- 30 Less than total parotidectomy, NOS
  - 31 Facial nerve spared
  - 32 Facial nerve sacrificed
- 33 Superficial lobe **only**
  - 34 Facial nerve spared
  - 35 Facial nerve sacrificed
- 36 Deep lobe (**with** or **without** superficial lobe)
  - 37 Facial nerve spared
  - 38 Facial nerve sacrificed
- 40 Total parotidectomy, NOS
  - 41 Facial nerve spared
  - 42 Facial nerve sacrificed
- 50 Radical parotidectomy, NOS
  - 51 **without** removal of temporal bone
  - 52 **with** removal of temporal bone
- 80 Parotidectomy, NOS
- 90 Surgery, NOS

- 99 Unknown if cancer-directed surgery performed; death certificate **only**

### Surgical Margins

#### Codes

- 0 All margins grossly and microscopically negative
- 1 Margins involved, NOS
  - 2 Microscopic involvement
  - 5 Macroscopic involvement
- 7 Margins not documented
- 8 No cancer-directed surgery of primary site
- 9 Unknown whether margins were involved or negative; death certificate **only**

### Scope of Regional Lymph Node Surgery

Regional cervical lymph nodes are:
------------------------------------

Buccal (facial) Caudal jugular (deep cervical) Cranial jugular (deep cervical) Dorsal cervical (superficial cervical) Medial jugular (deep cervical) Occipital Paratracheal (anterior cervical) Parotid Prelaryngeal (anterior cervical) Retroauricular (mastoid, posterior auricular) Retropharyngeal Submandibular (submaxillary) Submental Supraclavicular
--

#### Codes

- 0 No regional lymph nodes removed
- 1 Regional lymph nodes removed, NOS



- 2 Neck dissection, NOS
  - 3 Selective, limited; nodal sampling; "berry picking"
  - 4 Modified/modified radical
  - 5 Radical
- 9 Unknown; not stated; death certificate **only**

Terminology of neck dissection (Robbins et al. 1991): A radical neck dissection includes the removal of all ipsilateral cervical lymph node groups, i.e., lymph nodes from levels I through V (submental, submandibular, cranial jugular, medial jugular, caudal jugular, dorsal cervical nodes along the accessory nerve, and supraclavicular), and removal of the spinal accessory nerve, internal jugular vein and sternocleidomastoid muscle. In a modified radical neck dissection, the same lymph nodes are removed as in a radical neck dissection; however, one or more nonlymphatic structures are preserved. A selective neck dissection preserves one or more lymph node groups routinely removed in radical neck dissection.

## Number of Regional Lymph Nodes Examined

### Codes

- 00 No regional lymph nodes removed
- 01 One regional lymph node removed
- 02 Two regional lymph nodes removed
  
- 90 Ninety or more regional lymph nodes removed
- 95 No regional lymph nodes removed but aspiration of regional lymph nodes was performed
- 96 Regional lymph node removal documented as a sampling and number of lymph nodes unknown/not stated
- 97 Regional lymph node removal documented as dissection and number of lymph nodes unknown/not stated
- 98 Regional lymph nodes surgically removed but number of lymph nodes unknown/not stated and not documented as sampling or dissection
- 99 Unknown; not stated; death certificate **only**

## Surgery of Other Regional Site(S), Distant Site(S) or Distant Lymph Node(S)

**Codes**

- 0 None; no surgery to other regional or distant sites
- 1 Surgery to other sites or nodes, NOS; unknown if regional or distant
  - 2 Other regional sites
  - 3 Distant lymph nodes
  - 4 Distant sites
  - 5 Combination of 4 **with** 2 or 3
- 9 Unknown; not stated; death certificate **only**

**Reconstruction/Restoration - First Course**

**Codes**

- 0 No reconstruction/restoration
- 1 Flaps, grafts, or any type of "plasty," NOS
  - 2 **without** implant/prosthesis
  - 3 **with** implant/prosthesis
- 8 Reconstruction/restoration recommended, unknown if performed
- 9 Unknown; not stated; death certificate **only**

**Q1 Surgery Codes – PHARYNX (For Cases Diagnosed prior to January 1, 2003)**

Tonsil C09.0-C09.9, Oropharynx C10.0-C10.9, Nasopharynx C11.0-C11.9, Pyriform Sinus C12.9, Hypopharynx C13.0-C13.9, Pharynx C14.0

**Surgical Approach**

**Codes**

- 0 None; no cancer-directed surgery of primary site
- 4 Open
- 9 Death certificate **only**

**Surgery of Primary Site**

**Codes**

00 None; no cancer-directed surgery of primary site

10 Local tumor destruction, NOS (**without pathology specimen**)

11 Photodynamic therapy (PDT)

PDT: Exposing photo-sensitive drugs to specific wave lengths of light in the presence of oxygen causing drug to become cytotoxic.

12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)

13 Cryosurgery

14 Laser

No specimen sent to pathology from this surgical event.

20 Local tumor excision, NOS (**with pathology specimen**)

21 Photodynamic therapy (PDT)

22 Electrocautery

23 Cryosurgery

24 Laser ablation

25 Laser excision

26 Polypectomy

27 Excisional biopsy

Specimen sent to pathology from this surgical event.

30 Less than total parotidectomy, NOS

31 Facial nerve spared

32 Facial nerve sacrificed

33 Superficial lobe **only**

34 Facial nerve spared

- 35 Facial nerve sacrificed
- 36 Deep lobe (**with** or **without** superficial lobe)
  - 37 Facial nerve spared
  - 38 Facial nerve sacrificed
- 40 Total parotidectomy, NOS
  - 41 Facial nerve spared
  - 42 Facial nerve sacrificed
- 50 Radical parotidectomy, NOS
  - 51 **without** removal of temporal bone
  - 52 **with** removal of temporal bone
- 80 Parotidectomy, NOS
- 90 Surgery, NOS
- 99 Unknown if cancer-directed surgery performed; death certificate **only**

## **Surgical Margins**

### **Codes**

- 0 All margins grossly and microscopically negative
- 1 Margins involved, NOS
  - 2 Microscopic involvement
  - 5 Macroscopic involvement
- 7 Margins not documented
- 8 No cancer-directed surgery of primary site
- 9 Unknown whether margins were involved or negative; death certificate **only**

## Scope of Regional Lymph Node Surgery

Regional cervical lymph nodes are:
Buccal (facial)
Caudal jugular (deep cervical)
Cranial jugular (deep cervical)
Dorsal cervical (superficial cervical)
Medial jugular (deep cervical)
Occipital
Paratracheal (anterior cervical)
Parotid
Prelaryngeal (anterior cervical)
Retroauricular (mastoid, posterior auricular)
Retropharyngeal
Submandibular (submaxillary)
Submental
Supraclavicular

### Codes

- 0 No regional lymph nodes removed
- 1 Regional lymph nodes removed, NOS
  - 2 Neck dissection, NOS
    - 3 Selective, limited; nodal sampling; "berry picking"
    - 4 Modified/modified radical
    - 5 Radical
- 9 Unknown; not stated; death certificate **only**

Terminology of neck dissection (Robbins et al. 1991): A radical neck dissection includes the removal of all ipsilateral cervical lymph node groups, i.e., lymph nodes from levels I through V (submental, submandibular, cranial jugular, medial jugular, caudal jugular, dorsal cervical nodes along the accessory nerve, and supraclavicular), and removal of the spinal accessory nerve, internal jugular vein and sternocleidomastoid muscle. In a modified radical neck dissection, the same lymph nodes are removed as in a radical neck dissection; however, one or more nonlymphatic structures are preserved. A selective neck dissection preserves one or more lymph node groups routinely removed in radical neck dissection.

## Number of Regional Lymph Nodes Examined

### Codes

- 00 No regional lymph nodes removed
- 01 One regional lymph node removed
- 02 Two regional lymph nodes removed
- 90 Ninety or more regional lymph nodes removed
- 95 No regional lymph nodes removed but aspiration of regional lymph nodes was performed
- 96 Regional lymph node removal documented as a sampling and number of lymph nodes unknown/not stated
- 97 Regional lymph node removal documented as dissection and number of lymph nodes unknown/not stated
- 98 Regional lymph nodes surgically removed but number of lymph nodes unknown/not stated and not documented as sampling or dissection
- 99 Unknown; not stated; death certificate **only**

## Surgery of Other Regional Site(S), Distant Site(S) or Distant Lymph Node(S)

### Codes

- 0 None; no surgery to other regional or distant sites
- 1 Surgery to other sites or nodes, NOS; unknown if regional or distant
  - 2 Other regional sites
  - 3 Distant lymph nodes
  - 4 Distant sites
  - 5 Combination of 4 **with** 2 or 3
- 9 Unknown; not stated; death certificate **only**

## Reconstruction/Restoration - First Course

### Codes

- 0 No reconstruction/restoration
- 1 Flaps, grafts, or any type of "plasty," NOS
  - 2 **without** implant/prosthesis
  - 3 **with** implant/prosthesis
- 8 Reconstruction/restoration recommended, unknown if performed
- 9 Unknown; not stated; death certificate **only**

## Q1 Surgery Codes – PROSTATE (For Cases Diagnosed prior to January 1, 2003)

### C61.9

### Surgical Approach

#### Codes

- 0 None; no cancer-directed surgery of primary site
- 1 Endoscopy, NOS (transurethral)
- 2 Laparoscopic, NOS
- 3 Open, NOS
  - 4 Suprapubic
  - 5 Perineal
  - 7 Trans-sacral
  - 8 Retropubic

Code the approach for radical prostatectomy as retropubic unless otherwise specified.

- 9 Unknown; not stated; death certificate **only**

## Surgery of Primary Site

### Codes

- 00 None; no cancer-directed surgery of primary site
- 10 Local tumor destruction or excision, NOS
  - 11 Transurethral resection (TURP), NOS
    - 12 TURP cancer is incidental finding during surgery for benign disease
    - 13 TURP patient has suspected/known cancer
  - 14 Cryoprostectomy
  - 15 Laser
  - 16 Hyperthermia
  - 17 Other method of local resection or destruction

- 30 Subtotal or simple prostatectomy, NOS

A segmental resection or enucleation leaving the capsule intact.

- 40 Less than total prostatectomy, NOS

An enucleation using an instrument such as a Vaprotrode which may leave all or part of the capsule intact.

- 50 Radical prostatectomy, NOS; total prostatectomy, NOS

Excised prostate, prostatic capsule, ejaculatory ducts, seminal vesicle(s) and may include a narrow cuff of bladder neck.

- 70 Prostatectomy **with** en bloc resection of other organs; pelvic exenteration

Surgeries coded 70 are any prostatectomy **with** an en bloc resection of any other organs. The other organs may be partially or totally removed. **En bloc resection** is the removal of organs in one piece at one time. Procedures that may involve an en bloc resection include, but are not limited to: cystoprostatectomy, radical cystectomy and prostatectomy.



- 80 Prostatectomy, NOS
- 90 Surgery, NOS
- 99 Unknown if cancer-directed surgery performed; death certificate **only**

### Surgical Margins

The codes are hierarchical, if more than one code is applicable, use the numerically higher code. For example, if multiple margins are microscopically and macroscopically involved, code the macroscopic involvement (5).

Multiple margins are two separate margins, both of which are microscopically involved with tumor. **DO NOT CODE** multiple margins (4) if one margin has multiple foci of tumor.

### Codes

- 0 All margins grossly and microscopically negative
- 1 Margin(s) involved, NOS
  - 2 Microscopic involvement
    - 3 Single margin
    - 4 Multiple margins
  - 5 Macroscopic involvement, NOS
- 7 Margins not documented (TURP)
- 8 No cancer-directed surgery of primary site
- 9 Unknown whether margins were involved or negative; death certificate **only**

## Scope of Regional Lymph Node Surgery

The regional lymph nodes are:
Hypogastric Iliac, NOS (internal and external) Obturator Pelvic, NOS Periprostatic Sacral, NOS (lateral presacral, promontory [Gerota's] or NOS)

### Codes

- 0 No regional lymph nodes removed
- 1 Regional lymph nodes removed, NOS
- 9 Unknown; not stated; death certificate **only**

## Reconstruction/Restoration - First Course

### Codes

- 00 No regional lymph nodes removed
- 01 One regional lymph node removed
- 02 Two regional lymph nodes removed
- ..
- 90 Ninety or more regional lymph nodes removed
- 95 No regional lymph nodes removed but aspiration of regional lymph nodes was performed
- 96 Regional lymph node removal documented as a sampling and number of lymph nodes unknown/not stated
- 97 Regional lymph node removal documented as dissection and number of lymph nodes unknown/not stated
- 98 Regional lymph nodes surgically removed but number of lymph nodes unknown/not stated and not documented as sampling or dissection
- 99 Unknown; not stated; death certificate **only**

## Surgery of Other Regional Site(S), Distant Site(S) or Distant Lymph Node(S)

**DO NOT CODE** orchiectomy. For prostate primaries, code orchiectomies under Hormone Therapy.

The most commonly removed distant lymph nodes are: aortic (para-aortic, peri-aortic, lumbar), common iliac, inguinal, superficial inguinal (femoral), supraclavicular, cervical, and scalene.

### Codes

- 0 None; no surgery to other regional or distant sites
- 1 Surgery to other sites or nodes, NOS; unknown if regional or distant
  - 2 Other regional sites
  - 3 Distant lymph nodes
  - 4 Distant sites
  - 5 Combination of 4 **with** 2 or 3
- 9 Unknown; not stated; death certificate **only**

### Reconstruction/Restoration - First Course

#### Codes

- 0 No reconstruction/restoration
- 1 Reconstruction/restoration, NOS
  - 2 Collagen injection for incontinence
  - 3 Penile prosthesis
  - 4 Artificial urinary sphincter
  - 5 Combinations of 4 **with** 2 or 3
- 9 Unknown; not stated; death certificate **only**

## Appendix Q1 Surgery Codes – RECTOSIGMOID (For Cases Diagnosed prior to January 1, 2003)

### C19.9

#### Surgical Approach

##### Codes

- 0 None; no cancer-directed surgery of primary site
- 1 Endoscopy, NOS (includes laparoscopic)
- 4 Open, NOS
  - 5 Transanal
  - 6 Posterior; coccygeal; trans-sacral; abdominosacral
  - 7 Low anterior (LAR)
  - 8 Abdominal perineal (AP)
- 9 Unknown; not stated; death certificate **only**

#### Surgery of Primary Site

##### Codes

- 00 None; no cancer-directed surgery of primary site
  - 10 Local tumor destruction, NOS (**without pathology specimen**)
    - 11 Photodynamic therapy (PDT)
    - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
    - 13 Cryosurgery
    - 14 Laser ablation
- No specimen sent to pathology from this surgical event.
- 20 Local tumor excision, NOS (**with pathology specimen**)
    - 21 Photodynamic therapy (PDT)

- 22 Electrocautery
- 23 Cryosurgery
- 24 Laser ablation
- 25 Laser excision
- 26 Polypectomy
- 27 Excisional biopsy

Specimen sent to pathology from this surgical event.

**Procedures coded 30 include, but are not limited to:** Anterior resection; Hartmann's operation; Low anterior resection; Partial colectomy, NOS; Rectosigmoidectomy, NOS; Sigmoidectomy.

- 30 Wedge or segmental resection; partial proctosigmoidectomy, NOS

Also code the colostomy the in the data item Reconstruction/Restoration.

**Procedures coded 40 include but are not limited to:** Altemeier's operation; Duhamel's operation; Soave's submucosal resection; Swenson's operation; Turnbull's operation.

- 40 Pull through **with** sphincter preservation (colo-anal anastomosis)

**Procedures coded 50 include but are not limited to:** Abdominoperineal resection (A & P resection); Anterior/posterior resection (A/P resection)/Miles' operation; Rankin's operation

- 50 Total proctectomy
- 51 Total colectomy

Removal of the colon from cecum to the rectosigmoid or a portion of the rectum

- 60 Combination of 50 and 51
- 70 Colectomy or proctocolectomy **with** an en bloc

resection of other organs; pelvic exenteration

**En bloc resection** is the removal of organs in one piece at one time. Procedures that may be a part of an en bloc resection include, but are not limited to: an oophorectomy and a rectal mucosectomy. Code 70 includes any colectomy (partial, hemicolectomy, or total) **with** an en bloc resection of any other organs. The other organs may be partially or totally removed.

An **ileal reservoir** which is part of a pelvic exenteration should be coded in the data item Reconstruction/Restoration.

- 80 Colectomy, NOS; Proctectomy, NOS
- 90 Surgery, NOS
- 99 Unknown if cancer-directed surgery performed; death certificate **only**

## Surgical Margins

### Codes

- 0 All margins grossly and microscopically negative
- 1 Margins involved, NOS
  - 2 Microscopic involvement
  - 5 Macroscopic involvement
- 7 Margins not documented
- 8 No cancer-directed surgery of primary site
- 9 Unknown whether margins were involved or negative; death certificate **only**

## Scope of Regional Lymph Node Surgery

The pathology report often identifies regional lymph nodes by their anatomic location: colic; mesenteric; peri-/para-/ colic; perirectal; rectal.

The specific regional lymph nodes are:

Inferior mesenteric  
Left colic  
Middle rectal (hemorrhoidal)  
Perirectal  
Sigmoid mesenteric  
Sigmoidal  
Superior rectal (superior hemorrhoidal)

Superior mesenteric, external iliac and common iliac nodes are distant nodes. Code removal of these nodes under the data item Surgery of Other Regional Site(s), Distant Site(s), or Distant Lymph Node(s).

### Codes

- 0 No regional lymph nodes removed
- 1 Regional lymph nodes removed, NOS
- 9 Unknown; not stated; death certificate **only**

## Number of Regional Lymph Nodes Examined

### Codes

- 00 No regional lymph nodes removed
- 01 One regional lymph node removed
- 02 Two regional lymph nodes removed
  
- 90 Ninety or more regional lymph nodes removed
- 95 No regional lymph nodes removed but aspiration of regional lymph nodes was performed
- 96 Regional lymph node removal documented as a sampling and number of lymph nodes unknown/not stated
- 97 Regional lymph node removal documented as dissection and number of lymph nodes unknown/not

stated

- 98 Regional lymph nodes surgically removed but number of lymph nodes unknown/not stated and not documented as sampling or dissection
- 99 Unknown; not stated; death certificate **only**

### **Surgery of Other Regional Site(S), Distant Site(S) or Distant Lymph Node(S)**

**DO NOT CODE the incidental removal of appendix, gallbladder, or bile ducts. Incidental removal is when an organ is removed for a reason unrelated to the malignancy (gallbladder removed for obvious cholelithiasis).**

#### **Codes**

- 0 None; no surgery to other regional or distant sites
- 1 Surgery to other sites or nodes, NOS; unknown if regional or distant
  - 2 Removal of other regional sites, **only**
  - 3 Removal/surgical ablation of single liver metastasis
  - 4 Removal/surgical ablation of multiple liver metastases
  - 5 Combination of codes 2 and 3 or 2 and 4
  - 6 Removal of other distant sites or distant lymph nodes, **only**
  - 7 Combination of code 6 **with** 3, 4 or 5
  - 8 Combination of code 6 **with** 3 or 5
- 9 Unknown; death certificate **only**

### **Reconstruction/Restoration - First Course**

#### **Codes**

- 0 No reconstruction/restoration
- 1 Colostomy (permanent)
- 2 Ileostomy, NOS
  - 3 **without** a reservoir or pouch



- 4 **with** an abdominal reservoir or pouch
- 5 **with** an anal reservoir or pouch; artificial sphincter
- 9 Unknown; not stated; death certificate **only**

## **Q1 Surgery Codes – RECTUM (For Cases Diagnosed prior to January 1, 2003)**

### **C20.9**

#### **Surgical Approach**

##### **Codes**

- 0 None; no cancer-directed surgery of primary site
- 1 Endoscopy, NOS (includes laparoscopy)
- 4 Open, NOS
  - 5 Transanal (Kraske, York Mason)
  - 6 Posterior; coccygeal; trans-sacral; abdominosacral
  - 7 Low anterior (LAR)
  - 8 Abdominal perineal (AP)
- 9 Unknown; not stated; death certificate **only**

#### **Surgery of Primary Site**

**CODE** removal/surgical ablation of single or multiple liver metastases under the data item Surgery of Other Regional Site(s), Distant Site(s) or Distant Lymph Node(s).

##### **Codes**

- 00 None; no cancer-directed surgery of primary site
- 10 Local tumor destruction, NOS (**without pathology specimen**)
  - 11 Photodynamic therapy (PDT)
  - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
  - 13 Cryosurgery
  - 14 Laser

No specimen sent to pathology from this surgical event.

- 20 Local tumor excision, NOS (**with pathology specimen**)
  - 21 Photodynamic therapy (PDT)
  - 22 Electrocautery
  - 23 Cryosurgery
  - 24 Laser ablation
  - 25 Laser excision
  - 26 Polypectomy
  - 27 Excisional biopsy
  - 28 Curette and fulguration

Specimen sent to pathology from this surgical event.

**Procedures coded 30 include, but are not limited to:** Anterior resection; Hartmann's operation; Low anterior resection (LAR); Trans sacral rectosigmoidectomy.

- 30 Wedge or segmental resection; partial proctectomy, NOS

**Procedures coded 40 include but are not limited to:** Altemeier's operation; Duhamel's operation; Soave's submucosal resection; Swenson's operation; Turnbull's operation.

- 40 Pull through **with** sphincter preservation (colo-anal anastomosis)

**Procedures coded 50 include but are not limited to:** Abdominoperineal resection (A & P resection); Anterior/Posterior (A/P) resection/Miles' operation; Rankin's operation

- 50 Total proctectomy
- 60 Total proctocolectomy, NOS
- 70 Proctectomy or proctocolectomy **with** an en bloc resection of other organs; pelvic exenteration

**En bloc resection** is the removal of organs in one piece at one time. The creation of an ileal reservoir, which is a part of a pelvic exenteration, should be coded in the data item Reconstruction/Restoration.

- 80 Proctectomy, NOS
- 90 Surgery, NOS
- 99 Unknown if cancer-directed surgery performed; death certificate **only**

### Surgical Margins

#### Codes

- 0 All margins grossly and microscopically negative
- 1 Margins involved, NOS
  - 2 Microscopic involvement
  - 5 Macroscopic involvement
- 7 Margins not documented
- 8 No cancer-directed surgery of primary site
- 9 Unknown whether margins were involved or negative; death certificate **only**

### Scope of Regional Lymph Node Surgery

**The pathology report often identifies regional lymph nodes by their anatomic location: mesenteric nodes; perirectal nodes; rectal nodes.**

**The specific regional lymph nodes are:**

Inferior rectal (hemorrhoidal)  
Inferior mesenteric  
Internal iliac  
Lateral sacral  
Middle rectal (hemorrhoidal)  
Perirectal  
Presacral  
Sacral promontory (Gerotas)  
Sigmoid mesenteric  
Superior rectal (hemorrhoidal)

Superior mesenteric, external iliac and common iliac nodes are classified as distant lymph nodes. **Code** removal of these nodes under the data item Surgery of Other Regional Site(s), Distant Site(s), or Distant Lymph Node(s).

**Codes**

- 0 No regional lymph nodes removed
- 1 Regional lymph nodes removed, NOS
- 9 Unknown; not stated; death certificate **only**

**Number of Regional Lymph Nodes Examined**

**Codes**

- 00 No regional lymph nodes removed
- 01 One regional lymph node removed
- 02 Two regional lymph nodes removed
- ..
- 90 Ninety or more regional lymph nodes removed
- 95 No regional lymph nodes removed but aspiration of regional lymph nodes was performed
- 96 Regional lymph node removal documented as a sampling and number of lymph nodes unknown/not stated
- 97 Regional lymph node removal documented as dissection and number of lymph nodes unknown/not stated
- 98 Regional lymph nodes surgically removed but number of lymph nodes unknown/not stated and not documented as sampling or dissection
- 99 Unknown; not stated; death certificate **only**

**Surgery of Other Regional Site(S), Distant Site(S) or Distant Lymph Node(S)**

**DO NOT CODE** style="font-weight: normal;">the incidental removal of appendix, gallbladder, bile ducts, or spleen. Incidental removal is when an organ is removed for a reason unrelated to the malignancy (gallbladder removed for obvious cholelithiasis).

**Codes**

- 0 None; no surgery to other regional or distant sites
- 1 Surgery to other sites or nodes, NOS; unknown if regional or distant
  - 2 Removal of other regional sites, **only**
  - 3 Removal/surgical ablation of single liver metastasis
  - 4 Removal/surgical ablation of multiple liver metastases
  - 5 Combination of codes 2 with 3 or 2 with 4
  - 6 Removal of other distant sites or distant lymph nodes, **only**
  - 7 Combination of code 6 **with** 3, 4 or 5
  - 8 Combination of code 6 **with** 3 or 5
- 9 Unknown; death certificate **only**

### **Reconstruction/Restoration - First Course**

#### **Codes**

- 0 No reconstruction/restoration
- 1 Colostomy (permanent)
- 2 Ileostomy, NOS
  - 3 **without** a reservoir or pouch
  - 4 **with** an abdominal reservoir or pouch
  - 5 **with** an anal reservoir or pouch; artificial sphincter
- 9 Unknown; not stated; death certificate **only**

### **Q1 Surgery Codes – SKIN (For Cases Diagnosed prior to January 1, 2003)**

**C44.0-C44.9**

#### **Surgical Approach**

##### **Codes**

- 0 None; no cancer-directed surgery of primary site

- 4 Open approach
- 9 Death certificate **only**

## Surgery of Primary Site

### Codes

- 00 None; no cancer-directed surgery of primary site
- 10 Local tumor destruction, NOS (**without pathology specimen**)
  - 11 Photodynamic therapy (PDT)
  - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
  - 13 Cryosurgery
  - 14 Laser ablation

No specimen sent to pathology from this surgical event.

- 20 Local tumor excision, NOS (**with pathology specimen**)
  - 21 Photodynamic therapy (PDT)
  - 22 Electrocautery
  - 23 Cryosurgery
  - 24 Laser ablation
  - 25 Laser excision
  - 26 Polypectomy
  - 27 Excisional biopsy

Specimen sent to pathology from this surgical event.

- 30 Biopsy of primary tumor followed by a gross excision of the lesion
  - 31 Shave biopsy followed by a gross excision of the lesion
  - 32 Punch biopsy followed by a gross excision of the lesion

- 33 Incisional biopsy followed by a gross excision of the lesion

Less than a wide excision, less than 1 cm margin.

- 40 Wide excision or reexcision of lesion or minor (local) amputation, NOS

Margins of excision are 1 cm or more. Margins may be microscopically involved. Local amputation is the surgical resection of digits, ear, eyelid, lip, or nose.

- 50 Radical excision of a lesion, NOS

Margins of excision are greater than 1 cm and grossly tumor free. The margins may be microscopically involved.

- 60 Major amputation, NOS

- 90 Surgery, NOS

- 99 Unknown if cancer-directed surgery performed; death certificate **only**

## Surgical Margins

### Codes

- 0 All margins grossly and microscopically negative
- 1 Margins involved, NOS
- 2 Microscopic involvement
- 5 Macroscopic involvement
- 7 Margins not documented
- 8 No cancer-directed surgery of primary site
- 9 Unknown whether margins were involved or negative; death certificate **only**



## Scope of Regional Lymph Node Surgery

Regional lymph nodes are different for each anatomical subsite.

Head, neck	Cervical, ipsilateral preauricular, submandibular, and supraclavicular
Thorax	Ipsilateral axillary
Arm	Ipsilateral epitrochlear and axillary
Abdomen, loins, and buttocks	Ipsilateral inguinal
Anal margin and perianal skin	Ipsilateral inguinal
Leg	Ipsilateral inguinal and popliteal

There are **boundary zones between the subsites** (i.e., between the thorax and arm, the boundary zone is the shoulder and axilla). The boundary zones do not belong to either subsite. If a tumor originates in one of these 4 cm boundary zones, the nodes on either side of the bands are regional.

BETWEEN THE SUBSITES		THE BOUNDARY ZONE IS
Head and neck AND	Thorax	Clavícula-acromion-upper shoulder blade edge
Thorax AND	Arm	Shoulder-axilla-shoulder
Thorax AND	Abdomen, loins, and buttocks	Front: Middle between navel and costal arch Back: Lower border of thoracic vertebrae (midtransverse axis)
Abdomen, loins, and buttock AND	Leg	Groin-trochanter-gluteal sulcus
Right AND	Left	Midline

**Iliac, other pelvic, abdominal or intrathoracic lymph nodes are distant.** Code the removal of these nodes under the data item, Surgery of Other Regional Site(s), Distant Site(s), or Distant Node(s).

### Codes

- 0 No regional lymph nodes removed
- 1 Sentinel node, NOS

A sentinel node is the first node to receive drainage from a primary tumor. It is identified by an injection of a dye or radio label at the site of the primary tumor

- 2 Regional lymph nodes removed, NOS
- 9 Unknown; not stated; death certificate **only**

### Number of Regional Lymph Nodes Examined

#### Codes

- 00 No regional lymph nodes removed
- 01 One regional lymph node removed
- 02 Two regional lymph nodes removed
- ..
- 90 Ninety or more regional lymph nodes removed
- 95 No regional lymph nodes removed but aspiration of regional lymph nodes was performed
- 96 Regional lymph node removal documented as a sampling and number of lymph nodes unknown/not stated
- 97 Regional lymph node removal documented as dissection and number of lymph nodes unknown/not stated
- 98 Regional lymph nodes surgically removed but number of lymph nodes unknown/not stated and not documented as sampling or dissection
- 99 Unknown; not stated; death certificate **only**

### Surgery of Other Regional Site(s), Distant Sites(s), or Distant Lymph Nodes (s)

#### Codes

- 0 None; no surgery to other regional or distant sites
- 1 Surgery to other sites or nodes, NOS; unknown if regional or distant
  - 2 Other regional sites
  - 3 Distant lymph nodes
  - 4 Distant sites
  - 5 >Combination of 4 **with** 2 or 3
- 9 Unknown; not stated; death certificate **only**

**Reconstruction/Restoration - First Course  
Codes**

- 0 No reconstruction/restoration
- 1 Pedicle flap, free flap, skin graft, NOS
- 8 Reconstruction/restoration recommended, unknown if performed
- 9 Unknown; not stated; death certificate **only**

**Q1 Surgery Codes - SPLEEN & LYMPH NODES (For  
Cases Diagnosed prior to January 1, 2003)**

**Spleen C42.2**

**Lymph Nodes C77.0-C77.9**

**Surgical Approach**

**Codes**

- 0 None; no cancer directed surgery of primary site
- 1 Endoscopy, NOS
  - 2 Not image guided
  - 3 Image guided
- 4 Open, NOS
  - 5 Not assisted by endoscopy

- 6 Assisted by endoscopy
- 9 Unknown; not stated; death certificate **only**

## **Surgery of Primary Site**

### **Codes**

- 00 None; no cancer-directed surgery of primary site
- 10 Local excision, destruction, NOS
- 20 Splenectomy, NOS
  - 21 Partial splenectomy
  - 22 Total splenectomy
- 30 Lymph node dissection, NOS
  - 31 One chain
  - 32 Two or more chains
- 40 Lymph node dissection, NOS plus splenectomy
  - 41 One chain
  - 42 Two or more chains
- 50 Lymph node dissection, NOS and partial/total removal of adjacent organ(s)
  - 51 One chain
  - 52 Two or more chains
- 60 Lymph node dissection, NOS and partial/total removal of adjacent organ(s) **plus** splenectomy
  - 61 One chain
  - 62 Two or more chains
- 90 Surgery, NOS
- 99 Unknown if cancer-directed surgery performed; death certificate **only**



## Surgical Margins

### Codes

- 0 All margins grossly and microscopically negative
- 1 Margins involved, NOS
  - 2 Microscopic involvement
  - 5 Macroscopic involvement
- 7 Margins not documented
- 8 No cancer-directed surgery of primary site
- 9 Unknown whether margins were involved or negative; death certificate **only**

## Scope of Regional Lymph Node Surgery

**Note:** For primary sites C77.0-C77.9, code this field as 9.

### Codes

- 0 No regional lymph nodes removed
- 1 Regional lymph nodes removed, NOS
- 9 Unknown; not stated; death certificate **only**

## Number of Regional Lymph Nodes Examined

**Note: Spleen only.** For lymphomas, code this field to 99.

### Codes

- 00 No regional lymph nodes removed
- 01 One regional lymph node removed
- 02 Two regional lymph nodes removed
- ..
- Ninety or more regional lymph nodes removed
- 95 No regional lymph nodes removed but aspiration of regional lymph nodes was performed

- 96 Regional lymph node removal documented as a sampling and number of lymph nodes unknown/not stated
- 97 Regional lymph node removal documented as dissection and number of lymph nodes unknown/not stated
- 98 Regional lymph nodes surgically removed but number of lymph nodes unknown/not stated and not documented as sampling or dissection
- 99 Unknown; not stated; death certificate **only**

### **Surgery of Other Regional Site(s), Distant Sites(s), or Distant Lymph Nodes (s)**

#### **Codes**

- 0 None; no surgery to other regional or distant sites
- 1 Surgery to other sites or nodes, NOS; unknown if regional or distant
  - 2 Other regional sites
  - 5 Distant lymph nodes
  - 6 Distant sites
  - 7 Combination of 6 **with** 2 or 5
- 9 Unknown; not stated; death certificate **only**

### **Reconstruction/Restoration - First Course**

#### **Codes**

- 9 At this time, reconstructive procedures are not being collected for these sites

## Q1 Surgery Codes – SKIN (For Cases Diagnosed prior to January 1, 2003)

C44.0-C44.9

### Surgical Approach

#### Codes

- 0 None; no cancer-directed surgery of primary site
- 4 Open approach
- 9 Death certificate **only**

### Surgery of Primary Site

#### Codes

- 00 None; no cancer-directed surgery of primary site
- 10 Local tumor destruction, NOS (**without pathology specimen**)
  - 11 Photodynamic therapy (PDT)
  - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
  - 13 Cryosurgery
  - 14 Laser ablation

No specimen sent to pathology from this surgical event.

- 20 Local tumor excision, NOS (**with pathology specimen**)
  - 21 Photodynamic therapy (PDT)
  - 22 Electrocautery
  - 23 Cryosurgery
  - 24 Laser ablation
  - 25 Laser excision
  - 26 Polypectomy



27 Excisional biopsy

Specimen sent to pathology from this surgical event.

30 Biopsy of primary tumor followed by a gross excision of the lesion

31 Shave biopsy followed by a gross excision of the lesion

32 Punch biopsy followed by a gross excision of the lesion

33 Incisional biopsy followed by a gross excision of the lesion

Less than a wide excision, less than 1 cm margin.

40 Wide excision or reexcision of lesion or minor (local) amputation, NOS

Margins of excision are 1 cm or more. Margins may be microscopically involved. Local amputation is the surgical resection of digits, ear, eyelid, lip, or nose.

50 Radical excision of a lesion, NOS

Margins of excision are greater than 1 cm and grossly tumor free. The margins may be microscopically involved.

60 Major amputation, NOS

90 Surgery, NOS

99 Unknown if cancer-directed surgery performed; death certificate **only**

## Surgical Margins

### Codes

0 All margins grossly and microscopically negative

1 Margins involved, NOS

2 Microscopic involvement

- 5 Macroscopic involvement
- 7 Margins not documented
- 8 No cancer-directed surgery of primary site
- 9 Unknown whether margins were involved or negative; death certificate **only**

### Scope of Regional Lymph Node Surgery

Regional lymph nodes are different for each anatomical subsite.

Head, neck	Cervical, ipsilateral preauricular, submandibular, and supraclavicular
Thorax	Ipsilateral axillary
Arm	Ipsilateral epitrochlear and axillary
Abdomen, loins, and buttocks	Ipsilateral inguinal
Anal margin and perianal skin	Ipsilateral inguinal
Leg	Ipsilateral inguinal and popliteal

There are **boundary zones between the subsites** (i.e., between the thorax and arm, the boundary zone is the shoulder and axilla). The boundary zones do not belong to either subsite. If a tumor originates in one of these 4 cm boundary zones, the nodes on either side of the bands are regional.

BETWEEN THE SUBSITES		THE BOUNDARY ZONE IS
Head and neck AND	Thorax	Clavicle-acromion-upper shoulder blade edge
Thorax AND	Arm	Shoulder-axilla-shoulder
Thorax AND	Abdomen, loins, and buttocks	Front: Middle between navel and costal arch Back: Lower border of thoracic vertebrae (midtransverse axis)

Abdomen, loins, and buttock AND	Leg	Groin-trochanter-gluteal sulcus
Right AND	Left	Midline

**Iliac, other pelvic, abdominal or intrathoracic lymph nodes are distant.** Code the removal of these nodes under the data item, Surgery of Other Regional Site(s), Distant Site(s), or Distant Node(s).

**Codes**

- 0 No regional lymph nodes removed
- 1 Sentinel node, NOS

A sentinel node is the first node to receive drainage from a primary tumor. It is identified by an injection of a dye or radio label at the site of the primary tumor

- 2 Regional lymph nodes removed, NOS
- 9 Unknown; not stated; death certificate **only**

**Number of Regional Lymph Nodes Examined**

**Codes**

- 00 No regional lymph nodes removed
- 01 One regional lymph node removed
- 02 Two regional lymph nodes removed
- ..
- 90 Ninety or more regional lymph nodes removed
- 95 No regional lymph nodes removed but aspiration of regional lymph nodes was performed
- 96 Regional lymph node removal documented as a sampling and number of lymph nodes unknown/not stated
- 97 Regional lymph node removal documented as dissection and number of lymph nodes unknown/not stated
- 98 Regional lymph nodes surgically removed but number of lymph nodes unknown/not stated and not

documented as sampling or dissection

99 Unknown; not stated; death certificate **only**

### **Surgery of Other Regional Site(s), Distant Sites(s), or Distant Lymph Nodes (s)**

#### **Codes**

- 0 None; no surgery to other regional or distant sites
- 1 Surgery to other sites or nodes, NOS; unknown if regional or distant
  - 2 Other regional sites
  - 3 Distant lymph nodes
  - 4 Distant sites
  - 5 >Combination of 4 **with** 2 or 3
- 9 Unknown; not stated; death certificate **only**

### **Reconstruction/Restoration - First Course**

#### **Codes**

- 0 No reconstruction/restoration
- 1 Pedicle flap, free flap, skin graft, NOS
- 8 Reconstruction/restoration recommended, unknown if performed
- 9 Unknown; not stated; death certificate **only**

### **Q1 Surgery Codes – STOMACH (For Cases Diagnosed prior to January 1, 2003)**

#### **C16.0-C16.9**

#### **Surgical Approach**

#### **Codes**

- 0 None; no cancer-directed surgery of primary site

**Endoscopy procedures include:** Esophago-/gastro-/duodeno-

/jeuno-scopy; Gastroscopy; Laparoscopy.

- 1 Endoscopy, NOS
  - 2 Not image guided
  - 3 Image guided
- 4 Open, NOS
  - 5 Not assisted by endoscopy
  - 6 Assisted by endoscopy
- 9 Unknown; not stated; death certificate **only**

### **Surgery of Primary Site**

#### **Codes**

- 00 None; no cancer-directed surgery of primary site
- 10 Local tumor destruction, NOS (**without pathology specimen**)
  - 11 Photodynamic therapy (PDT)
  - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
  - 13 Cryosurgery
  - 14 Laser

No specimen sent to pathology from this surgical event.

- 20 Local tumor excision, NOS (**with pathology specimen**)
  - 21 Photodynamic therapy (PDT)
  - 22 Electrocautery
  - 23 Cryosurgery
  - 24 Laser ablation
  - 25 Laser excision

- 26 Polypectomy
- 27 Excisional biopsy

Specimen sent to pathology from this surgical event.

Code 30, partial gastrectomy, includes a sleeve resection of the stomach: Billroth I: anastomosis to duodenum (duodenostomy); Billroth II: anastomosis to jejunum (jejunostomy)

- 30 Gastrectomy, NOS (partial, subtotal, hemi-)
  - 31 Antrectomy, lower (distal)
    - Resection of less than 40% of stomach
  - 32 Lower (distal) gastrectomy (partial, subtotal, hemi-)
  - 33 Upper (proximal) gastrectomy (partial, subtotal, hemi-)
- 40 Near total or total gastrectomy
  - A total gastrectomy may follow a previous partial resection of the stomach.
- 50 Gastrectomy, NOS **with** removal of a portion of esophagus
  - 51 Partial or subtotal gastrectomy
  - 52 Near total or total gastrectomy
- 60 Gastrectomy **with** en bloc resection of other organs, NOS
  - 61 Partial or subtotal gastrectomy **with** en bloc resection
  - 62 Near total or total gastrectomy **with** en bloc resection (near total = 80% resection)
  - 63 Radical gastrectomy **with** en bloc resection

**En bloc resection** is the removal of organs in one piece at one time and may include an omentectomy.

- 80 Gastrectomy, NOS
- 90 Surgery, NOS
- 99 Unknown if cancer-directed surgery performed; death certificate **only**

## Surgical Margins

### Codes

- 0 All margins grossly and microscopically negative
- 1 Margins involved, NOS
  - 2 Microscopic involvement
  - 5 Macroscopic involvement
- 7 Margins not documented
- 8 No cancer-directed surgery of primary site
- 9 Unknown whether margins were involved or negative; death certificate **only**

## Scope of Regional Lymph Node Surgery

The regional lymph nodes are:	
Greater Curvature of Stomach	Gastroduodenal Gastroepiploic, left Gastroepiploic, right or NOS Greater omental Greater curvature Pancreaticoduodenal (anteriorly along the first part of duodenum) Pyloric, including subpyloric and infrapyloric
Pancreatic and Splenic Area:	Pancreaticolienal Peripancreatic Splenic hilum
Lesser Curvature of Stomach:	Cardioesophageal Celiac Common hepatic Hepatoduodenal Left gastric Lesser omental Lesser curvature Paracardial; cardial Perigastric, NOS



**Codes**

- 0 No regional lymph nodes removed
- 1 Regional lymph nodes removed, NOS
- 9 Unknown; not stated; death certificate **only**

**Number of Regional Lymph Nodes Examined**

**Codes**

- 00 No regional lymph nodes removed
- 01 One regional lymph node removed
- 02 Two regional lymph nodes removed
- ..
- 90 Ninety or more regional lymph nodes removed
- 95 No regional lymph nodes removed but aspiration of regional lymph nodes was performed
- 96 Regional lymph node removal documented as a sampling and number of lymph nodes unknown/not stated
- 97 Regional lymph node removal documented as dissection and number of lymph nodes unknown/not stated
- 98 Regional lymph nodes surgically removed but number of lymph nodes unknown/not stated and not documented as sampling or dissection
- 99 Unknown; not stated; death certificate **only**

**Surgery of Other Regional Site(s), Distant Sites(s), or Distant Lymph Nodes (s)**

**DO NOT CODE** the incidental removal of gallbladder, bile ducts, appendix, or vagus nerve. Incidental removal is when an organ is removed for a reason unrelated to the malignancy (gallbladder removed for obvious cholelithiasis)

**Codes**

- 0 None; no surgery to other regional or distant sites

- 1 Surgery to other sites or nodes, NOS; unknown if regional or distant
  - 2 Removal of other regional sites, **only**
  - 3 Removal of distant nodes
  - 4 Removal of distant site
  - 5 Combination of 2 **with** 3 and/or 4
- 9 Unknown; not stated; death certificate **only**

### **Reconstruction/Restoration - First Course Codes**

- 0 No reconstruction/restoration
- 1 Gastrostomy
  - 2 **without** reservoir/pouch
  - 3 **with** reservoir/pouch (abdominal)
- 9 Unknown; not stated; death certificate **only**

### **Q1 Surgery Codes – THYROID (For Cases Diagnosed prior to January 1, 2003)**

#### **C73.9**

### **Surgical Approach Codes**

- 0 None; no cancer-directed surgery of primary site
- 1 Endoscopy, NOS
  - 2 Not image guided
  - 3 Image guided
- 4 Open, NOS
  - 5 Not assisted by endoscopy
  - 6 Assisted by endoscopy

- 9 Unknown; not stated; death certificate **only**

## **Surgery of Primary Site**

### **Codes**

- 00 None; no cancer-directed surgery of primary site
- 10 Removal of less than a lobe, NOS
- 11 Local surgical excision
- 12 Removal of a partial lobe **only**
- 20 Lobectomy and/or isthmectomy
- 21 Lobectomy **only**
- 22 Isthmectomy **only**
- 23 Lobectomy **with** isthmus
- 30 Removal of a lobe and partial removal of the contralateral lobe
- 40 Subtotal or near total thyroidectomy
- 50 Total thyroidectomy
- 80 Thyroidectomy, NOS
- 90 Surgery, NOS
- 99 Unknown if cancer-directed surgery performed; death certificate **only**

## **Surgical Margins**

### **Codes**

- 0 All margins grossly and microscopically negative
- 1 Margins involved, NOS
- 2 Microscopic involvement
- 5 Macroscopic involvement
- 7 Margins not documented

- 8 No cancer-directed surgery of primary site
- 9 Unknown whether margins were involved or negative; death certificate **only**

## Scope of Regional Lymph Node Surgery

The regional lymph nodes are the cervical and upper mediastinal lymph nodes.

**Terminology of neck dissection** (Robbins et al. 19): A radical neck dissection includes the removal of all ipsilateral cervical lymph node groups, i.e., lymph nodes from levels I through V (submental, submandibular, cranial jugular, medial jugular, caudal jugular, dorsal cervical nodes along the accessory nerve, and supraclavicular), and removal of the spinal accessory nerve, internal jugular vein and sternocleidomastoid muscle. In a modified radical neck dissection the same lymph nodes are removed as in a radical neck dissection; however, one or more non lymphatic structures are preserved. A selective neck dissection is a neck dissection with preservation of one or more lymph nodes group routinely removed in radical neck dissection.

### Codes

- 0 No regional lymph nodes removed
- 1 Regional lymph nodes removed, NOS
- 2 Neck dissection, NOS
  - 3 Selective, limited; nodal sampling; "berry picking"
  - 4 Modified/modified radical
  - 5 Radical
- 9 Unknown; not stated; death certificate **only**

## Number of Regional Lymph Nodes Examined

### Codes

- 00 No regional lymph nodes removed
- 01 One regional lymph node removed
- 02 Two regional lymph nodes removed
- ..
- 90 Ninety or more regional lymph nodes removed
- 95 No regional lymph nodes removed but aspiration of regional lymph nodes was performed
- 96 Regional lymph node removal documented as a

sampling and number of lymph nodes unknown/not stated

- 97 Regional lymph node removal documented as dissection and number of lymph nodes unknown/not stated
- 98 Regional lymph nodes surgically removed but number of lymph nodes unknown/not stated and not documented as sampling or dissection
- 99 Unknown; not stated; death certificate **only**

### **Surgery of Other Regional Site(s), Distant Sites(s), or Distant Lymph Nodes (s)**

#### **Codes**

- 0 None; no surgery to other regional or distant sites
- 1 Surgery to other sites or nodes, NOS; unknown if regional or distant
  - 2 Other regional sites
  - 3 Distant lymph nodes
  - 4 Distant sites
  - 5 Combination of 4 **with** 2 or 3
- 9 Unknown; not stated; death certificate **only**

### **Reconstruction/Restoration - First Course**

#### **Codes**

- 9 Not applicable (There are no known reconstructive procedures for this site.)

## **Appendix Q1 Surgery Codes – TESTIS (For Cases Diagnosed prior to January 1, 2003)**

**C62.0-C62.9**

### **Surgical Approach**

#### **Codes**

- 0 None; no cancer-directed surgery of primary site

- 4 Open, NOS
- 5 Scrotal
- 6 Inguinal
- 9 Death certificate **only**

### **Surgery of Primary Site**

#### **Codes**

- 00 None; no cancer-directed surgery of primary site
- 10 Local or partial excision of testicle
- 30 Excision of testicle, NOS **without** cord
- 40 Excision of testicle, NOS **with** cord/or cord not mentioned
- 80 Orchiectomy, NOS
- 90 Surgery, NOS
- 99 Unknown if cancer-directed surgery performed; death certificate **only**

### **Surgical Margins**

#### **Codes**

- 0 All margins grossly and microscopically negative
- 1 Margins involved, NOS
  - 2 Microscopic involvement
  - 5 Macroscopic involvement
- 7 Margins not documented
- 8 No cancer directed surgery of primary site
- 9 Unknown whether margins were involved or negative; death certificate **only**

### **Scope of Regional Lymph Node Surgery**

**The regional lymph nodes are:**

Interaortocaval
Paraaortic (Periaortic)
Paracaval
Preaortic
Precaval
Retroaortic
Retrocaval

**Codes**

- 0 No regional lymph nodes removed
- 1 Regional lymph nodes removed, NOS; not stated if bilateral or unilateral
  - 2 Unilateral regional lymph nodes
  - 3 Bilateral regional lymph nodes
- 9 Unknown; not stated; death certificate **only**

**Number of Regional Lymph Nodes Examined**

**Codes**

- 00 No regional lymph nodes removed
- 01 One regional lymph node removed
- 02 Two regional lymph nodes removed
- ..
- 90 Ninety or more regional lymph nodes removed
- 95 No regional lymph nodes removed but aspiration of regional lymph nodes was performed
- 96 Regional lymph node removal documented as a sampling and number of lymph nodes unknown/not stated
- 97 Regional lymph node removal documented as dissection and number of lymph nodes unknown/not stated
- 98 Regional lymph nodes surgically removed but number of lymph nodes unknown/not stated and not documented as sampling or dissection
- 99 Unknown; not stated; death certificate **only**

**Surgery of Other Regional Site(s), Distant Sites(s), or Distant Lymph Nodes (s)**

**Codes**

- 0 None; no surgery to other regional or distant sites
- 1 Surgery to other sites or nodes, NOS; unknown if regional or distant



- 2 Other regional sites
- 3 Distant lymph nodes
- 4 Distant sites
- 5 Combination of 4 **with** 2 or 3
- 9 Unknown; not stated; death certificate **only**

### **Reconstruction/Restoration - First Course**

#### **Codes**

- 0 No reconstruction/restoration
- 1 Testicular implant
- 8 Reconstruction/restoration recommended, unknown if performed
- 9 Unknown; not stated; death certificate **only**

### **Q1 Surgery Codes - ALL OTHER SITES (For Cases Diagnosed prior to January 1, 2003)**

C14.1-C14.8, C17.0-C17.9, C23.9, C24.0-C24.9, C26.0-C26.9, C30.0-C30.1, C31.0-C31.9, C33.9, C37.9, C38.0-C38.8, C39.0-C39.9, C42.0-C42.1, C42.3-C42.4, C48.0-C48.8, C51.0-C51.9, C52.9, C57.0-C57.9, C58.9, C60.0-C60.9, C63.0-C63.9, C68.0-C69.9, C74.0-C76.8, C80.9

### **Surgical Approach**

#### **Codes**

- 0 None; no cancer-directed surgery of primary site
- 1 Endoscopy, NOS
  - 2 Not image guided
  - 3 Image guided
- 4 Open, NOS
  - 5 Not assisted by endoscopy
  - 6 Assisted by endoscopy
- 9 Unknown; not stated; death certificate **only**

## Surgery of Primary Site

### Codes

- 00 None; no cancer-directed surgery of primary site
- 10 Local tumor destruction, NOS (**without pathology specimen**)
  - 11 Photodynamic therapy (PDT)
  - 12 Electrocautery; fulguration
  - 13 Cryosurgery
  - 14 Laser

No specimen sent to pathology from this surgical event.

- 20 Local tumor excision, NOS (**with pathology specimen**)
  - 21 Photodynamic therapy (PDT)
  - 22 Electrocautery
  - 23 Cryosurgery
  - 24 Laser ablation
  - 25 Laser excision
  - 26 Polypectomy
  - 27 Excisional biopsy

Specimen sent to pathology from this surgical event.

- 30 Simple/partial surgical removal of primary site
- 40 Total surgical removal of primary site
- 50 Surgery stated to be "debulking"
- 60 Radical surgery

Partial or total removal of the primary site **with** an en bloc resection (partial or total removal) of other organs.

- 90 Surgery, NOS

- 99 Unknown if cancer-directed surgery performed; death certificate **only**

### **Surgical Margins**

#### **Codes**

- 0 All margins grossly and microscopically negative
- 1 Margins involved, NOS
- 2 Microscopic involvement
- 5 Macroscopic involvement
- 7 Margins not documented
- 8 No cancer-directed surgery of primary site
- 9 Unknown whether margins were involved or negative; death certificate **only**

### **Scope of Regional Lymph Node Surgery**

#### **Codes**

- 0 No regional lymph nodes removed
- 1 Regional lymph nodes removed, NOS
- 9 Unknown; not stated; death certificate **only**

### **Number of Regional Lymph Nodes Examined**

#### **Codes**

- 00 No regional lymph nodes removed
- 01 One regional lymph node removed
- 02 Two regional lymph nodes removed
- 90 Ninety or more regional lymph nodes removed
- 95 No regional lymph nodes removed but aspiration of regional lymph nodes was performed
- 96 Regional lymph node removal documented as a sampling and number of lymph nodes unknown/not stated
- 97 Regional lymph node removal documented as

dissection and number of lymph nodes unknown/not stated

- 98 Regional lymph nodes surgically removed but number of lymph nodes unknown/not stated and not documented as sampling or dissection
- 99 Unknown; not stated; death certificate **only**

### **Surgery of Other Regional Site(s), Distant Sites(s), or Distant Lymph Nodes (s)**

#### **Codes**

- 0 None; no surgery to other regional or distant sites
- 1 Surgery to other sites or nodes, NOS; unknown if regional or distant
  - 2 Other regional sites
  - 3 Distant lymph nodes
  - 4 Distant sites
  - 5 Combination of 4 **with** 2 or 3
- 9 Unknown; not stated; death certificate **only**

### **Reconstruction/Restoration - First Course**

#### **Codes**

- 9 At this time, reconstructive procedures are not being collected for these sites

## **Q2 FORDS SURGERY CODES**

### **Q2: ANUS (For Cases Diagnosed on or after January 1, 2003)**

#### **C21.0-C21.8**

(**Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, 9975-9992**)

#### **Codes**

- 00 *None; no surgery of primary site; autopsy ONLY*
- 10 *Local tumor destruction, NOS*

- 11 *Photodynamic therapy (PDT)*
- 12 *Electrocautery; fulguration (includes use of hot forceps for tumor destruction)*
- 13 *Cryosurgery*
- 14 *Laser*
- 15 *Thermal Ablation*

*No specimen sent to pathology from surgical events 10-15.*

- 20 *Local tumor excision, NOS*

- 26 *Polypectomy*
- 27 *Excisional biopsy*

*Any combination of 20 or 26-27 WITH*

*[SEER Guideline: the following codes INCLUDE local tumor excision, polypectomy or excisional biopsy]*

- 21 *Photodynamic therapy (PDT)*
- 22 *Electrocautery*
- 23 *Cryosurgery*
- 24 *Laser ablation*
- 25 *Laser excision*

*[SEER Guideline: margins of resection may have microscopic involvement]*

- 60 *Abdominal perineal resection, NOS (APR; Miles procedure)*

- 61 *APR and sentinel node excision*
- 62 *APR and unilateral inguinal lymph node dissection*
- 63 *APR and bilateral inguinal lymph node dissection*

*The lymph node dissection should also be coded under Scope of Regional Lymph Node Surgery or Scope of Regional Lymph Node Surgery at This Facility.*

*Specimen sent to pathology from surgical events 20-63.*

90 *Surgery, NOS*

99 *Unknown if surgery performed; death certificate ONLY*

## **Q2 BLADDER: (For Cases Diagnosed on or after January 1, 2003)**

**C67.0-C67.9**

**(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, 9975-9992)**

### **Codes**

00 None; no surgery of primary site; autopsy ONLY

10 Local tumor destruction, NOS

11 Photodynamic therapy (PDT)

12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)

13 Cryosurgery

14 Laser

15 Intravesical therapy

16 Bacillus Calmette-Guerin (BCG) or other immunotherapy

Clarification: Use code 16 if local tumor destruction occurs via the use of BCG and more extensive surgery is not performed. When BCG is administered via Intravesical Therapy, also use code 16. In addition, also code the item under "Immunotherapy" as code 01.

No specimen sent to pathology from surgical events 10-16.

20 Local tumor excision, NOS

26 Polypectomy

27 Excisional biopsy

Any combination of 20 or 26-27 WITH

[SEER Guideline: the following codes INCLUDE local tumor excision, polypectomy or excisional biopsy]

21 Photodynamic therapy (PDT)

22 Electrocautery

23 Cryosurgery

24 Laser ablation

25 Laser excision

30 Partial cystectomy

50 Simple/total/complete cystectomy

60 Radical cystectomy (male only)

[SEER Guideline: This code is used only for men. It involves removal of bladder and prostate, with or without urethrectomy. The procedure is also called cystoprostatectomy. If a radical cystectomy is the procedure for a woman, use code 71.]

61 Radical cystectomy PLUS ileal conduit

62 Radical cystectomy PLUS continent reservoir or pouch, NOS

63 Radical cystectomy PLUS abdominal pouch (cutaneous)

64 Radical cystectomy PLUS in situ pouch (orthotopic)

When the procedure is described as a pelvic exenteration for males, but the prostate is not removed, the surgery should be coded as a cystectomy (code 60-64).

70 Pelvic exenteration, NOS

71 Radical cystectomy (female only); anterior exenteration

For females, includes removal of bladder, uterus, ovaries, entire vaginal wall, and entire urethra. For males, includes removal of the prostate. When a procedure is described as a pelvic exenteration for males, but the prostate is not removed, the surgery should be coded as a cystectomy (code 60-64).

72 Posterior exenteration

For females, also includes removal of vagina, rectum and anus. For males, also includes prostate, rectum and anus.

73 Total exenteration

Includes all tissue and organs removed for an anterior and posterior exenteration.

The lymph node dissection should also be coded under Scope of Regional Lymph Node Surgery or Scope of Regional Lymph Node

Surgery at This Facility.

- 74 Extended exenteration  
Includes pelvic blood vessels or bony pelvis.
- 80 Cystectomy, NOS  
**Specimen sent to pathology from surgical events 20-80.**
- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

**Q2 BONES, PERIPHERAL NERVES and SOFT TISSUES  
(For Cases Diagnosed On or After January 1, 2003)**

BONES, JOINTS, AND ARTICULAR CARTILAGE C40.0-C41.9

PERIPHERAL NERVES AND AUTONOMIC NERVOUS SYSTEM C47.0-C47.9

CONNECTIVE, SUBCUTANEOUS, AND OTHER SOFT TISSUES C49.0-C49.9

**(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931,  
9945-9946, 9950-9967, 9975-9992)**

**Codes**

- 00 None; no surgery of primary site; autopsy ONLY
- 19 Local tumor destruction or excision, NOS [formerly SEER code 10 = local tumor destruction or excision]  
  
Unknown whether a specimen was sent to pathology for surgical events coded 19 (principally for cases diagnosed prior to January 1, 2003).
- 15 Local tumor destruction [formerly SEER code 10 = local tumor destruction or excision]  
  
No specimen sent to pathology from surgical event 15.
- 25 Local excision
- 26 Partial resection [formerly SEER code 20 = partial resection/internal hemipelvectomy (pelvis)]
- 30 Radical excision or resection of lesion WITH limb salvage
- 40 Amputation of limb
- 41 Partial amputation of limb



- 42 Total amputation of limb
- 50 Major amputation, NOS
  - 51 Forequarter, including scapula
  - 52 Hindquarter, including ilium/hip bone
  - 53 Hemipelvectomy, NOS
  - 54 Internal hemipelvectomy [formerly SEER code 20 = partial resection/internal hemipelvectomy (pelvis)]

Specimen sent to pathology from surgical events 25-54.

- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

## **Q2 BRAIN (For Cases Diagnosed on or after January 1, 2003)**

Meninges C70.0-C70.9, Brain C71.0-C71.9,

Spinal Cord, Cranial Nerves and Other Parts of Central Nervous System  
C72.0-C72.9

**(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, 9975-9992)**

Do not code laminectomies for spinal cord primaries.

Codes

- 00 None; no surgery of primary site; autopsy ONLY
- 10 [Local] Tumor destruction, NOS
  - No specimen sent to pathology from surgical event 10.
  - Do not record stereotactic radiosurgery (SRS), Gamma knife, Cyber knife, or Linac radiosurgery as surgical tumor destruction. All of these modalities are recorded in the radiation treatment fields.
- 20 Local excision (biopsy) of tumor, lesion or mass; excisional biopsy.
  - 21 Subtotal resection of tumor, lesion or mass in brain
  - 22 Resection of tumor of spinal cord or nerve
- 30 Radical, total, gross resection of tumor, lesion or mass in brain

- 40 Partial resection of lobe of brain, when surgery cannot be coded as 20-30.
- 55 Gross total resection of lobe of brain (lobectomy)  
  
Codes 30-55 are not applicable for spinal cord or spinal nerve primary sites.  
  
Specimen sent to pathology from surgical events 20-55.
- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

## **Appendix Q-2 BREAST (For Cases Diagnosed on or after January 1, 2003)**

C50.0-C50.9

**(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, 9975-9992)**

Codes

- 00 None; no surgery of primary site; autopsy ONLY
- 19 Local tumor destruction, NOS  
  
No specimen was sent to pathology for surgical events coded 19 (principally for cases diagnosed prior to January 1, 2003).
- 20 Partial mastectomy, NOS; less than total mastectomy, NOS [formerly SEER code 10]
  - 21 Partial mastectomy WITH nipple resection [formerly SEER code 11 = nipple resection]
  - 22 Lumpectomy or excisional biopsy [formerly SEER code 12]
  - 23 Reexcision of the biopsy site for gross or microscopic residual disease [formerly SEER code 13]
  - 24 Segmental mastectomy (including wedge resection, quadrantectomy, tylectomy) [formerly SEER codes 16 = segmental mastectomy, 14 = wedge resection, 15 = quadrantectomy, 17 = tylectomy]

Procedures coded 20-24 remove the gross primary tumor and some of the breast tissue (breast-conserving or preserving). There may be microscopic residual tumor.

30 Subcutaneous mastectomy

A subcutaneous mastectomy, also called a nipple sparing mastectomy, is the removal of breast tissue without the nipple and areolar complex or overlying skin. It is performed to facilitate immediate breast reconstruction. *Cases coded 30 may be considered to have undergone breast reconstruction.*

40 Total (simple) mastectomy, NOS

41 WITHOUT removal of uninvolved contralateral breast

43 Reconstruction NOS

44 Tissue

45 Implant

46 Combined (Tissue and Implant)

42 WITH removal of uninvolved contralateral breast

47 Reconstruction NOS

48 Tissue

49 Implant

75 Combined (Tissue and Implant)

A total (simple) mastectomy removes all breast tissue, the nipple, and areolar complex. An axillary dissection is not done, **but sentinel lymph nodes may be removed.**

For single primaries only, code removal of involved contralateral breast under the data item Surgical Procedure/Other Site or Surgical Procedure/Other Site at This Facility.

If contralateral breast reveals a second primary, each breast is abstracted separately. The surgical procedure is coded 41 for the first primary. The surgical code for the contralateral breast is coded to the procedure performed on that site.

Reconstruction that is planned as part of first course treatment is coded 43-49 or 75, whether it is done at the time of mastectomy or later.

50 Modified radical mastectomy

- 51 WITHOUT removal of uninvolved contralateral breast
- 53 Reconstruction, NOS
  - 54 Tissue
  - 55 Implant
  - 56 Combined (Tissue and Implant)
- 52 WITH removal of uninvolved contralateral breast
  - 57 Reconstruction, NOS
  - 58 Tissue
  - 59 Implant
  - 63 Combined (Tissue and Implant)

Removal of all breast tissue, the nipple, the areolar complex, and variable amounts of breast skin in continuity with the axilla. The specimen may or may not include a portion of the pectoralis major muscle.

[SEER Guideline: in continuity with or "en bloc" means that all of the tissues were removed during the same procedure, but not necessarily in a single specimen]

[SEER Guideline: "tissue" for reconstruction is defined as human tissue such as muscle (latissimus dorsi or rectus abdominis) or skin in contrast to artificial prostheses (implants).]

If contralateral breast reveals a second primary, it is abstracted separately. The surgical procedure is coded **41 or 51** for the first primary. The surgical code for the contralateral breast is coded to the procedure performed on that site.

For single primaries only, code removal of involved contralateral breast under the data item Surgical Procedure/Other Site or Surgical Procedure/Other Site at This Facility.

- 60 Radical mastectomy, NOS
  - 61 WITHOUT removal of uninvolved contralateral breast
    - 64 Reconstruction, NOS
    - 65 Tissue
    - 66 Implant

- 67 Combined (Tissue and Implant)
- 62 WITH removal of uninvolved contralateral breast
  - 68 Reconstruction, NOS
  - 69 Tissue
  - 73 Implant
  - 74 Combined (Tissue and Implant)

**76 *Bilateral mastectomy for a single tumor involving both breasts, as for bilateral inflammatory carcinoma.***

[SEER Guideline: Removal of breast tissue, nipple, areolar complex, variable amount of skin, pectoralis minor, pectoralis major. Includes en bloc axillary dissection. For single primaries only, code removal of involved contralateral breast under the data item "Surgery of other regional sites, distant sites, or distant lymph nodes."]

- 70 Extended radical mastectomy
  - 71 WITHOUT removal of uninvolved contralateral breast
  - 72 WITH removal of uninvolved contralateral breast

[SEER Guideline: Removal of breast tissue, nipple, areolar complex, variable amount of skin, pectoralis minor, pectoralis major. Includes removal of internal mammary nodes and en bloc axillary dissection. For single primaries only, code removal of involved contralateral breast under the data item "Surgery of other regional sites, distant sites, or distant lymph nodes."]

- 80 Mastectomy, NOS
  - Specimen sent to pathology for surgical events coded 20-80.
- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

**Q2 CERVIX UTERI (For Cases Diagnosed on or after January 1, 2003)**

**C53.0-C53.9**

**(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, 9975-9992)**

**For invasive cancers**, dilation and curettage is coded as an incisional biopsy (02) under the data item *Surgical Diagnostic and Staging Procedure*.

**Codes**

- 00 None; no surgery of primary site; autopsy ONLY
- 10 Local tumor destruction, NOS
  - 11 Photodynamic therapy (PDT)
  - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
  - 13 Cryosurgery
  - 14 Laser
  - 15 Loop Electrocautery Excision Procedure (LEEP)
  - 16 Laser ablation
  - 17 Thermal ablation

No specimen sent to pathology from surgical events 10-17.
- 20 Local tumor excision, NOS
  - 26 Excisional biopsy, NOS
  - 27 Cone biopsy
  - 24 Cone biopsy WITH gross excision of lesion
  - 29 Trachelectomy; removal of cervical stump; cervicectomy

Any combination of 20, 24, 26, 27 or 29 WITH

  - 21 Electrocautery
  - 22 Cryosurgery
  - 23 Laser ablation or excision
  - 25 Dilatation and curettage; endocervical curettage (for in situ only)
  - 28 Loop electrocautery excision procedure (LEEP)
- 30 Total hysterectomy (simple, pan-) WITHOUT removal of tubes and ovaries  
Total hysterectomy removes both the corpus and cervix uteri and may

- also include a portion of vaginal cuff.
- 40 Total hysterectomy (simple, pan-) WITH removal of tubes and/or ovary  
Total hysterectomy removes both the corpus and cervix uteri and may also include a portion of vaginal cuff.
- 50 Modified radical or extended hysterectomy; radical hysterectomy; extended radical hysterectomy
- 51 Modified radical hysterectomy
- 52 Extended hysterectomy
- 53 Radical hysterectomy; Wertheim procedure
- 54 Extended radical hysterectomy
- 60 Hysterectomy, NOS, WITH or WITHOUT removal of tubes and ovaries
- 61 WITHOUT removal of tubes and ovaries
- 62 WITH removal of tubes and ovaries
- 70 Pelvic exenteration
- 71 Anterior exenteration
- Includes bladder, distal ureters, and genital organs WITH their ligamentous attachments and pelvic lymph nodes.
- NOTE: Do not code removal of pelvic lymph nodes under Surgical Procedure/Other Site.
- 72 Posterior exenteration
- Includes rectum and rectosigmoid WITH ligamentous attachments and pelvic lymph nodes.
- NOTE: Do not code removal of pelvic lymph nodes under Surgical Procedure/Other Site.
- 73 Total exenteration
- Includes removal of all pelvic contents and pelvic lymph nodes.
- NOTE: Do not code removal of pelvic lymph nodes under Surgical Procedure/Other Site.
- 74 Extended exenteration
- Includes pelvic blood vessels or bony pelvis.

Specimen sent to pathology from surgical events 20-74.

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

## **Q2 COLON (For Cases Diagnosed on or after January 1, 2003)**

### **C18.0-C18.9**

(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, 9975-9992)

**Code** removal/surgical ablation of single or multiple liver metastases under the data item *Surgical Procedure/Other Site*.

### **Codes**

00 None; no surgery of primary site; autopsy ONLY

10 Local tumor destruction, NOS

11 Photodynamic therapy (PDT)

12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)

13 Cryosurgery

14 Laser

No specimen sent to pathology from surgical events 10-14.

20 Local tumor excision, NOS

27 Excisional biopsy

26 Polypectomy, NOS

28 Polypectomy-endoscopic

29 Polypectomy-surgical excision

Any combination of 20 or 26-29 WITH  
[SEER Guideline: the following codes INCLUDE local tumor excision, polypectomy (NOS, endoscopic or surgical excision) or excisional biopsy]

21 Photodynamic therapy (PDT)



California Cancer Reporting System Standards, Volume I

- 22 Electrocautery
- 23 Cryosurgery
- 24 Laser ablation
- 25 Laser excision
- 30 Partial colectomy, segmental resection
  - 32 Plus resection of contiguous organ; example: small bowel, bladder
- [SEER Guideline: codes 30-32 include but are not limited to: appendectomy (for an appendix primary only), enterocolectomy, ileocolectomy, partial colectomy, NOS, partial resection of transverse colon and flexures, segmental resection, e.g., cecectomy, sigmoidectomy]
- 40 Subtotal colectomy/hemicolectomy (total right or left colon and a portion of transverse colon)
  - 41 Plus resection of contiguous organ; example: small bowel, bladder
- 50 Total colectomy (removal of colon from cecum to the rectosigmoid junction; may include a portion of the rectum)
  - 51 Plus resection of contiguous organ; example: small bowel, bladder
- 60 Total proctocolectomy (removal of colon from cecum to the rectosigmoid junction, including the entire rectum)  
[SEER Guideline: commonly used for familial polyposis or polyposis coli]
  - 61 Plus resection of contiguous organ; example: small bowel, bladder
- 70 Colectomy or coloproctectomy with resection of contiguous organ(s), NOS (where there is not enough information to code 32, 41, 51, or 61)

Code 70 includes: Any colectomy (partial, hemicolectomy, or total) WITH a resection of any other organs in continuity with the primary site. Other organs may be partially or totally removed. Other organs may include, but are not limited to, oophorectomy, partial proctectomy, rectal mucosectomy, or pelvic exenteration.

[SEER Guideline: in continuity with or "en bloc" means that all of the tissues were removed during the same procedure, but not necessarily

in a single specimen]

80 Colectomy, NOS

Specimen sent to pathology from surgical events 20-80.

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

## **Q2 CORPUS UTERI (For Cases Diagnosed on or after January 1, 2003)**

**C54.0-C55.9**

**(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, 9975-9992)**

**For invasive cancers**, dilation and curettage is coded as an incisional biopsy (02) under the data item *Surgical Diagnostic and Staging Procedure*.

### **Codes**

00 None; no surgery of primary site; autopsy ONLY

19 Local tumor destruction or excision, NOS

Unknown whether a specimen was sent to pathology for surgical events coded 19 (principally for cases diagnosed prior to January 1, 2003).

10 Local tumor destruction, NOS

11 Photodynamic therapy (PDT)

12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)

13 Cryosurgery

14 Laser

15 Loop Electocautery Excision Procedure (LEEP)

16 Thermal ablation

No specimen sent to pathology from surgical events 10-16.

20 Local tumor excision, NOS; simple excision, NOS

24 Excisional biopsy

25 Polypectomy

26 Myomectomy

Any combination of 20 or 24-26 WITH  
[SEER Guideline: the following codes INCLUDE local tumor excision, polypectomy or excisional biopsy]

- 21 Electrocautery
- 22 Cryosurgery
- 23 Laser ablation or excision

[Margins of resection may have microscopic involvement]  
[SEER Guideline: Procedures in code 20 include but are not limited to: cryosurgery, electrocautery, excisional biopsy, laser ablation, thermal ablation]

30 Subtotal hysterectomy/supracervical hysterectomy/fundectomy WITH or WITHOUT removal of tube(s) and ovary(ies).

- 31 WITHOUT tube(s) and ovary(ies)
- 32 WITH tube(s) and ovary(ies)

[SEER Guideline: for these procedures, the cervix is left in place.]

40 Total hysterectomy (simple, pan-) WITHOUT removal of tube(s) and ovary(ies)

Removes both the corpus and cervix uteri. It may also include a portion of the vaginal cuff.

50 Total hysterectomy (simple, pan-) WITH removal of tube(s) and/or ovary(ies)

Removes both the corpus and cervix uteri. It may also include a portion of the vaginal cuff.

60 Modified radical or extended hysterectomy; radical hysterectomy; extended radical hysterectomy

- 61 Modified radical hysterectomy
- 62 Extended hysterectomy
- 63 Radical hysterectomy; Wertheim procedure
- 64 Extended radical hysterectomy

65 Hysterectomy, NOS, WITH or WITHOUT removal of tube(s) and ovary(ies) [formerly SEER code 70]

- 66 WITHOUT removal of tube(s) and ovary(ies) [formerly SEER code 71]

- 67 WITH removal of tube(s) and ovary(ies) [formerly SEER code 72]
- 75 Pelvic exenteration [formerly SEER code 80]
- 76 Anterior exenteration [formerly SEER code 81]
- Includes bladder, distal ureters, and genital organs WITH their ligamentous attachments and pelvic lymph nodes.
- NOTE: Do not code removal of pelvic lymph nodes under Surgical Procedure/Other Site.**
- 77 Posterior exenteration [formerly SEER code 82]
- Includes rectum and rectosigmoid WITH ligamentous attachments and pelvic lymph nodes.
- NOTE: Do not code removal of pelvic lymph nodes under Surgical Procedure/Other Site.**
- 78 Total exenteration [formerly SEER code 83]
- Includes removal of all pelvic contents and pelvic lymph nodes.
- NOTE: Do not code removal of pelvic lymph nodes under Surgical Procedure/Other Site.**
- 79 Extended exenteration [formerly SEER code 84] Includes pelvic blood vessels or bony pelvis.
- Specimen sent to pathology from surgical events 20-79.**
- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

## **Q2 ESOPHAGUS (For Cases Diagnosed on or after January 1, 2003)**

### **C15.0-C15.9**

**(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, 9975-9992)**

### **Codes**

- 00 None; no surgery of primary site; autopsy ONLY
- 10 Local tumor destruction, NOS
- 11 Photodynamic therapy (PDT)

California Cancer Reporting System Standards, Volume I

12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)

13 Cryosurgery

14 Laser

No specimen sent to pathology from surgical events 10-14.

20 Local tumor excision, NOS

26 Polypectomy

27 Excisional biopsy

Any combination of 20 or 26-27 WITH  
[SEER Guideline: the following codes INCLUDE local tumor excision, polypectomy or excisional biopsy]

21 Photodynamic therapy (PDT)

22 Electrocautery

23 Cryosurgery

24 Laser ablation

25 Laser excision

30 Partial esophagectomy

40 Total esophagectomy, NOS

50 Esophagectomy, NOS WITH laryngectomy and/or gastrectomy, NOS  
[SEER Guideline: esophagectomy may be partial, total, or NOS]

51 WITH laryngectomy

52 WITH gastrectomy, NOS

53 Partial gastrectomy

54 Total gastrectomy

55 Combination of 51 WITH any of 5254

80 Esophagectomy, NOS

Specimen sent to pathology from surgical events 20-80.

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

## **Q2 HEMATOPOIETIC/ RETICULOENDOTHELIAL/ IMMUNOPROLIFERATIVE/ MYELOPROLIFERATIVE DISEASE (For Cases Diagnosed on or after January 1, 2003)**

**C42.0, C42.1, C42.3, C42.4 for all histologies**

**Or**

**M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946,  
9950-9967, 9975-9992 for all sites**

### **Codes**

- 9 All
- 8 hematopoietic/reticuloendothelial/immunoproliferative/myeloproliferative disease sites and/or histologies, WITH or WITHOUT surgical treatment.

Surgical procedures for hematopoietic/reticuloendothelial/immunoproliferative/myeloproliferative primaries are to be recorded using the data item Surgical Procedure/Other Site or Surgical Procedure/Other Site at this Facility.

- 9 Death certificate only (*For CCR use only*)

9

NOTE: A hematopoietic case not otherwise specified in the list of standard exclusions (M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, 9975-9992) in the Surgery Code Appendix Q should be treated as an Unknown And III-Defined Primary Site.

## **Q2 KIDNEY, RENAL, PELVIS, and URETER (For Cases Diagnosed on or after January 1, 2003)**

**Kidney C64.9, Renal Pelvis C65.9, Ureter C66.9**

**(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931,  
9945-9946, 9950-9967, 9975-9992)**

### **Codes**

- 00 None; no surgery of primary site; autopsy ONLY
- 10 Local tumor destruction, NOS
  - 11 Photodynamic therapy (PDT)
  - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)

13 Cryosurgery

14 Laser

15 Thermal ablation

No specimen sent to pathology from this surgical event 10-15.

20 Local tumor excision, NOS

26 Polypectomy

27 Excisional biopsy

Any combination of 20 or 26-27 WITH  
[SEER Guideline: the following codes INCLUDE local tumor excision,  
polypectomy or excisional biopsy]

21 Photodynamic therapy (PDT)

22 Electrocautery

23 Cryosurgery

24 Laser ablation

25 Laser excision

30 Partial or subtotal nephrectomy (kidney or renal pelvis) or partial  
ureterectomy (ureter)

Procedures coded 30 include, but are not limited to:

Segmental resection

Wedge resection

40 Complete/total/simple nephrectomy for kidney parenchyma

Nephroureterectomy

Includes bladder cuff for renal pelvis or ureter.

50 Radical nephrectomy

May include removal of a portion of vena cava, adrenal gland(s),  
Gerota's fascia, perinephric fat, or partial/total ureter.

70 Any nephrectomy (simple, subtotal, complete, partial, simple, total,  
radical) in continuity with the resection of other organ(s) (colon,  
bladder)

The other organs, such as colon or bladder, may be partially or totally  
removed.

[SEER Guideline: in continuity with or "en bloc" means that all of the  
tissues were removed during the same procedure, but not necessarily  
in a single specimen]

- 80 Nephrectomy, NOS  
Ureterectomy, NOS  
Specimen sent to pathology from surgical events 20-80.
- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

## **Q2 Larynx (For Cases Diagnosed on or after January 1, 2003)**

### **C32.0-C32.9**

**(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, 9975-9992)**

#### **Codes**

- 00 None; no surgery of primary site; autopsy ONLY
- 10 Local tumor destruction, NOS
  - 11 Photodynamic therapy (PDT)
  - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
  - 13 Cryosurgery
  - 14 Laser
  - 15 Stripping

No specimen sent to pathology from surgical events 10-15.

- 20 Local tumor excision, NOS
  - 26 Polypectomy
  - 27 Excisional biopsy

Any combination of 20 or 26-27 WITH  
[SEER Guideline: the following codes INCLUDE local tumor excision, polypectomy or excisional biopsy]

- 21 Photodynamic therapy (PDT)
- 22 Electrocautery
- 23 Cryosurgery
- 24 Laser ablation



- 25 Laser excision
- 28 Stripping
- 30 Partial excision of the primary site, NOS; subtotal/partial laryngectomy NOS; hemilaryngectomy NOS
- 31 Vertical laryngectomy
- 32 Anterior commissure laryngectomy
- 33 Supraglottic laryngectomy
- 40 Total or radical laryngectomy, NOS
- 41 Total laryngectomy ONLY
- 42 Radical laryngectomy ONLY
- 50 Pharyngolaryngectomy
- 80 Laryngectomy, NOS
- Specimen sent to pathology from surgical events 20-80.
- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

## **Q2 LIVER AND INTRAHEPATIC BILE DUCTS (For Cases Diagnosed on or after January 1, 2003)**

### **C22.0-C22.1**

**(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, 9975-9992)**

#### **Codes**

- 00 None; no surgery of primary site; autopsy ONLY
- 10 Local tumor destruction, NOS
- 11 Photodynamic therapy (PDT)
- 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
- 13 Cryosurgery
- 14 Laser

California Cancer Reporting System Standards, Volume I

15 Alcohol (Percutaneous Ethanol Injection-PEI)

16 Heat-Radio-frequency ablation (RFA)

17 Other (ultrasound, acetic acid)

No specimen sent to pathology from surgical events 10-17.

*1/2008: Chemoembolization should only be coded in the Chemotherapy field. Do not code this in the surgery fields.*

20 Wedge or segmental resection, NOS

21 Wedge resection

22 Segmental resection, NOS

23 One

24 Two

25 Three

26 Segmental resection AND local tumor destruction

30 Lobectomy, [simple or] NOS

36 Right lobectomy

37 Left lobectomy

38 Lobectomy AND local tumor destruction

50 Extended lobectomy, NOS (extended: resection of a single lobe plus a segment of another lobe)

51 Right lobectomy

52 Left lobectomy

59 Extended lobectomy AND local tumor destruction

60 Hepatectomy, NOS [formerly SEER code 80]

61 Total hepatectomy and transplant [formerly SEER code 70]

65 Excision of a bile duct (for an intra-hepatic bile duct primary only) [formerly SEER code 40]

66 Excision of ***an intrahepatic bile*** duct PLUS partial hepatectomy

75 **Extrahepatic bile** duct and hepatectomy WITH transplant

Specimen sent to pathology from surgical events 20-75.

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

## **Q2 LUNG (For Cases Diagnosed on or after January 1, 2003)**

### **C34.0-C34.9**

(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, 9975-9992)

#### **Codes**

00 None; no surgery of primary site; autopsy ONLY

19 Local tumor destruction or excision, NOS [formerly SEER code 10]  
Unknown whether a specimen was sent to pathology for surgical events coded 19 (principally for cases diagnosed prior to January 1, 2003).

15 Local tumor destruction, NOS

12 Laser ablation or cryosurgery [formerly SEER code 12 = laser ablation or excision]

13 Electrocautery; fulguration (includes use of hot forceps for tumor destruction) [formerly SEER code 13 = cautery; fulguration]

No specimen sent to pathology from surgical events 12-13 and 15.

20 Excision or resection of less than one lobe, NOS

23 Excision, NOS [formerly SEER code 11 = Excision]

24 Laser excision [formerly SEER code 12 = laser ablation or excision]

25 Bronchial sleeve resection ONLY [formerly SEER code 14]

21 Wedge resection

22 Segmental resection, including lingulectomy

30 Resection of [at least one] lobe or bilobectomy, but less than the whole lung (partial pneumonectomy, NOS)

33 Lobectomy WITH mediastinal lymph node dissection

The lymph node dissection should also be coded under Scope of Regional Lymph Node Surgery or Scope of Regional Lymph Node Surgery at This Facility.

45 Lobe or bilobectomy extended, NOS

46 WITH chest wall

47 WITH pericardium

48 WITH diaphragm

55 Pneumonectomy, NOS [formerly SEER codes 40, 50, 51, 52, 53, 54]

56 WITH mediastinal lymph node dissection (radical pneumonectomy)

The lymph node dissection should also be coded under Scope of Regional Lymph Node Surgery or Scope of Regional Lymph Node Surgery at This Facility.

NOTE: Peribronchial or hilar lymph nodes are not included in any of the lung surgery codes. If peribronchial or hilar nodes are dissected as part of a surgical procedure which involves the destruction, excision or resection of the primary tumor then the extent of the nodal dissection is recorded in the item "Scope of Regional Lymph Node Surgery" and the number of nodes dissected is recorded as part of the cumulative Regional Lymph Nodes Examined."

65 Extended pneumonectomy

66 Extended pneumonectomy plus pleura or diaphragm

70 Extended radical pneumonectomy

[SEER Guideline: an extended radical pneumonectomy is a radical pneumonectomy (including removal of mediastinal nodes) and the removal of other tissues or nodes]

The lymph node dissection should also be coded under Scope of Regional Lymph Node Surgery or Scope of Regional Lymph Node Surgery at This Facility.

NOTE: Peribronchial or hilar lymph nodes are not included in any of the lung surgery codes. If peribronchial or hilar nodes are dissected as part of a surgical procedure which involves the destruction, excision or resection of the primary tumor then the extent of the nodal dissection is recorded in the item "Scope of Regional Lymph Node Surgery" and the number of nodes dissected is recorded as part of the cumulative "Regional Lymph Nodes Examined."

80 Resection of lung, NOS

Specimen sent to pathology from surgical events 20-80.

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

## **Q2 LYMPH NODES (For Cases Diagnosed on or after January 1, 2003)**

### **Lymph Nodes C77.0-C77.9**

**(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, 9975-9992)**

#### **Codes**

00 None; no surgery of primary site; autopsy ONLY

19 Local tumor destruction or excision, NOS [formerly SEER code 10 under spleen and lymph nodes]

**Unknown whether a specimen was sent to pathology for surgical events coded to 19** (principally for cases diagnosed prior to January 1, 2003).

15 Local tumor destruction, NOS

No specimen sent to pathology from surgical event 15.

25 Local tumor excision, NOS

Less than a full chain, includes an excisional biopsy of a single lymph node.

30 Lymph node dissection, NOS

31 One chain

32 Two or more chains

40 Lymph node dissection, NOS PLUS splenectomy

41 One chain

42 Two or more chains

50 Lymph node dissection, NOS and partial/total removal of adjacent organ(s)

51 One chain

52 Two or more chains

60 Lymph node dissection, NOS and partial/total removal of adjacent organ(s) PLUS splenectomy (Includes staging laparotomy for lymphoma.)

61 One chain

62 Two or more chains

Specimen sent to pathology for surgical events 25-62.

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

## **Q2 ORAL CAVITY (For Cases Diagnosed on or after January 1, 2003)**

**Lip C00.0-C00.9, Base of Tongue C01.9, Other Parts of Tongue C02.0-C02.9, Gum C03.0-C03.9, Floor of Mouth C04.0-C04.9, Palate C05.0-C05.9, Other Parts of Mouth C06.0-C06.9**

**(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, 9975-9992)**

### **Codes**

00 None; no surgery of primary site; autopsy ONLY

10 Local tumor destruction, NOS

11 Photodynamic therapy (PDT)

12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)

13 Cryosurgery

14 Laser

No specimen sent to pathology from surgical events 10-14.

20 Local tumor excision, NOS

26 Polypectomy

27 Excisional biopsy

Any combination of 20 or 26-27 WITH

[SEER Guideline: the following codes INCLUDE local tumor excision, polypectomy or excisional biopsy]

21 Photodynamic therapy (PDT)

22 Electrocautery

23 Cryosurgery

24 Laser ablation

25 Laser excision

[SEER Guideline: Codes 20-27 include shave and wedge resection]

30 Wide excision, NOS

Code 30 includes:

Hemiglossectomy

Partial glossectomy

40 Radical excision of tumor, NOS

41 Radical excision of tumor ONLY

42 Combination of 41 WITH resection in continuity with mandible  
(marginal, segmental, hemi-, or total resection)

43 Combination of 41 WITH resection in continuity with maxilla  
(partial, subtotal, or total resection)

[SEER Guideline: in continuity with or "en bloc" means that all of the  
tissues were removed during the same procedure, but not necessarily  
in a single specimen]

Codes 40-43 include:

Total glossectomy

Radical glossectomy

Specimen sent to pathology from surgical events 20-43.

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

## **Q2 OVARY (For Cases Diagnosed on or after January 1, 2003)**

### **C56.9**

**(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, 9975-9992)**

### **Codes**

- 00 None; no surgery of primary site; autopsy ONLY
- 17 Local tumor destruction, NOS  
No specimen sent to pathology from surgical event 17.
- 25 Total removal of tumor or (single) ovary, NOS
  - 26 Resection of ovary (wedge, subtotal, or partial) ONLY, NOS; unknown if hysterectomy done
  - 27 WITHOUT hysterectomy
  - 28 WITH hysterectomySpecimen sent to pathology from surgical events 25-28.
- 35 Unilateral (salpingo-)oophorectomy; unknown if hysterectomy done [formerly SEER code 14]
  - 36 WITHOUT hysterectomy [formerly SEER code 15]
  - 37 WITH hysterectomy [formerly SEER code 16]
- 50 Bilateral (salpingo-)oophorectomy; unknown if hysterectomy done [formerly SEER code 20]
  - 51 WITHOUT hysterectomy [formerly SEER code 21]
  - 52 WITH hysterectomy [formerly SEER code 22]
- 55 Unilateral or bilateral (salpingo-)oophorectomy WITH OMENTECTOMY, NOS; partial or total; unknown if hysterectomy done [formerly SEER code 30]
  - 56 WITHOUT hysterectomy [formerly SEER code 31]
  - 57 WITH hysterectomy [formerly SEER code 32]
- 60 Debulking; cytoreductive surgery, NOS
  - 61 WITH colon (including appendix) and/or small intestine resection (not incidental)



62 WITH partial resection of urinary tract (not incidental)

63 Combination of 61 and 62

Debulking is a partial or total removal of the tumor mass and can involve the removal of multiple organ sites. It may include removal of ovaries and/or the uterus (a hysterectomy). The pathology report may or may not identify ovarian tissue. A debulking is usually followed by another treatment modality such as chemotherapy.

70 Pelvic exenteration, NOS

71 Anterior exenteration

Includes bladder, distal ureters, and genital organs WITH their ligamentous attachments and pelvic lymph nodes.

**NOTE: Do not code removal of pelvic lymph nodes under Surgical Procedure/Other Site.**

72 Posterior exenteration

Includes rectum and rectosigmoid WITH ligamentous attachments and pelvic lymph nodes.

**NOTE: Do not code removal of pelvic lymph nodes under Surgical Procedure/Other Site.**

73 Total exenteration

Includes removal of all pelvic contents and pelvic lymph nodes.

**NOTE: Do not code removal of pelvic lymph nodes under Surgical Procedure/Other Site.**

74 Extended exenteration

Includes pelvic blood vessels or bony pelvis.

80 (Salpingo-)oophorectomy, NOS

Specimen sent to pathology from surgical events 25-80.

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

## **Q2 PANCREAS (For Cases Diagnosed on or after January 1, 2003)**

### **C25.0-C25.9**

**(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, 9975-9992)**

#### **Codes**

- 00 None; no surgery of primary site; autopsy ONLY
- 25 Local excision of tumor, NOS [formerly SEER code 10]
- 30 Partial pancreatectomy, NOS; example: distal [formerly SEER code 20]
- 35 Local or partial pancreatectomy and duodenectomy [formerly SEER code 50]
  - 36 WITHOUT distal/partial gastrectomy [formerly SEER code 51 "without subtotal gastrectomy"]
  - 37 WITH partial gastrectomy (Whipple) [formerly SEER code 52 "with subtotal gastrectomy (Whipple)"]
- 40 Total pancreatectomy
- 60 Total pancreatectomy and subtotal gastrectomy or duodenectomy
- 70 Extended pancreatoduodenectomy
- 80 Pancreatectomy, NOS
- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

## **Q2 PAROTID and OTHER UNSPECIFIED Glands (For Cases Diagnosed on or after January 1, 2003)**

### **Parotid Gland C07.9, Major Salivary Glands C08.0-C08.9**

**(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, 9975-9992)**

#### **Codes**

- 00 None; no surgery of primary site; autopsy ONLY
- 10 Local tumor destruction, NOS
  - 11 Photodynamic therapy (PDT)

California Cancer Reporting System Standards, Volume I

- 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
  - 13 Cryosurgery
  - 14 Laser
- No specimen sent to pathology from surgical events 10-14.
- 20 Local tumor excision, NOS
    - 26 Polypectomy
    - 27 Excisional biopsy
- Any combination of 20 or 26-27 WITH  
[SEER Guideline: the following codes INCLUDE local tumor excision, polypectomy or excisional biopsy]
- 21 Photodynamic therapy (PDT)
  - 22 Electrocautery
  - 23 Cryosurgery
  - 24 Laser ablation
- 25 Laser excision
- 30 Less than total parotidectomy, NOS; less than total removal of major salivary gland, NOS
    - 31 Facial nerve spared
    - 32 Facial nerve sacrificed
  - 33 Superficial lobe ONLY
    - 34 Facial nerve spared
    - 35 Facial nerve sacrificed
  - 36 Deep lobe (Total)  
[SEER Guideline: with or without superficial lobe]
    - 37 Facial nerve spared
    - 38 Facial nerve sacrificed
- 40 Total parotidectomy, NOS; total removal of major salivary gland, NOS
    - 41 Facial nerve spared

- 42 Facial nerve sacrificed
- 50 Radical parotidectomy, NOS; radical removal of major salivary gland, NOS
  - 51 WITHOUT removal of temporal bone
  - 52 WITH removal of temporal bone
  - 53 WITH removal of overlying skin (requires graft or flap coverage)
- 80 Parotidectomy, NOS  
Specimen sent to pathology from surgical events 20-80.
- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

## **Q2 PHARYNX (For Cases Diagnosed on or after January 1, 2003)**

**Tonsil C09.0-C09.9, Oropharynx C10.0-C10.9, Nasopharynx C11.0-C11.9, Pyriform Sinus C12.9, Hypopharynx C13.0-C13.9, Pharynx C14.0**

**(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, 9975-9992)**

### **Codes**

- 00 None; no surgery of primary site; autopsy ONLY
- 10 Local tumor destruction, NOS
  - 11 Photodynamic therapy (PDT)
  - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
  - 13 Cryosurgery
  - 14 Laser
  - 15 StrippingNo specimen sent to pathology from surgical events 10-15.
- 20 Local tumor excision, NOS
  - 26 Polypectomy

27 Excisional biopsy

Any combination of 20 or 26-27 WITH  
[SEER Guideline: the following codes INCLUDE local tumor excision,  
polypectomy or excisional biopsy]

21 Photodynamic therapy (PDT)

22 Electrocautery

23 Cryosurgery

24 Laser ablation

25 Laser excision

28 Stripping

30 Pharyngectomy, NOS

31 Limited/partial pharyngectomy; tonsillectomy, bilateral  
tonsillectomy

32 Total pharyngectomy

40 Pharyngectomy WITH laryngectomy OR removal of contiguous bone  
tissue, NOS (does NOT include total mandibular resection)

[SEER Guideline: code 40 includes mandibulectomy (marginal,  
segmental, hemi-, and/or laryngectomy) NOS]

[SEER Guideline: contiguous bone tissue refers to the mandible]

41 WITH Laryngectomy (laryngopharyngectomy)

42 WITH bone

43 WITH both 41 and 42

50 Radical pharyngectomy (includes total mandibular resection), NOS

51 WITHOUT laryngectomy

52 WITH laryngectomy

Specimen sent to pathology from surgical events 20-52.

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

## Q2 PROSTATE (For Cases Diagnosed on or after January 1, 2003)

### C61.9

(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, 9975-9992)

*Do not code an orchiectomy in this field. For prostate primaries, orchiectomies are coded in the data item Hematologic Transplant and Endocrine Procedures.*

### Codes

- 00 None; no surgery of primary site; autopsy ONLY
- 18 Local tumor destruction or excision, NOS [formerly SEER code 10]
- 19 Transurethral resection (TURP), NOS, **and no specimen sent to pathology or unknown if sent** [formerly SEER code 11]  
  
Unknown whether a specimen was sent to pathology for surgical events coded 18 or 19 (principally for cases diagnosed prior to January 1, 2003).
- 10 Local tumor destruction, [or excision] NOS
  - 14 Cryoprostatectomy
  - 15 Laser ablation
  - 16 Hyperthermia
  - 17 Other method of local tumor destructionNo specimen sent to pathology from surgical events 10-17.
- 20 Local tumor excision, NOS [formerly SEER code 10 = local tumor destruction or excision, NOS]
  - 21 Transurethral resection (TURP), NOS, **with specimen sent to pathology** [formerly SEER code 11 = transurethral resection (TURP) NOS]
  - 22 TURPcancer is incidental finding during surgery for benign disease [formerly SEER code 12]
  - 23 TURPpatient has suspected/known cancer [SEER code 13]Any combination of 20-23 WITH
  - 24 Cryosurgery

25 Laser

26 Hyperthermia

Specimen sent to pathology from surgical events 20-26.

30 Subtotal, segmental, or simple prostatectomy, which may leave all or part of the capsule intact

50 Radical prostatectomy, NOS; total prostatectomy, NOS [formerly SEER code 30 or 40]

Excised prostate, prostatic capsule, ejaculatory ducts, seminal vesicle(s) and may include a narrow cuff of bladder neck.

70 Prostatectomy WITH resection in continuity with other organs; pelvic exenteration

Surgeries coded 70 are any prostatectomy WITH resection in continuity with any other organs. The other organs may be partially or totally removed. Procedures may include, but are not limited to, cystoprostatectomy, radical cystectomy, and prostatectomy.

[SEER Guideline: in continuity with or en bloc means that all of the tissues were removed during the same procedure, but not necessarily in a single specimen]

80 Prostatectomy, NOS

Specimen sent to pathology from surgical events 20-80.

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

## **Q2 RECTOSIGMOID (For Cases Diagnosed on or after January 1, 2003)**

### **C19.9**

**(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, 9975-9992)**

**Code removal/surgical ablation of single or multiple liver metastases under the data item *Surgical Procedure/Other Site*.**

### **Codes**

00 None; no surgery of primary site; autopsy ONLY

10 Local tumor destruction, NOS

11 Photodynamic therapy (PDT)

12 Electrocautery; fulguration (includes use of hot forceps for tumor

destruction)

13 Cryosurgery

14 Laser ablation

No specimen sent to pathology from surgical events 10-14.

20 Local tumor excision, NOS

26 Polypectomy

27 Excisional biopsy

Any combination of 20 or 26-27 WITH  
[SEER Guideline: the following codes INCLUDE local tumor excision,  
polypectomy or excisional biopsy]

21 Photodynamic therapy (PDT)

22 Electrocautery

23 Cryosurgery

24 Laser ablation

25 Laser excision

30 Wedge or segmental resection; partial proctosigmoidectomy, NOS

31 Plus resection of contiguous organs; example: small bowel,  
bladder

Procedures coded 30 include, but are not limited to:

Anterior resection

Hartmann operation

Low anterior resection (LAR)

Partial colectomy, NOS

Rectosigmoidectomy, NOS

Sigmoidectomy

40 Pull through WITH sphincter preservation (colo-anal anastomosis)  
[SEER Guideline: Procedures coded 40 include but are not limited to:  
Altemeier's operation, Duhamel's operation, Soave's submucosal  
resection, Swenson's operation, Turnbull's operation.]

50 Total proctectomy

[SEER Guideline: Procedures coded 50 include but are not limited to:  
abdominoperineal resection (A & P resection), anterior/posterior  
resection (A/P resection)/Mile's operation, Rankin's operation]

51 Total colectomy [SEER Guideline: removal of the colon from cecum to



rectosigmoid or portion of rectum]

- 55 Total colectomy WITH ileostomy, NOS
- 56 Ileorectal reconstruction
- 57 Total colectomy WITH other pouch; example: Koch pouch
- 60 Total proctocolectomy, NOS [SEER Guideline: combination of 50 and 51]
- 65 Total proctocolectomy WITH ileostomy, NOS
- 66 Total proctocolectomy WITH ileostomy and pouch

Removal of the colon from cecum to the rectosigmoid or a portion of the rectum.

- 70 Colectomy or proctocolectomy resection in continuity with other organs; pelvic exenteration  
[SEER Guideline: Procedures that may be part of an en bloc resection include, but are not limited to: an oophorectomy and a rectal mucosectomy. Code 70 includes any colectomy (partial, hemicolectomy or total) with an en bloc resection of any other organs. There may be partial or total removal of other organs in continuity with the primary.]  
[SEER Guideline: in continuity with or "en bloc" means that all of the tissues were removed during the same procedure, but not necessarily in a single specimen]
- 80 Colectomy, NOS; Proctectomy, NOS  
  
Specimen sent to pathology from surgical events 20-80.
- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

## **Q2 RECTUM (For Cases Diagnosed on or after January 1, 2003)**

### **C20.9**

**(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, 9975-9992)**

**Code** removal/surgical ablation of single or multiple liver metastases under the data item *Surgical Procedure/Other Site*.

### **Codes**

- 00 None; no surgery of primary site; autopsy ONLY

- 10 Local tumor destruction, NOS
  - 11 Photodynamic therapy (PDT)
  - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
  - 13 Cryosurgery
  - 14 Laser

No specimen sent to pathology from surgical events 10-14.

- 20 Local tumor excision, NOS
  - 27 Excisional biopsy
  - 26 Polypectomy

Any combination of 20 or 26-27 WITH  
[SEER Guideline: the following codes INCLUDE local tumor excision, polypectomy or excisional biopsy]

  - 21 Photodynamic therapy (PDT)
  - 22 Electrocautery
  - 23 Cryosurgery
  - 24 Laser ablation
  - 25 Laser excision
  - 28 Curette and fulguration

- 30 Wedge or segmental resection; partial proctectomy, NOS  
Procedures coded 30 include, but are not limited to:
  - Anterior resection
  - Hartmanns operation
  - Low anterior resection (LAR)
  - Transsacral rectosigmoidectomy

- 40 Pull through WITH sphincter preservation (coloanal anastomosis)  
[SEER Guideline: Procedures coded 40 include but are not limited to: Altemeier's operation, Duhamel's operation, Soave's submucosal resection, Swenson's operation, Turnbull's operation.]

- 50 Total proctectomy  
Procedure coded 50 includes, but is not limited to:
  - Abdominoperineal resection (Miles Procedure)

[SEER Guideline: also called anterior/posterior (A/P) resection/Mile's operation, Rankin's operation]

- 60 Total proctocolectomy, NOS
- 70 Proctectomy or proctocolectomy with resection in continuity with other organs; pelvic exenteration  
[SEER Guideline: in continuity with or "en bloc" means that all of the tissues were removed during the same procedure, but not necessarily in a single specimen]
- 80 Proctectomy, NOS  
  
Specimen sent to pathology from surgical events 20-80.
- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

## **Q2 SKIN (For Cases Diagnosed on or after January 1, 2003)**

### **C44.0-C44.9**

**(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, 9975-9992)**

### **Codes**

- 00 None; no surgery of primary site; autopsy ONLY
- 10 Local tumor destruction, NOS
  - 11 Photodynamic therapy (PDT)
  - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
  - 13 Cryosurgery
  - 14 Laser ablationNo specimen sent to pathology from surgical events 10-14.
- 20 Local tumor excision, NOS
  - 26 Polypectomy
  - 27 Excisional biopsyAny combination of 20 or 26-27 WITH  
[SEER Guideline: the following codes INCLUDE local tumor excision, polypectomy or excisional biopsy]
  - 21 Photodynamic therapy (PDT)

California Cancer Reporting System Standards, Volume I

- 22 Electrocautery
  - 23 Cryosurgery
  - 24 Laser ablation
  - 25 Laser excision
  - 30 Biopsy of primary tumor followed by a gross excision of the lesion (does not have to be done under the same anesthesia)
  - 31 Shave biopsy followed by a gross excision of the lesion
  - 32 Punch biopsy followed by a gross excision of the lesion
  - 33 Incisional biopsy followed by a gross excision of the lesion
  - 34 Mohs surgery, NOS
  - 35 Mohs with 1-cm margin or less
  - 36 Mohs with more than 1-cm margin
  - 45 Wide excision or reexcision of lesion or minor (local) amputation with margins more than 1 cm, NOS. Margins MUST be microscopically negative. [formerly SEER code 40 or 50 = wide excision or re-excision of lesion or minor (local) amputation, NOS, margins of excision are 1 cm or more, margins may be microscopically involved.]
  - 46 WITH margins more than 1 cm and less than or equal to 2 cm
  - 47 WITH margins greater than 2 cm
- If the excision does not have microscopically negative margins greater than 1 cm, use the appropriate code, 20-36.
- 60 Major amputation [NOS]  
Specimen sent to pathology for surgical events 21-60.
  - 90 Surgery, NOS
  - 99 Unknown if surgery performed; death certificate ONLY

**Q2 SPLEEN (For Cases Diagnosed on or after January 1, 2003)**

**Spleen C42.2**

**(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, 9975-9992)**

**Note: Lymph Nodes surgery codes have been moved to a separate scheme**

**Codes**

- 00 None; no surgery of primary site; autopsy ONLY
- 19 Local tumor destruction or excision, NOS  
[formerly SEER code 10 = local excision, destruction, NOS]  
Unknown whether a specimen was sent to pathology for surgical events coded 19 (principally for cases diagnosed prior to January 1, 2003).
- 21 Partial splenectomy
- 22 Total splenectomy
- 80 Splenectomy, NOS [formerly SEER code 20]  
  
Specimen sent to pathology for surgical events 21-80.
- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

**Q2 STOMACH (For Cases Diagnosed on or after January 1, 2003)**

**C16.0-C16.9**

(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, 9975-9992)

**Codes**

- 00 None; no surgery of primary site; autopsy ONLY
- 10 Local tumor destruction, NOS
  - 11 Photodynamic therapy (PDT)
  - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
  - 13 Cryosurgery
  - 14 LaserNo specimen sent to pathology from surgical events 10-14.
- 20 Local tumor excision, NOS
  - 26 Polypectomy
  - 27 Excisional biopsy

Any combination of 20 or 26-27 WITH  
[SEER Guideline: the following codes INCLUDE local tumor excision,  
polypectomy or excisional biopsy]

- 21 Photodynamic therapy (PDT)
  - 22 Electrocautery
  - 23 Cryosurgery
  - 24 Laser ablation
  - 25 Laser excision
  - 30 Gastrectomy, NOS (partial, subtotal, hemi-)
    - 31 Antrectomy, lower (distal-less than 40% of stomach)\*\*\*
    - 32 Lower (distal) gastrectomy (partial, subtotal, hemi-)
    - 33 Upper (proximal) gastrectomy (partial, subtotal, hemi-)
- Code 30 includes:  
Partial gastrectomy, including a sleeve resection of the stomach  
Billroth I: anastomosis to duodenum (duodenostomy)  
Billroth II: anastomosis to jejunum (jejunostomy)
- 40 Near-total or total gastrectomy, NOS
    - 41 Near-total gastrectomy
    - 42 Total gastrectomy
- A total gastrectomy may follow a previous partial resection of the stomach.
- 50 Gastrectomy, NOS WITH removal of a portion of esophagus
    - 51 Partial or subtotal gastrectomy
    - 52 Near total or total gastrectomy
- Codes 50-52 are used for gastrectomy resection when only portions of esophagus are included in procedure.
- 60 Gastrectomy with a resection in continuity with the resection of other organs, NOS\*\*\*
    - 61 Partial or subtotal gastrectomy, in continuity with the resection of other organs\*\*\*

- 62 Near total or total gastrectomy, in continuity with the resection of other organs\*\*\*
- 63 Radical gastrectomy, in continuity with the resection of other organs\*\*\*

Codes 60-63 are used for gastrectomy resections with organs other than esophagus. Portions of esophagus may or may not be included in the resection.

[SEER Guideline: codes 60-63 may include omentectomy]

[SEER Guideline: in continuity with or "en bloc" means that all of the tissues were removed during the same procedure, but not necessarily in a single specimen]

- 80 Gastrectomy, NOS

Specimen sent to pathology from surgical events 20-80.

- 90 Surgery, NOS

- 99 Unknown if surgery performed; death certificate ONLY

\*\*\* Incidental splenectomy NOT included

## Q2 TEST (For Cases Diagnosed on or after January 1, 2003)

C62.0-C62.9

(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, 9975-9992)

**Do not code** an orchiectomy in this field. For prostate primaries, orchiectomies are coded in the data item *Hematologic Transplant and Endocrine Procedures*.

### Codes

- 00 None; no surgery of primary site; autopsy ONLY
- 12 Local tumor destruction, NOS  
No specimen sent to pathology from surgical event 12.
- 20 Local or partial excision of testicle
- 30 Excision of testicle WITHOUT cord
- 40 Excision of testicle WITH cord or cord not mentioned (radical orchiectomy)
- 80 Orchiectomy, NOS (unspecified whether partial or total testicle removed)



Specimen sent to pathology from surgical events 20-80.

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

## **Q2 THYROID GLAND (For Cases Diagnosed on or after January 1, 2003)**

### **C73.9**

(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, 9975-9992)

### **Codes**

00 None; no surgery of primary site; autopsy ONLY

13 Local tumor destruction, NOS  
No specimen sent to pathology from surgical event 13.

25 Removal of less than a lobe, NOS [formerly SEER code 10]

26 Local surgical excision [formerly SEER code 11]

27 Removal of a partial lobe ONLY [formerly SEER code 12]

20 Lobectomy and/or isthmectomy

21 Lobectomy ONLY

22 Isthmectomy ONLY

23 Lobectomy WITH isthmus

30 Removal of a lobe and partial removal of the contralateral lobe

40 Subtotal or near total thyroidectomy

50 Total thyroidectomy

80 Thyroidectomy, NOS

Specimen sent to pathology from surgical events 25-80.

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

## **Q2 OTHER SITES (For Cases Diagnosed on or after January 1, 2003)**

**C14.1-C14.8, C17.0-C17.9, C23.9, C24.0-C24.9, C26.0-C26.9, C30.0-C  
30.1, C31.0-C31.9, C33.9, C37.9, C38.0-C38.8, C39.0-C39.9, C48.0-  
C48.8, C51.0-C51.9, C52.9, C57.0-C57.9, C58.9, C60.0-C 60.9, C63.0-  
C63.9, C68.0-C68.9, C69.0-C69.9, C74.0-C74.9, C75.0-C75.9  
(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931,  
9945-9946, 9950-9967, 9975-9992)**

**Codes**

- 00 None; no surgery of primary site; autopsy ONLY
- 10 Local tumor destruction, NOS
  - 11 Photodynamic therapy (PDT)
  - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
  - 13 Cryosurgery
  - 14 Laser

No specimen sent to pathology from surgical events 10-14.

- 20 Local tumor excision, NOS
  - 26 Polypectomy
  - 27 Excisional biopsy

Any combination of 20 or 26-27 WITH  
[SEER Guideline: the following codes INCLUDE local tumor excision, polypectomy or excisional biopsy]

- 21 Photodynamic therapy (PDT)
  - 22 Electrocautery
  - 23 Cryosurgery
  - 24 Laser ablation
- 25 Laser excision
- 30 Simple/partial surgical removal of primary site
- 40 Total surgical removal of primary site; enucleation
  - 41 Total enucleation (for eye surgery only)
- 50 Surgery stated to be "debulking"
- 60 Radical surgery  
Partial or total removal of the primary site WITH a resection in continuity (partial or total removal) with other organs.  
[SEER Guideline: in continuity with or "en bloc" means that all of the tissues were removed during the same procedure, but not necessarily in a single specimen]

Specimen sent to pathology from surgical events 20-60.

90 Surgery, NOS

99 Unknown if surgery performed; death certificate ONLY

**Q2 UNKNOWN and ILL DEFINED PRIMARY Sites (For Cases Diagnosed on or after January 1, 2003)**

**C76.0-C76.8, C80.9**

**(Except for M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, 9975-9992)**

**Code**

98 All unknown and ill-defined disease sites, WITH or WITHOUT surgical treatment.

Surgical procedures for unknown and ill-defined primaries are to be recorded using the data item Surgical Procedure/Other Site or Surgical Procedure/Other Site at This Facility.

[99 Death certificate only]

## **APPENDIX R: ICD-O-3 Lymphatic and Hematopoietic Diseases - Subsequent Diagnoses**

The CCR is concerned with identifying lymphomas and leukemias that are or might be treatment induced, usually as a result of chemotherapy plus radiotherapy or chemotherapy with alkylating agents.

The ICD-O-3 version of the hematopoietic primaries table is very different from the ICD-O-2 version in both format and medical understanding of these diseases. As a result, it is not possible to use the tables interchangeably. The first link indicated below, [Definitions of Single and Subsequent Primaries for Hematologic Malignancies Based on ICD-O-3 Reportable Malignancies, Effective with Diagnoses 01/01/2001 and After](#), explains the reasoning that underlies the ICD-O-3 table.

### **From January 1, 2001 Forward**

Use the ICD-O-3 table found in [http://seer.cancer.gov/icd-o-3/hematopoietic\\_primaries.d03152001.pdf](http://seer.cancer.gov/icd-o-3/hematopoietic_primaries.d03152001.pdf), if both diseases are diagnosed after January 1, 2001 or if a first diagnosis was prior to 2001, but a second diagnosis was after January 1, 2001.

Also review the following errata files.

<http://seer.cancer.gov/icd-o-3/errata.d05222001.pdf>

<http://seer.cancer.gov/icd-o-3/errata.d05062003.pdf>

## **APPENDIX S: DSQC Memos**

[Click here to open an interactive link to DSQC Memos.](#)

## APPENDIX U: Table of Data Items and Their Required Status

Reporting requirements are not uniform for all cancer reporting facilities. Consult the following table to determine which data items must be reported:

### Key to Symbols

no	Not required. It is optional for the facility to submit this data item value to the central registry.
yes	Required. The facility must submit this data item value to the central registry.
yes*	Required if available. If the information can be obtained, the facility must submit it to the central registry. If not available or not applicable, may be left blank.
conditional	Required on selected cases dependent on one or more conditions being true, such as the case's diagnosis date being before or after a certain date.
gen	Required, but the facility's registry software must generate the data item value based on a standard algorithm, rather than a user manually entering the data item value.

Items that are facility-generated are described in more detail, including allowable values in Cancer Reporting in California, Data Standards for Regional Registries and California Cancer Registry (California Cancer Reporting System Standards, Volume III).

Data Item Name	Manual	RX Ctr	Hosp > CCR
Abstractor	III.1.1	yes	yes
Accession Number (Hosp)	II.2.3	yes	yes
ACoS Approved Flag	III.1.6	yes	yes
Address at Diagnosis City	III.2.5	yes	yes
Address at Diagnosis No. & Street	III.2.5	yes	yes
Address at Diagnosis No. & Street - Supplemental	III.2.5	yes*	yes*
Address at Diagnosis - State	III.2.5	yes	yes
Address at Diagnosis - Zip Code	III.2.5	yes	yes
Age at Diagnosis	III.2.11	gen	gen
Alias First Name	III.2.1.6	yes*	yes*
Alias Last Name	III.2.1.5	yes*	yes*
Ambiguous Terminology Dx	II.1.6.3	yes	yes
Birthplace	III.2.12	yes	yes
Casefinding Source	III.3.8	yes	yes
Cause of Death	VII.2.14	no	no
Chemotherapy at This Hospital	VI.4	yes	yes

California Cancer Reporting System Standards, Volume I

<b>Data Item Name</b>	<b>Manual</b>	<b>RX Ctr</b>	<b>Hosp&gt; CCR</b>
Chemotherapy Summary	VI.4	yes	yes
Class of Case	III.3.5	yes	yes
Coding Procedure	III.1.5	gen	yes
Comorbidity Complications 1	III.3.13	yes*	yes*
Comorbidity Complications 2	III.3.13	yes*	yes*
Comorbidity Complications 3	III.3.13	yes*	yes*
Comorbidity Complications 4	III.3.13	yes*	yes*
Comorbidity Complications 5	III.3.13	yes*	yes*
Comorbidity Complications 6	III.3.13	yes*	yes*
Comorbidity Complications 7	III.3.13	yes*	yes*
Comorbidity Complications 8	III.3.13	yes*	yes*
Comorbidity Complications 9	III.3.13	yes*	yes*
Comorbidity Complications 10	III.3.13	yes*	yes*
Contact City	VII.3	yes*	yes*
Contact Country	VII.3	yes*	yes*
Contact Name	VII.3	yes*	yes*
Contact State	VII.3	yes*	yes*
Contact Street	VII.3	yes*	yes*
Contact Street - Supplemental	VII.3	yes*	yes*
Contact Zip	VII.3	yes*	yes*
County of Residence at Diagnosis	III.2.5	yes	yes
CS Tumor Size	V.4.2	yes	yes
CS Extension	V.4.2	yes	yes
CS Tumor Size/Extension Evaluation	V.4.2	yes	yes
CS Lymph Nodes	V.4.2	yes	yes
CS Lymph Nodes Evaluation	V.4.2	yes	yes
CS Metastasis at Diagnosis	V.4.2	yes	yes
CS Metastasis at Diagnosis Bone	V.4.2.1	yes	yes
CS Metastasis at Diagnosis Brain	V.4.2.2	yes	yes
CS Metastasis at Diagnosis Liver	V.4.2.3	yes	yes
CS Metastasis at Diagnosis Lung	V.4.2.4	yes	yes
CS Metastasis Evaluation	V.4.2	yes	yes
CS Site Specific Factor 1	V.4.2	yes	yes
CS Site Specific Factor 2	V.4.2	yes	yes
CS Site Specific Factor 3	V.4.2	yes	yes
CS Site Specific Factor 4	V.4.2	yes	yes
CS Site Specific Factor 5	V.4.2	yes	yes
CS Site Specific Factor 6	V.4.2	yes	yes
CS Site Specific Factor 7	V.4.2	yes	yes
CS Site Specific Factor 8	V.4.2	yes	yes
CS Site Specific Factor 9	V.4.2	yes	yes
CS Site Specific Factor 10	V.4.2	yes	yes
CS Site Specific Factor 11	V.4.2	yes	yes
CS Site Specific Factor 12	V.4.2	yes	yes
CS Site Specific Factor 13	V.4.2	yes	yes

California Cancer Reporting System Standards, Volume I

<b>Data Item Name</b>	<b>Manual</b>	<b>RX Ctr</b>	<b>Hosp&gt; CCR</b>
CS Site Specific Factor 14	V.4.2	yes	yes
CS Site Specific Factor 15	V.4.2	yes	yes
CS Site Specific Factor 16	V.4.2	yes	yes
CS Site Specific Factor 17	V.4.2	yes	yes
CS Site Specific Factor 18	V.4.2	yes	yes
CS Site Specific Factor 19	V.4.2	yes	yes
CS Site Specific Factor 20	V.4.2	yes	yes
CS Site Specific Factor 21	V.4.2	yes	yes
CS Site Specific Factor 22	V.4.2	yes	yes
CS Site Specific Factor 23	V.4.2	yes	yes
CS Site Specific Factor 24	V.4.2	yes	yes
CS Site Specific Factor 25	V.4.2	yes	yes
CS Version Input Current	V.4.2	yes	yes
CS Version Latest	V.4.2	yes	yes
Date of Birth	III.2.10	yes	yes
Date of Birth Flag	III.2.10.1	yes	yes
Date Case Initiated	Vol. 2	gen	gen
Date of Conclusive DX	II.1.6.4	yes	yes
Date of Conclusive Dx Flag	V.1.7.2	yes	yes
Date of Chemotherapy	VI.1.3.2	conditional	yes*
Date of Chemotherapy Flag	VI.4.3.1	yes	yes*
Date of Diagnosis	III.3.1	yes	yes
Date of Diagnosis Flag	III.3.3.4	yes	yes
Date of First Admission	III.3.1	yes	yes
Date of First Contact Flag	III.3.1.1	yes	yes
Date of Inpatient Admission	III.3.2	no	yes*
Date of Inpatient Admission Flag	III.3.2.1	yes	yes
Date of Inpatient Discharge	III.3.2	no	yes*
Date of Inpatient Discharge Flag	III.3.2.2	yes	yes
Date of Hormone Therapy	VI.1.3.2	conditional	yes*
Date of Hormone Therapy Flag	VI.5.5.1	yes	yes*
Date of Immunotherapy	VI.1.3.2	conditional	yes*
Date of Immunotherapy Flag	VI.6.3.1	yes	yes
Date of Last Patient Contact or Death	VII.2.1	yes	yes
Date of Last Patient Contact or Death Flag	VII.2.1.1	yes	yes
Date of Last Tumor Status	VII.2.3	yes	yes
Date of Last Contact Flag	VII.2.2.1	yes	yes
Date of Most Definitive Surgery of the Primary Site	VI.2.5	gen	yes*
Date of Most Definitive Surgery of the Primary Site Flag	VI.2.5	yes	yes
Date of Multiple Tumors	V.1.7.4	yes	yes
Date of Multiple Tumors Flag	V.1.7.4.1	yes	yes
Date of Other Therapy	VI.1.3.2	conditional	yes*
Date of Other Therapy Flag	VI.8.2.1	yes	yes*



California Cancer Reporting System Standards, Volume I

<b>Data Item Name</b>	<b>Manual</b>	<b>RX Ctr</b>	<b>Hosp&gt; CCR</b>
Date of Radiation	VI.1.3.2	conditional	yes*
Date of Radiation Flag	VI.3.5.1	yes	yes*
Date of Systemic Therapy	VI.1.3.2	gen	yes*
Date of Systemic Therapy Flag	VI.1.3.2	yes	yes*
Date of Surgery	VI.1.3.2	gen	yes*
Date of Surgery Flag	VI.2.5.1	yes	yes*
Date of Surgery Diagnostic or Staging Procedures	VI.2.12	conditional	yes*
Date of Surgery Diagnostic or Staging Procedures Flag	V1.2.11.1	yes	yes
Date of Surgery Procedures 1-3	VI.2.5	conditional	yes
Date of Surgery Procedures 1-3 Flag	VI.2.5	yes	yes
Date of Therapy	Vol III	no	no
Date of Transplant/Endocrine Procedures	VI.7.2	conditional	yes
Date of Transplant/Endocrine Procedures Flag	VI.7.2.1	yes	yes
Death File Number	VII.2.14	no	no
Derived AJCC-7 T	V.4.2	yes	yes
Derived AJCC-7 T Descriptor	V.4.2	yes*	yes*
Derived AJCC-7 N	V.4.2	yes	yes
Derived AJCC-7 N Descriptor	V.4.2	yes*	yes*
Derived AJCC-7 M	V.4.2	yes	yes
Derived AJCC-7 M Descriptor	V.4.2	yes*	yes*
Derived AJCC-7 Stage Group	V.4.2	yes	yes
Derived SS2000	V.4.2	yes	yes
Derived SS1977	V.4.2	yes	yes
Derived AJCC - Flag	V.4.2	yes	yes
Derived SS2000 - Flag	V.4.2	yes	yes
Derived SS1977 - Flag	V.4.2	yes	yes
Diagnostic Confirmation	IV.2	yes	yes
Discovered by Screening	III.3.15	no	no
EOD Extension	V.4	yes	yes
EOD Extension (Path)	V.4	yes	yes
EOD - Lymph Node Involvement	V.4	yes	yes
First Name	III.2.1.2	yes	yes
Follow up Contact Address Other	VII.3	yes*	yes
Follow up Contact Address Other - Supplemental	VII.3	yes*	yes*
Follow up Contact City Other	VII.3	yes*	yes
Follow up Contact Name Other	VII.3	yes*	yes
Follow up Contact State Other	VII.3	yes*	yes
Follow up Contact Zip Other	VII.3	yes*	yes
Follow up Last Type (Patient)	VII.2.6.2	yes	yes
Follow up Last Type (Tumor)	VII.2.6.1	yes	yes
Follow up Next Type	VII.2.8	yes*	yes*

California Cancer Reporting System Standards, Volume I

<b>Data Item Name</b>	<b>Manual</b>	<b>RX Ctr</b>	<b>Hosp&gt; CCR</b>
Follow up Hospital (Next)	VII.2.9	no	no
Follow up Hospital (Last)	VII.2.7	yes	yes
Grade Path Value	V.3.5.11	yes	yes
Grade Path System	V.3.5.12	yes	yes
Histology Text	IV.1.7	yes	yes
Histology Behavior (ICD-O-2)	V.3.4	yes	yes
Histology Behavior (ICD-O-3)	V.3.4	yes	yes
Histology Grade/ Differentiation	V.3.5	yes	yes
Histology Type (ICD-O-2)	V.3	yes	yes
Histology Type (ICD-O-3)	V.3	yes	yes
Hormone Therapy at This Hospital	VI.5	yes	yes
Hormone Therapy Summary	VI.5	yes	yes
Hospital Number (Reporting)	III.1.4	yes	yes
Hospital Patient Number	Vol. 2	gen	yes
Hospital Referred From	III.3.10	yes	yes
Hospital Referred To	III.3.11	yes	yes
ICD Revision Comorbidities	III.3.14	yes	yes
ICD-O-3 Conversion Flag	Vol. 2	gen	yes
Immunotherapy at This Hospital	VI.6	yes	yes
Immunotherapy Summary	VI.6	yes	yes
Industry Text	III.2.13.2	no	yes
Last Name	III.2.1.1	yes	yes
Laterality	V.2	yes	yes
Lymph-Vascular Invasion	V.5.14	conditional	conditional
Maiden Name	III.2.1.4	yes*	yes*
Marital Status	III.2.6	yes	yes
Medical Record Number	III.2.2	yes*	yes*
Middle Name	III.2.1.3	yes*	yes*
Mothers First Name	III.2.1.9	yes*	yes*
Multiple Tumors Reported as One Primary	II.1.3.9.3	yes	yes
Multiplicity Counter	II.1.3.9.1	yes	yes
Name Suffix	III.2.1.8	yes*	yes*
Number of Regional Lymph Nodes Examined Surgery Summary	VI.2.2	gen	conditional
Number of Regional Lymph Nodes Examined Procedures 1-3	VI.2.3	yes	no
NPI Reporting Facility	III.1.4	yes*	yes*
NPI Hospital Referred From	III.3.10	yes*	yes*
NPI Hospital Referred To	III.3.11	yes*	yes*
NPI Following Registry	Appendix X	yes*	yes*
NPI Physician-Managing	III.3.12	yes*	yes*
NPI Physician-Primary Surgeon	III.3.12	yes*	yes*
NPI Physician-Follow-up	VII.2.10	yes*	yes*
NPI Physician 3	III.3.12	yes*	yes*

California Cancer Reporting System Standards, Volume I

<b>Data Item Name</b>	<b>Manual</b>	<b>RX Ctr</b>	<b>Hosp&gt; CCR</b>
NPI Physician 4	III.3.12	yes*	yes*
NPI Physician Other 1	III.3.12	yes*	yes*
NPI Physician Other 2	III.3.12	yes*	yes*
NPI Archive FIN	Appendix X	no	no
Occupation Text	III.2.13.1	yes	yes
Other Therapy at This Hospital	VI.7	yes	yes
Other Therapy Summary	VI.7	yes	yes
Over-ride Flags	Appendix T	yes	yes
Path Date Specimen Collected 1-5	IV.4.3	yes*	yes*
Path Report Numbers 1-5	IV.4.2	yes*	yes*
Path Report Type 1-5	IV.4.4	yes*	yes*
Path Reporting Facility ID 1-5	IV.4.1	yes*	yes*
Patient No Research Contact Flag	III.2.14	yes	yes
Payment Source (Primary)	III.3.9	yes	yes
Payment Source (Secondary)	III.3.9	yes*	yes*
Payment Source Text	III.3.9	yes	yes
Pediatric Stage	V.7.8	yes*	yes*
Pediatric Stage Coder	V.7.10	yes*	yes*
Pediatric Stage System	V.7.9	yes*	yes*
Phone Number (Patient)	III.2.4	yes*	yes*
Physician (Managing)	III.3.12	yes	yes
Physician (Following)	VII.2.10	yes*	yes*
Physician (Medical Oncologist)	III.3.12	yes*	yes*
Physician (Other)	III.3.12	yes*	yes*
Physician (Other)	III.3.12	yes*	yes*
Physician (Radiation Oncologist)	III.3.12	yes*	yes*
Physician (Referring)	III.3.12	yes*	yes*
Physician (Surgeon)	III.3.12	yes*	yes*
Place of Death	VII.2.14	yes*	yes*
Place of Diagnosis	III.3.4	yes*	yes*
Protocol Participation	VI.9	yes*	yes*
Quality of Survival	VII.2.5	no	no
Race 1	III.2.9	yes	yes
Race 2	III.2.9	yes	yes
Race 3	III.2.9	yes	yes
Race 4	III.2.9	yes	yes
Race 5	III.2.9	yes	yes
Radiation at This Hospital	VI.3	no	no
Radiation - Boost RX Modality	VI.3.4	yes	yes
Radiation - Location of Treatment	VI.3.8	yes	yes
Radiation - Regional RX Modality	VI.3.3	yes	yes
Radiation Summary	VI.3	yes	yes
Radiation/Surgery Sequence	VI.3.4	yes	yes

California Cancer Reporting System Standards, Volume I

<b>Data Item Name</b>	<b>Manual</b>	<b>RX Ctr</b>	<b>Hosp&gt; CCR</b>
Reason for No Radiation	VI.3.3	yes	yes
Reason for No Surgery	VI.2.10	yes	yes
Recurrence Date	VII.2.13.1	no	no
Recurrence Sites	VII.2.13.3	no	no
Recurrence Type	VII.2.12.2	no	no
Regional Data	--	no	yes*
EOD- Regional Nodes Examined	V.4	yes	yes
EOD- Regional Nodes Positive	V.4	yes	yes
Religion	III.2.8	yes	yes
Scope of Regional Lymph Node Surgery 98-02 Summary	VI.2.2	gen	conditional
Scope of Regional Lymph Node Surgery Summary	VI.2.2	gen	yes
Scope of Regional Lymph Node Surgery Procedures 1-3	V.7.12	yes	yes
Sequence Number	II.2.4	yes	yes
Sex	III.2.7	yes	yes
Site Text	IV.1	yes	yes
Site, Primary	V.1.1	yes	yes
Social Security Number	III.2.3	yes*	yes*
Social Security Number Suffix	III.2.3	yes*	yes*
Spanish/Hispanic Origin	III.2.9.2	yes	yes
Stage-Alternate	V.5.6	yes*	yes*
Staging Text	IV.3.5	yes	yes
Summary Stage 1977	V.5	conditional	conditional
Summary Stage 2000	V.5	conditional	conditional
Surgery at This Hospital Diagnostic or Staging Procedure	VI.2.11	yes	yes
Surgery at This Hospital Reconstructive	VI.2.8	no	no
Surgery at This Hospital	VI.2.1	gen	no
Surgery of Primary Site 9802 Summary	VI.2.1	gen	conditional
Surgery of Primary Site Summary	VI.2.1	gen	yes
Surgery of Primary Site Procedures 1-3	VI.2.1	yes	yes
Surgery of Other Site Summary 98-02	VI.2.4	gen	conditional
Surgery of Other Regional Site(s), Distant Site(s), or Distant Lymph Node(s) Summary	VI.2.4	gen	yes
Surgery of Other Regional Site(s), Distant Site(s), or Distant Lymph Node(s) Procedures 1-3	VI.2.4	yes	yes
Surgery Summary Diagnostic or Staging Procedure	VI.2.11	yes	yes
Surgery Summary Reconstructive	VI.2.8	yes	yes
Surgical Margins Procedures 1-3	VI.2.7	no	no
Surgical Margins Summary	VI.2.7	gen	no
Systemic/Surgery Sequence	VI.2.14	yes	yes

California Cancer Reporting System Standards, Volume I

<b>Data Item Name</b>	<b>Manual</b>	<b>RX Ctr</b>	<b>Hosp&gt; CCR</b>
Text RX Chemotherapy	VI.4	yes*	yes*
Text RX Hormone Therapy	VI.5	yes*	yyes*
Text RX Immunotherapy	VI.6	yes*	yes*
Text RX Other Therapy	VI.7	yes*	yes*
Text RX Radiation (Beam)	VI.3	yes*	yes*
Text RX Radiation (Other)	VI.3	yes*	yes*
Text RX Radiation Boost RX Modality	VI.3	yes*	yes*
Text RX Radiation Regional RX Modality	VI.3	yes*	yes*
Text RX Surgery	VI.2	yes*	yes*
Text DxProc Lab Tests	IV.1.5	yes*	yes*
Text DxProc Operative	IV.1.6	yes*	yes*
Text DxProc Pathological	IV.1.7	yes*	yes*
Text DxProc PE	IV.1.2	yes*	yes*
Text DxProc Scopes	IV.1.4	yes*	yes*
Text DxProc Xray	IV.1.3	yes*	yes*
Text Remarks	VIII.1	yes*	yes*
TNM Coder (Clinical)	V.7.6	yes*	yes*
TNM Coder (Path)	V.7.6	yes*	yes*
TNM Edition	V.7.7	yes*	yes*
TNM Stage (Clinical)	V.7.5	yes*	yes*
TNM Stage (Path)	V.7.5	yes*	yes*
TNM M Code (Clinical)	V.7.4	yes*	yes*
TNM M Code (Path)	V.7.4	yes*	yes*
TNM N Code (Clinical)	V.7.4	yes*	yes*
TNM N Code (Path)	V.7.4	yes*	yes*
TNM T Code (Clinical)	V.7.4	yes*	yes*
TNM T Code (Path)	V.7.4	yes*	yes*
Transplant/Endocrine Procedures At This Hospital	VI.7.1	yes	yes
Transplant/Endocrine Procedures Summary	VI.7.1	yes	yes
Treatment Hospital Number-Procedure 1-3	VI.2.6	yes	yes
Treatment Status	VI.9	yes	yes
Tumor Markers 1-3	V.6	conditional	conditional
Tumor Marker-CA-1	V.6.4	conditional	conditional
Tumor Size	V.4	yes	yes
Tumor Status	VII.2.4	yes	yes
Type of Admission	III.3.7	yes	yes
Type of Reporting Source	III.3.6	yes	yes
Vendor Version	Vol. 2	yes	gen
Vital Status	VII.2.2	yes	yes
Year First Seen	II.2.1	no	yes

## APPENDIX V: Brain and CNS Site/Histology Listing

Based on ICD-O-3 SEER Site/Histology Validation list

Reviewed by Neuropathologists: Drs. Roger McLendon, Janet Bruner, Steven Moore

SEER: Lynn Ries

CBTRUS: Dr. Bridget McCarthy, Carol Kruchko

**Underlined bold type** indicates histology codes with a benign or uncertain behavior code that have been added by CBTRUS and are not contained in the ICD-O-3 SEER Site/Histology Validation List.

**Bold type** indicates histology codes with a malignant behavior code that have been added by CBTRUS and are not contained in the ICD-O-3 SEER Site/Histology Validation List.

### MENINGES (CEREBRAL, SPINAL) C700-C709

NEOPLASM

800

8000/0 Neoplasm, benign

8000/1 Neoplasm, uncertain whether benign or malignant

8000/3 Neoplasm, malignant

8001/0 Tumor cells, benign

8001/1 Tumor cells, uncertain whether benign or malignant

8001/3 Tumor cells, malignant

8005/3 Malignant tumor, clear cell type

NEVI & MELANOMAS

872

8720/3 Malignant melanoma, NOS

8728/0 Diffuse melanocytosis

8728/1 Meningeal melanocytoma

8728/3 Meningeal melanomatosis

California Cancer Reporting System Standards, Volume I

SARCOMA, NOS	880	<p><u>8800/0 Soft tissue tumor, benign</u></p> <p>8800/3 Sarcoma, NOS</p> <p>8801/3 Spindle cell sarcoma</p> <p>8805/3 Undifferentiated sarcoma</p> <p>8806/3 Desmoplastic small round cell tumor</p>
FIBROMATOUS NEOPLASMS	881	<p><u>8810/0 Fibroma, NOS</u></p> <p>8810/3 Fibrosarcoma, NOS</p> <p><u>8815/0 Solitary fibrous tumor</u></p>
LIPOMATOUS NEOPLASMS	885	<p><u>8850/0 Lipoma, NOS</u></p> <p><u>8851/0 Fibrolipoma</u></p>
ANGIOLIPOMA	886	<p><u>8861/0 Angiolipoma, NOS</u></p>
MYOMATOUS NEOPLASMS	889	<p>8890/3 Leiomyosarcoma, NOS</p>
EMBRYONAL RHABDOMYOSARCOMA	891	<p>8910/3 Embryonal rhabdomyosarcoma, NOS</p>
TERATOMA	908	<p><u>9080/0 Teratoma, benign</u></p> <p><u>9080/1 Teratoma, NOS</u></p> <p>9080/3 Teratoma, malignant,</p>

California Cancer Reporting System Standards, Volume I

NOS

9084/0 Dermoid cyst, NOS

9084/3 Teratoma with malign.  
transformation

BLOOD VESSEL TUMORS 912

9120/0 Hemangioma, NOS

9121/0 Cavernous hemangioma

HEMANGIOPERICYTOMA 915

9150/0 Hemangiopericytoma, benign

9150/1 Hemangiopericytoma, NOS

9150/3 Hemangiopericytoma, malignant

HEMANGIOBLASTOMA 916

9161/1 Hemangioblastoma

OSSEOUS & CHONDROMATOUS NEOPLASMS 924

9240/3 Mesenchymal chondrosarcoma

MENINGIOMA 953

9530/0 Meningioma, NOS

9530/1 Meningiomatosis, NOS

9530/3 Meningioma, malignant

9531/0 Meningothelial meningioma

9532/0 Fibrous meningioma

9533/0 Psammomatous meningioma



California Cancer Reporting System Standards, Volume I

		<u>9534/0 Angiomatous meningioma</u>
		<u>9537/0 Transitional meningioma</u>
		<u>9538/1 Clear cell meningioma</u>
		9538/3 Papillary meningioma
		<u>9539/1 Atypical meningioma</u>
		9539/3 Meningeal sarcomatosis
MALIGNANT LYMPHOMA, NOS	959	
		9590/3 Malignant lymphoma, NOS
		9591/3 Malignant lymphoma, non-Hodgkin
		9596/3 Composite Hodgkin and non-Hodgkin lymphoma
HODGKIN LYMPHOMA	965	
		9650/3 Hodgkin lymphoma, NOS
		9651/3 Hodgkin lymphoma, lymphocyte-rich
		9652/3 Hodgkin lymphoma, mixed cellularity, NOS
		9653/3 Hodgkin lymphoma, lymphocytic deplet., NOS
		9654/3 Hodgkin lymphoma, lymphocyt. deplet., diffuse fibrosis
		9655/3 Hodgkin lymphoma, lymphocyt. deplet., reticular
		9659/3 Hodgkin lymphoma, nodular lymphocyte predom.
HODGKIN LYMPHOMA, NOD. SCLER.	966	
		9661/3 Hodgkin granuloma
		9662/3 Hodgkin sarcoma

California Cancer Reporting System Standards, Volume I

		9663/3 Hodgkin lymphoma, nodular sclerosis, NOS
		9664/3 Hodgkin lymphoma, nod. scler., cellular phase
		9665/3 Hodgkin lymphoma, nod. scler., grade 1
		9667/3 Hodgkin lymphoma, nod. scler., grade 2
ML, SMALL B-CELL LYMPHOCYTIC	967	
		9670/3 ML, small B lymphocytic, NOS
		9671/3 ML, lymphoplasmacytic
		9673/3 Mantle cell lymphoma
		9675/3 ML, mixed sm. and lg. cell, diffuse
ML, LARGE B-CELL, DIFFUSE	968	
		9680/3 ML, large B-cell, diffuse
		9684/3 ML, large B-cell, diffuse, immunoblastic, NOS
		9687/3 Burkitt lymphoma, NOS
FOLLIC. & MARGINAL LYMPH, NOS	969	
		9690/3 Follicular lymphoma, NOS
		9691/3 Follicular lymphoma, grade 2
		9695/3 Follicular lymphoma, grade 1
		9698/3 Follicular lymphoma, grade 3
		9699/3 Marginal zone B-cell lymphoma, NOS

California Cancer Reporting System Standards, Volume I

T-CELL LYMPHOMAS	970	<p>9701/3 Sezary syndrome</p> <p>9702/3 Mature T-cell lymphoma, NOS</p> <p>9705/3 Angioimmunoblastic T-cell lymphoma</p>
OTHER SPEC. NON-HODGKIN LYMPHOMA	971	<p>9714/3 Anaplastic large cell lymphoma, T-cell and Null cell type</p> <p>9719/3 NK/T-cell lymphoma, nasal and nasal-type</p>
PRECURS. CELL LYMPHOBLASTIC LYMPH.	972	<p>9727/3 Precursor cell lymphoblastic lymphoma, NOS</p> <p>9728/3 Precursor B-cell lymphoblastic lymphoma</p> <p>9729/3 Precursor T-cell lymphoblastic lymphoma</p>
PLASMA CELL TUMORS	973	<p>9731/3 Plasmacytoma, NOS</p> <p>9734/3 Plasmacytoma, extramedullary</p>
MAST CELL TUMORS	974	<p>9740/3 Mast cell sarcoma</p> <p>9741/3 Malignant mastocytosis</p>
NEOPLASMS OF HISTIOCYTES AND ACCESSORY LYMPHOID CELLS	975	<p>9750/3 Malignant histiocytosis</p> <p>9754/3 Langerhans cell</p>

California Cancer Reporting System Standards, Volume I

histiocytosis, disseminated  
 9755/3 Histiocytic sarcoma  
 9756/3 Langerhans cell  
 sarcoma  
 9757/3 Interdigitating dendritic  
 cell sarcoma  
 9758/3 Follicular dendritic cell  
 sarcoma

BRAIN, C710-C714 & C717-C719, (EXCL. VENTRICLE, CEREBELLUM)  
SPINAL CORD C720 , CAUDA EQUINA C721 & CRANIAL NERVES, C722-C725

NEOPLASM

800

8000/0 Neoplasm, benign  
8000/1 Neoplasm, uncertain  
whether benign or malignant  
8000/3 Neoplasm, malignant  
8001/0 Tumor cells, benign  
8001/1 Tumor cells, uncertain  
whether benign or malignant  
 8001/3 Tumor cells, malignant  
 8002/3 Malignant tumor, small  
 cell type  
 8003/3 Malignant tumor,  
 giant cell type  
 8004/3 Malignant tumor,  
 spindle cell type  
 8005/3 Malignant tumor,  
 clear cell type

PARAGANGLIOMA

868

8680/1 Paraganglioma, NOS

NEVI & MELANOMAS

872

California Cancer Reporting System Standards, Volume I

		8720/3 Malignant melanoma
SARCOMA, NOS	880	<u>8800/0 Soft tissue tumor, benign</u> 8800/3 Sarcoma, NOS 8801/3 Spindle cell sarcoma 8805/3 Undifferentiated sarcoma 8806/3 Desmoplastic small round cell tumor
LIPOMATOUS NEOPLASMS	885	<u>8850/0 Lipoma, NOS</u> <u>8851/0 Fibrolipoma</u> 8851/3 Liposarcoma
GERM CELL TUMORS	906	9060/3 Dysgerminoma 9064/3 Germinoma
EMBRYONAL CARCINOMA	907	9070/3 Embryonal carcinoma, NOS 9071/3 Yolk Sac Tumor
TERATOMA	908	<u>9080/0 Teratoma, benign</u> <u>9080/1 Teratoma, NOS</u> 9080/3 Teratoma, malignant, NOS

California Cancer Reporting System Standards, Volume I

		9081/3 Teratocarcinoma
		9085/3 Mixed germ cell tumor
TROPHOBLASTIC NEOPLASMS	910	9100/3 Choriocarcinoma, NOS
BLOOD VESSEL TUMORS	912	<u>9120/0 Hemangioma, NOS</u>
		<u>9121/0 Cavernous hemangioma</u>
		<u>9122/0 Venous hemangioma</u>
HEMANGIOENDOTHELIOMA	913	<u>9131/0 Capillary hemangioma</u>
HEMANGIOPERICYTOMA	915	<u>9150/1 Hemangiopericytoma, NOS</u>
HEMANGIOBLASTOMA	916	<u>9161/1 Hemangioblastoma</u>
CHORDOMA	937	9370/3 Chordoma, 9371/3 Chondroid chordoma 9372/3 Dedifferentiated chordoma
GLIOMA	938	

California Cancer Reporting System Standards, Volume I

		9380/3 Glioma, malignant
		9381/3 Gliomatosis cerebri
		9382/3 Mixed glioma
		<u>9383/1 Subependymoma</u>
		<u>9384/1 Subependymal giant cell astrocytoma</u>
EPENDYMOMA, NOS	939	
		9391/3 Ependymoma, NOS
		9392/3 Ependymoma, anaplastic
		9393/3 Papillary Ependymoma
		<u>9394/1 Myxopapillary ependymoma</u>
ASTROCYTOMA, NOS	940	
		9400/3 Astrocytoma, NOS
		9401/3 Astrocytoma, anaplastic
PROTOPLASMIC ASTROCYTOMA	941	
		9410/3 Protoplasmic astrocytoma
		9411/3 Gemistocytic astrocytoma
		<u>9412/1 Desmoplastic infantile astrocytoma</u>
		<u>9413/0 Dysembryoplastic neuroepithelial tumor</u>
FIBRILLARY ASTROCYTOMA	942	
		9420/3 Fibrillary astrocytoma
		<u>9421/1 Pilocytic astrocytoma</u>

California Cancer Reporting System Standards, Volume I

		9423/3 Polar spongioblastoma
		9424/3 Pleomorphic xanthoastrocytoma
ASTROBLASTOMA	943	
		9430/3 Astroblastoma
GLIOBLASTOMA, NOS	944	
		9440/3 Glioblastoma, NOS
		9441/3 Giant cell glioblastoma
		<u>9442/1 Gliofibroma</u>
		9442/3 Gliosarcoma
		<u>9444/1 Chordoid glioma</u>
OLIGODENDROGLIOMA, NOS	945	
		9450/3 Oligodendroglioma, NOS
		9451/3 Oligodendroglioma, anaplastic
OLIGODENDROBLASTOMA	946	
		9460/3 Oligodendroblastoma
PRIMITIVE NEUROECTODERMAL	947	
		9473/3 Primitive neuroectodermal tumor, NOS
GANGLIONEUROBLASTOMA	949	
		<u>9490/0 Ganglioneuroma</u>
		9490/3 Ganglioneuroblastoma
		<u>9492/0 Gangliocytoma</u>



California Cancer Reporting System Standards, Volume I

NEUROBLASTOMA, NOS 950

9500/3 Neuroblastoma,  
NOS

9501/3 Medulloepithelioma,  
NOS

9502/3 Teratoid  
medulloepithelioma

9503/3 Neuroepithelioma, NOS

9505/1 Ganglioglioma, NOS

9505/3 Ganglioglioma,  
anaplastic

9508/3 Atypical  
teratoid/rhabdoid tumor

MENINGIOMA 953

9530/0 Meningioma, NOS

9530/1 Meningioma, NOS

9530/3 Meningioma,  
malignant

9531/0  
Meningotheliomatous  
meningioma

9532/0 Fibrous meningioma

9533/0 Psammomatous  
meningioma

9534/0 Angiomatous  
meningioma

9537/0 Transitional  
meningioma

9538/1 Clear cell meningioma

9538/3 Papillary  
meningioma

9539/1 Atypical meningioma

9539/3 Meningeal

California Cancer Reporting System Standards, Volume I

sarcomatosis

NEUROFIBROSARCOMA	954	<p><u>9540/0 Neurofibroma, NOS</u></p> <p><u>9540/1 Neurofibromatosis, NOS</u></p> <p>9540/3 Malignant peripheral nerve sheath tumor</p> <p><u>9541/0 Melanotic neurofibroma</u></p>
PLEXIFORM NEUROFIBROMA	955	<p><u>9550/0 Plexiform neurofibroma</u></p>
NEURILEMOMA	956	<p><u>9560/0 Neurilemoma, NOS</u></p> <p><u>9560/1 Neurinomatosis</u></p> <p>9560/3 Neurilemoma, malignant</p> <p>9561/3 Triton tumor, malignant</p> <p><u>9562/0 Neurothekeoma</u></p>
NEUROMA	957	<p><u>9570/0 Neuroma, NOS</u></p> <p><u>9571/0 Perineurioma, NOS</u></p> <p>9571/3 Perineurioma, malignant</p>
MALIGNANT LYMPHOMA, NOS	959	<p>9590/3 Malignant lymphoma, NOS</p> <p>9591/3 Malignant lymphoma, non-Hodgkin</p>

California Cancer Reporting System Standards, Volume I

9596/3 Composite Hodgkin  
and non-Hodgkin lymphoma

ML, SMALL B-CELL  
LYMPHOCYTIC 967

9670/3 ML, small B  
lymphocytic, NOS  
9671/3 ML, lymphoplasmacytic  
9673/3 Mantle cell lymphoma  
9675/3 ML, mixed sm. and lg.  
cell, diffuse

ML, LARGE B-CELL,  
DIFFUSE 968

9680/3 ML, large B-cell,  
diffuse  
9684/3 ML, large B-cell, diffuse,  
immunoblastic, NOS  
9687/3 Burkitt lymphoma,  
NOS

FOLLIC. & MARGINAL  
LYMPH, NOS 969

9690/3 Follicular lymphoma,  
NOS  
9691/3 Follicular lymphoma,  
grade 2  
9695/3 Follicular lymphoma,  
grade 1  
9698/3 Follicular lymphoma,  
grade 3  
9699/3 Marginal zone B-cell  
lymphoma, NOS

T-CELL LYMPHOMAS 970

9701/3 Sezary syndrome  
9702/3 Mature T-cell  
lymphoma, NOS

California Cancer Reporting System Standards, Volume I

		9705/3 Angioimmunoblastic T-cell lymphoma
OTHER SPEC. NON- HODGKIN LYMPHOMA	971	9714/3 Large cell lymphoma 9719/3 NK/T-cell lymphoma, nasal and nasal- type
PRECURS. CELL LYMPHOBLASTIC LYMPH.	972	9727/3 Precursor cell lymphoblastic lymphoma, NOS 9728/3 Precursor B-cell lymphoblastic lymphoma 9729/3 Precursor T-cell lymphoblastic lymphoma
PLASMA CELL TUMORS	973	9731/3 Plasmacytoma, NOS 9734/3 Plasmacytoma, extramedullary
NEOPLASMS OF HISTIOCYTES AND ACCESSORY LYMPHOID CELLS	975	9750/3 Malignant histiocytosis 9754/3 Langerhans cell histiocytosis, disseminated 9755/3 Histiocytic sarcoma 9756/3 Langerhans cell sarcoma 9757/3 Interdigitating dendritic cell sarcoma 9758/3 Follicular dendritic cell sarcoma

California Cancer Reporting System Standards, Volume I

LEUKEMIA	993	9930/3 Myeloid sarcoma
<u>VENTRICLE C715</u>		
NEOPLASM	800	<u>8000/0 Neoplasm, benign</u> <u>8000/1 Neoplasm, uncertain whether benign or malignant</u> 8000/3 Neoplasm, malignant <u>8001/0 Tumor cells, benign</u> <u>8001/1 Tumor cells, uncertain whether benign or malignant</u> 8001/3 Tumor cells, malignant 8005/3 Malignant tumor, clear cell type
TERATOMA	908	9085/3 Mixed germ cell tumor
MISCELLANEOUS TUMORS	937	9370/3 Chordoma, NOS 9371/3 Chondroid chordoma 9372/3 Dedifferentiated chordoma
GLIOMA	938	9380/3 Glioma, malignant 9381/3 Gliomatosis cerebri

California Cancer Reporting System Standards, Volume I

		9382/3 Mixed glioma
		<u>9383/1 Gliomatosis cerebri</u>
		<u>9384/1 Subependymal giant cell astrocytoma</u>
EPENDYMOMA, NOS	939	
		<u>9390/0 Choroid plexus papilloma, NOS</u>
		<u>9390/1 Atypical choroid plexus papilloma</u>
		9390/3 Choroid plexus papilloma, malignant
		9391/3 Ependymoma, NOS
		9392/3 Ependymoma, anaplastic
		9393/3 Papillary ependymoma
ASTROCYTOMA, NOS	940	
		9400/3 Astrocytoma, NOS
		9401/3 Astrocytoma, anaplastic
PROTOPLASMIC ASTROCYTOMA	941	
		9410/3 Protoplasmic astrocytoma
		9411/3 Gemistocytic astrocytoma
FIBRILLARY ASTROCYTOMA	942	
		9420/3 Fibrillary astrocytoma
		<u>9421/1 Pilocytic astrocytoma</u>
		9423/3 Polar spongioblastoma
		9424/3 Pleomorphic xanthoastrocytoma

California Cancer Reporting System Standards, Volume I

ASTROBLASTOMA	943	9430/3 Astroblastoma
GLIOBLASTOMA, NOS	944	9440/3 Glioblastoma, NOS 9441/3 Giant cell glioblastoma 9442/3 Gliosarcoma <u>9444/1 Chordoid glioma</u>
OLIGODENDROGLIOMA, NOS	945	9450/3 Oligodendroglioma, NOS 9451/3 Oligodendroglioma, anaplastic
PRIMITIVE NEUROECTODERMAL	947	9473/3 Primitive neuroectodermal tumor (PNET)
GANGLIONEUROBLASTOMA	949	<u>9490/0 Ganglioneuroma</u> 9490/3 Ganglioneuroblastoma <u>9492/0 Gangliocytoma</u>
NEUROBLASTOMA, NOS	950	9500/3 Neuroblastoma, NOS 9501/3 Medulloepithelioma, NOS 9502/3 Teratoid medulloepithelioma 9503/3 Neuroepithelioma, NOS

9505/1 Ganglioglioma, NOS

9505/3 Ganglioglioma,  
anaplastic

9506/1 Central neurocytoma

9508/3 Atypical  
teratoid/rhabdoid tumor

MENINGIOMAS

953

9530/0 Meningioma, NOS

9530/1 Meningiomatosis,  
NOS

9530/3 Meningioma,  
malignant

9531/0 Meningotheliomatous  
meningioma

9532/0 Fibrous meningioma

9533/0 Psammomatosis  
meningioma

9534/0 Angiomatous  
meningioma

9537/0 Transitional  
meningioma

9538/1 Clear cell  
meningioma

9538/3 Papillary  
meningioma

MALIGNANT LYMPHOMA,  
NOS

959

9590/3 Malignant lymphoma,  
NOS

9591/3 Malignant lymphoma,  
non-Hodgkin

9596/3 Composite Hodgkin and  
non-Hodgkin lymphoma



California Cancer Reporting System Standards, Volume I

ML, SMALL B-CELL LYMPHOCYTIC	967	9670/3 ML, small B lymphocytic, NOS 9671/3 ML, lymphoplasmacytic 9673/3 Mantle cell lymphoma 9675/3 ML, mixed sm. and Ig. cell, diffuse
ML, LARGE B-CELL, DIFFUSE	968	9680/3 ML, large B-cell, diffuse 9684/3 ML, large B-cell, diffuse, immunoblastic, NOS 9687/3 Burkitt lymphoma, NOS
FOLLIC. & MARGINAL LYMPH, NOS	969	9690/3 Follicular lymphoma, NOS 9691/3 Follicular lymphoma, grade 2 9695/3 Follicular lymphoma, grade 1 9698/3 Follicular lymphoma, grade 3 9699/3 Marginal zone B-cell lymphoma, NOS
T-CELL LYMPHOMAS	970	9701/3 Sezary syndrome 9702/3 Mature T-cell lymphoma, NOS 9705/3 Angioimmunoblastic T-cell lymphoma
OTHER SPEC. NON-	971	

California Cancer Reporting System Standards, Volume I

HODGKIN LYMPHOMA

9714/3 Anaplastic large cell lymphoma, T-cell and Null cell type

9719/3 NK/T-cell lymphoma, nasal and nasal-type

PRECURS. CELL  
LYMPHOBLASTIC LYMPH.

972

9727/3 Precursor cell lymphoblastic lymphoma, NOS

9728/3 Precursor B-cell lymphoblastic lymphoma

9729/3 Precursor T-cell lymphoblastic lymphoma

PLASMA CELL TUMORS

973

9731/3 Plasmacytoma, NOS

9734/3 Plasmacytoma, extramedullary

NEOPLASMS OF  
HISTIOCYTES AND  
ACCESSORY LYMPHOID  
CELLS

975

9750/3 Malignant histiocytosis

9754/3 Langerhans cell histiocytosis, disseminated

9755/3 Histiocytic sarcoma

9756/3 Langerhans cell sarcoma

9757/3 Interdigitating dendritic cell sarcoma

9758/3 Follicular dendritic cell sarcoma

CEREBELLUM C716

California Cancer Reporting System Standards, Volume I

NEOPLASM	800	<p><u>8000/0 Neoplasm, benign</u></p> <p><u>8000/1 Neoplasm, uncertain whether benign or malignant</u></p> <p>8000/3 Neoplasm, malignant</p> <p><u>8001/0 Tumor cells, benign</u></p> <p><u>8001/1 Tumor cells, uncertain whether benign or malignant</u></p> <p>8001/3 Tumor cells, malignant</p> <p>8005/3 Malignant tumor, clear cell type</p>
SARCOMA, NOS	880	<p><u>8800/0 Soft tissue tumor, benign</u></p> <p>8800/3 Sarcoma, NOS</p> <p>8805/3 Undifferentiated sarcoma</p> <p>8806/3 Desmoplastic small round cell tumor</p>
FIBROMATOUS NEOPLASMS	881	<p>8810/3 Fibrosarcoma, NOS</p> <p><u>8815/0 Solitary fibrous tumor</u></p>
LIPOMATOUS NEOPLASMS	885	<p><u>8850/0 Lipoma, NOS</u></p>
GERM CELL NEOPLASMS	908	<p><u>9080/0 Teratoma, benign</u></p> <p><u>9080/1 Teratoma, NOS</u></p>

California Cancer Reporting System Standards, Volume I

		9080/3 Teratoma, malignant, NOS
		<u>9084/0 Dermoid cyst, NOS</u>
BLOOD VESSEL TUMORS	912	
		<u>9120/0 Hemangioma, NOS</u>
HEMANGIOENDOTHELIOMA	913	
		<u>9131/0 Capillary hemangioma</u>
HEMANGIOPERICYTOMA	915	
		<u>9150/1 Hemangiopericytoma, NOS</u>
HEMANGIOBLASTOMA	916	
		<u>9161/1 Hemangioblastoma</u>
CHORDOMA	937	
		9370/3 Chordoma, NOS
		9371/3 Chondroid chordoma
		9372/3 Dedifferentiated chordoma
GLIOMA	938	
		9380/3 Glioma, malignant
		9381/3 Gliomatosis cerebri
		9382/3 Mixed glioma
		<u>9383/1 Subependymoma</u>
EPENDYMOMA, NOS	939	
		9391/3 Ependymoma, NOS

California Cancer Reporting System Standards, Volume I

		9392/3 Ependymoma, anaplastic
		9393/3 Papillary ependymoma
ASTROCYTOMA, NOS	940	
		9400/3 Astrocytoma, NOS
		9401/3 Astrocytoma, anaplastic
PROTOPLASMIC ASTROCYTOMA	941	
		9410/3 Protoplasmic astrocytoma
		9411/3 Gemistocytic astrocytoma
FIBRILLARY ASTROCYTOMA	942	
		9420/3 Fibrillary astrocytoma
		<u>9421/1 Pilocytic astrocytoma</u>
		9424/3 Pleomorphic xanthoastrocytoma
ASTROBLASTOMA	943	
		9430/3 Astroblastoma
GLIOBLASTOMA, NOS	944	
		9440/3 Glioblastoma, NOS
		9441/3 Giant cell glioblastoma
		9442/3 Gliosarcoma
OLIGODENDROGLIOMA,	945	

California Cancer Reporting System Standards, Volume I

NOS		9450/3 Oligodendroglioma, NOS
		9451/3 Oligodendroglioma, anaplastic
MEDULLOBLASTOMA, NOS	947	
		9470/3 Medulloblastoma, NOS
		9471/3 Desmoplastic medulloblastoma
		9472/3 Medullomyoblastoma
		9473/3 Primitive neuroectodermal tumor
		9474/3 Large cell medulloblastoma
CEREBELLAR SARCOMA, NOS	948	
		9480/3 Cerebellar sarcoma, NOS
GANGLIONEUROBLASTOMA	949	
		<u>9490/0 Ganglioneuroma</u>
		9490/3 Ganglioneuroblastoma
		<u>9492/0 Gangliocytoma</u>
		<u>9493/0 Dysplastic gangliocytoma of cerebellum (Lhermitte-Duclos)</u>
NEUROBLASTOMA, NOS	950	
		9500/3 Neuroblastoma, NOS
		9501/3 Medulloepithelioma, NOS
		9502/3 Teratoid medulloepithelioma
		9503/3 Neuroepithelioma, NOS
		<u>9505/1 Ganglioglioma, NOS</u>
		<u>9506/1 Central neurocytoma</u>

9508/3 Atypical  
teratoid/rhabdoid tumor

MENINGIOMAS

953

9530/0 Meningioma, NOS

9530/1 Meningiomatosis,  
NOS

9530/3 Meningioma,  
malignant

9531/0 Meningotheliomatous  
meningioma

9532/0 Fibrous meningioma

9533/0 Psammomatous  
meningioma

9534/0 Angiomatous  
meningioma

9537/0 Transitional  
meningioma

9538/1 Clear cell  
meningioma

9538/3 Papillary meningioma

MALIGNANT LYMPHOMA,  
NOS

959

9590/3 Malignant lymphoma,  
NOS

9591/3 Malignant lymphoma,  
non-Hodgkin

9596/3 Composite Hodgkin and  
non-Hodgkin lymphoma

ML, SMALL B-CELL  
LYMPHOCYTIC

967

9670/3 ML, small B lymphocytic,  
NOS

9671/3 ML, lymphoplasmacytic

9673/3 Mantle cell lymphoma

California Cancer Reporting System Standards, Volume I

		9675/3 ML, mixed sm. and lg. cell, diffuse
ML, LARGE B-CELL, DIFFUSE	968	9680/3 ML, large B-cell, diffuse 9684/3 ML, large B-cell, diffuse, immunoblastic, NOS 9687/3 Burkitt lymphoma, NOS
FOLLIC. & MARGINAL LYMPH, NOS	969	9690/3 Follicular lymphoma, NOS 9691/3 Follicular lymphoma, grade 2 9695/3 Follicular lymphoma, grade 1 9698/3 Follicular lymphoma, grade 3 9699/3 Marginal zone B-cell lymphoma, NOS
T-CELL LYMPHOMAS	970	9701/3 Sezary syndrome 9702/3 Peripheral T-cell lymphoma, NOS 9705/3 Angioimmunoblastic T-cell lymphoma
OTHER SPEC. NON-HODGKIN LYMPHOMA	971	9714/3 Anaplastic large cell lymphoma, T-cell and Null cell type 9719/3 NK/T-cell lymphoma, nasal and nasal-type



California Cancer Reporting System Standards, Volume I

<p>PRECURS. CELL LYMPHOBLASTIC LYMPH.</p>	<p>972</p>	<p>9727/3 Precursor cell lymphoblastic lymphoma, NOS</p> <p>9728/3 Precursor B-cell lymphoblastic lymphoma</p> <p>9729/3 Precursor T-cell lymphoblastic lymphoma</p>
---	------------	--

<p>PLASMA CELL TUMORS</p>	<p>973</p>	<p>9731/3 Plasmacytoma, NOS</p> <p>9734/3 Plasmacytoma, extramedullary</p>
---------------------------	------------	--

<p>NEOPLASMS OF HISTIOCYTES AND ACCESSORY LYMPHOID CELLS</p>	<p>975</p>	<p>9750/3 Malignant histiocytosis</p> <p>9754/3 Langerhans cell histiocytosis, disseminated</p> <p>9755/3 Histiocytic sarcoma</p> <p>9756/3 Langerhans cell sarcoma</p> <p>9757/3 Interdigitating dendritic cell sarcoma</p> <p>9758/3 Follicular dendritic cell sarcoma</p>
--	------------	--

OTHER NERVOUS SYSTEM C728-C729

<p>NEOPLASM</p>	<p>800</p>	<p><u>8000/0 Neoplasm, benign</u></p> <p><u>8000/1 Neoplasm, uncertain whether benign or malignant</u></p>
-----------------	------------	--

California Cancer Reporting System Standards, Volume I

8000/3 Neoplasm, malignant

8001/0 Tumor cells, benign

8001/1 Tumor cells, uncertain whether benign or malignant

8001/3 Tumor cells, malignant

8002/3 Malignant tumor, small cell type

8003/3 Malignant tumor, giant cell type

8004/3 Malignant tumor, spindle cell type

8005/3 Malignant tumor, clear cell type

SARCOMA, NOS 880

8800/0 Soft tissue tumor, benign

8800/3 Sarcoma, NOS

8801/3 Spindle cell sarcoma

8802/3 Giant cell sarcoma

8803/3 Small cell sarcoma

8804/3 Epithelioid sarcoma

8805/3 Undifferentiated sarcoma

8806/3 Desmoplastic small round cell tumor

LIPOMATOUS NEOPLASMS 885

8850/0 Lipoma, NOS

8850/1 Atypical lipoma

8850/3 Liposarcoma, NOS

ANGIOLIPOMA 886

California Cancer Reporting System Standards, Volume I

		8861/0 Angiolipoma
MYOMATOUS NEOPLASMS	889	<u>8890/0 Leiomyoma, NOS</u> <u>8890/1 Leiomyomatosis, NOS</u> 8890/3 Leiomyosarcoma, NOS <u>8897/1 Smooth muscle              tumor, NOS</u>
RHABDOMYOSARCOMA	890	<u>8900/0 Rhabdomyoma, NOS</u> 8900/3 Rhabdomyosarcoma, NOS
EMBRYONAL RHABDOMYOSARCOMA	891	8910/3 Embryonal rhabdomyosarcoma, NOS
ALVEOLAR RHABDOMYOSARCOMA	892	8920/3 Alveolar rhabdomyosarcoma
GERM CELL TUMORS	906	9064/3 Germinoma
TERATOMA	908	<u>9080/1 Teratoma, NOS</u> 9080/3 Teratoma, malignant, NOS 9082/3 Malignant teratoma, undiff. <u>9084/0 Dermoid cyst, NOS</u>

California Cancer Reporting System Standards, Volume I

9084/3 Teratoma with malig.  
transformation

BLOOD VESSEL TUMORS 912

9120/0 Hemangioma, NOS

9120/3 Hemangiosarcoma

9121/0 Cavernous  
hemangioma

HEMANGIOENDOTHELIOMA 913

9130/0  
Hemangioendothelioma,  
benign

9130/1  
Hemangioendothelioma, NOS

9130/3  
Hemangioendothelioma,  
malignant

KAPOSI SARCOMA 914

9140/3 Kaposi sarcoma

HEMANGIOPERICYTOMA 915

9150/0 Hemangiopericytoma,  
benign

9150/1 Hemangiopericytoma,  
NOS

9150/3 Hemangiopericytoma,  
malignant

HEMANGIOBLASTOMA 916

9161/1 Hemangioblastoma

California Cancer Reporting System Standards, Volume I

MISCELLANEOUS BONE TUMORS	926	9260/3 Ewing sarcoma
CHORDOMA	937	9370/3 Chordoma, NOS 9371/3 Chondroid chordoma 9372/3 Dedifferentiated chordoma
NEUROBLASTOMA, NOS	950	9500/3 Neuroblastoma, NOS 9501/3 Medulloepithelioma, NOS 9502/3 Teratoid medulloepithelioma 9503/3 Neuroepithelioma, NOS 9508/3 Atypical teratoid/rhabdoid tumor
MENINGIOMA	953	<u>9530/0 Meningioma, NOS</u> <u>9530/1 Meningiomatosis, NOS</u> <u>9530/3 Meningioma, malignant</u> <u>9531/0 Meningothelomatous meningioma</u> <u>9532/0 Fibrous meningioma</u> <u>9533/0 Psammomatous meningioma</u> <u>9534/0 Angiomatous meningioma</u> <u>9537/0 Transitional meningioma</u> <u>9538/1 Clear cell meningioma</u>

California Cancer Reporting System Standards, Volume I

9538/3 Papillary meningioma

NEUROFIBROSARCOMA 954

9540/0 Neurofibroma, NOS

9540/1 Neurofibromatosis, NOS

9540/3 Malignant peripheral  
nerve sheath tumor

9541/0 Melanotic  
neurofibroma

PLEXIFORM  
NEUROFIBROMA 955

9550/0 Plexiform  
neurofibroma

NEURILEMOMA 956

9560/0 Neurilemmoma, NOS

9560/3 Neurilemmoma,  
malignant

9561/3 Triton tumor, malignant

9562/0 Neurothekeoma

NEUROMA 957

9570/0 Neuroma, NOS

9571/0 Perineurioma, NOS

9571/3 Perineurioma,  
malignant

MALIGNANT LYMPHOMA,  
NOS 959

9590/3 Malignant lymphoma,  
NOS

9591/3 Malignant lymphoma,  
non-Hodgkin

9596/3 Composite Hodgkin and

California Cancer Reporting System Standards, Volume I

		non-Hodgkin lymphoma
HODGKIN LYMPHOMA	965	<p>9650/3 Hodgkin lymphoma, NOS</p> <p>9651/3 Hodgkin lymphoma, lymphocyte-rich</p> <p>9652/3 Hodgkin lymphoma, mixed cellularity, NOS</p> <p>9653/3 Hodgkin lymphoma, lymphocytic deplet., NOS</p> <p>9654/3 Hodgkin lymphoma, lymphocyt. deplet., diffuse fibrosis</p> <p>9655/3 Hodgkin lymphoma, lymphocyt. deplet., reticular</p> <p>9659/3 Hodgkin lymphoma, nodular lymphocyte predom.</p>
HODGKIN LYMPHOMA, NOD. SCLER.	966	<p>9661/3 Hodgkin granuloma</p> <p>9662/3 Hodgkin sarcoma</p> <p>9663/3 Hodgkin lymphoma, nodular sclerosis, NOS</p> <p>9664/3 Hodgkin lymphoma, nod. scler., cellular phase</p> <p>9665/3 Hodgkin lymphoma, nod. scler., grade 1</p> <p>9667/3 Hodgkin lymphoma, nod. scler., grade 2</p>
ML, SMALL B-CELL LYMPHOCYTIC	967	<p>9670/3 ML, small B lymphocytic, NOS</p> <p>9671/3 ML, lymphoplasmacytic</p> <p>9673/3 Mantle cell lymphoma</p>

California Cancer Reporting System Standards, Volume I

		9675/3 ML, mixed sm. and lg. cell, diffuse
ML, LARGE B-CELL, DIFFUSE	968	9680/3 ML, large B-cell, diffuse 9684/3 ML, large B-cell, diffuse, immunoblastic, NOS 9687/3 Burkitt lymphoma, NOS
FOLLIC. & MARGINAL LYMPH, NOS	969	9690/3 Follicular lymphoma, NOS 9691/3 Follicular lymphoma, grade 2 9695/3 Follicular lymphoma, grade 1 9698/3 Follicular lymphoma, grade 3 9699/3 Marginal zone B-cell lymphoma, NOS
T-CELL LYMPHOMAS	970	9701/3 Sezary syndrome 9702/3 Mature T-cell lymphoma, NOS 9705/3 Angioimmunoblastic T-cell lymphoma
OTHER SPEC. NON-HODGKIN LYMPHOMA	971	9714/3 Anaplastic large cell lymphoma, T-cell and Null cell type 9719/3 NK/T-cell lymphoma, nasal and nasal-type



California Cancer Reporting System Standards, Volume I

<p>PRECURS. CELL LYMPHOBLASTIC LYMPH.</p>	<p>972</p>	<p>9727/3 Precursor cell lymphoblastic lymphoma, NOS</p> <p>9728/3 Precursor B-cell lymphoblastic lymphoma</p> <p>9729/3 Precursor T-cell lymphoblastic lymphoma</p>
<p>PLASMA CELL TUMORS</p>	<p>973</p>	<p>9731/3 Plasmacytoma, NOS</p> <p>9734/3 Plasmacytoma, extramedullary</p>
<p>MAST CELL TUMORS</p>	<p>974</p>	<p>9740/3 Mast cell sarcoma</p> <p>9741/3 Malignant mastocytosis</p>
<p>NEOPLASMS OF HISTIOCYTES AND ACCESSORY LYMPHOID CELLS</p>	<p>975</p>	<p>9750/3 Malignant histiocytosis</p> <p>9754/3 Langerhans cell histiocytosis, disseminated</p> <p>9755/3 Histiocytic sarcoma</p> <p>9756/3 Langerhans cell sarcoma</p> <p>9757/3 Interdigitating dendritic cell sarcoma</p> <p>9758/3 Follicular dendritic cell sarcoma</p>
<p>LYMPHOID LEUKEMIAS</p>	<p>982</p>	<p>9827/3 Adult T-cell</p>

California Cancer Reporting System Standards, Volume I

leukemia/lymphoma (HTLV-1 positive)

MYELOID LEUKEMIAS 986

9861/3 Acute myeloid leukemia, NOS

OTHER LEUKEMIAS 993

9930/3 Myeloid sarcoma

PITUITARY GLAND and CRANIOPHARYNGEAL DUCT C751-C752

NEOPLASM 800

8000/0 Neoplasm, benign

8000/1 Neoplasm, uncertain whether benign or malignant

8000/3 Neoplasm, malignant

8001/0 Tumor cells, benign

8001/1 Tumor cells, uncertain whether benign or malignant

8001/3 Tumor cells, malignant

8005/0 Clear cell tumor, NOS

8005/3 Malignant tumor, clear cell type

CARCINOMA, NOS 801

8010/0 Epithelial tumor, benign

8010/2 Carcinoma in situ, NOS

8010/3 Carcinoma, NOS

ADENOCARCINOMA, NOS 814

8140/0 Adenoma, NOS

California Cancer Reporting System Standards, Volume I

		8140/2 Adenocarcinoma in situ
		8140/3 Adenocarcinoma, NOS
		<u>8146/0 Monomorphic adenoma</u>
PAPILLARY ADENOMA, NOS	826	<u>8260/0 Papillary adenoma, NOS</u>
CHROMOPHOBE CARCINOMA	827	<u>8270/0 Chromophobe adenoma</u> 8270/3 Chromophobe carcinoma <u>8271/0 Prolactinoma</u> <u>8272/0 Pituitary adenoma, NOS</u> 8272/3 Pituitary carcinoma, NOS
ACIDOPHIL CARCINOMA	828	<u>8280/0 Acidophil adenoma</u> 8280/3 Acidophil carcinoma <u>8281/0 Mixed acidophil-basophil adenoma</u> 8281/3 Mixed acidophil-basophil carcinoma
OXYPHILIC ADENOCARCINOMA	829	<u>8290/0 Oxyphilic adenoma</u> 8290/3 Oxyphilic adenocarcinoma
BASOPHIL CARCINOMA	830	<u>8300/0 Basophil adenoma</u> 8300/3 Basophil carcinoma
CLEAR CELL	831	

California Cancer Reporting System Standards, Volume I

ADENOCA., NOS		<u>8310/0 Clear cell adenoma</u>
GRANULAR CELL CARCINOMA	832	8320/3 Granular cell carcinoma <u>8323/0 Mixed cell adenoma</u> 8323/3 Mixed cell adenocarcinoma
SOFT TISSUE TUMORS	880	<u>8800/0 Soft tissue tumor, benign</u> 8800/3 Sarcoma, NOS
LIPOMATOUS NEOPLASMS	885	<u>8850/0 Lipoma, NOS</u>
DYSGERMINOMA	906	9060/3 Dysgerminoma 9064/3 Germinoma 9065/3 Germ cell tumor, nonseminomatous
EMBRYONAL CARCINOMA, NOS	907	9070/3 Embryonal carcinoma, NOS 9071/3 Yolk sac tumor 9072/3 Polyembryoma
TERATOMA, NOS	908	<u>9080/0 Teratoma, benign</u> <u>9080/1 Teratoma, NOS</u> 9080/3 Teratoma, malignant, NOS 9081/3 Teratocarcinoma 9082/3 Malignant teratoma, undiff.

California Cancer Reporting System Standards, Volume I

		9083/3 Malignant teratoma, intermediate
		9084/3 Teratoma with malign. transformation
		9085/3 Mixed germ cell tumor
CRANIOPHARYNGIOMA	935	
		<u>9350/1 Craniopharyngioma</u>
		<u>9351/1 Adamantinomatous craniopharyngioma</u>
		<u>9352/1 Papillary craniopharyngioma</u>
CHORDOMA	937	
		9370/3 Chordoma
		9371/3 Chondroid chordoma
		9372/3 Dedifferentiated chordoma
NEUROBLASTOMA, NOS	950	
		9500/3 Neuroblastoma, NOS
		9501/3 Medulloepithelioma, NOS
		9502/3 Teratoid medulloepithelioma
		9503/3 Neuroepithelioma, NOS
		9505/3 Ganglioglioma, anaplastic
GRANULAR CELL TUMORS	958	
		<u>9580/0 Granular cell tumor, NOS</u>
FOLLIC. & MARGINAL LYMPH, NOS	969	
		9699/3 Marginal zone B-cell lymphoma, NOS

California Cancer Reporting System Standards, Volume I

PINEAL GLAND C753

NEOPLASM	800	<p><u>8000/0 Neoplasm, benign</u></p> <p><u>8000/1 Neoplasm, uncertain whether benign or malignant</u></p> <p>8000/3 Neoplasm, malignant</p> <p><u>8001/0 Tumor cells, benign</u></p> <p><u>8001/1 Tumor cells, uncertain whether benign or malignant</u></p> <p>8001/3 Tumor cells, malignant</p>
CARCINOMA, NOS	801	<p><u>8010/0 Epithelial tumor, benign</u></p>
DYSGERMINOMA	906	<p>9060/3 Dysgerminoma</p> <p>9064/3 Germinoma</p> <p>9065/3 Germ cell tumor, nonseminomatous</p>
EMBRYONAL CARCINOMA, NOS	907	<p>9070/3 Embryonal carcinoma, NOS</p> <p>9071/3 Yolk sac tumor</p> <p>9072/3 Polyembryoma</p>
TERATOMA, NOS	908	<p><u>9080/0 Teratoma, NOS</u></p> <p>9080/3 Teratoma, malignant, NOS</p> <p>9081/3 Teratocarcinoma</p> <p>9082/3 Malignant teratoma,</p>

California Cancer Reporting System Standards, Volume I

		undiff.
		9083/3 Malignant teratoma, intermediate
		<u>9084/0 Dermoid cyst, NOS</u>
		9084/3 Teratoma with malig. transformation
		9085/3 Mixed germ cell tumor
PINEALOMA, MALIGNANT	936	
		<u>9360/1 Pinealoma, NOS</u>
		<u>9361/1 Pineocytoma</u>
		9362/3 Pineoblastoma
CHORDOMA	937	
		9370/3 Chordoma, NOS
		9371/3 Chondroid chordoma
		9372/3 Dedifferentiated chordoma
PRIMITIVE NEUROECTODERMAL	947	
		9473/3 Primitive neuroectodermal tumor, NOS
GANGLIONEUROBLASTOMA	949	
		9490/3 Ganglioneuroblastoma
		<u>9492/0 Gangliocytoma</u>
NEUROBLASTOMA, NOS	950	
		9500/3 Neuroblastoma, NOS
		9501/3 Medulloepithelioma, NOS
		9502/3 Teratoid medulloepithelioma

California Cancer Reporting System Standards, Volume I

9503/3 Neuroepithelioma, NOS  
9505/1 Ganglioglioma, NOS  
9505/3 Ganglioglioma, anaplastic

ML, LARGE B-CELL,  
DIFFUSE 968

9680/3 ML, large B-cell, diffuse

FOLLIC. & MARGINAL  
LYMPH, NOS 969

9699/3 Marginal zone B-cell  
lymphoma, NOS



## **APPENDIX W: Race and Nationality Descriptions**

Appendix W consists of the Race and Nationality Descriptions from the 2000 Census and Bureau of Vital Statistics. This listing is an appendix to the 2004 SEER Race Coding Guidelines.

As a reminder, the CCR has added code 90 for Other South Asian. Please note that code 90 is not included in Appendix W because it is a code added by the CCR.

Refer to [Section III.2.9](#) for more detailed race coding information.

Races to be coded as 90 include:

- Bangladeshi
- Bhutanese
- Nepalese
- Sikkimese
- Sri Lankan

Do not use code 96 as Appendix W indicates for the races listed above.

## Appendix W.1: Race and Nationality Descriptions (Numeric)

**Note: Use these lists only when race is not stated but other information is provided in the medical record.**

### **References:**

1. *Race and Ethnicity Code Set, Version 1.0, Centers for Disease Control and Prevention, March 2000.*
2. *Instruction manual, part 4: Classification And Coding Instructions For Death Records, 1999-2001, Division of Vital Statistics, National Center for Health Statistics, undated*

### **Key**

*Use this code unless patient is stated to be Native American (Indian) or other race*

*\* Terms listed in reference 2, above.*

*! Description of religious affiliation rather than stated nationality or ethnicity; should be used with caution when determining appropriate race code.*

### **CODE 01 WHITE**

Afghan, Afghanistani  
Afrikaner  
Albanian  
Algerian\*  
Amish\*  
Anglo-Saxon\*  
Arab, Arabian  
Argentinian\*  
Armenian  
Assyrian  
Australian\*  
Austrian\*  
Azores\*  
Basque\*  
Bavarian\*  
Bolivian\*  
Bozniak/Bosnian  
Brava/Bravo\*  
Brazilian  
Bulgarian  
Cajun  
Californio  
Canadian\*

Caucasian\*  
Central American  
Chechnyan  
Chicano\*  
Chilean  
Colombian\*  
Costa Rican\*  
Croat/Croatian  
Crucian\*  
Cuban (*unless specified as Black*)\*  
Cypriot  
Czechoslovakian\*  
Eastern European  
Ebian\*  
Ecuadorian\*  
Egyptian  
English  
English-French\*  
English-Irish\*  
European\*  
Finnish\*  
French  
French Canadian\*  
Georgian\*  
German  
Greek\*  
Guatemalan  
Gypsy\*  
Hebrew\*!  
Herzegovenian  
Hispanic\*  
Honduran  
Hungarian\*  
Iranian, Iran  
Iraqi  
Irish  
Islamic\*!  
Israeli  
Italian  
Jordanian\*  
Kurd/Kurdish  
Kuwaitian\*  
Ladina/Ladino\*  
Latin American\*  
Latino  
Latvian\*  
Lebanese  
Libyan\*

Lithuanian\*  
Maltese\*  
Marshenese\*  
Mauritian\*  
Moroccan\*  
Mediterranean\*  
Mexican  
Middle Eastern  
Moroccan\*  
Moslem\*!  
Muslim\*  
Near Easterner  
Nicaraguan  
Nordic\*  
North African  
Norwegian\*  
Other Arab  
Palestinian  
Panamanian  
Paraguayan  
Parsi\*  
Persian\*  
Peruvian\*  
Polish  
Portuguese\*  
Puerto Rican (*unless specified as Black*)  
Romanian\*  
Rumanian  
Russian\*  
Salvadoran  
Saudi Arabian\*  
Scandanavian\*  
Scottish, Scotch  
Semitic\*!  
Serbian\*  
Servian\*  
Shiite!  
Sicilian\*  
Slavic, Slovakian\*  
South American  
Spanish\*, Spaniard  
Sunni\*!  
Swedish\*  
Syrian  
Tunisian\*  
Turkish, Turk\*  
Ukranian\*  
United Arab Emirati

Uruguayan  
Venezuelan\*  
Welsh\*  
White  
Yemenite\*  
Yugoslavian\*  
Zoroastrian\*

**CODE 02 BLACK OR AFRICAN AMERICAN**

African  
African American  
Afro-American  
Bahamian  
Barbadian  
Bilalian\*  
Black  
Botswana  
Cape Verdean\*  
Dominica Islander (*unless specified as White*)  
Dominican/Dominican Republic (*unless specified as White*)  
Eritrean\*  
Ethiopian  
Ghanian\*  
Haitian  
Hamitic\*  
Jamaican  
Kenyan\*  
Liberian  
Malawian\*  
Mugandan\*  
Namibian  
Nassau\*  
Negro  
Nigerian  
Nigritian  
Nubian\*  
Other African  
Santo Domingo\*  
Seychelloise\*  
Sudanese\*  
Tanzanian\*  
Tobagoan  
Togolese\*  
Trinidadian  
West Indian  
Zairean

**CODE 03 AMERICAN INDIAN AND ALASKA NATIVE**

*(see separate list of tribes )*

Alaska Native  
 Aleut  
 American Indian  
 Central American Indian  
 Eskimo  
 Meso American Indian  
 Mexican American Indian  
 Native American  
 South American Indian  
 Spanish American Indian

**ASIAN RACE CODES**

<u>Code</u>	<u>Definition</u>
96	Amerasian
16	Asian Indian
15	Asian Indian or Pakistani, NOS
96	Asian
96	Asiatic
96	Bangladeshi
96	Bhutanese
96	Bornean
96	Bruneian
96	Burmese
13	Cambodian
96	Celebesian
96	Ceram
96	Ceylonese
04	Chinese
96	Eurasian
06	Filipino
12	Hmong
09	Indian (from India) Retired as of 1/1/2010, replaced by 15, 16, and
17.	
96	Indo-Chinese
96	Indonesian
05	Iwo Jiman
05	Japanese
96	Javanese
13	Kampuchean
08	Korean
11	Laotian
96	Maldivian
96	Madagascar
96	Malaysian
96	Mongolian
96	Montagnard

96	Nepalese
05	Okinawan
96	Oriental
96	Other Asian
17	Pakistani
96	Sikkimese
96	Singaporean
96	Sri Lankan
96	Sumatran
04	Taiwanese
14	Thai
96	Tibetan
10	Vietnamese
96	Whello
96	Yello

**NATIVE HAWAIIAN AND OTHER PACIFIC ISLANDER CODES**

<u>Code</u>	<u>Definition</u>
20	Bikinian
20	Carolinian
21	Chamorro
20	Chuukese
25	Cook Islander
20	Eniwetok, Enewetak
31	Fijian
22	Guamanian
07	Hawaiian
20	Kirabati
20	Kosraean
20	Kwajalein
97	Maori
20	Mariana Islander
20	Marshallese
30	Melanesian
20	Micronesian, NOS
07	Native Hawaiian
97	Nauruan
30	New Caledonian
30	New Hebrides
97	Other Pacific Islander
97	Pacific Islander
20	Palauan
32	Papua New Guinean
07	Part Hawaiian
20	Pohnpeian
25	Polynesian
20	Ponapean
20	Saipanese

27	Samoan
30	Solomon Islander
26	Tahitian
20	Tarawan
20	Tinian
25	Tokelauan
28	Tongan
20	Trukese
25	Tuvaluan
30	Vanuatuan
20	Yapese

**98 OTHER RACE, NOT ELSEWHERE CLASSIFIED**

*Do not use this code for Hispanic, Latino or Spanish, NOS.*

**OTHER RACE DESCRIPTIONS**

Note 1: The following descriptions of ethnic origin cannot be coded to a specific race code. Look for other descriptions of race in the medical record. If no further information is available, code as 99 Unknown.

Aruba Islander  
Azerbaijani  
Belizean  
Bermudan  
Cayenne  
Cayman Islander  
Creole  
Guyanese  
Indian (*not specified as Native American, Eastern Indian, Northern, Central, or South American Indian*)  
Mestizo  
Morena  
South African  
Surinam  
Tejano

Note 2: The following terms self-reported in the 2000 Census cannot be coded to a specific race code. Look for other descriptions of race in the medical record. If no further information is available, code as 99 Unknown.

Biracial  
Interracial  
Mixed  
Multiethnic  
Multinational



Multiracial

**Indian Tribes of the United States, Canada and Mexico (Race Code 03)**

Source: National Center for Health Statistics: *Appendix C, Instruction Manual, part 4: Classification and Coding Instructions For Death Records, 1999-2001.*

Abnaki  
Absentee-Shawnee  
Acoma  
Ak Chin  
Alabama-Coushatt Tribes of Texas  
Alsea  
Apache  
Arapaho  
Arikara  
Assiniboin  
Atacapa  
Athapaskan  
Atsina  
Aztec  
Bear River  
Beaver  
Bella Coola  
Beothuk  
Blackfoot  
Boold Piegan  
Blue Lake  
Brotherton  
Caddo  
Cakchiquel-Ienca  
Calapooya  
Carrier  
Catawba  
Cattaraugus  
Cayuga  
Cayuse  
Chasta Costa  
Chehalis  
Chemehuevi  
Cherokee  
Chetco  
Cheyenne  
Cheyenne River Sioux  
Chickahominy  
Chickasaw  
Chinook

Chipewyan  
Chippewa  
Chippewa-Ojibwa  
Chiricahua Apache  
Chitimacha  
Choctaw  
Chol  
Chontal  
Chorti  
Chuckchansi  
Chumash  
Clallam  
Clatsop  
Clackamus  
Clear Lake  
Coast Salish  
Cochimi  
Cochiti  
Cocopa  
Coeur D'Alene Tribe of Idaho  
Cocopah  
Columbia  
Colville  
Comox  
Comanche  
Concow  
Conquille  
Coushatta  
Covelo  
Cow Creek  
Cowichan  
Cowlitz  
Coyotero Apache  
Cree  
Creek  
Crow  
Crow Creek Sioux  
Dakota  
Delaware  
Diegueno  
Digger  
Dog Rib  
Duckwater  
Eskimo  
Euchi  
Eyak  
Flathead  
Fort Hall Res. Tribe of Idaho

French Indian  
Gabrieleno  
Galice Creek  
Gay Head  
Gosiute  
Gros Ventre  
Haida  
Han  
Hare  
Hat Creek  
Hawasupai  
Hidatsa  
Hoh  
Hoopa  
Hopi  
Houma  
Hualapai  
Huastec  
Humboldt Bay  
Hupa  
Huron  
Illinois  
Ingalik  
Iowa  
Iroquois  
Isleta  
Jemez  
Joshua  
Juaneno  
Jicarilla Apache  
Kaibah  
Kalispel  
Kanosh Band of Paiutes  
Kansa  
Karankawa  
Karak  
Kaska  
Kaw  
Kawai  
Keresan Pueblos  
Kern River  
Kichai  
Kickapoo  
Kiowa  
Kiowa Apache  
Kitamat  
Klamath  
Klikitat

Koasati  
Kootenai Tribe of Idaho  
Kusa  
Kutchin  
Kutenai  
Kwakiutl  
Lac Courte Dreille  
Laguna  
Lakmuit  
Lipan Apache  
Lower Brule Sioux  
Luiseno  
Lummi  
Maidu  
Makah  
Malecite  
Mandan  
Maricopa  
Mary's River  
Mashpee  
Mattaponi  
Maya  
Mayo  
Mdewakanton Sioux  
Menominee  
Menomini  
Mequendodon  
Mescalero Apache  
Miami  
Micmac  
Mission Indians  
Missouri  
Miwok  
Mixe  
Mixtec  
Modoc  
Mohave  
Mohawk  
Mohegan  
Molala  
Monachi  
Mono  
Montagnais  
Montauk  
Muckleshoot  
Munsee  
Nambe  
Namsemond

Nanticoke  
Narragansett  
Naskapi  
Natchez  
Navaho  
Navajo  
Nez Perce  
Niantic  
Nipmuck  
Nisenan-Patwin  
Nisqually  
Nomelaki  
Nooksak  
Nootka  
Northern Paiute  
Oglala Sioux  
Okanogan  
Omaha  
Oneida  
Onondaga  
Opata  
Opato  
Osage  
Oto  
Otoe  
Otomi  
Ottawa  
Ozette  
Paiute  
Pamunkey  
Panamint  
Papago  
Passamaquoddy  
Patwin  
Pawnee  
Pen d'Oreille  
Penobscot  
Peoria  
Pequot  
Picuris  
Pima  
Pit River  
Pojoaque  
Pomo  
Ponca  
Poosepatuck  
Potawatomi  
Potomac

Powhatan  
Pueblos  
Puyallup  
Quapaw  
Quechan  
Quileute  
Quinaielt  
Quinault  
Rappahannock  
Rogue River  
Rosebud Sioux  
Sac and Fox  
Saginaw  
Salish  
Sandia  
San Felipe  
San Ildefonso  
San Juan  
San Lorenzo  
San Luis Obispo  
San Luiseno  
Sanpoil  
Sanpoil Nespelem  
Sant'ana  
Santa Barbara  
Santa Clara  
Santa Ynez  
Santee  
Santee Sioux  
Santiam  
Sauk and Fox  
Scaticook  
Sekane  
Seminole  
Seneca  
Seri  
Shasta  
Shawnee  
Shinnecock  
Shiwits Band of Paiutes  
Shoshone  
Shoshone-Bannock  
Shuswap  
Siouans  
Sioux  
Sisseton  
Sisseton-Wahpeton Sioux  
Siuslaw

Skagit Suiattle  
Skokomish  
Slave  
Smith River  
Snake  
Snohomish  
Snoqualmi  
Songish Southern Paiute  
Squaxin  
Stockbridge  
Sumo-Mosquito  
Suquamish  
Swinomish  
Taimskin  
Tanana  
Tanoan Pueblos  
Taos  
Tarahumare  
Tarascan  
Tawakoni  
Tejon  
Tenino or Warm Springs  
Tesuque  
Teton  
Teton Sioux  
Tillamook  
Timucua  
Thlinget  
Tolowa  
Tonawanda  
Tonkawa  
Tonto Apache  
Topinish  
Totonac  
Tsimshian  
Tulalip  
Tule River Indians  
Tunica  
Tuscarora  
Tututni  
Umatilla  
Umpqua  
Upper Chinook  
Ute  
Waca  
Waicuri-Pericue  
Wailaki  
Walapai

Walla Walla  
Wampanoag  
Wapato  
Warm Springs  
Wasco  
Washo  
Washoe  
Western Apache  
Western Shoshone  
Whilkut  
Wichita  
Wikchamni  
Wind River Shoshone  
Winnebago  
Wintu  
Wintun  
Wishram  
Wyandotte  
Xicaque  
Yahooskin  
Yakima  
Yamel  
Yana  
Yankton  
Yanktonnais Sioux  
Yaqui  
Yaquina  
Yavapai  
Yawilmani  
Yellow Knife  
Yerington Paiute  
Yokuts  
Yokuts-Mono  
Yomba Shoshone  
Yuchi  
Yuki  
Yuma  
Yurok  
Zacatec  
Zapotec  
Zia  
Zoque  
Zuni



## Appendix W.2: Race and Nationality Descriptions Alphabetic

From the 2000 Census and Bureau of Vital; Statistics Alphabetic Index.

Note: Use these lists only when race is not stated but other information is provided in the medical record.

### References:

1. "Race and Ethnicity Code Set, Version 1.0," Centers for Disease Control and Prevention, March 2000.
2. "Instruction manual, part 4: Classification And Coding Instructions For Death Records, 1999-2001," Division of Vital Statistics, National Center for Health Statistics, undated

### Key

Use this code unless patient is stated to be Native American (Indian) or other race

\* Terms listed in reference 2, above.

! Description of religious affiliation rather than stated nationality or ethnicity; should be used with caution when determining appropriate race code.

### A

03	Abnaki
03	Absentee-Shawnee
03	Acoma
01	Afghan, Afghanistani
02	African
02	African American
01	Afrikaner
02	Afro-American
03	Ak Chin
03	Alabama-Coushatt Tribes of Texas
03	Alaska Native
01	Albanian
03	Aleut
01	Algerian*
03	Alsea
96	Amerasian
03	American Indian
01	Amish*
01	Anglo-Saxon*
03	Apache
01	Arab, Arabian
03	Arapaho

California Cancer Reporting System Standards, Volume I

01 Argentinian\*  
03 Arikara  
01 Armenian  
96 Asian  
16 Asian Indian  
15 Asian Indian or Pakistani, NOS  
96 Asiatic  
03 Assiniboin  
01 Assyrian  
03 Atacapa  
03 Athapaskan  
03 Atsina  
01 Australian\*  
01 Austrian\*  
01 Azores\*  
03 Aztec

**B**

02 Bahamian  
96 Bangladeshi  
02 Barbadian  
01 Basque\*  
01 Bavarian\*  
03 Bear River  
03 Beaver  
03 Bella Coola  
03 Beothuk  
96 Bhutanese  
20 Bikinian  
02 Bilalian\*  
02 Black  
03 Blackfoot  
03 Blue Lake  
01 Bolivian\*  
03 Bould Piegan  
96 Bornean  
02 Botswana  
01 Bozniak/Bosnian  
01 Brava/Bravo\*  
01 Brazilian  
03 Brotherton  
96 Bruneian  
01 Bulgarian  
96 Burmese

**C**

03 Caddo  
01 Cajun

California Cancer Reporting System Standards, Volume I

03 Cakchiquel-Ienca  
03 Calapooya  
01 Californio  
13 Cambodian  
01 Canadian\*  
02 Cape Verdean\*  
20 Carolinian  
03 Carrier  
03 Catawba  
03 Cattaraugus  
01 Caucasian\*  
03 Cayuga  
03 Cayuse  
96 Celebesian  
01 Central American  
03 Central American Indian  
96 Ceram  
96 Ceylonese  
21 Chamorro  
03 Chasta Costa  
01 Chechnyan  
03 Chehalis  
03 Chemehuevi  
03 Cherokee  
03 Chetco  
03 Cheyenne  
03 Cheyenne River Sioux  
01 Chicano\*  
03 Chickahominy  
03 Chickasaw  
01 Chilean  
04 Chinese  
03 Chinook  
03 Chipewyan  
03 Chippewa  
03 Chippewa-Ojibwa  
03 Chiricahua Apache  
03 Chitimacha  
03 Choctaw  
03 Chol  
03 Chontal  
03 Chorti  
03 Chuckchansi  
03 Chumash  
20 Chuukese  
03 Clackamus  
03 Clallam  
03 Clatsop

California Cancer Reporting System Standards, Volume I

03 Clear Lake  
03 Coast Salish  
03 Cochimi  
03 Cochiti  
03 Cocopa  
03 Cocopah  
03 Coeur D'Alene Tribe of Idaho  
01 Colombian\*  
03 Columbia  
03 Colville  
03 Comanche  
03 Comox  
03 Concow  
03 Conquille  
25 Cook Islander  
01 Costa Rican\*  
03 Coughatta  
03 Covelo  
03 Cow Creek  
03 Cowichan  
03 Cowlitz  
03 Coyotero Apache  
03 Cree  
03 Creek  
01 Croat/Croatian  
03 Crow  
03 Crow Creek Sioux  
01 Crucian\*  
01 Cuban (*unless specified as Black*)\*  
01 Cypriot  
01 Czechoslovakian\*

**D**

03 Dakota  
03 Delaware  
03 Diegueno  
03 Digger  
03 Dog Rib  
02 Dominica Islander (*unless specified as White*)  
02 Dominican/Dominican Republic (*unless specified as White*)  
03 Duckwater

**E**

01 Eastern European  
01 Ebian\*  
01 Ecuadorian\*  
01 Egyptian  
01 English

California Cancer Reporting System Standards, Volume I

01 English-French\*  
01 English-Irish\*  
20 Eniwetok, Enewetak  
02 Eritrean\*  
03 Eskimo  
02 Ethiopian  
03 Euchi  
96 Eurasian  
01 European\*  
03 Eyak

**F**

31 Fijian  
06 Filipino  
01 Finnish\*  
03 Flathead  
03 Fort Hall Res. Tribe of Idaho  
01 French  
01 French Canadian\*  
03 French Indian

**G**

03 Gabrieleno  
03 Galice Creek  
03 Gay Head  
01 Georgian\*  
01 German  
02 Ghanian\*  
03 Gosiute  
01 Greek\*  
03 Gros Ventre  
22 Guamanian  
01 Guatemalan  
01 Gypsy\*

**H**

03 Haida  
02 Haitian  
02 Hamitic\*  
03 Han  
03 Hare  
03 Hat Creek  
07 Hawaiian  
03 Hawasupai  
01 Hebrew\*!  
01 Herzegovenian  
03 Hidatsa  
01 Hispanic\*

California Cancer Reporting System Standards, Volume I

12 Hmong  
03 Hoh  
01 Honduran  
03 Hoopa  
03 Hopi  
03 Houma  
03 Hualapai  
03 Huastec  
03 Humboldt Bay  
01 Hungarian\*  
03 Hupa  
03 Huron

**I**

03 Illinois  
09 Indian (from India) Retired as of 1/1/2010, replaced by 15, 16, and  
17.  
96 Indo-Chinese  
96 Indonesian  
03 Ingalik  
03 Iowa  
01 Iranian, Iran  
01 Iraqi  
01 Irish  
03 Iroquois  
01 Islamic\*!  
03 Isleta  
01 Israeli  
01 Italian  
05 Iwo Jiman

**J**

02 Jamaican  
05 Japanese  
96 Javanese  
03 Jemez  
03 Jicarilla Apache  
01 Jordanian\*  
03 Joshua  
03 Juaneno

**K**

03 Kaibah  
03 Kalispel  
13 Kampuchean  
03 Kanosh Band of Paiutes  
03 Kansa  
03 Karankawa

California Cancer Reporting System Standards, Volume I

03 Karok  
03 Kaska  
03 Kaw  
03 Kawai  
02 Kenyan\*  
03 Keresan Pueblos  
03 Kern River  
03 Kichai  
03 Kickapoo  
03 Kiowa  
03 Kiowa Apache  
20 Kirabati  
03 Kitamat  
03 Klamath  
03 Klikitat  
03 Koasati  
03 Kootenai Tribe of Idaho  
08 Korean  
20 Kosraean  
01 Kurd/Kurdish  
03 Kusa  
03 Kutchin  
03 Kutenai  
01 Kuwaitian\*  
20 Kwajalein  
03 Kwakiutl

**L**

03 Lac Courte Dreille  
01 Ladina/Ladino\*  
03 Laguna  
03 Lakmuit  
11 Laotian  
01 Latin American\*  
01 Latino/Latina  
01 Latvian\*  
01 Lebanese  
02 Liberian  
01 Libyan\*  
03 Lipan Apache  
01 Lithuanian\*  
03 Lower Brule Sioux  
03 Luiseno  
03 Lummi

**M**

96 Madagascar  
03 Maidu

California Cancer Reporting System Standards, Volume I

03	Makah
02	Malawian*
96	Malaysian
96	Maldivian
03	Malecite
01	Maltese*
03	Mandan
97	Maori
20	Mariana Islander
03	Maricopa
20	Marshallese
01	Marshenese*
03	Mary's River
03	Mashpee
03	Mattaponi
01	Mauritian*
03	Maya
03	Mayo
03	Mdewakanton Sioux
01	Mediterranean*
30	Melanesian
03	Menominee
03	Menomini
03	Mequendodon
03	Mescalero Apache
03	Meso American Indian
01	Mexican
03	Mexican American Indian
03	Miami
03	Micmac
20	Micronesia, NOS
01	Middle Eastern
03	Mission Indians
03	Missouri
03	Miwok
03	Mixe
03	Mixtec
03	Modoc
03	Mohave
03	Mohawk
03	Mohegan
03	Molala
03	Monachi
96	Mongolian
03	Mono
03	Montagnais
96	Montagnard
03	Montauk



California Cancer Reporting System Standards, Volume I

01 Moroccan\*  
01 Moroccan\*  
01 Moslem\*!  
03 Muckleshoot  
02 Mugandan\*  
03 Munsee  
01 Muslim\*!

**N**

03 Nambe  
02 Namibian  
03 Namsemond  
03 Nanticoke  
03 Narragansett  
03 Naskapi  
02 Nassau\*  
03 Natchez  
07 Native Hawaiian  
97 Nauruan  
03 Navaho  
03 Navajo  
01 Near Easterner  
02 Negro  
96 Nepalese  
30 New Caledonian  
30 New Hebrides  
03 Nez Perce  
03 Niantic  
01 Nicaraguan  
02 Nigerian  
02 Nigritian  
03 Nipmuck  
03 Nisenan-Patwin  
03 Nisqually  
03 Nomelaki  
03 Nooksak  
03 Nootka  
01 Nordic\*  
01 North African  
03 Northern Paiute  
01 Norwegian\*  
02 Nubian\*

**O**

03 Oglala Sioux  
03 Okanogan  
05 Okinawan  
03 Omaha

California Cancer Reporting System Standards, Volume I

03 Oneida  
03 Onondaga  
03 Opata  
03 Opato  
96 Oriental  
03 Osage  
02 Other African  
01 Other Arab  
96 Other Asian  
97 Other Pacific Islander  
98 Other race, not elsewhere classified  
03 Oto  
03 Otoe  
03 Otomi  
03 Ottawa  
03 Ozette

**P**

97 Pacific Islander  
03 Paiute  
17 Pakistani  
20 Palauan  
01 Palestinian  
03 Pamunkey  
01 Panamanian  
03 Panamint  
03 Papago  
32 Papua New Guinean  
01 Paraguayan  
01 Parsi\*  
07 Part Hawaiian  
03 Passamaquoddy  
03 Patwin  
03 Pawnee  
03 Pen d'Oreille  
03 Penobscot  
03 Peoria  
03 Pequot  
01 Persian\*  
01 Peruvian\*  
03 Picuris  
03 Pima  
03 Pit River  
20 Pohnpeian  
03 Pojoaque  
01 Polish  
25 Polynesian  
03 Pomo

California Cancer Reporting System Standards, Volume I

20 Ponapean  
03 Ponca  
03 Poosepatuck  
01 Portuguese\*  
03 Potawatomi  
03 Potomac  
03 Powhatan  
03 Pueblos  
01 Puerto Rican (*unless specified as Black*)  
03 Puyallup

**Q**

03 Quapaw  
03 Quechan  
03 Quileute  
03 Quinaielt  
03 Quinault

**R**

03 Rappahannock  
03 Rogue River  
01 Romanian\*  
03 Rosebud Sioux  
01 Rumanian  
01 Russian\*

**S**

03 Sac and Fox  
03 Saginaw  
20 Saipanese  
03 Salish  
01 Salvadoran  
27 Samoan  
03 San Felipe  
03 San Ildefonso  
03 San Juan  
03 San Lorenzo  
03 San Luis Obispo  
03 San Luiseno  
03 Sandia  
03 Sanpoil  
03 Sanpoil Nespelem  
03 Santa Barbara  
03 Santa Clara  
03 Santa Ynez  
03 Sant'ana  
03 Santee  
03 Santee Sioux

California Cancer Reporting System Standards, Volume I

03 Santiam  
02 Santo Domingo\*  
01 Saudi Arabian\*  
03 Sauk and Fox  
01 Scandanavian\*  
03 Scaticook  
01 Scottish, Scotch  
03 Sekane  
03 Seminole  
01 Semitic\*!  
03 Seneca  
01 Serbian\*  
03 Seri  
01 Servian\*  
02 Seychelloise\*  
03 Shasta  
03 Shawnee  
01 Shi'ite!  
03 Shinnecock  
03 Shivwits Band of Paiutes  
03 Shoshone  
03 Shoshone-Bannock  
03 Shuswap  
01 Sicilian\*  
96 Sikkimese  
96 Singaporean  
03 Siouans  
03 Sioux  
03 Sisseton  
03 Sisseton-Wahpeton Sioux  
03 Siuslaw  
03 Skagit Suiattle  
03 Skokomish  
03 Slave  
01 Slavic, Slovakian\*  
03 Smith River  
03 Snake  
03 Snohomish  
03 Snoqualmi  
30 Solomon Islander  
03 Songish Southern Paiute  
01 South American  
03 South American Indian  
03 Spanish American Indian  
01 Spanish\*, Spaniard  
03 Squaxin  
96 Sri Lankan  
03 Stockbridge

California Cancer Reporting System Standards, Volume I

02 Sudanese\*  
96 Sumatran  
03 Sumo-Mosquito  
01 Sunni\*!  
03 Suquamish  
01 Swedish\*  
03 Swinomish  
01 Syrian

**T**

26 Tahitian  
03 Taimskin  
04 Taiwanese  
03 Tanana  
03 Tanoan Pueblos  
02 Tanzanian\*  
03 Taos  
03 Tarahumare  
03 Tarascan  
20 Tarawan  
03 Tawakoni  
03 Tejon  
03 Tenino or Warm Springs  
03 Tesuque  
03 Teton  
03 Teton Sioux  
14 Thai  
03 Thlinget  
96 Tibetan  
03 Tillamook  
03 Timucua  
20 Tinian  
02 Tobagoan  
02 Togolese\*  
25 Tokelauan  
03 Tolowa  
03 Tonawanda  
28 Tongan  
03 Tonkawa  
03 Tonto Apache  
03 Topinish  
03 Totonac  
02 Trinidadian  
20 Trukese  
03 Tsimshian  
03 Tulalip

California Cancer Reporting System Standards, Volume I

03 Tule River Indians  
03 Tunica  
01 Tunisian\*  
01 Turkish, Turk\*  
03 Tuscarora  
03 Tututni  
25 Tuvaluan

**U**

01 Ukranian\*  
03 Umatilla  
03 Umpqua  
01 United Arab Emirati  
03 Upper Chinook  
01 Uruguayan  
03 Ute

**V**

30 Vanuatuan  
01 Venezuelan\*  
10 Vietnamese

**W**

03 Waca  
03 Waicuri-Pericue  
03 Wailaki  
03 Walapai  
03 Walla Walla  
03 Wampanoag  
03 Wapato  
03 Warm Springs  
03 Wasco  
03 Washo  
03 Washoe  
01 Welsh\*  
02 West Indian  
03 Western Apache  
03 Western Shoshone  
96 Whello  
03 Whilkut  
01 White  
03 Wichita  
03 Wikchamni  
03 Wind River Shoshone  
03 Winnebago  
03 Wintu  
03 Wintun  
03 Wishram

03 Wyandotte

**X**

03 Xicaque

**Y**

03 Yahooskin

03 Yakima

03 Yamel

03 Yana

03 Yankton

03 Yanktonnais Sioux

20 Yapese

03 Yaqui

03 Yaquina

03 Yavapai

03 Yawilmani

96 Yello

03 Yellow Knife

01 Yemenite\*

03 Yerington Paiute

03 Yokuts

03 Yokuts-Mono

03 Yomba Shoshone

03 Yuchi

01 Yugoslavian\*

03 Yuki

03 Yuma

03 Yurok

**Z**

03 Zacatec

02 Zairean

03 Zapotec

03 Zia

03 Zoque

01 Zoroastrian\*!

03 Zuni

Note: The following terms cannot be coded to a specific race code. Look for other descriptions of race in the medical record. If no further information is available, code as 99 Unknown.

Aruba Islander

Azerbaijani

Belizean

Bermudan

Biracial

California Cancer Reporting System Standards, Volume I

Cayenne  
Cayman Islander  
Creole  
Guyanese  
Indian (*not specified as Native American, Eastern Indian, Northern, Central, or South American Indian*)  
Interracial  
Mestizo  
Mixed  
Morena  
Multiethnic  
Multinational  
Multiracial  
South African  
Surinam  
Tejano



## **APPENDIX X: National Provider Identifier (NPI) Codes**

The National Provider Identifier (NPI) is a unique identification number for health care providers. It is scheduled for 2007 implementation by the Centers for Medicare and Medicaid Services (CMS) as part of the Health Insurance Portability and Accountability Act of 1996 (HIPAA). Health care providers have started the process of obtaining NPI codes, and hospitals have until May 2007 to meet the HIPAA deadline. NPI numbers are being distributed by CMS to all health care providers in the United States. CMS has mandated use of the assigned NPI in all administrative and financial transactions between "large" health plans and CMS starting in May 2007. For billing purposes, these providers will be required to use NPI codes by May 2007, but indications are that some health care facilities will start using these codes in advance of this deadline. If a facility starts to use the NPI codes, that information should be available from the provider's billing department.

NPI numbers are only assigned to health care providers who meet the definition of a "covered entity," and this only includes individuals and entities licensed to provide health care. NPI's are not being issued to physicians who have opted out of government programs; entities that bill or are paid for health care services furnished by other health care providers; or clearing houses, vendors, administrative, and billing services (*Federal Register* [Friday, January 23, 2004]).

Registries should be able to record the NPI for their hospital or individual physicians with January 1, 2007, diagnoses. It is necessary, however, to be aware that NPI's may not have been assigned to all eligible parties by January 1, 2007. Historic facilities or physicians may no longer be in business or licensed and therefore, may not have an NPI assigned.

The NPI is a 10 byte numeric data item. The NPI consists of 9 numeric digits followed by one numeric check digit. The NPI will not have embedded intelligence. The NPI format and check digit calculation will be compatible with the card issuer identifier on a standard health identification card. The card standard was developed by the National Committee for Information Technology Standards (NCITS), which is accredited by the American National Standards Institute. NPI's will be issued initially with the first digit equal to 1 or 2. NPIs with the first digit equal to 1 are assigned to individual health care providers (i.e., physicians); hospitals or other entities that provide health care services will be assigned the first digit of NPI equal to 2. These digits will not be used as the first digits for other card issuer identifiers. NPI numbers will be generated using a scattering algorithm that has the capability to use all possible numeric combinations beginning with 1 or 2.

Each NPI generated will be unique, without requiring database access for verification.

When a facility starts to use the NPI codes, that information should be entered and transmitted in the appropriate NPI data item fields. It is

anticipated that the implementation of the NPI will vary by facility, provider, and data collection reporting software. Hospital registries should become aware of how the NPI will be implemented in their specific software.

The following data items are all components of the NPI implementation effort.

NPI--Registry ID (NAACCR #45)

The National Provider Identifier (NPI) code that represents the data transmission source. This item stores the NPI of the facility registry that transmits the record.

NPI--Reporting Facility (NAACCR #545)

The NPI code for the facility submitting the data in the record.

NPI--Inst Referred From (NAACCR #2415)

The NPI code that identifies the facility that referred the patient to the reporting facility.

NPI--Inst Referred To (NAACCR #2425)

The NPI code that identifies the facility to which the patient was referred for further care after discharge from the reporting facility.

NPI--Following Registry (NAACCR # 2445)

The NPI code that records the registry responsible for following the patient.

NPI--Physician—Managing (NAACCR # 2465)

The NPI code that identifies the physician who is responsible for the overall management of the patient during diagnosis and/or treatment for this cancer.

NPI--Physician--Follow-Up (NAACCR # 2475)

The NPI code for the physician currently responsible for the patient's medical care.

NPI--Physician--Primary Surg (NAACCR # 2485)

The NPI code for physician who performed the most definitive surgical procedure.

NPI--Physician 3 (NAACCR # 2495)

The NPI code for another physician involved in the care of the patient.

NPI--Physician 4 (NAACCR # 2505)

The NPI code for another physician involved in the care of the patient.

## **APPENDIX Y 1 Index to CSv02.03 Site Specific Factors**

[Click here to open the interactive appendix.](#)

Note, this is a large file and may take 1 to 20 seconds to open.

## **APPENDIX Y 2 Index to CSv02.02 Site Specific Factors**

[Click here to open the interactive appendix.](#)

Note, this is a large file and may take 1 to 20 seconds to open.

## **APPENDIX Z.1: CER Data Dictionary**

The collection of data items for the Comparative Effectiveness Research Project (CER) are optional except for Region 3 reporting facilities. The CCR Data Collection Unit will be obtaining these data items in cooperation with Region 3 reporting facilities. The CER Project is a one year project. Data collection is for breast, colorectal, and chronic myelogenous leukemia cases diagnosed January 1, 2011 through December 31, 2011. The CER Data Dictionary includes the data item codes and coding instructions.

[Click here to open Appendix Z.1, the CER Data Dictionary.](#)

The California Cancer Registry is one of 13 state registries selected for participation in the *National Program of Cancer Registries (NPCR) Project, "Enhancing Cancer Registry Data Systems for Comparative Effectiveness Research."* This project is funded through the American Recovery and Reinvestment Act of 2009 for Patient Centered Health Research (also called Comparative Effectiveness Research).

The purpose of this project is to establish Specialized Cancer Registries by enhancing data collected through a subset for comparative effectiveness research (CER) The goal is to develop sustainable methods to enhance cancer registry data. Outcomes will include a dataset to be used for CER and other research.

## **APPENDIX Z.2: CER Required CSv02.03 Site Specific Factors**

**Click to View One of the Following Tables:**

<a href="#">Breast</a>	<a href="#">Colon</a>	<a href="#">Rectum</a>	<a href="#">Appendix</a>	<a href="#">CML</a>
	<a href="#">NET Colon</a>	<a href="#">NET Rectum</a>	<a href="#">Carcinoid / NET Appendix</a>	

	<a href="#">GIST Colon</a>	<a href="#">GIST Rectum</a>	<a href="#">GIST Appendix</a>	
--	----------------------------	-----------------------------	-------------------------------	--

## CER Required Site Specific Factor

### Breast C50.0-C50.6, C50.8-C50.9

SITE	HISTOLOGY
C50.0-C50.6, C50.8-C50.9	8000-9136, 9141-9582, 9700-9701

Factor	CCR/SEER	CoC	CER	Description
SSF 1	X	X	X	Estrogen Receptor (ER) Assay
SSF 2	X	X	X	Progesterone Receptor (PR) Assay
SSF 3	X	X	X	Number of Positive Ipsilateral Level I-II Axillary Lymph Nodes
SSF 4	X	X	X	Immunohistochemistry (IHC) of Regional Lymph Nodes
SSF 5	X	X	X	Molecular (MOL) Studies of Regional Lymph Nodes
SSF 6	X	X	X	Size of Tumor--Invasive Component
SSF 7	X	X	X	Nottingham or Bloom-Richardson (BR) Score/Grade
SSF 8	X	X	X	HER2: Immunohistochemistry (IHC) Lab Value
SSF 9	X	X	X	HER2: Immunohistochemistry (IHC) Test Interpretation
SSF 10	X	X	X	HER2: Fluorescence In Situ Hybridization (FISH) Lab Value
SSF 11	X	X	X	HER2: Fluorescence In Situ Hybridization (FISH) Test Interpretation
SSF 12	X	X	X	HER2: Chromogenic In Situ Hybridization (CISH) Lab Value
SSF 13	X	X	X	HER2: Chromogenic In Situ Hybridization (CISH) Test Interpretation
SSF 14	X	X	X	HER2: Result of other or unknown test

California Cancer Reporting System Standards, Volume I

Factor	CCR/ SEER	CoC	CER	Description
SSF 15	X	X	X	HER2: Summary Result of Testing <b>(NEW)</b>
SSF 16			X	Combinations of ER, PR, and HER2 Results <b>(NEW)</b>
SSF 17				
SSF 18				
SSF 19				
SSF 20				
SSF 21	X	X	X	Response to Neoadjuvant Therapy
SSF 22	X	X	X	Multigene Signature Method
SSF 23	X	X	X	Multigene Signature Results
SSF 24				
SSF 25				

## CER Required Site Specific Factor

### Colon C18.0, C18.2-C18.9

SITE	HISTOLOGY
C18.0, C18.2-C18.9	8000-8152, 8154-8231, 8243-8245, 8247-8248, 8250-8934, 8940-9136, 9141-9582, 9700-9701

Factor	CCR/SEER	CoC	CER	Description
SSF 1	X	X	X	Carcinoembryonic Antigen (CEA)
SSF 2	X	X	X	Clinical Assessment of Regional Lymph Nodes
SSF 3	X	X	X	Carcinoembryonic Antigen (CEA) Lab Value
SSF 4	X	X	X	Tumor Deposits
SSF 5				
SSF 6	X	X	X	Circumferential Resection Margin (CRM)
SSF 7			X	Microsatellite Instability (MSI)
SSF 8	X	X	X	Perineural Invasion
SSF 9	X	X	X	KRAS
SSF 10			X	18q Loss of Heterozygosity (LOH)
SSF 11				
SSF 12				
SSF 13				
SSF 14				
SSF 15				
SSF 16				
SSF 17				

California Cancer Reporting System Standards, Volume I

<b>Factor</b>	<b>CCR/ SEER</b>	<b>CoC</b>	<b>CER</b>	<b>Description</b>
SSF 18				
SSF 19				
SSF 20				
SSF 21				
SSF 22				
SSF 23				
SSF 24				
SSF 25				

## CER Required Site Specific Factor

### NET Colon C18.0, C18.2-C18.9

SITE	HISTOLOGY
C18.0, C18.2-C18.9	8153, 8240-8242, 8246, 8249

Factor	CCR/SEER	CoC	CER	Description
SSF 1				OBSOLETE - Carcinoembryonic Antigen (CEA)
SSF 2	X	X	X	Clinical Assessment of Regional Lymph Nodes
SSF 3				
SSF 4				
SSF 5				
SSF 6				
SSF 7				
SSF 8				
SSF 9				
SSF 10				
SSF 11				
SSF 12				
SSF 13				
SSF 14				
SSF 15				
SSF 16	X	X	X	Serum Chromogranin A (CgA) Lab Value
SSF 17	X	X	X	Urinary 5-Hydroxyindoleacetic Acid (5-HIAA) Lab Value



California Cancer Reporting System Standards, Volume I

Factor	CCR/ SEER	CoC	CER	Description
SSF 18				
SSF 19				
SSF 20				
SSF 21				
SSF 22				
SSF 23				
SSF 24				
SSF 25				

## CER Required Site Specific Factor

### GIST Colon C18.0, C18.2-C18.9

SITE	HISTOLOGY
C18.0, C18.2-C18.9	8935-8936

Factor	CCR/SEER	CoC	CER	Description
SSF 1				OBSOLETE FOR 2010 (Pre-Operative Carcinoembryonic Antigen (CEA))
SSF 2				OBSOLETE FOR 2010 (Clinical Assessment of Regional Lymph Nodes)
SSF 3				
SSF 4				
SSF 5				
SSF 6				
SSF 7				
SSF 8				
SSF 9				
SSF 10				
SSF 11	X	X	X	Mitotic Count
SSF 12	X	X	X	KIT Gene Immunohistochemistry (IHC)
SSF 13				
SSF 14				
SSF 15				
SSF 16				
SSF 17				

California Cancer Reporting System Standards, Volume I

<b>Factor</b>	<b>CCR/ SEER</b>	<b>CoC</b>	<b>CER</b>	<b>Description</b>
SSF 18				
SSF 19				
SSF 20				
SSF 21				
SSF 22				
SSF 23				
SSF 24				
SSF 25				

## CER Required Site Specific Factor

### Rectum C19.9, C20.9

SITE	HISTOLOGY
C19.9, C20.9	8000-8152, 8154-8231, 8243-8245, 8247, 8248, 8250-8934, 8940-9136, 9141-9582, 9700-9701

Factor	CCR/ SEER	CoC	CER	Description
SSF 1	X	X	X	Carcinoembryonic Antigen (CEA)
SSF 2	X	X	X	Clinical Assessment of Regional Lymph Nodes
SSF 3	X	X	X	Carcinoembryonic Antigen (CEA) Lab Value
SSF 4	X	X	X	Tumor Deposits
SSF 5			X	Tumor Regression Grade
SSF 6	X	X	X	Circumferential Resection Margin (CRM)
SSF 7			X	Microsatellite Instability (MSI)
SSF 8	X	X	X	Perineural Invasion
SSF 9	X	X	X	KRAS
SSF 10			X	18q Loss of Heterozygosity (LOH)
SSF 11				
SSF 12				
SSF 13				
SSF 14				
SSF 15				
SSF 16				
SSF 17				

California Cancer Reporting System Standards, Volume I

<b>Factor</b>	<b>CCR/ SEER</b>	<b>CoC</b>	<b>CER</b>	<b>Description</b>
SSF 18				
SSF 19				
SSF 20				
SSF 21				
SSF 22				
SSF 23				
SSF 24				
SSF 25				

## CER Required Site Specific Factor

### NET Rectum C19.9, C20.9

SITE	HISTOLOGY
C19.9, C20.9	8153, 8240-8242, 8246, 8249

Factor	CCR/ SEER	CoC	CER	Description
SSF 1				OBSOLETE - Carcinoembryonic Antigen (CEA)
SSF 2	X	X	X	Clinical Assessment of Regional Lymph Nodes
SSF 3				
SSF 4				
SSF 5				
SSF 6				
SSF 7				
SSF 8				
SSF 9				
SSF 10				
SSF 11				
SSF 12				
SSF 13				
SSF 14				
SSF 15				
SSF 16	X	X	X	Serum Chromogranin A (CgA) Lab Value
SSF 17	X	X	X	Urinary 5-Hydroxyindoleacetic Acid (5-HIAA) Lab Value
SSF				

California Cancer Reporting System Standards, Volume I

<b>Factor</b>	<b>CCR/ SEER</b>	<b>CoC</b>	<b>CER</b>	<b>Description</b>
18				
SSF 19				
SSF 20				
SSF 21				
SSF 22				
SSF 23				
SSF 24				
SSF 25				

## CER Required Site Specific Factor

### GIST Rectum C19.9, C20.9

SITE	HISTOLOGY
C19.9, C20.9	8935-8936

Factor	CCR/ SEER	CoC	CER	Description
SSF 1				OBSOLETE FOR 2010 (Pre-Operative Carcinoembryonic Antigen (CEA))
SSF 2				OBSOLETE FOR 2010 (Clinical Assessment of Regional Lymph Nodes)
SSF 3				
SSF 4				
SSF 5				
SSF 6				
SSF 7				
SSF 8				
SSF 9				
SSF 10				
SSF 11	X	X	X	Mitotic Count
SSF 12	X	X	X	KIT Gene Immunohistochemistry (IHC)
SSF 13				
SSF 14				
SSF 15				
SSF 16				
SSF 17				
SSF				



California Cancer Reporting System Standards, Volume I

<b>Factor</b>	<b>CCR/ SEER</b>	<b>CoC</b>	<b>CER</b>	<b>Description</b>
18				
SSF 19				
SSF 20				
SSF 21				
SSF 22				
SSF 23				
SSF 24				
SSF 25				

## CER Required Site Specific Factor

### Appendix C18.1

SITE	HISTOLOGY
C18.1	8000-8152, 8154-8231, 8243-8245, 8247-8248, 8250-8934, 8940-9136, 9141-9582, 9700-9701

Factor	CCR/ SEER	CoC	CER	Description
SSF 1	X	X	X	Carcinoembryonic Antigen (CEA)
SSF 2	X	X	X	Clinical Assessment of Regional Lymph Nodes
SSF 3	X	X	X	Carcinoembryonic Antigen (CEA) Lab Value
SSF 4				
SSF 5				
SSF 6				
SSF 7			X	Microsatellite Instability (MSI)
SSF 8				
SSF 9				
SSF 10			X	18q Loss of Heterozygosity (LOH)
SSF 11	X	X	X	Histopathological Grading
SSF 12				
SSF 13				
SSF 14				
SSF 15				
SSF 16				
SSF 17				

California Cancer Reporting System Standards, Volume I

<b>Factor</b>	<b>CCR/ SEER</b>	<b>CoC</b>	<b>CER</b>	<b>Description</b>
SSF 18				
SSF 19				
SSF 20				
SSF 21				
SSF 22				
SSF 23				
SSF 24				
SSF 25				

## CER Required Site Specific Factor

### Carcinoid / NET Appendix C18.1

SITE	HISTOLOGY
C18.1	8153, 8240-8242, 8246, 8249

Factor	CCR/ SEER	CoC	CER	Description
SSF 1				OBSOLETE FOR 2010 (Pre-Operative Carcinoembryonic Antigen (CEA))
SSF 2	X	X	X	Clinical Assessment of Regional Lymph Nodes
SSF 3				
SSF 4				
SSF 5				
SSF 6				
SSF 7				
SSF 8				
SSF 9				
SSF 10				
SSF 11				
SSF 12				
SSF 13				
SSF 14				
SSF 15				
SSF 16				
SSF 17				

California Cancer Reporting System Standards, Volume I

<b>Factor</b>	<b>CCR/ SEER</b>	<b>CoC</b>	<b>CER</b>	<b>Description</b>
SSF 18				
SSF 19				
SSF 20				
SSF 21				
SSF 22				
SSF 23				
SSF 24				
SSF 25				

## CER Required Site Specific Factor

### GIST Appendix C18.1

SITE	HISTOLOGY
C18.1	8935-8936

Factor	CCR/ SEER	CoC	CER	Description
SSF 1				OBSOLETE FOR 2010 (Pre-Operative Carcinoembryonic Antigen (CEA))
SSF 2				OBSOLETE FOR 2010 (Clinical Assessment of Regional Lymph Nodes)
SSF 3				
SSF 4				
SSF 5				
SSF 6				
SSF 7				
SSF 8				
SSF 9				
SSF 10				
SSF 11	X	X	X	Mitotic Count
SSF 12	X	X	X	KIT Gene Immunohistochemistry (IHC)
SSF 13				
SSF 14				
SSF 15				
SSF 16				
SSF 17				
SSF				

California Cancer Reporting System Standards, Volume I

18				
SSF 19				
SSF 20				
SSF 21				
SSF 22				
SSF 23				
SSF 24				
SSF 25				

## CER Required Site Specific Factor

### Chronic Myelogenous Leukemia (CML) C42.1

SITE	HISTOLOGY
C42.1	9863, 9875, 9876, 9945, 9946

Factor	CCR/ SEER	CoC	CER	Description
SSF 1	X	X	X	JAK-2 (also known as Janus Kinase 2 and JAK 2 Exon 12)
SSF 2				
SSF 3				
SSF 4				
SSF 5				
SSF 6				
SSF 7				
SSF 8				
SSF 9				
SSF 10				
SSF 11				
SSF 12				
SSF 13				
SSF 14				
SSF 15				
SSF 16				
SSF 17				
SSF 18				
SSF				



California Cancer Reporting System Standards, Volume I

Factor	CCR/ SEER	CoC	CER	Description
19				
SSF 20				
SSF 21				
SSF 22				
SSF 23				
SSF 24				
SSF 25				

### **APPENDIX Z.3: CER Required Biomarker - BCR-ABL - for CML**

<b>CER Project Item Name</b>
BCR-ABL Cytogenetic
BCR-ABL Cytogenetic Date
BCR-ABL Cytogenetic Date Flag
BCR-ABL FISH
BCR-ABL FISH Date
BCR-ABL FISH Date Flag
BCR-ABL RT-PCR Qualitative
BCR-ABL RT-PCR Qualitative Date
BCR-ABL RT-PCR Qualitative Date Flag
BCR-ABL RT-PCR Quantitative
BCR-ABL RT-PCR Quantitative Date
BCR-ABL RT-PCR Quantitative Date Flag

### **APPENDIX Z.4: CER Required Growth Factors for Breast, Colon, Rectum, Appendix, and CML**

<b>CER Project Item Name</b>
Granulocyte CSF Status
Erythrocyte Growth Factor Status
Thrombocyte Growth Factor Status